**European Journal of Hospital Pharmacy** offers a high-quality, peer-reviewed platform for the publication of practical and innovative research and aims to strengthen the profile and professional status of European hospital pharmacists.

### International Advisory Board Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Allwood</td>
<td>UK</td>
</tr>
<tr>
<td>Jo-Anne Brien</td>
<td>Australia</td>
</tr>
<tr>
<td>Damian Child</td>
<td>UK</td>
</tr>
<tr>
<td>Moses S S Chow</td>
<td>USA</td>
</tr>
<tr>
<td>Lona Christrup</td>
<td>Denmark</td>
</tr>
<tr>
<td>George Dranitsaris</td>
<td>Canada</td>
</tr>
<tr>
<td>Mirjana Gasperlin</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Robert Janknegt</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Lene Juel Kjeldsen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Mark Stuart</td>
<td>UK</td>
</tr>
<tr>
<td>Helmut Viernstein</td>
<td>Austria</td>
</tr>
<tr>
<td>Vesna Vrca-Bacic</td>
<td>Croatia</td>
</tr>
</tbody>
</table>

Guidelines for Authors and Reviewers

Full instructions are available online at [http://ejhp.bmj.com/ifora](http://ejhp.bmj.com/ifora). Articles must be submitted electronically [http://mc.manuscriptcentral.com/ejghp](http://mc.manuscriptcentral.com/ejghp). Authors are required to transfer copyright in their work to the European Association of Hospital Pharmacists [http://group.bmj.com/products/journals/instructions-for-authors/](http://group.bmj.com/products/journals/instructions-for-authors/) and [licence-forms](http://group.bmj.com/products/journals/instructions-for-authors/licence-forms).

Included in Science Citation Index.

### Subscription Information

**EJHP** is published bimonthly (subscribers receive all supplements).

**Institutional rates 2015**

- **Print and online**
  - £536; €724; $1046 (small)
  - £670; €905; $1307 (medium)
  - £771; €1041; $1504 (large)
- **Online only**
  - £482; €651; $940 (small)
  - £602; €813; $1174 (medium)
  - £693; €936; $1352 (large)
- **ISSN 2047-9956** (print), 2047-9964 (online)

**Personal rates 2015**

- **Print** (includes online access at no additional cost)
  - £188; €254; $367
- **Online only**
  - £165; €223; $322

### Contact Details

**Editorial Office**

E: EJHP Editorial Office, BMA House, Tavistock Square, London, WC1H 9JR, UK
T: +44 (0)20 7383 6222
E: info.ejhp@bmj.com

**Permissions**

[http://journals.bmj.com/misc/permissions.dtl](http://journals.bmj.com/misc/permissions.dtl)

**Production Editor**

Malcolm Smith
production.ejhp@bmj.com

**Supplement Enquiries**

- T: +44 (0)20 7383 6795
- journals@bmj.com

**Subscriptions**

- T: +44 (0)20 7111 1105
- E: support@bmj.com

**Display Advertising Sales**

Mark Moran (Sales Manager)
T: +44 (0)20 7383 6161
E: mmoran@bmj.com
http://group.bmj.com/group/advertising

**Online Advertising Sales**

Marc Clifford (Sales Manager)
T: +44 (0)20 7383 6161
E: mcclifford@bmj.com
http://group.bmj.com/group/advertising

**Display & Online Advertising Sales (USA)**

Jim Cunningham
T: +1 201 767 4170
E: jccunningham@cumnasso.com

**Author Reprints**

Reprint Administrator
T: +44 (0)20 7383 6305
E: admin.reprints@bmj.com

**Commercial Reprints (except USA & Canada)**

Nadia Guney-Randall
T: +44 (0)20 8445 5825
M: +44 (0)7866 262344
E: nguneyrandall@bmj.com

**Commercial Reprints (USA & Canada)**

Marsha Fogler
T: +1 800 482 1450 (toll free in the USA)
T: +1 856 489 4446 (outside the USA)
E: mfogler@medicalreprints.com
Contents

Abstracts from the EAHP 2015 Congress

A1  Clinical pharmacy
A72  Drug distribution
A78  Drug information and pharmacotherapy
A116  General management
A121  Production and preparation
A135  Pharmacokinetics and pharmacodynamics
A142  Patient safety and risk management
A194  Other hospital pharmacy topics
A209  International posters
A213  Author index

This abstract book has been produced by the BMJ Publishing Group from electronic files supplied by the authors. The abstracts have been formatted for consistency but not edited for content. Every effort has been made to reproduce faithfully the abstracts as submitted. However, no responsibility is assumed by the publishers or organisers for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instruments, or ideas contained in the material herein. We recommend independent verification of diagnoses and drug dosages.
# POSTER AWARD NOMINEES

## Presentations on Wednesday, 25 March, 14:00 to 15:30, Hall D

<table>
<thead>
<tr>
<th>Time</th>
<th>Poster number</th>
<th>Poster nominee oral presentations</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>PKP-001</td>
<td>Current vancomycin dosing recommendations for paediatric patients: a pharmacokinetic evaluation</td>
<td>N Rasouli</td>
</tr>
<tr>
<td>14:15</td>
<td>PP-002</td>
<td>Compatibility and stability of hyoscine N-butyl bromide and furosemide admixtures for use in palliative care</td>
<td>C Bosch-Ojeda</td>
</tr>
<tr>
<td>14:30</td>
<td>PS-042</td>
<td>Parenteral nutrition in premature infants: risk analysis after redesigning a production process</td>
<td>C Salazar</td>
</tr>
<tr>
<td>14:45</td>
<td>PS-046</td>
<td>Evaluation of a systematic tool to reduce inappropriate prescribing (STRIP) in adults with intellectual disability: a pilot study</td>
<td>R Zaal</td>
</tr>
<tr>
<td>15:00</td>
<td>CP-061</td>
<td>Long-term cost-effectiveness analysis of infliximab, etanercept and adalimumab in rheumatoid arthritis patients in real-life clinical practice</td>
<td>I Viguera-Guerra</td>
</tr>
<tr>
<td>15:15</td>
<td>DI-040</td>
<td>Long-term effect of an individualised medication plan with drug administration recommendations on the patients’ drug knowledge</td>
<td>AFJ Send</td>
</tr>
</tbody>
</table>

## Presentations on Thursday, 26 March, 09:00 to 10:30, Hall D

<table>
<thead>
<tr>
<th>Time</th>
<th>Poster number</th>
<th>Poster nominee oral presentations</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>CP-136</td>
<td>Inappropriate prescribing in older patients: assessment of a screening tool based on the stopp and start criteria</td>
<td>A-L Sennesael</td>
</tr>
<tr>
<td>09:15</td>
<td>CP-143</td>
<td>Involvement of microbial flora in aetiology of surgical site infections</td>
<td>D Calina</td>
</tr>
<tr>
<td>09:30</td>
<td>PP-028</td>
<td>Long-term stability of diluted solutions of the monoclonal antibody infliximab</td>
<td>N Navas</td>
</tr>
<tr>
<td>09:45</td>
<td>PS-116</td>
<td>Exposure to anticholinergic and sedative drugs: relationship between drug burden index, anticholinergic risk scales and falls in elderly hospitalised patients</td>
<td>E Jean-Bart</td>
</tr>
</tbody>
</table>
GAZYVARO™ (obinutuzumab, GA101) The only antibody with proven superiority vs. MabThera® (rituximab) in first-line CLL

Demonstrated by a head-to-head comparison of GAZYVARO and MabThera, both in combination with chlorambucil, in adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine-based therapy, as per the GAZYVARO licence.

NEW treatment option for first-line CLL

ENGINEERED FOR SUPERIORITY EFFECTIVE IN THE REAL WORLD

- GAZYVARO is the first glycoengineered type II anti-CD20 monoclonal antibody for CLL proven to be superior to MabThera.
- In a typical CLL patient population (median age 73 with at least 1 comorbidity), GAZYVARO+chlorambucil:
  - Added almost 1 year median progression-free survival vs. MabThera+chlorambucil
  - (26.7 months vs. 15.2 months; p<0.001) – CLL11 primary endpoint
  - Is the first antibody to demonstrate improved overall survival vs. chlorambucil monotherapy in CLL, showing a 59% reduction in the risk of death (p=0.002); 80% of chlorambucil monotherapy patients vs. 91% of GAZYVARO+chlorambucil patients alive at median 23.0 month follow-up (data not yet mature)
  - Offers a manageable tolerability profile

References:
3. Feinberg L et al. british journal of hematology 2014; 164:603-611

Prescribing information can be found overleaf
Clinical pharmacy

IMPACT OF A PHARMACEUTICAL CARE PROGRAMME FOCUSED ON SOLID ORGAN TRANSPLANT PATIENTS


10.1136/ejhpharm-2015-000639.1

Background Patient and organ survival is dependent on the use of immunosuppressant drugs. The doses are reduced several months after the surgery to low maintenance phase levels. Treatments are complex and require drug treatment monitoring.

Purpose To analyse the impact of a Pharmaceutical Care Programme focused on solid organ transplant patients for the prevention and correction of drug-related problems (DRPs). DRPs include medication errors in the process of prescribing, dispensing or administering a drug.

Material and methods Study design: retrospective observational study. Sample: 222 solid organ transplant patients: 94 kidney (9 with pancreas), 31 lung, 86 liver and 19 heart. The IASER method (identify, act, monitor, evaluate and results) was used as a tool to analyse and categorise the DRPs. Variables: number and type of DRP, drugs, recommended actions, acceptance and cost savings (acquisition drug cost, preparation and administration time cost, GRD cost, etc.).

Results 125 DRPs were detected in 88 patients (0.5 problem/solid organ transplant patient). 60.8% of the patients were males and the average of age was 53 years (7–86). Identified by validation (71.2%) and analytical parameters (24.0%). 41.6% of DRPs reached the patient. The main problems were over dosage (24%) in kidney transplant and (8%) in liver transplant patients, the need for additional treatment (12%) in lung transplant and (1.6%) in heart transplant patients. The DRPs were categorised into safety (45.6%), indication (33.6%), effectiveness (18.4%) and adherence (2.4%). The therapeutic groups involved were mainly antibiotics (50%) and immunosuppressants (26%). 81.6% of the actions were accepted by physicians. 72% were relevant to improving patient care. The financial impact was €69,926/year saved (€38,123/year in kidney transplant, €19,106/year in lung transplant, €9,658/year in liver transplant and €2,939/year in heart transplant patients).

Conclusion Management of complex treatments requires the involvement of all health professionals. A pharmaceutical care programme based on pharmacotherapeutic monitoring resolved DRPs in solid organ transplant patients. It improved the quality of treatment and saved money.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

Clinical pharmacy

PHARMACEUTICAL CARE SYSTEM FOR LIVER TRANSPLANT PATIENTS USING ELECTRONIC CONSULTATION

1M Fernández-Megía*, 2R López-Andújar, 1 Font-Noguera, 1M Montero-Hernández, 1Puchalt-Escribano, 1I Poveda-Andrés, 2Hospital Universitario Y Politécnico La Fe, Pharmacy, Valencia, Spain; 2Hospital Universitario Y Politécnico La Fe, Hepatobiliary Surgery Unit, Valencia, Spain

10.1136/ejhpharm-2015-000639.2

Background Information and education for transplant patients can improve their health outcomes. Communication between health professionals through the electronic medical record is used in the management of hospitalised patients.

Purpose To evaluate a pharmaceutical care program in liver transplantation patients through electronic consultation.

Material and methods Setting: tertiary hospital of 1,000 beds. Design: observational prospective study. Population: 90 liver transplant patients during 2013. System: the physician requests the pharmacist consultation via the electronic medical record. The pharmacist delivers the documentation and training to the patient in collaboration with the medical and nursing team. At discharge, the pharmacist gives education about drugs by an informative newsletter and planning schedule. One week after discharge, he telephones the patient to complete a survey on the training level and satisfaction. Variables: patient characteristics, diagnosis, treatment, level of understanding and satisfaction.

Results During the study period, 63 patients met the criteria for inclusion in the system. 100% of the consultations were performed and recorded. (Median; range): 57 years (26–69); 80% male; stay: 14 days (8–60); number of diseases contributing to the patient’s condition: 2.5 (1–9); drugs at admission: 5.5 (0–14); drugs at discharge: 10 (5–10). The main reason for transplantation was viral hepatitis: HCV (58%), HBV (14%), alcoholic cirrhosis (30%) and hepatocellular carcinoma associated with previous cases (14%). 31 surveys were obtained with a level of understanding 4.8 out of 5. 90% of patients used the schedule delivered. 58% claimed to know what it was for each drug, 90% were not confused with taking the medicines and 97% did not forget to take their medicines. Finally, 97% said they were satisfied with the information received.

Conclusion The participation of a pharmacist in this system can contribute to a better understanding of the treatments by the transplant patient. Electronic consultation has proved a useful and efficient tool for coordinating activities among professionals involved.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CLINICAL PHARMACIST INTERVENTIONS ON PARENTERAL NUTRITION APPROPRIATENESS IN A TEACHING HOSPITAL

G Meers, K Noeren*, H Collier, P Cortoos. UZ Brussel, Hospital Pharmacy, Brussels, Belgium

10.1136/ejhpharm-2015-000639.3

Background Total Parenteral Nutrition (TPN) isn’t always prescribed according to international guidelines: nutritional screening is frequently lacking, the prescribed therapy is not always adapted accordingly and subsequent monitoring is often absent. Our objective was to assess the potential benefit of a clinical pharmacist reviewing prescribed TPN.

Purpose Evaluation of the appropriateness of prescribed TPN.

Material and methods Setting: A prospective pre-post intervention study in a tertiary care teaching hospital with a high percentage of cancer and critically ill patients.

Method: Adult hospitalised patients on TPN were included. The presence of a Nutritional Risk Screening-2002 and the calculation of energy requirements, the indication, the therapy appropriateness and the therapy duration were assessed by a
Clinical pharmacy

clinical pharmacist. During the intervention period feedback was provided to the physician and dietician in multidisciplinary collaboration. The ESPEN guidelines were taken as golden standard. All data were obtained from the electronic patients files.

Results We assessed 272 hospitalisations, 152 pre-interventional (10/2013–01/2014) and 120 post-interventional (02/2014–04/2014). During the latter period an intervention was needed in 83.7% (176 interventions) of the cases. Prevalence of nutritional screening increased from 25.0% to 61.7% (p < 0.001) as did energy requirement calculation (30.9% vs. 67.5%; p < 0.001). Therapy appropriateness increased from 58.8% to 75.8% (p < 0.05). The median duration (6.0 vs. 7.0 days) of the therapy was not significantly reduced (p = 0.36). We avoided the production of at least 81 TPNs on a total of 1172. During the 3 month intervention period an estimated total saving of 20736€ could be obtained.

Conclusion The additional monitoring of the appropriateness of TPN by a clinical pharmacist has a positive influence on therapy quality and healthcare costs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 ESPEN guidelines (http://www.espen.org/education/espen-guidelines)
2 Nutrition support team

No conflict of interest.

CP-004 AGE-RELATED MACULAR DEGENERATION: ECONOMIC IMPACT OF IMPLEMENTING TREATMENT GUIDELINES
I Blasco-Mascons*, G Mercadal-Orfila, R Romero-Del Barco. Hospital Mateu Orfila, Pharmacy, Mahon, Spain

Introduction

Background Drugs for age-related neovascular macular degeneration (AMD) reverse the disease process, usually leading to gains in visual acuity. Ranibizumab (Lucentis) was licensed for AMD in the EU in 2007. Bevacizumab (Avastin), has been widely used globally off-label by splitting up doses licensed for cancer.

Purpose To assess the use and cost of intravitreal ranibizumab and bevacizumab, after the implementation of AMD treatment guidelines.

Methods A retrospective analysis of the use of both drugs in our hospital from 2007 to 2013 was conducted. At the end of 2009 AMD treatment guidelines were implemented in our hospital: ranibizumab 0.5 mg only can be prescribed after poor response to three monthly injections of bevacizumab 1.25 mg.

Results A total of 494 doses of ranibizumab were administered to 107 patients. Bevacizumab was administered to 418 patients with a total of 1325 doses.

Prescriptions for each drug were as follows (from 2007 to 2013):

- Ranibizumab: 23, 147, 179, 32, 27, 25, 61.
- Bevacizumab: 0, 56, 63, 204, 259, 340, 403.

In 2010 after the implementation of the protocol, ranibizumab prescriptions decreased 82.1%, from 179 (2009) to 32 (2010). Bevacizumab prescriptions increased 223.8%, from 63 (2009) to 204 (2010).

Ranibizumab injection average cost was €985.69 per injection. Each bevacizumab injection cost €16.40. Ranibizumab costs in the whole seven year period were €486,929. Bevacizumab costs in the same period were €21,730. Global saving costs for implementing this protocol in our hospital were €1,151,128.

Conclusions Our study showed that considerable savings may be obtained by promoting the most cost-effectiveness alternative as first line treatment for AMD. The role of hospital pharmacists was crucial, involving the process of splitting up bevacizumab doses.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-005 ASSESSMENT OF DRUG-DRUG INTERACTIONS INVOLVING PSYCHIATRIC AGENTS IN HOSPITALISED PATIENTS

M Freire*, C Sobino, M De Sebastian, L Balade, M Bravo, C Lara, E Villamañán, A Herrero. La Paz University Hospital, Pharmacy, Madrid, Spain

10.1136/ejhpharm-2015-000639.5

Background The use of psychiatric agents in hospitals increases the complexity of pharmacotherapy and the risk of drug–drug interactions.

Purpose To assess the frequency and clinical relevance of interactions associated with the use of antipsychotics, anxiolytics, antidepressants and sedative/hypnotics. They assessed drug–drug interactions and their clinical significance as described in the literature. Reference sources were the Micromedex database and the Spanish Society of Hospital Pharmacist’s professional guide to drug interactions.

Results Treatment of 393 patients was analysed. Of these, 179 (45.5%) were prescribed one of the drugs studied; 53.6% were female and 46.4% male with mean age 65 (SD ± 17.7) years. The average number of drugs prescribed per patient was 12 (SD ± 4.41). A total of 221 drug interactions was detected (9.5% pharmacokinetic, 90.5% pharmacodynamic), affecting 70.4% of patients. A total of 42.8% were due to prescription of antipsychotics, 31.1% due to antidepressants, 18.5% to anxiolytics and 7.6% to hypnotics/sedatives. The medical specialties involved were surgery (22.4%), oncology (11.1%), cardiology (8.9%), internal medicine (8.9%) and psychiatry (8.4%). Based on clinical significance, 47.5% of interactions were severe, 25.3% moderate and 27.1% mild. Potential interactions with significant clinical effects were haloperidol-tramadol (increased seizure risk), escitalopram-low molecular weight heparin (increased risk of bleeding) and midazolam-morphine (increased sedation). Three contraindicated combinations were detected: escitalopram-metoclopramide for increased QT interval, linezolid-aminopyrine for serotonin syndrome and risperidone-metoclopramide for neuroleptic syndrome and extrapyramidal reactions.

Conclusion Prescription of antipsychotic drugs, antidepressants, anxiolytics and sedatives/hypnotics to inpatients is very common. These drugs cause numerous drug interactions, which can potentially have serious consequences for hospitalised patients.
Background Inosine triphosphatase (ITPA) genotyping is used for predicting anaemia in patients with genotype 1 chronic hepatitis C. The AA and CA genotypes have the lowest incidence of anaemia.

Purpose To compare the incidence of anaemia, the reduction in ribavirin (RBV) dose and the use of darbepoetin in patients treated with boceprevir or telaprevir before and after the introduction of ITPA genotyping in a tertiary care hospital.

Material and methods Observational, pre-post intervention study using pharmacotherapeutic records of patients treated with telaprevir or boceprevir before and after the introduction of ITPA genotyping. Anaemia was defined as haemoglobin (Hb) <10.5 mg/dL. Baseline characteristics were age, sex, fibroscan, basal Hb, nadir Hb and ITPA genotype. Homogeneity of baseline characteristics was evaluated by the t-test. Comparisons of the incidence of anaemia, the reduction of RBV dose and the use of darbepoetin were made with the independent proportions test.

Results Before genotyping 37 patients were included (27 male, 10 female): Mean fibroscan was 22 kpa, mean basal Hb was 15.6 mg/dL and mean nadir Hb was 10.4 mg/dL. After genotyping 20 patients were included (16 male, 4 female): 18 patients were CC (90%) and two were AC (10%). Mean fibroscan was 11.9 kpa (significantly lower than before genotyping). Mean basal Hb was 16.1 mg/dL and mean nadir Hb was 10.9 mg/dL. After genotyping the incidence of anaemia was 17 (47.2%) compared to before treatment 25 (69.2%) (7 (43.8%) for TLV and 5 (55.6%) for BOC). The total number of patients who experienced anaemia was 17 (47.2%) (9 (39.1%) for TLV and 8 (61.5%) for BOC), 16 patients (44.4%) had a reduction in their ribavirin dose (8 (34.8%) for TLV and 8 (61.5%) for BOC) and 12 patients (33.3%) used darbepoetin (6 (26.1%) for TLV and 6 (46.1%) for BOC); 8 of these 12 (66.6%) patients showed SVR, 1 relapsed and 3 abandoned treatment due to adverse events (4 (66.6%) for TLV and 4 (66.6%) for BOC).

Conclusion 1. Among our genotype 1-infected patients treated with BOC or TLV anaemia was not associated with higher rates of SVR.

2. Patients with darbepoetin did not have higher rates of SVR.

3. Percentages of SVR were similar between TLV and BOC.

No conflict of interest.
Clinical pharmacy

- Is the medicine still needed?
- Is the medicine beneficial, taking into account co-morbidities?
- Are any appropriate medicines not being prescribed?

Following the MDT meeting, residents were asked their views before any intervention was made. Residents were followed up after the review to identify any adverse events. Any residents taking psychotropic medicines were discussed with a Psychiatry of Old Age Services consultant where appropriate.

Results In total, 422 residents in 20 care homes were reviewed; 1,346 interventions were made in 384 (91%) residents, with the most common intervention being to stop a prescription. 704 medicines were stopped in 298 residents. 1.7% medicines were stopped for every resident reviewed (range 0 to 9 medicines; SD 1.7), giving a 17.4% reduction in medicines prescribed. The main reasons for stopping medicines were a lack of current indication (57%) and residents not wanting to take the medicine (17%). 41 medicines (6%) were stopped because of safety concerns. Follow-up found 9 minor events following stopping medicines. The net annualised savings against the medicines budget were €99,340 or €235 per resident reviewed.

Conclusion This project demonstrated that a multidisciplinary medicines review involving a pharmacist, doctor, care home nurse and the resident can safely reduce over-prescribing and inappropriate medication whilst generating significant savings from the medicines budget.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

**CP-009 IMPACT OF PHARMACEUTICAL INTERVENTION ON QUALITY OF LIFE AND COPING STRATEGIES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES**

1M Opesomer*, 2A Anota, 3M Noblot-Rossignol, 2F Bonetain, 1C Pernot, 1M Chretien, 3C Legouge, 1D Callot, 1M Boulin. CHU Bocage, Pharmacy, Dijon, France. 2University Hospital Besancon, Methodology and Quality of Life in Oncology Unit EA 3181 & Quality of Life and Cancer Clinical Research Platform, Besancon, France. 3CHU Bocage, Department of Haematology, Dijon, France

10.1136/ejhpharm-2015-000639.9

**BACKGROUND**

Chemotherapy especially that used in Haematological Malignancies (HMs) has severe biological and clinical adverse effects (AEs). Such symptoms often impair patients’ quality of life (QoL). Adjuvant drugs are prescribed to patients to prevent these AEs. For patients at home, taking these adjuvant drugs is complicated because of the different regimens: only if necessary (antiemetics), only in the presence of symptoms such as fever (antibiotics), etc.

**PURPOSE**

In our hospital, patients receiving their first chemotherapy benefit from a pharmaceutical intervention (PI). We conducted a prospective study approved by the local ethics committee to determine the impact of the PI on pain, fatigue, QoL and coping strategies in patients undergoing chemotherapy for an HM.

**MATERIAL AND METHODS**

Patients received either usual care (UC + PI (PI group) or UC alone (UC group). They had to complete the QLQ-C30 and MAC 21 questionnaires before starting the 1st chemotherapy session (T1), during the inter-treatment interval (T2) and the day before starting the 2nd chemotherapy session (T3).

To determine predictive factors of pain, fatigue and QoL at T3, a univariate followed by a multivariate ANOVA was used. The time until definitive deterioration was estimated using a Kaplan-Meier method.

**RESULTS**

68 patients were included in the PI (n = 34) or UC groups (n = 34). Ninety-two percent of the patients returned all the questionnaires. At T3, pain and fatigue were lower in the PI group. Between T1 and T3, QoL remained stable. We identified a significant improvement of 5 points in QoL for patients in the PI group.

**CONCLUSION**

Whatever the statistical model used, the pharmacist intervention at the beginning of chemotherapy had a less than significant impact on pain and fatigue but nevertheless it was confirmed to have had a significantly positive impact on QoL.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**
The authors thank Philip Bastable.

No conflict of interest.

**CP-010 ADHERENCE TO LONG-TERM MEDICINES IN HIV-INFECTED PATIENTS**

11M Cantudo-Cuenca, 11C Haro Martínez, 1M Cantudo-Cuenca, 1M González-Medina*, 2C Gómez-Peña, 1AM Tristán-Chávez, 1E Calvo-Cidóncha, 1R Morillo Verdugo. 1Área de Gestión Sanitaria Sur de Sevilla, UGC Farmacia, Sevilla, Spain; 2Hospital San Juan de Dios, Farmacia, Sevilla, Spain; 3Hospital Universitario San Cecilio, UGC Intercentros Interniveles Farmacia Granada, Granada, Spain

10.1136/ejhpharm-2015-000639.10

**BACKGROUND**

Comorbid chronic conditions have increased among HIV-infected patients. Little work has studied adherence rates for long-term medicines (LTMs).

**PURPOSE**

To assess adherence to other LTMs (non-antiretroviral therapy) among HIV-infected patients as well as to evaluate its relationship with clinical and therapeutic factors.

**MATERIAL AND METHODS**

A cross-sectional study was conducted from May to July 2014 in HIV-infected patients treated with ART and ≥1 LTM. The following variables were collected: sex, age, living situation, employment status, mode of transmission, T-CD4, viral load, CDC classification, type of ART and adherence to other LTM (non-antiretroviral treatment), using the 4-item Morisky Medication Adherence Scale. The chi-squared test was applied to examine the role of the different variables on adherence, using SPSS 20.0.

**RESULTS**

126 patients were included (80.4% male, mean age 50.4 ± 8.3). Injection drug use was the main mode of transmission (61.9%). The median T-CD4 was 538.5 cells/mm³ (IQR: 341.1–778.2). Most of patients presented T-CD4 ≥ 500 cells/mm³ (56.3%) and undetectable viral load (74.6%). 63.5% of them had AIDS. ART was mainly (36.3%) two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) with one non-nucleoside reverse transcriptase inhibitor (NNRTI). The percentage of patients adherent to other LTMs (non-antiretroviral therapy) was 46.0%. The variable AIDS exhibited a statistically significant relationship with non-adherence (OR = 2.2; CI [1.1–4.7]; p = 0.041). The most common long-term medicines were sedatives and anxiolytics (42.9%), lipid-lowering drugs (35.7%), antihypertensives (33.3%), gastrointestinal (28.6%), antidepressants (15.1%), antidiabetics (12.7%), analgesics (11.1%), antiasthmatics (9.5%) and cardiovascular drugs (87.9%).

A4

Abstract CP-010 Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Non-Adherent (n = 68)</th>
<th>Adherent (n = 58)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 50 years</td>
<td>30 (44.1)</td>
<td>26 (44.8)</td>
<td>1.000</td>
</tr>
<tr>
<td>Gender: female</td>
<td>14 (20.6)</td>
<td>12 (20.7)</td>
<td>1.000</td>
</tr>
<tr>
<td>Living alone</td>
<td>18 (26.5)</td>
<td>11 (19.0)</td>
<td>0.399</td>
</tr>
<tr>
<td>Employment status: employed</td>
<td>16 (23.5)</td>
<td>19 (32.8)</td>
<td>0.399</td>
</tr>
<tr>
<td>Mode of transmission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexual</td>
<td>21 (30.9)</td>
<td>27 (46.6)</td>
<td></td>
</tr>
<tr>
<td>Injection drug use</td>
<td>47 (69.1)</td>
<td>31 (63.4)</td>
<td>0.097</td>
</tr>
<tr>
<td>Detectable viral load (&gt;20 copies/ml)</td>
<td>18 (26.5)</td>
<td>14 (24.1)</td>
<td>0.839</td>
</tr>
<tr>
<td>T-Cd4 ≥ 500 Cells/mm³</td>
<td>38 (55.9)</td>
<td>33 (56.9)</td>
<td>1.000</td>
</tr>
<tr>
<td>AIDS</td>
<td>49 (72.5)</td>
<td>31 (53.4)</td>
<td>0.041</td>
</tr>
<tr>
<td>Type of ART</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2NRTIs + NNRTI</td>
<td>25 (36.8)</td>
<td>21 (36.2)</td>
<td></td>
</tr>
<tr>
<td>2NRTIs + IP/Tr</td>
<td>20 (29.4)</td>
<td>21 (36.2)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>23 (33.8)</td>
<td>16 (27.6)</td>
<td>0.657</td>
</tr>
</tbody>
</table>

Conclusion Patients showed a low level of adherence to other LTM. This study allowed us to attempt to educate HIV-infected patients with suboptimal adherence.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.

CP-012 MEDICATIONS RECONCILIATION & IMPLEMENTATION BY CLINICAL PHARMACISTS IN THE OTORHINOLARYNGOLOGY CLINIC

N Pinder*, S Amelung, J Horsch, M Lukasova, S Paasch, K Green, T Hoppe-Tichy. University Hospital of Heidelberg, Pharmacy Department, Heidelberg, Germany

10.1136/ehjpharm-2015-000639.12

Background Taking a complete medical history of patients before hospital admission includes an accurate assessment of the current drug history which provides the basis for appropriate pharmacotherapy during the stay in hospital and at discharge as we know from the literature, this is best performed by a clinical pharmacist.

Purpose To evaluate specific aspects of medicines reconciliation by pharmacists performed as part of the clinical routine.

Material and methods Throughout a 4 week pilot phase, 178 patients were seen by a pharmacist for medicines reconciliation. During an interview, the current medicines were assessed including brand name, administration form and strength, dosing scheme and temporarily discontinued treatment. Moreover, information about patients’ allergies, intolerances and concomitant diseases was collected. After verifying the medicines (check for omissions, duplications, dosing errors or drug interactions), the appropriate medicines were switched to the hospital drug formulary. If drug-related problems were found the attending physician was informed by the clinical pharmacist and possible solutions were discussed. As a follow-up, patients’ medical records were reviewed and physicians’, nurses’ and pharmacists’ feedback on the project was evaluated.

Results Clinical pharmacists performed medicines reconciliation as part of the clinical routine. In the pilot phase, 133 patients were regularly taking medicines and 36 brought a medicines list, however, this list was out-of-date or differed from patients’ statements in many cases. The average total time required per patient was 18 (2–80) min. Frequent discrepancies or medicines errors were associated with fixed combinations, statins, ASA and bridging of anticoagulants. Feedback was generally positive although process optimisation possibilities were identified.

Conclusion Our project has shown the successful integration of a clinical pharmacist in the clinical routine of preadmission. Pharmaceutical interventions were largely accepted by the physicians, (potential) medicines errors and critical drugs could be revealed, and new SOPs will be created. We intend to continue the project.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
ETANERCEPT ON STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE

S González-Munigua*, 1M Pérez León, 1M Piñero González, 1M Díaz-Pestano, 1R Molero Gómez, 1H Lázaro-Henríquez, 1Hospital Universitario de Gran Canaria Dr. Negrín, Farmacia Hospitalaria, Las Palmas de Gran Canaria, Spain; 1Hospital Universitario de Gran Canaria Dr. Negrín, Hematología Y Hemoterapia, Las Palmas de Gran Canaria, Spain

10.1136/ehjpharm-2015-000639.13

Background Allogeneic hematopoietic stem cell transplantation (HSCT) is the first-line treatment for many haematological diseases. Graft-versus-host disease (GVHD) is the major complication of HSCT.

Steroids are the mainstay treatment of GVHD for reducing the systemic pro-inflammatory response. In about half of the patients, steroid treatment fails and they have to be treated with other immunosuppressant drugs. Of these, treatment with anti-TNF drugs such as etanercept is becoming an option for digestive manifestations of GVHD.

Purpose To describe etanercept use and effectiveness in steroid-refractory acute graft-versus-host disease, after hematopoietic cell transplantation.

Material and methods Patients treated with etanercept, an off-label use for steroid-refractory acute graft-versus-host disease, were selected and each patient’s medical history was reviewed to assess the clinical response.

Results The study included 5 patients: 4 presented with digestive manifestations and one 1 presented pulmonary and liver manifestations. 4 patients showed a clinical response: 3 of them a partial response and 1 a total response.

In 4 cases, etanercept 25 mg was administered twice a week with variable duration of treatment, achieving no response in 1 case (3 weeks), partial response in 2 cases (4 weeks and 8 weeks) and a complete response in 1 case (8 week period). Only one patient was treated with etanercept 50 mg administered twice a week for 5 weeks with a partial treatment response.

Conclusion Previously published data estimated the response rates at about 60–62%, which was consistent with our results. These update the scarce bibliographic information about etanercept use in steroid-refractory acute graft-versus-host disease. Due to clinical design limitations and the small patient population, further clinical studies should be conducted to assess the efficacy and safety of etanercept in these patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.

IMPACT OF PHARMACIST INTERVENTION USING SHARED DECISION MAKING ON ADHERENCE AND MEASURABLE DEPRESSED PATIENT OUTCOMES

K Aljamah*, 1M Hassali. 1Al Amal Psychiatric Hospital, Riyadh, Saudi Arabia; 2Universiti Sains Malaysia, School of Pharmaceutical Sciences, Penang, Malaysia

10.1136/ehjpharm-2015-000639.15

Background Adherence to antidepressant treatment is an essential step for the management of major depressive disorder patients. Patients actively make decisions about their adherence to medicines.

Purpose To evaluate the effectiveness of a pharmacist intervention based on shared decision making (SDM) to improve adherence and patient outcomes compared to usual care in patients diagnosed with major depression disorder (MDD).

Material and methods A prospective randomised controlled study, with 6-month follow-up, with randomisation of participants to two alternative groups as follows: 1) interventions based on SDM, to enhance patient adherence (IG) 2) usual pharmaceutical care group (CG). The study was conducted in an outpatients department in a psychiatric hospital. Patient adherence, treatment beliefs, patient satisfaction with depression treatment, severity of depression, health-related quality of life and quality of patients’ involvement in SDM were collected at baseline, three and six months.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PARENTERAL NUTRITION, IS STANDARIZATION ACCEPTABLE?

Cl. Dúvila Fajardo*, X Díaz Villamarín, R Morón Romero, M González Medina, M Marín, J Cabeza Barreto. San Cecilio University Hospital, Pharmacy, Granada, Spain

10.1136/ehjpharm-2015-000639.14

Background A prospective study in which the standard parental nutrition prescribed by physicians for adult patients was compared with that designed by a resident pharmacist taking advantage of nutritional knowledge acquired during an internship in the area of nutrition with another hospital.

Purpose To weigh the advantages and disadvantages of individualized and standardised parenteral nutrition formulas.

Material and methods We selected 20 patients hospitalised in surgical wards in our hospital. The standardised parenteral nutrition prescribed by physicians was studied. We evaluated: indication, nutritional status of the patients, the incidence of complications during the process and the suitability of the standardised parenteral nutrition prescribed according to the clinical practice guidelines established by the Working Group on Nutrition – Spanish Hospital Pharmacists Society.

Results

• From a total of 20 patients, 40% of them had been prescribed standard parental nutrition that did not fit with the recommended guidelines.

• 80% of standardised parenteral nutrition did not fit with the caloric and water requirements recommended in clinical practice guidelines.

• 50% of patients had hypertriglyceridemia that was not controlled with the standardised parenteral nutrition.

• 40% of patients needed a correction in the contribution of electrolytes to suit the requirements published in the clinical practice guidelines.

Conclusion

• There is an excess of standardisation of parenteral nutrition in our hospital.

• The consequence is a decrease in the quality of treatment.

• Parenteral nutrition is used in off-label clinical situations.

• There is a lack of adequate monitoring.

• Parenteral nutrition can be adapted to the specific requirements of the patients and this is indicated especially in critical patients.

• The standard parenteral nutrition is useful in patients with standard energy and nutrient requirements.
Results 239 patients were met the inclusion criteria during recruitment for this study, randomised to the IG (n = 119) or CG (n = 120); 19 patients completely dropped out of the study (10 patients from CG and 9 from IG). The average age was 39 years in the experimental group and 40 years in the control group. At the end of six months’ follow-up patients in the IG showed significant different in adherence to medicines, treatment satisfaction, general overuse beliefs, specific concerns beliefs and the total general beliefs about medicines compared with CG. On the other hand severity of depression and health-related quality of life showed statically insignificant differences at the end of six months comparing with CG.

Conclusion Pharmacist intervention based on SDM significantly improved adherence, treatment satisfaction and patients’ belief in antidepressants compared to usual care. We believe it will be a useful practice for regular psychiatric pharmacy care after a cost-effectiveness evaluation of this intervention.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

CP-016 ASSESSMENT OF SEVERITY OF DEPRESSION, HEALTH-RELATED QUALITY OF LIFE AND ADHERENCE IN DEPRESSED PATIENTS

K Aljumah*, M Hassali. 1 Al Amal Psychiatric Hospital, Riyadh, Saudi Arabia; 2 Universiti Sains Malaysia, School of Pharmaceutical Sciences, Penang, Malaysia

Background Health-Related Quality of Life (HRQoL) evaluation is becoming increasingly recognised as an important outcome measure in assessing quality of life and health outcomes in mental illness patients. Evidence shows that chronically-ill patients have a lower quality of life and lower adherence to their drug treatment. A limited number of studies has investigated the relationship between HRQoL, adherence to antidepressant and severity of depression.

Purpose To assess the effect of severity of depression on adherence to medicines and on the HRQoL.

Material and methods A questionnaire-based, cross-sectional descriptive study was carried out between August 2013 and January 2014 in an outpatient clinic at a psychiatric hospital. All patients meeting the inclusion criteria were invited sequentially to participate. Written consent was sought from the patients, eligible participants met one of the research coordinators to assess adherence to medicines by using the Morisky Medication Adherence Scale, severity of symptoms was measured by the Montgomery-Åsberg Depression Rating Scale and health-related quality of life was measured by the EuroQol-5 dimensional questionnaire (EQ-5D).

Results A total of 187 patients participated in this study. 53.5% were females. Mean EQ-5D descriptive score was 0.67 ±0.35 for males and 0.63 ±0.38 for females. A total of 54 different EQ-5D health states were described by the patients. The data showed no effect of age, education level, duration of illness and number of antidepressants on the EQ-5D score. Using Pearson’s correlation coefficient to examine the relationship between EQ-5D and EQ-VAS scores and the topics of this study, resulted in a positive association between adherence and both EQ-5D (0.2899) and EQ-VAS (0.2116) with significant correlation at the 0.01 level. There was at the same time a negative association between EQ-5D and EuroQol-visual analogue scale (EQ-VAS) scores and severity of depression (0.6962);(0.4869) respectively with significant correlation at the 0.01 level.

Conclusion Association between severity of depression and HRQoL reflects the importance of evaluating the severity of the depression and its impact on HRQL and adherence. An appreciation of the severity and appropriate management enable healthcare providers to control depression better.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

CP-017 DIFFERENCES IN VALUES OF BODY SURFACE AREA IN CHEMOTHERAPY PATIENTS

R Díez Fernandez*, R Vázquez Sánchez, T Molina García. Hospital Universitario de Getafe, Pharmacy, Getafe, Spain

Background Chemotherapy drug dosing in adult patients with cancer has traditionally been based on patient’s estimated body surface area (BSA). BSA can be calculated using several standard formulas and none of them is recommended above the others.

Purpose To assess the variation in BSA calculated in oncology patients using different validated formulas.

Material and methods All patients receiving chemotherapy in our hospital, whose weight and height were recorded, were included. BSA was calculated for all patients using six formulas (DuBois, Mosteller, Gehan and George, Haycock, Fujimoto and Takahira). All calculated BSAs were compared against DuBois BSA, as this is the most widely-used formula.

Results In 55 months, a total of 1,868 patients was included. 1,192 (63.8%) were overweight patients (BMI > 25.00) and 32 (1.71%) were underweight (BMI < 18.50).

<table>
<thead>
<tr>
<th>Factor</th>
<th>Interventions Group</th>
<th>Control Group</th>
<th>T-Value</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Medicines</td>
<td>Std. Deviation Mean</td>
<td>Std. Deviation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T-Value Sig</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adherence Scale</td>
<td>5.99</td>
<td>1.88</td>
<td>4.94</td>
<td>1.94</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BMI</th>
<th>SC Mosteller</th>
<th>SC Gehan</th>
<th>SC Haycock</th>
<th>SC Fujimoto</th>
<th>SC Takahira</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;16.00</td>
<td>9</td>
<td>2.69%</td>
<td>2.34%</td>
<td>3.91%</td>
<td>3.26%</td>
</tr>
<tr>
<td>16.00</td>
<td>17.00</td>
<td>18.00</td>
<td>18.50</td>
<td>25.00</td>
<td>30.00</td>
</tr>
<tr>
<td>25.00</td>
<td>29.99</td>
<td>7761.78%</td>
<td>2.97%</td>
<td>2.82%</td>
<td>2.16%</td>
</tr>
<tr>
<td>Obese Class I</td>
<td>34.99</td>
<td>3083.08%</td>
<td>4.59%</td>
<td>4.79%</td>
<td>1.84%</td>
</tr>
<tr>
<td>Obese Class II</td>
<td>39.99</td>
<td>86</td>
<td>4.35%</td>
<td>6.19%</td>
<td>6.72%</td>
</tr>
<tr>
<td>Obese Class III</td>
<td>≥40.00</td>
<td>22</td>
<td>5.73%</td>
<td>7.94%</td>
<td>8.83%</td>
</tr>
</tbody>
</table>

Clinical pharmacy
Clinical pharmacy

Conclusion There are remarkable differences in values of BSA depending on the formula used to calculate it, especially at the extremes of BMI. This may result in great differences in dosing, especially in overweight patients. Therefore, when calculating BSA, the formula used should always be stated.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

CP-018 PARENTERAL NUTRITION GIVEN IN THE PEROPERATIVE PERIOD IN ABDOMINAL SURGERY: COMPLIANCE WITH GUIDELINES
1C Van Wetter*, 4P Mestrez, 4E Carribeir, 4N Tinton, 4O Brandt, 4O Tassin. 1Grand Hôpital de Charleroi, Hospital Pharmacy, Gilly, Belgium; 2Grand Hôpital de Charleroi, Nutrition, Gilly, Belgium; 3Grand Hôpital de Charleroi, Abdominal Surgery, Gilly, Belgium
10.1136/ehjpharm-2015-000639.18

Background A significant proportion of patients are receiving parenteral nutrition (PN) for elective surgery in our abdominal surgery unit.
Purpose To assess compliance of prescriptions with international guidelines.
Material and methods Patients who underwent elective surgery and who received PN were selected during a 6-month period (January 2013–June 2013). The ESPEN guidelines were considered the reference guidelines. The clinical pharmacist assessed conformity with guidelines with information from prescriptions and medical files.
Results 23 patients were selected: 15 patients had uncomplicated surgery (US), 6 had postoperative ileus (PI) and 2 another complication (OC). ESPEN guidelines recommend preoperative PN in severely undernourished patients who cannot be adequately orally or enterally fed. Postoperative PN is recommended for undernourished patients in whom enteral nutrition is not feasible or tolerated, or when patients with postoperative complications impairing gastrointestinal functions are unable to meet energy requirements for at least 7 days. Only 6 treatments (26%) complied with the guidelines: as none of the patients qualified as undernourished and all patients had gastrointestinal impairment due to surgery, only patients with PN at least 7 days after surgery complied with guidelines.
Conclusion This study demonstrates most PN treatments in elective abdominal surgery are not in agreement with the guidelines. A multidisciplinary group (nutritionist, dietician, surgeon and pharmacist) was created to implement specific protocols. Measures for improvement will be taken and monitored in 2014.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

CP-019 ALBUMIN CONSUMPTION IN FIVE YEARS 2009–2013: AN EXAMPLE OF IMPROVED PRESCRIBING APPROPRIATENESS
G De Marco*, F Urso. Azienda Ospedaliera Cosenza, U. O. C. Farmacia, Cosenza, Italy
10.1136/ehjpharm-2015-000639.19

Background Albumin has a significant impact on spending and it poses a risk to economic sustainability. Prescriptions are often inappropriate and corrective actions are required.
Purpose Albumin consumption was analysed in some departments to improve the appropriateness of prescriptions. The Drug Commission in September 2009 approved a new form, which is now used in our Region, with indications of documented effectiveness. The prescription of the specialist must also be approved by transfusion centre doctors to evaluate clinical parameters.
Material and methods Albumin consumption was analysed in the first 8 months from 2009 to 2013 in hospital wards with higher requests (Cardiology, Gastroenterology, Geriatrics, Internal Medicine, Hepato-biliary-pancreatic Surgery, Vascular Surgery). Data were extrapolated from XPharmacy management software and analysed using Microsoft Excel.
Results Introduction of a new form reduced albumin consumption significantly: from 8067 vials in 2009 to 1371 vials in 2013 for the same period (6696 fewer vials, a reduction of 83%). Over the years, consumption has continuously reduced with satisfactory overall results in all the departments examined (performance% reductions 2013/2009: Geriatrics minus 94.83%, Gastroenterology, minus 92.01%, Hepato-Biliary-Pancreatic Surgery minus 84.47%, Internal Medicine minus 75.71%, Cardiology minus 75.53%, Vascular Surgery minus 40.47%). The comparison 2013/2010 presents significant results (down by 40.44% total, Gastroenterology minus 78.21%, Internal Medicine minus 51.72%).
Conclusion Corrective action against inappropriate use of albumin has immediately resulted in a decrease in vials dispensed in all departments.
Hospital pharmaceutical consumption has declined dramatically, with significant savings.
Collaboration with transfusion centre doctors reduced off-label and inappropriate prescriptions: synergy of Pharmacy, Blood Transfusion Centre and departments showed that appropriate pharmacological treatment can also save money.
The steady decline in consumption in years analysed is the result of sustained and careful appropriateness checks even after the introduction of the new model (see comparison 2013/2010), and demonstrates the effectiveness of the measures taken.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

CP-020 RECONCILIATION ERRORS AT HOSPITAL DISCHARGE: EFFECTIVENESS OF A PHARMACIST INTERVENTION
1C García-Molina Sáez, 1E Urbeta Sanz, 1C Caballero Requejo*, 1A Trujillano Ruiz, 1M Onteniente Candela, 1M Antequera Lardín, 1M Madrigal de Torres. 1Hospital General Universitario Reina Sofia, Pharmacy Department, Murcia, Spain; 2Hospital General Universitario Reina Sofia, Department of Surgery, Murcia, Spain
10.1136/ehjpharm-2015-000639.20

Background Medicines reconciliation at discharge is a key strategy to ensure proper drug prescription and the effectiveness and safety of any treatment.
Purpose To analyse the effectiveness of an information technology-based medicines reconciliation intervention to reduce reconciliation errors at discharge.
Material and methods A quasi-experimental interrupted time series study carried out in the cardio-pneumology unit of a general hospital from February to April 2013. The study consisted of three phases: pre-intervention, intervention and post-intervention, each involving 23 days of observations. The intervention consisted of incorporating a pharmacist in the medical team, who included the patient’s pre-admission medicines in an information technology-based application integrated into the electronic clinical history of the patient. The effectiveness was evaluated by a segmented regression analysis of the mean daily proportion of reconciliation errors per patient in the discharge report using the Prais–Winsten method. The types of error identified and their potential seriousness were then analysed, as was the effectiveness of the intervention to reduce the errors considered to be of clinical importance.

Results 321 patients (119, 105 and 97 in each phase, respectively) were included in the study. For the 3966 medicines recorded, 1087 reconciliation errors were identified in 77.9% of the patients. Pharmaceutical intervention led to a gradual reduction in these errors (β1 = −0.42; p = 0.553), especially in the case of those of clinical importance (β3 = −0.54; p = 0.029). When pharmaceutical intervention was withdrawn, the number of errors increased again, both overall (β4 = 29.06; p = 0.003) and in the case of clinically important errors (β4 = 10.8; p = 0.002). Most errors involved omission of medicines (46.7%) or incomplete prescription (43.8%), 35% being considered of clinical importance.

Conclusion The proposed intervention highlighted the high incidence of reconciliation errors at discharge and was effective in reducing both the overall percentage of errors and those considered to be of clinical importance.

REFERENCES AND/OR ACKNOWLEDGEMENTS
We would like to thank the participating patients and physicians who supported our study.

No conflict of interest.
The use of intensive doses of statins after acute myocardial infarction in an emergency room with a clinical pharmacist

RM Damas Fuentes*, H Alonso Ramos, M Pérez León, MA Padrón García, L Oliva Hernandez, R Molero Gómez, Hospital Universitario Dr. Negrín Las Palmas de Gran Canaria, Pharmacy, Las Palmas de Gran Canaria, Spain

10.1136/ejpharm-2015-000639.23

Background The administration of an intensive dose of statins after acute myocardial infarction (AMI) has proved to be superior to conventional doses in reducing morbidity and mortality (IA evidence) but application in clinical practice is variable.

Purpose To find out whether intensive statins doses are being used after AMI and the involvement of an emergency clinical pharmacist in this quality measure.

Material and methods The study was conducted from February to April 2014 in an emergency room with a clinical pharmacist of a tertiary hospital. Patients with AMI were recorded and their discharge reports of hospitalisation and blood tests were reviewed. An Excel sheet with the following items was prepared: Patient sex, age, basal low density lipoproteins (LDL), intensive doses of statins after AMI (YES/NO), pharmaceutical intervention to modify the dose of statins to intensive dose (YES/NO), LDL levels at discharge, type and dose of statin scheduled in the discharge report. The target LDL levels after AMI were lower than 70 mg/dl according to clinical practice guidelines (GPC) of the European society of Cardiology (ESC) 2013.

Results 32 AMIs were recorded. A previous blood test including LDL levels was available in 22 patients, in 95.5% these exceeded 70 mg/dl. 84.4% of the patients received intensive doses of statins in the emergency room, 40.7% prescribed by the physician and 59.3% prescribed after a recommendation by the clinical pharmacist. At hospital discharge all patients except one were prescribed an statin. No patients were discharged with intensive doses.

Conclusion

• The use of intensive statins doses in the emergency room is high but it is necessary to unify criteria at hospital discharge.

• The pharmaceutical recommendation to use intensive doses of statins after AMI implies an increase in compliance with evidence-based recommendations of the GPC.

References


No conflict of interest.
Purpose To investigate the relationship between beliefs (necessity and concern) of HIV-infected patients about comedication and their adherence.

Material and methods We conducted a cross-sectional study between May–July 2014, that included HIV-infected patients treated with antiretroviral treatment (ART) and ≥1 additional drugs for other chronic diseases. The variables analysed in the study were demographics (sex, age), mode of transmission, CD4⁺, HIV plasma viral load, beliefs about comedication and adherence to treatment for chronic conditions.

The Beliefs about Medicines Questionnaires (BMQ) was used to assess patients’ beliefs about drugs for additional diseases. The BMQ-Specific has two scales (necessity and concern) with five questions each that uses a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, 5 = strongly agree). A total score per scale was calculated. Self-reported adherence was measured using the 4-item Morisky Medication Adherence Scale (MMAS). MMAS scores were dichotomised into adherent/non-adherent.

Internal consistency within BMQ scales was measured with Cronbach’s α and their association with adherence was assessed with t-Student tests, using SPSS 20.0.

Results We included 126 patients (80.4% male, mean age 50.4 ± 8.3). Injected drug use was the main mode of transmission. 43.7% of patients presented CD4⁺ ≥ 500 cells/mm³ and 25.4%, detectable viral load. The mean number of additional medicines was 2.9 ± 2.0.

The percentage of non-adherent patients was 54.0%. Belief in necessity was positively related to self-reported adherence. No relationship between adherence and concern was found. Internal consistency for BMQ-Specific was high (Cronbach α = 0.724) which indicates high intercorrelation between items.

Conclusion Greater conviction that comedication is necessary was associated with higher self-reported adherence in HIV infected-patients, suggesting that it could be important to focus on the necessity of this treatment to improve adherence.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-026 EFFICACY OF TRIPLE THERAPY WITH PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS IN CLINICAL PRACTICE

Purpose Given the large number of new drugs for the treatment of hepatitis C virus (HCV) and the high economic cost, it is important to decide which treatment is best suited to each patient.

Material and methods Two-year retrospective study including all patients treated with triple therapy for HCV.

Parameters analysed were: sex, age, HCV genotype, liver fibrosis, type of patient (pretreated/treatment-naive) HIV co-infection and HCV viral load (VL).

The collected data were obtained by reviewing medical records, and Savac prescription and validation program.

Results A total of 26 patients were included, 19 (73%) men. The median age was 52 years. Regarding genotype, 11 (42%) had genotype 1a and 15 (58%) had genotype 1b. Only four (15%) patients had simultaneously HIV infection. The most common liver fibrosis was grade 3.

After finishing the treatment, 23 patients had undetectable viral load (one of the patients presented detectable viral load at week 4 and two of them at week 12). Twenty-four weeks after the treatment, 22 of them had sustained viral response (SVR). In the table we can see the response rates based on the drug and/or patient characteristics.

Abstract CP-026 Table 1

<table>
<thead>
<tr>
<th>Drug</th>
<th>No. of patients</th>
<th>Week 4</th>
<th>Week 12</th>
<th>Week 24</th>
<th>Week 48</th>
<th>SVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>26</td>
<td>96.15%</td>
<td>92.31%</td>
<td>92.31%</td>
<td>88.46%</td>
<td>84.82%</td>
</tr>
<tr>
<td>Telaprevir</td>
<td>19</td>
<td>94.74%</td>
<td>89.47%</td>
<td>89.47%</td>
<td>89.47%</td>
<td>84.21%</td>
</tr>
<tr>
<td>Boceprevir</td>
<td>7</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>Naive</td>
<td>10</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>Previously-Treated</td>
<td>16</td>
<td>83.75%</td>
<td>87.50%</td>
<td>87.50%</td>
<td>87.50%</td>
<td>81.25%</td>
</tr>
<tr>
<td>Relapsers</td>
<td>8</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Partial Response</td>
<td>7</td>
<td>87.50%</td>
<td>75.00%</td>
<td>75.00%</td>
<td>75.00%</td>
<td>62.50%</td>
</tr>
<tr>
<td>Null Responders</td>
<td>1</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Conclusion The triple therapy regimen is a highly effective treatment that gets a SVR in most patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-027 EFFICACY AND SAFETY OF RIBAVIRIN USED FOR RESPIRATORY SYNCYTIAL VIRUS TREATMENT IN HAEMATOLOGICAL PATIENTS

Purpose Ribavirin is a drug used to treat hepatitis, but it is also used (off-label) for the treatment of respiratory syncytial virus (RSV)

Material and methods Retrospective study during the RSV season. Parameters analysed were: sex, age, dose and treatment...
Clinical pharmacy

duration, laboratory confirmation of RSV, haemoglobin, LDH, bilirubin, and the need for transfusions.

The collected data were obtained by reviewing medical records and consulting the Savac prescription and validation program.

Results A total of 9 patients were included, 4 (44%) men. The median age was 49 years (range 13–69). The median number of days of treatment was 14 days (range 7-14) and all tested positive for RSV. The dose for all patients was 200 mg/day on the first two days and 1200 mg/day until the end of treatment. By the end of the treatment, the virus had been eradicated in 100% of patients.

Regarding safety, none of the patients presented symptoms of haemolytic anaemia. Haemoglobin remained constant throughout the treatment, with a median of 88 g/L at baseline and 91 g/L and 86 g/L at 7 and 14 days of treatment, respectively, with LDH constant at 400 IU/L throughout treatment and regular indirect bilirubin levels. Six (67%) of the patients received blood transfusions, but all of them had already received transfusions before ribavirin treatment. None of the patients presented symptoms of haemolytic anaemia, and no adverse effects were detected attributable to ribavirin.

Conclusion Treatment with ribavirin for RSV proved to be an effective treatment in our patients.

From haemoglobin levels remained constant during treatment, and patients required transfusion due to the disease, treatment with ribavirin at this dose appears to be a safe treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-029 ANTI-TNF AGENTS FOR THE TREATMENT OF BEHCET’S DISEASE

S Fernández Cañabate*, L García López, V Cabezas Martín, S Fernández Peña, E Cárdenas García, J Varela González-Alber, C Cárdenas Perez. Hospital Clínico Universitario de Valladolid, Pharmacy, Valladolid, Spain

Background Behçet’s disease (BD) is an inflammatory disease characterised by recurrent oral aphthous ulcers and numerous potential systemic manifestations.

Purpose To describe the experience of our centre with the use of adalimumab, etanercept and infliximab for the treatment of severe clinical manifestations in patients with BD in whom immunosuppressive treatment had failed.

Material and methods Retrospective review of medical records of 36 months (January 2010–December 2013) from patients with BD treated with adalimumab, etanercept or infliximab as compassionate use. Demographic and clinical data included age, sex, previous treatment, indication, side effects, concomitant drugs and clinical outcome.

Results 12 patients were included (5/7 women/men) 3/12 treated with infliximab, 2/12 etanercept, and 7/12 adalimumab; with a mean age of 36 years (range 21–55). We decided to start treatment due to the lack of response in the control of symptoms (3/12 patients had cutaneous lesions), and ocular involvement (9/12 patients with uveitis of repetition and visual deterioration). The patients had received conventional treatment: 4/12 had received two drugs, 4/12 three drugs, 2/12 four drugs, 1/12 five drugs and one had received six drugs previously. The most prescribed drugs were corticosteroids, azathioprine and cyclosporine. 1/12 patient had received previous treatment with infliximab before adalimumab with relapse of symptoms. We did not detect any adverse effects in patients treated. In all patients, clinical improvement was evident from the first administration. 8/12 patients showed reduction of symptoms, while 4/12 patients became asymptomatic. They continue in treatment.

Conclusion Anti-TNF agents are a good option for patients with severe BD who are resistant to steroid and immunosuppressive treatment, with a good safety profile. The benefit of this treatment supports the hypothesis that TNF-a is an important factor in the pathogenesis of BD. Moreover, no adverse effects were detected in the treated patients, in agreement with the few cases described in the literature reviewed.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
At Amgen, biologic medicines are rooted in quality and nurtured by reliability.

Robust quality control and a reliable supply are every bit as important as scientific innovation.

For more than 30 years, Amgen has poured commitment, passion, and a drive for perfection into every medicine we make.

So you can turn to Amgen for the biologic medicines that matter so much to your patients’ treatment... for generations to come.

To learn more about Amgen’s commitment to consistent quality and reliable supply, visit biotechnologybyamgen.com

Amgen (Europe) GmbH, Darn plutensee 23, 6301 Zug, Switzerland
©2013 Amgen Inc. All rights reserved.
When science and passion connect, innovation happens.

Seeing patients as individual human beings with unique needs helps us transform the way people live with cancer. We work with patient groups and healthcare professionals to better understand and address patient needs through innovative programs that improve outcomes and availability of our treatments.

Connect with us today. www.novartisoncology.com

European Journal of Hospital Pharmacy
Keep up-to-date with the latest podcasts, featuring interviews and debates on key topics.

BMJ

ejhpm.com
EFFECTIVENESS OF BIOLOGICAL DRUGS IN RHEUMATOID ARTHRITIS PATIENTS: A COMPARATIVE ANALYSIS

D Fedele*, R Carletti, A Marra, C Crespi, P Scavanacca. Azienda Ospedaliera Universitaria S. Anna, Pharmaceutical Department, Ferrara, Italy

10.1136/ewhpharm-2015-000639.30

Background Today rheumatoid arthritis (RA) treatments are: 1) conventional drugs, such as DMARDs (Disease Modifying Antirheumatic Drugs), glucocorticoids, analgesics and NSAIDs (Nonsteroidal anti-inflammatory drugs); 2) biological drugs which, possibly combined with traditional drugs, are intended to reduce joint damage, disability and functional loss, improving quality of life.

Purpose As the first therapeutic goal is faster disease remission, the aim of this study was to evaluate the effectiveness of biological drugs in RA patients treated from April 2010 to March 2013 in a Rheumatology Unit.

Material and methods Therapeutic effectiveness of 6-month biological treatment periods was evaluated according to EULAR standards, using as therapeutic target the reduction of DAS28 index (tM medium – t0 medium). The results were analysed by “paired Student’s t-test” to determine their statistical significance.

Results In the period of analysis, 99 prescriptions were considered. After six months of treatment with biological drugs, there was a moderate response in 64.6% of the patients by EULAR criteria with etanercept scoring the highest (18.2%, 25). Of the moderate responses, 61% (39) were achieved by a combination of biologicals + DMARDs. In the patients examined an average reduction of distribution of DAS28 from 5.13 at t0 to 3.39 was recorded at t6. Using the “paired Student’s t-test”, the difference between the average DAS28 values before and after the treatment was significant at the p < 0.001 level. As to specific molecules, the most relevant average DAS28 reduction was achieved by tocilizumab (−3.00 ± 1.77) followed by adalimumab (−1.79 ± 1.65), abatacept (−1.62 ± 1.86), etanercept (−1.59 ± 1.25) and rituximab (−0.95 ± 1.34).

Conclusion These results suggest that combination therapy with DMARDs was more effective than monotherapy with biological drugs. Tocilizumab recorded the highest average decrease in comparison to other molecules.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.

STUDY OF DEXAMETHASONE INTRAVITREAL IMPLANTS IN PATIENTS WITH DIABETIC MACULAR OEDEMA

S Fernández Calabarte*, V Cabacas Martín, S Fernández Peña, L García López, E Cárdenas García, J Varela González-Aller, C Cardaba Perez. Hospital Clínico Universitario de Valladolid, Pharmacy, Valladolid, Spain

10.1136/ewhpharm-2015-000639.31

Background Diabetic macular oedema (DME) is the main cause of impairment of visual acuity in diabetic patients. The current standard treatment for patients with DME (focal/grid laser photocoagulation) does not usually improve impaired vision, and many patients continue to lose vision despite laser treatment. Intravitreal drug treatments are important new options for the treatment of diabetic retinopathy. Dexamethasone intravitreal (DI) implants are not approved for the treatment of DME, although traditionally corticosteroids such as triamcinolone have been used intravitreally to decrease the DME.

Purpose To evaluate the safety and tolerability of DI implants and to assess compliance with the protocol for the treatment of DME.

Material and methods Retrospective review of 34 patients with decreased visual acuity, due to refractory DME, who received a single injection of dexamethasone between January 2012 and July 2014.

Our protocol recommended ranibizumab as the drug of first choice for DME and that dexamethasone should be administered to non-responders to ranibizumab or high cardiovascular risk patients (patients with a history of stroke within the last 6 months).

Results 34 patients were included in the study; 5/34 patients started with DI directly while 29/34 patients started with ranibizumab. The reason for the change was therapeutic failure (18/29 patients) and cardiovascular risk (11/29 patients). We did not detect any adverse effects in patients treated. Average transition time was 4 months. 13/34 patients received a single dose, 21/13 patients received two or more doses. The repeat interval was less than 6 months in 12/34 patients (median 3.3 months), longer than 6 months in 22/34 patients.

Conclusion High level of compliance with the protocol. In most patients the recommended interval of 6 months between doses of dexamethasone remains.

There was a tendency to shorten the interval between insertions of DI implants.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

OFF-LABEL USE OF ADAлимUMAB IN BEHÇET’S DISEASE. A CASE REPORT

1MH García Laguna, 1M Gutiérrez Cívicos, 1R Guerrero Bautista, 1E Ferrís Villanueva, 1A García Márquez, 1I Muñoz García, 1M Martínez Penella*, 1D Lacruz Guzmán, 1MS García Álvarez, 1Álvarez Álvarez, 1Hospital General Universitario Santa Lucía, Farmacia Hospitalaria, Cartagena, Spain; 2Hospital General Universitario Santa Lucía, Traducción, Cartagena, Spain

10.1136/ewhpharm-2015-000639.32

Background Behçet’s disease (BD) is a rheumatic disease characterised by polyarthritis, urogenital ulcers, uveitis, cutaneous lesions, alterations in the central nervous system and vascular disease.

Purpose To describe the use of adalimumab in a patient with BD in whom immunosuppressant treatment had failed.

Material and methods Follow-up of a patient with BD treated with adalimumab after trying other treatments without success.

The most common parameters used when monitoring BD are: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Data were collected from the medical history (Selene) and the outpatients dispensing software (Savac).

Results A 43-year-old woman visited the rheumatologist in April 2010 because of polyarthritis and symptoms of inflammatory disease; she had had recurrent episodes of red eye, cutaneous lesions and urogenital ulcers.

She started symptomatic treatment with allopurinol and colchicine because she was suspected of suffering from BD. In June 2011, positive HLA-B51 was determined and methotrexate...
treatment was initiated. Despite the initial improvement, after seven months she had aphthous and cutaneous lesions and corticosteroids were added to the treatment.

In May 2012, she visited the ophthalmologist and she was diagnosed with uveitis and this confirmed the diagnosis of BD. The dose of methotrexate was increased but without results.

Finally, adalimumab was added to the methotrexate (baseline CRP = 0.7 mg/dL and ESR = 65 mm/h). She presented clear improvement (month 1: CRP < 0.4 mg/dL and ESR = 6 mm/h; month 4: CRP = 0.4 mg/dL and ESR = 6 mm/h; month 12: CRP = 0.5 mg/dL and ESR = 11 mm/h). To date, after a follow-up of 21 months, the patient is continuing to have adalimumab, with good clinical control and no side effects.

Conclusion Our patient responded well to the treatment. Although more data are needed, there are previous studies that suggest that adalimumab represents a valid option for patients with BD and severe symptoms.

REFERENCES AND/OR ACKNOWLEDGEMENTS


The support of the entire department has allowed this work.

No conflict of interest.

**CP-033 USE OF INFlixIMAB IN A PREGNANT WOMAN WITH ANKYLosing SPONDylitis**


10.1136/ejhp pharm-2015-000639.33

Background The use of drugs during pregnancy is always controversial. There is limited information about the use of infliximab during pregnancy.

Purpose To describe the effectiveness and safety of infliximab in a patient with ankylosing spondylitis during pregnancy.

Material and methods Retrospective and observational study of a pregnant woman with ankylosing spondylitis who was treated with infliximab.

The data collected was: week of gestation, infliximab dosage and laboratory data: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

Results A 32-year-old woman was diagnosed with ankylosing spondylitis in 2005 and she started treatment with infliximab 5 mg/kg every 8 weeks in 2007. In 2012, she got pregnant and stopped treatment (CRP < 0.3 mg/dL and ESR = 2 mm/h).

Due to this treatment interruption, she started suffering diffuse polyarthritis, soreness and disabling pain. At week 14 of pregnancy, her ankylosing spondylitis flared up with pain in several joints. She was prescribed corticosteroids without success and she asked to resume treatment with infliximab.

The teratogens centre indicated that there was no absolute contraindication. Therefore, the hospital’s Medical Director authorised the off-label use of infliximab in a pregnant woman.

At week 16 of pregnancy, she was treated with infliximab (previous values: CRP = 1.1 mg/dL and ESR = 40 mm/h). After that, she showed a significant improvement (ESR = 9 mm/h).

She was retreated at weeks 23 and 30 of pregnancy (values after the second dosage during pregnancy: CRP = 0.4 mg/dL and ESR = 2 mm/h).

At week 40 of pregnancy, she gave birth without any problems. The newborn weight was 3.420 kg and the APGAR score was 9/10.

She restarted the treatment with infliximab two weeks after birth, the previous values were CRP = 7.4 mg/dL and ESR = 33 mm/h, but they quickly normalised (CRP < 0.4 mg/dL and ESR = 6 mm/h).

Conclusion In our limited clinical experience, infliximab was safe and effective in our patient. However, the use of infliximab during pregnancy should be studied on a case-by-case basis.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.
Background Major bleeding complications with LMWH treatment have been reported both in clinical studies and during post-marketing surveillance. Monitoring of anti-factor Xa activity is recommended in special populations treated with low molecular weight heparins (LMWH).

Purpose To evaluate the effectiveness and safety of LMWH administration as prophylaxis and treatment of venous thromboembolism and acute coronary syndromes in selected patients.

Material and methods Prospective, descriptive study included patients with renal impairment, obese or elderly patients treated with LMWH over five months (January–May 2014). Study variables collected: sex, age, indication and doses of enoxaparin, anti-factor Xa, creatinine and platelets. The data were obtained from clinical records and prescriptions.

Results Anti-factor Xa was studied in 62 patients, 39 men (63%) and 23 women (37%) with a mean age of 67 years (32–90). 40% of patients had renal failure, 45% obesity and 15% were elderly patients.

The treatment dose of LMWH is 1 mg/kg/12 h (including for obese patients) but in renal impairment 1 mg/kg/24 h is recommended and in elderly patients, 1.5 mg/kg/24 h. 58 patients (93.5%) received therapeutic doses. There were 34.5% low doses, 51.7% correct doses and 13.8% high doses, and the average age of anti-factor Xa was 0.3 IU/ml, 0.74 IU/ml and 1.5 IU/ml respectively.

The prophylactic dose is 40 mg/24 h but in renal impairment 20 mg/24 h is recommended and in obese patients, 60 mg/24 h. 4 patients (6.5%) received prophylactic doses. There were 25% low doses and 75% correct doses, and the average of anti-factor Xa was 0.6 IU/ml and 0.26 IU/ml, respectively. Our pharmaceutical interventions were to increase or reduce and repeat the control. All our recommendations were approved.

Regarding safety, there were six thrombocytopenic (9.7%) patients and no bleeding.

Conclusion Anticoagulation monitoring optimises the effectiveness in patients with special requirements, such as patients with renal failure, obesity and elderly patients. 60% of prescriptions were for low doses, therefore the Pharmacy Service proposed making a protocol for coagulation.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 Br J Clin Pharmacol 2007;64:428–3

No conflict of interest.

CP-036 DRUG INTERACTIONS INVOLVING ANTIBIOTICS: DO THEY CARE?
D Briegas Morera*, C Borilla Galán, L Menees Mangas, LM Bravo García-Cuevas, S Martín Clavo, JF Rangel Mayoral, R Medina Comas, L Romero Soria. Hospital Infantil Cristina, Hospital Pharmacy Service, Badajoz, Spain

Background Drugs interact when the effect of a drug is modified by another co-administered drug, food or herb. According to a number of studies, almost half the prescriptions are accompanied by interactions (8–43%, depending on the ward), but few (12–25%) are clinically relevant. Antibiotics are a wide group of drugs used a great deal in our environment (in 49.8% of patients), and are associated with important interactions. Pharmacists help doctors to manage them by writing an intervention on the patient history, after evaluating patient clinical status.

Purpose To describe quantitative and qualitative antibiotic-drug interactions among our patients, assessing their expected clinical impact and intervening if they are relevant; to see how doctors modify prescriptions.

Material and methods We searched interactions involving antibiotics in all available prescriptions of every ward at the time of screening. We used Medscape app as screening tool, adopting their rating system (minor, significant, serious or contraindicated), considering intervention only in the relevant ones. SPSS20 was used for data coding and statistical processing. To improve intervention quality, additional data were reviewed in trusted sources like Stockley or Lex Interact.

Results Antibiotics were found in 156 prescriptions, mostly penicillins (45 prescriptions), quinolones (35) and carbapenems (34). A total of 1,415 interactions were detected (average per patient 9.07 ± 9.39), only 271 (19.2%) involving antibiotics. Among those, 76 minor, 116 significant, 78 serious and one contraindicated interaction were found. We intervened in only 16 cases (mostly about nephro/ototoxicity, serotonergic syndrome involving linezolid and monoamine-oxidase inhibitors, and proarrhythmic combinations). Only four prescriptions were modified after the interaction had been reported.

Conclusion Antibiotics play an important role in interactions; despite this few are dangerous, and must be filtered before choosing to intervene. Despite their relevance, doctors seem to underestimate the associated risks, ignoring the advice given. To improve their knowledge and respect for this topic, our Service will soon be teaching a course for healthcare professionals.

REFERENCES AND/OR ACKNOWLEDGEMENTS
(NONE)

No conflict of interest.

CP-037 EFFICACY OF ABIRATERONE IN THE TREATMENT OF PROSTATE CANCER
D Blanquez Martinez, A Caballero Romero, MDC Gonzalez Medina*, R Moro Romero, C Gómez Peña, C García Fernández, S Ruiz Fuentes, M Valle Corpas, I Casas Hidalgo. Hospital Universitario San Cecilio, Farmacia Hospitalaria, Granada, Spain

Background Hormone treatment based on analogues of gonadotropin releasing hormone (GnRH) with antidirogens is the first-line treatment for prostate cancer. This treatment produces a PSA reduction, improvement of symptoms and tumour regression. When PSA increases again it is considered to have developed resistance and other treatment lines such as abiraterone are used.

Abiraterone is an androgen synthesis inhibitor in the testes, adrenals and prostate tumour tissue.

Purpose To analyse the response to, and safety of, abiraterone in the population of a tertiary level hospital.
Material and methods A retrospective observational study was carried out including all patients who started on abiraterone from 2011 to present. Demographical, diagnostic, therapeutic and clinical variables were gathered.

The response was assessed by a 50% PSA reduction or more as compared to baseline values. To assess the safety, abiraterone-related adverse events were recorded.

Outpatient dispensing application Farmatools and electronic medical records were used for patient identification and data collection.

Results 18 patients were included, 89% diagnosed with metastatic prostate cancer. 50% had poor tumor differentiation with high aggressiveness (Gleason 7–10).

As a first-line of treatment, 83% received GnRH analogues plus an antiandrogen, 11% GnRH analogues alone and 6% ketoconazole. No patients orchitectomized. As a second-line treatment, 28% received docetaxel, 44% estramustine, 22% abiraterone and 6% ketoconazole. Abiraterone was started as third-line or later treatment and after tumor progression, except in 3 patients who received it as second-line treatment. 44% were considered responders and 56% non-responders because of an increase or non-reduction of PSA.

The median duration of treatment was 5 months (1–25). In all cases, the reason for suspension was disease progression. 17% had fatigue as the only adverse effect.

Conclusion Abiraterone is a well-tolerated drug that has shown low activity in previously-treated prostate cancer patients who had responded poorly to ketoconazole, docetaxel and estramustine.

Best responding patients were those who received only GnRH analogues as pre-treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

CP-039 PRESCRIPTION PROFILE AND IMPACT AFTER THE PEGYLATED LIPOSOMAL DOXORUBICIN SHORTAGE ALERT
A Madrid Parede*, I Vallejo, M Carrasco, C Valencia, F Antimé, M Calleja. Virgen de Las Nieves University Hospital, Pharmacy, Granada, Spain 10.1136/ehjpharm-2015-000639.39

Background The normal supply of Caelyx was interrupted worldwide in December 2011. Because of the limited number of vials available, medicines agencies established a plan to control the distribution and use, restricting it only to patients with advanced ovarian cancer on second-line treatment and Kaposi's sarcoma associated with AIDS.

Purpose To assess the Caelyx prescription profile and how the alert has affected the off-label use of this drug.

Material and methods A retrospective observational study was performed of Caelyx prescriptions. Data were collected from the oncologic electronic prescription program by reviewing the patients' medical history. We set break points for data collection when the shortage and the re-establishment of the supply alerts were published (December 2011 and October 2012, respectively). Variables included: total of patients, diagnosis, off-label uses and the number of treatments initiated before and after the alerts were published.

Results Forty-nine patients have been treated with Caelyx since the shortage alert publication until the re-establishment of the supply. Variables included: total of patients, diagnosis, off-label uses and the number of treatments initiated before and after the alerts were published.

CP-038 ADEQUACY OF NUTRITION ENERGY DELIVERY IN SURGICAL INTENSIVE CARE
1C Jolly*, 1F Raffy, 2G Audibert, 2J Perrier, 2D Quillot. 1Chu Nancy, Pharmacy, Nancy, France; 2Chu Nancy, Surgical Intensive Care Unit, Nancy, France; 3Chu Nancy, Nutrition Unit, Nancy, France

10.1136/ehjpharm-2015-000639.38

Background Underfeeding is correlated with a higher morbidity rate, mortality and length of stay. Measuring and managing nutritional risk are therefore important tasks.

Purpose Evaluation of nutrition adequacy energy delivery in surgical intensive care unit (ICU), compliant with European recommendations.

Material and methods Prospective study, of one month, in 3 surgical ICU with daily analysis of all nutritional supports. Were taken into account oral alimentation and enrichment, enteral and parenteral nutrition, micronutrients and electrolytes supplies, energy delivery data and adequacy of nutritional support, duration, indication, weight loss. Energy targets were set at 15 kcal/kg/day for Day 3 (D3) and 20 kcal/kg/day for D7. Kruskal Wallis and Fischer tests were used for values of p < 0.05 considered significant ones.

Results Sixty six patients: mean age 57.9 ± 17.3 years and mean BMI 26.9 ± 5.2 kg/m². Mean of length of stay was 10.1 ± 5.3 days (p > 0.05). Nutrition was initiated with parenteral nutrition for 39.4% patients versus 37.9% with enteral nutrition versus 22.7% with oral nutrition (p < 0.01). Time to feeding was 2.2 ± 1.1 days (p > 0.05). Energy target was reached at D3 for 53% patients vs 62% at D7 (p > 0.05). Time needed to achieve the target rate was 5.3 ± 2.9 days (p > 0.05). Energy delivery was lower than the energy target during the first 3 days (p < 0.001). Difference between energy target and delivery decreased from −19.7 kcal/kg/day as a mean during the first day, to a mean of −3.3 kcal/kg/day at D7. Proportion of energy target provided by the enteral, parenteral or oral route was not significantly different from D1 to D7 (p > 0.05). Cumulated energy balance was 5023 ± 38.9 kcal/kg/day. At the last day, protein intake was <1.2 g/kg/day for 32% of patients receiving parenteral nutrition vs. 38.5% receiving enteral nutrition (p < 0.05).

Conclusion One can reach the caloric target at D3 and D7 and provide a better balance between enteral and parental nutrition as defined by European recommendations.
Excluding the stock-out period, the number of patients whose treatments were initiated before and after the re-establishment of the supply was reduced by 66%.

Conclusion The shortage of Caelyx has changed the prescription profile. Currently, less Caelyx is being prescribed and the clinical practice is more consistent with the Summary of Product Characteristics.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

---

**CP-040**

**SWITCHING TO TENOFOVIR/EMTRICITABINE/RILPIVIRINE IN HIV-1 PATIENTS PREVIOUSLY TREATED WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ**

J González Chávez*, M Del Barrio Aranda, A Linares Alarcón, R Tamayo Bermejo, M Gajardo Álvarez. Hospital Regional Universitario de Málaga, Pharmacy, Málaga, Spain
10.1136/ehjpharm-2015-000639.40

**Background** The new combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) produces fewer adverse central nervous system effects, encouraging better adherence while being as effective as the tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) combination.

**Purpose** To analyse the progress of patients with HIV-1 infection who changed treatment from TDF/FTC/EFV to TDF/FTC/RPV. To evaluate the maintenance of viral suppression and the adherence.

**Material and methods** Retrospective observational study. Study duration: 1 year. Patients were switched to treatment with TDF/FTC/RPV. We excluded patients who had not been treated previously with TDF/FTC/EFV and treatment-naive patients. We developed a database with viral load (VL) and CD4 T lymphocyte level (LTCD4) before switching and after 6 months of treatment. We also considered the adherence to the new antiretroviral by number and date of prescriptions dispensed.

**Results** In the study period, 149 patients were treated with TDF/FTC/RPV. Of these, 50.3% (75) had previously been treated with TDF/FTC/EFV. The remaining patients were excluded for not meeting the study criteria. 94.7% (71) of the patients maintained virological suppression to less than 37 copies/ml. Three patients with 523, 400, 64.04 and 48.58 copies/ml, respectively, were able to achieve a VL of fewer than 37 copies/ml after 6 months treatment with TDF/FTC/RPV. The LTCD4 level increased or remained at figures close to those already obtained from previous treatment in all patients. All patients maintained their adherence due to continuing with a single tablet daily, having a better side effect profile.

**Conclusion** In patients with HIV infection, change of treatment from TDF/FTC/EFV to TDF/FTC/RPV proved effective, and maintained or decreased the levels of VL. The results obtained in this study are similar to Nelson et al.’s study, which concludes that we must identify patients with adverse effects to EFV so they can benefit from TDF/FTC/RPV.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

---

**CP-041**

**ONE-STOP DISPENSING: EXPERIENCES REPORTED BY PHYSICIANS AND NURSING STAFF AT AN ORTHOPAEDIC WARD**

1M Gemmer*, 1M Andersen, 2S Skyfog Olsen, 2K Kirketerp-Møller, 1H McNulty. 1The Capital Region Pharmacy, Hvidovre, Copenhagen, Denmark; 2Department of Orthopaedic Surgery, Hvidovre, Copenhagen, Denmark; 3The Capital Region Pharmacy, Herlev, Copenhagen, Denmark
10.1136/ehjpharm-2015-000639.41

**Background** The healthcare sector is constantly being challenged to achieve the best health and value for money. Dispensing and administration of medicines are time consuming processes for the nursing staff. The patient role is changing to include further patient involvement and empowerment.

**Purpose** To evaluate the senior doctors’ and nursing staff’s experiences with the OSD system.

**Material and methods** The pilot OSD project ran from April to December 2013. Before inclusion, a nurse or senior doctor assessed whether individual patients were suitable for self-administration (OSD-II) according to the criteria set by the regional medicine guidelines. The medicine was placed in a bedside locker, after a pharmacist had recorded a medicines history and checked the quality of the patient’s own medicines. Two sets of focus group interviews; one with 3 senior doctors and one with 6 nursing staff were conducted by the Centre for Patient Experience and Evaluation. The interviews were recorded, transcribed and analysed by condensations of meanings in two categories: positive and negative experiences with the OSD system.

**Results** Physicians (n = 3) as well as nursing staff (n = 6) reported that the OSD system had improved the quality of patient-specific medicines management. The nursing staff all stated that the model did save time. The physicians all stated that the interdisciplinary collaboration with the Hospital Pharmacy was valuable. A challenge with the OSD system included documentation of “as needed” medicines (n = 9). Another challenge related to patients not able to administer their medicines at the bedside. The dispensing process was reported as time consuming and technically challenging (n = 6).

**Conclusion** Physicians and nursing staff reported positive experiences with the OSD-system, but some challenges have to be addressed, before the OSD system can work well for all patients.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**
No conflict of interest.

---

**CP-042**

**ASSESSMENT OF INCIDENCE AND MANAGEMENT OF HAEMATOLOGIC TOXICITY IN AMBULATORY GASTROINTESTINAL CANCER PATIENTS**

1M Dobravc Vertač*, 2K Homec, 3A Mihar. 1University Medical Centre Ljubljana, Pharmacy, Ljubljana, Slovenia; 2Faculty of Pharmacy – University of Ljubljana, The Chair of Biopharmaceutics and Pharmacokinetics, Ljubljana, Slovenia
10.1136/ehjpharm-2015-000639.42

**Background** Haematological toxicity (HT) is a well-known side effect of chemotherapy. Neutropenia and thrombocytopenia are common reasons for dose reductions and treatment delays in chemotherapy treatment. Correct management of chemotherapy-induced HT is essential to achieve optimal treatment outcomes.
Clinical pharmacy

Purpose To assess the incidence and review the management of HT in ambulatory patients with gastrointestinal cancer receiving intravenous chemotherapy.

Material and methods Haematological parameters which had been measured before the application of chemotherapy were retrospectively collected for 121 patients treated in 2012. In patients with HT (defined as leukaopenia, neutropenia, thrombocytopenia or anaemia) dose reductions and treatment delays were reviewed and compared to available international guidelines for the management of HT.

Results HT occurred in 73 (60.3%) patients. 41 (33.9%) patients presented with leukaopenia, 33 (27.3%) with neutropenia, 25 (20.6%) with thrombocytopenia and 52 (42.9%) with anaemia. According to international guidelines, treatment adjustments were required in 24 patients (19.8%) and altogether in 64 chemotherapy cycles. Dose reductions were required in 18/64 (28.1%) cycles, and treatment delays in 58/64 (90.6%) cycles. Actual dose reductions were lower than stated in the guidelines in 7 (38.9%) cycles; treatment dates were not rescheduled in 21 (36.2%) out of 58 cycles in which treatment delays were required. Overall, treatment adjustments were not suitable in 9/24 (37.5%) patients. Higher dose reductions or longer treatment delays than stated in the guidelines were not considered inappropriate, since these may have occurred due to other conditions, not related to HT.

Conclusion Incidence of thrombocytopenia and anaemia in gastrointestinal cancer patients was comparable, while incidence of neutropenia was lower than in similar previous studies. The high number of incorrectly adjusted treatments demonstrated the necessity for a clinical pharmacist to review chemotherapy prescriptions together with laboratory parameters and to create hospital guidelines for the management of HT.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-043 IMPLEMENTATION OF EXTENDED TOP-UP SERVICE INCREASED CORRECT RECORDING IN THE ELECTRONIC MEDICATION MODULE

T Vaever*, M Kragelund, Region North Hospital Pharmacy, Clinical Pharmacy, Aalborg, Denmark

10.1136/ehjpharm-2015-000639.43

Background Patient safety is compromised when incorrect data are recorded in the electronic medication module (EMM). To ensure increased consistency between the medicines consumed by the patient with the medicines prescribed in the EMM, the hospital pharmacy scaled up the top-up service from a logistical and cytogenetic response and major molecular response (CHR, CCR, MMR) in patients who continued with imatinib at the time of the data compilation.

Data was compiled through the electronic prescription programme and medical records.

Results We analysed 48 patients. 45.8% (n = 22) were male, with a mean age of 58.7 (9–82). Mean time since diagnosis was 8.2 years (3–13).

31 patients continued with imatinib when data were collected. The 17 remaining changed to 2G–TKIs (10 to nilotinib, 7 to dasatinib). Reasons for termination were: intolerance (n = 9); failure and intolerance (n = 5), loss of response (n = 1), and inclusion in a clinical trial (n = 2).

Notifications ADRs in our 48 patients were: skin rash-pruritus (4), musculoskeletal pain-myalgia (8), oedema (11, 8 palpebral), gastrointestinal problems (3), haematological reactions (2), other (5).

CP-044 EFFECTIVENESS AND SAFETY OF IMATINIB IN CHRONIC MYELOID LEUKAEMIA IN A TERTIARY HOSPITAL

CM Valencia Soto*, R Lopez-Sepulveda, C Alarcon-Payer, J Pérez-Morales, M Carrasco-Gomariz, MA Calleja-Hernández, Hospital Universitario Virgen de Las Nieves, Farmacia, Granada, Spain

10.1136/ehjpharm-2015-000639.44

Background Imatinib was the first BCR-ABL tyrosine kinase inhibitor (TKI) available for chronic myeloid leukaemia (CML) treatment. Newer drugs, with a faster and better response, were subsequently developed.

Purpose To analyse the effectiveness and safety of imatinib in CML patients.

Material and methods Retrospective, observational study. Patients who picked up imatinib in our hospital (June 2011–June 2014), including those who were subsequently changed to second generation (2G–TKI), were included.

Variables included demographics (sex, age) and clinical data (time since diagnosis, reason for termination, 2G–TKI received). Adverse drug reactions (ADRs) were compiled in relation to safety.

In terms of effectiveness, we considered complete haematological and cytogenetic response and major molecular response (CHR, CCR, MMR) in patients who continued with imatinib at the time of the data compilation.

The authors would like to thank the participating wards from Aalborg University Hospital and The Danish Research Unit for Hospital Pharmacy, Amgros I/S, Copenhagen, Denmark for scientific guidance.

No conflict of interest.
Effectiveness in patients who continued with imatinib was: 27 patients presented CHR, CCR, MMR; 1 had just died, 3 had no data available.

Conclusion

- A considerable proportion of our patients continue with imatinib, and currently present a MMR.
- The main reason for termination was intolerance.
- All the notified ADRs were included as frequent or very frequent in the Summary of Product Characteristics.

Even with the development of newer drugs, imatinib demonstrated a good profile among our patients and continues to be a good alternative for CML treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

**Clinical pharmacy**

**CP-046**

**HYPERSENSITIVITY REACTIONS TO CHEMOTHERAPY: SO... WHAT DO WE DO NOW?**

1O Briegas Morera*, 1J Santos Hurtado, 1R Pérez Calderón, 1LM Bravo García-Cuevas, 1C Bonilla Galán, 3C Meneses Mangas, 1L Romero Sonia, 3S Martín Clavo, 1R Rangel Mayoral. 1Hospital Infanta Cristina, Hospital Pharmacy Service, Badajoz, Spain; 2Hospital Infanta Cristina, Drug Allergy Service, Badajoz, Spain

10.1136/ehjpharm-2015-000639.46

Background Despite using steroid premedication before administering potentially highly allergic chemotherapy (taxanes, platinum drugs, biological macromolecules, etc.), some patients get sensitised during the first cycles and tend to develop hypersensitivity reactions. This leads to early treatment interruption, which could be critical for the patient’s outcome. Once identified, the allergen may be re-administered under a desensitisation protocol, inducing a tolerance state in which the patient doesn’t react again. During each session, the whole dose is administered starting at a very low infusion rate, which is periodically increased until the regular rate is achieved. Patients with a positive skin test, severe reaction despite negative test, and those who react again during controlled administration are candidates for desensitisation.

Purpose To describe the management and outcomes of patients who reacted to chemotherapy, and how oncologists changed their prescriptions to available options.

Material and methods We carried out a retrospective study (period 2011–2014), obtaining data from patients’ clinical histories and chemotherapy records. SPSS20 was used for data coding and statistical processing.

Results Sixteen patients (81.2% female, average 62.9 ± 7.3 years, diagnosed with ovarian cancer) experienced mild (9), moderate (3) or severe (4) hypersensitivity reactions to chemotherapy (68.8% platinum drugs). Five patients had a positive skin test; only three were enrolled on desensitisation programmes, the remaining two switched treatment line. Two patients had a severe reaction but a negative test, one of them was enrolled and the other switched treatment. The remaining nine (negative test, mild-moderate reaction) didn’t experience a second reaction during controlled infusions, so they kept the same treatment; just one reacted and was proposed for the programme. Four desensitisations were carried without incident, the remaining one had to be stopped due to a reaction when the infusion reached the top rate during the first session.

Conclusion Desensitisation, provided by Drug Allergy and Hospital Pharmacy departments, allows standard treatment lines to be continued, modifying oncologists’ decisions and improving patient outcomes.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

**CP-047**

**PHARMACIST’S CONTRIBUTION TO THE OPTIMISATION OF DRUG THERAPY IN ONCOLOGY INPATIENTS**

JR Ruiz-Gutiérrez*, V Alonso-Castro, B Escudero-Vilaplana, A Martín-Alonso, A Sánchez-Guerrero, Hospital Universitario Puerta de Hierro Majadahonda, Pharmacy, Majadahonda, Spain

10.1136/ehjpharm-2015-000639.47

Background Numerous studies have shown that the presence of a pharmacist on hospital rounds as a full member of the patient care team prevents drug errors.
Purpose To analyse pharmaceutical interventions made by a fourth-year pharmacy resident to optimise drug treatment in oncology inpatients, as well as the acceptance rate of recommendations.

Material and methods 2-month prospective observational study, conducted during the rotation of a fourth-year pharmacy resident in the Oncology ward. In order to perform the patient daily follow-up, the following pharmaceutical care was carried out: 1) participation in medical rounds; 2) review of medical records and analytical data; 3) prescription validation; 4) medicines reconciliation upon admission and discharge; 5) discharge medication information. Pharmaceutical interventions and their acceptance by the medical team were recorded.

Results An average of 16 patients were followed up every day. 85 interventions were recorded, classified into: different dose/frequency (29.4%), omission (14.1%), medicines reconciliation (10.6%), prescription clarification (5.9%), antibiotic duration (3.5%), duplicate treatment (2.4%), pharmacological interactions (2.4%), dose adjustment due to renal impairment (2.4%), discharge medication information (2.4%) and other (11.8%). 82.4% of recommendations were accepted by the medical team.

Conclusion The presence of a pharmacist on the ward contributed to close monitoring of the drug treatment in oncology inpatients. Thanks to this daily follow-up multiple pharmaceutical interventions were made, mainly related to change in dose or frequency, which had a high acceptance rate by the medical team. This shows the need and importance of the integration of pharmacists in the medical team, to improve the quality and safety of the drug treatment provided to oncology inpatients.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-048 ANALYSIS OF THE AMBULATORY USE OF BOTULINUM TOXIN TYPE A IN A TERTIARY HOSPITAL: AUTHORISED AND OFF-LABEL INDICATIONS

MA Fernandez de Palencia Espinosa*, V Arocas Casal, MJ Sánchez Garre, L Menéndez - Naranjo, MM Galindo Rueda, S Vicente Sánchez, A De la Rubia Nieto. University Hospital Virgen de La Arrixaca, Pharmacy, Murcia, Spain

Background In Spain, the authorised indications for botulinum toxin type A (BTTA, Botox) are:

- Neurological diseases: focal spasticity (foot, wrist and hand, ankle), blepharospasm, hemifacial spasm and associated focal dystonias, cervical dystonia and chronic migrain in adults.
- Bladder disorders: urinary incontinence in adults with neurogenic detrusor overactivity or idiopathic overactive bladder.
- Skin disorders: Severe primary axillary hyperhidrosis.

Purpose To analyse the ambulatory use of BTTA in our hospital for one year.

Material and methods A retrospective descriptive analysis of all patients treated with BTTA from May 2013 to April 2014 was carried out. Records from the hospital’s electronic prescribing software (Silicon software) were reviewed and the following data were collected: number of patients and prescriptions dispensed, indications and clinical department.

Results A total of 431 patients were treated with BTTA, counting 611 prescriptions dispensed. Two patients received 4 doses, 18 patients 3 doses, 138 patients 2 doses and 273 patients one dose.

The distribution of administrations by clinical department and indication was:

- Pain Unit: focal spasticity (5), hemifacial spasm (1), off-label: different pains in back, neck and extremities (5)
- Maxillofacial Surgery: hemifacial spasm and associated focal dystonias or disorders in the facial nerve (27)
- Ophthalmology: blepharospasm (2) and off-label: strabismus or esotropia (33)
- General surgery: off-label: anal fissure (8)
- Plastic Surgery: hemifacial spasm and associated focal dystonias (12)
- Dermatology: hyperhidrosis (41)
- Neurophysiology: off-label: idiopathic peripheral neuropathy (1) and paralysis of vocal cords (3)
- Neurology: blepharospasm (32), cervical dystonia (48), hemifacial spasm (23), focal spasticity (64), hyperhidrosis (10), migraine (7)
- Otolaryngology: off-label: sialorrhea (10) and oropharynx malignant neoplasm (2)
- Urology: urinary incontinence (57)
- Rehabilitation: cervical dystonia (1), hemifacial spasm (1), focal spasticity (247), off-label: complication of amputation stump (1)

Conclusion In our hospital, BTTA is mainly used in authorised conditions. Neurology and Rehabilitation call on BTTA most frequently. General Surgery, Ophthalmology and Otolaryngology respond to off-label conditions in most of their patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-049 CLINICAL RELEVANCE OF RECONCILIATION ERRORS AT ADMISSION FROM EMERGENCY DEPARTMENT AVOIDED BY THE CLINICAL PHARMACIST

C Caballero Requejo*, E Urbeta Sanz, M Onteniente Candela, C García-Molina Sáez, A Trajillano Ruiz, L Rentero Redondo, MT Antequera Lardón. Hospital General Universitario Reina Sofía, Pharmacy Department, Murcia, Spain

Background Medicines reconciliation in the emergency department (ED) is essential to optimising the safe and effective use of medicines.

Purpose To analyse reconciliation errors avoided by the ED pharmacist and to assess the severity and clinical relevance.

Material and methods The study was conducted between November 2013 and June 2014 in a general hospital of 330 beds. A pharmacist attended the daily ED meeting, selecting patients at higher risk of medicines error. The pharmacist wrote the home medicines history using primary care electronic records and interviews with the patient/caregiver, and compared it with the prescription in the ED. Medicines reconciliation was carried out with the emergency physician. Any unjustified discrepancy was considered a reconciliation error (RE). REs were classified according to the Consensus Statement of the Spanish Society of Hospital Pharmacy (SEFH). The severity of REs were estimated using the categorization of The National Coordinating Council for Medicines Error Reporting and Prevention, considering
pharmacist intervention clinically relevant if it avoided potential patient harm.

**Results**

132 patients were included. 51% were female and the mean age was 75.8 ± 9.4 years. The average number of drugs per patient was 11.4 ± 4.2. 239 REs were found affecting 89 patients (67.4%), the average error per patient was 1.8 ± 2. Types of RE were omission (71.1%), different route, dose or regimen (14.6%), incomplete prescription (8.8%), different drug (3.8%), and interaction (1.7%). The severity of the RE was: 14.2% reached the patient without causing harm (C), 35.2% reached the patient and required intervention/monitoring (D), 33.9% would have caused temporary harm (E) and 16.7% harm that would have prolonged hospitalisation (F). 85.9% of interventions on clinically relevant REs (category E–F) were accepted, thus avoiding potential patient harm to 61.8% of patients with reconciliation errors.

**Conclusion**

The high proportion of patients in which the ED pharmacist intervention prevented a potential harm highlights the importance of his role in the reconciliation process.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Thanks to the Emergency Department.

No conflict of interest.
THE PREVALENCE OF CLOSTRIDIUM DIFFICILE AND USE OF THE ANTIBIOTIC CLINDAMYCIN

CP-052

1 Antolovic-Amidzic*, 2 Vukovic, 3 Stiblik-Stipesivic, 1 Clinical Hospital Osijek, Osijek, Croatia; 2 Clinical Hospital Center Osijek, Microbiology, Osijek, Croatia; 3 Clinical Hospital Osijek, Pharmacy, Osijek, Croatia

Purpose To demonstrate that restricting the use of clindamycin reduces the number of isolates of C. difficile in KBCO and thus reduces the cost of treatment.

Material and methods The antibiotic clindamycin was placed on the list of reserve antibiotics in November 2013, which means that it can be issued from hospital pharmacy only with the approval of the Nosocomial Infections Committee. We analysed the number of cases of C. difficile positively identified by the KBCO Microbiological Laboratory from January 1st to September 30th 2013 and January 1st to September 30th 2014. In parallel, we analysed data on consumption of clindamycin obtained from BIS3000 electronic records in the Hospital pharmacy.

Results The number of positive isolates of C. difficile in the period January 1st to September 30th 2013 was 454, while in the period from January 1st to September 30th 2014 that number was 171. Consumption of the antibiotic clindamycin from January 1st to September 30th 2013 amounted to a total of 8,359 DDD, costing HRK 335,442 (£1 = HRK 7.5), while in the period from January 1st to September 30th 2014 the cost was 4,153 DDD, HRK 118,628.

Conclusion Restrictions in the use of clindamycin resulted in consumption falling by 50% and costs decreased by 65%. The number of positive cases of C. difficile was reduced by 62%.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

IDENTIFICATION OF A NATIONAL PORTFOLIO OF UNLICENSED PHARMACEUTICAL PREPARATIONS IN DENMARK

CP-053

1 CT Villesen*, 2 JAM Schmidt, 3 Jensen, 4 Herkell, 5 Iversen, 6 Andersen, 5 Nørregaard, 6 Esner, 7 Hospital Pharmacy – The North Region of Denmark; Clinical Pharmacy, Aalborg, Denmark; 8 Hospital Pharmacy – Central Denmark Region, Skejby, Aarhus C, Denmark; 9 Hospital Pharmacy – The Capital Region of Denmark, Drug Information, Copenhagen NV, Denmark; 10 Hospital Pharmacy Region Zealand, Logistics and Clinical Pharmacy, Roskilde, Denmark; 11 Hospital Pharmacy Region of Southern Denmark, Clinical Pharmacy, Odense C, Denmark; 12 Hospital Pharmacy Region of Southern Denmark, Clinical Pharmacy Svendborg, 5700 Svendborg, Denmark; 13 Amgros V5, Amgros V5, Copenhagen Ø, Denmark

Background In Denmark, hospital pharmacies manufacture as well as buy unlicensed pharmaceutical preparations prescribed by physicians. Each Danish hospital pharmacy is responsible for manufacturing and supplying preparations within their own Region; however cross-Regional coordination is limited. This has resulted in a vast portfolio of unlicensed pharmaceutical preparations with possibly many duplications and similar preparations and with different or unknown clinical use, even though the clinical needs are similar throughout the country.

Purpose To identify a common national portfolio corresponding to clinical need by analysing and categorising the use of unlicensed pharmaceutical preparations from all Danish hospital pharmacies.

Material and methods The study was a retrospective analysis of sales data from 2012 and 2013, which were collected from the electronic system of all Danish hospital pharmacies.

The total sales data were analysed by 6 clinical pharmacists representing all major hospital pharmacies. The process was facilitated by a project manager.

The clinical pharmacists categorised the existing portfolio according to preparation, formulation and indication. They identified identical preparations, alternatives and estimated the overall clinical relevance. The pharmacists consulted colleagues, physicians and guidelines to ensure broad and accepted categorization.

Results A total of 2,754 unlicensed pharmaceutical preparations were identified in the existing portfolio. Of these, 739 preparations were considered to be of clinical relevance and should be included in the updated national portfolio of unlicensed pharmaceutical preparations.

Indications were allocated to all 739 preparations.

Conclusion A national portfolio of extemporaneous pharmaceutical preparations with corresponding indications was identified. The portfolio helps secure a unified content and use of unlicensed pharmaceutical preparations across Denmark, which potentially could lead to increased patient safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 MartinHej, Emendo A/S

No conflict of interest.

OFF-LABEL USE OF EMTRICITABINE/RILPIVIRINE/TENOFOVIR

CP-054

R Castaño*, V Torres, C García, C Corder, S Chavernas, D Amar, E Torres. University Hospital of Ceuta, Pharmacy, Ceuta, Spain

Background Emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) was initially approved for the treatment of human immunodeficiency virus type 1 in treatment-naive adult patients with a viral load ≤ 100,000 copies/mL.

Purpose To evaluate the effectiveness and safety of off-label use of FTC/RPV/TDF after this drug was included in our hospital’s formulary.

Material and methods This retrospective observational study included all patients for whom FTC/RPV/TDF was dispensed from our university hospital’s pharmacy department from October 2013 to March 2014. We collected the following information from medical records: age, sex, drug history, prior antiretroviral treatment, reasons for treatment change, viral load, CD4 count and atherogenic index at the start and end of the study period, adherence, side effects and reasons for discontinuing treatment.

Results We included 19 consecutive patients (14 men and 5 women; mean age, 44.7 years). All patients were treatment-experienced; 78% had previously been treated with efavirenz/
emtricitabine/tenofovir. The most frequent reasons for changing antiretroviral treatment were hyperlipidaemia (38.8%) and interaction with methadone (22%). The viral load was <50 copies/mL in 10 patients. The mean CD4 count was 634.6/mm³ at baseline and 596.4/mm³ at study end (normal range: 450–1400/mm³).

The mean atherogenic index, recorded in 16 patients, was 4.5 (normal range: 0–5) at both the beginning and end of the study. No side effects were documented. Two patients discontinued treatment for reasons unrelated to the antiretroviral (pregnancy and death). We detected no non-adherence to the treatment.

**Conclusion** In our centre, changing treatment to FTC/RPV/TDF is mostly due to side effects and interactions in the previous treatment. Although our preliminary data preclude definitive conclusions, FTC/RPV/TDF seems safe and effective.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

---

**Clinical pharmacy**

**Conclusion** In almost half of the patients included in the study the VTE prophylaxis prescriptions did not agree with the PRETEMPED guide recommendations and most of them were related to treatment omission. Pharmacists improved patients’ treatment by working with the assistants’ team in making interventions that were mostly accepted.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**CP-055** PHARMACY INTERVENTIONS IN VENOUS THROMBOEMBOLISM PROPHYLAXIS IN MEDICAL PATIENTS

M Marzal-Alfaro*, A Iglesias Bolaños, C Capilla Montes, T Cruz Cruz. Hospital Universitario Del Sureste, Pharmacy, Arganda Del Rey – Madrid, Spain

10.1136/ehjpharm-2015-000639.55

**Background** Venous thrombosis and pulmonary embolism are potentially preventable causes of hospital-related morbidity and mortality. Thromboprophylaxis is thought to be underused in medical inpatients. The PRETEMPED guide is a risk assessment tool used to quantify the risk of venous thromboembolism (VTE) in medical inpatients.

**Purpose** To evaluate the appropriateness of VTE prophylaxis in medical inpatients and to describe Pharmacy Interventions to improve this treatment.

**Material and methods** Cross-sectional study in a medical ward in a public hospital with 120 beds. VTE risk factors and VTE prophylaxis prescribed were assessed in patients admitted from the emergency department. Patients treated with low molecular weight heparin (LMWH) or enoxaparin for therapeutic purposes were excluded. The PRETEMPED guide was used as a risk assessment tool to evaluate the appropriateness of the prophylaxis given to patients.

**Results** 168 patients were analysed and 113 included in the study with indications for VTE prophylaxis, 60 of them (53%) were men, mean age 75 years (SD 18.3). According to the PRETEMPED guide, 13.3% of patients had low risk of VTE, 6.2% moderate and 80.5% high. In 49 patients (43%) there were discrepancies between the VTE prophylaxis prescribed and the PRETEMED guide recommendation: 32% treatment omission, 7% no treatment indication and 4% overdoses.

Thirty-one pharmacy interventions in 27% of patients were made during this period. Sixteen (52%) were related to the need for LMWH and fifteen (48%) to the dose of enoxaparin prescribed (wrong dose, wrong frequency or adjustment for renal impairment needed). Twenty-three (74%) of them were accepted, 14 were treatment initiation and 9 were dose adjustments.

---

**CP-057** DOSAGE ADJUSTMENT OF EPOETIN β AND DARBEPOETIN α IN CHRONIC KIDNEY DISEASE

C Pérez Diez*, H Navarro, N De la Llama, J Pérez-Pérez, J Navarro, M Abad. Univeritary Hospital Miguel Servet, Pharmacy Department, Zaragoza, Spain

10.1136/ehjpharm-2015-000639.56

**Background** Erythropoietin (EPO) is indicated in the treatment of anemia associated with chronic kidney disease (CKD).

**Purpose** To determine the average dose of epoetin β and darbe-poetin α required to achieve adequate levels of haemoglobin (Hb) in patients with CKD not yet undergoing dialysis and the rate conversion factor between the two EPOs.

**Material and methods** Retrospective study. Patients included: stage 3 to 5 CKD who started treatment with EPO between January 2012–December 2012. Follow-up period: 6 months. Hb target range: 10.0 g/dL–12.5 g/dL. Data collected: sex, age, CKD stage; baseline, 3 and 6 months data analysis; type of EPO and posology. Data: medical and pharmacotherapeutic history (Farmatools).

**Results** 81 patients. Median baseline characteristics: 59.3% men, age 73.8 years (30–88), stage 3 CKD (29.7%), 4 (57.8%) and 5 (12.5%); Hb 10.2 ± 1.2 g/dL; 63.0% had serum ferritin values >100 ng/ml. 40.7% received epoetin β (average weekly dose: 7,718.2 ± 6,155.7 IU) and 59.3% darbe-poetin α (average weekly dose: 20.6 ± 10.3 µg). 46.9% (38/81) of patients changed EPO treatment: 71.1% (27/38) dosage. Hb level increased statistically significantly after 3 (1.5 g/dL average increase, p < 0.001) and 6 months of treatment (1.6 g/dL, p < 0.001); haematocrit level also did at 3 (4.8 g/dL, p < 0.001) and 6 months (5.1 g/dL, p < 0.001). After 3 months 53.1% of patients had Hb 10.0–12.5 g/dL. Average weekly dose to achieve Hb target range: 6,875.0 IU of epoetin β and 20.4 µg of darbe-poetin α, which represent a relationship between the two doses of EPOs: 337:1.

**Conclusion** EPO increased Hb and haematocrit baseline levels statistically significantly after 3 and 6 months of treatment. The relationship between the two doses of EPOs to achieve Hb target range (epoetin β: darbe-poetin α) found in our study was different from the relationship described in the Summary of Product Characteristics (3.37:1 vs. 200:1 respectively).

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.
Clinical pharmacy

CP-058 PHARMACEUTICAL CARE SYSTEM FOR CHRONIC PAEDIATRIC PATIENTS

1CM Fernández-Llamazares*, 2L Alonso Pérez, 3MJ Cabañas Poy, 4FR Rosa, 5B Garido, 6V Gallego, 7H Ramírez-Gago, 8M Manrique-Rodríguez, 9P Perea, 10MT Pozas del Río.

1Hospital Mater de la Salle, Pharmacy Service, Madrid, Spain; 2Hospital 12 de Octubre, Pharmacy Service, Madrid, Spain; 3Hospital Vall d’Hebron, Pharmacy Service, Barcelona, Spain; 4Hospital San Juan de Deu, Pharmacy Service, Barcelona, Spain; 5Hospital Virgen de la Arrixaca, Pharmacy Service, Murcia, Spain; 6Hospital Matero-Infantil, Pharmacy Service, Las Palmas, Spain; 7Hospital General Universitario Gregorio Marañón, Pharmacy Service, Madrid, Spain; 8Hospital Reina Sofia, Pharmacy Service, Cordoba, Spain; 9Hospital Universitario Niños Jesus, Pharmacy Service, Madrid, Spain.

10.1136/ehjpharm-2015-000639.57

Background Meeting chronic patient needs is essential to improve health outcomes.

Purpose To design a pharmaceutical care plan for chronic paediatric patients using a risk stratification tool.

Material and methods The care plan was developed in 4 steps from April to June 2014:

1. 1. Literature review.
2. 2.4 workshops were held with experts. The chronic conditions and the variables of each patient with their corresponding relative weights were defined, varying from 1(low) to 4 (high risk) in ascending order of risk, and resulted in a risk matrix with increasing levels, which included the pharmaceutical care actions to be carried out in each level.
3. 3. pre-test was developed and used in 195 patients from 7 hospitals.
4. 4.5 case studies were performed.

Results The care plan was applied to patients with different chronic conditions, classified into 15 groups (autoimmune, gastrointestinal, oncology, etc.). 13 variables divided into 3 categories were defined: demographic (age, obesity/malnutrition, social/cognitive problems); clinical (visits to the emergency room), comorbidities, clinical conditions that require special monitoring);and drug treatment (polypharmacy, complex patterns, changes in regular regimen, suspected non-adherence, suspicion/risk of medication-related problem, high-risk medicine). Afterwards, 4 risk levels were defined according to the total variable score: level 4, for patients with ≤17 points; level 3, 18 to 22 points; level 2, 23 to 26 points; and level 1, for ≥27 points. For each risk level 3 types of care actions were defined: pharmacotherapy monitoring, training/education to patient/parent/caregiver, and coordination activities with the care team.

We evaluated the distribution of 195 real patients into the defined risk levels: 60% were scored into level 4, 20% into level 3, 13% into level 2 and 7 into level 1. This was considered an adequately stratified population distribution.

Conclusion The pharmaceutical care plan adequately stratified chronic paediatric patients into different risk levels and can be used to prioritise those patients that will benefit more from our interventions.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-059 EVALUATION OF CLINICAL PHARMACEUTICAL INTERVENTIONS IN A TERTIARY CARE HOSPITAL

S Calisanes-Paz*, P Nieto Guindo, F Verdejo Reche, JM Ruiz Gonzalez, D Fernandez Ginés. Hospital Torrecardenas, Pharmacy, Almería, Spain

10.1136/ehjpharm-2015-000639.58

Background Interventions made by clinical pharmacists have shown to reduce the frequency of drug-related problems.

Purpose To describe all Pharmaceutical Interventions performed, assessing the type, medical units involved and the pharmacotherapeutic group of the drugs.

Material and methods A retrospective observational study of the pharmaceutical interventions was performed in a tertiary care hospital with 590 beds between January 2009 and September 2014. The medical records were consulted to obtain this data.

Results

- 11,985 interventions were performed during the study period in 5 major therapeutic classes: antibacterial (64.66%), gastrointestinal drugs (23.01%), blood formation and coagulation (4.64%), dietary supplements (2.79%) and hormones (2.62%).
- There were 23 different types of pharmaceutical interventions, the more frequent were: 38.33% related to restricted antibiotic justification, 23.63% sequential treatment, 7.54% treatment duration, 4.04% underdosing, 2.32% therapeutic duplication.
- The most frequent medical units involved were: Internal medicine (30.5%), pneumology (12.58%) and surgery (11.23%).

Conclusion This study shows the importance of Pharmaceutical interventions detecting potential drug interactions and drug-related problems in order to optimise the pharmacotherapeutic treatment. A clinical pharmacist optimises pharmacotherapy for all patients, improves treatment efficacy and safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Dr. Cotrina

No conflict of interest.

CP-060 COMPARISON OF ETHNIC CHRISTIAN AND MUSLIM POPULATIONS ON ANTIRETROVIRAL TREATMENT

V Torres*, R Castaño, C Garcia, M Mohamed, E Torres. University Hospital of Ceuta, Pharmacy, Ceuta, Spain

10.1136/ehjpharm-2015-000639.59

Background Highly active antiretroviral treatment (HAART) has achieved infection control for human immunodeficiency virus type 1, decreasing the morbidity and mortality associated with it. But on the other hand, it can produce short and long-term side effects. Previous studies have shown that the ethnic Muslim population has a better lipid profile than the ethnic Christian population in Spain.

Purpose To analyse differences in the lipid profile, blood glucose levels, CD4 count and viral load (VL) between the ethnic Christian and Muslim populations with antiretroviral treatment in a university hospital.

Material and methods A descriptive cross-sectional study of patients with antiretroviral treatment, who collected medicines
from the outpatient unit of our pharmacy department (PD). The information collected was: age, sex, current drug treatment (obtained from PD program) and glucose, triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL, CD4 count (obtained from the hospital’s clinical laboratory program). The results were analysed using SPSS version 15.0.

**Results** 85 patients were included; 47 (55.3%) were Christians and the rest Muslims. 59 (69.4%) were men, of whom 23 (39%) belonged to the Muslim ethnic and 36 (61%) to Christian ethnic. Of the 26 women, 15 (77.6%) were Muslim and 11 (42.3%) Christian. The mean age of patients was 47.8 years (SD: 10.1). We found 19 different pharmacological treatments and the most prescribed were: efavirenz/emtricitabine/tenofovir (32.9%), lopinavir/ritonavir monotherapy (29.4%) and lopinavir/ritonavir + emtricitabine/tenofovir (9.4%). 24 Christian and 11 Muslim patients had hypertriglyceridemia (value >150 mg/dL) with statistically significant differences (p = 0.039). 21 Christian patients had CD4 counts below 450/mm3; this number of patients was statistically significant (p = 0.044). No statistical significance was found in the other laboratory test values.

**Conclusion** Our results show that ethnic Christians had a higher rate of hypertriglyceridemia and low levels of CD4. However, other studies would be needed to confirm these findings, which could contribute to a better selection of antiretroviral therapy.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


---

**CP-062 COST IMPACT OF BELIMUMAB IN A HOSPITAL SETTING**

**Background** Belimumab is a monoclonal antibody indicated as add-on treatment in adult patients with active systemic lupus erythematosus (SLE) despite standard treatment. Given its modest efficacy and the lack of data for severe forms, the improvement in actual benefit (IAB) of belimumab was assessed to be minor. Thus, Health Authorities approved the hospital use of belimumab but its administration in hospital settings is not supported by health insurance.

**Purpose** To assess the cost impact of belimumab treatment in adult patients with SLE in our hospital.

**Material and methods** Data available from the SLE population in the Internal Medicine Department was used as input in the model. An Excel model was adopted for the analysis, which was performed from our hospital perspective. The recommended dose regimen was 10 mg/kg on days 0, 14 and 28 and at 4-week intervals thereafter. Patients received their treatment as part of a day hospital admission. Total charges and costs details were obtained from the National Tariffs Databases.

**Results** A retrospective analysis was conducted on a dataset of 12 female patients followed over a period of 15 months (from January 2013 to May 2014).

Based on a cost of €162.65 for a 120 mg vial and €542.15 for a 400 mg vial, the cost of belimumab per course and per patient was estimated at €972.5 whereas only €30 (drug-related reimbursement in the total hospital daily costs) were refunded to the hospital. 113 courses of treatment were recorded during this period. Therefore, a total of €106,504 remained chargeable to the hospital.

**Conclusion** Despite some evidence of its clinical effectiveness, the health benefits could be outweighed by the significant costs associated with belimumab. It is important to target patients most likely to benefit from belimumab, to establish well-defined
optimal treatment duration, or even to consider other therapeutic alternatives.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Thanks to N. MEBAIKI JVR Bondy.
No conflict of interest.

CP-063 PHARMACY ASSISTANCE FOR FRAIL PATIENTS WITH NASOGASTRIC TUBE

A Moreno Villar*, BM Muñoz Cegado, I Nade Lopez, T Ruiz-Rico Ruiz-Morín. Hospital San Juan de la Cruz, Pharmacy, Ubeda, Spain
10.1136/ehjpharm-2015-000639.62

Background A frail patient is an immobilised person and/or a nursing home resident and/or in a terminal stage. This population is hyper-frequent in primary health care (PHC) centres and hospitals. This group generates large expenses in drugs and they usually need a nasogastric tube (NGT).

Purpose To evaluate the implementation of pharmacy assistance for frail patients with NGT after hospital discharge.

Material and methods Prospective study conducted between June and September 2014. Sequence of activities: a physician or nurse selected the patients who require pharmaceutical intervention to guarantee the correct administration of drugs via NGT, compatibility with enteral nutrition and stability of solid solutions or dispersions of drugs. A report with recommendations, substitutions and interruptions of treatments was issued to the patient. Variables: age, drugs per patient, therapeutic group (TG) according to the Anatomical Therapeutic Chemical (ATC) classification system and active substances with submitted recommendations and levels of approval. Sources of information: electronic medical history (DIRAYA), electronic prescription program (APD – ATHOS) and specialised bibliography. Data was analysed using SPSS 15.0.

Results 23 requests were received. The mean age of the patients was 81.65 (± 8.97) years. The mean prescribed drugs per patient was 8 (2-19). 75% (138/184) of the patients required specific recommendations (a mean of 6 drugs per patient). The most common TGs were related to the nervous system 29.71% (41) and the cardiovascular system 25.36% (35). The most frequent active principles were: omeprazole 9.42% (13) and acetylsalicylic acid 5.8% (8). 100% of the recommendations were accepted.

Conclusion This system guarantees a constant information flow between PHC centres and hospitals that will avoid problems and guarantee correct drug administration. Future studies will show the economic impact and the improvement in the quality of life with the reduction of visits to PHC centres and hospitals.

REFERENCES AND/OR ACKNOWLEDGEMENTS

None.
No conflict of interest.

CP-064 ANALYSIS OF ORAL IMMUNOSUPPRESSANT USE IN OFF-LABEL INDICATIONS IN A HOSPITAL PHARMACY SERVICE

A Lizard*, P Carmina, G Liceaga, J Baral, M Umevez, M Umetaviczaya, E Eseola, MJ Gayán, MB Irazoza, MP Bachiller. Donostia University Hospital, Hospital Pharmacy, San Sebastian, Spain
10.1136/ehjpharm-2015-000639.63

Background Our Hospital Pharmacy Service (HPS) participates in the process of authorising off-label indications (OLIs) of drugs. Immunosuppressants are often used in OLIs.

Purpose To analyse prescriptions for oral immunosuppressants dispensed as OLI in our HPS Outpatient Unit (HPSOU) to identify points in the system that could be improved.

Material and methods Retrospective study of oral immunosuppressants dispensed at our centre between March 2012 and March 2014.

Variables collected were age, sex, drug, prescribing service and indication; obtained from the HPSOU database and the electronic medical history.

Results 269 patients (median age 52 years (5-92), 135 women (50%) and 134 men (50%)) were evaluated.

6 drugs were dispensed in 8 different medicinal products: tacrolimus 94 patients (35%), mycophenolate mofetil 78 (29%), mycophenolic acid 56 (21%), ciclosporin 34 (17%), everolimus 6 (2%) and sirolimus 1 (0.3%).

11 services were involved: Haematology (89 patients: 33%), Rheumatology (61: 23%), Nephrology (56: 21%), Ophthalmology (15: 6%), Digestive (14: 5%), Pneumology (10: 4%), Paediatrics (9: 3%), Neurology (8: 3%), Internal Medicine (4: 1%), Dermatology (2: 0.7%) and Oncology (1: 0.3%).

Immunosuppressants were dispensed for 35 different indications. Main indications and their treatments were: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for 75 patients (28%), with tacrolimus (71%), mycophenolate mofetil (17%) and ciclosporin (12%); Systemic Lupus Erythematosus (SLE) for 46 (17%), with mycophenolate mofetil (62%), mycophenolic acid (30%) and tacrolimus (8%) and Membranous Glomerulonephritis (MGN) for 20 (7%), with mycophenolic acid (50%) and tacrolimus.

Conclusion The use of oral immunosuppressants as OLI is an established treatment for various indications, specially, allo-HSCT, SLE and GMN. The creation of multidisciplinary groups to develop protocols for the management of these drugs is required.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Summaries of product characteristics of the evaluated medicinal products.
No conflict of interest.

CP-065 SWITCHING ANTIRETROVIRAL THERAPY: REASONS AND ASSOCIATED COSTS IN A COHORT OF HIV-INFECTED PATIENTS

1MF lorit, 1AR etamer, 1S Luque, 1S Grau, R Garcia*, 2A Gueler, 2H Knoebel, 2E Salas.
1Hospital Del Mar Parc de Salut Mar, Pharmacy, Barcelona, Spain; 2Hospital Del Mar Parc de Salut Mar, Infectious Diseases, Barcelona, Spain
10.1136/ehjpharm-2015-000639.64

Background Several factors, such as toxicity, virological failure or low adherence can justify the need for switching antiretroviral therapy (ART) in HIV patients.

Purpose To study the reasons for switching ART in an HIV unit in a tertiary hospital. Secondary objectives were to study the number of switches over time and their estimated annual cost (EAC).

Material and methods We recorded ART switches performed every 6 months from January 2012–June 2014 in our cohort of 1,550 HIV-infected patients. Date collected: previous and new
ART, reason for switching and EAC (difference in the daily acquisition cost between the new and the previous ART calculated for 365 days of treatment). The Spearman test was used for bivariate correlations.

Results 685 switches were performed: 117 (7.5%), 98 (6.3%), 130 (8.4%), 157 (10.1%) and 183 (11.8%) in each 6-month period. An increase in the number of changes/6 months over time was observed (Spearman rho: 0.9; p < 0.05). The total number of switches/6 months correlated only with toxicity (Spearman rhow: 0.95; p < 0.05).

Conclusion • An increase in the number of switches per 6-month period was observed over time. Total number of switches/6 months was correlated to those associated with toxicity. The availability of new and less toxic ARTs may explain these results.

• Toxicity remained the most frequent reason for switching, representing between 58% and 63% depending on the year.

• Switches due to virological failure entailed an increase in the EAC, while those due to simplification brought cost savings. Overall, the economic impact of this strategy on the annual acquisition cost of ARTs in our hospital seems to be minimal.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

Abstract CP-065 Table 1 Reasons for switching and EAC (euros)

<table>
<thead>
<tr>
<th>Year</th>
<th>2012</th>
<th>2013</th>
<th>First six months of 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Switches/EAC</td>
<td>215/10,851</td>
<td>280/58,725</td>
<td>187/200,616</td>
</tr>
<tr>
<td>Annual</td>
<td>10,318,403</td>
<td>10,325,638</td>
<td>5,063,660</td>
</tr>
<tr>
<td>acquisition</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cost of ART</td>
<td>125/12,189</td>
<td>180/73,408</td>
<td>249,597</td>
</tr>
<tr>
<td>Toxicity</td>
<td>37/102,712</td>
<td>33/53,084</td>
<td>249,597</td>
</tr>
<tr>
<td>Virological</td>
<td>45/103,271</td>
<td>49/68,650</td>
<td>35/35,371</td>
</tr>
<tr>
<td>failure</td>
<td>8/1,898</td>
<td>22/25,551</td>
<td>112,974</td>
</tr>
</tbody>
</table>

1Three for pregnancy.

CP-066 PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: A CASE REPORT

1S Sanchez, 2V Valiente, 1Andujar, 1G Sario, 1MA Rodriguez, 1MD Ramírez, 1Hospital La Vega Lorenzo Guirao, Pharmacy, Cierra Murcia, Spain; 2Hospital de La Vega Lorenzo Guirao, Pharmacy, Cierra España, Spain

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, limited lung fibrosing interstitial pneumonia of unknown cause with poor prognosis and few therapeutic options, with a median survival of 2–5 years from diagnosis. It is characterised by fibroblast proliferation and abnormal accumulation of extracellular matrix molecules, particularly collagen fibres. Pirfenidone is the first IPF-specific antifibrotic, with anti-inflammatory and antifibrotic properties whose mechanism of action has not been fully established. To date, pirfenidone is the only drug with proven efficacy in the treatment of IPF. It is considered an orphan drug, and is not yet marketed in all European countries, so that additional monitoring is required.

Purpose To describe the progress of a patient treated with pirfenidone as well as the safety of this new treatment.

Material and methods A prospective observational study was conducted. The patient, a 65-year-old male, stopped smoking 2 years ago (with a cumulative tobacco consumption index of 57 packs/year). He was diagnosed with IPF in 2012 by clinical and radiological criteria. Pirfenidone was approved as a foreign drug for a period of three months by the Ministry of Health.

Results After titration, the usual pirfenidone dose was administered (2403 mg daily). After 3 months of treatment, forced vital capacity (FVC) experienced less than 10% decrease (only 1.2%) and diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) decreased by 6.1% showing no radiological progression. There were no increase in transaminases, no digestive disturbances or weight loss.

Conclusion Pirfenidone has been used successfully to date in our case, so it is possible to continue the treatment until a new patient evaluation at 6 months in order to prevent a lung transplant. Although more and longer treatment periods are needed, pirfenidone seems to be a well-tolerated treatment option for IPF.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 C Lopez Martin*, 1J Arenas, 1M Nieto, 2A Robustillo, 2R Morillo, 1E Aguilera, 1E Rios, 1M Girando, 1F Faus, 1B Tortajada. 1Agencia Sanitaria Hospital Costa Del Sol, Pharmacy, Marbella, Spain; 2Hospital Nuestra Señora de Valme, Pharmacy, Sevilla, Spain; 2Hospital Universitario Virgen de La Victoria, Pharmacy, Malaga, Spain; 2Hospital Universitario Puerto Real, Pharmacy, Puerto Real, Spain

Background Care quality indicators are used to quantify quality of care. The Spanish HIV group (GESIDA) has developed care quality indicators for the care of persons infected by HIV/AIDS, some of them related to pharmaceutical activities.

Purpose To determine the compliance with GESIDA indicators and identify areas in which to improve HIV pharmaceutical care.

Material and methods Prospective multicentre study. Inclusion criteria: treatment-naïve patients beginning antiretroviral therapy in 2012 and 2013, 48 weeks of treatment and patient monitoring in pharmaceutical care consultations of the centres involved (PSITAR cohort). The care quality indicators were obtained from the GESIDA consensus document/National AIDS Plan on antiretroviral treatment in adults (2014).

Results 102 patients were studied, 86.3% male, mean age of 39.4 years (SD 11.79). At the beginning of the treatment the median viral load was 69,700 and mean CD4 was 316 (SD 39.4 years). In 57% of patients it was <350. 5.8% of patients showed resistance to any treatment. The most common treatments were tenofovir, emtricitabine and efavirenz combination (44%), darunavir, ritonavir, tenofovir, and emtricitabine combination (10%) and tenofovir, emtricitabine and raltegravir combination (8%).

Abstract CP-067 Table 1

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Dimension</th>
<th>Result</th>
<th>Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compliance of initial treatment with GESIDA guidelines</td>
<td>Effectiveness</td>
<td>92.15%</td>
<td>95%</td>
</tr>
<tr>
<td>Undetectable viral load (&lt;50 copies/ml) at week 48</td>
<td>Effectiveness</td>
<td>88.25%</td>
<td>80%</td>
</tr>
<tr>
<td>Treatment modifications within the first year</td>
<td>Effectiveness</td>
<td>28.43%</td>
<td>&lt;30%</td>
</tr>
<tr>
<td>Resistance study in virological failures</td>
<td>Effectiveness</td>
<td>74%</td>
<td>90%</td>
</tr>
<tr>
<td>Abacavir initiation without HLA-B*5701 screening</td>
<td>Safety</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Treatment adherence measure</td>
<td>Follow-up</td>
<td>54.9%</td>
<td>95%</td>
</tr>
<tr>
<td>Average annual expenditure per patient</td>
<td>Efficiency</td>
<td>88,552</td>
<td>88,633</td>
</tr>
</tbody>
</table>
Clinical pharmacy

Conclusion Effectiveness, efficiency and safety care quality indicators are mostly achieved. We can conclude that more resistance studies are required in the event of virological failure and we should improve treatment adherence records.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 www.gesida-seim.org
No conflict of interest.

COMPATIBILITY ANALYSIS OF PROPPOFOL– OPTIMISATION OF DRUG TREATMENT SAFETY

F Gersonde*, 1S Eisend, 2T Kunze, 3H Haake. 1University Hospital Schleswig-Holstein, Campus Kiel, Dispensary, Kiel, Germany; 2Pharmaceutical Institute, Christian-Albrechts University of Kiel, Department of Clinical Pharmacy, Kiel, Germany; 3University Hospital Schleswig-Holstein, Campus Kiel, Department of Cardiovascular Surgery, Kiel, Germany

Background Infusions are an essential part in the treatment of intensive care patients. Due to increasingly complex treatments the simultaneous application of several drugs through a central multi-lumen catheter is unavoidable. This entails the risk of physicochemical and chemical incompatibility reactions.

One standard sedative used on the intensive care unit is propofol. Because of its physicochemical and optical properties propofol poses a special risk in identifying stability problems and incompatibilities. Additionally, only limited compatibility data are available.

Purpose To optimise the safety of drug treatment in a cardiovascular intensive care unit by preventing drug incompatibilities between propofol and other analgesic and sedative drugs.

Material and methods On the cardiovascular intensive care unit documented propofol drug combinations were narrowed down to practice-oriented combinations of propofol 2% with clonidine, midazolam, sufentanil, remifentanil, piritramide, lormetazepam, γ-hydroxybutyric acid and dexmedetomidine which were diluted to standardised concentrations. Mixtures at a ratio of 1:1 were stored at room temperature for 7 days. Samples were taken at defined points of time.

The physical and the emulsion stability in particular were determined by pH value, zeta potential and globule size distribution measurements using light backscattering. Analyses on crystal and microbiological growth gave additional information about the stability.

The chemical stability determination was carried out by high performance liquid chromatography (HPLC).

Results The light backscattering and zeta potential analyses resulted in three stability groups. The least stable group consisted of propofol, remifentanil and lormetazepam. All other mixtures remained stable over a defined period of time. No crystal and bacterial growth could be detected.

The HPLC data indicated the chemical stability of all previously tested propofol drug combinations.

Conclusion We found evidence of incompatibilities and compatibilities of propofol with analgesic and sedative drugs. Through further investigations the safety of drug treatment should be increased.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

QUALITY OF ANTIBIOTIC TREATMENT IN PRETERM NEONATES: A READY-TO-USE FORMULATION OF GENTAMICIN SULPHATE

MS De Meo*, 1C Poldori, 2P Pomplio, 3V Carnelli, 4S Savini, 5F Cuccarelli, 6E Andreati, 7A Garzone, 8L Carloni, 9V Moresi. Università Degli Studi Di Camerino, SSO, Camerino, Italy; 2Azienda Ospedali Riuniti Di Ancona, SOD Farmacia, Ancona, Italy; 3Azienda Ospedali Riuniti Di Ancona, SOD Igiene Ospedaliera, Ancona, Italy

Background Intravenous (IV) drug treatment of preterm neonates is affected by: clinical status (i.e. sepsis/infections, immature physiology, pharmacokinetic/pharmacodynamic variation), shortage of ready-to-use formulations, small doses of drug required and the dangers of the IV route.

Purpose To identify the most prescribed IV antibiotics so that ready-to-use formulations can be prepared with standard concentrations (SCs) of drug avoiding handling (reconstitution/dilution) in the ward.

Material and methods The Hospital Pharmacy, Neonatology and Hygiene Department of “Azienda Ospedali Riuniti-Ancona” conducted this multiphase study. Phase I: a review of IV antibiotics prescribed to preterm neo-nates 2004–2013. Phase II: study of pharmaceutical quality and stability of SC (2 mg/ml) gentamicin sulphate (the gold standard in sepsis/infections). Aqueous solutions were prepared by pharmacists in two different ways: with and without filtration. Both batches were stored in polyethylene syringes for 90 days at 2–8°C and 25°C and were examined for: endotoxin absence with the LAL test (Limulus amoebocyte lysate, Endosafe Portable Test System) in accordance with the Italian Pharmacopoeia 12th edition (kinetic-chromogenic technique); sterility test (BacT/ALERT FA, six days of incubation at 36°C) for aerobic bacteria/fungi; quantification with HPLC-MS/MS technique of gentamicin components (C1, C2, C14) at 0–3–7–14–21–28–60–90 days. Limits of detection (LOD) and quantitation (LOQ) were 0.25 ng. The SC was derived from the usual dose (2.5 mg/ kg/12 h) for a 1,000 g patient.

Results Phase I studies found: 1,011 preterm inpatients (521 males, 420 females), 222 cases of sepsis (52 early, 170 late) and 102 infections. Gentamicin was the most used antibiotic with 1,126 doses for 88 patients per year. Phase II studies certified: sterility (no microbiological growth), absence of endotoxins and stability of GS 2 mg/ml stored 90 days at 2–8°C and 25°C. No significant changes in concentration of gentamicin components: P not significant, t-test >0.05.

Conclusion After this “pilot study” the next target could be to provide standard concentration unit dose treatments directly from the pharmacy to paediatric patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

THE IMPACT OF HOSPITAL ANTIBIOTIC GUIDELINES ON SURGICAL PROPHYLAXIS IN PAEDIATRIC PATIENTS SUFFERING UPPER AND LOWER EXTREMITY INJURIES

S Vieestina*, D Mozgis. University Children’s Hospital, Riga, Latvia; 3Riga Stradins University, Public Health and Epidemiology Department, Riga, Latvia

Background The Hospital Pharmacy, Neonatology and Hygiene Department of “Azienda Ospedali Riuniti-Ancona” conducted this multiphase study. Phase I: a review of IV antibiotics prescribed to preterm neo-nates 2004–2013. Phase II: study of pharmaceutical quality and stability of SC (2 mg/ml) gentamicin sulphate (the gold standard in sepsis/infections). Aqueous solutions were prepared by pharmacists in two different ways: with and without filtration. Both batches were stored in polyethylene syringes for 90 days at 2–8°C and 25°C and were examined for: endotoxin absence with the LAL test (Limulus amoebocyte lysate, Endosafe Portable Test System) in accordance with the Italian Pharmacopoeia 12th edition (kinetic-chromogenic technique); sterility test (BacT/ALERT FA, six days of incubation at 36°C) for aerobic bacteria/fungi; quantification with HPLC-MS/MS technique of gentamicin components (C1, C2, C14) at 0–3–7–14–21–28–60–90 days. Limits of detection (LOD) and quantitation (LOQ) were 0.25 ng. The SC was derived from the usual dose (2.5 mg/ kg/12 h) for a 1,000 g patient.

Results Phase I studies found: 1,011 preterm inpatients (521 males, 420 females), 222 cases of sepsis (52 early, 170 late) and 102 infections. Gentamicin was the most used antibiotic with 1,126 doses for 88 patients per year. Phase II studies certified: sterility (no microbiological growth), absence of endotoxins and stability of GS 2 mg/ml stored 90 days at 2–8°C and 25°C. No significant changes in concentration of gentamicin components: P not significant, t-test >0.05.

Conclusion After this “pilot study” the next target could be to provide standard concentration unit dose treatments directly from the pharmacy to paediatric patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
Background Surgical prophylaxis may account for 1/3 of all antibiotic use in paediatric hospitals and 80% of all antibiotic use in surgery. Appropriate surgical antimicrobial prophylaxis can prevent post-operative infection of the surgical site.

Purpose To evaluate antibiotic use for surgical prophylaxis in paediatric patients suffering upper and lower extremity injuries.

Material and methods Retrospective review of patients’ medicines records before guidelines introduction in July/August and two months after in November/December 2013. Comparative analysis of the appropriateness of prophylaxis: number and percentage of patients who got prophylaxis on time, correct antibiotic dose and duration of prophylaxis.

Results Total number of patients: 201 in July/August and 81 in November/December. Prophylaxis was needed for 94 (47%) patients in July/August and 53 (65%) in November/December. 14 (15%) in July/August and 16 (30%) patients in November/December didn’t receive prophylaxis although it was indicated in the guidelines.

Prophylaxis was too early in 13 (16%) patients in July/August, 9 (24%) in November/December; on time: 40 (50%) in July/August and 17 (46%) in November/December, too late (started during or after surgery): 21 (26%) in July/August, 10 (27%) in November/December. No information about time: 6 (7%) in July/August, 1 (3%) November/December.

64 (87%) patients received a single dose in July/August and 32 (86%) in November/December; multiple doses within 24 h: 6 (8%) patients in July/August and 1 (3%) in November/December; prophylaxis >1 day: 7 (9%) patients in July/August and 4 (11%) in November/December.

Cefazolin dose was too low in 16/79 (20%) patients in July/August and 3/37 (8%) patients in November/December.

Conclusion Although the guidelines were discussed and accepted by surgeons and there had been a two-month introduction period as well, only low positive trends were observed, with antibiotic treatment guidelines not having a major impact on antibiotic use. There is a need for new ways of promoting adherence to guidelines and appropriate antibiotic use.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

Clinical pharmacy

CP-071 ENZALUTAMIDE: EXPERIENCE IN METASTATIC PROSTATE CANCER

1C Bonilla Galán*, 2D Briegas Morera, 3UM Bravo García-Cuevas, 3C Meneses Mangas, 2Romero Soria, 5S Martín Clavo, 5R Medina Comas, 2If Rangel Mayoral, 5Luso Rubio.
1Hospital Infanta Cristina, Hospital Pharmacy, Badajoz, Spain; 2Hospital Infanta Cristina, Hospital Pharmacy Service, Badajoz, Spain; 3Hospital Infanta Cristina, Hospital Pharmacy, Badajoz, Spain.

Background Enzalutamide, an androgen receptor inhibitor administered orally, is approved for use in metastatic prostate cancer refractory to castration, when disease progresses during docetaxel treatment or after finishing it.

Purpose To describe the results of using enzalutamide in terms of effectiveness and safety.

Material and methods We conducted a retrospective study over eleven months (1/10/2014–30/09/2014), including every patient being treated with enzalutamide. Age, disease stage, previous treatment lines, enzalutamide start date and adverse effects were gathered from the patient’s clinical history and our Farmatoools outpatient records module. In order to assess enzalutamide effectiveness, baseline and end-of-study prostatic specific antigen (PSA) levels were measured to calculate percentage PSA decrease; a response higher than 50% was considered positive.

Results We gathered data from five patients (average age 67.8 years, 80 maximum and 61 minimum), all diagnosed with stage IV (bone metastases) prostate cancer, refractory to chemical castration and docetaxel chemotherapy. Before starting, all of them received abiraterone (1 g, average treatment length 5.8 months). Average enzalutamide dose was 160 mg. Three patients experienced a PSA decrease of greater than 50% compared to baseline (95.2% maximum), while the remaining two dropped out of treatment because of ineffectiveness. Average length of enzalutamide treatment was 3 months. With regard to safety and adverse events, diarrhoea and asthenia were found in one patient, improving after a 25% dose reduction for 2.5 months, returning to the original dose after complete recovery.

Conclusion In this study, enzalutamide showed a response rate and safety profile similar to those observed in clinical trials and other available clinical evidence resources.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-072 GOOD PRACTICE IN COMPLEX PARENTERAL IRON REGIMENS: A SURVEY IN 5 SURGICAL DEPARTMENTS

1C Dosda*, H Junot, P Tilleul. Pitie Salpêtrière Hospital, Paris Hospital Public Assistance, Paris, France

Background Because of the risk of anaphylaxis, the national drug agency published guidelines for the prescription and administration of parenteral iron complexes. Two drugs have been available since 2013: iron sucrose generics and more recently ferric carboxymaltose (Ferinject).

Purpose To analyse prescriptions for intravenous iron treatment and biological follow up in 5 surgical units (urology, orthopaedics, digestive surgery, stomatology, kidney transplant unit).

Material and methods Over 2 months the biological monitoring of all patients hospitalised in surgery who received parenteral iron complex were analysed: haemoglobin, red blood cells count, blood iron status (serum ferritin, transferrin, iron, and transferrin saturation rate).

Results Among 70 patients, the majority of prescriptions were written in orthopaedics (83%, N = 58) of which 98% (N = 57) included iron sucrose. 14% (N = 11) were treated with ferric carboxymaltose principally prescribed by other surgery units (N = 10). The majority of patients had anaemia (N = 66) but only in 2 was it associated with microcytosis. Blood iron status was only done for 5 patients (7%) of whom 2 presented iron deficiency.

In this study, the majority of prescriptions were to reduce the need for transfusion in orthopaedic surgery, the efficacy of which has been proven. Notice that the full market approval of iron sucrose includes post-surgical treatment when the oral route is not possible. The majority of ferric carboxymaltose prescriptions cause probably more controversy because of no information about blood iron status although absence of iron deficiency is a contraindication.
Clinical pharmacy

Conclusion Prescribers have to be reminded of the necessity for blood iron status assessment especially when ferric carboxymaltose is prescribed. Good practice in oral and parenteral iron treatment will be discussed in a multidisciplinary approach (physicians, pharmacists, and biologists). This work will be completed with a pharmacoeconomic study comparing costs between iron sucrose generics and ferric carboxymaltose, which seems to be better tolerated but more expensive.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

OPTIMISING INFliximAB TREATMENT IN INFLAMMATORY BOWEL DISEASE

1S Fernández Peña*, M Cardaba García, 2S Fernández Cañabate, 1M García López, 1V Cabezas Martín, 1Hospital Clínico Universitario, Servicio de Farmacia, Valladolid, Spain; 2Hospital Clínico Universitario, Farmacia Hospitalaria, Valladolid, Spain

Background Infliximab (INF) is a chimeric immunoglobulin antibody to tumour necrosis factor (A-TNF) approved for the treatment of Crohn’s disease and ulcerative colitis.

Guidelines recommend a 5 mg/kg dose given as induction regimen in weeks 0, 2 and 6, followed by a maintenance regimen of 5 mg/kg every 8 weeks. However, a significant rate of patients with an initial response, later experience the return of the active disease despite ongoing INF maintenance treatment. International guidelines suggest intensifying the INF regimen if the treatment fails, by increasing the dose to 10 mg/kg, or decreasing the interval to 5 mg/kg every 6 weeks.

Purpose To analyse the different intensification strategies used in a tertiary university hospital, and their results.

Material and methods Single-centre, retrospective, observational study. Information was obtained from both the Farmatools application and clinical histories. Fifty-five patients were included in our study; all of them started INF treatment between 2005 and 2013.

Results Out of 55 patients enrolled: 60% (33) were responders, 9% (5) were non-responders, 27% (15) loss of response, and (4%) 2 didn’t tolerate INF.

The treatment of the 22 patients who didn’t respond satisfactorily was modified: in 73% (16) the interval was shortened, 9% (2) stepped up to 10 mg and 5% (1) the interval were shortened and the dose stepped up to 10 mg. The other 14% (3) were moved to another A-TNF.

In our study, shortening the interval was effective in 52% of cases (9/16), stepping up to 10 mg in 100% (2/2), and the combination of the two strategies in 100% (1/1).

Conclusion INF induces remission in most of the patients following the usual maintenance regimen.

In our hospital the favourite intensification strategy is to shorten the interval. The use of another A-TNF is reserved for hypersensitivity reactions or for failure of the previous intensification.

Both intensification strategies were effective, though more information is required to choose the best strategy.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

INTERVENTIONS TO IMPROVE MEDICINES ADHERENCE IN PATIENTS WITH SEVERAL CHRONIC CONDITIONS: AN OVERVIEW OF SYSTEMATIC REVIEWS

1J González-Bueno, 2E Calvo-Cidochica, MD Santos Rubio*, 3MD Vega-Coca, 4A Rodríguez Peretz, 4MD Toscano Guzmán, 5B Santos-Ramos. Virgen Del Rocío Hospital, Pharmacy Department, Sevilla, Spain; 6Virgen De Valme Hospital, Pharmacy Department, Sevilla, Spain

Background Non-adherence in patients with multiple chronic conditions (PMCC) is associated with poor disease control, reduced quality of life and increased risk of morbidity and mortality.

Purpose To assess the available scientific evidence regarding the efficacy of interventions aimed to improve medicines adherence that are applicable to PMCC.

Material and methods Overview of systematic reviews (SRs). The following databases were consulted (September 2013): PubMed, EMBASE, the Cochrane Library, CRD and WoS to identify SRs of clinical trials focused on PMCC, or otherwise, patients with chronic diseases common in the PMCC, or polypharmacy. SRs that compared the efficacy of any intervention aiming to improve compliance with medicines with clinical practice or other interventions were included. For every SR and type of intervention (behavioural, educational and combined) the percentage of clinical trials in which adherence improved was estimated. Rates were combined between SRs by means and ranges.

Meta-analysis could not be conducted because of the heterogeneity of the data. This analysis was also applied to the components from those interventions described in ≥1 SR.

Results 566 articles were retrieved of which 9 SRs were included. None was specifically focused on PMCC but considered patients with chronic diseases common in PMCC, patients with more than one chronic disease and polypharmacy.

Seven, three and six SRs reported behavioural, educational and combined interventions, respectively. The mean efficacy rates were 49% [0–100], 51% [0–100] and 53% [44–75]. The components from those interventions which reported higher efficacy were: counselling about the patients’ target disease, the importance of treatment and compliance with treatment (5 SR, 79% [47–100]), reminders (4 SR, 70% [50–100]), simplified dosing (3 SR, 90% [75–100]) and special pill packaging (2 SR, 83% [66–100]).

Conclusion There is a large heterogeneity in the efficacy of interventions aimed to improve medicines adherence that are applicable to PMCC. Nevertheless, they seem to have a modest impact on adherence. Some components of the interventions appear to have greater efficacy.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1Arch Intern Med 2007;167:340–50

No conflict of interest.

NATALIZUMAB: EFFECTIVENESS AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN A TERTIARY HOSPITAL

1F Artime-Rodríguez-Hermida, CM Valencia Soto*, M Carrasco-Gomariz, M Rodríguez-Góceceha, A Jimenez-Morales. Hospital Universitario Virgen de las Nieves, Farmacia, Granada, Spain

Background Natalizumab (Natalizumab) is a humanized monoclonal antibody against α4-integrin. This drug is used to treat relapsing–remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). In Spain, natalizumab is available to patients with severe RRMS and in whom disease-modifying agents have failed.

Aims To evaluate the effectiveness and safety of natalizumab in patients with RRMS and PPMS.


Results In the study, 1862 (50%) patients were included. The mean age of patients was 35.8 years and the mean duration of the disease was 5.8 years.

The most frequent adverse events were: headache (3.8%); infections (1.0%) and papilloedema (0.1%).

Conclusion Natalizumab is an effective and safe option for patients with RRMS and PPMS.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1No conflict of interest.
Background Natalizumab is indicated in relapsing-remitting multiple sclerosis (RRMS) that remains highly active despite treatment with interferon B and glatiramer acetate, and in rapidly evolving severe RRMS.

Purpose To analyse the effectiveness, safety and results in comparison with the reference clinical trial (CT) in natalizumab patients.

Material and methods Retrospective observational study including patients on natalizumab at the time of data collection (August 2014). Variables included: demographics, time from diagnosis, time with natalizumab, indication, previous treatments, pre/post disability (EDSS), outbreaks before/after change, JC virus antibodies, adverse reactions (ADRs), discontinuations and causes.

Data were obtained from medical records and the electronic prescription software.

Results We analysed 24 patients. 58.3% were women. Mean age was 37.8 years, median time from diagnosis 9.3 years and time on natalizumab 36.6 months.

Previous treatments received were: 13/24 interferon B 1A SC (INF), 10/24 INFB 1A IM, 10/24 glatiramer acetate (GA), 3/24 INFB 1B, 1/24 fingolimod, 1/24 azathioprine and 1 no immunomodulators.

Before natalizumab, mean EDSS was 4.3. EDSS after treatment was 4.6.

33.3% patients had JC + antibodies.

11 patients reported ADRs: 5 infections, 4 skin disorders, 4 fatigue, 3 headaches, 2 insomnia and 1 diarrhoea.

Mean flare-ups before changing were 2.1. Only 6 patients had flare-ups during treatment.

Conclusion Our baseline characteristics and selected variables were not always comparable with the reference CT. Moreover, our small sample size and the daily clinical practice characteristics of our patients made an exhaustive comparison difficult. However, as in the CT, our population presented a maintained EDSS, with a decrease in outbreaks and the ADRs were consistent with the most frequent observed in the CT.

With these results, and according to the published studies, we have demonstrated that natalizumab is an effective alternative to immunomodulators for non-responders.

Notified ADRs in our population are consistent with the known safety profile.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.

CP-076 POST-MARKETING ACTIVE PHARMACOVIGILANCE IN A CENTRAL HOSPITAL

1A Parola*, 1P Chambel, 1F Faínhia, 2F Falclo. 1Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, Pharmaceutical Services, Lisbon, Portugal; 2Centro Hospitalar Lisboa Ocidental, iMed. ULisboa, Pharmacy Faculty, Lisbon University, Portugal

Background Hospital settings are of great value in collecting pharmacovigilance data. Introduction of innovative drugs in hospital settings raises safety concerns, but allows the study of these drugs’ safety profile in real life. Hospital Pharmacists may play an important role in these activities.

Purpose To assess the adverse drug reactions (ADRs) profile of 3 recently marketed drugs, introduced in a central hospital.

Material and methods As part of our active pharmacovigilance programme, a prospective, observational study was carried out on patients receiving fingolimod, telaprevir or boceprevir, between January 2012 and September 2014. ADRs encountered were analysed for age, sex, ADR category and seriousness. Severe, unexpected, frequent, uncommon or rare ADRs were reported to the National Pharmacovigilance System (NPS).

Results A total of 41 patients were enrolled, median age 44 years, 41% male and 59% female. 253 ADRs were observed in 37 patients. 28 reports regarding 173 ADRs were sent to NPS. As defined by the Naranjo causality assessment of ADRs, 90 were considered to have a possible, 53 a probable, and 1 a definitive causal relation with the studied drugs (NPS response rate: 83%). Most frequently observed ADRs (n = 159) in boceprevir/telaprevir regimens were: anaemia (70%), thrombocytopenia (78%), and pruritus (57%). Regarding fingolimod (n = 94), most frequently observed ADRs were: lymphopenia (60%) and paresthesia (24%); initial dose ECG monitoring was performed in all patients, but symptomatic bradycardia was seen in only two cases, without stopping treatment.

Severe ADRs occurred in 5%, and moderate ADRs in 16% of the patients. Some patients had to stop taking the drug in all drugs studied.

Conclusion ADRs were common in patients taking the triple drug regimen for hepatitis C, while fingolimod was relatively well tolerated, which is in line with international literature data. Frequency and severity of ADRs can be managed by laboratory and clinical vigilance and instituting appropriate measures.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-077 ANALYSIS OF COSTS AND PRESCRIPTION GUIDELINES OF ETANERCEPT AND ADALIMUMAB IN PATIENTS OF RHEUMATOLOGY, DERMATOLOGY AND GASTROENTEROLOGY SERVICES ON THE PHARMACY OUTPATIENT UNIT

S Martínez*, A Minguez, JJ García, M Andres, V Goitia, C Martínez. Hospital Universitario Araba-Txagorritxu, Pharmacy, Vitoria-Gasteiz, Spain

Background Nowadays the physicians are changing TNF-blockers prescribing guidelines which influence the pharmaceutical expense.

Purpose To analyse adalimumab and etanercept prescriptions practice on the outpatient unit.

Material and methods Retrospective observational study in which patients of Rheumatology, Gastroenterology and Dermatology services were included. After analysing the total cost of etanercept and monoclonal antibodies used in these services during 2011 and 2013, a large variation was observed in expense, seeing a decrease of 18% in Rheumatology, an increase of 85% in Gastroenterology and an increase of 10% in Dermatology service. Therefore, in a first phase, we decided to analyse prescribing patterns of adalimumab and etanercept. The information was obtained from outpatient internal program, Global Clinic® and SAP®.


No conflict of interest.
Clinical pharmacy

Results

Regarding the expense on the outpatient unit, Rheumatology service was the only one that reduced it between these years with a decrease of 15.1%. In Dermatology, an increase of 10% was observed; partly due to ustekinumab’s dispensation (6 patients were treated in 2011 and 7 in 2013; moreover, in 2013 the administration regimen was more frequently than in 2011). In Gastroenterology service an increase of 63% was observed. The reason of this was the change in number of patients and in prescription guides, as noted in table 1.

Conclusion After analysing Hospital’s prescribing guidelines of these two drugs, we could observe we have treated more patients in rheumatic diseases without increasing spending because of the less frequently administration of these drugs. In Dermatology service, we have more expense not due to adalimumab or etanercept drugs, probably ustekinumab instead. With the studied drugs we only treat two more patients administering them less frequently. Finally, in Gastroenterology service the expense has increased probably because more patients have been treated and not due to administration schedules.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-078 OPTIMISING RESOURCES IN COMPOUNDING PREPARATIONS: SIMPLE MEASURES AIMED AT REDUCING COSTS
A Montero Alonso, A Cerezo Lara, R Espino Muscas, C García Martínez, B López García, R García Patiño, E Salas Sánchez, S Grau Cerrato, Hospital Del Mar. Parc de Salut Mar, Pharmacy Department, Barcelona, Spain
10.1136/ejhpharm-2015-000639.77

Background The growing use of expensive drugs has brought about the introduction of new strategies to optimise financial resources in hospital pharmacy. Some sterile preparations of expensive drugs are reconstituted in medical wards. Frequently, available preparations don’t match with patient doses, therefore part of the reconstituted drug is lost.

Purpose To assess the financial impact of pharmacy reconstitution of preparations for individual patients, in order to improve the drug reconstitution process.

Material and methods A prospective study was carried out in a university hospital between June 2013 and June 2014. We studied drugs reconstituted in a laminar fluid cabinet (LFC) excluding cytotoxics, biological drugs and parenteral nutrition solutions. Additionally, we reviewed the most expensive drugs reconstituted in out-patients, chosen after a pilot financial study. These drugs were reconstituted by pharmacy staff by a volumetric method of preparation instead following the manufacturer’s instructions, using the entire volume of the vial, including over-fill and without discarding drug leftovers. Data collected: number of treatments, type of drugs, time of preparation and savings.

Results The most expensive drug reconstituted in outpatient wards was levsimendan. In LFCs ganciclovir and foscarnet were chosen. Total of treatments: 44, levsimendan 12 (27.27%), ganciclovir 26 (59.09%), foscarnet 6 (13.64%). Savings: €9,100.68; levsimendan: €3,629.4 (39.88%), ganciclovir €2,249 (59.09%), foscarnet: €3,221.84. Pharmacy compounding time: 5 (3–8) minutes. In terms of the technician’s annual salary, average cost per preparation was €0.75 (0.45–1.33). Total cost of technician per year: 33€. Total savings: € 9,067.68.

Conclusion Preparation by the Pharmacy staff represents an efficient strategy. The estimated annual savings were up to €9000, with only €40 of investments. The implementation of strategic cost management in the process of drug reconstitution is key to improve efficiency and profitability.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-079 RELATIONSHIP BETWEEN ADHERENCE TO HEPATITIS C TREATMENT AND RAPID, EARLY AND SUSTAINED VIRAL RESPONSE
1S Santulari-Verdú, 1M Conas-Sugranes, 2E Van Den Eynde-Otero, 1M Colls-González, 3F Xiol-Quingles, 3P Márquez-Rodríguez, 1N Padullés-Zamora, 1Hospital Universitari de Bellvitge, Hospital Pharmacy Department, Barcelona, Spain; 2Hospital Universitari de Bellvitge, HIV Department, Barcelona, Spain; 3Hospital Universitari de Bellvitge, Gastroenterology and Hepatology Department, Barcelona, Spain
10.1136/ejhpharm-2015-000639.78

Background The level of adherence to hepatitis C virus (HCV) treatment is associated with response. High adherence throughout the initial 12 weeks is related to better virological outcomes. Several factors can influence adherence.

Purpose To assess HCV treatment adherence and to evaluate the relationship between adherence and rapid (RVR), early (EVR) and sustained virological response (SVR).

Material and methods Retrospective observational study of HCV-infected patients receiving pegylated interferon (peg-IFN) + ribavirin (RBV) ± protease inhibitor (PI) from January 2011–December 2013. Demographic and clinical data recorded: age, sex, weight, HJV infection, HCV genotype; quantitative HCV RNA; peg-IFN, RBV and PI doses, frequency and quantities dispensed; psychiatric disorders.

Results 183 patients (31.1% women); 14.2% HIV co-infected; 71.2% genotype 1. IL28B CT/TT genotype rate: 33/46. 79.8% were treated with peg-IFN + RBV and 20.2% with peg-IFN + RBV + PI. 11.7% received reduced RBV/peg-IFN doses. 3.3% required growth factor.

RVR: 97.4% (mean reduction: 1.91 log IU/ml). EVR: 46.1%. SVR: 57.3% (genotype 1: 47.1% vs. others: 73.8%; p = 0.011). SVR among PI treated patients: 72.7%.

Overall adherence according to quantities dispensed and the Morisky-Green test were 97.35% (95.8% with >80% adherence) and 99.56% (100% > 85% adherence), respectively. Mean adherence according to quantities dispensed at 4 and 12 weeks was 100% and 99.8%, respectively.

Sex, HIV co-infection or psychiatric diseases were not associated with lower adherence.
Clinical pharmacy

No relationship was found between RVR and adherence but the EVR was found to be significantly greater with adherence levels >85% (11.1% vs. 48.3%). Adherence 280% was associated with (not significantly) higher rates of SVR (57.7% vs. 50%).

Conclusion Adherence >80% is associated with higher cure rates and adherence >85% at 12 weeks is related to greater EVR. No relationship was found between HCV-RNA decrease at 4 weeks and adherence. Neither psychiatric disorders nor HIV co-infection influenced adherence.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 Mathes I, Antoine SL, Pipher D. BMC Infectious Diseases 2014;14:203–16

No conflict of interest.

THROMBOPOIETIN RECEPTOR AGONIST TREATMENT IN IDIOPATHIC THROMBOCYTOPENIC PURPURA

1MH García Lagunar, 1E Español Morales, 1M Martínez Penella, 1M Muñoz García, 1M Gutiérrez Cívicos, 1E Ferris Villanueva, 1R Guerrero Bautista, 1A García Márquez, 1D Lacruz Guzmán, 1MS García Simón. 2Hospital General Universitario Santa Lucía, Farmacia Hospitalaria, Cartagena, Spain; 2Hospital General Universitario Santa Lucía, Hematología, Cartagena, Spain
10.1136/ejhpharm-2015-000639.79

Background Idiopathic thrombocytopenic purpura (ITP) is a disease characterised by decreased platelet count. Romiplostim and eltrombopag are thrombopoietin receptor agonists (TRAs) that stimulate platelet production.

Purpose To evaluate the effectiveness and safety of TRAs in patients with ITP in a university hospital.

Material and methods Retrospective observational study including patients with ITP who were treated with TRAs.

The information collected was: age, gender, previous treatments, length of treatment, response to treatment and side effects.

Results From October 2009 to July 2014, fourteen patients with ITP [10 women (71.4%) and 4 men (28.6%) with an average age of 48.0 ± 16.7 years] were treated with TRAs.

Patients were classified according to treatment received: 7 patients with eltrombopag (50.0%), 2 patients with romiplostim (14.3%), and 5 patients with both drugs in succession (35.7%).

Four patients (28.6%) had received one previous treatment line, nine patients (64.3%) two previous lines and one patient (7.1%) had received three.

Only one patient had been splenectomised before the treatment.

The average treatment duration was 6.6 ± 5.3 months in the romiplostim group and 7.1 ± 5.9 months in the eltrombopag group.

The responses to eltrombopag were: 4 complete responses (57.1%) and 3 responses (42.9%); and to romiplostim: 1 complete response (50.0%) and 1 response (50.0%); in the group with both drugs: 3 complete responses (60.0%), 1 no response (20.0%) and 1 complete remission sustained and prolonged after having stopped the treatment (20.0%).

No side effects were observed, with the exception of one deep venous thrombosis (DVT) with eltrombopag.

Conclusion Our results, as well as previous studies, show that patients with ITP, despite having received multiple lines of treatment, respond well to TRAs, including complete remissions and sustained remissions after having stopped the treatment.

Tolerance of TRAs is good although DVT may appear.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

MANAGEMENT OF UNCONTROLLED BLOOD PRESSURE IN PATIENTS WITH MULTIPLE DRUG INTOLERANCE REFERRED TO A SPECIALIST HYPERTENSION CLINIC

5 Antonioiu*, 5H Nhami, 5S Sauena, 5R Brier, 5R Robinson, 5V Kapil, 5M Lobo. 5St Bartholomew’s Hospital, Barts Health NHS Trust, Barts Hypertension Clinic and Department of Pharmacy, London, UK; 5London Chest Hospital, Barts Health NHS Trust, Department of Pharmacy, London, UK; 5St Bartholomew’s Hospital, Barts Health NHS Trust, Barts Hypertension Clinic, London, UK
10.1136/ejhpharm-2015-000639.80

Background The management of hypertension in patients with known multiple drug intolerance (MDI) is a fundamental challenge. Our hypertension specialist centre has devised an alternative protocol to standard dosing for patients referred with MDI. This includes use of fractional tablet dosing, liquid formulations and trans-dermal formulations of standard anti-hypertensive (s).

Purpose To assess the effects of an innovative approach to blood pressure (BP) control in patients with known MDI.

Material and methods We retrospectively analysed clinic letters for the first 25 patients with a diagnosis of MDI who had at least 3 clinic visits. Clinic BP and any modification to treatment were extracted. A change in clinic BP from baseline through subsequent visits was analysed. Data are expressed as mean ± Standard deviation.

Results 25 (15 female) patients (mean age 62.1 ± 12.0 years) were intolerant of 6.3 ± 3.6 anti-hypertensive medicines at the first visit with baseline clinic BP of 170 ± 21/98 ± 15 mmHg. Patients had 4.6 ± 1.5 follow-up visits over 1.2 ± 1.0 yrs. Clinic systolic/diastolic BP (SBP/DBP) were reduced compared to baseline over the period of follow-up (p < 0.001, p = 0.05 respectively, table 1).

Abstract CP-081 Table 1

<table>
<thead>
<tr>
<th>Change in clinic systolic and diastolic BPs compared to baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Visit (n)</strong></td>
</tr>
<tr>
<td>Δ SBP</td>
</tr>
<tr>
<td>Δ DBP</td>
</tr>
</tbody>
</table>

Conclusion Fractional tablet dosing may target multiple physiological pathways but minimise dose-dependent adverse effects. Liquid formulations avoid excipients that may contribute to adverse effects and trans-dermal patches overcome gastro-intestinal intolerance associated with tablets. This is the first dedicated anti-hypertensive protocol for high-risk patients with multiple medicines intolerance and application of our novel strategy. It demonstrated BP control improving consistently over subsequent visits.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:2560–72

No conflict of interest.
Differences in Effectiveness and Safety of Triple Therapy-Based Treatment Between Mono and Co-infected Hepatitis C Patients

Background: Triple therapy-based treatment with protease inhibitors in infected genotype 1 hepatitis C (HCV) patients improves efficacy measured as sustained virological response (SVR).

Purpose: To compare the effectiveness and safety of triple therapy-based treatment in mono-infected and co-infected HCV-HIV patients.

Material and methods: All treatments started between 2012/07/01 and 2013/12/31 were analysed. A retrospective evaluation was made of electronic medical records and outpatient pharmacy records. SVR was defined as undetectable viral load at week 60.

Results: 83 patients were included, 80 treated with telaprevir and 3 with boceprevir, 58 mono-infected and 25 co-infected patients. Baseline characteristics in mono-infected patients were: 83% male, mean age 54 years; 26 genotype 1a, 30 1b, 2 1u, 64% F4; 64% treatment-naive, 28% relapsers, 12% partial responders, 12% null responders and 8% no data. In co-infected patients: 84% male, mean age 50 years; 17 genotype 1a, 71b, 1 untypable; 64% F4; 40% were treatment-naive, 28% relapsers, 12% partial responders, 12% null responders and 8% no data.

We were able to assess the effectiveness of treatment in 71 patients, who achieved 60 weeks of treatment: 51 mono-infected and 20 co-infected.

In the mono-infected group: 21 (41%) achieved SVR (86% treatment-naive or relapsers), 20 (39%) had a detectable viral load (50% null responders) (3 boceprevir-treated) and 10 (20%) discontinued treatment due to toxicity or disease progression. This compared with 11 (55%) (73% treatment-naive or relapsers), 8 (40%) (38% null responders) and 1 (5%) in the co-infected group.

Adverse events were: anaemia 58%, neutropenia 81% and thrombocytopenia 36% in mono-infected vs. 44%, 80% and 80% in co-infected patients. This compared with 11 (55%) (73% treatment-naive or relapsers), 8 (40%) (38% null responders) and 1 (5%) in the co-infected group.

Conclusion: The rate of SVR was about 50%, higher in co-infected than in mono-infected HCV patients. However, it may have been affected by a greater proportion of null responders in the mono-infected group (p > 0.05), because as in published trials, the rates of SVR differed among patients with different responses to previous treatments.

References and/or acknowledgements:

No conflict of interest.

Prevalence of Malnutrition and Associated Risk Factors

Background: Malnutrition is a serious disorder that is frequently underestimated in patients hospitalised for other conditions.

Purpose: The principal objective was to assess the prevalence of malnutrition in elderly patients hospitalised to the Internal Medicine ward. The secondary objective was to determine the possible association between this condition and patient’s clinical characteristics in terms of comorbidity, functional status, cognitive impairment and dysphagia.

Material and methods: Descriptive, observational and cross-sectional study including 122 patients over 3 months (May–July 2014). We recorded: general data (age, sex, length of stay, Body Mass Index [BMI]), comorbidity (Charlson), cognitive impairment (Pfeiffer), functional status (Barthel), analytic parameters of interest (albumin, total protein, lymphocyte count and cholesterol) presence or not of dysphagia and pressure ulcers. Results were expressed in mean, standard deviation and percentages.

Results: The age of our group was 76.8 ± 6.2 (53.3% men). 55.7% of the elderly were malnourished when they were admitted. The Charlson index showed that 59% of them had comorbidity. The Barthel index was 34.7 ± 4, where 64.4% had severe or total dependence, and 28.7% had mild to severe cognitive impairment (Pfeiffer). The BMI was 22.9 ± 3.4 kg/m². The prevalence of dysphagia was 35%. We found an association between malnutrition and weight/BMI (p = 0.001 for both), age (p = 0.013), Pfeiffer (p = 0.003), Barthel (p = 0.000), dysphagia (p = 0.001), total protein (p = 0.015), lymphocyte count (p = 0.008) and presence of pressure ulcers (p = 0.002).

Conclusion: Malnutrition is a problem of high prevalence and impact in our population and our results are similar to those of other studies. It is of paramount importance to correctly evaluate the presence of risk factors and diagnose this condition in order to prevent/treat it correctly.

References and/or acknowledgements:

No conflict of interest.

Use of Infliximab for Steroid-Refractory Graft-Versus-Host Disease

Background: Corticosteroids are the standard care in graft-versus-host disease (GVHD). However, when the condition becomes refractory to steroids, one alternative is the off-label use of Infliximab.

Purpose: To evaluate the use of Infliximab in the treatment of Steroid-Refractory GVHD, in a tertiary care hospital.

Material and methods: Retrospective observational study of patients with Steroid-Refractory GVHD after stem cell transplantation (SCT), who received infliximab between Jan/2013 and Sep/2014. Data collected from medical records and the electronic prescribing database were: age, gender, underlying disease, SCT characteristics (date, sources of hematopoietic stem cells), GVHD characteristics (start date, stage and affected organs), infliximab dosage, duration of treatment, adverse events (AEs) and clinical results.

No conflict of interest.
Results Five patients (60% men) with an average age of 51.8 years [22–68] were included. The underlying diseases were myelodysplastic syndrome (n = 2), multiple myeloma (n = 1), Hodgkin’s lymphoma (n = 1) or acute myeloid leukaemia (n = 1). Patients underwent bone marrow (n = 4) or peripheral blood (n = 1) HLA-matched allogeneic SCT. In all but one patient stem cells were obtained from unrelated donors. The onset of GVHD was acute in 3 patients and chronic in 2, was classified as stage II (n = 2), III n = 2) or IV (n = 2) and the main organs involved were the gastrointestinal tract (100%) and skin (60%). Infliximab 10 mg/kg/week was administered after failure of corticosteroids and photopheresis. The average number of doses administered was 3.8 [1–6]. 3 patients failed to respond (2 died due to complications of GVHD) while the other two achieved a partial and a complete response. Infliximab intravenous infusion was well tolerated and the most common AEs were infections.

Conclusion Infliximab could be a feasible option for treating Steroid-Refractory GVHD in the opinion of the literature and our findings. Its administration has been shown to be related to an increased risk of infections. Future research with larger populations is needed to obtain stronger conclusions.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-085 COMPARISON OF BILIRUBIN LEVELS WITH TWO INTRAVENOUS LIPID EMULSIONS IN PREMATURE INFANTS REQUIRING PARENTERAL NUTRITION

R López-Sepúlveda, CM Valencia Soto, Pérez-Morales, Vallejo-Capilla. Hospital Universitario Virgen de las Nieves, Pharmacy, Granada, Spain; Hospital Universitario Virgen de las Nieves, Farmacia, Granada, Spain

Background Soybean lipid emulsions in parenteral nutrition (PN) are associated with liver disease. This has led to the development of alternative intravenous lipid emulsions (ILEs).

Purpose To compare the effects of two new ILEs: Lipoplus (soybean with fish oil) and Clinoleic (soybean with olive oil).

Material and methods Retrospective observational study using pharmacotherapeutic records of premature infants who started PN between December 2012 and May 2014 in a tertiary care hospital. We included infants requiring 25 days of PN with a gestational age <34 weeks and birth weight between 0.5 and 2 kg. Clinical information included gender, gestational age and body weight. Laboratory data recorded included total (TB), conjugated (CB) and unconjugated bilirubin (UB) (mg/dL). Either Lipoplus or Clinoleic was used as the clinician requested. Comparisons were done using t-tests.

Results 24 children were included (16 male and 8 female); 17 (70.8%) treated with Lipoplus and 7 (29.2%) with Clinoleic. Mean gestational age was 29 weeks for both treatments. Average weight at the beginning of PN was 1.23 kg for Lipoplus and 1.32 kg for Clinoleic.

No differences were detected in bilirubin levels between groups at baseline (Lipoplus: CB: 0.9; UB: 8.7; TB: 8.7. vs. Clinoleic: CB: 0.3; UB: 7.8; TB: 9.0; p = n.s.) or at completion of treatment (Lipoplus: CB: 0.7; UB: 9.8; TB: 8.7 vs. Clinoleic: CB: 0.5; UB: 9.2; TB: 9.4; p = n.s.). No decrease in TB, CB or UB vs. baseline was observed for either treatment.

Conclusion We found no significant difference in benefit or less persistent hyperbilirubinaemia between infants treated with Lipoplus or Clinoleic. Treatment with soybean emulsion vs. new ILEs has resulted in a significant decrease in total/conjugated bilirubin vs. baseline. However previous studies also showed no significant differences in total/conjugated bilirubin levels between the new ILE treatments.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 M. Rayan, et al. 2012

No conflict of interest.
Clinical pharmacy

Incorporation of the pharmacist in this unit makes it possible to monitor patient nutrition during hospitalisation.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-087  ANTIRETROVIRAL THERAPY: ARE WE USING THE MOST EFFICIENT TREATMENT?

1F Artime-Rodriguez-Hermida, 2EM Gonzalez-Gonzalez, 1AM Marzano-Bonilla, 1CM Valencia Soto*, 1Hospital Universitario Virgen de Las Nieves, Farmacia, Granada, Spain; 2Hospital de Santa Ana, Farmacia, Motril, Spain

Background The arsenal of drugs available to antiretroviral therapy (ART) is extensive. It’s important to optimise HIV treatment basing on recommendations established by experts.

Purpose To analyse prescription profile, treatment changes, causes and financial impact of the changes in a first level hospital.

Material and methods Observational retrospective study from January 2013 to March 2014. The variables studied included: demographics (age, gender), clinical data (age at diagnosis, HCV/ HBV co-infection, stage, HLAB5701 allele, viral load (VL) and CD4 cells before/after the change, reason for change) and financial analysis (cost per month before/after the change). Data were obtained from medical records and the electronic prescription programme.

GESIDA 2014 recommendations were considered as therapeutic strategies to improve efficiency and safety.

Results Out of the 178 patients receiving ART, 40 (22.5%) patients, who switched treatment were analysed.

The average age was 44.7 (22–57), 72.5% were male, 60% co-infected with HCV. The most frequent stage was C3 (40%). The average time since diagnosis was 14.6 years.

Before changing treatment 62.5% patients had undetectable VL (68% for at least six months) and the mean CD4 cell was 596.68 cells/mm³. HLAB5701 determination was available only in 15% (100% negative).

Reasons for change were: 52.5% adverse reactions (ADRs) (38% renal failure), 12.5% prevention of ADRs, 10% virological failure, 10% development of resistance, 7.5% reduction in the number of tablets, 2.5% immune failure, 2.5% unknown reason and only 2.5% therapeutic simplification.

These changes assumed an average cost increase of 21% per patient/month.

With these data 25% of our patients could be candidates for monotherapy and 17.5% for changing the combination of NRTI (Tenofovir/Emtricitabine for Lamivudine/Abacavir).

Conclusion ART has a high impact on the hospital budget. It is necessary to include efficiency strategies in changes of treatment and ART initiation.

We suggest developing with the infectious unit a protocol consistent with the existing recommendations, including an algorithm to support medical decision-taking in the light of safety and efficiency criteria.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-088  EVALUATION OF STANDARD PARENTERAL NUTRITION IN SURGICAL PATIENTS

1M Moya-Martín*, 1M Donoso Rengifo, 1 Castañoa Macías, 1M Vázquez-Real, 1S Santana, 1A María Dolores, 1C Menaes Mangas. 1Hospital Universitario Virgen Macarena, Pharmacy, Seville, Spain; 2Hospital Infantia Cristina, Pharmacy, Badajoz, Spain

Background Surgical patients are especially susceptible to nutritional disorders; additionally an adequate nutritional status is important in achieving prompt recovery.

Purpose To describe and analyse possible shortcomings related to nutritional status of surgical patients associated with an inadequate prescription of parenteral nutrition (PN).

Material and methods A prospective, observational study, lasting two months, of post-surgical patients in a third level hospital with PN support.

Estimated calorie requirements (CR) of surgical patients were calculated. The Harris-Benedict formula was the method used to evaluate CR taking into account the degree of metabolic stress in each surgical patient.

Data were collected from the medical history of each patient: age, diagnosis, duration of PN support, glycaemia, electrolytes, total proteins and other haematological parameters.

An assessment was made of how many blood tests were requested for every patient, at the beginning, during and at the end of parenteral support.

Results A total of 75 patients were studied. In 19.2% of cases the CR were successfully supplied. In 72.6% of cases the prescribed caloric intake was insufficient compared to their estimated CR. In the remaining 8.2% of cases the caloric intake exceeded their estimated CR.

23.2% of the patients studied were obese. In 76.5% of them, the prescribed caloric intake differed from the estimated CR, despite the body weight calculation being adjusted for these patients.

Conclusion Our study showed that 80.8% of patients were not given sufficient nutritional support, missing their estimated CR. It shows the lack of a structured protocol to addresses the nutritional assessment in surgical patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.

CP-089  TIME EFFECTS OF INTRAVENOUS LIPID EMULSIONS ON PREMATURES

R López-Sepúlveda, J Pérez-Morales*, CM Valencia Soto, P Vallecillo-Capilla. Hospital Universitario Virgen de Las Nieves, Pharmacy, Granada, Spain

Background Liver disease is associated with soybean lipid in parenteral nutrition (PN). This has led to the development of alternative intravenous lipid emulsions (ILEs).

Purpose Here we compare the effects of Lipoplus (medium chain triglyceride combined with soybean and fish oil) in treatments of 7 days vs. longer treatments.
Material and methods Retrospective observational study using pharmacotherapeutic records of premature infants who initiated PN between December 2012 and May 2014 in a tertiary care hospital. Infants were included with a gestational age <34 weeks and birth weight between 0.5 and 2 kg. Data recorded included gender, gestational age, body weight and total (TB), conjugated (CB) and unconjugated bilirubin (UB) (mg/dL). Comparisons were made with t-tests.

Results Of the 17 infants selected, 10 (58.8%) (7 male, 3 female) were treated for 5 to 7 days (Group A) and 7 (41.2%) (5 male, 2 female) were treated for more than a week (Group B). Mean gestational age was 29 weeks for both groups. Average weight at the beginning of PN was 1.37 kg for Group A and 1.03 kg for Group B.

Differences vs. baseline were observed between the two treatments:

Group A = CB: 0.35 vs. 0.39; p = n.s. UB: 7.9 vs. 11.25; p = 0.04. TB: 8.25 vs. 11.61; p = 0.04.

Group B = CB: 1.71 vs. 1.5; p = n.s. UB: 7.74 vs. 6.15; p = n.s. TB: 9.46 vs. 4.47; p = 0.04.

A significant increase in CB and TB was observed in group A, therefore a significant decrease in TB was detected in group B.

Conclusion We found that treatments longer than 7 days with new ILEs significantly lowered TB levels in premature infants as described previously. On the other hand, shorter treatments with alternative ILEs might have an effect similar to the use of soybean oil-based emulsion in that previous study, where CB even showed a significant increase.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 Rayan et al. 2012
No conflict of interest.

Clinical pharmacy

Material and methods Retrospective observational study using pharmacotherapeutic records of premature infants who initiated PN between December 2012 and May 2014 in a tertiary care hospital. Infants were included with a gestational age <34 weeks and birth weight between 0.5 and 2 kg. Data recorded included gender, gestational age, body weight and total (TB), conjugated (CB) and unconjugated bilirubin (UB) (mg/dL). Comparisons were made with t-tests.

Results Of the 17 infants selected, 10 (58.8%) (7 male, 3 female) were treated for 5 to 7 days (Group A) and 7 (41.2%) (5 male, 2 female) were treated for more than a week (Group B). Mean gestational age was 29 weeks for both groups. Average weight at the beginning of PN was 1.37 kg for Group A and 1.03 kg for Group B.

Differences vs. baseline were observed between the two treatments:

Group A = CB: 0.35 vs. 0.39; p = n.s. UB: 7.9 vs. 11.25; p = 0.04. TB: 8.25 vs. 11.61; p = 0.04.

Group B = CB: 1.71 vs. 1.5; p = n.s. UB: 7.74 vs. 6.15; p = n.s. TB: 9.46 vs. 4.47; p = 0.04.

A significant increase in CB and TB was observed in group A, therefore a significant decrease in TB was detected in group B.

Conclusion We found that treatments longer than 7 days with new ILEs significantly lowered TB levels in premature infants as described previously. On the other hand, shorter treatments with alternative ILEs might have an effect similar to the use of soybean oil-based emulsion in that previous study, where CB even showed a significant increase.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 Rayan et al. 2012
No conflict of interest.
A dose modifications protocol, based on published guidelines and agreed with the departments involved, should be implemented in all units administering treatment to cancer patients. Other considerations apart from laboratory tests, such as tolerability and tumour response, should be taken into account.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

CP-092
ESTIMATED RATE OF THERAPEUTIC FAILURE WITH PALIVIZUMAB IN THE PROPHYLAXIS OF RESPIRATORY SYNCTIAL VIRUS
V Cabezas, S Fernandez, L Garcia*, S Fernandez, ME Cardaba. Hospital Clínico Universitario Valladolid, Farmacia, Valladolid, Spain
10.1136/ejhpharm-2015-000639.91

Background There is doubt about the criteria for selection of patients eligible to receive palivizumab prophylaxis for respiratory syncytial virus (RSV) and the potential therapeutic failures.

Purpose To estimate the rate of therapeutic failure with palivizumab and drug use profile in the study centre.

Material and methods Observational, retrospective study. Patients who received palivizumab in 3 seasons (2006–2009) were selected and medical records were reviewed.

Variables:
- Dependent: Rate of therapeutic failure with palivizumab.
- Independent: Profile of drug use in the study centre.

Results Data were obtained from 104 patients: 15/104 were children <2 years with hemodynamically significant congenital heart disease, 10/104 children <2 years with bronchopulmonary dysplasia (BPD), 65/104 patients were preterm born before the 35th week of gestation and 14/104 patients did not fit the approved indications.

In 100% of patients, palivizumab was prescribed according to the recommended dosage, and the number of doses prescribed was correct in 99% of cases. 81.7% of patients received all prescribed doses.

Other risk factors analysed:
- 66/104 were male.
- 13/104 had a chronological age <10 weeks at the start of the season and 9/104 were born in the first 10 weeks of the season.
- 40/99 had low birth weight (1,500–2,500 g), 45/99 very low birth weight (<1,500 g), 14/99 the right birth weight, 5/104 unknown birth weight.
- Breastfeeding was continued for at least 2 months in 42/93 patients.

The rate of therapeutic failure with palivizumab was 3.8%, of the total 104 patients receiving prophylaxis with palivizumab, 4 required hospitalisation for RSV infection.

Conclusion
- The drug use profile in the study centre matched the licensed indications in the SmPC. A protocol that allows an annual review of the criteria for selecting patients for treatment with palivizumab was developed.
- The rate of therapeutic failure in our study context was very low, so the drug can be considered effective.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

CP-093
USE OF FAMPRIDINE IN MULTIPLE SCLEROSIS PATIENTS
10.1136/ejhpharm-2015-000639.92

Background Fampridine is a drug indicated to improve walking in adult patients with multiple sclerosis (MS). Patients should be evaluated after two weeks and treatment should be stopped for those who have not shown any improvement.

Purpose To evaluate walking improvement in multiple sclerosis patients treated with fampridine and compliance with the condition of stopping the drug at two weeks in the absence of improvement.

Material and methods Retrospective study in MS patients treated with fampridine (January/2014–September/2014). Timed 25-Foot Walk (T25FW) and Twelve Item MS Walking Scale (MSWS-12) were used to evaluate drug response. Data recorded were age, gender, and results of T25FW and MSWS-12 at baseline and after two weeks of treatment. Drug discontinuation in non-responders was evaluated. Means were calculated and comparisons were performed by using Wilcoxon Signed Rank test.

Results 10 adult MS patients were included in the study (40% male; mean age 53 ± 9.7 years). 90% improved their walking tests. Baseline mean time for T25FW was 12.2 ± 5.9 s initially and 8.96 ± 3.8 s after 2 weeks (p = 0.007).

MSWS-12 reflected a significant improvement in the following items: balance, time standing, walking speed and distance (p ≤ 0.05). No difference was detected for the following items: ability to run (p = 0.317) and the need for using a walking support outdoors (p = 0.590) or indoors (p = 0.157).

There was only one non-responding patient who didn’t stop drug treatment.

Conclusion The walking of most patients on fampridine had improved at two weeks especially regarding balance, distance and time standing. The stopping criterion was not observed in one non-respondor.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 EMA Product information fampridine
No conflict of interest.

CP-094
THE EFFECT OF ADDING ANTI-HCV TO ANTIRETROVIRAL TREATMENT ON ADHERENCE
1 E Calvo-Cidoncha, 1 J Gonzalez-Bueno, 2 MD Santos Rubio*, 2 MI Sierra Torres, 1 AM Tristán-Pérez, 1 R Morillo Verdugo. 1Nuestra Señora de Valme Hospital, Pharmacy, Sevilla, Spain; 2Virgen Del Rocío Hospital, Pharmacy, Sevilla, Spain
10.1136/ejhpharm-2015-000639.93

Background The addition of anti-HCV treatment to highly active antiretroviral treatment (HAART) in HIV/HCV co-infected patients leads to an increase in the treatment complexity which may result in reduced adherence.

Purpose To determine whether the number of patients adherent to HAART decreased after the addition of anti-HCV treatment to HAART.

Material and methods We conducted a prospective two-centre observational study. HIV/HCV co-infected patients on HAART who started anti-HCV dual or triple therapy between January 2011 and December 2013 were included. Patients were excluded if they were virologically uncontrolled (>50 copies RNA VIH/mL) or their HAART had been modified in the six
months before starting anti-HCV treatment. Variables collected were: demographics, anti-HCV treatment, weeks on anti-HCV treatment and adherence. Medicines adherence was assessed using electronic pharmacy repeat dispensing records. The threshold for optimal adherence was ≥95%. McNemar’s test was applied to compare adherence before and after the addition of anti-HCV treatment to HAART using SPSS-20.

**Results** 66 patients were included (86% male, mean age 47 ± 5). 53 (80%) patients were on dual therapy with peg-interferon and ribavirin, 11 (17%) patients were on triple anti-VHC treatment with telaprevir and 2 (3%) were treated with boceprevir. The median duration of the anti-HCV treatment was 45.6 (IQR: 20.4–49.1) weeks. 50 (76%) patients were considered adherent to HAART before starting anti-HCV treatment. After the addition of anti-HCV treatment, the number of adherent patients decreased to 45 (68%), p > 0.05. Subgroup analysis based on the anti-HCV treatment showed that patients adherent on anti-HCV dual therapy decreased from 42 (64%) to 37 (56%), p > 0.05. The number of adherent patients did not change in those on anti-HCV triple therapy.

**Conclusion** The introduction of anti-HCV dual therapy to HAART is associated with a tendency towards a decrease in the number of adherent patients.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

**REFERENCES**

1. *AIDS Behav* 2013;17:94–103

No conflict of interest.

**CP-095 KETOCONAZOLE IN CHEMO-NAÏVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER**

1. Gonzalez-Bueno, 2. E. Calvo-Cidona, 3. MD Vega-Coca, 4. MD Santos Rubio*, 5. M. Sierra Torres, 6. E. Bautista-Paloma, 7. Virgen Del Rosario Hospital, Pharmacy Department, Seville, Spain; 8. Virgen de Valme Hospital, Pharmacy Department, Seville, Spain

10.1136/ejhpharm-2015-000639.94

**Background** Kетoconazole has been extensively used in chemo-naive patients with metastatic castration-resistant prostate cancer (mCRPC) due to the absence of therapeutic alternatives.

**Purpose** To determine the effectiveness of ketoconazole in chemo-naive patients with mCRPC.

**Material and methods** Retrospective observational study of chemo-naive patients treated with ketoconazole for ≥3 months for mCRPC between 06/2010–06/2014 in a tertiary hospital.

**Results** In accordance with the literature review, drugs were selected using the following criteria: frequency of preparation above 250 preparations per year. Implementation of DB could reduce patient waiting time and improve capacity planning of our cytotoxic preparation unit (CPU).

**Conclusion** Before implementation, this DB project should be approved by the medical staff and some practical constraints such as software, system management, storage, control should be developed. On the other hand, the status of these preparations has not been clearly established by the health authorities in France. They can be considered hospital preparations (authorisation request, statement, and compliant with Good Manufacturing Practice) or compounded medicines requiring an early prescription.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.
Clinical pharmacy

**CP-097** DOE ADJUSTMENT OF TENOFOVIR IN HIV PATIENTS WITH URINARY TRACT IMPAIRMENT

R Vázquez Sánchez*, I Sánchez-Rubio, T Molina Garcia. Hospital Universitario de Getafe, Farmacia, Madrid, Spain

10.1136/ejhpharm-2015-000639.96

**Background** Tenofovir (TDF) is used in combination for first-line treatment in HIV infection due to its efficacy and tolerability. However, the use of TDF may be associated with renal toxicity, so it is recommended to tailor the dose in patients with CrCl < 50 mL/min.

**Purpose** To determine the number of patients receiving TDF with CrCl < 50 mL/min, and to evaluate whether dose adjustment is being performed properly in accordance with the recommendations.

**Material and methods** A retrospective and observational study in HIV-infected adult patients treated with TDF (January 2010–December 2012) was carried out in a tertiary General Hospital (600 beds). The Inclusion criteria were: baseline normal CrCl, more than six months on TDF treatment and three CrCl determinations. Potential risk factors analysed were: age, gender, baseline CD4 and HIV RNA, previous treatment, comorbidities and use of co-formulated presentation. The CrCl was calculated using the MDRD formula. The prevalence of renal insufficiency (CrCl < 50 mL/min) and the degree of compliance with the GESIDA guidelines (300 mg/48 h for patients with CrCl < 50 mL/min and 300 mg/72–96 h for patients with CrCl < 30 mL/min) were calculated.

**Results** 451 patients were included (68.2% male, mean age = 46.2 ± 8.2 years), 4.8% of patients had renal impairment with CrCl < 50 mL/min. 14% of patients had CrCl < 30 mL/min. 59.1% of patients were treated with combined TDF and boosted protease inhibitor (PI) treatment. 100% of patients used a co-formulated TDF presentation.

No doses were tailored in any patients according to renal impairment, while 40% of patients changed the treatment to TDF-free combinations.

**Conclusion** Patients on treatment with TDF rarely need a dose adjustment due to renal impairment. Moreover, the dose was not adjusted for any patients with renal impairment, while a change of treatment was preferred.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

1 GEFIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus

No conflict of interest.

**CP-098** RISK FACTORS OF URINARY TRACT INFECTION IN PATIENTS TREATED WITH ABRIRATERONE

R Vázquez Sánchez*, L López Esteban, B Reques Sastre, A Onteniente-González, ME Martínez Nuñez, T Molina Garcia. Hospital Universitario de Getafe, Pharmacy, Madrid, Spain

10.1136/ejhpharm-2015-000639.97

**Background** Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer. One of the most common side effects (affecting more than 10% of patients) associated with abiraterone is urinary tract infection (UTI).

**Purpose** To assess abiraterone-associated UTI prevalence in cancer patients and the potential factors that contribute to this adverse effect.

**Material and methods** Retrospective observational study (September 2011–September 2014). All patients on treatment for at least one cycle of 28 days with abiraterone were included. The data recorded were: age, duration of treatment with abiraterone, whether patients suffered UTI during treatment with abiraterone, the urinary pathogen and the treatment of the infection. The potential risk factors found were: pre-infection surgical manipulation of the urinary tract, previous use of antibiotics and urinary catheterization. Categorical variables were compared by Chi-square test. Multivariate analysis was performed on parameters with p < 0.10 in univariate models. The p-values <0.05 were regarded as significant.

**Results** 31 patients were included in the study. The mean duration of treatment was 195.28 days. 5 patients suffered UTI (16%).

In the univariate analysis, variables related to UTI were urinary catheterization (OR = 10.67; CI 95% 1.91–59.62; p = 0.007) and surgical manipulation of the urinary tract (OR = 14.67; CI 95% 1.83–117.68; p = 0.011). In multivariate analysis, none of these factors were significantly associated with UTI (urinary catheterization: OR = 8.07; CI 95% 0.7–96.52; p = 0.099); surgical manipulation: OR = 9.17; CI 95% 0.97–87.25; p = 0.054).

Nonetheless, there was a trend towards a higher risk of UTI in patients with previous urologic surgery.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

**CP-099** FAMPRIpine, A NEW APPROACH IN THE TREATMENT OF MULTIPLE SCLEROSIS: Efficacy in Improving Walking and Quality of Life

5 S Barbadillo*, 1 V Benito, 1 Aicua, 2 S Calvo, 1 C Hermida, 7 N Hernera, 7 M Fernandez, 1 Cabia. 1Hospital Universitario de Burgos, Hospital Pharmacy, Burgos, Spain; 2Hospital Universitario de Burgos, Neurology, Burgos, Spain; 7Hospital Universitario de Burgos, Investigation, Burgos, Spain

10.1136/ejhpharm-2015-000639.98

**Abstract CP-098 Table 1**

<table>
<thead>
<tr>
<th>Urinary pathogen</th>
<th>Risk factors</th>
<th>Surgical manipulation</th>
<th>Use of antibiotic</th>
<th>Catheter</th>
</tr>
</thead>
<tbody>
<tr>
<td>UTI pathogen</td>
<td>*Non typical UTI pathogen</td>
<td>2</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

**Conclusion** There are patients treated with abiraterone who suffer UTI, but it is necessary to consider other possible risk factors before thinking of it as a direct side effect.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.
Background Multiple Sclerosis (MS) is a neurological disease in which myelin is destroyed, impairing nerve impulse conduction.

Fampridine is the first drug authorised for improving walking. It is a potassium channel blocker that improves electrical transmission for muscle stimulation.

Purpose To describe changes in quality of life of patients receiving fampridine regarding health perception (subjective change) and improved walking (objective change).

Material and methods Prospective study during the first two weeks of patient treatment. Patients received fampridine 10 milligrams every 12 h plus their usual MS drugs. Health perception was measured by MS Quality Of Life-54 questionnaires and point-in-time assays of physical and mental health before and after taking fampridine. Changes in walking were measured by the Timed 25-Foot Walk (T25FW) test (time to walk 7.5 metres).

Sample population was characterised by age, type of MS, and Expanded Disability Scale System (EDSS) point-in-time assays (disability due to MS from 1 to 10, 10 being death). Results before and after treatment were analysed with Student’s t-test. Statistically significant relationships between variables were evaluated by applying appropriate tests.

Results 39 patients, mean age 49, standard deviation (σ) 12.6. 15.4% had Relapsing-Remitting MS, 69.2% Secondary Progressive MS and 15.4% Primary Progressive MS. Mean EDSS score 5.5, σ 1.15.

Physical health improved 9.05 points, confidence interval CI (5.57–12.52), p < 0.05. Mental health improved 6.62 points CI (3.58–9.68) p < 0.05. TW25F was reduced by 9.04 s CI (~11.93, ~6.14), p < 0.05. Improvement was independent of MS type and EDSS punctuation, p < 0.05. Physical and mental improvement were directly related.

Conclusion The rapid effect of fampridine was obvious. Improvement in physical health (both subjective and objective measures) was observed. This might be because the mechanism of action directly targets the motor system. The relationship between physical and mental improvement is coherent, because personal autonomy raises self-esteem. Evaluation in larger samples and over a longer period is needed in order to substantiate a maintained benefit.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-100 PHARMACEUTICAL INTERVENTION IN NUTRITIONAL SUPPORT IN POSTSURGICAL INTENSIVE CARE UNIT


10.1136/ejhpharm-2015-000241.100

Background The clinical pharmacist’s main functions in parenteral nutrition (PN) are to ensure the appropriate assessment and monitoring of nutritional support according to the type of illness and the patient’s condition and to verify the quality and safety of the solutions prepared.

Purpose To describe the pharmaceutical interventions (PIs) made in patients hospitalised in a postsurgical intensive care unit.

To find the degree of acceptance of the PIs and their relevance to patient care.

Material and methods Retrospective six-month study (January–June 2014).

All PIs were recorded in each patient’s electronic medical record and in a special data sheet which included the indication for PN, laboratory data, type of nutrition, type of intervention and acceptance.

Results Nutritional monitoring was performed in 40 patients. 442 PIs were carried out during the study period, with a mean of 11 PIs/patient.

The PIs were categorised as the following:

- Nutrition assessment (n = 158; 36%)
- Intravenous fluids needs (n = 26; 6%)
- Electrolyte imbalances (n = 136; 30%)
- Prevention of liver disease caused by PN (n = 34; 8%)
- Others (food allergies, glucose management, laboratory monitoring, administration of glutamine and omega 3 fatty acids) (n = 88; 20%)

The overall degree of acceptance of the interventions was 99%.

Conclusion The high number and variety of types of PI performed by the pharmacist contributed to improving nutritional support and reducing complications, ensuring a more effective and safer use of PN.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. ESPEN Guidelines for adult parenteral nutrition

No conflict of interest.

CP-101 COLLABORATION BETWEEN HOSPITAL PHARMACY AND PRIMARY CARE PHARMACY: ASSESSMENT OF ANTIRETROVIRAL AND ANTINEOPLASTIC TREATMENT PRESCRIBED WITH ANTIULCER TREATMENT

1. A López Insua*, 2C Marquina Verde, 2C Ramos Hernández, 1S Barbado Villanueva, 1V Benito Ibáñez, 1L Izquierdo Acosta, 1M Fernandez Vicente, 1R Martinez de Arriba, 1B Oca Luis. 1University Hospital of Burgos, Hospital Pharmacy, Burgos, Spain; 2 Primary Care Management, Primary Care Pharmacy, Burgos, Spain.

10.1136/ejhpharm-2015-000241.100

Background Some patients get prescriptions from the Primary Care Physician (PCP) and the Specialist Attention Physician (SAP) at the same time, without pharmaceutical validation to detect potential interactions between them.

One example is antiretroviral and antineoplastic drugs given concomitantly with antiulcer treatment. Combination of these drugs leads to the decreased absorption and the consequent loss of efficacy of antiretrovirals and antineoplastics.

Purpose To identify patients who are under antiretroviral/antineoplastic and antiulcer treatment concomitantly.

To suggest suitable antiulcer treatment to PCPs and SAPs.

To evaluate the effect of this strategy.

Material and methods Patients on treatment with rilpivirine, elotibin, gefitinib, dasatinib and lapatinib were identified from the Hospital Pharmacy Outpatient Unit.

Patients on treatment with proton pump inhibitors (PPI) and H2 receptor antagonists (H2RA) were identified from the Primary Care Information System, from May 2014 to September 2014.

Once our target patients were identified, the Primary Care Pharmacy Department reported the interaction to the PCPs involved, suggesting either a switch from PPI to H2RA, a dosage modification or treatment termination.
SUCCESSFUL ANTIDEPRESSANT TREATMENT WITH AN
OPTIMISATION OF ANTIBIOTIC TREATMENT IN
A42

Mean age was 66.8 years (range 49–82); 68.75% men.
Treatments: 1 patient rilpivirine plus PPI, 6 erlotinib plus PPI,
1 erlotinib plus antiH2, 4 gefitinib plus PPI, 2 dasatinib plus PPI
and 2 lapatinib plus PPI.

After notification, 4 patients had a change in their treatments
(25%), mean age 64.8 years (range 59–68) 75% men: 2 PPI
treatment terminations and 2 switches from PPI to H2,RA.

Conclusion It is necessary improves coordination between Pri-
mary Care Pharmacy and Hospital Pharmacy to identify and
minimise drug-related problems.

Moreover, it would be advisable to develop a unique medi-
cines record in order to provide effective pharmaceutical care.
A better tool of communication with physicians should be investi-
gated because the effect of the intervention was moderate
(25%).

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
of which 75% were accepted, eventually resulting in 11% inappropriate treatments.

Antibiotic prescription patterns had changed during the POST-period. There was a reduction in overall carbapenem use with an increased narrow-spectrum prescription (DDD-100 bed-days): amoxicillin-clavulanate (37.3 vs. 32.6), piperacillin-tazobactam (2.7 vs. 1.6), ciprofloxacin (7.6 vs. 6.9) and metronidazole (4.7 vs. 4.3). Carbapenems consumption went down to 15.2 DDD/100 bed-days in the post-period vs. 18.5 DDD/100 bed-days in the Pre-period.

Conclusion

- Use of broad-spectrum antibiotics is reduced and de-escalating has been promoted.
- Taking samples prior to initiation of antibiotic treatment is encouraged.
- The increased treatment length (26%) was probably due to more serious infections.
- The multidisciplinary approach is one of the main tools of optimisation-antimicrobial-use-programs.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-104 ROLE OF STATINS ADDED TO INTERFERON TREATMENT IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS: A META-ANALYSIS

L López Esteban*, A. Linas Medina, B. Reques Sastre, R. Vázquez Sánchez, J. Sánchez-Rubio Ferrández, T Molina García. Hospital Universitario de Getafe, Pharmacy, Getafe, Spain

10.1136/ejhpharm-2015-000639.103

Background Multiple sclerosis is a chronic inflammatory disorder of the central nervous system. Statins have demonstrated anti-inflammatory and immunomodulatory properties in this setting. Several clinical studies of different statins, given alone or in combination with interferon, for relapsing-remitting multiple sclerosis (RRMS) have been conducted with conflicting results.

Purpose To review the efficacy and safety of statins in combination with interferon treatment in patients with RRMS.

Material and methods A systematic review of the literature and meta-analysis was performed by searching in MEDLINE, Cochrane CENTRAL Registry and EMBASE, to October 2014. Trials comparing the use of interferon alone or combined with statins in adult patients with RRMS were identified. Trials with a period of follow-up ≥ 3 according to the Jadad scale were considered. Pooled effect was calculated for the following outcomes: risk of relapse, treatment withdrawal due to adverse effects and risk of myalgia.

A DerSimonian-Laird random-effects model was used to calculate pooled Odds Ratios. Statistical heterogeneity was examined using the I² statistic. For significant differences, publication bias was estimated by using the Rosenthal index.

Results Six trials were included in the analysis (n = 1,484; range of follow-up = 6–36 months). The evaluated statin was simvastatin in three trials and atorvastatin in two trials. The other trial also included pravastatin, lovastatin and fluvasatin. No significant difference was found between the statin and control group regarding the risk of relapse (OR, 1.06; 95% confidence interval [CI], 0.64 to 1.74; p = 0.82), risk of myalgia (OR, 1.56; 95% CI, 0.59, 4.11; p = 0.36) or risk of withdrawal due to adverse effects (OR, 1.37; 95% CI, 0.57 to 3.30; p = 0.49). I² test revealed that heterogeneity was low for all the analyses performed.

Conclusion Our results revealed that the addition of statins to interferon treatment did not significantly affect the risk of relapse, myalgia or treatment withdrawal due to adverse effects in patients with RRMS.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-105 EFFECTIVENESS AND SAFETY OF PROTEASE INHIBITORS TELAPREVI AND BOCEPREVI IN THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS IN CLINICAL PRACTICE

O Delgado Sánchez*, P Ventayol Bosch, J Serrano Lopez de las Hazas, A. Anoz Jiménez, G Mercadal Orfila, M Maestre Fullana, F Fernández Cortés, M Vilanova Molto, M Boronat Moreiro, M Zaforteza Descallar, Son Espases University Hospital, Pharmacy, Palma de Mallorca, Spain; Son Llàtzer Hospital, Pharmacy, Palma de Mallorca, Spain; Can Misses Hospital, Pharmacy, Ibiza, Spain; Hospital Maesto Orfila, Pharmacy, Mahón, Spain; Hospital de Manacor, Pharmacy, Manacor, Spain; Hospital de Inca, Pharmacy, Inca, Spain; Servicios Centrales Ib-Salut, Pharmacy, Palma, Spain

10.1136/ejhpharm-2015-000639.104

Background The efficacy of triple therapy (pegylated-interferon/ribavirin with boceprevir (BOC) or telaprevir (TVR) in phase III trials is known but not the effectiveness of HCV treatment in clinical practice.

Purpose To investigate the effectiveness and safety of triple therapy with protease inhibitors TVR or BOC in the treatment of patients with Hepatitis C Virus (HCV) in clinical practice.

Material and methods A retrospective observational study with HCV-infected patients treated with TVR or BOC who had completed 60 weeks from the start of treatment in six public hospitals serving 1,100,000 inhabitants. Patients who started treatment between January 2012 and March 2013 were included. We assessed the percentage of patients with a 12-week sustained viral response (SVR12) and the percentage of treatments discontinued due to adverse effects.

Results 160 patients were treated; 9 patients were excluded as SVR12 had not been recorded, leaving 151 patients for analysis. Characteristics: male 66%, age 51 years (range 28–70); 98% genotype-1; 73% HCV-RNA > 800,000 IU/ml; Previous treatment: 48% treatment-naïve, 25% relapers, 13% partial responders, 11% null responders, 1% post-transplant reinfection and 1% unknown. Fibrosis stage: 55% F4, 33% F3, 9% F2, 2% F1, 1% unknown. 87% with TVR and 13% with BOC.

Of the patients, 57% achieved SVR12 (60% naïve, 68% relapers, 40% partial responders, 37% null-responders or unknown, 100% post-transplant reinfection). According to fibrosis stage the response was 0% F1, 28% F2, 62% F3, 61% F4.

Treatment was discontinued in 17 patients (11.3%) due to severe adverse effects.

Conclusion Although the treated population presented an advanced stage of fibrosis (88% F3-F4), 57% achieved SVR12, lower than the pivotal TVR study. Compared to the International Telaprevir Access Program (similar to this cohort), we achieve a lower response in almost all types of patients, especially in partial responders (15% lower response rate). The side effect profile was slightly lower than other published series.

REFERENCES AND/OR ACKNOWLEDGEMENTS

None

No conflict of interest.
Clinical pharmacy

**CP-106** OSELTAMIVIR USE

L Ruiz González*, MT Perez Maroto. Hospital Universitario de Guadalajara, Farmacia, Guadalajara, Spain

10.1136/ehjpharm-2015-000639.105

**Background** Oseltamivir is an antiviral approved for treatment and chemoprophylaxis of uncomplicated illness caused by influenza A or B virus for people of all ages over 3 months.

**Purpose** With the increase in the incidence of influenza A in Guadalajara in the winter of 2013–2014, reaching epidemic proportions, it was decided to analyse the use of oseltamivir in the treatment of influenza A.

**Material and methods** Retrospective observational study of patients treated with oseltamivir between November 2013 and February 2014.

Variables: age, sex and risk factors (RFs), ward, dose, duration and confirmation of influenza vaccination status. It was felt that the treatment was completed after 5 days of treatment in the case of 75 mg and 10 days of 150 mg.

The information was obtained from the Farmatools drug history and Mambriino and Turinno electronic medical records.

**Results** 174 patients were collected on treatment with oseltamivir. 51% were male and 49% female with a mean age of 63.61 years (2–92). 82% of patients had some RFs. The main RFs were age >65 years (53%), respiratory failure (36%), diabetes (25%), heart failure (22%), obesity (17%), immunosuppression (17%) and renal failure (15%).

The main prescriber service was Internal Medicine (37%).

The dose was 75 mg/12 h in 87% of patients, and 150 mg/12 h in 13%. 7% required titration to 30 mg/12 and 2% changed regimen during hospitalisation. 67% of patients completed the treatment.

57% (n = 93) had a confirmed diagnosis of influenza A. In this subgroup 10% did not complete the treatment with oseltamivir, 40% had been vaccinated previously for influenza and 18% had no RFs. In the subgroup of patients without influenza (n = 81) 36% completed treatment with oseltamivir.

**Conclusion** Oseltamivir has been used in a similar percentage for both treatment and prophylaxis and it has mainly been used in patients with advanced age and associated RFs.

Most patients were treated as uncomplicated influenza A. In the subgroup of patients with a diagnosis of influenza A were patients whom the vaccine didn’t protect against influenza A and others who did not complete the treatment.

It would be interesting to analyse the efficacy of the vaccine against influenza in a second phase of the study.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**CP-107** MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN OUR INSTITUTE: PRACTICE EVALUATION

1Costes*, 1C Moret, 2A Éche, 3M Montastruc, 2A Staub, 1V Flanzy, 1C Combis, 1Y Puiset.

1Institut Claudius Regaud, Pharmacy, Toulouse, France; 2Institut Claudius Regaud, Medical Oncology, Toulouse, France

10.1136/ehjpharm-2015-000639.106

**Background** In France, the arrival of a new antiemetic (palonosetron) forced us to define its place in chemotherapy-induced nausea and vomiting (CINV) management.

**Purpose** To review prescription practice in our institute and to find out what guidelines are applied. The efficiency of treatments was evaluated.

**Material and methods** Evaluation was performed on patients receiving moderately emetogenic chemotherapy. Questionnaires were given to patients. They had to report on which antiemetics they were treated with for three days following chemotherapy. Physicians noted which antiemetic treatment had been administered to the patient in the acute phase. Criteria of evaluation were:

- Type of guidelines applied (AFSOS, ASCO) according to the drugs reported.
- Effectiveness in controlling the number of nausea and vomiting episodes in the acute and delayed phases.

Questionnaires were distributed for two months.

**Results** 231 questionnaires were analysed. The AFSOS and ASCO guidelines were followed for the management of CINV in the acute phase for 184 patients (79.7%). For the delayed phase, 120 questionnaires (51.9%) were in accordance with the AFSOS guidelines and 16 with those of the ASCO guidelines (6.9%). During the delayed phase, 46 patients (19.9%) reported they had received setrons and 27 (11.7%) indicated they had had no antiemetic treatment. 110 (47.6%) of them took an adjunctive drug.

Among patients interrogated, 139 (60.2%) were not controlled on nausea and 40 (17.3%) had vomiting.

40 patients were (chemotherapy) treatment-naïve. 22 (55%) reported having nausea and 3 had vomiting in the days following chemotherapy.

**Conclusion** Great heterogeneity in prescribing practices in the same institute was noted. Results highlight a greater proportion of uncontrolled patients than expected. Thus, CINV still represents an important adverse effect and it is necessary to continually evaluate efficiency of prophylactic antiemetic treatments in the hope of improving treatment.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

**CP-108** INFECTIONS CAUSED BY CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE IN A TERTIARY HOSPITAL

I Vigaure-Guerra*, F Franco-García, MD Aumente. Hospital Universitario Reina Sofía de Córdoba, Serció de Farmacia, Córdoba, Spain

10.1136/ehjpharm-2015-000639.107

**Background** The increasing incidence of carbapenem-resistant Klebsiella pneumoniae (CR-KP) has become a significant problem and treatment of infections caused by these pathogens is a major challenge for clinicians.

**Purpose** To describe infections caused by CR-KP in the setting of a single tertiary Spanish hospital outbreak between June 2012 and February 2013.

**Material and methods** Eighty-one patients with confirmed KPC-producing isolates were included. Demographic and clinical records, antibiotic use and patient outcomes were collected retrospectively.

**Results** Eighty-one patients with confirmed CR-KP-producing isolates were included. Post-antibiogram treatment data were
collected from 69 patients. The most used antibiotics were tigecycline (n = 44, 63.8%), gentamicin (n = 36, 52.2%), meropenem (n = 13, 18.8%), fosfomycin (n = 11, 15.9%) and colistin (n = 8, 11.6%). In 28 patients (40.6%) the regimen consisted of a single drug. Most patients (n = 41, 59.4%) received ≥2 drugs against the CR-KP isolate. The most common combination was tigecycline plus gentamicin, which was used in a total of 23 cases, alone (n = 19), or with a third drug (n = 4).

The most active agent against CR-KP was tigecycline (72.8% susceptibility). Resistance rates to gentamicin, fosfomycin and colistin were 64.2%, 82.7% and 93.8%, respectively.

The mean initial dose of gentamicin was 4.1 ± 1.4 mg/kg/day with a mean Cmax = 10.7 ± 5.6 mcg/ml and mean Cmin = 0.9 ± 1.3 mcg/ml. The pharmacokinetic monitoring of gentamicin allowed the mean daily dose to be increased to 3.5 ± 1.2 mg/kg reaching a mean Cmax = 16.5 ± 2.7 mcg/ml and mean Cmin = 0.6 ± 0.4 mcg/ml.

We recorded a clinical cure or improvement in 44 patients (54.3%) and microbiological cure in 14 patients (17.3%). The overall mortality of the 81 patients was 27.2%, but just 13.6% of deaths were considered attributable to infection.

**Conclusion** To our knowledge this is the largest reported series of infections caused by CR-KP in the setting of a single-centre outbreak with such high levels of resistance and provides further input on the clinical management of this type of infection.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**CP-110 IMPACT OF A PHARMACEUTICAL PROGRAM ON ANTIRETROVIRAL TREATMENT SIMPLIFICATION**

L López Esteban*, B Reques Sastre, R Vázquez Sánchez, J Sánchez-Rubio Fernández, ME Martínez Núñez, T Molina García. Hospital Universitario de Getafe, Pharmacy, Getafe, Madrid, Spain

10.1136/ehjpharm-2015-000639.109

**Background** Treatment of human immunodeficiency virus (HIV) infected patients usually involves the use of complex regimens and adverse effects. Current guidelines recommend treatment simplification in patients with effective infection control by switching from Boosted Protease Inhibitors (PI/r) to another group of drugs and by using once daily (qd) schedules where possible in order to improve tolerance and adherence.

**Purpose** To analyse the results of a pharmaceutical intervention program to promote the simplification of antiretroviral treatment (ART) in HIV+ eligible patients and to assess associated cost savings.

**Material and methods** Prospective study (July 2013 to April 2014). Adult patients on ART with PI/r-based combinations for more than 6 months, undetectable viral load and no known resistance mutations for Reverse Transcriptase Inhibitors Nucleoside analogues (NNRTIs) were selected. After evaluating the patient, the pharmacist suggested switching the current regimen to a simpler one according with patient characteristics. Based on the annual cost for each combination, switch-derived savings were calculated.

**Results** 488 HIV+ patients were treated during the study period, 32% with PI/r combinations. 66 potential candidates for simplification were selected. Pharmaceutical intervention was accepted in 10 patients (15.2%). Of these, 40% were taking atazanavir, 50% lopinavir and 10% fosamprenavir. Main reason for non-acceptance was the lack of updated drug resistance studies. All patients switched, swapped an IP/r for a qd NNRTI (90% rilpivirine and 10% efavirenz). 60% of patients changed to a single tablet regimen.

Overall calculated cost savings were €17,500 per year.

**Conclusion** A pharmaceutical intervention program of antiretroviral treatment simplification led to cost savings in HIV infection treatment. However the rate of acceptance was low due to lack of updated resistance reports.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.
Clinical pharmacy

**CP-111** Efficacy of Telaprevir in treatment of Chronic Hepatitis C

B Oca Luiz, R Martínez de Arriba*, S Casais Muñoz, S Delgado Cuesta, H Hernida Perez, M Gómez García, I Izquierdo Acosta, M Ubeira Iglesias. Hospital Universitario de Burgos, Hospital Pharmacy, Burgos, Spain; Hospital Universitario de Burgos, Clinical Analysis, Burgos, Spain

**Background** The use of protease inhibitors in the treatment of hepatitis C virus (HCV) infection has significantly increased the recovery rate.

**Purpose** To analyse the efficacy of triple therapy – telaprevir (TVP), peginterferon (P-IFN) and ribavirin (RBV) – as treatment for HCV genotype 1.

**Material and methods** Retrospective and observational study of patients who finished the triple therapy from September 2012 to January 2014.

The following data was gathered: age, sex, genotype, stage of hepatic fibrosis (FibroScan), frequencies of IL28B polymorphisms, response in case of pre-treatment, viral levels before starting treatment and 4, 12, 24 and 48 weeks afterwards (RT-PCR), as well as sustained virological response (SVR).

Data was obtained from the Electronic Clinical History (Jimena), Outcome Patients Program (Farmatools) and the laboratory program (Omega 3000 and 4000).

**Results** Of the 24 patients studied – 19 of whom were men – 2 were co-infected with HIV and another one with HBV. 33.33% of them were treatment-naive, 25% null responders, 20.83% partial responders, 16.67% relapers and 4.17% unknown. Genotypes 1a, 1b, 1c corresponded to 8, 9 and 1 patients respectively. Hepatic fibrosis stage F4/F3/F2/F0 corresponded to 54.16%, 37.5%, 4.17% and 4.17% respectively.

Two patients started the treatment with F < 3 because of several extrahepatic symptoms (MALT lymphoma and Porphyria Cutanea Tarda). IL28B polymorphisms were 50% CT, 33.33% CC, 12.5% TT and 4.16% not specified. The average viral load pre-treatment was 3,496,125 IU/ml (log = 6.54).

83.33% of patients achieved an undetectable viral load after 4 weeks, maintained after 12, 24 and 48 weeks, except for one patient. Two patients achieved viral suppression in the 12th week. The load did not decrease for the other two patients, therefore it was stopped. All of them improved, by at least one fibrosis stage.

**Conclusion** The introduction of TVP in HCV genotype 1 treatment increased the SVR rate for all patients, and was effective for 87.5% of them. There is a relationship between SVR and IL28B polymorphism, being 100% effective for CC patients and 80% for T allele carriers (CT and TT)

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**CP-112** Effectiveness and Safety of Long-Acting Octreotide in the Treatment of Chronic Bleeding from Gastrointestinal Angiodysplasia

C Ruiz Martínez*, Á Giménez Manzorno, E Lobato Matilla, C Casado Reina, B Monje García, M Tovar Pozo, M Sanjurjo Sáez. Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain

**Background** Angiodysplasia (AD) is the most common vascular malformation of the gastrointestinal (GI) tract and causes significant morbidity. Long-acting octreotide, administered intramuscularly once per month might be useful for controlling chronic bleeding from angiodysplasia as an off-label use. Some case reports have demonstrated a significant benefit.

**Purpose** To evaluate the effectiveness and safety of long-acting octreotide as an off-label use in patients suffering from chronic GI bleeding from AD.

**Material and methods** A retrospective observational study of all patients treated in our hospital with long-acting octreotide for chronic GI bleeding because of AD was performed. We analysed three time periods: one year before starting long-acting octreotide (t0), one year after (t1) and two years after (t2) starting long-acting octreotide treatment. Data, collected from the patient’s medical record, included: demographic data, treatment-related data, haemoglobin levels and number of hospitalizations as efficacy data, and side effects. The statistical analysis was performed with SPSS.

**Results** Twenty five patients were included, 85% men with a mean age of 76.1 years [58.7–91.7]. Dosage pattern used was: 10 mg (48%), 20 mg (40%) and 30 mg (12%). Mean treatment duration was 31.1 months [3.2–97.4]. The mean of haemoglobin levels was: t0 9.14 (Standard deviation (SD): 1.12), t1 10.37 (SD: 1.69) and t2 10.37 (SD: 2.02). There was statistical differences in haemoglobin levels between t1-t0 (p = 0.001) and between t2-t0 (p = 0.05). Furthermore, hospitalizations decreased when compared at t1 (3.61 ± 2.69) to t0 (5.29 ± 4.26), p = 0.028; and t2 (2.43 ± 2.44) to t0 (5.29), p = 0.042. No major adverse events were recorded; two patients experienced cholelithiasis and another two glycaemic alteration.

**Conclusion** Patients treated with long-acting octreotide had a significant reduction in hospitalizations and higher mean haemoglobin concentrations after treatment, with an acceptable safety profile. Besides, case reports by Bon et al. 2012, Scaglione et al. 2007 and Molina Infante et al. 2009, showed a significant reduction in transfusion requirements and iron supplementations.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**CP-113** Financial Impact of the use of reduced doses of tocilizumab in the treatment of rheumatoid arthritis

C Lara-Ramos*, E Sánchez-Yañez, E Márquez-Fernández, B Muruz-Fuentes, M Morales-Lara, IM Fernández-Ovies. Hospital Universitario Virgen de La Victoria, Farmacia Hospitalaria, Málaga, Spain

**Background** The use of biological drugs such as tocilizumab for rheumatoid arthritis (RA) is very expensive. However, some observational studies and recommendations from guidelines (BBF) suggest the possibility of reducing the dose of biologicals to the minimum effective dose in patients with good control of the disease.

**Purpose** To assess the financial impact, measured as direct costs, of the use of reduced doses of tocilizumab for the treatment of RA in a tertiary hospital.

**Material and methods** Observational, descriptive and retrospective study with patients diagnosed with RA. We included patients
who received low doses of tocilizumab, because they had achieved remission or low disease activity with standard doses of tocilizumab (8 mg/kg every 28 days).

Results Seven patients were included, all of them treated with tocilizumab 6 mg/kg every 28 days. The average weight was 75 kg (55–100). The average annual cost per patient with a dose of 6 mg/kg every 28 days was €9,394 (6,647–13,899). The average annual cost for the same patient in the previous year, with doses of 8 mg/kg every 28 days, had been €12,178 (8,863–16,115). The average saving per patient/year was €2,784 (2,215–3,939). The use of reduced doses of tocilizumab for these 7 patients resulted in annual savings for the hospital of €19,490.

Conclusion Reducing the dose of tocilizumab in patients who have achieved remission or low disease activity having previously been treated with standard doses of tocilizumab provided direct savings for the hospital. Therefore, we are aware of the need to implement optimisation strategies in relation to the treatment of RA with tocilizumab in selected patients. However, more studies should be performed in order to determine the effectiveness of these dose reduction strategies and their financial impact on both direct and indirect costs.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DIFFERENCES IN TREATMENT COMPLEXITY BETWEEN MULTIMORBIDITY PATTERNS IN THE OLDER POPULATION

E Calvo-Cidoncha, J González-Bueno, MD Santos Rubio, MD Toscano Guzmán, MA Roblesillo-Cortés, B Santos-Ramos. Nuestra Señora de Valme Hospital, Pharmacy, Sevilla, Spain; Virgen Del Rocío Hospital, Pharmacy, Sevilla, Spain

Background In the context of population ageing, polypharmacy is strongly associated with multimorbidity. Studies have revealed the existence of multimorbidity patterns. No studies have evaluated whether the complexity of the medicines regimen varies with the multimorbidity patterns.

Purpose To analyse the extent to which treatment complexity differs between multimorbidity patterns in the older population.

Material and methods We conducted a retrospective observational study. We included patients ≥65 years with more than one chronic condition (according to the Quality and outcomes framework database) and with criteria of polypharmacy (>5 medicines/day) who were admitted to an internal medical unit between September/October 2014. Patients who were assigned twice: at the moment of change and 24 weeks after it.

Results 51 patients (52.9% male) were included. 15 (29.4%) aged 65–74 years, 29 (56.9%) 75–84 and 7 (13.7%) >85 years. The average number of diseases and medicines were 5.6 ± 2.5 and 10.5 ± 4.0, respectively. The average MRCI was 32.5 ± 15.2. The most decisive factor contributing to the complexity was the dosing frequency (13.7 ± 6.8), followed by the dosage form (12.7 ± 5.5) and the additional directions (6.0 ± 4.3). 31 (60.8%) patients were assigned to a cardiometabolic pattern (5.8 ± 2.8 diseases, 11.2 ± 3.9 medicines, 35.3 ± 15.7 MRCI); 13 (25.5%) patients presented a mechanical pattern (5.4 ± 2.25 diseases, 10.2 ± 4.7 medicines, 30.9 ± 16.4 MRCI) and 7 (13.7%) were assigned a psychogeriatric pattern (5.1 ± 1.6 diseases, 8 ± 1.3 medicines, 23.5 ± 4.8 MRCI). There were no significant differences between the MRCI in the patterns of multimorbidity.

Conclusion Treatment complexity does not differ between multimorbidity patterns in the older population.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.

CHANGING TREATMENT IN HIV PATIENTS TREATED WITH EFAVIRENZ/EMTRICITABINE/TENOFOVIR TO RILPIVIRINE/EMTRICITABINE/TENOFOVIR

MD Toscano Guzmán, A Sánchez Vidal, A Rodríguez Peréz, HM Sierra Torres, J González Bueno, Lluch Colomer, MD Santos Rubio. Hospital Universitario Virgen Del Rocío, Pharmacy, Sevilla, Spain; Hospital Virgen Del Rocío, Pharmacy, Sevilla, Spain

Background Rilpivirine is a non-nucleoside reverse transcriptase inhibitor approved for use in a highly active antiretroviral therapy combination. A single-tablet formulation of rilpivirine, tenofovir and emtricitabine is commercially available, and the same for efavirenz, tenofovir and emtricitabine. There are many articles comparing their effectiveness but not many about their use in routine practice.

Purpose To evaluate the impact, in terms of effectiveness and safety, of replacing emtricitabine/tenofovir/efavirenz by emtricitabine/tenofovir/rilpivirine in HIV patients.

Material and methods Retrospective observational study in a tertiary hospital. HIV patients were included who had changed from antiretroviral therapy based on emtricitabine/tenofovir/efavirenz combination to emtricitabine/tenofovir/rilpivirine between February and April 2013.

Both demographic and laboratory variables (HIV viral load, count and CD4 percentage and lipid profile) were measured twice: at the moment of change and 24 weeks after it.

Undetectable viral load was defined as two consecutive determinations of viral load lower than 20 HIV copies/mL.

Data were obtained from medical records and from the outpatient dispensing module of ATHOS-APD Pharmacy Service software.

Results Twenty patients (three women) were included. The mean age was 47 (minimum 38, maximum 79) years old. The results of laboratory variables at baseline and 24 weeks of change were: undetectable viral load [18 (90%) patients vs. 19 (95%)]; and percentage of CD4 lymphocytes count [652 cells/μL (35%) vs. 675 (37%)].

Regarding the lipid profile, the mean value of cholesterol (mg/dL) before and after changing was 195 and 175, respectively. The average triglyceride levels (mg/dL) were 126 and 116.

Conclusion Our results suggest that emtricitabine/tenofovir/efavirenz and emtricitabine/tenofovir/rilpivirine can be exchanged without affecting the effectiveness and safety of antiretroviral

treatment. This strategy could be useful in the future to provide a treatment based on efficiency criteria.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-116

APPROPRIATENESS OF TICAGRELOR AND PRASUGREL USE AFTER THE IMPLEMENTATION OF AN ANTIPLATELET PROTOCOL IN ACUTE CORONARY SYNDROME

EA Álvarez Alonso*, MDC Herero Dominguez-Beruela, S Sanz Márquez, R Collado Bonell, A Leganés Ramos, M Pérez Encinas. Hospital Universitario Fundación Alcorcón, Pharmacy, MADRID, Spain

10.1136/ehjpharm-2015-000639.115

Background Due to the inclusion of new antiplatelet treatment in the pharmacotherapeutic guide, the Cardiology Department developed a protocol for management of antiplatelet treatment in Acute Coronary Syndrome (ACS) in May 2013.

Purpose To check whether the new antiplatelet drugs ticagrelor (T) and prasugrel (P) were being used in accordance with a protocol for managing antiplatelet treatment in ACS.

Material and methods Prospective, observational study of patients receiving T or P. Study period: October 2013–March 2014. In ACS patients with ST-segment elevation (STEACS) the protocol required the location of the myocardial area affected, increased ST visualisation in at least a 3-lead electrocardiogram (ECG), and a score of ≥3 on the TIMI scale. Treatment of patients with non-ST-segment elevation SCA (NST-ACS) required a TIMI score ≥3. Sex, age, weight, presence of diabetes mellitus (DM), history of stroke/transient ischaemic attack (TIA), kidney failure (KF), pharmacotherapeutic history and prior antiplatelet treatment were recorded. A database was created with the variables described.

Results 92 patients were included, 77 males (83.69%), mean age 61.92 ± 10.73 years. 27 patients (29.35%) received ticagrelor and 65 (70.65%) prasugrel. In 12 patients T and P were the usual treatment and they were not considered. Diagnosis: 57/80 (71.25%) STEACS; and 23/80 (28.75%) NST-ACS. Of the 57 patients with STEACS, the infarcted area was anterior/anterolateral in 22 patients, inferior/inferoposterior in 33 and lateral in 2. ST-segment elevation in ≥3 ECG leads (84.21%) was observed in 48 patients. TIMI ≥3 in 44 patients (77.20%). Of the 23 patients with NST-ACS, TIMI score was ≥3 in 20 (86.95%). No patients had stroke/TIA background. However, 18.75% and 1.25% had DM and KF respectively. The total percentage of appropriate use of T and P was 91.25%, reaching 94.55% for P and 84.00% for T. The reasons for non-compliance with the protocol were: in the case of P, not meeting the infarct area (1 patient) or no diagnosis of NST-ACS (1 patient); and in the case of T: no diagnosis of STEACS (2 patients) or NST-ACS with TIMI <3 (1 patient).

Conclusion The use of this management protocol has facilitated both medical prescription and pharmaceutical validation of antiplatelet treatment in patients with ACS.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-117

PROSPECTIVE STUDY OF NECROTIZING ENTEROCOLITIS (NEC) TREATMENT IN NEONATAL INTENSIVE CARE UNIT (NICU)

1N Avela*, 1D Spadaro, 1D Spadaro, 1S Gazzardi, 1E Marietta, 1A Valero, 1M Tirantello, 1G Caccagia. 1P. O. Umberto I – ASP SR, U. O. C. Farmacia, Siracusa, Italy; 2Università Degli Studi Di Catania, Scuola Di Specializzazione in Farmacia Ospedaliera, Catania, Italy; 1P. O. Umberto I – ASP SR, U. O. C. UTIN, Siracusa, Italy

10.1136/ehjpharm-2015-000639.116

Background Necrotizing enterocolitis (NEC) affects the gastrointestinal part of premature infants and results in inflammation and bacterial invasion of the bowel wall; there isn’t yet a well-established preventative treatment for this disease. Despite advances in the care of premature infants, NEC occurs in 5–10% of all very low birth-weight infants (<1,500 g). Medical treatment typically consists of bowel rest and decompression, antibacterial treatment, and management of other haematological or electrolyte imbalances. Risk factors for NEC are prematurity, enteric nutrition, gut microbial colonisation; moreover antibiotic treatment, frequently used to prevent sepsis, may develop resistant strains, delay colonisation and reduce microbial diversity predisposing to later intestinal disease.

Purpose To identify NEC incidence and treatment in NICU.

Material and methods The pharmacist monitored the antibiotic treatment of preterm infants and NEC incidence and treatment, from 01/09/2013 to 30/06/2014.

Results Antibiotic treatment (ampicillin/sublactam, cefotaxime, amikacin, amphotericin B, cefepime, teicoplanin, gentamicin and ceftriaxone, cefotaxime and gentamicin, ampicillin/sublactam and gentamicin, ceftriazone and amikacin and teicoplanin) was prescribed to all (90) preterm (under 37 weeks of gestation) infants admitted. NEC affected 17 preterm infants, who were treated with metronidazole. When the first NEC symptoms appeared (protruding abdomen, gastric or enteric retention) metronidazole was administered, in off-label (15 mg/kg loading dose followed by 7.5 mg/kg at different intervals depending on gestational age), intravenously or orally for 3 weeks on average. In 6 cases it was necessary to administer other antibiotics (fluconazole, imipenem/cilastatin, teicoplanin, amikacin). In 4 cases the patients on average did not evacuate for 8 days, probably due to NEC and also the administration of metronidazole. All patients recovered except two: one died from NEC and the other from sepsis.

Conclusion The incidence of NEC was 19% of preterm infants. Treatment with metronidazole and antibiotics made it possible to prevent the complications of NEC and all patients but one recovered.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-118

WOUND INFECTION IN PATIENTS WITH SILVER DRESSINGS

C Elias*, M Oliveira, C Costa, N Badracim, M Oliveira, R Brito, R Alonso. Hospital Prof Dr Fernando Fonseca, Hospital Pharmacy, Amadora, Portugal

10.1136/ehjpharm-2015-000639.117

Background Wound infection diagnosis should be based on signs and symptoms of wound and surrounding skin such as exudate, bleeding surface, necrotic tissue, smell, erythema and oedema. The evaluation of local signs and the clinical evaluation of the patient are important to decide the best treatment.
Purpose To investigate the complexity of treatment with silver dressings.

Material and methods A retrospective observational study conducted between January and July 2014. All patients with prescriptions for silver dressings were identified using the Pharmacy system Hosix and Sivisa. Data from clinical records were collected from Soranian and recorded in Excel. Data were analysed using SPSS.

Results We identified 62 patients with silver dressings (66.1% male; average age 71.1). Silver dressings were prescribed mainly for surgical wounds (27.4%) and stage 4 pressure ulcers (27.4%). The average length of treatment was 20.9 days. Rubor of the skin around the wound in 40.3% of wounds and purulent exudate in 67.7% were the main signs of infection identified. Necrotic tissue that can encourage bacterial growth was found in 85.5% of the wounds. In 25.8% of the patients, nurses used an antiseptic solution to clean the wound between dressings. Systemic antimicrobials were prescribed in 79% of patients, 53.2% of whom had a diagnosis of wound infection. The group of patients to whom antiseptics were administered locally had fewer days of treatment with silver dressing, although it was not statistically significant (p = 0.26). Also, the group of patients with prescriptions for silver dressings for longer than 10 days was statistically associated with wound complications (p = 0.05).

Conclusion All patients had clinical signs of wound infection that supported the use of silver dressings and most of them (79%) also needed systemic antibiotic treatment. We found it crucial that clinical records should be more complete regarding odour, local pain, oedema and other local signs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

Effect of treatment complexity on treatment persistence in HIV patients

1E Calvo-Cidoncha, 1,2J González-Bueno, 1MD Santos Rubio, 1,2E Chamorro de Vega, 1R Cantudo-Cuenca, 1R Molino Verdugo, 1Nuestra Señora de Valme Hospital, Pharmacy, Seville, Spain; 1Virgen Del Rocio Hospital, Pharmacy, Seville, Spain

10.1136/ejhpharm-2015-000639.118

Background The complexity of highly active antiretroviral treatment (HAART) may be one of the main causes of discontinuation of HAART. Martin et al. in 2007 developed a score which calculates a complexity index considering number of pills taken per day, dosing schedule, dosage form and any specific instructions related to drug use.

Purpose To determine the effect of treatment complexity on medicines persistence in treatment-naive HIV patients.

Material and methods We conducted a retrospective observational study. Treatment-naive HIV patients who started HAART between January 2012 and December 2013 in a secondary hospital were included. The data collected were: age, gender, antiretroviral treatment, complexity index and persistence with the HAART regimen. The complexity index was calculated based on the score developed by Martin et al. Persistence was defined as the length of time from initiation to discontinuation of treatment. Data were collected through outpatient electronic medical records and by reviewing each patient’s medical history. The Kaplan-Meier method was performed using SPSS 20.0.

Results 68 patients were included (93% male, mean age 37 ± 10 years). The most common treatments were a nucleoside reverse transcriptase inhibitor (NRTI) in combination with a non-nucleoside (NNRTI) (72%) followed by a NRTI with a protease inhibitor (PI) (22%). The mean complexity score for the combination of NRTI + NNRTI, 2.1 ± 0.5, was significantly lower than that of the combination NRTI + PI, 4.4 ± 0.5 (difference -2.3, 95% CI: -2.5 to -2.05, p < 0.001). 36 (53%) patients discontinued the treatment. The median overall persistence was 55 [95% CI: 37–73] weeks. Persistence with HAART was significantly higher (p = 0.006) for NRTI + NNRTI, 57 [95% CI: 54–60] weeks, in comparison with NRTI + PI, 28 [95% CI 23 to 34] weeks.

Conclusion Patients treated with less complex antiretroviral treatment are significantly more persistent with HAART.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 AIDS 2011;25:279–90

No conflict of interest.
management program. The program might also have had an impact on antibiotic consumption.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
pharmacy teams was developed to identify hospital in-patients receiving antipsychotics, mood stabilisers or dementia medicines. A specialist pharmacist reviewed the patient and referred him/her to psychiatric liaison services if indicated. Data were recorded in line with national [Caldicott] ethical guidelines.

**Results** Between 17/09/2012 and 28/10/2013 the pharmacist made 41 referrals to psychiatric liaison services, accounting for 45% of the total number of referrals in this patient cohort. The mean time from hospital admission to pharmacist referral was 4.4 days (107 h, SD: 110 h). Increased access to psychiatric services was also seen with 47% (n = 138) patients being referred representing a 14% absolute increase from baseline.

**Conclusion** A specialist pharmacist linking acute and psychiatric services in an acute, general hospital improves access and reduces delays from admission to psychiatric expertise.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**CP-124** IMPACT OF HOSPITAL PHARMACIST INTEGRATION ON PATIENT SAFETY IN A GENERAL SURGERY SERVICE AND THE RELATED DIRECT FINANCIAL SAVINGS

1. JI Arenas Villafranca*, 1B María Eugenia, 1N Miriam, 1A Alberto, 1A Elena, 1F Begolia.
2. Hospital Costa Del Sol, Pharmacy and Nutrition, Marbella, Spain; 2Hospital Costa Del Sol, General Surgery, Marbella, Spain

10.1136/ijphparm-2015-000639.123

**Background** In recent years, patient safety has become a Healthcare Systems’ priority. An expert panel has established the presence of a Hospital Pharmacist in hospital settings and their direct collaboration with nurses and doctors as a key factor in the safe use of medicines.1

**Purpose** We wanted to investigate the effect that this integration is having on patient safety and whether cost savings are directly related.

**Material and methods** A pharmacist worked full-time on the General Surgery service for two months. The pharmacist took part daily in clinical sessions, patients’ visits, drug monitoring advice, discharge information, home medicines reconciliation, among other duties. All work carried out by the pharmacist was recorded. Cost saving derived from switching treatment and non-necessary drugs stopped by the pharmacist were calculated as (cost of initial treatment × days with the new treatment) – (cost of new treatment × days of treatment).

**Results** 166 patients were admitted to the Surgery Service during this period. The Pharmacist made at least one treatment recommendation in 56% of these patients which ended in a treatment change or drug monitoring by doctors. 108 treatment reconciliation reports were made (65% of patients) by pharmacist-patient interview. Because of these reports, 106 drugs were added to patients’ hospital treatment, 18% were drugs that guidelines recommended not to stop at admission. The treatment was changed for 37 drugs, and 19 unnecessary drugs were stopped. Direct cost savings derived from that switching and non-necessary drugs were in total €1,372 (€686/month).

**Conclusion** Hospital pharmacists play an important role as part of multidisciplinary teams, improving medical care and increasing treatment safety. Direct cost savings are also related to pharmacist clinical practice.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**CP-125** EVALUATION OF COMPLIANCE AND TOLERABILITY IN TREATMENT-NAÏVE PATIENTS SUFFERING FROM IDIOPATHIC PULMONARY FIBROSIS (IPF) AND TREATED WITH PIRFENIDONE

1. F Caparo*, 2C Larda, 3G Bandelli, 3A Filieri, 3C Albera, 3D Ielo. 1A. O. U San Luigi Gonzaga, Pharmacy, Orbassano TO, Italy; 2University of Turin, School of Hospital Pharmacy, Turin, Italy; 3University of Turin, School of Medicine, Turin, Italy

10.1136/ijphparm-2015-000639.124

**Background** Idiopathic pulmonary fibrosis (IPF) is a rare disease with significant morbidity and mortality, with a 18.07/1,00,000 prevalence in our Region. Pirfenidone is an orally administered antifibrotic approved for the treatment of mild-to-moderate IPF. Pirfenidone is generally well tolerated, the most common side effects being on the gastro-intestinal (GI) tract and photosensitivity. However, side effects may partly offset treatment benefits and reduce compliance.

**Purpose** To assess side effects (tolerability) and compliance in (treatment-naïve) IPF patients receiving pirfenidone.

**Material and methods** In this prospective observational study, adherence was examined in patients treated between September 2013 and September 2014. Side effects and treatment compliance were recorded in a database. Adherence data were compared with the incidence of side effects occurring in the studied population.

**Results** 34 IPF patients were evaluated during a 12 month follow-up.

<table>
<thead>
<tr>
<th>Abstract CP-125 Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study population (# 34)</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Mean Age (yrs)</td>
</tr>
</tbody>
</table>

Comparison between prescribing and dispensing data showed that 19 (56%) of patients received 100% of the prescribed treatment, 22 (65%) received more than 90%, and only 3 (9%) received less than 50%.

<table>
<thead>
<tr>
<th>Abstract CP-125 Table 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment adherence</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Interruption (#)</td>
</tr>
<tr>
<td>Causes of Interruption:</td>
</tr>
<tr>
<td>- disease progression</td>
</tr>
<tr>
<td>- toxicity</td>
</tr>
<tr>
<td>- death</td>
</tr>
<tr>
<td>- missed</td>
</tr>
<tr>
<td>- not specified</td>
</tr>
<tr>
<td>Suspension (#)</td>
</tr>
<tr>
<td>Causes of suspension:</td>
</tr>
<tr>
<td>- toxicity</td>
</tr>
<tr>
<td>- smoke</td>
</tr>
</tbody>
</table>
Side effects led to only 15% of patients discontinuing pirenidone and were more evident during the first six months of treatment, as observed in clinical trials.

Conclusion With reliability most side effects were manageable with supportive measures.

Compliance: overall it was good. Closer pharmacist/physician interaction could further improve patient compliance.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

1 EMA summary of product characteristics

No conflict of interest.

**CP-126** VALIDATION OF INHALATION TECHNIQUE VIDEOTAPED IN ASTHMATIC CHILDREN UNDER 5 YEARS

1,2S Spaggiari*, 1G Hafen, 1,4L De Groumoens, 1,3M Gehri, 1,3E Di Paolo, 1,3A Pannatier, 1University Hospital CHUV, Department of Pharmacy, Lausanne, Switzerland; 2University of Lausanne – University of Geneva, School of Pharmaceutical Sciences, Geneva, Switzerland; 3University Hospital CHUV, Respiratory Unit – Department of Pediatrics, Lausanne, Switzerland; 4University Hospital CHUV, Children’s Hospital, Lausanne, Switzerland

10.1136/ehjpharm-2015-000639.125

**Background** Asthma and virus-induced wheezing are among the most common diseases in childhood, with the special problem that the response to treatment relies heavily on the correct use of the inhalation device to deliver the drug. However correct delivery of inhaled drugs is difficult for the majority of caregivers and patients, particularly for pressurised metered dose inhalers (pMDI) with spacer. Clinical inhalation situations recorded by video in conjunction with the use of a point-to-point checklist of correct inhalation technique could help to train caregivers and patients.

**Purpose** The aim of the study was to test the reliability and validity of a video of inhalation technique in the clinical setting using a 10-step checklist.

**Material and methods** Three experts in paediatric pulmonology (clinical nurse, clinical pharmacist and respiratory consultant), and one new observer scored 40 videoed inhalation sessions using pMDIs with spacer to assess inter- and intra-observer reliability. Intra-observer reliability was assessed for each observer after 1 month by scoring the inhalation demonstrations a second time. Both inter- and intra-observer reliability were expressed by mean Kappa scores.

**Results** All individual steps revealed a high mean percentage agreement and a substantial or almost perfect Kappa scoring for both inter- and intra-observer reliability. The 10-step checklist was precise enough to allow a new observer to evaluate the videotaped demonstrations by herself.

**Conclusion** The use of a videotaped recording plus a 10-step checklist represents a reliable and reproducible method for the evaluation of inhalation techniques in a clinical setting. It also represents an educational opportunity.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**CP-127** ONE-STOP DISPENSING: SELF-ADMINISTRATION OF MEDICINES IN HOSPITAL – PATIENTS’ PERSPECTIVES

1M Andersen*, 1M Gemmer, 4K Sennov, 4H Morshut. 1The Capital Region Pharmacy, Hvidovre, Copenhagen, Denmark; 4Roskilde University, Psychology and Educational Studies, Roskilde, Denmark; 2The Capital Region Pharmacy, Herlev, Copenhagen, Denmark

10.1136/ehjpharm-2015-000639.126

**Background** The patient role is changing to include further patient involvement, control and empowerment. Little is known about patients’ perspectives on self-medication or nurse administration of medicines and the use of Patients Own Drugs (PODs). With respect to tailoring a patient-specific clinical pharmaceutical service to this new patient profile, the One-Stop Dispensing (OSD) medication system was tested.

**Purpose** To determine patients’ perspectives about self-medication within the OSD system on an acute orthopaedic ward.

**Material and methods** The pilot project ran from April to December 2013. Before inclusion, a nurse or senior doctor assessed whether individual patients were suitable for self-medication according to the regional medicine guidelines. Medicines including PODs were placed in a bedside locker, after a pharmacist had taken a medicines history, performed quality assurance and provided drug information to the patient. After surgery, patients were discharged with all prescribed medicines in the original packages to cover treatment to 10 days. Structured telephone interviews were conducted with 35 patients. The interviews were recorded, transcribed and analysed qualitatively and quantitatively.

**Results** All OSD patients were satisfied with administering their own medicine during admission. Of the OSD patients, 89% (n = 31) felt they had been provided with sufficient drug information and been empowered regarding their drug treatment during hospitalisation. Of the OSD patients 92% (n = 32) were satisfied with the drug information provided at discharge. The majority (97% (n = 32)) of the OSD patients felt secure and comfortable due to provision of medicine cover for 10 days from discharge. However, some (9% (n = 3)) OSD patients reported that they were left by themselves by the nursing staff, and some (11% (n = 4)) missed a medicines reminder system.

**Conclusion** This study found that the patients who were capable of self-administration benefited from the OSD system during hospitalisation and at discharge, but some challenges have to be addressed in the interdisciplinary culture to improve the OSD system.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**CP-128** ASSESSMENT OF ERROR AND PHARMACEUTICAL INTERVENTION IN PARENTERAL NUTRITION PRESCRIBING IN NEONATOLOGY

C. Valério*, S Valongo, S Homem de Mello, D Palma. Hospital Dr. José de Almeida, Pharmacy, Cascais, Portugal

10.1136/ehjpharm-2015-000639.127

**Background** Parenteral Nutrition (PN) prescriptions are not free from error. To validate a PN prescription the pharmacist is responsible for assessing the prescribed intake of nutrients, based on the information regarding the newborn (NB), such as gestational age (GA), weight, medical record and lab test results, in order to reduce medication errors.

**Purpose** To evaluate errors detected during validation of the PN prescriptions from Neonatology and the acceptance by the physicians of the pharmaceutical interventions.

**Material and methods** Retrospective study of pharmaceutical interventions in PN prescriptions from Neonatology, carried out between July 2012 and August 2014. The parameters used were:
number of PN prescriptions, number and type of errors detected and number of interventions accepted by the physician. Errors were categorised in relation to the PN prescription data, NB identification, NB data (weight, GA, birth date), enteral nutrition, micronutrients intake, Ca/P ratio, addition/omission of heparin, osmolarity, addition/omission of the volume and type of serum used in the infusion. The statistical analysis was performed in Excel.

Results From 953 PN prescriptions, 78 errors were detected, corresponding to 8% of all pharmaceutical interventions made. Of these, 3 were in PN prescription data, 6 in NB identification, 11 in NB data (weight, GA, birth date), 3 in enteral nutrition, 19 in micronutrient intake, 3 in Ca/P relation, 18 in addition/omission of heparin, 4 in osmolarity, and 11 in addition/omission of the volume and type of serum used in the infusion. Seventy-two pharmaceutical interventions (90%) were accepted by physicians.

Conclusion The number of errors detected was relatively low, the main errors being found in micronutrient intake and in addition/omission of heparin. The pharmaceutical interventions were accepted by the physicians in the majority of the cases. Therefore, the Pharmacist has an indispensable role in PN prescription validation, in order to reduce medication errors and increase the efficacy and safety of drugs.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-129 ANALYSIS OF THE IMPACT ON THE RATES OFNosocomial Infection (NI) AFTER THE IMPLANTATION OF A FAST TRACK (FT) PROTOCOL IN ELECTIVE COLON SURGERY

B Jaione*, F Carmen. Hospital San Eloy, Pharmacy, Barakaldo, Spain

10.1136/ejhpharm-2015-000639.128

Background The incidence of NI in colon surgery in our hospital in 2012 was 27.3% so it was decided to introduce a FT protocol in order to reduce that incidence and to establish new guidelines of antibiotic prevention and new recommendations for the use of venous central catheters.

Purpose To analyse and to compare information of NI and data about the fulfilment of antibiotic prevention, the use of venous central catheters, parenteral nutrition (PN) prescription as well as the pharmaceutical expense before and after the implantation of a FT protocol in such procedures of elective colon surgery.

Material and methods Retrospective review of the clinical histories of patients who undergo elective colon surgery between Oct-13 and Jul-14 in order to get the data for the analysis. The pharmaceutical expense is compared in the above mentioned period opposite to the expense in the same period of the previous year. Out of 58 procedures of colon surgery carried out, 28 were patients included in the FT programme.

Results The overall rate of NI in colon surgery during the analysed period was 22.4% whereas the rate of infection in the FT group is 10.7%.

The inadequate antibiotic prevention has diminished from 26% to 14.3% (FT group).

The number of patients with venous central catheters has diminished from 57% to 25%.

The number of patients with PN has diminished from 29% to 14.3% and also the number of days of patients treated with PN has diminished from 6 to 4.5 days.

The overall pharmaceutical expense for these patients has also diminished a 12.4%.

Conclusion FT program has considerably reduced nosocomial infection data associated with this surgery and the inappropriate use of anti-infectives, which has affected the spending.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-130 ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF INFLIXIMAB IN THE TREATMENT OF PSORIASIS IN A TERTIARY HOSPITAL

A De Rivas-Braza*, A Maestro-Nombela, E De la Piedra-Ríos, A Martín-Alonso, A Sánchez-Guerrero. Hospital Universitario Puerta de Hierro Majadahonda, Pharmacy, Majadahonda, Spain

10.1136/ejhpharm-2015-000639.129

Background Psoriasis is an inflammatory skin disease characterised by increased cell signalling via cytokines and chemokines. A wide variety of treatment options are available including systemic biological treatments such as tumour necrosis factor antagonist infliximab.

Purpose To evaluate the effectiveness and safety of infliximab for the treatment of psoriasis in adults.

Material and methods Observational, retrospective study, from 2008 to 2014, in patients with psoriasis treated with infliximab in a tertiary hospital.

Data were obtained from the electronic medical history supported by Selene Clinical Station. Data collected were demographics, average treatment dose and duration, previous treatments, dose escalation and Psoriasis Area and Severity Index (PASI).

Results The study included 27 patients (66.7% males), mean age 49.7 years (25–88). The treatment protocol was infliximab 5 mg/kg infused as indicated in the Summary of Product Characteristics. The average dose and duration were 393.38 mg (300–585.22) and 4.07 years (1–6), respectively. Previous treatments used were 44.4% topical corticosteroids, 14.8% phototherapy, 18.5% ciclosporin, 44.4% methotrexate, 18.5% adalimumab and 7.4% etanercept.

Regarding treatment effectiveness, 7.4% of patients showed some resistance, 33.3% experienced some outbreaks and 59.2% became totally asymptomatic. The average PASI at baseline was 6.83 (0–50) and 1.9 (0–16) at the end. Intensification of treatment was indicated in 25.9% of patients who changed their infusion from every 8 to 6 weeks. Dose reduction was possible in 7.4% of patients with a dose of 4 mg/kg.

During treatment, 7.4% of patients had lower respiratory tract infections, 7.4% tonsillitis and 3.7% herpes zoster.

Conclusion

- Most of the patients had a good response to treatment. Infliximab should be considered in patients who have failed to respond to, have a contraindication for, or are intolerant of, other systemic treatments.
- Some of the patients developed infections. Risks and benefits of infliximab must be carefully considered prior initiating treatment in patients with chronic or recurrent infections.
Review of neutropenic fever and mucositis in patients undergoing peripheral blood stem cell transplantation

J Pardo Pastor, M March López, R Garriga, P Arcenillas Quevedo, S Redondo Capafons, E Clot Silla, M Mongoni, M Trullàs, R Pla. Hospital Universitari Mutua Terrassa, Pharmacy, Terrassa, Spain

10.1136/ejhpharm-2015-000639.130

Background Peripheral blood stem cell transplantation (PBSCT) has reduced morbidity and mortality and it is probably one of the most important of the autologous transplantations.

Purpose The objective is to describe the complications (neutropenic fever and mucositis) and progress observed in haematological patients undergoing a PBSCT.

Material and methods Observational, descriptive and retrospective study carried out during 2013 in a 500-bed university hospital. All patients undergoing a PBSCT were included in the study.

Two different groups were established, depending on the conditioning regimen administered, depending on the usual clinical practice.

- Group A: Patients treated with BCNU, etoposide and cytosine arabinoside and melphalan (BEAM)
- Group B: Patients treated with melphalan

Data collected included: sex, age, types of conditioning regimen, NF and mucositis during the bone marrow aplasia phase, as well as the patients’ situation three months after the PBSCT.

Results During the bone marrow aplasia phase patients presented neutropenic fever and mucositis (Table 1).

Three months after the PBSCT, nine patients in group A presented a complete response, two patients partial response, and one patient success. In group B, ten patients presented complete response and one patient partial response.

Abstract CP-131 Table 1

<table>
<thead>
<tr>
<th></th>
<th>Number of patients Group A</th>
<th>Number of patients Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Neutropenic fever</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>1.1. No microbiological isolation</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>1.1.1. Non-persistent</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>1.1.2. Persistent</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>1.2. Microbiological isolation</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>1.2.1. Bacteremia</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>2. Mucositis</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>2.1. Required parenteral nutrition</td>
<td>7</td>
<td>4</td>
</tr>
</tbody>
</table>

Conclusion Most of the patients undergoing a PBSCT presented neutropenic fever and mucositis. Eight of them required an antimicrobial treatment of high complexity and 11 required parenteral nutritional support.

Three months after the PBSCT, the number of complete responses in group B was superior to those in group A.

References and/or acknowledgements

I wish to acknowledge the help provided by the pharmacy members.

No conflict of interest.

Impact of implementing a carbapenem stewardship program

R Pérez Serano, A Martin Sigüero, M Porras Leal, J Castón Osorio, G González Gascón, H Abudhadi Alavéz, S Illescas Fernández-Bermúdez, S González Rodríguez, V Caballero Martínez, A Fernández Marchante. Hospital General Universitario de Ciudad Real, Pharmacy, Ciudad Real, Spain; Hospital General Universitario de Ciudad Real, Internal Medicine, Ciudad Real, Spain; Hospital General Universitario de Ciudad Real, Critical Care, Ciudad Real, Spain; Hospital General Universitario de Ciudad Real, Microbiology, Ciudad Real, Spain; Hospital General Universitario de Ciudad Real, Preventive Medicine, Ciudad Real, Spain

10.1136/ejhpharm-2015-000639.131

Background A carbapenem stewardship program was developed by a multidisciplinary team of specialists in Infectious Diseases, Critical Care, Pharmacy, Microbiology and Preventive Medicine. It expects to promote and improve the appropriate use of carbapenems.

Purpose To analyse the stewardship recommendations regarding the use of carbapenems.

Material and methods This prospective study lasted four months (May–August 2014) and was conducted in a tertiary hospital. The stewardship pharmacist selected patients who started carbapenem treatment, then a medical infections specialist recommended continuing or not with carbapenems, at the beginning and on the fifth and the tenth days of treatment, through oral and written communication with the prescriber. Resuscitation and paediatric patients were excluded. The variables analysed were: number and timing of interventions; type of recommendations and level of acceptance; cost (€) and defined daily dose (DDD) of carbapenems/100 stays of the period studied and compared with the same period last year; impact on other antimicrobials DDD/100 stays index.

Results A total of 210 recommendations were made, of which 69% were at the beginning, 22% on the fifth day and 9% on the tenth day. The recommendations were: antibiotic de-escalation (42%), continuation (38%), suspension of carbapenem (15%) and change of regimen (5%). 89.3% of the recommendations were accepted. Cost and DDD/100 stays of carbapenems were reduced by 63% and 58% over the same period in 2013. Regarding other antimicrobials, we must highlight the increase of DDD/100 stays for cloxicillin (74.6%) and piperacillin/tazobactam (27.4%) over the same period in 2013.

Conclusion The implementation of the carbapenem stewardship program has identified more than 60% of carbapenem prescriptions that could be improved. The high level of acceptance of recommendations has significantly reduced the use of carbapenems because many inappropriate treatments were suspended and the use of narrow-spectrum antimicrobials increased. In future analyses, the impact on the Hospital’s resistance profile should be considered.

References and/or acknowledgements

No conflict of interest.

Patient program with siltuximab in multicentric Castleman’s disease: a case report

F Bocchio*, M Bonfichi, M Calvi, M Tizzoni, G Rebagliati. Fondazione IRCCS Policlinico San Matteo Pavia, Hematology Department, Pavia, Italy; Fondazione IRCCS Policlinico San Matteo Pavia, Pharmacy Department, Pavia, Italy

10.1136/ejhpharm-2015-000639.132

Background A carboxylin program with siltuximab, a monoclonal antibody against interleukin-6 receptor, is an effective treatment option for patients with refractory multicentric Castleman’s disease (MCD).

Purpose To present a case report of a patient with refractory MCD treated with a carboxylin program with siltuximab.

Material and methods A retrospective analysis of the clinical data of a patient with refractory MCD treated with a carboxylin program with siltuximab was conducted.

Results The patient presented with refractory MCD despite treatment with rituximab and tocilizumab. A carboxylin program with siltuximab was initiated and the patient achieved complete remission.

Conclusion A carboxylin program with siltuximab is an effective treatment option for patients with refractory MCD.

References and/or acknowledgements

No conflict of interest.
Background Multicentre Castleman’s disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 (IL-6) production. MCD can be associated with human immunodeficiency virus (HIV) and Herpes Virus 8 (HHV8) infections. Siltuximab is a chimeric monoclonal antibody with high binding affinity for IL-6, blocking the abnormal growth of immune cells. Siltuximab was designated an orphan drug on November 2007. FDA (April 2014) and EMA (May 2014) approved siltuximab in subjects with HIV-negative, HHV8-negative MCD. In Italy siltuximab can currently only be requested as part of a named patient program (NPP), supplied free of charge by the manufacturing company.

Purpose To describe a case report and analyse current treatment options for MCD and the safety profile of siltuximab.

Material and methods We examined siltuximab treatment prepared by the Pharmacy from February to September 2014.

Results One 65-year-old man, 107 kg, was diagnosed with MCD in our centre and treated with siltuximab 11 mg/kg IV every 3 weeks for 10 cycles with a good response. A computed tomography (CT) check showed reduction of mediastinal nodal enlargement without new disease locations. Siltuximab was well tolerated and demonstrated a consistent safety profile.

Conclusion Current results strongly suggest that siltuximab, the first drug approved for MCD, is effective and safe. Further studies are needed in order to confirm the validity of these results.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
Clinical pharmacy

- High EP (Kit-3): Kit-1 plus granisetron 1 mg in the evening following chemotherapy.

If the patient had no emesis on the previous cycle, the regime was reduced, but if nausea/vomiting were felt, the regime was stepped up. Patient/family was always involved in treatment decisions. Patient data, prescriptions and monitoring were collected from the Oncofarm application and Pharmacy Database and analysed using SPSS.

**Results** 93 BC patients (all female) received a total of 400 chemotherapy cycles. 357 antiemetic prescriptions were dispensed, so 89.25% of the time a patient received chemotherapy, came to pharmacy for antiemetic drugs. 87.3% of anti-emesis patients started with Kit-3, and 12.9% with kit-1. Antiemetics were reduced in 61.4% of patients, 15.1% continued with the same regime and 21.5% required reinforcement: taking metoclopramide around-the-clock (16.1%), stepping up from kit-1 to kit-3 (3.2%) or adding lorazepam due to anticipatory nausea/vomiting (2.2%).

**Conclusion** The large number of antiemetic prescriptions states the good acceptance from patients of the healthcare provided by the pharmacy. Progressive reduction of antiemetics in more than 60% of patients shows the good control and monitoring of nausea/vomiting with the antiemetic treatment prescribed.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**CP-136 INAPPROPRIATE PRESCRIBING IN OLDER PATIENTS: ASSESSMENT OF A SCREENING TOOL BASED ON THE STOPP AND START CRITERIA**

1 AL Sennesael*, 2 O Dalleur, 2 C Artoisien, 2 JH Hecq, 2 DB Schoevaerts, 1 A Spinewine. 1 CHU Dinant Godinne UCL Namur, Pharmacy, Yvoir, Belgium; 2 Cliniques Universitaires UCL St Luc, Pharmacy, Brussels, Belgium; 3 CHU Dinant Godinne UCL Namur, Geriatric Medicine, Yvoir, Belgium

10.1136/ejhpharm-2015-000639.136

**Background** Inappropriate prescribing is a problem of major concern in older patients, given the increased risk of adverse drug events and mortality. In this context, a 24-item tool based on the Screening Tool for Older Person’s Prescriptions (STOPP) and Screening Tool to Alert doctors to Right Treatment (START) criteria was developed and applied in the geriatric unit.

**Purpose** To find out whether the implementation of this screening tool led to a reduction in potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) during the hospitalisation.

**Material and methods** We conducted a retrospective interrupted time series analysis. Four periods were selected between February and September 2013: (1) baseline evaluation; (2) the tool was made available in the unit; (3) three months later; and (4) a clinical pharmacist held weekly meetings with interns to review treatments using the tool, which was incorporated in the electronic medical record. Data were collected from the discharge letter. The primary outcome was the rate of PIMs discontinued and PPOs corrected during hospitalisation.

**Results** 120 patients (median age 85 years) were included. The prevalence of PIMs and PPOs on admission were 56% and 51% respectively. At baseline (period 1), one fifth of PIMs were discontinued during hospitalisation while 22% of PPOs were corrected. The reduction in PIMs and amendment of PPOs increased when the screening tool was made available in the unit (period 2; 26% and 38% respectively), but three months later this effect had disappeared (period 3; 15% and 19% respectively). We observed the greatest reduction in PIMs and PPOs for the last study period (period 4; 58% and 43% respectively).

**Conclusion** The use of a screening tool contributes to improving appropriateness of prescribing in older patients. A multidisciplinary approach provides the greatest reduction in PIMs and PPOs.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

---

**CP-137 IMPACT OF THE PHARMACIST IN THE OPTIMISATION OF ANTIRETROVIRAL TREATMENT IN HIV PATIENT CONSULTATIONS**

B Escudero*, A Diez, A Martin, V Alonso, A Sánchez. University Hospital Puerta de Hierro, Pharmacy, Madrid, Spain

10.1136/ejhpharm-2015-000639.136

**Background** HIV is an expensive disease. Therefore, multidisciplinary collaboration is essential to improve treatment efficiency. **Purpose** To evaluate the impact of the integration of a pharmacist in HIV consultations to optimise antiretroviral treatment (ART).

**Material and methods** Quasi-experimental prospective study in HIV patients with ART in a university hospital. The resident pharmacist was integrated in the HIV specialist consultations for one month (October 2013). Viral load (VL), CD4, duration and treatment lines, resistances and comorbidities were evaluated. The pharmacist reviewed the ART and possible switches to optimise it in order to reach the pharmacoeconomic indicator set by the Health System in 2013 (683 euros/month per patient). Costs were assessed using ex-factory prices.

**Results** 70 patients (75% male) were included, mean age 47 (range 28–73) years old. 9 patients had detectable VL (VL ≥ 50 copies/ml): 4 non-adherent (adherence < 90%), 2 treatment-naïve patients, 2 blips and 1 resistant to ART. Mean CD4 cell count was 583 (49–1,484) mm$^3$. Regarding ART, 5 patients were on monotherapy, 4 dual therapy, 59 triple therapy and 2 with four drugs. Monthly drug costs per patient were between 358 and 1,483 euros.

40% (28 patients) did not reach the pharmacoeconomic indicator goal. Of them, after the pharmacist’s intervention, in 18% (5 patients) one ART drug was modified or suspended and in 32% (9 patients), although the interventions were accepted, the ART changes depended on the next blood test. In the other 50% (14 patients), a change was not appropriate: 6 low adherence, 2 on treatment less than 6 months, 2 psychiatric conditions, 2 resistant patients and 2 HBV co-infections. The drug savings due to the pharmacist’s interventions were 14,615 euros/year in our hospital.

**Conclusion** The inclusion of the pharmacist for a month, extrapolated to the total of patients on ART in our hospital (661 patients), would yield annual drug savings of €138,005. Therefore, pharmacist integration into the medical team improves ART efficiency.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.
Reduce Clot Risk
Protect Your Patients

Driving Innovation in the
Venous Arterial Thromboembolic Area
To learn more about thrombosis, please visit www.thrombosisadviser.com
When science and passion connect, innovation happens.

Seeing patients as individual human beings with unique needs helps us transform the way people live with cancer. We work with patient groups and healthcare professionals to better understand and address patient needs through innovative programs that improve outcomes and availability of our treatments.

Connect with us today. www.novartisoncology.com

European Journal of Hospital Pharmacy

The only official journal of EAHP

The European Journal of Hospital Pharmacy (EJHP) continues to evolve, offering quality content to help your daily practice, improve your general and specific knowledge of evidence-based practice, and give you some tools to support your activities.

What’s new in EJHP?

- We have added a whole host of features to the journal in line with the continuing development of this essential resource:
  - New medicines information section
  - Each issue contains a special report on evidence-based pharmacy
  - Themed issues focus on topics that are important to the hospital pharmacist
  - Key research addressing the needs of clinical pharmacists

EJHP.BMJ.COM

HELPING HOSPITAL PHARMACISTS PROVIDE BETTER PATIENT CARE
**Material and methods** A retrospective service evaluation was conducted at a UK teaching hospital. Appointments for ECV and ablation procedures from August 2012 to August 2013 were studied; 72 patients (cancellation group) experienced cancellations and 89 patients (control group) experienced none. ‘Electronic Patient Records’ and ‘TOMCAT’ software were used to obtain data. For the Mann-Whitney U and chi-squared tests, \( p < 0.05 \) was considered significant.

**Results** Of the 98 reasons identified for cancellations, high and low international normalised ratio (INR) ranges were the most common at \( n = 14 \) (14%) and \( n = 12 \) (12%), respectively. Patients who experienced a longer waiting time were more likely to experience subsequent cancellations (\( p = 0.006 \)); more patients from the cancellation group breached the 18-week target waiting limit (\( p < 0.001 \)). Procedure cancellations showed no significant impact on reaching sinus rhythm or experiencing recurrences of arrhythmia (\( p = 0.946 \)) however a total loss in revenue resulted of around £215,000.

**Conclusion** Prescribing direct-acting oral anticoagulants (DOAC) may prevent INR-related cancellations and this is an expanding area of use. Post-marking surveillance is still ongoing but the risk of poor patient adherence to treatment and post-procedure bleeding needs to be balanced with the potentials gains to the hospital department.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.
The consumption of all antimicrobials studied reduced in 2013: 17.4% carbapenems (36.99 vs. 30.55 DDD/100 BD), linezolid 38.6% (3.76 vs. 2.31 DDD/100 BD), daptomycin 82.2% (2.86% vs. 0.51 DDD/100 BD), tigecycline 64.9% (4.98 vs. 1.75 DDD/100 BD) and echinocandins 13.8% (3.61 vs. 3.11 DDD/100 BD).

ICU mortality was 12.8% in 2012 and 10.9% in 2013.

Conclusion Antibiotic treatment protocols in the ICU have resulted in significant antibiotics savings, not only in financial terms but also in number of doses, without increasing mortality. This effect may be relevant to the need to optimise their use in order to prolong their useful life and reduce the selection of resistant organisms. In turn, protocols might be useful to reduce the variability of prescriptions.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

**CP-141** BOSENTAN TREATMENT FOR AUTOIMMUNE DISEASES

1M Montfort Gauqué, E Laclale Fabo, M Castrieveso Eizondo, 2P Fano Mateo, M Gutierrez Valencia, M Carrasco del Amo, M Elvio Llorens, E Pelegor Hernandez, 1 Montesin Garrastabu. 1Complejo Hospitalario de Navarra, Pharmacy Service, Pamplona, Spain; 2Complejo Hospitalario de Navarra, Internal Medicine Service, Pamplona, Spain

10.1136/ehjpharm-2015-000639.140

Background Bosentan, an orphan drug, is a dual endothelin receptor antagonist indicated in pulmonary hypertension and in the prevention of new digital ulcers (DU) in patients with systemic sclerosis and ongoing digital ulcer disease.

Purpose To evaluate the effectiveness and safety of bosentan in the treatment of clinical manifestations associated with underlying autoimmune disease (Raynaud’s phenomenon (RP), DU and other location skin ulcers (SU)), all of them considered rare diseases.

Material and methods Retrospective observational study including patients treated with bosentan from January 2012 to September 2014, on compassionate use.

Variables collected were: sex, age, underlying disease, indication, previous treatments, dose and follow-up time.

Effectiveness was evaluated as: absence of new ulcers, improvement of the basal ulcers and decrease in the number of RP episodes.

The safety profile was determined according to the adverse reactions.

Results 14 patients were included; follow up (median, range): 22 (2–55) months; sex: 10 (71%) female; age: 52 (25–81) years.

All of them had previously been treated with first-line treatment until resistance or intolerance had developed.

In 11 cases bosentan was indicated to treat RP and prevent/treat DU (4 systemic sclerosis, 3 pre-systemic sclerosis, 2 systemic lupus erythematosus (SLE), 1 dermatomyositis and 1 Buerger’s disease. Getting the next results: 63.6% effective (7), 18.2% ineffective (2) and 18.2% could not be evaluated.

In the other 3 cases, bosentan was used to treat other location SUs (1 polyarteritis nodosa, 1 SLE and 1 necrobiosis lipoidica) with 100% effectiveness.

The treatment was discontinued in two cases due to digestive intolerance. In another two cases, the dose was adjusted as a consequence of an initial increase in the hepatic enzymes.

Conclusion Bosentan may be considered an appropriate alternative in these diseases which have been refractory to conventional treatment. The number of patients is limited due to the low prevalence of these diseases and to the off-label use of the drug. Therefore, it could be said that value of research lies in the possibility of opening new therapeutic perspectives with this drug.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

**CP-142** BIOLOGICAL TREATMENTS FOR PSORIASIS: FINANCIAL IMPACT OF DOSE MODIFICATION

E Rios Sanchez*, I Fenix-Caballero, M Gandara-Ladron de Guevara, C Palomo-Palomino, I Diaz-Navarro, I Barrero-Rubio, J Amario-Hita. Puerto Real University Hospital, Pharmacy, Puerto Real, Spain; Puerto Real University Hospital, Dermatology, Puerto Real, Spain

10.1136/ehjpharm-2015-000639.141

Background Biological drugs are effective treatments for chronic plaque psoriasis. The doses tend to be reduced when the drug has demonstrated sustained effectiveness.

Purpose The main objective was to assess the average cost per patient of each anti-TNF drug based on its prescribed doses. The secondary objective was two-fold: to estimate the annual costs per responder and the incremental cost.

Material and methods A cross-sectional observational study was conducted from January to June 2014. Patients with psoriasis who had received biological treatment for at least six months were included. The effectiveness endpoint was the proportion of patients with at least 75% improvement in the psoriasis area-and-severity index (PASI75). Mean prescribed doses of each anti-TNF drug were calculated and translated into a percentage of the label doses. The average cost per patient for each drug was assessed with the mean prescribed doses (real costs, RC) and the theoretical costs (TC) were estimated based on the label doses of the drugs. The incremental cost (IC) was calculated by comparing the theoretical vs. real costs. For the purpose of calculating the annual costs, the real costs of six months of treatment were extrapolated. This study was performed from the pharmacoeconomic perspective of the hospital.

Results We included 143 patients.

Abstract CP-142 Table 1

<table>
<thead>
<tr>
<th>Adalimumab</th>
<th>Etanercept</th>
<th>Ustekinumab</th>
<th>Infliximab</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N = 45)</td>
<td>(N = 44)</td>
<td>(N = 32)</td>
<td>(N = 22)</td>
</tr>
<tr>
<td>Cost per patient based on the doses prescribed</td>
<td>€4,777.06</td>
<td>€4,722.38</td>
<td>€5,337.34</td>
</tr>
<tr>
<td>Cost per patient based on its label doses</td>
<td>€6,245.72</td>
<td>€5,788.19</td>
<td>€5,689.02</td>
</tr>
<tr>
<td>Proportion of patients with PASI75</td>
<td>98%</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>Estimated annual real costs per responder</td>
<td>€9,771.27</td>
<td>€10,389.24</td>
<td>€11,778.95</td>
</tr>
<tr>
<td>Estimated TC</td>
<td>€12,491.44</td>
<td>€11,576.38</td>
<td>€11,378.05</td>
</tr>
<tr>
<td>Estimated IC</td>
<td>€9,554.13</td>
<td>€9,444.76</td>
<td>€10,674.68</td>
</tr>
<tr>
<td>IC</td>
<td>€2,937.30</td>
<td>€2,133.62</td>
<td>€6,703.96</td>
</tr>
</tbody>
</table>

Conclusion The average RC of each biological drug was lower than TC, except for infliximab. Both the annual RC and the IC of adalimumab were better than the other drugs, followed by etanercept and ustekinumab. Infliximab did not allow dose reduction. Reducing doses of biological treatments permits cost minimisation while maintaining clinical effectiveness.
No conflict of interest.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

**INVOLVEMENT OF MICROBIAL FLORA IN AETIOLOGY OF SURGICAL SITE INFECTIONS**

1. Stăcioru C, 2. Călina D, 3. Rosu A, 4. Zlatan O. University of Medicine and Pharmacy, Faculty of Medicine, Craiova, Romania; 2. Faculty of Pharmacy, Clinical Pharmacy Department, Craiova, Romania; 3. Faculty of Medicine, Microbiology Department, Craiova, Romania

10.1136/ejhp-2015-000639.143

**Background** The most common complications of surgical wounds are abscesses and necrosis.

**Purpose** To establish the aetiology of surgical wound infections in post-surgery patients from the hospital and to assess the resistance of the germs isolated to antimicrobials. Variations in antibiotic resistance profile in relation to the type of suppuration and surgical wards were compared in order to establish the most effective therapeutic protocols.

**Material and methods** From 165 hospitalised and ambulatory patients we collected: pus from abscesses/phlegmons, ear, nose and throat suppurations, discharge from superficial and deep surgical wounds. We performed classical bacteriological diagnosis and Kirby Bauer testing.

**Results** Staphylococcus aureus was isolated in 41.15% of cases, coagulase-negative staphylococci in 4.31% and in the remainder Gram-negative bacilli: Klebsiella spp. (13.88%), Escherichia coli (13.40%), Pseudomonas (8.13%), Proteus (6.22%), non-fermentative Gram-negative bacilli (4.78%), Enterobacter (1.91%) and Citrobacter (0.48%).

Staphylococcus aureus was resistant to ceftriaxone (100%), penicillin (91.36%), amoxicillin (83.33%), amikacin (80.00%) and ampicillin (67.92%). E. coli strains were resistant to chloramphenicol (100.00%), amoxicillin clavulanate (87.50%) and ampicillin (64.50%). Klebsiella was resistant to ampicillin (100%), amoxicillin clavulanate (87.50%) and amikacin (50.00%). Pseudomonas was found to be highly resistant to cefpirome (87.50%), meropenem (66.67%) and tigecycline (66.67%).

36.84% of all strains were resistant to more than five antibiotics. The average resistance index of strains isolated from the superficial suppurations was higher than those isolated from the deep suppurations (Student’s t = -3.025, p = 0.0014). The resistance index also indicated that the strains isolated from hospitalised patients were more resistant than those from ambulatory patients (Student’s t = -3.4237, p = 0.0008).

**Conclusion** This study shows the prevalence of multidrug-resistant strains in our hospital and their involvement in surgical wound infections. Continuous microbiological surveillance of germs isolated from surgical suppurations and their resistance to antimicrobials is essential for defining antibacterial policies on surgical wards.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**EFFECT OF A TRAINING INITIATIVE TO IMPROVE ADHERENCE TO THE RECOMMENDATIONS FOR THERAPEUTIC MONITORING VANCOMYCIN**


10.1136/ejhp-2015-000639.144

**Background** Respiratory syncytial virus (RSV) infections can be prevented by good hygiene and prophylactic palivizumab, a monoclonal antibody against the fusion protein of VRS. The criteria for selecting patients for palivizumab prescription in our hospital are: <28 weeks preterm infants (PI) and age <12 months (criterion 1), <32 weeks PI and age <6 months (criterion 2), age <2 years with bronchopulmonary dysplasia (criterion 3), age <2 years with haemodynamically significant congenital heart disease (criterion 4).

**Purpose** To describe the use of palivizumab in the vaccination campaign in our hospital, evaluating the appropriateness of its use by the established criteria and its effectiveness.

**Material and methods** We performed a retrospective observational study. All patients who received palivizumab between 01/10/2013 and 31/03/2014 were included. The data collected using the clinical records were: sex, gestational age, selection criteria, and number of hospitalizations due to acute bronchiolitis between 01/10/2013 and 30/09/2014. RSV was analysed in these patients by Polymerase Chain Reaction (PCR).

**Results** Palivizumab was administered to 68 patients (48.5% female) with a median gestational age of 209 days (176–287). 24 patients (35.3%) fulfilled criterion 2, 14 (20.6%) criterion 1, 10 (14.7%) criterion 4, 5 (7.3%) criteria 1 and 3, 4 (5.9%) criteria 2 and 4, 3 (4.4%) criteria 3, 2 (2.9%) criteria 3 and 4. 4 patients did not meet any criteria and 2 had no data. Only 6 patients who received palivizumab were hospitalised with a diagnosis of acute bronchiolitis and their RSV PCRs were negative.

**Conclusion** Palivizumab is used under the established criteria in our hospital. The study data show that immunising these at-risk patients with the palivizumab vaccine was an effective strategy for at least one year. Although the study period was 1 year, it would be desirable to measure effectiveness over a longer period.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**ANALYSIS OF THE USE AND EFFECTIVENESS OF PALIVIZUMAB IN A TERTIARY HOSPITAL**

A Lizardi*, MA Aranguren, MB Iztueta, M Ercilla, M Umerez, J Barral, P Carmona, MP Bachiller. Donostia University Hospital, Hospital Pharmacy, San Sebastián, Spain

10.1136/ejhp-2015-000639.143

**Background** Up to 50% of antibiotic treatments prescribed have been estimated to be incorrect. This is probably caused by the high level of knowledge required for the appropriate use. Training may be a way to improve antibiotic use.

**Purpose** To analyse the impact of training on the correct use of trough vancomycin plasma concentrations as a tool for monitoring effectiveness and safety in a teaching hospital.

**Material and methods** The training was conducted by disseminating local antibiotic guidelines including the recommendations contained in the consensus document on therapeutic monitoring of vancomycin. A before-after study was conducted comparing before the training period (January–April 2012) with a later
Clinical pharmacy

period (September–December 2013). We selected patients treated with vancomycin and we collected data on duration and concomitant treatment, demographic variables, serum creatinine before and during treatment. Creatinine clearance was calculated by MDRD-4, considering impaired renal function if <80 ml/min. To compare the two periods the McNemar-Bowker test (SPSS v.15) was used.

Results 85 patients were treated with intermittent infusion of vancomycin, 30 patients before vs. 45 after the training. The median age was 66 vs. 65 years. Mostly men, 70% vs. 55.6%. Median days of treatment were 7 [7 (1–46) vs. 7 (1–24)]. No levels were requested in 90% vs. 73.3% for the two periods, which met one or more criteria; monitoring was 63% vs. 51.1%, no statistically significant difference (p = 0.379). The criterion of more than five days duration was 100%; monitoring was 86.9% in both periods.

Conclusion The implementation of an educational activity did not meet expectations in terms of an increase in adherence to recommendations. It is necessary to intensify these training activities and the role of the clinical pharmacist on the usefulness and advantages of monitoring vancomycin, particularly during prolonged treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 Delitt TH. Clin Infect Dis.
2 Rybak M. Am J Health Syst Pharm
No conflict of interest.

CP-146 THE PHARMACOTHERAPEUTIC MANAGEMENT OF PARAPNEUMONIC PLEURISY
1 Stărică*, 2 Dălină, 3 Rousu, 4 Aţ Rosu, 5 O Zlatian, 1 University of Medicine and Pharmacy, Faculty of Medicine, Craiova, Romania; 2 Faculty of Pharmacy, Clinical Pharmacy Department, Craiova, Romania; 3 Faculty of Medicine, Microbiology Department, Craiova, Romania

Background Confirmation of infectious aetiology of pleurisy requires a complete microbiological diagnosis. An antibiogram is mandatory for correct and effective treatment.

Purpose To investigate the resistance pattern of the flora involved in parapneumonic pleurisy.

Material and methods We attempted to identify possible causative organisms and their sensitivity to antibiotics in the pleural fluids collected from 150 patients hospitalised between 01.05.2010 and 01.05.2011.

Results In 43.33% of pleural fluids germs were detected such as: Pseudomonas spp., anaerobic bacteria, non-fermentative Gram negative rods, Staphylococcus aureus, MRSA, Escherichia coli, Klebsiella, Streptococcus pyogenes, Enterococcus, Candida albicans.

Pseudomonas strains were 100% resistant to ampicillin, amoxicillin, cefpirome, ceftriaxone (91.67%), penicillin (90.00%), cefuroxime (87.50%), cefazidime (85.00%), amoxicillin with clavulanic acid (75.00%), gentamicin (73.33%) cefepime (71.43%), teicoplanin (9.09%) and linezolid (11.11%).

Staphylococcus aureus was 100% resistant to ampicillin, amoxicillin, amoxicillin with clavulanic acid, cefoxime, cefepine, cefpirome (90.91%), ceftriaxone (87.50%), cefazidime (87.50%), penicillin (80.00%), amikacin (11.1%) and rifampicin (20.00%). No resistance to linezolid, teicoplanin or piperacillin with tazobactam was observed.

Non-fermentative Gram-negative rods were 100% resistant to ampicillin and amoxicillin, cefuroxime (90.91%), cefpirome (88.89%), amoxicillin with clavulanic acid (75.00%), ceftriaxone (73.00%). We found low resistance to piperacillin with tazobactam (20.00%), amikacin (25.00%), and tigecycline (33.33%).

Klebsiella pneumoniae was 100% resistant to ampicillin, amoxicillin, clavulamic acid, amoxicillin, cefazidime, gentamycin, cefpirome, cefuroxime, penicillin (75.00%), rifampicin [JM1] (75.00%), oxacillin (66.67%), tigecycline (66.67%). All strains were 100% susceptible to linezolid, meropenem and teicoplanin.

These resistance patterns show the nosocomial potential of these strains.

In the evolution of pleurisy, especially due to Pseudomonas, there was a correlation between prolonged hospitalisation and rapid development of resistance to drug treatment once it has started.

Conclusion It is recommended to research and evaluate the effectiveness of strategies to prevent the emergence of microbial strains resistant to drug treatment in the case of parapneumonic pleurisy.

REFERENCES AND/OR ACKNOWLEDGEMENTS
[JM1]
No conflict of interest.

CP-147 METASTATIC BREAST CANCER: COST ANALYSIS AND SUSTAINABILITY OF TREATMENT WITH ERIBULIN IN MULTI-TREATED PATIENTS
1 C Scorsone*, 2 G Bellavia, 3 G Rizza, 4 V Cascone. 1 ASP Agrigento, Hospital Pharmacy AG 2 District, Sciacca, Italy; 2 ASP Ragusa, Hospital Pharmacy AG 1 District, Ragusa, Italy

Background The prognosis for metastatic breast cancer is unfavourable but the treatments available today allow us to control the development of the disease. Eribulin is approved for use in pretreated patients. Eribulin has shown to increase OS by 2.5 months and PFS by 1.5 months compared to other drugs, contributing to the OS.

Purpose To make a pharmacoeconomic analysis of new therapeutic options from a hospital perspective.

Material and methods We analysed the treatment of patients treated in the 3rd and 4th line for metastatic disease. PFS, average cost of treatment (drug cost) per patient, per cycle were calculated. We assumed reimbursement by the pharmaceutical company in accordance with the arrangements negotiated with AIFA equal to 100% of the cost of the vials for patients who did not respond within the first 3 months of treatment.

Results Treatment for these patients cost €121,859.8. The average cost of treatment per cycle was €1,934.28, for each patient in our sample and totalled €9,373.83. Considering the PFS, the average cost of a day’s PFS was equal to €38.64. Evaluating the repayments by the pharmaceutical company, they amounted to €22,992.4 for non-responding patients. Payment was according to AIFA equal to 100% of the cost of the vials for patients who did not respond within the first 3 months of treatment.

Results Treatment for these patients cost €1,934.28, for each patient in our sample and totalled €9,373.83. Considering the PFS, the average cost of a day’s PFS was equal to €38.64. Evaluating the repayments by the pharmaceutical company, they amounted to €22,992.4 for non-responding patients. Payment was according to AIFA equal to 100% of the cost of the vials for patients who did not respond within the first 3 months of treatment.

Conclusion This therapeutic opportunity in pretreated metastatic patients on their III/IV line of treatment, is missed by a
high percentage of non-responding patients who already died before this point. Pay By Result, helping to make the cost of treatment more sustainable for the NHS, offers responding patients another chance. Using left-over drug prepared for other treatments when it has been shown to be microbiologically and physicochemically stable, contributes to reducing the government’s spending on pharmaceuticals by enabling greater sustainability of treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS
1 Eribulin SPC

No conflict of interest.

**CP-148** SURVIVAL BENEFIT WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MYELOMA: AREA UNDER THE CURVE-BASED REANALYSIS

S Fenix-Caballos*, J Díaz-Navarro, El Alegre Del Rey, J Borrego-Rubio, M Blanco-Castaño, M Gandara-Ladron De Guevara, C Palomo-Palomo, J García De Paredes-Esteban, M Camean-Castillo. Puerto Real Univerisy Hospital, Pharmacy, Puerto Real, Spain

10.1136/ejhpharm-2015-000639.147

Background Benboubker et al. recently reported the results of lenalidomide + dexamethasone (Ld) in transplant-ineligible patients with melanoma versus the standard treatment, with a difference between medians of 4.3 months in progression-free survival (PFS). Nevertheless, as seen in the shape of the curves, difference in median survival (DMS) may not provide a good estimate of the survival benefit.

Purpose To reanalyse the survival benefit of lenalidomide from the PFS curves using an area-under-the-curve (AUC)-based method.

Material and methods Kaplan-Meier PFS and OS curves were extracted from Benboubker et al.’s article. Graphical AUC methods were applied to continuous Ld vs. standard treatment curves and compared to DMS. The AUC was calculated according to a previously published method. Vertical cutting lines at the tail ends of the graphs were made based on the number of patients at risk. It was agreed that this cut-off point was defined as placing at least 10 at-risk patients in each group or 30 in total. The AUC method quantified the difference between areas, and the results were expressed in time units. Photoshop-CS6 was used for graphical AUC calculation.

Results AUC-based reanalysis of PFS curves included 67.5% patients with 47 months of follow-up, at least 30 patients remaining at risk. PFS was 17.0 vs. 14.3 months, a benefit of 2.7 months in favour of continuous Ld. For OS, with 43.5% patients analysed and 50 months of follow-up, the AUC method showed a benefit of 5.3 months (25.5 vs. 20.2).

Conclusion AUC-based analysis showed a shorter survival benefit than the difference in median survival. This is probably related to the shape of the curves, which diverged at the medium zone of the graph. OS reanalysis is very limited because the observation time is insufficient to provide mature data.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

**CP-149** INFLUENCE OF CLINICAL TRIALS ON THE CONSUMPTION OF ANTIBIOTICS IN HOSPITAL

M Espona Quer, R García Paricio*, S Luque Pardos, B Lopez García, D Conde Estevez, S Ortonobes Roig, E Salas Sanchez, S Grau Cerrato. Hospital Del Mar Parc de Salut Mar, Pharmacy Department, Barcelona, Spain

10.1136/ejhpharm-2015-000639.148

Background Defined daily dose per 100 occupied bed-days (DDD/100 OBD) is a quality indicator used for controlling antimicrobial use in the hospital setting. Information is lacking about the impact of clinical trials (CT) focused on infectious diseases in the overall consumption of antimicrobials.

Purpose To assess the impact of the antibiotic consumption (AC) from CT performed in Infectious Diseases (ID), General Surgery (GS) and Intensive Care Unit (ICU) departments on the AC of these settings.

Material and methods Retrospective study performed in an university hospital from June 2012 to April 2014. Data collected: No CT with antibiotics in ID, GS and ICU wards; number of patients for each CT. Overall DDD/100 OBD of AC from the hospital and CTS were calculated and compared for each department by means of the standard WHO formula.

DDD/100 OBD for investigational drugs were estimated from the available antibiotics used as comparators.

Results No CT: ID:5, GS:1 and ICU:1. No patients: ID:18, GS:6 and ICU:1.

Abstract CP-149 Table 1

<table>
<thead>
<tr>
<th>ANTIBIOTIC</th>
<th>DEPARTMENT</th>
<th>DDD/100 OBD</th>
<th>PROPORTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CT</td>
<td>HOSPITALCT</td>
<td>HOSPITAL</td>
</tr>
<tr>
<td>CEFTAZIDINE</td>
<td>ID</td>
<td>0.66</td>
<td>0.74</td>
</tr>
<tr>
<td></td>
<td>GS</td>
<td>0.09</td>
<td>0.50</td>
</tr>
<tr>
<td>VANCOMYCIN</td>
<td>ID</td>
<td>0.63</td>
<td>2.56</td>
</tr>
<tr>
<td>AZTREONAM</td>
<td>ID</td>
<td>0.25</td>
<td>0.94</td>
</tr>
<tr>
<td>MEROPENEM</td>
<td>ICU</td>
<td>0.23</td>
<td>16.35</td>
</tr>
<tr>
<td>METRONIDAZOLE</td>
<td>GS</td>
<td>0.12</td>
<td>3.03</td>
</tr>
<tr>
<td>CIPROFLOXACIN</td>
<td>ID</td>
<td>0.47</td>
<td>3.27</td>
</tr>
<tr>
<td>SULFAMETHOXAZOLE</td>
<td>ID</td>
<td>0.07</td>
<td>3.29</td>
</tr>
<tr>
<td>TRIMETHOPRIM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>ID+GS+ICU</td>
<td>2.72</td>
<td>48.59</td>
</tr>
</tbody>
</table>

Abstract CP-149 Figure 1
Clinical pharmacy

Conclusion

- DDD/100 OBD of investigational antibiotics from CT should be added to the overall hospital AC data to avoid an underestimation of the antibiotic selection pressure mainly from cefadroxil consumption.
- This indicator should be also used to calculate more accurately the AC in those departments that conduct a high number of CT like the ID.
- Further studies should be designed to know which actions should be triggered from these results.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.

INCIDENCE OF LACTIC ACIDOSIS IN PATIENTS TREATED WITH METFORMIN


10.1136/ejhpharm-2015-000639.149

Background Metformin is one of the most commonly prescribed drugs for the treatment of type 2 DM. A potential complication of metformin is lactic acidosis (LA). This potential increased risk remains controversial.

Purpose To evaluate the occurrence of LA in type 2 DM patients treated with metformin. To study the prevalence of acute renal failure in these patients and the final outcome.

Material and methods Retrospective observational study in a general hospital. Discharge certificates including codes for LA and DM (ICD-9) during 2013 were classified; we selected those under treatment with metformin.

Exclusion criteria: Patients with decompensated diabetes/ketoadiposis and patients with chronic renal failure.

Results 126 discharge certificates coding LA, DM, and treatment with metformin were classified. 87 of these patients met some exclusion criteria. Among the 39 remaining patients, in 14 of them “LA related to the use of metformin” was specifically described in the discharge certificate.

Distribution in sex and age was 58% men and 81 ± 10 years. In 100% of the cases acute renal failure was observed.

One patient died, the rest of them were discharged after a median stay of 8 ± 3 days.

According to data provided by the health service, 9,713 patients were being treated with metformin in our area. This equates to an incidence of 14/10,000 patient-years.

Conclusion We found a much higher incidence of LA than described in the literature. This potentially fatal complication should be avoided by controlling risk factors. We consider education of physicians and patients essential; in this point, pharmacists have an important role.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1 Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of metformin associated lactic acidosis. Diabetes Obes Metab 2001;3:195–201

No conflict of interest.
Background Brentuximab vedotin (SGN-35) is a treatment option for patients with relapsed or refractory Hodgkin’s lymphoma (HL) and systemic anaplastic large-cell lymphoma (ALCL), with only two phase II studies.

Purpose To evaluate the effectiveness and safety of SGN-35 in patients with relapsed or refractory HL and ALCL.

Material and methods Type of study: retrospective observational cohort study.

Inclusion criteria: patients with relapsed or refractory HL and ALCL, treated with SGN-35 in monotherapy from 05/2012 to 09/2014.

Variables: age, sex, type of lymphoma, stage and International Prognostic Index (IPI score); number of prior courses of chemotherapy, autologous stem-cell transplantation (auto-SCT) and clinical response to prior treatment; number of cycles, dose reductions, clinical response according to the Revised Response Criteria for Malignant Lymphoma: complete remission (CR), partial remission (PR), stable disease (SD) and progressed disease (PD). Incidence and severity of side effects (CTCAE v4.03 criteria).

Results We included 5 patients (3 women, 2 men) aged 47 (30; 52) years. 4 patients suffered from HL, stages II-A, II-B, III-A, IV-B, and 1 ALCL stage IV-A. The IPI score was: III 2 patients, IV 1 patient (2 patients not specified).

Our patients had received 2 (2; 4) chemotherapy cycles before SGN-35 and 3 of them had undergone an auto-SCT. Clinical response to prior therapy was CR in 2 and PR in 3 patients.

After 4 (2; 16) cycles (1 patient with a 17% reduction of dose because of his previous hepatic impairment) 2 patients achieved CR, 1 PR and 1 PD. At the end of the follow-up period, 3 patients carried on with the treatment (1 without evaluation of the response) and 2 patients had died (1 CR and 1 PD) with a time to progression of 2.5 (2; 3) months.

1 patient suffered from side effects: facial rash and a post-infusion reaction grades I-II.

Conclusion In our population 3 of 5 patients treated with SGN-35 achieved an objective response for 2.5 months, with favourable safety profile.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1 JC030 (18):2190–6
2 JC030 (18):2183–9

No conflict of interest.

CP-153 CLINICAL EXPERIENCE WITH FIDAXOMICIN FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION

MJ Company Abri*, AA García Robles, R Luna Reina, M Martín Cereueloa, C Favieres Puig Cerver, P Pérez Huertas, C Borrell García, P José Luis. Hospital La Fe, Pharmacy, Valencia, Spain

10.1136/ehjpharm-2015-000639.152

Background The increasing prevalence, morbidity and mortality rates of Clostridium difficile infection (CDI) turn its treatment into a challenge for researchers. Fidaxomicin is a new treatment option which has been shown to be effective for treating both primary and recurrent CDI in clinical trials but there is limited clinical experience.

Purpose To evaluate the use and outcome in patients with CDI treated with fidaxomicin in a tertiary hospital.

Material and methods Between May 2013 and September 2014 patients undergoing treatment with fidaxomicin were assessed. Demographic and clinical data were collected from the patient electronic medical record. The outcome measure was Symptom-Free Interval (SFI), calculated in patients who were monitored for at least 1 month.

Results Thirteen patients were analysed (n = 13), 53.8% male, median age 54 years (range 27–83) and all had baseline disease which increased the risk of recurrent CDI, so fidaxomicin treatment was indicated by current clinical guidelines. Seven had a history of recurrent CDI and eleven had received previous treatment with vancomycin and/or metronidazole. Treatments with fidaxomicin were 200 mg twice daily for 10 days. Recurrence was found in 30.8% patients after the first treatment with fidaxomicin, but 6 patients were lost to follow-up (died). SFI varied with number of courses received. After the first treatment, the median SFI was 75 days (range 15–395). After the second course (2 patients) SFI was 66 and 180 days and following the third treatment (2 patients) SFI was 133 and 64 days.

Conclusion Use of fidaxomicin is more common in patients with recurrence or non-responders to standard treatment (84.6%); the recurrence rate was high (30.8%). This study was limited by the number lost to follow-up and high inter-individual variability in SFI. More clinical experience is needed to determine which patients may benefit most. Alternative dose regimens should be considered to improve treatment outcomes.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-154 EFFECT OF REGIMEN COMPLEXITY ON THE PREMATURE DISCONTINUATION OF TREATMENT WITH BOCEPREVIR OR TELAPREVIR IN HEPATITIS C VIRUS-HIV COINFECTED PATIENTS

1 R Jiménez-Galán, 2 J González-Bueno, 3 MR Cantudo-Cuenca, 4 MDC González-Medina*, 5 M Manzano-García, 6 MDLA Robustillo-Cortés, 7 AM Tristán-Pérez, 8 E Calvo-Cidoncha, 9 HC Haro Márquez, 10 RM Morillo Verdugo, 11 Ags Sur de Sevilla, Pharmacy, Sevilla, Spain; 12 Hospital Virgen del Rocio, Pharmacy, Sevilla, Spain; 13 Ags Sur de Sevilla, Pharmacy, Sevilla, Spain; 14 Hospital Universitario San Cecilio, Pharmacy, Sevilla, Spain

10.1136/ehjpharm-2015-000639.153

Background Medication regimen complexity index (MRCI) has been identified as a predictor of sustained virologic response in patients treated with peginterferon and ribavirin for chronic hepatitis C.

Purpose To determine the influence of the MRCI in the premature discontinuation of triple therapy treatment with boceprevir or telaprevir in hepatitis C virus-HIV coinfected patients.

Material and methods We conducted a multicentre and prospective study that included HCV/HIV coinfected patients treated with triple therapy with boceprevir or telaprevir in combination with peginterferon-alpha plus ribavirin between January and December 2013. Basal variables collected were: age, gender, hepatitis C treatment-naive or previously treated, presence of cirrhosis, psychiatric disorder. We evaluated the proportion of patients achieve extended rapid virologic response (RVRe), defined as HCV RNA negative between 4 and 12 weeks of treatment with telaprevir and between 8 and 24 weeks of treatment with boceprevir. The rate of premature therapy discontinuation with the PI and reasons were collected. To calculate the MRCI, we considered all prescribed drugs and used the tool developed by McDonald et al. To determine the independent predictors of therapy discontinuation, we performed a multivariate logistic regression analysis.

A63
Clinical pharmacy

Results 55 patients of three different centres were included (86.4% were men and the mean age was 48 years (SD = 3.7)). 68.0% were non-naïve. 90.7% had cirrhosis. 83.1% achieved RVRe. 18 patients (30.5%) prematurely discontinued the treatment. Reasons for treatment discontinuation included adverse events (50.0%), lack of efficacy (33.0%) and refusal to continue the medication (17.0%). The mean MRCI was significantly higher in patients who discontinued the therapy (31.11 vs. 26.16). In the multivariate analysis, the only predictor of premature discontinuation of the therapy was the MRCI (OR = 1.17, p = 0.009; 95% CI (1.04–1.53).

Conclusion The MRCI is an independent predictor of premature discontinuation of the triple therapy with beceprevir and telaprevir in HCV/HIV coinfected patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

COMPARATIVE PHARMACOECONOMICS STUDY: TUMOUR NECROSIS FACTOR - ALPHA ANTAGONISTS TREATMENT FOR RHEUMATOID ARTHRITIS

O García Molina*1, MA Fernandez De Palencia Espinosa, V Avoces Casaf, F Mendloza Otero, J Mateo Camorra, C Peller Franco, A De La Rubia Neto. Hospital Universitary Virgen de La Arrixaca, Pharmacy, Murcia, Spain

Background Treatment with Tumour Necrosis Factor (TNF-α) antagonists in patients with Rheumatoid Arthritis (RA) is expensive for the National Health Service.

Purpose To analyse the financial impact of this group of drugs and identify discrepancies between the theoretical cost and the actual cost.

Material and methods A retrospective, descriptive study of all patients with RA treated with adalimumab, etanercept or infliximab for the last three years in a tertiary hospital. The variables studied were: number of patients, number of units dispensed and cost per patient per year for each drug. Financial calculations used the official price of drugs plus VAT and took discounts into account.

Results The total cost generated of etanercept, adalimumab and infliximab was €4,053,861 in the study period. 92 patients were treated with adalimumab: 3,717 units were dispensed (mean 13.46 units/patient/year), mean cost €8,333/patient/year. 69 patients were treated with etanercept: 5,239 units were dispensed (mean 25.3 units/patient/year), mean cost €6,837/patient/year. 59 patients were treated with infliximab: the number of administrations was 1,050 (mean 5.9 administrations/patient/year), mean cost €8,431/patient/year. Theoretical cost calculated per (70 kg)/patient/year was €6,977 for infliximab (3 mg/kg), €11,254 for etanercept (50 mg/week) and €12,120 for adalimumab (40 mg/2 weeks). The underspend was €4,417/patient/year and €3,787/patient/year for etanercept and adalimumab respectively, whereas the actual cost of infliximab represented an increase of €1,454/patient/year compared to the theoretical cost.

Conclusion The actual cost of treatment with adalimumab and etanercept per patient/year was less than theoretically calculated, unlike infliximab, where the true cost per patient/year was greater than the theoretical cost.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

EVALUATION OF THE INCIDENCE AND EFFECTIVENESS OF ANTI-TNF-Α DRUG DOSE INTENSIFICATION IN CROHN’S DISEASE PATIENTS

A Andrés Rosado*, Y Castellanos Clemente, B Hernández Muniesa, C Bravo Lázaro, F J. Fafán Sedano. Fuenterabada University Hospital, Hospital Pharmacy, MADRID, Spain

Background There are two approved biological drugs, infliximab and adalimumab, for the treatment of Crohn’s disease (CD). For patients who lose their initial response, consideration can be given to dose intensification (DI) to regain therapeutic benefit.

Purpose Evaluation of the occurrence and effectiveness of DI of infliximab and adalimumab in CD patients who were primary responders.

Material and methods Observational retrospective study in a second level hospital, which included patients with CD on treatment with infliximab or adalimumab, from January 2004 to December 2013, and who responded to an induction regimen of the anti-TNF-α drug.

The variables collected were: anti-TNF-α drug, patient’s response, requirement for DI and time of follow-up.

The effectiveness of DI was determined by the numbers of patients responding to anti-TNF-α drugs at an intensified dose. This variable and the numbers of DI were calculated as the percentage of patient-years of follow-up.

Results A total of 40 primary responders to infliximab and 15 to adalimumab were included, who provided 125.2 and 23.1 patient-years of follow-up, respectively.

The proportion of patients who required intensified infliximab treatment was 8.8% (11/125.2) per patient-year and for adalimumab 8.6% (2/23.1) per patient-year. The times with intensified treatment were 18.8% and 5.3% patient-years follow-up, for infliximab and adalimumab, respectively. The percentage of patients maintaining a response to intensified doses of the drugs was 16% (3/18.8) per patient-year for infliximab and 37.7% (2/5.3) per patient-year for adalimumab.

Conclusion The proportion of patients who required DI was similar for the two drugs and it was less than 10% per patient-year. The effectiveness of DI was relatively low, due to the fact that the proportion of patients maintaining a response to DI was less than 40% per patient-year.

In other studies (Gisbert and Billioud et al.), the proportion of patients who needed intensified infliximab was similar to our results (13% per patient-year) and the annual risk of DI for adalimumab was greater (24.8% per patient-year).

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

EVALUATION OF FAMPRIFINE EFFECTIVENESS IN ADULT MS PATIENTS

1V Campion Turlán*, 2M Merchante Andreu, 3M Cumbraos Sánchez, 4M Gimeno Gracia, 2A Sanabria Sanchinel, 2C Iñiguez Martínez, 4E Fernández Alonso. 1Hospital Clinico Lozano Blesa, Pharmacy, Zaragoza, Spain; 2Hospital Clinico Lozano Blesa, Pharmacy, Zaragoza, Spain

Background Multiple sclerosis (MS) is a chronic and progressive inflammatory disease that attacks the central nervous system.
Impaired walking is the most significant disability; about half the patients suffer from this pathology 20 years after diagnosis. Fampridine has been approved for the improvement of walking capacity (WC) in adult MS patients with Expanded Disability Status Scale (EDSS) 4–7.

**Purpose** To determine the effectiveness of fampridine in improving the walking of adult MS patients 15 days and 45 days after starting the drug.

**Material and methods** Retrospective study by reviewing patient clinical records from the Neurology department and pharmacist reports.

Parameters measured: timed 25-foot walk test (T25FW), 12-item MS walking scale (MSWS-12) questionnaire at baseline, 15 days and 45 days after the first dose.

Response criteria were defined as an improvement of at least 20% in the T25FW and 6 points of the MSWS-12.

**Results** We included 22 patients in the study. Mean age: 50.95 years, 61.9% women, 61.8% Relapsing Remitting MS and 20% in the T25FW and 6 points of the MSWS-12.

Twelve patients (57.1%) were found to be responders, T25FW decreased on average by 39.8% at 15 days and 41.1% at 45 days from the baseline. The average WC improvement in T25FW decreased on average by 39.8% at 15 days and 41.1%

**Conclusion** Fampridine has been shown in clinical trials to improve WC in approximately one third of MS patients (42.9 and 35% in the pivotal clinical trials). In our study we’ve found a significantly greater improvement.

In responders this increase was maintained across the treatment period or even improved.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

---

**CP-158 OUR EXPERIENCE WITH FAMPRIDINE IN PATIENTS WITH MULTIPLE SCLEROSIS AFTER 2 YEARS OF TREATMENT**

1. Escolano Pueyo*, 1H Navarro, 1C Perez, 2B Sebastian, 2M Seral, 1M Abad. 1Universitary Hospital Miguel Servet, Pharmacy, Zaragoza, Spain; 2Universitary Hospital Miguel Servet, Neurology Service, Zaragoza, Spain

10.1136/ejhpharm-2015-000639.157

**Background** Fampridine is indicated for the improvement of walking in patients with multiple sclerosis (MS) (EDSS 4–7).

**Purpose** To assess the effectiveness, undesirable effects and adherence to fampridine.

**Material and methods** A 30-month retrospective study was conducted, including MS patients receiving fampridine 10 mg BID. Medical records were reviewed for data on Timed 25-Foot Walk (T25FW) and 12-item MS walking scale (MSWS-12), from baseline over a 24-month period (screening at baseline, day 15, months 3, 12, 18 and 24). Adverse events (AEs) were also recorded from medical records and hospital admissions and emergency department (ED) visits were analysed in order to identify suspected AEs. The adherence rate was calculated from pharmacy dispensing records.

**Results** 19 patients (68.4% women), mean age 61.9 (40–80) years with different forms of MS (relapsing remitting 26.3%, primary progressive 42.1% and secondary progressive 42.1%) were included. Effectiveness data are shown in Table 1. 58.9% of patients (11/19) were hospitalised or visited the ED. The AEs identified were mostly urinary tract infections (37.3%) and dizziness, causing falls, (36.4%) (causal relationship not established). A high level of adherence (97.5%) was achieved.

**Conclusion** More than a half of the patients treated with fampridine experienced a clinically relevant improvement in walking ability (increase of over 20% in T25FW and MSWS-12 scale reduction ≥6), which was sustained for at least 24 months. Side effects were mild and acceptable.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

---

**CP-159 ASSESSMENT OF EFFECTIVENESS IN WALKING ABILITY AND SAFETY OF FAMPRIDINE IN MULTIPLE SCLEROSIS PATIENTS**

A Andrés Rosado*, A Carrasco Torrents, A Ontañón Nasarre, FJ Farfán Sedano. Fuenlabrada University Hospital, Hospital Pharmacy, Madrid, Spain

10.1136/ejhpharm-2015-000639.158

**Background** Fampridine is a voltage-dependent potassium channel blocker. It’s indicated to improve walking ability (WA) in patients with multiple sclerosis (MS). Patients should be evaluated after two weeks and treatment should be stopped for those who have not shown an improvement.

**Purpose** To assess the effectiveness of fampridine in patients with multiple sclerosis (MS) with walking impairment. Secondary endpoint is evaluation of safety.

**Material and methods** Observational retrospective study (November 2013 to September 2014) that included patients with MS who started treatment with fampridine 10 mg twice daily, in a second level hospital.

**Abstract CP-158 Table 1**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline (n = 19)</th>
<th>15 days (n = 17)</th>
<th>3 months (n = 17)</th>
<th>1 year (n = 16)</th>
<th>1.5 years (n = 16)</th>
<th>2 years (n = 15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T25FW (seconds)</td>
<td>21 ± 16.4</td>
<td>13.2 ± 10.2</td>
<td>14.9 ± 16.4</td>
<td>14.4 ± 14.5</td>
<td>9.8 ± 6.5</td>
<td>10.6 ± 6.6</td>
</tr>
<tr>
<td>Average increase in T25FW speed from baseline (%)</td>
<td>62.2 ± 57.9</td>
<td>59.8 ± 44.6</td>
<td>50.4 ± 23.3</td>
<td>61.7 ± 23.7</td>
<td>49.7 ± 25.8</td>
<td></td>
</tr>
<tr>
<td>MSWS-12 (points)</td>
<td>47.9 ± 9.2</td>
<td>37.4 ± 8.8</td>
<td>36.7 ± 7.6</td>
<td>40 ± 9.8</td>
<td>43.3 ± 10.2</td>
<td>38.6 ± 10.4</td>
</tr>
<tr>
<td>MSWS-12 reduction (points)</td>
<td>11.9 ± 8.2</td>
<td>12.7 ± 7.8</td>
<td>9.2 ± 7.3</td>
<td>6.4 ± 5.8</td>
<td>10.7 ± 9.13</td>
<td></td>
</tr>
<tr>
<td>% patients with MSWS-12 ≥ 6 points</td>
<td>70.6</td>
<td>82.4</td>
<td>75</td>
<td>50</td>
<td>57.1</td>
<td></td>
</tr>
<tr>
<td>% responding patients</td>
<td>64.7</td>
<td>70.6</td>
<td>62.5</td>
<td>50</td>
<td>58.3</td>
<td></td>
</tr>
<tr>
<td>EDSS</td>
<td>5.9 ± 0.6</td>
<td>5.9 ± 0.79</td>
<td>5.67 ± 0.8</td>
<td>5.9 ± 0.78</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clinical pharmacy

The main measure of effectiveness was based on improvements in walking speed along a path of 25 feet (7.5 metres) (T25FW) and in the 12-item Multiple Sclerosis Walking Scale (MSWS-12), questionnaire that measures the patient’s impression of the effect of their MS related walking disability on their ability to perform activities of daily life. Assessments were performed at baseline and after 2 weeks of treatment.

Effectiveness was defined as 20% improvement in T25FW or a minimum reduction of 6 points in the MSWS-12 score. The results were compared with the efficacy results of the pivotal clinical trials (CT).

The safety of fampridine was evaluated through side effects (SE).

Results 11 patients were included (mean age, 47 years; mean EDSS 6; mean T25FW, 47 s and mean MSWS-12, 40 points).

After 2 weeks, 54% (6/11) of patients walked ≥20% faster (mean 26 s), and 72% (8/11) of patients MSWS-12 (mean 32 points). 81% (9/11) of patients improved WA after two weeks.

The most common SE were constipation, balance disorder, dizziness and difficulty speaking. Due to this SE, two patients left treatment.

Conclusion Fampridine has been demonstrated to be effective in improving the WA of patients with MS, with an acceptable SE profile. Rate of response after two weeks was 81%, greater than the results of the CT (43% and 35%).

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

Background

Inappropriate use of antibiotics has become a serious problem in the hospital setting. We implemented a stewardship programme in order to optimise antimicrobial treatment at our hospital.

Purpose

1. To analyse the contribution of an antibiotic pharmacist, as part of an antibiotic stewardship programme, resulted in a reduction of excessively prolonged antimicrobial courses and improvements in accordance with culture results, dose to patient condition, adjustment of empirical treatment to recommendations, and selection of a suitable route for administration.
2. Interventions in antifungal treatment were associated with greater savings.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-160 HOSPITAL PHARMACIST-LED PROJECT TO IMPROVE ANTIBIOTIC USE IN THE HOSPITAL SETTING

1 S Murrieta Perichet*, 1 N Sangil Monroy, 2 J Ramos Báez, 1 S González Munguía, 3 R Molero Gómez, 3 M Amat López, 3 M Pérez León, 3 G Herrero Ortega, 3 V Morales León.

1 Hospital Universitario de Gran Canaria Doctor Negrín, Pharmacy Department, Las Palmas de Gran Canaria, Spain; 2 Centro de Atención Sociosanitaria El Pino, Pharmacy Department, Las Palmas de Gran Canaria, Spain.

10.1136/etpharm-2015-000639.159

Background

Inappropriate use of antibiotics has become a serious problem in the hospital setting. We implemented a stewardship programme in order to optimise antimicrobial treatment at our hospital.

Purpose

1. To analyse the contribution of an antibiotic pharmacist after the introduction of the antimicrobial stewardship programme.
2. To analyse the economic impact of pharmacists’ recommendations.

Material and methods

An antibiotic pharmacist designed a protocol to optimise antibiotic treatment in agreement with infectiologists and microbiologists. The programme started running in December 2013.

On a daily basis, the pharmacist obtains a list of inpatients prescribed antibiotics from the computerised prescription order entry system and recovers information from the electronic health record. The pharmacist checks the following items: (1) conformity of empirical and targeted antimicrobial treatment to clinical practice guidelines; (2) local flora and culture results; (3) dose adjustment to the clinical situation; (4) appropriate duration and (5) route of administration. If treatments are susceptible to improvement, the pharmacist contacts physicians to propose recommendations. The recommendations are recorded in a database. Additionally, the financial impact is evaluated in antimicrobial or dose changes.

Results

We analysed 2,250 prescriptions (32% of total) over a 10-month period. Physicians were contacted on 347 occasions; 96% related to antibiotics and 4% to antifungals. In 86% of the cases they agreed with the proposals. Reasons to act were: 36% administered for too long, 20% inappropriate antibiotic selected, 18% unadjusted dose, 14% inappropriate empirical treatment, and 11% unestablished sequential treatment.

Direct costs could be estimated in 32% of the antibiotic and antifungal recommendations, leading to net savings of €9,566 (49%) and €10,041 (51%).

Conclusion

1. The contribution of an antibiotic pharmacist, as part of an antibiotic stewardship programme, resulted in a reduction of excessively prolonged antimicrobial courses and improvements in accordance with culture results, dose to patient condition, adjustment of empirical treatment to recommendations, and selection of a suitable route for administration.
2. Interventions in antifungal treatment were associated with greater savings.
increased sensitivity to platinum. The median overall survival in PS was 172.9 weeks versus 69.7 in PR (log rank \( p < 0.005 \)).

Conclusion The addition of PLD when treating ROC was associated with significant increases in the long term median OS. The benefit obtained in this population (median OS 78.0 weeks) was higher than that reported in the literature (median OS 62.7 weeks) and was found to be even greater in the subgroup of patients with platinum-sensitive disease (including intermediate sensitivity).

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.

CP-162 EVALUATION OF BENZODIAZEPINE USE IN HIV-POSITIVE PATIENTS

1R Andrade*, 1M Ferri, 1T Martínez, 1E Domingues, 1MA Hernández. 1Virgen de Las Nieves University Hospital, Pharmacy, Granada, Spain; University of Granada, Pharmacy, Granada, Spain

Material and methods Retrospective study evaluating the medical records of HIV-positive patients aged 18 years or older, both sexes, enrolled at a University Hospital.

Results Of 782 HIV-positive patients aged 18 years or older, both sexes, enrolled at a University Hospital, 193 had benzodiazepines prescribed in electronic medical records in 2014. Of these patients who had benzodiazepine prescriptions, 179 had been diagnosed with HIV before 2013. Only 10.3% of them had been diagnosed with HIV-positive patients on antiretroviral treatment.

Purpose To evaluate the use of benzodiazepines in HIV patients receiving antiretroviral treatment.

Background The prevalence of anxiety in human immunodeficiency virus (HIV)-positive people on antiretroviral therapy is higher than that of the general population and also than in other chronic incurable conditions. Benzodiazepine are often prescribed inappropriately long-term and benzodiazepines are commonly prescribed with antiretrovirals although contraindicated.

Purpose To evaluate the use of benzodiazepines in HIV patients receiving antiretroviral treatment.

Material and methods Retrospective study evaluating the medical records of HIV-positive patients aged 18 years or older, both sexes, enrolled at a University Hospital.

Results Of 782 HIV-positive patients aged 18 years or older, both sexes, enrolled at a University Hospital, 193 had benzodiazepines prescribed in electronic medical records in 2014. Of these patients who had benzodiazepine prescriptions, 179 had been diagnosed with HIV before 2013 and 14 in 2013. Only 10.3% of them had been diagnosed with HIV before 2013.

Conclusion These data suggest the need for intervention by the pharmacist with other health professionals to clarify the necessity and quality of use of these anxiolytics. In addition, pharmacotherapeutic follow-up and pharmaceutical education by a pharmacist may promote the rational use of benzodiazepines in these patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1 Ciências sem Fronteiras - CNPq – Brasil

No conflict of interest.

CP-163 EVALUATION OF EFFECTIVENESS AND SAFETY OF RILПИРINE/EMTRICITABINE/ TENOFOVIR

A Andrés Rosado*, A Ontáñon Nasame, A Carrasco Torrents, FJ Farías Sedano. Fuenlabrada University Hospital, Hospital Pharmacy, Madrid, Spain

Background The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) has been approved for the treatment of patients with HIV infection with a viral load (VL) ≤100,000 copies/mL.

Purpose To evaluate the effectiveness and safety of RPV/TDF/FTC in treatment-naïve and pretreated patients with HIV infection in a second level hospital.

Material and methods Retrospective observational study (June 2013–September 2014). We included patients with HIV infection, treatment-naïve and pretreated, being treated with RPV/TDF/FTC. The effectiveness was measured by the virological and immunological response. Virological response was considered when VL was undetectable (VL <50 copies/mL) and immunological response when CD4 count was greater than 200 cells/mm³ after 6 months of treatment. VL and CD4 count were collected at baseline and 6 months later. Patients who had less than 3 months on treatment were excluded, because no analytical data are available to assess the effectiveness. Safety was evaluated through side effects (SE).

Results 15 patients were included, 3 treatment-naïve and 12 pretreated. 42% (5/12) of pretreated patients switched treatment to RPV/TDF/FTC due to SE, 25% (3/12) to simplify treatment, 25% (3/12) for psychiatric reasons and 8% (1/12) for poor adherence.

67% (8/12) of pretreated patients had an undetectable baseline VL, 8% (1/12) had VL 50–100 copies/mL and 25% (3/12) had VL > 100 copies/mL. Baseline CD4 count average was 377 cells/mm³ (79–655). Baseline VL average of treatment-naïve patients were 31,043 copies/mL (3,530–49,000) and baseline average CD4 count was 329 cells/mm³ (200–430).

After 6 months, treatment were effective in 75% (9/12) of pretreated and 67% (2/3) of treatment-naïve patients.

13% (2/15) reported SE. 1 patient reported insomnia and another patient fatigue, gastrointestinal disorders and dyspnoea due to which he left treatment.

Conclusion RPV/TDF/FTC has been shown to be effective in treatment of HIV infection, in treatment-naïve (67%) and in pre-treated patients (75%). The SE profile is low, however one patient had to leave treatment for this reason.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-164 USE OF IVERMECTIN FOR STRONGYLOIDOSIS: AN APPROACH TO CLINICAL PRACTICE

1A Caballero Romero*, 2D Blázquez Martínez, 2J Casas Hidalgo, 3M González Medina, 4M Valles Cupres, 5C García Fernández, 6C Gómez Pena, 7J Cabeza Barrena. 1Unidad Intercentros-Intervileges, Pharmacy, Granada, Spain; 2Unidad Intercentros-Intervileges de Farmacia, Pharmacy, Granada, Spain

Background Strongyloides stercoralis is one of the most common parasites in tropical areas. Nowadays, the treatment of such parasite is based on ivermectin. However, ivermectin is not marketed in Spain. Hospital pharmacists are responsible for permitting this treatment to patients, only after drawing up an exhaustive report. In this article, we have reviewed all the reports as well as classified the information in order to present our clinical practice.

Purpose To present our clinical experience regarding the treatment of strongyloides.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
Clinical pharmacy

Material and methods Descriptive observational study. Patients’ data were obtained from their clinical history. Variables examined: age, sex, nationality, doses, diagnostic methods (ELISA and coproparasitological test), co-infections, eosinophilia and immunosuppressed patients.

Results Ivermectin was first used in February 2012. 15 patients were analysed 8 men and 7 women. The average age was 36. Nationality: 12 patients from Bolivia, 1 from Guinea-Conakry, 1 from Cuba and 1 with unknown nationality. Posology: 1 oral dose of 200 mcg/kg/day of ivermectin for two days in 100% of patients. The ELISA test and the coproparasitological test were used in 100% and 86% of the patients respectively. The ELISA test result was positive in 93.3% of patients, whereas the coproparasitological test result was negative in 84.3%. Co-infections: Chaga’s disease, toxocariasis, tuberculosis, schistosomiasis, intestinal amoebiasis, unciniariasis (hookworm) and hymenolepis (tapeworm).

Before [JM1] the treatment, the average eosinophilia was 15.99%. However, after the treatment, it decreased to 4.67%. No patients were diagnosed with HIV-1 or treated with corticosteroids.

Conclusion The decrease in eosinophilic cells reveals that ivermectin is effective for the treatment of strongyloidiasis. As our study shows, most of the patients also carry other coexisting parasitic diseases, likewise transmitted by the faecal-oral cycle. Therefore, pharmacists could play an important role in the prevention of this type of diseases. Both by ensuring the appropriate use of this drug as well as by providing some useful advice on healthy practices.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-165 EFFECTIVENESS OF TRIPLE THERAPY WITH BOCEPREVIR IN CHRONIC HEPATITIS C PATIENTS

C Sargiador Peluza*, P Taberner Bonastre, E Soler Company, F Maüres Lleoor, J Navaró Fernández, L Barañón Pérez, Hospital Arnau de Vilanova, Pharmacy, Valencia, Spain

10.1136/ehp.2015-000639.164

Background Observational studies in clinical practice have revealed lower rates of effectiveness than those achieved in clinical trials. Therefore it is of particular interest to evaluate the success of treatment in our clinical practice as well as the results in underrepresented populations such as cirrhotic patients.

Purpose To evaluate the effectiveness of treatment with ribavirin, boceprevir and peginterferon alfa in our clinical practice in patients with chronic hepatitis C who had completed the treatment.

Material and methods Retrospective observational study (January 2012–June 2014). All patients with HCV genotype 1 were included who had completed treatment with boceprevir. Variables were collected to characterise patients and treatment.

Effectiveness evaluation: viral load <15 IU/ml at week 24 post-treatment. A descriptive and comparative statistical analysis was performed with SPSS version 15.0.

Results 57 patients (66% male) were included with a mean age of 53.5 ± 8.8 years and 70% with genotype 1b. Results at 24 weeks: 63.2% cures, 24.6% treatment failures, 10.5% suspensions due to toxicity and 1.8% discontinued treatment. Regarding treatment failures, 17.5% of failures occurred during triple therapy and 7.0% during the 12 weeks after the end of treatment.

In patients who completed treatment (n = 50), overall effectiveness was 72%. Effectiveness according to degree of fibrosis: 91.7% for grade F2, 80% for F3 and 60.7% for F4. Greater effectiveness in non-cirrhotic patients (86.4% vs. 60.7% p = 0.044). Higher effectiveness in patients younger than 45 years (100% vs. 68.2% p = 0.123), men (72.7% vs. 70.6% p = 0.562) and genotype 1b (77.1% vs. 60% p = 0.185), although not statistically significant. No differences about effectiveness were apparent between mono-infected patients (71.7%) and those co-infected with HIV (75% p = 0.690).

Conclusion Our effectiveness results are within the range established by the major publications of efficacy and effectiveness. We conclude that cirrhosis of the liver is the primary factor that determines the effectiveness.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CP-166 FACTORS ASSOCIATED WITH PERSISTENCE WITH ANTIRETROVIRAL TREATMENT IN HIV INFECTED PATIENTS

1R. Jiménez-Galán, 2M. Marzoa-García, 3R. Cantado-Cuenca, 4M. González-Medina*, 5E. Gómez-Fernández, 6E. Calvo-Cabotona, 7M. Guzman-Ramon, 8M. Rubisuillo-Cardís, 9R. Morillo Verdugo. 1AGS Sur de Sevilla, Sevilla, Spain; 2AGS Sur de Sevilla, Pharmacy, Sevilla, Spain; 3Hospital San Cecilio, Pharmacy, Granada, Spain

10.1136/ehp.2015-000639.165

Background Short persistence with antiretroviral treatment (ART) is associated with worse clinical outcomes. Persistence with single-tablet regimens (STRs) and less-drug regimens (LDRs) in HIV-infected patients has been insufficiently assessed in current research.

Purpose The main objective was to compare persistence with the two strategies and identify factors associated with non-persistence.

Material and methods This was a retrospective study that included HIV-infected patients treated with a STR or LDR between January 2007 and June 2014. STRs were based on efavirenz/emtricitabine/tenofovir or emtricitabine/tenofovir/rilpivirine combined in a fixed-dose tablet administered once daily and LDR consisted of protease inhibitor (PI/r) or dual treatment with a PI/r plus another drug. Data collected included age, gender, risk of transmitting HIV, hepatitis C virus (HCV) coinfection, treatment-naïve, presence of a psychiatric disorder and drug abuse consumption during the treatment. Persistence with treatment was defined as the time from start of treatment to discontinuation. Reasons for discontinuation were collected. To identify independent predictors of non-persistence we developed a multivariate Cox regression analysis.

Results 348 patients were included, 280 with STR and 68 with LDR. The mean age was 44.9 years (SD = 10.45), 82.4% were men and 29.9% were treatment-naïve. 30.2% had HCV coinfection, 10.3% presented a psychiatric disorder and 7.20% abused drugs. 86 (30.1%) patients discontinued in the STR group and 13 (19.1%) in the LDR group. The Cox regression model showed that the only variable associated with higher risk of non-persistence was the drug abuse [Hazard ratio = 2.58, p = 0.002, 95% CI (1.39–4.67)]. There were no statistically significant differences according to type of regimen. Adverse events
were the main reason for ART discontinuation in the STR group and virological failure in the LDR group.

**Conclusion** Persistence with STR and LDR seems to be similar in HIV-infected patients. Drug abuse is the only factor identified with a higher risk of non-persistence.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

---

**CP-167**

**SUITABILITY OF THE “BELIEFS ABOUT MEDICINES” QUESTIONNAIRE FOR HIV PATIENTS ON COMBINED ANTIRETROVIRAL TREATMENT**

1. M Capoulas*, 1L França, 1S Castro, 1P Santos, 2Ching, 1Y Lobo, 1D Ferreira, 1E Marques, 2F Fernández-Ulloa, 1C Santos. 1University Hospital Angélico Hospital, Pharmacy, Lisbon, Portugal; 2Faculty of Pharmacy, Lisbon University, Department of Social Pharmacy, Lisbon, Portugal

10.1136/ejhpharm-2015-000639.166

**Background** Non-adherence to combined anti-retroviral treatment (cART) is one of the key factors leading to treatment failure, higher morbidity, mortality, and health costs. Tools to evaluate adherence are beneficial since they allow health care workers to focus on patients with adherence problems. “Beliefs about Medicines Questionnaire” (BMQ) is a tool that evaluates the patient’s awareness of the “need” for and “concerns” about their medicines.

**Purpose** To evaluate whether the findings of the BMQ questionnaire correlated with adherence in HIV patients.

**Material and methods** BMQ was applied to HIV-infected patients on cART with three or more pharmacy visits who gave informed consent. Adherence was evaluated through refill date records.

**Results** Of a total of 175 patients, 80 (45.7%) were women, 97 (55.4%) were previously treatment-naïve, and the median age was 44 years old. Average BMQ-specific “need” and “concerns” scores were 22.6 [Standard Deviation (SD) = 2.7] and 18.6 [SD = 5.0], respectively. The average difference between “need” and “concerns” scores (N-C) was 4.0 [SD = 6.1]. Average refill adherence was 101% [SD = 9.1%] with values between 59% and 129%. The majority of patients (86.3%) had refill adherence between 80% and 110%, and 2.3% had refill adherence below 80%. Although we observed a tendency for higher values of N-C in patients with higher refill adherence, it was not possible to establish a correlation due to lack of statistical significance.

**Conclusion** It wasn’t possible to correlate the results of the BMQ-specific questionnaire with adherence, probably due to the fact that there was a high proportion of treatment-naïve patients. We observed higher refill adherence rates in treatment-naïve patients, which may be due to the fact that these patients are most likely to be aware of the “need” for ART. It’s possible that the BMQ-specific questionnaire is more useful in treatment – experienced patients in order to identify causes of non-adherence.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**CP-168**

**ADDING VALUE: PHARMACIST INTERVENTIONS IN ONCO-HAEMATOLOGICAL OUTPATIENTS**

1. Escudero-Vilaplana*, 1A Ribed, 1RM Romero-Jiménez, 1Buendia-Bravo, 1González-Haba, 1C Codina, 1A Herranz-Alonso, 1M Sanjuán-Sáez. 1Hospital General Universitario Gregorio Marañón, Pharmacy, Madrid, Spain; 2Hospital Clínico de Barcelona, Pharmacy, Barcelona, Spain

10.1136/ejhpharm-2015-000639.167

**Background** The continuing launch of new oral antineoplastic agents (OAAs) is changing the management of chemotherapy. Onco-haematological outpatient have acquired more autonomy and responsibility since OAAs require self-administration by patients at home. Therefore, hospital pharmacists are the latest health professionals in touch with patients and should detect the problems related to these drugs (DRPs).

**Purpose** To assess a pharmaceutical care program based on pharmacist interventions that aims to increase the effectiveness and safety of OAAs.

**Material and methods** The pharmaceutical care program, performed in November 2012, was evaluated in outpatients who started treatment with OAA during 2013. Pharmacist interventions took place during pharmacist interviews at the beginning of the treatment, after one and six months. Other variables were: demographics, ECOG, type of tumour, OAA and concur-rent medicines.

**Results** 134 patients (mean age = 68.5 years old, 63.4% male) were included. 10.8% of patients had ECOG ≥ 1. Renal cancer (20.1%), prostate cancer (19.4%) and multiple myeloma (17.9%) were the most common tumours and the most frequent OAAs were abiraterone (20.1%) and lenalidomide (15.7%). On average, patients were taking 5 drugs concurrently. 362 pharmacist interventions were performed (84.3% with patients and 15.7% with doctors): 111 at the beginning of the treatment, 173 after the first month and 78 after six months. Interventions were classified as follows: 38.1% reinforcement of health education and literacy (management of side effects and improvement of healthy lifestyle); 30.4% drug-drug interactions (mainly with omeprazole and antihypertensives, 30.3% were type D or X according to the FDA); 9.9% correcting inappropriate drug administration; 6.1% dose modification; 3.8% adding, removing or substituting a drug and 11.7% others. The percentage of acceptance was 87.6% (range 62–100%).

**Conclusion** Pharmaceutical interventions and follow-up succeeded in detecting DRPs and improved the treatment of onco-haematological outpatients with high acceptance. The most frequent interventions consisted of improving the management of side effects and identifying drug interactions.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**CP-169**

**DEXMEDETOMIDINE FOR SEDATION IN CRITICALLY ILL PATIENTS: A SINGLE CENTRE EXPERIENCE**

1. C Abraira Meriel*, 1E Martinez de Ilanduya Bolado, 1A Gomez Esteban, 1M Ochagavia Sugrategui, 1M Valero Domínguez, 2MI Domínguez Artiga, 2C Blanco Huelga, 2A Gonzalez Castro, 2C González Fernández, 2JC Rodríguez Borregán. 1Hospital Universitario Marqués de Valdecilla, Hospital Pharmacy, Santander, Spain; 2Hospital Universitario Marqués de Valdecilla, Intensive Care Unit, Santander, Spain

10.1136/ejhpharm-2015-000639.168

No conflict of interest.
Clinical pharmacy

Background The use of dexmedetomidine (dex) in Spanish intensive care units (ICU) patients is still unusual.

Purpose To describe the use of dex as a sedative agent and assess the adherence to the 2013-SEMICYUC guideline recommendations, in a 20-bed Spanish ICU.

Material and methods Retrospective six-month study (10/13–03/14) of patients treated with dex for sedation. The variables analysed were: indication for and duration of dex use, starting-maximum-maintenance doses, time to reach maintenance dose, co-administration of other sedatives, proportion of time in target sedation range (defined as a RASS score between −3 and 0) before and after dex initiation, duration of mechanical ventilation, % of patients with adverse events (AE) and causes of dex discontinuation.

Results 14 patients were included. Dex indications were: to facilitate weaning (8; 57%), patient-ventilator synchrony (5; 36%), or to reduce other sedatives (1; 7%). The mean length of the treatment was 4.1 days (0.2–14.5). The mean starting-maximum-maintenance doses were 0.36 ± 0.15/0.91 ± 0.34/0.87 ± 0.33 μg/kg/h. The starting dose was 51% lower than the recommended (0.7 μg/kg/h) and it took over 53 h (3–192) to reach the maintenance dose. All patients received other sedatives prior to dex, and in 6 (43%) those sedatives could be discontinued. No patients were in the target sedation range >50% of the time prior to dex, 8 (57%) reached this status after dex. The mean duration of mechanical ventilation was 17.1 ± 13 days. All patients suffered several AE (28 AE recorded). Hypotension (8; 57%) and bradycardia (6; 43%) were the most common. The causes of dex discontinuation were extubation (8; 57%), death (2; 14%), lack of efficacy (2; 14%) and AE (2; 14%, extreme bradycardia).

Conclusion All the dex indications met the SEMICYUC guidelines. It seems to be useful to reach the sedation range and facilitate weaning. The high rate of predictable AE and the need for dosage optimisation make dex a target drug for pharmaceutical monitoring.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

Acknowledgements

CP-170 ACCEPTANCE OF PHARMACEUTICAL INTERVENTIONS IN DRUG DOSING IN RENAL DISEASE

L Lombessa Sanz*, 1 A Aguirre Zubia, M Bachiller Cacho, M Ripa Ciaurri, M Gayan Lena, M Ercilla Lizaga, M Aranguren Redondo, L Leunda Eizmendi, M Carmona Oyaga, A Lizardi Matutea. Donostia University Hospital, Pharmacy Department, Donostia-San Sebastian, Spain

Background A drug adjustment programme for patients with renal disease was started in 2013 in our hospital.

In this system, information from the electronic prescription programme is linked (using an Access application) with information sent by the laboratory (creatinine) and with a list of drugs that may require renal adjustment. Afterwards, an adjustment warning for the physician is added to the electronic prescription programme.

Purpose To assess the acceptance by the physicians of pharmaceutical interventions in drug dosing in renal disease.

Material and methods This prospective descriptive study was conducted in a tertiary university hospital with 1,200 beds. The study period was 39 days (from January 21st to March 20th, 2014).

The pharmaceutical interventions were recorded during daily practice.

The following data were collected: date of pharmaceutical intervention, clinical chart number, medical service, age, sex, creatinine, glomerular filtration rate, adjusted drug, adjustment warning.

Finally, the degree of acceptance of these interventions by the physicians was reviewed.

Results During the study period, 153 patients (mean age 75.3 years, 78 male and 75 female) were included and 271 renal adjustment interventions were performed (mean: 7 interventions per day).

The degree of acceptance of the interventions was: accepted 84 (51.0%), partially accepted 25 (9.2%), not assessable 49 (18.1%), not accepted 112 (41.3%) and other (not an appropriate intervention) 1 (0.4%). Excluding not assessable and inappropriate interventions (finally 221 interventions), the result was: accepted 84 (38.0%), partially accepted 25 (11.3%) and not accepted 112 (50.7%).

Conclusion The acceptance of pharmaceutical interventions by the physicians is approximately 40%, which is relatively low. One of the reasons of this low acceptance could be the location of the adjustment warning.

Finally, it is necessary to consider what could be done to improve the acceptance of this type of pharmaceutical interventions.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

Acknowledgements

CP-171 MEDICINES RECONCILIATION ON ADMISSION: A PATIENT SAFETY STRATEGY

1MD ambérie*, 1SG enay, 2B Décaudin, 2P Odou. 1CHRU de Lille, Pharmacie Centrale, Lille Cedex, France; 2CHRU Lille, Pharmacie Centrale, Lille, France

Background Medicines Reconciliation on Admission (MRA) aims to identify and solve Unintended Medicines Discrepancies (UMDs) defined as differences between the home treatment prescription and the first hospital prescription.

Purpose To assess the impact of MRA on UMDs and to identify risk factors for the development of UMDs.

Material and methods This retrospective study was conducted in six services: vascular surgery, geriatrics, haematology, infectious diseases, nephrology and urology. Pharmacy students, who were supervised by clinical pharmacists, performed MRA within 48 h of the patient’s admission. Students asked the patients about the treatment prescribed at home, self-medication, allergies, adverse events and therapeutic adherence. Students called community pharmacists to get information on the drugs dispensed in the last 3 months and collected further information from other sources: the patient’s medical record, an interview with the family, letters from community doctors. Two pharmacists retrospectively assessed the potential harm of each UMD (high, moderate or minor risk). Correlations between the parameters were tested statistically.

Results In 2013, 645 patients were enrolled (5,673 medicines analysed). 23.4% of patients had at least one UMD and 10.1% of patients had at least three UMDs. Of the UMDs detected, 47.3% were associated with a moderate to major risk for the patient. The number of lines on the home treatment
prescription was a risk factor for UMD, as was the type of service in which the activity took place (R = 0.1918; p < 0.0001). Medicines adherence did not correlate with the incidence of UMDs.

Conclusion MRA is a useful process for detecting UMDs. Pharmacy students sometimes have trouble identifying UMDs, so it is necessary to supervise them. MRA will develop in parallel with the use of new information technologies for communications. It plays a role in structuring the “community-hospital” link.

REFERENCES AND/OR ACKNOWLEDGEMENTS

I would like to thank all those who worked on this project. No conflict of interest.

**CP-172 CYTOMEGALOVIRUS INFECTION AFTER ANTI-THYMOCYTE GLOBULIN IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION**

1MGonzalez-Marquez, 1MD Santos Rubio*, 2FGonzalez-Roncero, 3MSuher-Poblet, 1MV Gil-Navarro. Hospital Virgen Del Rocio, Pharmacy Department, Seville, Spain; 2Hospital Virgen Del Rocio, Nephrology Department, Seville, Spain; 3Hospital Virgen Del Rocio, Pharmacy Department, Seville, Spain

Background Immunosuppressive treatment for kidney transplantation is tailored to the clinical and immunological features of donors and recipients.

Purpose To describe the incidence of infection with cytomegalovirus (CMV) after immunosuppressant treatment with rabbit anti-thymocyte globulin (ATG) in kidney transplant patients, and the relationship with CMV serology and ATG dose.

Material and methods A retrospective descriptive study was carried out that included all kidney transplant patients who received ATG immunosuppressant induction treatment in 2012. The following variables were collected:

- Patient data: weight, sex
- Transplant data: type of donor: living donor or dead (brain death or asystole)
- Treatment data: dose and cumulative dose
- CMV: donor and recipient serology; CMV viral load

All ATG protocols include ganciclovir or valganciclovir prophylaxis from the third day post-transplant for three months.

Results 36 patients (25 men) were included. Regarding the type of donor: 19 were from brain death, 12 from asystole and 5 were from living donors.

12 of the 36 patients (33.33%) who received ATG developed CMV infection. 20 transplants were donor positive – recipient positive (D+/R+), and 4 of them were infected (20%). 10 patients were (D-/R+) and 3 of them were infected (30%). Only one patient was (D-/R-) and was not infected.

The most important result was in the high risk group (D+/R-) because 4 patients were included and all of them developed primary infections. Another R+ patient was infected but we didn’t know the donor serology.

No differences were found in the average dose received in infected patients (0.97 mg/kg/day) versus non-infected patients (1.01 mg/kg/day).

The dose of ganciclovir and valganciclovir were switched from prophylaxis to treatment until viral load control was achieved in all of them.

Conclusion There was a high percentage of kidney transplant patients with ATG immunosuppression. Despite prophylaxis with ganciclovir or valganciclovir they had CMV infections, mainly in the D+/R- serology group, in which all of them developed CMV infection.

No relationship were found with CMV infection and ATG dose received.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

**CP-173 ASSESSMENT OF EFFICACY OF MULTIPLE ANTIRETROVIRAL THERAPY**

A Martinez Valero*, R Gutiérrez Vozmediano, R Antón Torres, F Rodríguez-Lucena, E García Irazo, A Navarro Ruiz. Hospital General Universitario de Elche, Servicio de Farmacia, Elche, Spain

Background Patients with multiple antiretroviral therapy (MAT), defined as a combination of at least 3 drugs with different mechanisms of action, are on a difficult and costly treatment which may also affect treatment adherence.

Purpose To describe characteristics of HIV patients with multiple antiretroviral therapy and to evaluate the efficacy and adherence to the treatment.

Material and methods Retrospective observational study from June to December 2013. The inclusion criteria for our study were: MAT patients without changes in their treatment in the last 24 weeks. Data collected: demographics, current MAT, duration of treatment for HIV, adherence, resistance profile, viral load (VL) and CD4 count. Patients were classified as adherent (>90%) and non-adherent (<90%) by two independent methods: pharmacy dispensing records and SMAQ (simplified medicines adherence questionnaire) interview. Efficacy was evaluated by CD4 cells count and VL < 50 copies/mL, however we also considered CV < 200 copies/mL as a good indicator of treatment response.

Results A total of 49 patients were eligible in this study, 76% male, mean age 46.5 ± 9.9 years. The mean no. of MAT drugs was 4 (range 3–6) and the mean duration of treatment for HIV was 12 (range 1–17) years. Regarding resistance studies: 9 patients were resistant to some antiretroviral, it was not possible to perform resistance studies in 10 patients (20.4%) due to the low VL (<1,000 copies/mL), it was not requested in 28 patients (57.1%) and 2 patients did not show resistance. Seven, eight and two patients showed resistance to analogues, non-analogues and protease inhibitors, respectively. The mean adherence was 94% and 40 patients (81.6%) had a percentage adherence superior to 90%. As to the efficacy variables: 32 (65.3%) and 46 (93.8%) patients had VL < 50 copies/mL and <200 copies/mL, respectively and 40 patients (81.6%) had a CD4 cell count >250 copies/mL.

Conclusion Most patients had effective treatments. The complexity of the treatment did not have a negative impact on adherence. All patients with a resistance profile had their treatment optimised according to it.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
HEALTHCARE PROFESSIONALS’ KNOWLEDGE OF INTRAVENOUS FLUID TREATMENT

Background Intravenous (IV) fluid treatment is a routine but essential part of care for a significant proportion of hospitalised patients. However one in five hospitalised patients suffers from fluid-related complications with associated morbidity and mortality. In 2013, a NICE clinical guideline was published with the aim of improving IV fluid management. A lack of knowledge was identified as a key factor contributing to poor fluid management.

Purpose To assess the knowledge among nurses, junior doctors and pharmacists of IV fluid treatment in adults. Knowledge was assessed of the daily fluid and electrolyte requirements and composition of commonly-used IV fluids.

Material and methods The study was conducted as a self-administered questionnaire survey. An anonymous questionnaire in multiple-choice format was designed based on the NICE guideline and existing questionnaires. Data collection was carried out over a four-week period in June 2014. Responses were marked as correct, incorrect or unsure.

Results 193 healthcare professionals including 96 nurses, 45 junior doctors and 52 pharmacists completed the questionnaire. 17%, 33% and 54% of nurses, junior doctors and pharmacists correctly identified the daily water requirements. Respectively 8%, 33% and 68% of nurses, junior doctors and pharmacists accurately estimated the daily sodium requirements. Only 16% of nurses, whereas 71% of junior doctors and 94% of pharmacists correctly identified the daily potassium requirements. The inadequate knowledge of junior doctors confirms the poor, which is of particular concern as this guides fluid prescription. The inadequate knowledge of junior doctors confirms the findings of previously published studies, whereas to current knowledge no studies have been published with regards to nurses and pharmacists.

Conclusion Despite the development of a new guideline, knowledge of IV fluid treatment remains poor. Measures are needed to increase awareness and reduce the high number of fluid-related complications.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

Drug distribution

EFFECT OF AUTOMATED DISPENSING CABINETS ON DRUG DISTRIBUTION IN 5 HOSPITALS

R Caldwell*, B Jamriska. Omnicell, Marketing. Mountain View – California, USA

Background As hospital pharmacies face an ever-changing landscape with new responsibilities, the need to find more efficient drug distribution methods becomes increasingly important. Omnicell conducted a comprehensive time and motion study at five large U.S. hospital sites of varying bed number, which were operating different cabinet-based drug distribution systems.

Purpose To determine whether the use of automated dispensing cabinets (ADCs) helped in creating more efficient drug distribution systems.

Material and methods In each facility, 5 to 6 days were spent recording time and motion to compare medicines management using a traditional patient-specific fill model and an ADC-based model. The times and costs associated with filling first doses, missing doses, batch doses and returning medicines were compared between the two models.

Results Cost and time savings were adjusted for a 350-bed facility. First doses filled via ADC took 111 s less per dose. First doses filled via ADC cost US $0.23 per dose, compared to US $1.93 per dose via traditional methods. This resulted in eight times lower first dose cost when dispensed from the ADC. Missing doses took 64 s less in the ADC model. Returns took 25 s per dose in the patient-specific fill process. The time savings associated with using ADCs accounted for a total decrease of 35 labour hours per week, which resulted in a savings of US $64,300 in labour annually.

Conclusion Healthcare facilities can realise clear and measurable time and cost-saving benefits by using ADCs in their medicines distribution model. The change can significantly increase efficiency for both nursing and pharmacy.

REFERENCES AND/OR ACKNOWLEDGEMENTS


Conflict of interest.

AN INTERVENTION IN AN ANTIBIOTICS DISTRIBUTION SYSTEM: UNIT-DOSE VS. BULK EVALUATION IN A COUNTY HOSPITAL

M Petrongonas, E Rinaki, L Tzimi*. Chania General Hospital, Hospital Pharmacy, Chania, Crete, Greece

Background This study was performed in a medium-sized public hospital of 460 beds, which supports the 150,000 inhabitants. Until August 2010, only restricted–use antibiotics were distributed as unit doses; the rest were distributed in bulk. Since September 2010 all antibiotics have been administered as unit doses per patient.

Purpose To evaluate the effect of this intervention on antibiotic administration.

Material and methods We investigated the amount of antibiotics used, expressed in DDDs/100 patient-days, for the years 2009 and 2011. Antibiotics were classified according to the ATC system, excluding J05, J06 and J07. The mean amounts administered were tested by the Bonferroni t test. Difference in use for each antibiotic were tested by the Bonferroni t test.

Results In total, in 2009 71 antibiotics were used (153.28 DDDs/100 patient-days) while in 2011 64 (145.31 DDDs/100 patient-days); mean difference was not statistically significant (t = 0.78, p = 0.44). 36 antibiotics were administered in both years (mean difference in DDDs/100 patient-days: 0.38, statistically significant, t = 2.91, p = 0.0063). In 16 of these antibiotics, the use of which was more than 1 DDD/100 patient-day, the mean difference was not statistically significant (difference: 0.69, t = 2.56, p = 0.22). When the Bonferroni t test was applied for each antibiotic, a statistically significant difference was observed.
for 6 infrequently prescribed antibiotics (DDD/100 patient-day < 1): erythromycin, phenoxymethylpenicillin, streptomycin, ketocanazole, ofloxacin and benzathine benzylpenicillin.

Conclusion: Unit dose intervention led to a reduction in the use of specific antibiotics, although it did not prove statistically significant for antibiotics of DDD/100 patient-day > 1. A significant difference was only observed in infrequently prescribed antibiotics, which could be justified by the small number of patients. Nevertheless, all antibiotics are still distributed in a unit dose system in hospitalised patients as it contributes decisively to pharmaceutical patient care and records.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DD-003 ANALYSIS OF THE USE OF AUTOMATED MEDICINES DISPENSING CABINETS WITHOUT ELECTRONICALLY ASSISTED PRESCRIBING
L Izquierdo Acosta*, MD Viviola, V Benito, B Oca, O Alamo, J Chico, R Martinez, C Hermida. Hospital Universitario de Burgos, Servicio de Farmacia, Burgos, Spain
10.1136/ejhpharm-2015-000639.176

Background: Automated medicines dispensing cabinets (ADCs) have recently been introduced in all areas of a tertiary hospital.

Purpose: To analyse the changes made by nurses when using the ADCs to the prescriptions made by physicians without electronically assisted prescribing.

Material and methods: A retrospective observational study was made looking over the computerised clinical histories of inpatients from the Internal Medicine and Traumatology wards. These were compared to the records of drug withdrawals, analysing consumption per patient, classes and length of treatment. Consumption per patient was the net amount, taking into account withdrawals, returns to stock and drawer returns.

Results: 22 patients were included, 15 belonged to Traumatology and 7 to Internal Medicine. The mean hospital stays were 13.9 and 7.6 days, respectively. 145 drugs were prescribed in Traumatology (9.6 per patient) and 117 in the Internal Medicine Service (16.7 per patient). The study was conducted on the drugs contained in the ADCs (124 and 83). The rest belonged to restricted drugs and those not included in the hospital guidelines.

The consumption per patient and dose changed in 40.3% of the cases in Traumatology and in 39.7% of cases in Internal Medicine. Moreover, in Traumatology a mean of 2.46 medicines per patient were taken from the cabinets without having being prescribed in the clinical history (4.3 in the case of Internal Medicine).

In Internal Medicine (though not in Traumatology) we found that on 67 occasions the quantities of drugs withdrawn from the ADCs exceeded the corresponding quantities administered.

Conclusion: The improper use of the ADCs calls into question the correct administration of the drug treatment to the patients.

So as electronically assisted prescribing is being phased in order to improve safety and to prevent drug errors.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DD-004 QUALITY INDICATORS IN A UNITARY DOSE DRUG DISPENSATION SYSTEM: MEASUREMENT, ANALYSIS AND IMPROVEMENT
M Llorente Serano*, C Marti Gil, L Recuerdo Galve, J Sanchez Gundib, A Muñoz Alberola, D Barreda Hermández. Vigen de La Luz Hospital, Pharmacy, Cuenca, Spain
10.1136/ejhpharm-2015-000639.177

Background: Quality indicators (QIs) are measures of health care quality in order to achieve the planned results in a Quality Management System.

Purpose: To evaluate the results of some QIs in a Unitary Dose Drug Dispensation System (UDDDS) in a Hospital Pharmacy Department (HPD).

Material and methods: Prospective observational 3-weeks study (September ’14) performed in a second level hospital (411 beds, 52.8% of them with UDDDS and manual transcription by nurses and validation by pharmacists). QIs and standars to achieve maximum quality were established by a working group.

- QI1: %Filling errors = [errors/number of dispensed drugs (n/DD)]*100; SV < 1%
- QI2: %Transcription errors = [errors/number of prescription lines (n’PL)]*100; SV < 3%
- QI3: %Validation errors (by a second pharmacist) = [errors/n’PL]*100; SV < 0.5%
- QI4: %Returns = [returned drugs/n’DD]*100; SV < 5%

Three days a week a “pilot cart” (PC) was selected by a random method (extraction balls) and checked by a pharmacist. Data were recorded and analysed using a form designed for that purpose, Farmatools-Dominion® programme and Microsoft Office Excel®.

Results: 9 PC were checked (474 PL, 1736 DD, 207 patients). QIs real values were: QI1 (5.9%); QI2 (8.2%); QI3 (1.4%); QI4 (7.8%). Major error types during filling UDDDS-carts and transcription were treatment omission (44 vs. 11, respectively). Another common errors: a) filling: different amount (26) and commission (16) – drug should be discontinued but remained in patient’s treatment; b) transcription: different dose/dosage regimen (14). The mean causes of returns were: not administered drug (88), transfer/discharge (30) and finished treatment after cart distribution (16).

Conclusion: Even though UDDDS may reduce medication errors, the QIs analysed were superior to SV previously defined. The measurement of QIs showed non-compliance and required corrective actions to resolve mistakes in order to improve patient security: regular training sessions for HPD staff, instructive note for nursing, technical instructions for nursing assistant and design of a specific form for returned drugs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No.

No conflict of interest.

DD-005 DEVELOPING A MANAGEMENT STRATEGY FOR MEDICATION UNITS FREE OF SECONDARY PACKAGING IN A HOSPITAL PHARMACY
C Skalafours*, JL Pons, F Plassart, JM Deschutes. Centre Hospitalier Victor Dupouy, Hospital Pharmacy, Argenteuil, France
10.1136/ejhpharm-2015-000639.178

Background: Quality indicators (QIs) are measures of health care quality in order to achieve the planned results in a Quality Management System.

Purpose: To evaluate the results of some QIs in a Unitary Dose Drug Dispensation System (UDDDS) in a Hospital Pharmacy Department (HPD).

Material and methods: Prospective observational 3-weeks study (September ’14) performed in a second level hospital (411 beds, 52.8% of them with UDDDS and manual transcription by nurses and validation by pharmacists). QIs and standars to achieve maximum quality were established by a working group.

- QI1: %Filling errors = [errors/number of dispensed drugs (n/DD)]*100; SV < 1%
- QI2: %Transcription errors = [errors/number of prescription lines (n’PL)]*100; SV < 3%
- QI3: %Validation errors (by a second pharmacist) = [errors/n’PL]*100; SV < 0.5%
- QI4: %Returns = [returned drugs/n’DD]*100; SV < 5%

Three days a week a “pilot cart” (PC) was selected by a random method (extraction balls) and checked by a pharmacist. Data were recorded and analysed using a form designed for that purpose, Farmatools-Dominion® programme and Microsoft Office Excel®.

Results: 9 PC were checked (474 PL, 1736 DD, 207 patients). QIs real values were: QI1 (5.9%); QI2 (8.2%); QI3 (1.4%); QI4 (7.8%). Major error types during filling UDDDS-carts and transcription were treatment omission (44 vs. 11, respectively). Another common errors: a) filling: different amount (26) and commission (16) – drug should be discontinued but remained in patient’s treatment; b) transcription: different dose/dosage regimen (14). The mean causes of returns were: not administered drug (88), transfer/discharge (30) and finished treatment after cart distribution (16).

Conclusion: Even though UDDDS may reduce medication errors, the QIs analysed were superior to SV previously defined. The measurement of QIs showed non-compliance and required corrective actions to resolve mistakes in order to improve patient security: regular training sessions for HPD staff, instructive note for nursing, technical instructions for nursing assistant and design of a specific form for returned drugs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No.

No conflict of interest.
Background Our pharmacy has recently purchased an automated storage and dispensing robot (Rowa VMAX). While offering greater safety and better management of pharmaceuticals, automated globalised distribution encounters limits: unit doses and bulky pharmaceuticals cannot be stored in this type of robot contributing to the loss of the benefits of automation.

Such a system is not suitable for the management of Medication Units Free of Secondary Packaging (MUF-SP) when drugs are returned from the wards to the pharmacy.

Purpose To present an original management system for MUF-SP and to measure its financial impact.

Material and methods We developed software that enabled us to print a DATAMATRIX specific label recognised by our robot when we entered the drug reference, an expiry date and the batch number.

Boxes were purchased to allow the Recycling of Drug Units (RDU) and were identified by their label. Returned drugs put in one of these boxes join the conventional automated system of globalised distribution.

Eligibility criteria for the RDU were: a unit price between €0.50 and 5 (for medicines distributed at least once a week); units over €5 and all the antibiotics.

Over one month, the amounts saved by not discarding the units eligible for the RDU and the costs of the whole process were estimated.

Results 1576 drug units were returned to the pharmacy from the wards.

40.6% were MUF-SP. Of these units, 45% were eligible for the RDU and saved €115.43 (86% of the price of the MUF-SP).

22 different drugs were recycled, of which 19 were antibiotics.

The estimated average time required to generate the whole system was 108 s per item and cost €0.84 per item (including staff and consumables costs). The total cost of the process was €191.14.

Conclusion This solution enables savings (compared to the described process costs), better safety and management. Such a method could reasonably be extended to other hospitals.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
storage (11.0%), and included interventions caused by expired medicines (15), lack of opiate prescriptions (6), damaged medicines (3), cabinet start-up (1), quarantine drug unload (19), and other reasons (6).

Conclusion The most common interventions on automated dispensation process are related to handling of cabinets. Therefore it’s necessary to remind nurses periodically that correct handling of ADCs is essential to guarantee medicine availability and optimal storage, both necessary for safe drug use.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DD-008 MONITORING OF THE ADHERENCE TO THERAPIES FOR THE TREATMENT OF PULMONARY HYPERTENSION

1D De Luca, 1C Di Giorgio, 1P Polidori, 1ISMETT, Pharmacy, Palermo, Italy; 2University of Palermo, School of Specialization in Hospital Pharmacy, Palermo, Italy

10.1136/ejhpharm-2015-000639.181

Background Adherence to the treatment for pulmonary arterial hypertension (PAH) is an important aspect of chronic disease management to improve the efficacy of treatment.

Purpose The study aimed to evaluate adherence to long-term drug treatments for PAH.

Material and methods From 01/01/2010 to 04/01/2014 a retrospective analysis was done on therapeutic plans and prescriptions related to patients in treatment for at least one year by the Pulmonary Unit. Items dispensed by the Clinical Pharmacist were analysed through data entered into the database F file. Mean therapeutic adherence, according to the literature, was calculated using the "pharmacy-refill" method: days of dispensed treatment/(days between the first and the last prescription dispensed + 90 days)100.

Results In the study period, 80 patients were treated with drugs for PAH. Of them, 34% (27/80) were on treatment with sildenafil, 20% (16/80) with bosentan, 10% (8/80) with ambrisentan. The remaining 36% (29/80) were treated with a combination of drugs. Twenty-nine patients received at least one year of treatment: 41% (12/29) male and 59% (17/29) female. 16.7% (2/12) of males aged >60 years had adherence of 88%; 41.6% (5/12) aged between 40 and 60 years were 91% adherent; 25% (3/12) aged between 30 and 40 years were 92% adherent and 16.7% (2/12) aged <30 years were 98% adherent. With regard to the females treated, 35% (6/17) of them aged >60 years showed 96% adherence; 47% (8/17) aged between 40 and 60 were 96% adherent; 11.7% (2/17) aged between 30 and 40 years were 100% adherent and 6% (1/17) aged <30 years were 100% adherent. All female patients showed adherence of >95%, while male patients in all categories had an adherence >80%.

Conclusion Analysis showed that patients more adherent to therapy were those who were younger and of female gender. Data were shared with physicians, and it was decided to carry out more specific training sessions targeted at patients aged >60 years in order to ensure greater adherence to treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.
Drug distribution

At the beginning July 2014 our hospital set up a pharmacy dedicated to hospital discharges.

**Purpose** To verify the increase in number of hospital departments and patients following this new method of dispensing and the savings gained by distributing the first cycle of treatment.

**Material and methods** The analysis was performed by comparing drugs supplied in the period July–September 2013 vs. the same period in 2014. We assessed all requests to which the hospital pharmacies responded and the hospital departments that sent them. We also analysed the number of items dispensed and the cost of the drugs. (hospital vs. regional pharmaceutical expenditure).

**Results** Hospital pharmacies received 311 requests during 2013 vs. 629 in 2014, an increase of 67%. The number of hospital divisions that requested drugs went from 8 to 12.

In all, 1,157 items were supplied vs. 1,595 items, an increase of 35%.

We distributed about 90 active drugs and the drugs most commonly distributed were enoxaparin 15%, pantoprazole 11% and ramipril 7%.

The pharmaceutical cost for the delivery of medicines to citizens was €4,336. An estimated €21,239 was saved comparing with the cost of drugs from community pharmacies (€25,575).

**Conclusion** The supply of medicines by direct distribution has increased the number of patients receiving the first cycle of treatment.

This method of dispensing is significant not only for cost reduction but above all for the clinical care of the patient and the guarantee of continuity of care between hospital and the surrounding region.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

---

**DD-011**

**PATIENT COMPLIANCE WITH BIOLOGICAL DRUGS: EFFECTIVENESS OF DRUG SWITCHING IN MULTIPLE SCLEROSIS**

1 Fantini*, 2 Ambrosio Spinnella, 3 Polidori, 4 Resta, 5 Ugucioni, 6 Servi, 2 Vitali, 1 Istituto Ortopedico Rizzoli, Farmacia Ospedaliera, Bologna, Italy; 2 Area Vasta 1 ASUR Marche, Area Farmaco E PMC – Servizio Farmaceutico, Fano, Italy; 3 Università Di Camerino, Diretto della Scuola Di Specializzazione in Farmacia Ospedaliera, Camerino, Italy; 4 Area Vasta 1 ASUR Marche, Servizio Farmaceutico, Urbino, Italy; 5 Area Vasta 1 ASUR Marche, Area Farmaco E PMC – Servizio Farmaceutico, Fossombrone, Italy

10.1136/ehjpharm-2015-000639.184

**Background** Multiple sclerosis develops differently in different patients (P), demands personalised drug treatment and is difficult to manage. Biological drugs (BD) may reduce symptoms and modify the progression of the disease.

**Purpose** We sought to measure P compliance when prescribed BDs, and to evaluate whether switching drugs could increase their compliance.

**Material and methods** Patients were interviewed in the period from January to April 2014.

Specifically:

- 24 P with INTERFERON BETA1a (9 Avonex, 15 Rebif)
- 6 P with INTERFERON BETA1b (4 Betaferon, 2 Extavia)
- 14 P with GLATIRAMER (Copaxone)
- 2 P with FINGOLIMOD (Gilenya).

**Results** Only 9 P expressed dissatisfaction with the treatments listed above.

- 5 of the patients complained of adverse drug reactions, 3 objected to the number of administrations and 1 lamented the poor efficacy.

Specifically:

- The side effects of AVONEX and BETAFERON were well tolerated with 1 dissatisfied patient.
- The side effects of REBIF and EXATVIA were less tolerable with 5 patients reporting flu-like symptoms (in accordance with SPC data on side effects) which caused them to miss days at work. Differences in efficacy and tolerability were observed between these interferons, in agreement with literature.
- COPAXONE caused minimal side effects, but P complained about the multiple administrations.
- GILENYA as second-line treatment was the best tolerated with no side effects.

In twenty cases, in response to P complaints, treatment was switched to a different drug. Thirteen of these P subsequently exhibited better compliance, while 7 were dissatisfied with the different treatment as well.

The treatments of these twenty P were switched for two reasons. In fifteen cases, the switch was motivated by side effects, while in the remaining five, the change was due to reactivation of the pathology.

**Conclusion** Compliance with all the MS treatments is generally very high. The same active ingredient has given different outcomes therefore it is recommended to switch the treatment.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.

**DD-012**

**DESIGNING SUPPLY QUOTAS OF DRUGS IN CARE UNITS: HOW CAN WE IMPROVE THE METHODOLOGY FOR DOUBLE BIN REPLENISHMENT SYSTEMS?**

1 Stuck, 2 Gibert*, 3 Thorne, 4 Brudieu, 5 Fortin, 6 Allenet. 1 Grenoble-University Hospital, Pharmacy, Grenoble, France; 2 University Grenoble-Alpes THEMAS TIMC-IMAG UMR CNRS 5525, Grenoble-University Hospital, Pharmacy

10.1136/ehjpharm-2015-000639.185

**Background** In our hospital, Double Bin Replenishment Systems (DBRS) are being progressively introduced into care units. For each DBRS, a supply quota of medicines is defined based on the unit’s consumption during 6 months before the installation.

**Purpose** In September 2014, 43 care units were equipped by DBRS. Many qualitative and quantitative readjustments of the supply quotas are needed after installing them all. The purpose of this study was to analyse the supply quotas already established in order to critique our method of designing and to find a way to improve it.

**Material and methods** Qualitative analysis of drugs present in supply quotas in the care units where DBRS are already set up, according to the Anatomical Therapeutic Chemical classification (ATC) system.

**Results** There are 956 different drugs throughout the 43 supply quotas, which represent 45% of the drugs available in our hospital. None of them is found in every supply quota but 40 pharmaceutical specialties are present in more than 80% of care units and 139 in more than 50%.
Qualitatively, all classes of the ATC classification system are represented in these 139 drugs, except for the antineoplastic and immunomodulating drugs and for the sensory organs’ drugs, which are expensive drugs that are not commonly used in every medical ward.

Based on these observations, we could improve the design of the supply quotas for the list of the 139 most represented pharmaceutical specialties. We propose developing a “standard supply quota” that could be used in all care units. These core supplies could then be added to by drugs specific to the unit.

**Conclusion** Supply quotas that are already implemented contain drugs of all ATC classes and may serve to define a “standard supply quota” that would be common to every care unit.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**Drug distribution**

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**DD-014** EVALUATION AND OPTIMISATION OF THE USE OF ALBUMIN BY RESTRICTED PRESCRIPTION IN A GENERAL HOSPITAL

M Cumbraos Sánchez*, M Merchante Andreu, E Fernández Alonso, MA Alcácer López. Hospital Clínico Lozano Blesa, Hospital Pharmacy, Zaragoza, Spain

10.1136/ejpharm-2015-000639.187

**Background** A number of studies have shown that albumin is used wrongly in hospitals, basically related to its use in hypoalbuminaemia-hypoproteinaemia. Therefore, prescription of albumin should be limited to specific indications. Until recently, pharmacists didn’t know the indication for the use of albumin at the time of dispensing in our hospital.

**Purpose** To find out what albumin is commonly used for in clinical practice. To design and introduce a permission form bearing specific indications for albumin. To find out whether the implementation of this monitored prescription has affected the amount of albumin dispensed.

**Material and methods** In order to make the application form, we formed a working group including the main hospital services that use albumin. After introducing it, we examined how much albumin was dispensed during the first 6 months of using the application form, contrasting data with the previous 6 months.

**Results** This working group reviewed literature recommendations for the use of albumin, developed a permission form, including data about the physician and the patient, and the indications authorised for albumin: bacterial peritonitis, paracenteresis, hepatorenal syndrome, hyponatraemic hypervolemia, multiple myeloma and hypoalbuminaemia associated with other factors. It was decided that only three days of treatment would be dispensed.

The most common indications were: paracentesis and hypoalbuminaemia.

The amount of albumin dispensed was reduced to 37.9% of the use over the previous 6 months, when the permission form had not yet been introduced.

**Conclusion** Up to now, in our hospital we dispensed albumin without knowing the indication for which it was prescribed. Since the introduction of pharmaceutical validation of the prescription by the permission form, there has been a decrease in and optimisation of its use.

---

**DD-015** HOW SHOULD DRUG SHORTAGES BE DEFINED? A REVIEW

E De Weerdt*, K Pauwels, D Preu, R Price, S Simoons, M Casteels, KU Leuven, Pharmaceutical and Pharmacological Sciences, Leuven, Belgium; European Association of Hospital Pharmacists, Policy and Advocacy, Brussels, Belgium

10.1136/ejpharm-2015-000639.188

No conflict of interest.

---
**Drug information and pharmacotherapy**

**Background** Drug shortages are currently on the rise. In-depth investigation of the problem of drug shortages is necessary; however, a variety of definitions for ‘drug shortages’ are adopted by different organisations, e.g. Food and Drug Administration (FDA) and the American Society of Hospital Pharmacies (ASHP). For international comparison, it is important to clearly denote which definition is used by the national authorities or by (inter)national organisations.

**Purpose** To identify and compare different definitions and analyse the overlap and missing info in each definition.

**Material and methods** A literature review was performed searching the scientific databases MEDLINE and Embase for definitions of drug shortages. Grey literature, such as websites and documents of (inter)national drug agencies, was also incorporated.

**Results** More than 15 different definitions for drug shortages were identified. Articles in the scientific literature often refer to existing definitions. Only a few articles describe their own definition. After comparison of the definitions some overlap was observed. Sometimes drug shortages are defined as situations in which a drug is undeliverable for a certain period; this period ranges from one day to 20 days. However, delaying treatment of infectious diseases for 20 days will have a serious effect on patients. Other definitions only consider those drugs used for the treatment of serious diseases or drugs for which no alternative is available; this underestimates the size of the problem.

**Conclusion** The ultimate goal is to formulate a general European definition for reporting drug shortages, which is essential for international comparison. Indicating a time limit in the definition is an essential element for the comparison of nationally reported drug shortages. This time limit might be even one day if the patient’s health warrants it. A definition of drug shortages covering all types of drugs is crucial to acknowledge the size of the problem.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**DI-001** ANALYSIS OF THE USE, EFFECTIVENESS AND SAFETY OF TREATMENT WITH TRASTUZUMAB-EMTANSINE IN METASTATIC BREAST CANCER

M Díaz*, C Manuel, V Aró, D Escher, P Sergio, G Eva María, M Nuría, R Gregorio, M José. Complejo Hospitalario Universitario de Albacete, Farmacia, Albacete, Spain

**Background** Trastuzumab-emtansine (TDM1) is designed to inhibit the HER2 pathway and directly release DM1 chemotherapy inside HER2-positive cells.

**Purpose** To analyse the use, progression-free survival (PFS) and adverse drug reactions (ADRs) in patients with metastatic breast cancer treated with TDM1.

**Material and methods** Retrospective observational study including all women treated with trastuzumab-emtansine from March to October 2014. To obtain data, the electronic medical record (XXI Mambriño) was reviewed and analysed using SPSS. The variables were age, line of treatment, ADRs and PFS. ADRs were classified according to Common Toxicity Criteria v4.0. The effectiveness variable was PFS.

**Results** Five women (median age 51 years old (39–64)) were included at the beginning of the treatment. In 2 of them trastuzumab-emtansine was used in 1st line treatment of metastases; while in the rest it was used in 3rd, 5th and 6th line. The most frequent ADRs according to their severity were thrombocytopenia G2 and enzymatic hepatic alterations G3. The rest of the ADRs were mild and as described in the literature. Regarding PFS, 2 of the 5 patients progressed, obtaining a median PFS of 6 months. The other three patients have a median follow-up of 5 months to the time of writing.

**Conclusion** The use of TDM-I is off-label in 2 of the 5 cases. One is being used first line with a progression time exceeding 6 months (10 months) and the other due to the inability to use the combination pertuzumab-trastuzumab-doctetaxel due to prior taxane-induced neuropathy. The median PFS (6 months) was lower than that obtained in clinical studies (EMILLA 9.6 months, compared to lapatinib-capcitabine and TH3ERESA 6.2 months, compared to a medical treatment choice in patients who have previously been treated with both trastuzumab and lapatinib). Currently 3/5 patients continue with the treatment, thus, the median PFS will increase. TDM-I by its toxicity profile has been a safe drug in our cases.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**DI-002** DRUG INTERACTIONS: AN EXAMPLE OF SCIENTIFIC COOPERATION BETWEEN THE HOSPITAL PHARMACIST AND GENERAL PRACTITIONERS (GPs)

1V Vinciguerra*, 2R Fantacci, 3C Rolle, 4Università Degli Studi Di Torino, University of Turin, Scuola Di Specializzazione in Farmacia Ospedaliera, Higher School of Hospital Pharmacy, Turin, Italy; 4Università Degli Studi Di Torino, University of Turin, Dipartimento Di Scienza E Tecnologia Del Farmaco, Department of Drug Science and Technology, Turin, Italy; 5ASL TO1, Local Health District ASL TO1, S.C. Assistenza Farmaceutica Territoriale, Community Drug Assistance, Turin, Italy

**Background** Interactions frequently occur between drugsand can generate Adverse Drug Reactions (ADRs). In 2013, pharmacists from the Local Health District joined a project with 48 General Practitioners (GPs), who chose drug combinations for which they invited monitoring of their prescriptions for interactions: verapamil + simvastatin (1), potassium chloride + potassium canrenoate (2), calcium carbonate + Proton Pump Inhibitors (PPIs) (i3A), sevelamer + PPIs (i3B), levohthyroxine + PPIs (i3C), fluconazole + PPIs (i3D), amoxicillin + lansoprazole (i3E), verapamil + simvastatin + cetimibe (4), amoxicillin clavulanic acid + lansoprazole (5), calcium carbonate + vitamin D + PPIs (6).

**Purpose** To evaluate GPs opinions of the efficacy and applicability of the cooperation project between pharmacists and GPs using a questionnaire.

**Material and methods** Strategies included: verifying the prescribing habits before the project, a literature review, consulting the Codifà database for practical solutions for the management of interactions, monitoring prescriptions in 2012, meetings and the questionnaire which was submitted to GPs. Results with reports obtained were given to the GPs.

**Results** 73% of the GPs contacted answered the questionnaire. Results were as follows: i) literature analysis was considered interesting by 94%, while 6% did not answer, ii) solutions were useful as follows: 20% i3C, 18% i5, 13% i3A and i3E, 10% i3D, 9% i1, 4% i2, 4%, and 1% i3B, while 4% did not.
answer, iii) clinical improvement after the solutions were applied were observed in 34%, and iv) 80% of patients were satisfied. Such clinical improvements were monitored with blood tests, where possible (i1, i3A, i3C, i4, i6), by 30% of the GPs. 1/36 GPs found ADRs related to the drug interactions.

Conclusion The multidisciplinary approach was effective in increasing GP awareness of drug interactions. Furthermore, we learned of clinical improvements and patients’ satisfaction from GP questionnaires. The project is continuing, monitoring prescriptions in 2013 and 2014.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-004
STUDY ON PRESCRIPTION PATTERN AND COST ANALYSIS OF ANTIRETROVIRAL DRUGS IN A TERTIARY CARE HOSPITAL

E Molina*, P Nieto, R Jose Manuel, F Verdejo, F Siera, D Fernández. SAS Hospital Pharmacy, ALMERIA, Spain; SAS Hospital Pharmacy, 04009, Spain
10.1136/ejhpharm-2015-000639.192

Background Antiretroviral treatment for human immunodeficiency virus type 1 (HIV-1) infection has improved steadily since the advent of combination therapy.

Purpose To assess the prescription patterns and cost of antiretroviral treatment in a tertiary care hospital.

Material and methods Drug treatments for HIV-1 were compared in adult patients affiliated to a tertiary care hospital of the Spanish Health System. All had been in treatment for more than six months (January–June 2014). The data were collected from the institution’s medical records. Annual cost data were calculated by multiplying the monthly up-to-date antiretroviral treatment cost by twelve.

Results 604 patients were treated in this period using a total of 71 different combinations. The age range of patients was from 10 to 78 years and 73.01% were men. The total expenditure for the hospital was €4,267,561 accounting for 16.77% of the whole budget for outpatient treatments. The average cost per patient was €7,065. The seven most common combinations (number of patients, %), their costs (€) and their financial impact on the hospital of the antiretroviral treatments (€, %) were:

1. Emtricitabine/tenofovir/efavirenz (155, 25.66%), €5,805, (€899,794, 21.08%),
2. Emtricitabine/tenofovir/ritonavir (64, 10.60%), €6,723, (€430,241, 10.08%),
3. Emtricitabine/tenofovir + lopinavir/Ritonavir (52, 8.61%), €8,125, (€422,523, 9.90%),
4. Emtricitabine/tenofovir + atazanavir/Ritonavir (48, 7.95%), €8,629, (€414,184, 9.71%),
5. Emtricitabine/tenofovir + darunavir/Ritonavir (28, 4.64%), €8,617, (€241,265, 5.65%),
6. Emtricitabine/tenofovir + nevirapine (25, 4.14%), €4,489, (€112,218, 2.63%),
7. Emtricitabine/tenofovir + raltegravir (22, 3.64%), €9,263, (€203,792, 4.78%).

Conclusion Despite the fact that a wide variety of combinations is used for HIV-1, the emtricitabine/tenofovir/efavirenz combo has been by far the most used. It is also one of the cheapest options among the most common therapies. These seven aforementioned options account for almost 64% of antiretroviral costs and cover 65% of the HIV-1 treatments. Additionally it is highly remarkable that all of them are emtricitabine/tenofovir-based therapies.

REFERENCES AND/OR ACKNOWLEDGEMENTS
We thank the hospital pharmacists for their support.
No conflict of interest.
Drug information and pharmacotherapy

**Background** Enzyme Replacement Therapy (ERT) is the current standard treatment which significantly improves the quality of life of patients with type-1 Gaucher’s Disease (GD-1).

**Purpose** To evaluate the use of ERT in patients with GD-1.

**Material and methods** Retrospective observational study with review of the patient’s clinical history. Adult patients were included with GD-1 treated with imiglucerase or velaglucerase. ERT response based on: haemoglobin (≥11–12 g/dl), platelets (≥120 × 109/L), chitotriosidase (<600 nmol/mL h), liver volume (<1.25 times normal), spleen volume (<5 times normal) and bone pain (none/mild/moderate/severe). The type of response was established according to compliance with these criteria: OR optimal response (5/6), SR suboptimal response (3–4/6) and none ≤2. Detection of Adverse Drug Events (ADEs).

**Results** We included 3 patients (2 treated with imiglucerase and 1 with velaglucerase). Previously with thrombocytopenia and/or anaemia, hepato-splenomegaly and associated bone pathologies. They started treatment with imiglucerase and velaglucerase at equal dosage 60 IU/kg/2 weeks with reductions of up to 25% or 15 IU/kg. Median follow-up time: 7 years. We currently have 2 patients with ERT, 2 changed to substrate reduction treatment with miglustat but 1 patient returned to ERT therapy due to intolerance. All patients met the haematological criteria and maintained the following averages over time: Hb 14.7 (13.2–15.8), platelets 207 (174–312), optimal levels of chitotriosidase and reduction of hepatic and splenic volumes. Bone pain was not resolved in all patients with associated bone pathologies (1 patient with an episode of generalised bone pain). Clinical Response: OR all 3 patients met 5/6 criteria. Similar safety profile and very well tolerated without unexpected adverse events. ADEs: 1 velaglucerase (rash and diarrhoea resolved) and 1 patient with imiglucerase (infusion-related warmth). We prepare infusion solutions in the pharmacy, optimising the use of vials of imiglucerase by arranging appointments for 2 patients on the same day.

**Conclusion** In patients studied with GD-1, ERT was shown to be effective and safe. Imiglucerase and velaglucerase presented similar responses and maintained optimal blood levels and liver-spleen volume, with improvements in the quality of life in these patients. Patients reached and maintained the OR with good tolerance. Communication between the medical and pharmaceutical professionals is essential for appropriate dose adjustment and optimisation of the vials.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**DI-006 PHARMACOVIGILANCE: ANALYSIS OF REPORTING OF ADVERSE REACTION TO MEDICATION FOR THE PREVENTION OF CARDIOVASCULAR DISEASE**

1M Parrilli*, 2F Mando Tacconi, 3V Noccolii, 4A De Angelis, 5T Torró Martinez. 1ASL 10, Florence, Pharmacovigilance Center, Florence, Italy, 2University of Florence, School of Hospital Pharmacy, Florence, Italy, 3University of Florence, Department of Psychology Neuroscience, Drug and Child Health Area Neurolfarba, Florence, Florence, Italy

10.1136/ehjpharm-2015-00639.194

**Background** Around the year 2000, cardiovascular diseases were the direct cause of death of more than 4 million people in Europe. Cases of sudden cardiac death outside the hospital constitute a large part of cardiovascular mortality, from which it is necessary to identify the adverse drug reactions (ADRs) that have generated a cardiovascular episode.

**Purpose** To monitor ADRs related to cardiovascular events, in order to increase prescription appropriateness and patient safety.

**Material and methods** We analysed all ADRs that generated an Emergency Department Acceptance (DEA), exhibiting cardiovascular symptoms. The ADRs were collected and classified on the basis of frequency of occurrence and the type of drug suspected.


**Conclusion** This type of analysis allows the collection of data useful for the construction of a constantly updated database, through which it can appropriately monitor the patients, obtaining prescription appropriateness. Patients also can be followed in appropriate and relevant centres, resulting in reduction of cardiovascular events.

**REFERENCE**

1 Linea guida europea sulla prevenzione delle malattie cardiovascolari nella pratica clinica: riassunto esecutivo — Il Pensiero Scientifico Editore downloaded by IP 159.213.50.2 Mon, 15 Sep 2014, 11:17:09

No conflict of interest.

**DI-007 ASSESSMENT OF THE EFFECT OF PATIENT EDUCATION ON COMPLIANCE WITH ANTIBIOTIC TREATMENT IN AMBULATORY PATIENTS**

1M Ormeci*, 1C Macit, 1O Kocaagaoglu, 1S Yalcin, 1G Guvenengolu, 1Yeditepe University, Faculty of Pharmacy, Istanbul, Turkey, 2Yeditepe University, Faculty of Pharmacy, Pharmacology, Istanbul, Turkey

10.1136/ehjpharm-2015-00639.195

**Background** Compliance has a crucial role for better therapeutic outcomes. Patient education correlates with compliance because informed patients are more conscious of their medicines. Many studies have highlighted the importance of taking antibacterial agents properly.

**Purpose** To evaluate the effect of patient education on compliance with prescribed antibacterial agents.

**Material and methods** A prospective, controlled trial was performed with 99 and 100 participants in a study group (better informed and educated) and control group (basic information), respectively. Participants completed a two-part questionnaire. The first part recorded socio-demographical info, diagnosis and details of prescribed antibiotics of the patients. The second part was presented one day after the end of the treatment. To measure the non-compliance, questions were asked about the number of pills remaining in blisters or containers, omitting the treatment or missing a dose, at what time patient took the drugs, feeling better or not and whether the patient leaflet had been read. Non-compliance was assessed both objectively using “tablet count” and subjectively using a “self-report”.
Results The non-compliance rate was found to be statistically significantly higher in the control group compared to the study group \((p < 0.05)\). Patients in the study group educated by a pharmacist did not quit antibiotic treatment \((p < 0.05)\). Patients who reported not having recovered from their infection were more commonly observed in the control group \((p < 0.05)\). Patients who used antibiotics at the right dose and time were also more numerous in the study group than the control group.

Conclusion Higher compliance rates with antibacterial treatment and improved clinical outcomes were found in the study group.

REFERENCES


No conflict of interest.

DI-009 VITAMIN K ANTAGONIST/NEW ORAL ANTICOAGULANT IN ATRIAL FIBRILLATION: MONITORING OF HAEMORRHAGIC RISK

V Contet*, J Beuchard, J Charles. Centre Hospitalier Cote de Lumiere, Vendee, Les Sables D’olonne, France

Background 2 years after obtaining marketing authorisation for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), the new oral anticoagulants (NOAs) are trying to establish their market position against the Vitamin K antagonists (VKAs).

Purpose To compare the side effects, in particular bleeding, of the NOAs versus VKAs in the treatment of AF in hospitalised patients.

Material and methods 100 cases of hospitalised patients treated by oral anticoagulants (50 VKAs, 50 NOAs) were analysed using an assessment table (Table 1). An interview with the patient and with his doctor, assessing his compliance, completed the observation. The data were then entered for statistical processing by Sphinx.

Results

Abstract DI-009 Table 1

<table>
<thead>
<tr>
<th>Oral anticoagulant (OA)</th>
<th>VKA</th>
<th>NOA</th>
<th>VKA + NOA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population and haemorrhagic risk factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average age</td>
<td>83.1</td>
<td>78.9</td>
<td>81</td>
</tr>
<tr>
<td>Sex ratio (female/male)</td>
<td>1.08</td>
<td>1.5</td>
<td>1.29</td>
</tr>
<tr>
<td>BMI &lt; 18.5</td>
<td>10%</td>
<td>2%</td>
<td>6%</td>
</tr>
<tr>
<td>Kidney failure</td>
<td>42%</td>
<td>26%</td>
<td>34%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>66%</td>
<td>72%</td>
<td>69%</td>
</tr>
<tr>
<td>Heart failure &gt; 2NYHA</td>
<td>18%</td>
<td>12%</td>
<td>15%</td>
</tr>
<tr>
<td>CHADS2-VASc score</td>
<td>4.38</td>
<td>4.12</td>
<td>4.25</td>
</tr>
<tr>
<td>HAS BLED</td>
<td>2.52</td>
<td>2.26</td>
<td>2.39</td>
</tr>
<tr>
<td>Prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OA</td>
<td>62%</td>
<td>74%</td>
<td>50% VKA</td>
</tr>
<tr>
<td>38% warfarin</td>
<td>26% dabigatran</td>
<td>50% NOA</td>
<td></td>
</tr>
<tr>
<td>Introduction to hospital</td>
<td>7%</td>
<td>22%</td>
<td>14.5%</td>
</tr>
<tr>
<td>Class Switch OA</td>
<td>28%</td>
<td>12%</td>
<td>20%</td>
</tr>
<tr>
<td>Continued OA</td>
<td>65%</td>
<td>66%</td>
<td>65.5%</td>
</tr>
<tr>
<td>Number of non-recommended drug interactions</td>
<td>2.32</td>
<td>0.42</td>
<td>1.37</td>
</tr>
<tr>
<td>Side effects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal bleeding</td>
<td>10%</td>
<td>6%</td>
<td>8%</td>
</tr>
<tr>
<td>Renal haemorrhage</td>
<td>2%</td>
<td>0%</td>
<td>1%</td>
</tr>
<tr>
<td>Stroke</td>
<td>10%</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Other</td>
<td>8%</td>
<td>4%</td>
<td>6%</td>
</tr>
</tbody>
</table>

Conclusion This study shows that patients treated for AF with VKAs/NOAs appear to have the same risk of haemorrhage. These results correlate with those obtained by the RELY and ROCKET studies,1 while our population was more at risk (CHADS2-VASc was higher). Population treated for AF was an elderly population, polymedicated, with many risk factors. It is pertinent to validate the anticoagulation by AVK, except for
Drug information and pharmacotherapy

patients whose INR is unstable, where NOA becomes a real therapeutic alternative. The question of first-line use of an NOA in the Hospital is increasingly discussed for polymedicated elderly patients, all the more since VKAs are less easy to use in term of drug interactions, compliance and stability of INR.

REFERENCE
1 RELY and ROCKET studies
No conflict of interest.

DI-010 FACTORS INFLUENCING THE APPEARANCE OF HAEMATOLOGICAL AND THYROID ADVERSE EFFECTS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 TREATED WITH TELAPREVI/RBOCEPREVI PLUS PEG-INFERNER AND RIBAVIRIN

1A Manzaneque*, 1J M Sotoca, 2S Lens, 3B Kostov, 4C Codina. 1Hospital Clinic I Provincial de Barcelona, Pharmacy, Barcelona, Spain; 2Hospital Clinic I Provincial de Barcelona, Hepatology, Barcelona, Spain; 3Hospital Clinic I Provincial de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Barcelona, Spain

Background Telaprevir (TVR) or boceprevir (BOC) with peg-interferon/ribavirin (PR) to treat HCV genotype 1 is associated with haematological adverse effects like anaemia, neutropenia or thrombocytopenia and alterations in thyroid function. Factors influencing the appearance of these adverse effects remain undefined.

Purpose We aimed to assess the relationship between the characteristics of our population undergoing triple therapy (TT) and those adverse events.

Material and methods 61 patients with hepatitis C genotype 1 treated with triple therapy (TT) during the period between January 2012 to June 2014 were included. We collected demographic data (age, sex), HCV genotype 1 (1a, 1b), fibrosis stage at the beginning of treatment (Metavir score) and TT treatment with TVR or BOC. The adverse effects analysed were: anaemia, thrombocytopenia, decreased granulocyte count and hypothyroidism/hyperthyroidism. Fisher exact test was used to study the associations between adverse effects and factors corresponding to patients’ characteristics. Statistical analysis were conducted using the statistical software R.

Results The characteristics of the patients were: 47 men (14 woman), mean age 57 ± 9.3 years, 49 genotype 1b, 53 patients in TT with TVR (9 BOC) and 55 patients fibrosis stage F3–F4.

Anaemia (haemoglobin ≤ 10 g/dL) appeared in 29 (47.5%) patients. Neutropenia (granulocytes ≤ 0.75 × 10^9/L) appeared in 15 (24.6%) patients. Thrombocytopenia (platelet count ≤ 0.50 × 10^9/L) appeared in 5 (8.2%) patients. Hyper or Hypothyroidism (THS levels ≤ 0.4 or ≥ 4 mIU/mL respectively) appeared in 18 (29.5%) patients.

Only statistically significant relationship was observed between age and anaemia (p = 0.013).

Conclusion Age and not fibrosis stage was the main factor associated to the development of anaemia during triple therapy.

REFERENCES
2 Hézode C, et al. Gastroenterology 2014;147

No conflict of interest.

DI-011 PHARMACIST’S ROLE ON ADHERENCE AND LITERACY IN A CANCER OUTPATIENT SETTING

1A Ribed*, 1RM Romero-Jiménez, 1Y Escudero-Vilaplana, 1S Buendía-Braño, 1B Morales García, 1M Tovar Pozo, 2S Osorio, 1A Hernanz-Antonio, 2C Codina, 1M Sanyajo Saez. 1Hospital Universitario Gregorio Marañon, Pharmacy, Madrid, Spain; 2Hospital Universitario Gregorio Marañon, Haematology, Madrid, Spain; 1Hospital Clinic, Pharmacy, Barcelona, Spain

Background Oral anticancer agents (OAs) require self-administration by patients at home, increasing the risk of non-adherence and consequently, costs and decreasing overall patient survival.

Purpose To assess the impact of a comprehensive pharmaceutical care service on oncology outpatients’ adherence. Secondary objectives were to analyse influencing factors and to compare different adherence tests.

Material and methods A comprehensive care program was developed in 2012. Pharmacist interviews and literacy reinforcement took place at the beginning of the treatment, after one and six months. A pre-post study was conducted. Patients starting treatment with OAAs in 2011 formed the control group and the ones who started in 2013, the intervention group. Demographics, tumour, OAA, current drug treatment, adherence evaluated by dispensing records and by Morisky-Green and Haynes-Sacket test data were collected at every visit. A patient was considered adherent when reaching 90% adherence.

Results 115 patients formed the control group and 134 the intervention group (158 men and 91 women; mean age of 66.9). The most common diagnosis was lung cancer (26%). On average, patients were taking 5 drugs concurrently.

The adherence rate in the first month was 94.7% in the control group and 95.7% in the intervention group (p > 0.05); after 6 months on treatment, it was 87.7% in the control group and 95.0% in the intervention group (p = 0.025). Moreover, the percentage of adherent patients increased in the intervention group after 6 months of treatment by 20% (60.5% vs. 80.8%, p = 0.001). In the intervention group, self-reported measurements depicted higher adherence rates that did not correlate with the record of prescriptions issued. Age and gender did not affect adherence. In contrast, differences were observed between OAAs (p = 0.008): sunitinib and pazopanib had the lowest rate of adherence (88.0%) in the first month and sorafenib (82.8%) in the 6th month.

Conclusion A comprehensive pharmaceutical care program improves adherence, resulting in a 20% increase in adherent patients after 6 months of treatment. Differences in adherence were observed between OAAs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-012 RITUXIMAB EFFICACY IN THE TREATMENT OF AUTOIMMUNE DISEASES

J Garcia Romero*, M Vazquez Del Castillo, M Mañes Sevilla, B Rubio Cabrian, M Segura Bedmar. Hospital Universitario de Móstoles, Servicio de Farmacia, Móstoles, Spain

Background: The 6th month. A pre-post study was conducted. Patients starting treatment with OAAs in 2011 formed the control group and the ones who started in 2013, the intervention group. Demographics, tumour, OAA, current drug treatment, adherence evaluated by dispensing records and by Morisky-Green and Haynes-Sacket test data were collected at every visit. A patient was considered adherent when reaching 90% adherence.

Results 115 patients formed the control group and 134 the intervention group (158 men and 91 women; mean age of 66.9). The most common diagnosis was lung cancer (26%). On average, patients were taking 5 drugs concurrently.

The adherence rate in the first month was 94.7% in the control group and 95.7% in the intervention group (p > 0.05); after 6 months on treatment, it was 87.7% in the control group and 95.0% in the intervention group (p = 0.025). Moreover, the percentage of adherent patients increased in the intervention group after 6 months of treatment by 20% (60.5% vs. 80.8%, p = 0.001). In the intervention group, self-reported measurements depicted higher adherence rates that did not correlate with the record of prescriptions issued. Age and gender did not affect adherence. In contrast, differences were observed between OAAs (p = 0.008): sunitinib and pazopanib had the lowest rate of adherence (88.0%) in the first month and sorafenib (82.8%) in the 6th month.

Conclusion A comprehensive pharmaceutical care program improves adherence, resulting in a 20% increase in adherent patients after 6 months of treatment. Differences in adherence were observed between OAAs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
Background The treatment of rare autoimmune diseases presents for patients the additional problem of limited therapeutic options, which are usually reduced to corticosteroids and immunosuppressants. The use of rituximab could be an effective alternative.

Purpose To determine the efficacy of treatment with rituximab in autoimmune diseases.

Material and methods Retrospective observational study of patients with autoimmune diseases who were treated with rituximab between January 2008–March 2014. Data was collected from electronic prescription records. Diagnosis, reason for prescribing, previous and concomitant treatments, dose, recurrence and treatment outcome were collected as study variables.

Results 11 patients (36% male), mean age 47 years were analysed. The diseases were lupus erythematosus (36%) autoimmune thrombocytopenia (9%) and a miscellaneous group: vasculitis, pemphigus, scleroderma, cryoglobulinaemia, Sjögren’s syndrome, antiphospholipid syndrome (55%). The reason for using rituximab was: treatment failure with pre-treatments in 81% of cases or first choice in the remaining 19%. 81% of administrations followed the pattern 375 mg/m²/week for 4 weeks while 19% followed the pattern of 1,000 mg on days 1 and 15 of each cycle. With respect to previous treatment, 81% of patients had received high doses of corticosteroids, 54% corticosteroids with immunosuppressant; 1 patient was on prior treatment with intravenous immunoglobulin. Rituximab was administered concomitantly with corticosteroids for the majority of patients (91%). Treatment efficacy was assessed according to the response as: complete response (27%), partial response (54%) and no response (18%). Of the 11 patients studied, 6 (54%) received only one cycle of rituximab, 3 (27%) currently remain in treatment and 2 patients (18%) died due to progression of their disease.

Conclusion Although its efficacy is variable, rituximab may be a valid therapeutic option in autoimmune diseases. Randomised controlled studies are necessary to ensure the various indications of rituximab.

REFERENCE

No conflict of interest.

DI-013 BOCEPREVIR VS. TELAPREVIR: RESULTS IN THE CLINICAL MANAGEMENT AFTER 24 AND 48 WEEKS

1 F Genio Zumalave, 1 M Gutiérrez Pérez, 2 C Camona Torres, 3 S Martín Clavo, 2 JF Rangel Mayoral, 4 M Ladrón de Guevara, 4 E Parra Alonso, 2 H Hospital Di-014 THERAPY IN NON-INFECTIOUS UVEITIS

1 Hospital Clínic I Provincial de Barcelona, Pharmacy, Barcelona, Spain; 2 Hospital Clínic I Provincial de Barcelona, Ophthalmology, Barcelona, Spain

10.1136/ejhpharm-2015-000639.201

Background No

Purpose To evaluate the prescription pattern and efficacy of telaprevir (TLP) and boceprevir (BOC) in the clinical management of chronic hepatitis C (HCV) infection in a region.

Material and methods Multicentre observational cohort study of HCV patients treated with protease-inhibitor triple therapy from September 2002 to April 2014. The information extracted from electronic health records was: age, gender, comorbidity and previous experience of HCV treatment. The virological response (VR) was assessed in patients who reached 24 and 48 weeks treatment; quick virological response rate (QVR) and discontinued treatment rates were also assessed.

Results 124 patients were included (TLP = 82; BOC = 42), 65% were male (63.4% treated with TVR and 69% with BOC p = 0.533). There was no difference between the selection of treatment according to comorbidity, with the exception of HIV co-infected patients (total: 8.9%; TVR: 13.6% vs. BOC: 0%; p = 0.012) or with mental illness (21.2%; 27.3% vs. 10.5%; p = 0.044). The distribution of patients according to previous experience was: treatment-naïve patients (total: 41.1%; TLP: 36.6% vs. BOC: 50%; p = 0.151), null responders (18.5%; 14.6% vs. 26.2%; p = 0.117), partial responders (12.9%; 11% vs. BOC = 16.7%; p = 0.371), relapers (26.6%; 36.6% vs. 7.1%; p = 0.0001). At week 24, 83 patients achieved VR: 62.7% (TLP = 66.7% BOC = 55.2%; p = 0.346). QVR rates were 53.1% (62.2% vs. 50.7%; p = 0.233). According the previous treatment experience, VR were: relapers 81.8%, treatment-naïve patients 63.8%, partial responders: 58.3% and null responders: 37.5% (p = 0.048). At week 48, 61 patients achieved VR or 57.4% (TLP: 62.2% vs. BOC: 50%; p = 0.348). Discontinuation rate was 13.6% (TLP: 20% vs. BOC: 3.8%; p = 0.062).

Conclusion TLP was the preferred treatment in HIV co-infected patients, mentally ill patients or relapers. The statistical trend shows higher efficacy and discontinued treatment rate with TLP, but the differences are statistically irrelevant. Both drugs showed worse results in clinical management than reported in clinical trials.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-014 OFF LABEL USE AND ECONOMIC IMPACT OF BIOLOGIC THERAPY IN NON-INFECTIOUS UVEITIS

1 A Manzaneque*, 1 M Sotoa, 2 A Rivero, 3 A Carros, 1 T Matas, 1 A Adán, 1 C Codina. 1 Hospital Clínico i Provincial de Barcelona, Pharmacy, Barcelona, Spain; 2 Hospital Clínico i Provincial de Barcelona, Ophthalmology, Barcelona, Spain

10.1136/ejhpharm-2015-000639.202

Background Non-infectious uveitis represents a heterogeneous group of inflammatory intraocular diseases. Conventional treatment with corticosteroids and immunosuppressive agents may not be sufficient in refractory patients. Off-label use of biological response modifiers has been studied as an alternative.

Purpose To describe the use and financial impact of biological treatment in refractory non-infectious uveitis.

Material and methods Retrospective, observational study. We included patients with non-infectious uveitis treated with biological agents between 2009 and June 2014. Patients were identified by reviewing off-label uveitis authorizations and data was collected from electronic medical records. Individual costs were calculated using the hospital acquisition prices.

Results 79 patients (117 biologicals) were identified: 75% women, 41 ± 16 years old. Anatomic diagnosis was: posterior (46.8%), anterior (32.9%), panuveitis (13.9%) and intermediate (6.3%) uveitis.

Of the biological agents prescribed to the 85.5% of patients with anti-TNF (14.5% tocilizumab), the most prescribed was adalimumab (55%), followed by infliximab (33%), golimumab (9%) and certolizumab (3%).

Over 80% of patients received one drug, 10% two, 9% three and only one patient received four.
The main reason for switching was: loss of efficacy (18.2% infliximab, 44.4% golimumab, 33% certolizumab, 11.8% infliximab) and side effects (9.1% adalimumab, 11.8% tocilizumab). 23.1% of anti-TNF and 20% of tocilizumab could be discontinued for stable disease.

In the financial analysis (n = 54), overall cost/patient varied from €2,030 to 98,250 (median €12,940). The cost associated with each drug was: €23,430, €21,100, €12,320, €3,960, and €21,025; with a mean duration of 15.4, 18.6, 13.6, 4.9, and 11.3 months, until the final follow-up date, for infliximab, adalimumab, golimumab, certolizumab and tocilizumab respectively.

Conclusion TNF blockers and tocilizumab may benefit patients when conventional immunosuppressive therapy has failed or has been poorly tolerated. Given their cost as well as the lack of studies related to effectiveness and long-term safety, they cannot be used routinely.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-015 EVALUATION OF PHARMACOLOGICAL PAIN CONTROL MANAGEMENT IN CANCER PATIENTS: A PATIENT-CENTRED APPROACH TO PREVENT EXPOSURE TO INEFFECTIVE MEDICATION

1. Persikou, 2. Vakoumou, 3. Quis, 4. Spiliopoulos Hospital, Hospital Pharmacy, Athens, Greece. 5. Spiliopoulos Hospital, Clinic of Internal Medicine, Athens, Greece

10.1136/eorhaph-2015-000639.203

Background Pain experienced by patients with end-stage cancer represents a continuing source of frustration for them, their families and the healthcare team. While some patients over-report pain, the reverse is often true, so these patients could be over/under treated for pain.

Purpose To evaluate the pharmacological management of pain in cancer patients, being nursed in an internal medicine clinic without previous experience in palliative care.

Material and methods Given the increased numbers of end-stage cancer patients being admitted to this clinic, it was decided in 2014 that all pharmacological choices for pain alleviation for inpatients who remained more than one week should be systematically reviewed. A brief questionnaire was prepared to identify both patients’ satisfaction with analgesic treatment and the quality of relevant information imparted to them by the healthcare team.

Results During the first six months of 2014, 42 end-stage cancer patients participated in the study (82% of patients admitted). 26% did not need any analgesics, while an indwelling system for intravenous infusion of morphine was inserted for one patient. 45% of patients’ pain management involved some mild opioid (codeine ± paracetamol) or tramadol, 38% transdermal/transmucosal fentanyl, 26% adjuvant therapy with an antidepressant/anticonvulsant agent. Full satisfaction was reported by 68% of patients, 32% declared themselves adequately satisfied, while 60% were very pleased with the quality of information they received about their analgesic treatment.

Conclusion Since per os normal or modified release morphine formulations are not widely available in our country, tramadol (in contrast to nonsteroidal anti-inflammatory drugs) seem to be most preferred before moving to increased doses of fentanyl. In order to prevent overexposure to analgesics any pain control strategy in cancer patients should ensure that both the individual needs are being met and the ever-changing expression of pain is being captured.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-016 DEVELOPMENT OF A QUICK REFERENCE GUIDE FOR SYRINGE DRIVER DRUG COMPATIBILITIES

1. McCabe, 2. Kehoe*. 1. Mater Misericordiae University Hospital, Pharmacy, Dublin, Republic of Ireland; 2. Mater Misericordiae University Hospital, Dublin, Republic of Ireland 10.1136/eorhaph-2015-000639.204

Background Drug administration via syringe driver is safe, simple, non-invasive and cost effective. A continuous subcutaneous (SC) infusion is used to provide symptom control in patients unable to tolerate oral administration, particularly in the palliative care setting. Various drug combinations are used in clinical practice and typically include opiates, anti-emetics, anxiolytics and anticholinergics.

Many parenteral formulations of drugs may be suitable for subcutaneous administration however evidence and clinical experience with their use is lacking. In particular, information on the inherent risk of physical and/or chemical incompatibility associated with the process of mixing multiple parenteral drugs is neither readily accessible nor easily interpretable for frontline staff. In 2012, Medicines Information (MI) received 57 enquiries pertaining to the compatibility of parenteral drugs prescribed for continuous SC infusion via syringe pump, reflecting the need for a local reference compatibility chart.

Purpose To develop continuous SC infusion compatibility charts for the administration of 2- and 3-drug combinations.

Material and methods
1. Review of previous MI enquiries relating to drug compatibility in syringe drivers.
2. Search for available stability data on specific 2- and 3-drug combinations using past MI enquiries and palliative care resources.
3. Compile the data and develop compatibility charts for commonly prescribed 2- and 3-drug combinations.

Results A continuous SC infusion 2- and 3-drug combination compatibility chart was developed. The 3-drug compatibility charts focused on morphine and fentanyl in combination with another two drugs.

Conclusion The administration of continuous SC infusions via syringe driver has become fundamental in symptom management within the palliative care setting. It is anticipated that these charts will enable frontline staff to readily access compatibility data at the time of prescribing. Monitoring of MI queries will continue to direct updating the resource to reflect hospital practice.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-017 USAGE PROFILE, EFFECTIVENESS AND SAFETY OF COFORMULATED RILPIVIRINE/EMTRICITABINE/ TENOFOVIR


10.1136/eorhaph-2015-000639.205

Background In 2012, Medicines Information (MI) received 57 enquiries pertaining to the compatibility of parenteral drugs prescribed for continuous SC infusion via syringe pump, reflecting the need for a local reference compatibility chart.

Purpose To develop continuous SC infusion compatibility charts for the administration of 2- and 3-drug combinations.

Material and methods
1. Review of previous MI enquiries relating to drug compatibility in syringe drivers.
2. Search for available stability data on specific 2- and 3-drug combinations using past MI enquiries and palliative care resources.
3. Compile the data and develop compatibility charts for commonly prescribed 2- and 3-drug combinations.

Results A continuous SC infusion 2- and 3-drug combination compatibility chart was developed. The 3-drug compatibility charts focused on morphine and fentanyl in combination with another two drugs.

Conclusion The administration of continuous SC infusions via syringe driver has become fundamental in symptom management within the palliative care setting. It is anticipated that these charts will enable frontline staff to readily access compatibility data at the time of prescribing. Monitoring of MI queries will continue to direct updating the resource to reflect hospital practice.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
**DI-018**  
**SIMPLIFICATION TO SINGLE-DRUG REGIMEN WITH A RITONAVIR-BOOSTED PROTEASE INHIBITOR FOR HIV PATIENTS**

J Sánchez Gundín*, A Flor García, I Recuero Galve, C Martí Gil, L Martínez Valdívieso, D Barreda Hernández. Virgen de La Luz Hospital, Pharmacy Department, Cuenca, Spain

10.1136/ehjpharm-2015-000639.206

**Background** Single-drug regimens (SDR) with ritonavir-boosted protease inhibitors (PI) could potentially be a regimens simplification to avoid nucleoside reverse transcriptase inhibitor (NRTI) toxicities in patients carrying human immunodeficiency virus (HIV) who fulfil several requirements: virological suppression, high level of medicines adherence, no previous IP virological failure and high CD4 count (>100 cell/mL).

**Purpose** To evaluate the effectiveness and safety of SDR with ritonavir-boosted lopinavir (LP/r) and ritonavir-boosted darunavir (Dr/r) in HIV-positive patients pre-treated with three-drug regimens (TDRs) including an NRTI.

**Material and methods** Retrospective observational study of HIV-positive patients with treatment switches from TDR to SDR in a second-level hospital.

Data were collected from the Farmatools-Dominion program and medical records. Variables included: sex, age, duration of previous TDR, plasma viral load (PVL) pre- and post-treatment switching, virological failure with PI, CD4 cell count before switching and months of SDR to date (June’11–September’14).

**Results** Twenty-two patients were identified, 9 treated with LP/r (5 men) and 13 with Dr/r (all men). Mean age at the time of the study: 48 ± 6 years. 4 patients (2 with LP/r and 2 with Dr/r) were co-infected with Hepatitis C virus and all subjects had been treated with TDR for a minimum of 12 months prior to treatment change. In all subjects basal PVL was undetected for at least 6 months before switching and remained undetectable during the entire study. One exception was a single patient with confirmed viral rebound which led to treatment re-intensification with two NRTIs included in the previous TDR.

No patients presented virological failure with the previous PI and the median CD4 counts at treatment switch were normal (825 ± 583 cell/mL). All subjects were treated with SDR for a median period of 22 months and both adherence and tolerance were considered successful before and after switching.

**Conclusion** SDR with a ritonavir-boosted PI might be an alternative as effective as traditional combinations. It involves a clear benefit for HIV-positive patients because it simplifies treatment with minor toxicity and a small number of interactions.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.
Results Of 44 patients treated with IC, 19 of them met the study inclusion conditions as they could be monitored when visiting the Pharmacy Service with the Nebulizer device. The average age was 69.4 years (SD: 17.4) and 52.6% were women. Regarding the type of colonisation it was initial in 6 patients (31.6%), intermittently in 2 (10.5%) and chronic in 9 (47.4%). Only two patients had no culture and treatment was initiated empirically.

The data from the nebulization system were: 1. Complete treatment took on average 6.1 min (SD: 3.8), exceeding 10 min with only two patients. 2. 95.5% of patients used the device correctly. 3. Adherence to treatment was 93.9%, being less than 80% in one patient. After completion of the treatment, which lasted 3.5 months (SD: 2.2), cultures became negative in 9 patients (42.1%).

Conclusion Most of our patients were adherent to the treatment (73.7%) which suggests that the Nebulizer was easy to use. The role of the pharmacist is relevant because in the few cases where the average length of complete treatments was higher or adherence was low, the importance of these concepts was reinforced during the monthly clinical interview.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

**DI-020** EFFECTIVENESS OF SORAFENIB IN ADVANCED HEPATOCELLULAR CARCINOMA IN REAL-LIFE CONDITIONS

Background Sorafenib is an oral multikinase inhibitor used for the treatment of hepatocellular carcinoma (HCC). It is the only systemic treatment indicated for advanced HCC and was included in our Hospital’s formulary in 2007.

Purpose To assess the characteristics of the patients receiving sorafenib for the treatment of HCC in our hospital and to describe the treatment effectiveness in real-life conditions.

Material and methods Retrospective observational study. We included all patients who had started treatment with sorafenib for HCC in our hospital between 1st January 2007 and 31st December 2013. Demographic and clinical variables (tumour stage according to BCLC, ECOG PS, Child Pugh, presence of macroscopic vascular invasion and/or extrahepatic spread) were recorded. The main outcomes were time to progression and overall survival, assessed by Kaplan-Meier plots. Results were also analysed with the log-rank test stratified by BCLC stage.

Results 72 patients were included. They had predominantly BCLC C stage C HCC (77.8%), PS between 0–1 (88.9%) and compensated cirrhosis. At the end of the study, 53 patients had discontinued treatment. The most common reasons for treatment discontinuation were clinical worsening (35.1%) and occurrence of uncontrollable adverse events (24.6%). The median time to progression was 4.8 months (95% CI 3.8, 5.9). The median time to progression was 3.1 months (95% CI 2.5, 3.7) in the BCLC C group, as compared with 5.3 months in the BCLC C group (95% CI 4.4, 6.1), \( p = 0.024 \). At the end of the study, 44 deaths had occurred. Median overall survival (OS) was 15.2 months (95% CI 11.2, 19.3). There was no significant difference between the two groups in the median OS: 19.5 months (95% CI 9.6, 29.4) in the BCLC B group vs. 14.2 months (95% CI 8.9, 19.5) in the BCLC C group, \( p = 0.75 \).

Conclusion The effectiveness of sorafenib in the treatment of advanced HCC under real-life conditions is consistent with the data from the clinical trials. Our results seem to indicate that in patients with BCLC stage C, sorafenib is more likely to delay disease progression. Nevertheless, overall survival was longer in the patients with BCLC stage B carcinoma.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

**DI-021** IMPROVEMENT STRATEGIES IN QUALITY PRESCRIBING INDICATORS ON A HEALTHCARE AREA

Background Our Public Healthcare Service have developed some quality indicators (QI) based on the selection of drugs that support better evidence of efficiency in areas of prescribing where more deviations were detected in the past.

Purpose To describe the strategies for improving the indicators, measuring compliance with them after three years and evaluating their financial impact on the public budget.

Material and methods Retrospective observational study. The percentage of prescriptions of three QIs (omeprazole versus total PPIs, simvastatin versus total lipid-lowering drugs and ACE inhibitors versus total renin-angiotensin-aldosterone-system inhibitors) was evaluated before and after an educational program consisting of clinical sessions, meetings with the head of medical team (HMT) and Medical Director, periodic written reports for doctors and interviews with low-compliance-rate doctors. Prescription rates were measured in March 2011 and February 2014. Prescribing data and financial impact were obtained from the reimbursed drugs Program (Microstrategy), which enabled us to calculate the possible savings if the optimal level of prescriptions were to be reached.

Results 24 clinical sessions were held in 2011, 17 in 2012 and 10 in 2013. Meetings with the HMT and Medical Director were biannual in 2011 and annual in 2012–13. 23 interviews were held, all in 2013. Reports were distributed in 100% of Units and possible periods. Omeprazole prescription was 69.3% at the beginning and increased to 85.4% three years later. Simvastatin prescribing also increased from 18.07% to 40.4%, and the percentage of ACE inhibitors rose from 28.44% to 52.82%. Regarding cost savings, in March 2011 drug expenditure in our Healthcare Area was €244,717 more than with the theoretical optimum level of prescription, but in February 2014, this excess had reduced to just €44,803.

Conclusion The strategies adopted were well received by the doctors, resulting in a considerable improvement of the indicators evaluated. This improvement now produces direct annual savings of €200,000 in the public budget in our Healthcare Area compared to three years ago.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
NEW CHANCES IN MULTIPLE SCLEROSIS TREATMENT: SUSTAINED-RELEASE FAMPRIDINE

M. Gajardo Álvarez*, L. Yunquera Romero, J. González Chávez. Hospital Regional Universitario Carlos Haya, Ugc Farmacia, Malaga, Spain

10.1136/ejhpharm-2015-000639.210

Background Walking impairment is one of the major primary symptoms in patients with multiple sclerosis (MS), which greatly affects their quality of life and emotional state.

Fampridine is a new oral treatment used to improve walking ability in adults with MS. Its use was approved by the EMA in 2011 for patients with an Expanded Disability Status Scale (EDSS) score between 4 and 7. Patients who do not experience clinical benefits (reported by the physician and patient) after two weeks’ treatment should discontinue fampridine. This condition was established due to the results of Phase III trials, which demonstrated improved walking ability in only 35–43% of the patients treated with fampridine and an increase in absolute walking speed in 20% of the patients.

Purpose To evaluate the effectiveness of sustained-release fampridine in patients with MS and walking disability, after 2 weeks of treatment.

Material and methods A one-year prospective, observational study. Patient characteristics (age, sex), clinical data (EDSS, clinical benefits perceived by the physician and patient) and treatment-related information (drug, dose and number of tablets dispensed) were obtained from the available databases in our hospital.

Results 91 patients started taking fampridine between October 2013 (when the Pharmacy Commission approved its use in our hospital) and October 2014. They were reviewed after two weeks of treatment by their neurologist and pharmacist to evaluate improvement in their walking ability and physical condition. In this reassessment, 71 patients (78%) showed an improvement in their walking ability and moving speed, and continued the treatment. Only 18 of these (25%) experienced a reduction of their EDSS (mean 0.5 points). None of them suffered adverse effects due to fampridine.

Conclusion Our patients responded better than anticipated from the clinical trials. Although fampridine has shown limited efficacy it covers a current treatment gap in this disease.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DI-024 OFF-LABEL USE OF GABAPENTIN AND PREGABALIN IN A TERTIARY HOSPITAL

1J González-Bueno, 2E Calvo-Cidóncha, 1F Desongrás-Corrala, 1MD Santos Rubio*, 1E Chamorro de Vega, 1FJ Bautista-Palomar, 1Virgen Del Rocio Hospital, Pharmacy Department, Seville, Spain; 2Virgen de Valme Hospital, Pharmacy Department, Seville, Spain

10.1136/ejhpharm-2015-000639.212

Background Gabapentin and pregabalin are two GABA analogues, example of an evergreening strategy. Both have been associated with a markedly off-label use.

Purpose To describe the extent and nature of the off-label use of gabapentin and pregabalin.

Material and methods Prospective observational study performed in a tertiary hospital. We included patients being treated with gabapentin or pregabalin at any time between June and August 2014. The variables collected were: sex, age, drug, therapeutic indication, dose and cost per patient-month (according to retail prices). These data were used to describe the rate and nature of the overall use and off-label use by drug. Data were collected through review of medical records and by electronic pharmacy refill records. Statistical analysis was performed using SPSS Statistics 20.0.

Results Sixty-five patients (54% male, mean age 60 ± 14 years) were included. Eighteen (28%) were being treated with gabapentin and 47 (28%) with pregabalin. The overall off-label use was 43% (28 patients), with no differences between the drugs (44% gabapentin and 43% pregabalin). The off-label use was related to the therapeutic indication (25 patients) or the dose (3 patients). The off-label indications for gabapentin were: central neuropathic pain (6), subacute or chronic low back pain (3),...
generalised anxiety disorder (3) and refractory visceral pain (1). The off-label indications for pregabalin were: subacute or chronic low back pain (6 patients), fibromyalgia (5), and essential tremor (1). The average cost per patient-month was €25 ± 11 for gabapentin and €156 ± 65 for pregabalin.

**Conclusion** Gabapentin and pregabalin are often prescribed for off-label use. Despite having failed to demonstrate clinically relevant differences over gabapentin, pregabalin holds a high prescription rate with consequent extra costs for the hospital, representing an area in which rational drug use could be promoted.


No conflict of interest.
Data collected: age, line of treatment, cycles received, ECOG, previous treatments, progression free survival (PFS) and levels of TS.

We compared patients who completed the treatment with those being followed up (routine determination of TS).

In the second group we measured PFS from the first cycle up to date (now in treatment).

Results 31 patients were enrolled on treatment: median age 62 years (56.5–66.5), median cycles of pemetrexed received 4 (3–7). 41.9% patients had ECOG 0, 48.4% ECOG 1, and 9.7% ECOG 2. 41.9% received pemetrexed in the first step, 41.9% in the second, 9.7% in the third and 6.5% in the fourth.

When the study finished: 21 patients had completed the treatment, median PFS being 1.3 months (1–3.4). Among this group, TS levels were not determined in 8 (38.1%). In the rest of patients, 12 showed low levels, only remaining high in 1 patient.

Of the 10 patients still being followed up, levels of TS were determined, with the exception of 1 (treatment initiated in 2011). All patients showed low levels, the median of stable disease being at least 6.5 months (5–13).

Conclusion Patients who start treatment without previous scoring of TS have a worse response to pemetrexed.

TS level determination is considered an indicator of the effectiveness of the treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
HEALTH OF THE COUPLE AND TRANSMISSION OF HIV INFECTION TO THE OFFSPRING: AN EPIDEMIOLOGICAL ANALYSIS OF CHILDREN BORN FROM SEROPOSITIVE PATIENTS IN SIRACUSA, SICILY

Andrea Di Giacomo, Federica Nappi, Giuseppe Sguaiaro, Paola D’Agostino

Background About 50% of all HIV patients in the world are females. Monitoring of therapies is important to prevent renal failure and osteoporosis, to preserve the immune system in order to plan a pregnancy, to avoid the teratogenic effects, and to prevent vertical transmission of infection during labour.

Purpose The aim of this retrospective observational study is to analyse all pregnancies occurred among HIV patients treated in last decade.

Material and methods We examined all HIV-seroconcordant and -discordant couples taking ART. For patients we considered the number of pre-term/full-term pregnancies, spontaneous/caesarean deliveries, intrauterine deaths, miscarriages, and all cases of breast-feeding or bottle-feeding.

Results Overall, 76 couples were examined. In the 78.9% (60 couples) of cases an optimal compliance to the treatment were verified. Of these, 40 (52.6%) were couples without children. Of remaining 47.4%, 18 were multiparous (44 pregnancies). Full-term pregnancies occurred in 74% of cases, all from couples with optimal therapeutic compliance. Pre-term pregnancies occurred in 11% of cases, intrauterine death in 11%, miscarriages in 4%: all adverse events were reported in couples with poor compliance. Of all children, 29 (65.9%) were born spontaneously and 15 (34.1%) with caesarean delivery. Moreover, 38 (86.4%) children were bottle-fed and became seronegatives within first year. Only 6 (13.6%) children were breast-fed and seropositive, but in two cases mothers were not treated because undiagnosed before pregnancy.

Conclusion Our study showed that an adequate treatment of HIV is important to prevent the adverse events of pregnancies in HIV-couples. Although the therapeutic option is not conditioning in couples without born, our results demonstrate that in patients with an optimal compliance to the ART no miscarriages and other adverse events occurred. Social status and drug use are important factors determining the risk of infection in the offspring.

REFERENCE


No conflict of interest.
Results We included 73 patients, 84% males, median age 54 years (IQR 52–59) who had been diagnosed with HIV for 17 years (IQR 11–20). Median CD4 count 684 cells/mm³ (IQR 469–882) and 93% with undetectable viral load. Adherence according to dispensing records was 93% (89–98) and by SMAQ, 67% were adherent. The most prescribed antiretrovirals were darunavir and tenofovir, 32% of patients had been prescribed an unconventional regimen and 29% PI/r monotherapy, median of three tablets/day (IQR 3–4) and 75% once daily. The domains of HrQL, physical (PHS) and mental (MHS) were significantly higher in: patients over 60 years, patients with more than 10 years of ART and with fewer than 3 tablets/day. Patients not on PI/r had higher scores on all dimensions of HrQL with significant differences in cognitive functioning (p = 0.015).

Conclusion Patients presented antiretroviral therapy in unconventional combinations, more than 90% adherence and undetectable viral load. Antiretroviral treatment strategy could improve the quality of life perceived by the patient.

REFERENCE
No conflict of interest.

DI-033 DRUG-INDUCED SWEET’S SYNDROME (DISS): THE CASE OF ALLOPURINOL

R Maci*, V Sima, C Giardina, E Garafò, G Polleni, V Arcangeli, A O. U. Policlinico G. Martino, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; Hospital S. Marta E S. Venere, ASP CT, Internal Medicine, Messina, Italy; Sicilian Regional Centre of Pharmacovigilance, Clinical Pharmacology Unit – A. O. U. Policlinico “G. Martino”, Messina, Italy

Background Sweet’s syndrome (acute febrile neutrophilic dermatosis) is an uncommon, severe cutaneous condition. It may be induced by several drugs but it has not been previously associated with allopurinol treatment.

Purpose To describe a case of Sweet’s syndrome in a patient treated with allopurinol.

Material and methods The case was identified within an active pharmacovigilance project.

PubMed and Micromedex databases were used to carry out a literature search. Diagnostic criteria for DISS reported in the literature were evaluated.

The Naranjo algorithm was used to evaluate the likelihood of causality between the DISS and allopurinol.

Results An 87-year-old woman with type 2 diabetes mellitus, obesity, arterial hypertension, osteoporosis and arthritis was prescribed allopurinol for hyperuricaemia. Eight days later she developed fever, painful oedema in the hands and lower limbs with non-pruritic erythematous plaques topped by pus-filled skin blisters, right eye conjunctivitis and joint pain. Two days later the patient discontinued the drug and went to the hospital. Blood tests showed neutrophilic leucocytosis (20.58 × 10⁹/L), inflammatory state and altered liver function. Treatment with three different antibiotics was not effective; culture of pus samples was negative for bacterial, fungal, and mycobacterial organisms.

The levels of the main tumour markers were within the normal ranges. Splenomegaly was observed. The patient showed a rapid clinical improvement of symptoms after the administration of intravenous corticosteroids.

Conclusion The following observed symptoms are consistent with a diagnosis of Sweet’s syndrome: 1) painful erythematous plaques or nodules of sudden onset, 2) pyrexia, 3) temporal relation between the drug ingestion and clinical presentation 4) rapid response to systemic corticosteroid therapy.

The Naranjo algorithm indicated the association as probable.

because the symptoms of Sweet’s syndrome resemble an infectious process, the correct diagnosis may be delayed and an inappropriate treatment regimen with antibiotics may often precede glucocorticoid therapy.

REFERENCE
No conflict of interest.

DI-034 ELTROMBOPAG AS AN ALTERNATIVE FOR REFRACTORY APLASTIC ANAEMIA

C Bonilla Galán*, D Bregas Moreira, G Groso Buiza, LM Bravo García-Cuevas, C Meneses Mangas, L Romero Soria, S Martín Cacho, R Medina Comas, RF Rangel Mayoral, Ll Liso Rubido, Hospital Infanta Cristina, Hospital Pharmacy, Badajoz, Spain; Hospital Infanta Cristina, Hematology Service, Badajoz, Spain

Background Aplastic anaemia comes from a bone marrow failure which affects all blood lineages. Treatment is based on immunosuppression or allogeneic transplant, but some patients are refractory to these options. Eltrombopag, a thrombopoietin receptor agonist administered orally, promotes megakaryopoiesis and platelet release.

Purpose To assess eltrombopag effectiveness as off-label treatment for immunosuppression-refractory aplastic anaemia.

Material and methods A 10-month (1/12/2013–30/09/2014) retrospective study was carried out including immunosuppression-refractory aplastic anaemia patients who weren’t allotransplantation candidates. After approval by the Regional Committee for drug use under Special Circumstances, each patient received different eltrombopag doses. In order to assess the effect, data were gathered from platelet count at baseline and subsequently, considering the response positive when the platelet count increased enough to avoid transfusion. Clinical data were obtained from the patient’s history and from Outpatient records.

Results We recovered data from two patients (male, aged 26 and 34) diagnosed with aplastic anaemia refractory to anti-thymocyte globulin, ciclosporin and high-dose steroids. Neither of them were candidates for allotransplantation. Initial dose was 50 mg/day, causing a platelet count increase of 7 and 272 mill/mm³ after three weeks. Then, doses were modified according to current response to an average of 6.25 mg/day, reaching counts of 5–125 mill/mm³ (average 44.33 mill/mm³) in one patient and 1–553 mill/mm³ (average 139.76 mill/mm³) in the other. The average treatment length was 6.75 months. Those results are similar, even better, to the ones shown in a phase-II study (Olnes et al, 2012) involving 25 patients with the same diagnosis and dose (response in 44%; average increase 44.0 mill/mm³, nine of them transfusion independent).

Conclusion Both patients reached platelet counts higher than 100 mill/mm³, avoiding transfusions and their associated risks, with an improvement in their quality of life. Because of the unavailability of other treatments for this kind of patients, the off-label use of eltrombopag is a promising alternative when there’s little chance of cure.
Drug information and pharmacotherapy

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

**DI-035 SHOULD WE MAKE PATIENTS AND NURSES AWARE OF THEIR DRUG ADMINISTRATION PROBLEMS AND TRAINING NEEDS?**

A Lampert*, WE Haefeli, HM Sedling. University of Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology, Cooperation Unit Clinical Pharmacy, Heidelberg, Germany

10.1136/ehjopharm-2015-000639.223

**Background** Medicines administration errors are a well-known safety risk for patients and a lack of knowledge is one major cause of errors. Therefore, every effort is made to close knowledge gaps among medicine users to make drug administration safe. However, rarely the medicine users were prospectively asked for specific drug administration problems and training needs.

**Purpose** The first step in preventing errors is to study their aetiology. Therefore, we qualitatively assessed the medicine users’ drug administration problems in order to investigate causes of errors and training needs.

**Material and methods** Focus groups with patients, caring relatives, and nurses were conducted using semi-structured interview guides for a focused exploration of participants’ drug administration experiences and training needs. All discussions were audio-taped and videotaped. After verbatim transcription, data were analysed using Mayring’s qualitative content analysis. Ethical approval was obtained from the local ethics committee and informed consent was signed by all participants prior to the study.

**Results** We conducted three focus groups with eleven patients and caring relatives, two focus groups with ten nurses from a nursing home, and one focus group with four nurses from a university hospital. In accordance with the available literature, patients and nurses reported drug administration problems related to different dosage forms, and potentially at every step in the administration process. The qualitative content analysis revealed that patients frequently trivialised drug administration, were unaware of errors, and primarily blamed the dosage form for administration problems. In contrast, nurses also sought out the patient as potential causes of administration problems e.g. due to dysphagia.

**Conclusion** Patients who are unaware of problems will not ask for help, and hence might not be reached by a traditional educational intervention. For the implementation and evaluation of the success of an educational intervention it is crucial to ask the intended target group, i.e. medicine users, for training needs.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Conflict of interest.

**DI-036 INTRAVITREAL AFLIBERCEPT IN REFRACTORY AGE-RELATED MACULAR DEGENERATION**

1A Riestra*, 2S Berisa, 3E Cuello, 4E Villota, 5A Fernandez-Vega. 1Instituto Oftalmológico Fernández-Vega, Oviedo, Spain; 2Hospital Quiron Zaragoza, Pharmacy, Zaragoza, Spain; 3Instituto Oftalmológico Fernández-Vega, Instituto Oftalmológico Fernández-Vega, Oviedo, Spain; 4Instituto Oftalmológico Fernández-Vega, Retina, Oviedo, Spain

10.1136/ehjopharm-2015-000639.224

**Background** Intravitreal aflibercept is approved in the treatment of neovascular age-related macular degeneration (AMD). The duration of its effect is higher than that of ranibizumab and bevacizumab but the effectiveness in patients who do not respond to these treatments is unknown.

**Purpose** To evaluate the efficacy of intravitreal aflibercept on best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in refractory AMD.

**Material and methods** Prospective observational study in patients diagnosed with AMD treated with aflibercept, who didn’t respond to ranibizumab and/or bevacizumab.

**Variables:** BCVA (ETDRS optotypes) and CRT obtained on optical coherence tomography (OCT; 3-D).

**Statistics:** Wilcoxon test for paired data and Student t test for paired data, considering results significant if p value <0.05.

**Results** A total of 27 eyes from 24 patients were included, 20 of them were females. The median age was 76.98 ± 9.9 years old. 12.5% of the patients received bilateral treatment. 22.2% of the eyes were previously treated with photodynamic therapy (PDT), 70.4% with ranibizumab (average 7.5 injections/eye, range 2–24) and 77.8% with bevacizumab (average 8 injections/eye, range 1–33). 52% of the eyes had been treated with both ranibizumab and bevacizumab.

The average number of aflibercept injections per eye was 3.3 (1–10). In 63% of the eyes there was an increase in BCVA, 7.5% of the eyes maintained the previous BCVA and 29.6% lost vision. ETDRS before and after treatment was 60.4 ± 2.5 vs. 62.3 ± 3.2 letters (p = 0.0504). 89% of eyes experienced a decrease in the CRT measured by OCT, 324.9 ± 22.2 vs. 245.5 ± 13.4 mcm (p < 0.01).

**Conclusion** Aflibercept is effective in refractive AMD. We obtained a better anatomical response than visual. Due to the duration of the study we expected a greater effect with repeated administrations.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**DI-037 TOXIC EPIDERMAL NECROLYSIS PROBABLY DUE TO CHEMOTHERAPY: A CASE REPORT**

I Rodriguez Legazpi, M García Verde*, L Fuster Sanjurjo, I Rodriguez Penin, AM Gonzalez Rodriguez. Ferrol Health Care Area, Hospital Pharmacy, Ferrol, Spain

10.1136/ehjopharm-2015-000639.225

**Background** Toxic epidermal necrolysis (TEN) is a rare but severe cutaneous adverse reaction with a high rate of mortality and morbidity.

**Purpose** To report a case of TEN after abiraterone and zoledronic acid exposure.

**Material and methods** Retrospective review of the electronic medical record (Ianus) and records of chemotherapy ordered and dispensed (Farmis and Silicon).

A literature search was conducted of keyword terms “abiraterone AND toxic epidermal necrolysis” and “zoledronic AND toxic epidermal necrolysis” in PubMed and EudraVigilance database until March 2014.

The suspicion was reported to the pharmacovigilance centre.

**Results** The case involved a 74 year-old male without any history of drug allergies, diagnosed with prostate adenocarcinoma in 2004, who received a second-line treatment with abiraterone

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Conflict of interest.
1,000 mg/day, prednisone 10 mg/day and zoledronic with dose adjusted for renal function. 48 h after zoledronic administration (15 days after starting abiraterone) fever and purpuric erythema appeared on the chest, but later extended involving the face, oral and nasal mucosa and back of the hands, sloughing of 70% of the body surface area.

SCORTEN scale, severity-of-illness score validated for TEN, was 24; mortality ≥60%.

The patient received supportive care without complications, after 2 weeks had been discharged.

No case reports were found in the published literature. This is the first case report in EudraVigilance for abiraterone and the seventh for zoledronic.

He was not re-exposed to the suspected offending agents zoledronic and abiraterone.

The causality assessment of TEN was regarded as possible by pharmacovigilance centre for both drugs.

Conclusion TEN is a rare life-threatening reaction; it is important for health care professionals to evaluate and report any severe reactions that may be associated with newly-marketed drugs.

Post-marketing drug experience is needed to develop an accurate safety profile.

REFERENCES
1 J Invest Dermatol 2008;128:35-44
2 Fam Hosp 2015;37:74-84

No conflict of interest.

DI-038 APPROPRIATE USE OF ANTI-DEMENTIA DRUGS IN THE ELDERLY: PRESCRIPTION PRACTICE EVALUATION IN NURSING HOMES

P Quillet*, C Mongaret, M Bonnet, M Legrand. CHU de Reims, Pharmacie Robert Debré, Reims, France

Background Anti-dementia drugs (ADDs), including cholinesterase inhibitors and memantine, are used to improve cognitive function in patients with Alzheimer’s disease. However, the literature analysis shows only short-term efficiency of these drugs, with questionable clinical relevance and risk of drug interactions increased by polypharmacy.

Purpose To investigate the prescription practice of ADDs and assess the appropriateness of these medicines in nursing homes.

Material and methods A prospective study was carried out over 60 days, based on all prescriptions received in the pharmacy from 3 nursing homes. Each prescription was analysed and patient records were consulted.

Results Of the 416 patients, 145 were treated with at least one ADD. The stage of the disease was: 11% mild, 26% moderate, 36% moderately severe, 27% severe. 75 patients (52%), including 3 at the mild stage, were receiving memantine monotherapy, marketed for moderate-to-severe stages. 41 patients (28%), including 3 at the severe stage, were receiving anticholinesterase drug monotherapy, marketed for mild-to-moderately severe stages. 29 patients (20%) were taking two drugs, memantine + anticholinesterase, including 3 at the mild and 4 at the severe stage. The treatment had been introduced more than 12 months ago for 114 patients, usually without clinical reassessment. It was often associated with benzodiazepines (n = 63), sometimes with antipsychotic (n = 7) or atropinic drugs (n = 4).

Conclusion The choice of ADD was appropriate for 91% of patients, but the treatment is rarely reassessed and in almost half of cases was associated with a drug known to cause acute cognitive impairment. This study will help us to develop a cross-functional approach between physicians and pharmacists to improve the prescribing of ADDs in nursing homes.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-039 PRELIMINARY STUDY TO ESTABLISH A NEW LINK BETWEEN HOSPITAL AND RETAIL PHARMACISTS TO FOLLOW UP PATIENTS TREATED WITH VITAMIN K ANTAGONISTS

Background Overdose of vitamin K antagonists (VKA) is the most common cause of iatrogenic adverse drug reactions in France. Since 2013, the French health authorities have asked retail pharmacists to conduct patient education sessions about VKA treatment.

Purpose To assess the operation of a new link between hospital pharmacists and retail pharmacists in order to improve patients’ knowledge of VKAs.

Material and methods A consultation focused on VKA treatment management was implemented in the cardiology unit. All patients treated with VKAs were invited to attend an information session (led by a nurse or a pharmacist). A patient information form (comorbidities, indication, initiation date, target INR values, caregiver) and a 10-item questionnaire on knowledge of their medicine (name of VKA and indication, monitoring, risk of overdose, daily management) were filled in after each consultation. Then, all this information were sent to the retail pharmacist by email/fax. After 1 month, this questionnaire was taken again during a consultation with the patient at the retail pharmacy. The questionnaires were then compared (before and after hospital discharge).

Results 11 patients were enrolled in this 2-month preliminary prospective study. 9 retail pharmacies agreed to participate. We received 7 complete answers from retail pharmacists. 4 patients’ knowledge of VKA treatment improved after the second consultation. How to deal with a missing dose and the importance of treatment monitoring were the 2 items least understood. Name of VKA, INR target values and time to take the drug were well understood. One of these 11 patients was hospitalised for drug overdose one week after hospital discharge.

Conclusion This first study is encouraging. To improve the follow-up of these patients, a link between pharmaceutical services and general practitioners should also be developed. More patients need to be enrolled to assess the efficiency of this collaboration in improving patient knowledge.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
LONG-TERM EFFECT OF AN INDIVIDUALISED MEDICATION PLAN WITH DRUG ADMINISTRATION RECOMMENDATIONS ON THE PATIENTS’ DRUG KNOWLEDGE

AFJ Send*, WE Haelefi, HM Selting. University Hospital of Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany

10.1136/ejhpharm-2015-000639.228

Background Inadequate patient knowledge of their drugs correlates with medication errors. An enhanced medication plan with recommendations about drug administration increased patients' drug knowledge at hospital discharge by 64% [Send et al. 2014]. However, because behavioural changes may soon be lost, the benefits of such patient education measures may be only short-term.

Purpose To assess the long-term effect of a medication plan with recommendations about drug administration in a prospective randomised controlled study in an outpatient setting.

Material and methods The study was conducted in four family practices with patients using five or more drugs. After inclusion, the patients’ current knowledge of their drugs was assessed using three standardised questions about their pharmacotherapy. Thereafter, patients were randomised to receive a medication plan either containing only standard information (i.e. drug name, active ingredient name, strength, drug regimen, dosage form; control group) or enhanced with drug administration recommendations and indications (intervention group). After approximately two months, patients were contacted again and their drug knowledge was reassessed.

Results Of the 120 patients enrolled (60 per group), 42 patients in the control group (8.4 ± 3.3 drugs) and 45 in the intervention group (7.4 ± 2.8 drugs; p = 0.12) completed the study. Drug knowledge was similar in both groups at the beginning of the study (43.7% vs. 40.7% correct answers; p = 0.63). After 2 months, patient drug knowledge had increased in the intervention group compared to the control group (65.2% vs. 46.0% p = 0.002) with 14 patients in the intervention group answering all three questions correctly compared to only 4 patients in the control group (p = 0.012).

Conclusion Positive long-term effects of patient education in the form of an active intervention are possible. A personalised medication plan enhanced with drug administration recommendations persistently increased the drug knowledge of patients with polypharmacy.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DI-042 ANTIBIOTIC CONSUMPTION IN PATIENTS WITH SEVERE PRESSURE ULCERS

K Perdikouri*, G Vasilepoulos, K Kei, K Nikola. Spilopoulos Hospital, Hospital Pharmacy, Athens, Greece; Spilopoulos Hospital, Nursing Services Division, Athens, Greece; Spilopoulos Hospital, Administrative Services Division, Athens, Greece; General Hospital of Chest Diseases "Sotira", Hospital Pharmacy, Athens, Greece

10.1136/ejhpharm-2015-000639.230

Background Pressure ulcers are a painful, debilitating and potentially serious outcome of failures of routine medical and nursing care, which represent a significant unnecessary cost to the healthcare system. In contrast with other adequately described guidelines (e.g. positioning, support surfaces, nutrition, wound dressings), limited data concerning the systematic use of antibiotics in these cases has been reported.

Purpose To investigate the use of antibiotics in patients with severe pressure ulcers (of grade 3 or 4) being nursed in a hospital ward, specialised in admitting patients who require prolonged continuation of treatment (after having been hospitalised in an acute care facility).

Material and methods Data concerning antibiotic consumption (converted to daily defined doses, DDDs) in this clinic in the year 2013 was extracted from the hospital pharmacy Data Information System. Data concerning antibiotic use in the group of patients under investigation, was compared to the total antibiotic use in the clinic in the same year.
Drug information and pharmacotherapy

consumption in this clinic over the same period of time, to generate percentages of antibiotic use these patients.

Results Although only 2.5% of inpatients (though accounting for the 10% of occupied bed days) suffered from pressure ulcers of grade 3 or 4 at the time of their admittance for continuation of treatment, they required a significant percentage of the total DDDs of antibiotics consumed in that clinic, e.g. 90% of colimycin, 71.5% of piperacillin/tazobactam, 100% of teicoplanin, 100% of ceftipime, 87% of amoxicillin/clavulanic, 62% of vancomycin, 37% of meropenem, 44% of cefazidine and 43% of clindamycin.

Conclusion Given the concomitant morbidities in these patients, it is difficult to define pressure ulcers as the primary indication for the systematic use antibiotics; however the presence of an ulcer of such a grade is substantially equivalent to a life-threatening infection, hence is in accordance with the high antibiotic consumption reported.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-043 BIOLOGICS ARE A NEW CHALLENGE FOR HOSPITAL PHARMACISTS - PILOT STUDY OF PATIENT ADHERENCE

1Et Borzsa*, 2L Botz, 3A Fittler, 4C Kiss. 1Csólnoky Ferenc Regional Hospital, Veszprém, Hungary, Veszprém, Hungary; 2University of Pécs Medical School, Department of Pharmaceutics and Central Clinical Pharmacy, Pécs, Hungary; 3University of Pécs Medical School, Department of Rheumatology, Veszprém, Hungary

Background Dispensing biological drugs has become an exclusive competency of hospital pharmacists both in- and outpatient in recent years in Hungary. Biologicals are the most important treatment for patients with rheumatoid diseases, but poor adherence can undermine the effectiveness of these medicines. Although routine monitoring has been recommended, there are no standardised methods to track adherence to biologicals.

Purpose Pilot study to measure rheumatology outpatients’ adherence to biologicals, to identify medicines errors, to improve storage and use so they are safe and effective and to identify critical intervention points for hospital pharmacists.

Material and methods A 31-item questionnaire using a four point Likert scale was developed based on the Rheumatology Compliance Questionnaire. Questions focused on factors modifying treatment and adherence. Patients were interviewed by a hospital pharmacist. The data were evaluated by descriptive analysis and chi-square test.

Results 106 rheumatology patients filled in our questionnaire; 21.7% of respondents were identified as non-adherent. Neither side effects (p = 0.303), therapeutic switch (p = 0.578) nor complexity of treatment (p = 0.712) correlated significantly with adherence category. Patient-centred care significantly influenced adherence (p = 0.057). A higher rate of adherence was measured amongst patients receiving an infusion in the hospital (67%), than those self-administering biologicals at home (59%, p = 0.260). Numerous medicines use errors were detected during the personal interviews. 29% of responders found patient education ineffective, 19% emphasised the lack of patient-centred care.

Conclusion Adding a pharmacist to the healthcare team has many benefits in improving adherence. Based on our findings hospital pharmacists must focus on:

• identification of non-adherent patients during personal interviews
• providing information about storage and administration of biologicals at home
• the elderly, who do not accept the invasive nature of administration

As an outcome of our study a specific patient leaflet has been developed aiming to optimise outcomes and minimise risks of biologicals used in rheumatoid diseases.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DI-044 USE OF KETAMINE RINSING SOLUTION FOR REFRACTORY PAIN IN A PAEDIATRIC ONCOLOGY PATIENT: A CASE REPORT

1D Fernández Ginés, 2P Nieto Guindo, 3TB Rodríguez Cuadros, 2F Verdejo Reche*, 2A Llera García, 2F Sierra García. 1Hospital Torrecárdenas, Almería, Spain; 2Hospital Torrecárdenas, Pharmacy, Almería, Spain; 3Hospital Torrecárdenas, Family and Community Medicine, Almería, Spain

Background Refractory cancer pain is often difficult to manage. Ketamine is a drug with evidence of efficacy in the treatment of chronic cancer pain.

Purpose To evaluate the efficacy and safety of ketamine rinse solution in paediatric patients with refractory cancer pain.

Material and methods We report on a paediatric oncology patient who presented with painful conditions refractory to conventional analgesic treatment. Intravenous ketamine was diluted to a final concentration of 10 mg/mL in sterile water to rinse. Mouth rinses with 3 mL (30 mg) once daily was prescribed, specifying two rinses daily if required. Efficacy was measured on a visual analogue scale for pain (VAS pain), the Clinical Global Impression – Global Improvement (CGI-I) Scale, and the reduction of dose or withdrawal of analgesic drug base. Safety was measured in terms of variation in some clinical parameters (blood pressure, heart rate, oxygen saturation) and onset of drug-related symptoms (feeling drunk, drowsiness, nausea, vomiting, nyctagmus or hallucinations).

Results The case of a male patient 13 years of age [33 kg and 143 cm] is presented. The patient was receiving morphine chloride rescue until the treatment; morphine rescue was no longer needed on the second day of initiating treatment. The VAS pain score before rinsing was 9 and remained on 2 for 24 h after the rinse was applied, achieving a score of 0 on day four. CGI-I Scale at the end of the treatment score was 1 (Very much improved). The patient had no changes in clinical parameters. The total rinsing treatment time was four days, requiring two rinses the first day only. The pain stopped within 10 min of beginning the rinsing.

Conclusion Ketamine rinsing was effective and safe in our paediatric oncology patient with painful conditions refractory to standard analgesic treatment. Further studies are needed to strengthen our results.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Specially thanks Dr Manuel Cortiñas

No conflict of interest.
Drug information and pharmacotherapy

**DI-045** SHOULD PATIENTS OF THAI, HAN CHINESE AND HONG KONG CHINESE ORIGIN BE TESTED FOR THE HLA-B*1502 ALLELE PRIOR TO PHENYTOIN TREATMENT?

R.E-Sharkawi*, Aberdeen Bro Morgannwg University Health Board, Pharmacy Department, Swansea, UK

10.1136/ehjpharm-2015-000639.233

**Background** The potentially fatal adverse drug reactions Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/ TEN) are ten times higher in Thai, Han Chinese and Hong Kong Chinese (T/HC/HKC) than the Caucasian population. This is associated with the presence of the human leukocyte antigen HLA-B*1502 which is present in 6.1%/9%/7.2% of the T/HC/ HKC populations respectively. It is already established that carbamazepine (CBZ)-induced SJS/TEN is greater in patients with HLA-B*1502. The Medicines and Healthcare products Regulatory Agency and the Food and Drug Administration advise testing for HLA-B*1502 prior to initiation of CBZ in T/HC/HKC patients. They recommend that phenytoin (PHT) should be avoided if the patient is known to have HLA-B*1502 but do not advise routine testing for the allele. However, there is increasing evidence regarding the link between HLA-B*1502 and PHT-induced SJS/TEN that may alter the management of patients of T/HC/HKC origin.

**Purpose** To assess the association of HLA-B*1502 and PHT-induced SJS/TEN in patients of T/HC/HKC origin.

**Material and methods** A literature search was performed on PubMed and ScienceDirect databases until October 2014, using search words “phenytoin”, “HLA-B*1502”, “SJS” and “TEN”. Other articles used were those cited in papers identified via the literature search, and analysis was restricted to systematic reviews and meta-analyses to establish the odds ratio (OR).

**Results** In total, 45 cases and 217 controls were assessed. There was an increased risk of PHT-induced SJS/TEN in patients with the HLA-B*1502 allele compared to those who did not possess the allele. This was statistically significant with OR = 5.87, 95% confidence intervals, 2.87 to 12.04, p value < 0.0001.

**Conclusion** There is strong evidence associating PHT-induced SJS/TEN and individuals with HLA-B*1502 of T/HC/HKC origin. The occurrence of SJS/TEN could be prevented by routine testing for the HLA-B*1502 allele in patients of T/HC/HKC origin and avoiding use of phenytoin treatment in this subset of patients.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**DI-046** INTRAVITREAL BEVACIZUMAB VS. LASER PHOTOCOAGULATION IN RETINOPATHY OF PREMATURITY

D Fernández Ginés, H Mateo Carrasco, TB Rodríguez Cuadros, NI Nieto Guindo, VE Verdejo Reche*, Hospital Torrecárdenas, Almería, Spain; NH Northampton General Hospital, Pharmacy, Northampton, UK; NH Hospital Torrecárdenas, Family and Community Medicine, Almería, Spain; NH Hospital Torrecárdenas, Pharmacy, Almería, Spain

10.1136/ehjpharm-2015-000639.234

**Background** Laser photocoagulation (LPC) is considered the standard treatment for retinopathy of prematurity (ROP), but LPC is destructive, causes complications, and does not prevent all vision loss. Recently, bevacizumab (a vascular endothelial growth factor inhibitor) has been used with po-itive results.

**Purpose** To evaluate the efficacy and safety of intravitreal bevacizumab vs. LPC in preterm infants with ROP grades 1 to 3+.

**Material and methods** Ten-month retrospective study that included patients with gestational age of less than 30 weeks diagnosed with ROP grades 1 to 3+, and weight <1,500 g. The subjects received either a single dose of bevacizumab 0.625 mg at three months post-gestational age, or LPC at four-to-eight weeks. The primary efficacy and safety endpoints for both arms of treatment were: complete vascularisation (CV) in both eyes, and absence of adverse events.

**Results** Twelve patients were included, six for each treatment arm The proportion of females was 50% for the bevacizumab group and 66.6% for the LPC group. Mean gestational age was 25 weeks [23–29] in both groups. Efficacy: CV was achieved in five cases (83.3%) in the bevacizumab arm, and in two patients (33.3%) of those receiving LPC. Safety: no adverse effects were observed in the antiangiogenic treatment arm. In the LPC group, two cases of retinal detachment (inoperable in one case), one of localised reversible haemorrhage, one of retinal fibrosis, and one of laser-related scarring were found.

**Conclusion** In this cohort, intravitreal bevacizumab was more effective and safer than LPC in the treatment of ROP grades 1–3+. This is consistent with previous published studies, and supports the use of the antiangiogenic over LPC in the treatment of ROP.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**DI-047** ANALYSIS OF THE USE OF LINEZOLID IN A TERTIARY LEVEL HOSPITAL IN SPAIN

S Fernández Cañabate*, L García López, V Cabezas Martín, E Cardaba Perez, S Fernández Peña, C Cardaba Perez, J Varela Gonzalez-Aller. Hospital Clínico Universitario de Valladolid, Pharmacy, Valladolid, Spain

10.1136/ehjpharm-2015-000639.235

**Background** Linezolid is the first oxazolidinone available for clinical use. Linezolid is indicated in the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) or Streptococcus pneumoniae; and complicated skin and skin structure infections without concomitant osteomyelitis, caused by MRSA, Streptococcus pyogenes, or Streptococcus agalactiae; Vancomycin-resistant Enterococcus faecium infections; uncomplicated skin infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain their effectiveness, linezolid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial treatment.

**Purpose** To evaluate the appropriateness of linezolid prescribing in our hospital.

**Material and methods** Retrospective study of patients treated with linezolid from January 2013 to April 2014 who continued with linezolid at discharge. Demographic and clinical data included age, sex, previous treatment, indication for linezolid, duration, side effects, antibiogram and clinical outcome.
Results 69 patients were treated with linezolid (median age 67.4 years, 47/69 male). Median days with treatment was 20.41. The indication was the most prevalent infection of the skin and soft tissues (36/69 patients). In 42% of cases, indications did not conform to those adopted by the regulatory agency. Linezolid treatment was used as directed (38/69) mainly against coagulase-negative Staphylococcus. Clinical cure was obtained in 57/69 of cases, and microbiological cure in 36/69. Treatment-related adverse reactions were reported in 2 patients. Thrombocytopenia, classified as conditional by the modified Karch-Lasagna algorithm, forced the discontinuation of linezolid and change to amoxicillin/clavulanate. A pruritic urticarial rash resolved with hydroxyzine. 3 patients died during the infectious episode.

Conclusion The effectiveness and safety of linezolid is similar to that described in the assays. Off-label use and the large number of empirical treatments mean that treatment strategies should be developed.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-048 MANAGEMENT OF CYCLOPHOSPHAMIDE-INDUCED SYNDROME OF INAPPROPRIATE ANTI DIURETIC HORMONE SECRETION IN A PATIENT WITH LYMPHOCYTIC B LYMPHOMA

I Viguera-Guerra*, M Garzás, F Franco-García. Hospital Universitario Reina Sofía de Córdoba, Servicio de Farmacia, Córdoba, Spain
10.1136/ejhpharm-2015-000639.236

Background Cyclophosphamide is an alkylating agent widely used in haematology. Among its adverse effects we find infections, immunosuppression, hypersensitivity reactions, haemorrhagic cystitis and neurological toxicity. The appearance of syndrome of inappropriate antidiuretic hormone secretion (SIADH) has also been described rarely.

Purpose To report a case of SIADH induced by cyclophosphamide in an elderly patient with lymphocytic B lymphoma.

Material and methods An 87 year-old man was diagnosed with lymphocytic lymphoma in June 2013. Treatment with chlorambucil 0.1 mg/kg/day was started with progression detected on day 9 of treatment. Second line with COP (cyclophosphamide 750 mg/m² and vincristine 1 mg) was then started resulting in severe neutropenia and a count of 640 cells/mm³. On day 23 the patient was hospitalised with pneumonia, severe hyponatraemia, decompensated cardiac insufficiency and hypoxemia. SIADH induced by cyclophosphamide was suspected.

Results Laboratory tests showed: [Na⁺] = 119 mEq/L and Osmoᵦ = 282 mOsm/Kg. Cyclophosphamide was stopped and fluid restriction and administration of hypertonic saline was commenced. Off-label treatment with bendamustine 90 mg/m² day 1 and 2 was started on day 55 (not considering fludarabine because of the history of neutropenia and pneumonia in this patient), delivering a total of 3 cycles. On computerised tomography of day +139 adenopathies had disappeared. The Karl-Lasagna algorithm indicated a probable association between SIADH and cyclophosphamide administration. The case was reported to the Andalusian Pharmacovigilance Centre and given reference number OL-2819.

Conclusion It is highly important to closely monitor plasma sodium levels during treatment with cyclophosphamide for the possible occurrence of SIADH. Bendamustine treatment in mono-therapy provided a safe and effective alternative in this patient.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-049 DRUG INTERACTION BETWEEN LINEZOLID AND SEROTONERGIC AGONISTS: THE APPEARANCE OF SEROTONIN SYNDROME

V Benito Ibáñez*, M Ubela Iglesias, MA Machín Morón, R Martínez de Arriba, I Izquierdo Acosta, M Vivas Cal, S Barbardillo Villaneuva, O Álamo González. University Hospital of Burgos, Hospital Pharmacy, Burgos, Spain
10.1136/ejhpharm-2015-000639.237

Background Linezolid is an antibiotic which has been reported to possess monoamine oxidase (MAO) inhibitory effects. According to the prescribing information, it should not be used with MAO inhibitors, considering that such drugs may enhance its toxic effects, including side effects such as hypertension and serotonin syndrome (SS). SS is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system. It may include mental status changes, autonomic dysfunction and neuromuscular abnormalities.

Although this interaction is well reported, the MAOI properties of linezolid are not very well known.

Purpose To detect interactions between linezolid and serotonergic modulators (X risk according to the Lexi Comp classification) and the appearance of SS.

Material and methods An observational retrospective study of patients treated with linezolid was made over two months (January–February 2014). The clinical history of every patient was checked, looking for associated prescriptions with serotonergic agonists in order to detect symptoms related to the SS. The possibility of other drug interactions was ruled out.

Results In two months 90 patients received antimicrobial treatment with linezolid (aged 15 to 89 years, 63.3% were male). 18.8% of the patients were also taking serotonergic psychiatric drugs such as clomipramine, trazodone, citalopram, escitalopram, venlafaxine and aripiprazole.

Looking over the clinical history in these patients, it was found that four of them met clinical criteria for SS (confusional states, agitation and high heart rate). None of the symptoms were referred as having an iatrogenic cause.

Conclusion Although an interaction was detected that can lead to symptoms related to SS, neither of the drugs were referred to as possible sources of an interaction in the clinical history.

We strongly recommend a pharmacist check of the whole treatment with the purpose of informing the physician about any interactions of this type. Moreover, some patients will continue the treatment with oral linezolid at home, and they should be made aware of any possible symptoms.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-050 PAMIDRONATE TREATMENT FOR HYPERCALCEMIA IN A PREMATURE NEWBORN

1D Fernández Ginés, 2TB Rodríguez Cuadros, 3P Nieto Guindo, 3F Verdejo Reche*. 1Hospital Torrecárdenas, Almería, Spain; 2Hospital Torrecárdenas, Family and Community Medicine, Almería, Spain; 3Hospital Torrecárdenas, Pharmacy, Almería, Spain
10.1136/ejhpharm-2015-000639.238

Background Pamidronate is a bisphosphonate used to treat hypercalcemia. In 750 mg/m² and vincristine 1 mg) was then started resulting in severe neutropenia and a count of 640 cells/mm³. On day 23 the patient was hospitalised with pneumonia, severe hyponatraemia, decompensated cardiac insufficiency and hypoxemia. SIADH induced by cyclophosphamide was suspected.
Background
Hypercalcaemia can cause life-threatening complications. Pharmacological treatment of severe hypercalcaemia is complicated by lack of experience with some effective medicines such as bisphosphonates in newborns.

Purpose
To describe the pharmacotherapeutic management of pamidronate in severe hypercalcaemia of a premature newborn.

Material and methods
We report on a preterm infant [weight: 1.080 kg, length 38 cm] who had required total parenteral nutrition (TPN) since birth. In routine blood tests, serum calcium was 15.6 mg/dl on the seventh day of life, reaching as high as 17.2 mg/dl as a consequence of suspected adrenal insufficiency of central origin.

Results
Hypercalcaemia persisted despite the conventional treatment for excessive calcium, including removal of calcium from the TPN. The patient received intravenous pamidronate (1 mg/kg) for 1 day. Pamidronate 6 mg was diluted in 30 millilitres of 5% dextrose saline solution, only 10 millilitres were infused in 4 h. His serum calcium level decreased significantly, and about 15 h later, his total calcium level normalised (10.6 mg/dl). His serum calcium concentration returned to normal without any adverse reactions.

Conclusion
Intravenous pamidronate appeared to be a safe and effective treatment for severe hypercalcaemia in a premature newborn.

REFERENCES AND/OR ACKNOWLEDGEMENTS
To my pharmacist colleagues.

No conflict of interest.

DI-051 EFFECTIVENESS AND SAFETY OF TELAPREVIR AND BOCEPREVIR FOR HEPATITIS C IN LIVER TRANSPLANT PATIENTS
10.1136/ejhpharm-2015-000639.239

Background
There are limited data that tackle safety and effectiveness of the triple treatment based on protease inhibitors (telaprevir or boceprevir) in liver transplant patients.

Purpose
To describe effectiveness and safety of the triple treatment used by liver transplant patients.

Material and methods
We performed an observational retrospective study, from November 2012 to September 2014. Transplant patients who started triple treatment before May 2013 were included. Baseline variables included demographic data, treatment and infection related data, and laboratory data.

The effectiveness outcome was sustained virological response (SVR). Safety outcomes included haematological toxicity and skin toxicity. Moreover, we recorded the requirements to treat those side effects.

Results
Seven patients were included; 100% were male. The average age of patients was 57.5 (standard deviation 4.2). Telaprevir was used in 3 (42.9%) patients and boceprevir in 4 (57.1%).

As far as grade of fibrosis was concerned, 6 (85.7%) patients were cirrhotic or F4 and 1 (14.3%) patient was F2. Median fibroscan value was 16.6 Kpa (IQR 12.1–28.6 Kpa). Two (28.6%) patients were treatment-naïve, 1 (14.3%) patient was a null responder and 4 (57.1%) patients were relapsers from previous treatment.

At the beginning of treatment the median haemoglobin level was 13.6 g/dl (IQR 12.1–16.4 g/dl), the median neutrophil count was 3.0/mL (1.2–4.8/mL) and the median platelet count 164/mL (126–197/mL). Four (66.7%) patients achieved SVR.

One patient died during treatment.

Haematological toxicity included anaemia (85.7%), neutropenia (28.6%) and thrombocytopenia (42.9%). Skin rash was present in 2 (28.6%) patients. Five (71.4%) patients required ribavirin dose reductions, erythropoietin and blood transfusions. The median number of red blood units administered was 28 (IQR 3–31).

Conclusion
Despite the severe disease of the included patients, we found that response rates to triple treatment exceeded 60%. As the treatment-related anaemia was considerable, most of the patients required supportive care.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Conflict of interest.

DI-052 ANALYSIS OF HEPATITIS B VIRUS REACTIVATION AFTER CYTOTOXIC CHEMOTHERAPY WITH RITUXIMAB
L García López*, S Fernández Calabuig, V Cabezas Martín, S Fernández Peña, T Sánchez Sánchez. Hospital Clínico Universitario, Servicio de Farmacia, Valladolid, Spain
10.1136/ejhpharm-2015-000639.240

Background
Reactivation of hepatitis B virus (HBV) is a well-recognised complication in patients with chronic HBV infection who receive cytotoxic or immunosuppressant treatment.

Patients undergoing rituximab treatment should be checked routinely for HBV serologic markers and serum HBV DNA levels and this is not a fully established practice.

Purpose
To assess whether prophylaxis to prevent HBV reactivation in patients treated with rituximab is being initiated in line with the recommendations of reference guides.

Material and methods
Patients treated with rituximab from January 2013 to May 2014 were selected, the HBV serology reviewed, and whether they received prophylaxis with antivirals.

Results
94 patients received rituximab, 9 patients were excluded due to death. Serology requested at baseline was HBs Ag and anti-HBc. 72/83 (87%) patients were seronegative. 11/83 (13%) were positive for HBsAg and anti-HBc. 6/11 (54%) had been given prophylaxis, two with lamivudine 100 mg/day, two with entecavir 0.5 mg/day, one with Tenofovir 245 mg/day and the last with tenofovir/emtricitabine. In two of the cases treatment began after rituximab had been started.

5/11 received no prophylaxis. In one HBV reactivation occurred within three months of the start of rituximab with blood tests becoming positive, significant increase in serology and DNA but without clinical involvement. This patient received entecavir 0.5 mg/day following reactivation.

Conclusion
Every patient undergoing rituximab treatment should be checked for HBsAg and total anti-HBc before the initiation of treatment.

It is very important to identify patients who have a serological risk of developing fulminant hepatitis with associated HBV reactivation. These are patients with HBs Ag – with anti-HBc+. Prophylaxis should begin one week before and continue for up to 6–12 months after the end of rituximab treatment.

REFERENCE
1 Guidelines: Journal of Hepatology
No conflict of interest.
**DI-053** EVALUATION OF TREATMENT ADHERENCE WITH RILPIVIRINE/EMTRICITABINE/TENOFOVIR

A Trujillano Ruiz, J Franco Miguel, M García Cornejo, E Benal Morell, C Caballero Requejo*, CM Valencia Soto, M Ontelente Candela, C García-Molina Sáez. Hospital Universitario Reina Sofia, Hospital Pharmacy, Murcia, Spain

10.1136/ejhpharm-2015-000639.241

**Background** Rilpivirine is a recently authorised antiretroviral. Adherence is essential in this kind of drug.

**Purpose** To evaluate treatment adherence with rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) using the SMAQ questionnaire and pharmacy dispensing records (FDR) and the correlation between these in HIV/AIDS mono-infected patients.

**Material and methods** Propective observational study. We included patients treated with RPV/FTC/TDF from September 2013 until September 2014 with adherence data available of at least 3 months. Demographics data and reason for treatment were collected.

Adherence was calculated across the SMAQ questionnaire (qualitative and semi-quantitative) and FDR, considering the patient adherent when any of these parameters was ≥95%. The correlation between the methods was assessed using the kappa (k) index.

**Results** 33 patients started treatment with RPV/FTC/TDF during the above-mentioned period. 21 were included in the study. 71% were men (average age: 40 ± 10 years). 38% were treatment-naive and the rest were changes of therapeutic strategy (33% adverse reactions and 29% simplification of treatment strategies).

26% of patients were considered adherent from a qualitative point of view in the SMAQ questionnaire, 76% from a semi-quantitative perspective and 95% via the FDR. The results between the three analysis only coincided in 6 patients.

As for the results of k index, we observed the following strength of agreements: fair between the SMAQ quantitative and qualitative questionnaires (k = 0.22) and slight between the SMAQ qualitative questionnaire and FDR (k = 0.04) and between semi-quantitative SMAQ and FDR questionnaire (k = 0.01).

**Conclusion** Our study highlights a low adherence to treatment (B) 1 September–15 September’14 performed in the Unit-Dose Drug Dispensing System (UDDDS) with manual prescription, nurse transcription and subsequent validation by a pharmacist, in a level-III hospital (411 beds, 32.8% of them with UDDDS). During period B the pharmacist wrote an advisory note in the CMR (MambrixxIV 5.4.4) called “Pharmaceutical Care”, in addition to submitting the printed PR form (PPRF) with the prescription; while during period A, only the PPRF was sent. End points: ward [medical, surgical, medical-surgical (MS)], drug, type of PR, degree of acceptance. Data collection and processing: Farmatools-Dominion, Excel.

**Results** 93 PRs were recorded [period A (38 PRs, 32 patients, 74.9 ± 13.4 years old; 63.2% male); period B (55 PRs, 47 patients, 72.8 ± 17.6 years old, 74.5% male)]. Type of ward: medical (39.5% A vs. 36.4% B), surgical (57.9% A vs. 52.7% B) and MS (2.7% A vs. 10.9% B). Main drugs involved: proton pump inhibitors (15.8% A vs. 9.1% B), potassium-fluid replacement treatment (15.8% A vs. 5.5% B), not included in guide (NIG) (42.1% A vs. 36.4%B). Major types of PR: substitution of medicines NIG for available therapeutic alternatives (36.8% A vs. 34.5% B), dose/dosage regimen modification (10.5% A vs. 16.4% B), drug interactions (10.4% A vs. 8.9% B), monitoring hypo/hyperkalaemia (21.1% A vs. 5.5% B). The degree of acceptance was 63.3% A vs. 79.5% B.

**Conclusion** The QMS identified weak points in order to establish IA. Moreover, sharing the CMR and making it accessible to health personnel was found to improve coordination and communication of care, creating an opportunity for pharmacists to develop a comprehensive patient-centred plan and to promote their integration in the interdisciplinary healthcare team.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**DI-055** HAEMATOLOGICAL AND CUTANEOUS ADVERSE EVENTS ASSOCIATED WITH CHRONIC HEPATITIS C TREATMENT

V Granja Bernal*, C Sanchez Gil, V Collados Arroyo, MI Aguilera Vizcaino. Hospital Infanta Elena, Pharmacy, Valdemoro, Spain

10.1136/ejhpharm-2015-000639.243

**Background** To increase the pharmacist presence in the computerised medical record (CMR) emerged as one of the improvement actions (IA) when internal customer feedback (satisfaction surveys to medical staff) was examined during the implementation of a Quality Management System (QMS) based on ISO 9001:2008 standard in a Pharmacy Service.

**Purpose** To analyse the degree of acceptance (DA) of the pharmaco-therapeutic recommendations (PRs) after pharmacist participation in the CMR.

**Material and methods** 4-week ambispective quasi-experimental study (pre-intervention (A) 15 August–30 August’14; post-intervention (B) 1 September–15 September’14) performed in the Hospital Infanta Elena Rehabilitation Hospital. The study (pre-intervention (A) 15 August–30 August’14; post-intervention (B) 1 September–15 September’14) performed in the Unit-Dose Drug Dispensing System (UDDDS) with manual prescription, nurse transcription and subsequent validation by a pharmacist, in a level-II hospital (411 beds, 32.8% of them with UDDDS). During period B the pharmacist wrote an advisory note in the CMR (MambrixxIV 5.4.4) called “Pharmaceutical Care”, in addition to submitting the printed PR form (PPRF) with the prescription; while during period A, only the PPRF was sent. End points: ward [medical, surgical, medical-surgical (MS)], drug, type of PR, degree of acceptance. Data collection and processing: Farmatools-Dominion, Excel.

**Results** 93 PRs were recorded [period A (38 PRs, 32 patients, 74.9 ± 13.4 years old; 63.2% male); period B (55 PRs, 47 patients, 72.8 ± 17.6 years old, 74.5% male)]. Type of ward: medical (39.5% A vs. 36.4% B), surgical (57.9% A vs. 52.7% B) and MS (2.7% A vs. 10.9% B). Main drugs involved: proton pump inhibitors (15.8% A vs. 9.1% B), potassium-fluid replacement treatment (15.8% A vs. 5.5% B), not included in guide (NIG) (42.1% A vs. 36.4%B). Major types of PR: substitution of medicines NIG for available therapeutic alternatives (36.8% A vs. 34.5% B), dose/dosage regimen modification (10.5% A vs. 16.4% B), drug interactions (10.4% A vs. 8.9% B), monitoring hypo/hyperkalaemia (21.1% A vs. 5.5% B). The degree of acceptance was 63.3% A vs. 79.5% B.

**Conclusion** The QMS identified weak points in order to establish IA. Moreover, sharing the CMR and making it accessible to health personnel was found to improve coordination and communication of care, creating an opportunity for pharmacists to develop a comprehensive patient-centred plan and to promote their integration in the interdisciplinary healthcare team.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.
Material and methods Retrospective observational study in which the authors collected cutaneous and haematological AEs reported by all HCV patients between January 2013 and April 2014. The CTCAE V 4.0 scale was used to evaluate the severity of AEs.

Results 30 patients received HCV treatment, 18 men and 12 women. The average age was 46.5 ± 8.4 years. 13 (43.3%) were treated with TT; 6 with telaprevir and 7 with boceprevir. 15 patients (50%) had anaemia (7 with TT), which became grade 2 (<10 g/dL) in 5 patients (30%) treated with TT (2 with boceprevir and 3 with telaprevir). These five patients required ribavirin dose reduction. No patient required transfusion or erythropoietin treatment. 17 (56.7%) developed thrombocytopenia (10 treated with TT). Only one patient required peginterferon dose reduction to 135 mcg because he had a platelet count <50,000/μL. 21 patients (70%) had skin reactions, of which 10 (47.6%) were treated with TT. Skin reactions became grade 2 in 6 patients with TT in comparison with 2 patients with dual therapy.

Conclusion The frequency of observed cutaneous and haematological AEs in our study fits our expectations in the light of the published studies. Considering the higher cost of these treatments and the higher risk of non-adherence due to their AEs, pharmacotherapy follow-up on these patients is essential.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-056  DYSPNEA INVOLVING DIMETHYL FUMARATE: FIRST CASE REPORT

1A Picard, 1B Leroy, 1C Casulli, 1A Grandvuillenin, 1J Coutey, 1J Penaud, 1Centre Hospitalier William Morey, Pharmacie, Chalon Sur Saône, France; 2Centre Hospitalier William Morey, Neurologie, Chalon Sur Saône, France; 3CHU Dijon, Pharmacovigilance, Dijon, France

Background Tecfidera (dimethyl fumarate, DMF) has recently been approved for multiple sclerosis. The most common adverse reactions reported in clinical trials are flushing and gastro-intestinal events. Indeed, dose reduction is necessary for the first 7 days from 240 mg to 120 mg bid to minimise the occurrence of these adverse effects.

Purpose We report on a patient treated with DMF who experienced dyspnoea after the dose was increased.

Material and methods An adverse reaction was reported from the Department of Neurology. The Naranjo algorithm was used to estimate the probability score.

Results A 48-year-old woman with no medical or surgical history was given DMF for multiple sclerosis started at a dose of 120 mg bid. The dose was increased on day 7 to a dose of 240 mg bid.

24 h later, she experienced dyspnoea that required hospitalisation on day 20. Dyspnoea was classified as NYHA stage III.

93% oxygen saturation, 68 mmHg pO2, 48 mmHg pCO2 were observed during hospitalisation while electrocardiogram was normal. Biological assessment with negative troponin, D-dimer, CRP and a normal pulmonary radiography excluded pulmonary embolism.

DMF was reduced to 120 mg bid and complete resolution was achieved 24 h later. Two months later, pulmonary function tests were normal. New dose escalation led to a recurrence of dyspnoea with breathlessness in the next 24 h.

DMF was finally stopped. The Naranjo score was 9 so this ADR was considered as definite.

Conclusion This was the first case of dyspnoea reported to the French Pharmacovigilance system. Since this event, another case of dyspnoea involving DMF has been reported in our hospital. It seems important to monitor the tolerance of DMF treatment particularly after the dose escalation, whatever the symptoms. It may be necessary to manage some adverse reactions by reducing the dose.

REFERENCE

No conflict of interest.

DI-057 THE CONTRIBUTION OF THE HOSPITAL PHARMACY TO THE HEALTHCARE OF PATIENTS ON ANTIRETROVIRAL THERAPY: AN IDENTIFICATION OF PATIENT NEEDS AND AN EVALUATION OF SERVICES PROVIDED

1M Malliarou, 2N Pitsounis, 3D Gennimatas, 4Marini, 5Pentepetsis, 5P Peisteraki, 1M Chini, 1L Lazanas. 1Korgialenio-Benakio Red Cross General Hospital, 3rd Department of Internal Medicine-Infectious Diseases Unit, Athens, Greece; 2Korgialenio-Benakio Red Cross General Hospital, Pharmacy, Athens, Greece; 3VIANEX, Department of Business Intelligence & Data Management, Athens, Greece

Background In our country, HIV-positive ambulatory patients are monitored by the Infectious Diseases Units of designated hospitals, monthly. Antiretroviral medication (ART) is prescribed in each Unit and dispensed at the hospital pharmacy. An extracurricular collaboration of the two departments, has been implemented, since November 2010 and its impact is assessed in this study.

Purpose To evaluate the contribution of the collaboration between the hospital pharmacy and the Infectious Diseases Unit to the healthcare of HIV-positive patients and identify their needs.

Material and methods 210 patients of the Infectious Diseases Unit, receiving ART from the hospital pharmacy participated in the study. A social worker employed by the Infectious Diseases Unit but offering services in the hospital pharmacy assisted in the dispensing of the medications. Demographic data and evaluation of provided services were collected through the use of a questionnaire and were analysed by EXCEL®.

Results Among the patients, 91% were male, 76% had an income, 11% were Welfare beneficiaries, 23% were unemployed and 7% had no insurance. An 80% reported difficulties in issuing and renewal of a Healthcare Card. An 86% considered the services offered either very good or exceptional. Moreover, 78% welcomed the presence of a social worker in the pharmacy, providing help in HIV related issues (88%) and solutions in socioeconomic matters (86%). An 83.5% wished that the pharmacy dispensed medication more than twice a week. Most of them worried about the possibilities of antiretroviral shortage due to the economic crisis (76%) and having to take generics (49%).

Conclusion The extracurricular cooperation between the two departments of the Hospital contributed to the improvement of the provided healthcare services to patients under ART in our country. Problems and needs were identified and most of them addressed. The presence of the social worker in the hospital pharmacy was considered effective and valuable. The collaboration is on-going.
EXPERIENCE WITH DIAZOXIDE IN CONGENITAL HYPERINSULINISM

J Mateo Carmona*, I Menéndez Naranjo, M Almendral Rivadeneyra, M Muñoz Contreras, A Tomas Luiz, M Valderrey Pulido. University Hospital Arrixaca, Pharmacy, Murcia, Spain

10.1136/ehjpharm-2015-000639.246

Background Diazoxide is indicated for the treatment of symptomatic hypoglycemia hyperinsulinism of diverse aetiology and diazoxide is used in congenital hyperinsulinism in neonates and infants.

Purpose To describe the experience of diazoxide in the treatment of congenital hyperinsulinism in tertiary hospital.

Material and methods We describe the case of two infants with persistent hypoglycemia due to hyperinsulinism. The following data were collected: age, sex, blood glucose, pre-treatment, dose and duration of treatment, and side effects.

Results In both cases the starting dose was 10 mg/kg/day divided in three doses.

Case 1: Infant 9 month old with blood glucose of 30 mg/dL with a diagnosis of focal congenital hyperinsulinism by pancreatic hyperplasia. He received dextrose infusions maintaining persistent hypoglycemia in 40–55 mg/dL. Diazoxide had answer within 24 h with blood glucose above 65 mg/dL. Two years later, the patient presented hypertrichosis in back and arms, which did not reach result in suspension of diazoxide, but required dose adjustment to 5 mg/kg/day in three divided doses, with good glycemic control.

Case 2: Infant 6 months old who presented blood glucose of 37 mg/dL with a diagnosis of diffuse congenital hyperinsulinism. He received dextrose infusions and enteral nutrition with a high content carbohydrate with no increase in blood glucose. The treatment was initiated with diazoxide, but was necessary to increase the dose to 15 mg/kg/day for blood glucose levels above 65 mg/dL. Several days later, he presented low urine output and increased blood pressure, so the physician was decided to initiate treatment with hydrochlorothiazide 1 mg/kg/day. One year later, he presented a petechial rash and the treatment was discontinued. Finally, the treatment with diazoxide is reintroduced without presenting new episode of thrombocytopenia and with good glycemic control.

Conclusion In both cases the use of diazoxide was effective in controlling blood glucose levels in persistent hyperglycemia.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
class M05 in the year 2013. For this analysis the Italian Medicines Agency guideline (Nota AIFA 79) was followed, which regulates prescriptions of these drugs carried out at the expense of the NHS.

Results We examined all prescriptions dispensed to 11,471 patients: 96% women; mean age 71 years; 2% <50 years of age; 14% between 50–60 years; 32% between 61–70 years; 34% between 71–80 years; 16% between 81–90 years; 2% nineties. The Defined Daily Dose per 1,000 inhabitants was 77 for bisphosphonates (M05BA), 22 for strontium ranelate (M05BX) and 57 for the association alendronate/cholecalciferol (M05BB), the most prescribed (34% of prescriptions). 13% of patients were also having corticosteroid treatment (H02AB), 19% took cholecalciferol (A11CC) and 9% calcium/cholecalciferol (A12AX), 16% had collected only one pack of one of these drugs (21% of M05BA04 and 23% of M05BX03).

Conclusion The analysis performed shows that prescriptions were appropriate for age in 98% and for corticosteroid treatment in 13%. 16% of patients received only one pack of medicine, a sign of lack of adherence to treatment that affects its effectiveness and represents a waste of resources.

REFERENCE
1 NOTAAIFA 79

No conflict of interest.

ID-061 A CASE OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CIDOFOVIR TREATMENT
A Fayet Perez, A Martos Rosa, J Unda Romacho, D González-Vaquero, P Acosta-Robles, I Amorín Móliba, M Colls-González. Agencia Sanitaria Poniente, Pharmacy Department, El Ejido, Spain; 2Hospital de Bellvitge, Pharmacy Department, Bellvitge, Spain

Background Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by reactivation of the JC polyomavirus (JCV). It is characterised by severe demyelination of the central nervous system, which is invariably fatal. PML mainly occurs in immunosuppressed individuals. Within the context of HIV infection, the prognosis with highly active antiretroviral therapy (HAART) is of only 50 percent of patients with PML surviving longer than one year.

No specific treatment exists for JCV infection. The main treatment approach involves HAART to reverse the immunosuppression. Cidofovir has been used in patients with HIV infection as treatment for PML, but the largest clinical studies have reported no benefit.

Purpose To describe and evaluate the efficacy of cidofovir for the treatment of PML in HAART-treated HIV patients.

Material and methods A 43-year-old man was diagnosed with HIV infection for 10 years without treatment. In June 2011 the patient began treatment with tenofovir/emtricitabine/efavirenz (11 cells/mm3 CD4, HIV-RNA 111,560 copies/mL). After three months the patient presented aphasia, hemiparesis and visual field deficits (almost blind).

His medical record was reviewed with a focus on drug treatments, laboratory results and clinical evolution.

Results On admission he had 68 cells/mm3 CD4, HIV-RNA undetectable, JCV PCR of the CSF was 5,417,063 copies/mL. Toxoplasma gondii and BK virus were negative. He was diagnosed with PML, with magnetic resonance imaging supporting the disease. Treatment started with cidofovir 325 mg bi-weekly and optimised HAART (abacavir/lamivudine/efavirenz).

Cidofovir was withdrawn after 2 months; the result showed an improvement in his motor deficit. However dysphasia and visual loss continued. Three years after infection the patient is still alive with neurological deficits.

Conclusion In patients with HIV and PML, the main treatment approach should be the restoration of the host adaptive immune response by optimising the effective HAART. Cidofovir can be useful to help reduce the progression of PML.

REFERENCE

No conflict of interest.

ID-062 EVIDENCE-BASED MEDICINE AND CASE REPORTS: STUDY OF AN OPTIMISED METHOD OF REPORTING MATERNAL DRUG EXPOSURE CASES

A Ribiero*, A Santos, A Ribeiro. 1Universidade de Coimbra, Coimbra, Portugal; 2Centro Hospitalar E Universitário de Coimbra, Serviço de Reprodução Humana, Coimbra, Portugal; 3Centro Hospitalar E Universitário de Coimbra, Serviço de Informação e Medicações, Coimbra, Portugal

Background Case reports and case series are a widely-used source of scientific evidence. Although usually associated with a low strength of evidence, they are ideal for narrating events observed during clinical practice. On the other hand, the existing gap in the scientific literature relative to maternal drug exposure, due to several constraints, justifies the use of case reports and case series as a method for generating evidence in these situations.

Purpose To develop an optimised method of reporting clinical cases of maternal drug exposure, with the goal of increasing the strength of evidence associated with these sources.

Material and methods A Medline search was performed in PubMed and other databases, and on the instructions provided by working groups and scientific journals, to analyse and compile guidelines for writing case studies. 79 cases of pregnant women exposed to drugs were examined to identify the most relevant reports. In the second phase, medical and pharmacological information was analysed related to each type of clinical situation, to be included in clinical reports suitable for future publications.

Results Several guidelines to publishing case reports were obtained. Although considerably heterogeneous, it was possible to develop a reporting model. As part of the model, we included the most relevant general clinical and pharmacological data for reporting cases of maternal drug exposure. The model was applied to 3 cases of pregnant women exposed to antidepressants, since they were the most prevalent, 25 out of 79, and was evaluated with a tool to measure quality.

Conclusion Clinical records analysis showed the absence of relevant, systematic and consistent information to build a case report. We have developed an evidence-based method tailored to report cases of maternal drug exposure, useful not only to strengthen their evidence and quality, but also to systematically collect clinical and pharmacological data.
REFERENCES AND/OR ACKNOWLEDGEMENTS
I thank the physicians from the Hospital for their cooperation.
No conflict of interest.

DI-063  REVIEW OF ALZHEIMER’S TREATMENT IN ELDERLY PATIENTS
M Ibarra*, B Basagotia, V Saavedra, A Escudero, A Sánchez. Hospital Universitario Puerta de Hierro, Pharmacy, Madrid, Spain
10.1136/ejhpharm-2015-000639.251

Background The prevalence of Alzheimer’s disease (AD) reaches up to 20% in Spain’s population over 80 years old. Even though several medicines are available today, there is limited evidence regarding their effectiveness, without forgetting their potential adverse events. Consequently, close therapeutic monitoring is necessary to identify cases in which there are no clear signs of therapeutic benefit.

Purpose To analyse the use of anti-dementia drugs in patients diagnosed with AD with the purpose of optimising it in the future.

Material and methods Retrospective observational study of poly-medicated patients living in nursing homes aged over 75 years, who took part in a medicines reconciliation project during 2013.

Data collection included age, sex, degree of dementia, number of chronic drugs and type of drug to treat AD.

Clinical guidelines were reviewed in order to check recommendations for AD treatment (Cholinesterase Inhibitors (CIs) are recommended in mild-moderate AD, whereas memantine is indicated in severe AD).

Results Eighty four (13.9%) out of 604 patients analysed were being treated with anti-dementia drugs (59.5% females, with an average age of 85.9 years and taking a median of 10.5 drugs daily). Memantine was the most common anti-dementia drug among our patients: 31 patients (36.9%) were taking it, 17 in monotherapy (20.24%), and 14 (16.7%) in association with CIs.

The most frequently used CIs were rivastigmine and donepezil, with 29 (34.52%) and 27 (32.4%) patients respectively. On the other hand, galantamine was prescribed in 12 patients (14.29%). With regard to the degree of dementia, 8 patients with severe dementia weren’t being treated with memantine, whilst 4 with mild dementia were using this drug. Moreover, one case of association of donepezil and rivastigmine was identified.

Conclusion Twelve cases (14.29%) were identified whose treatment did not accord with the clinical guidelines consulted. These findings reflect the need to revise and update treatments, adapting them to the medical condition of patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS
UpToDate
No conflict of interest.

DI-064  OFF-LABEL DRUGS USE IN PAEDIATRICS SERVICES
J Mateo Carmona*, V Arcas Casafi, O García Molina, MA Fernandez de Palencia Espinosa, S Vicente Sánchez, A De La Rubia Nieto. University Hospital Arrixaca, Pharmacy, Murcia, Spain
10.1136/ejhpharm-2015-000639.252

Background The off-label use in paediatrics is high and there are few studies undertaken on off-label drug use in Spain.

Purpose To analyse off-label drugs use in paediatrics services, to analyse which clinical units requested more often off-label drugs and which were the causes that led to the consideration of off-label treatment.

Material and methods Descriptive observational study from October 2009 to September 2014. We included all individual requests of off-label drugs received in the Pharmacy Department by the different paediatrics clinical units. Individualised assessment reports were developed with an analysis of efficacy, safety, convenience and cost, which were referred to hospital medical administration to make the decision to authorise or deny its use.

Results A total of 141 requests were analysed, of which 95.1% (134) were finally authorised and 4.9% (7) were denied. The most petitioned drugs were Levosimendan with 14.9% (14 requests in cardiac surgery using extracorporeal circulation and 7 in diastolic dysfunction), Adalimumab with 8.5% (6 requests for juvenile idiopathic arthritis, 3 in ulcerative colitis and 3 for Crohn’s disease), Palivizumab with 6.4% (6 requests for prophylaxis of Human respiratory syncytial virus (RSV) in immunocompromised patients and 3 in treatment of RSV) and Pegfilgrastim with 4.9% (7 requests for neutropenia after chemotherapy in paediatric patients).

According to cause which led to the consideration of off-label, in 58.2% (82) was due to an unauthorised indication. Furthermore, the reason for off-label in 41.8% (59) due to unauthorised indication for patient age.

The most petitioned paediatrics clinical units were oncology with 46.1% (65), rheumatology with 12.1% (17), cardiology with 9.9% (14) and paediatric Intensive Care Unit with 8.5% (12).

Conclusion There is a variety of off-label drugs used in paediatric clinical units. Off-label drugs were requested mostly in the field of oncology and rheumatology. There were a high number of requests for drugs approved in adults but not in paediatric indications.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DI-065  FOLLOW UP STUDY OF HIV PATIENTS WITH BOOSTED PROTEASE INHIBITOR MONOTHERAPY IN ROUTINE CLINICAL PRACTICE
J Serra López-Matencio*, M Concepcion, E Ramirez Hernández, D Esha, M Alberto. Hospital de La Princesa, Pharmacy, Madrid, Spain
10.1136/ejhpharm-2015-000639.253

Background Strategies to simplify HIV treatment are driven by concerns about the long-term toxicity of chronic combination antiretroviral therapy (ART), cost, and the risk of drug resistance over time due to non-adherence. Ritonavir-boosted protease inhibitors (PIs) can be an alternative.

Purpose To assess the effectiveness and safety of ritonavir-boosted PI monotherapy and whether the switching has been done in compliance with European AIDS Clinical Society guidelines.

Material and methods A large, retrospective observational, non-interventionist study was carried out including 91 patients on ritonavir-boosted PI monotherapy. Patients were followed since they started ART to December 2013 (the date at which all of
the patients had been switched for at least 6 months). Data were collected and summarised in a table with the following characteristics: Date of HIV diagnose, PI/r monotherapy toxicity, Adherence and Date of starting with PI/r monotherapy, viral load at the moment of the simplification, viral load in December 2013.

**Results** 21 out of 91 (23%) patients had detectable HIV-RNA at the moment of the simplification thus they did not meet the guideline recommendations for switching. 15 out of 91 (16%) patients had a detectable viral load on December 2013 thus the switching had failed in them. Patients had fewer episodes of lipo-dystrophy, only 14 out of 91 (15%), and cardiovascular complications, only 4 out of 91 (4.35%). 84 out of 91 (92%) patients had more than 85% adherence to the treatment.

**Conclusion** The overall effectiveness of ritonavir-boosted protease inhibitor monotherapy is inferior to ART. However 84% of patients have no viral rebound with HIV-RNA levels above 50 copies/ml, which is why there may be a subset of patients with a history of prolonged viral suppression who may benefit from switching to ritonavir-boosted protease inhibitor (PI) monotherapy to reduce adverse reactions and costs, and achieve more adherence.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Hospital de La Princesa Team

No conflict of interest.

**DI-066 TOPICAL AMPHOTERICIN B USED IN CANDIDA KRUSEI VAGINITIS REFRACTORY TREATMENT**

1 E Chamorro de Vega, 2 MV Gil-Navarro, 3 MD Santos Rubio, 3 JL Perez-Blanco, 2 G Bernál-Blanco, 3 J González-Bueno. 1Virgen Del Rocio University Hospital, Pharmacy, Sevilla, Spain; 2Virgen Del Rocio University Hospital, Nephrology, Sevilla, Spain

10.1136/ehjpharm-2015-000639.254

**Background** Candida krusei is an unusual cause of fungal vaginitis. Conventional antymycotic treatments, including azoles, are less active in vitro against C. krusei than C. albicans. Amphotericin B has demonstrated favourable in vitro antifungal activity but is not available as topical preparations.

**Purpose** To describe a case of persistent vaginal candidiasis due to C. kru sei unresponsive to conventional antifungal therapy, treated with topical Amphotericin B.

**Material and methods** A 61-year-old woman, presented with vulvo-vaginitis with vaginal culture isolation of C. krusei. She was treated with ketoconazole ovaules 400 mg per day for four days. Twenty days later, the patient came to the medical consultation with a labia majora lesion. Furthermore, the vaginal culture remained positive for C. krusei, with a higher yeast proportion than in normal flora. Consensually between Nephrology, infectious diseases and the pharmacy service, it was decided to develop a topical formulation of amphotericin 3% for vaginal application. Effectiveness was assessed by the presence of clinical symptoms and vaginal culture one month later. Information was compiled from digital medical records.

**Results** To prepare this formulation, amphotericin B deoxycolate was combined in Aquagel lubricating jelly. As amphotericin is lipid soluble propylene glycol was used for lubricant incorporation. 1.4 grams of this formulation was applied daily at night for 14 days. This preparation has an unknown shelf life and is obtainable from the pharmacy manufacturing unit. One month after, the patient’s symptoms had resolved, but the vaginal cultures continued positive.

**Conclusion** Despite the vaginal cultures remaining positive, the symptoms had resolved, showing that amphotericin in lubricating jelly may be effective in vaginal C. krusei infection where conventional azole treatment has failed. This topical formulation has emerged as a potentially effective regimen but more studies are needed to set the optimal dosing regimen. Vaginitis caused by C. krusei demands special efforts, and additional treatments must be developed.

**REFERENCES**


No conflict of interest.
BELIEFS, KNOWLEDGE AND EXPECTATIONS ABOUT MEDICINES AND PHARMACISTS IN ASTHMA AND PULMONARY ARTERIAL HYPERTENSION PATIENTS: PRELIMINARY RESULTS

Background Chronic diseases have changed the management of patients and their status, to move toward a new “patient-healthcare providers” partnership. Asthma and pulmonary arterial hypertension (PAH) are two chronic thoracic diseases with differences in terms of prevalence and drug delivery process. Little is known regarding patient’s beliefs (B), knowledge (K) and expectations (E) of their illness, medicines and healthcare providers, despite these parameters influencing their adherence, behaviour and outcomes.

Purpose To gain detailed insight into B, K and E of medicines and pharmacists from asthma or PAH patients.

Material and methods For this observational prospective monocentric study, an interview guide was designed and validated to perform the semi-structured interviews (SSI). Each interview was recorded and fully transcribed. An inductive approach was conducted for the remaining text to inventory verbatim. All were classified according to the key ideas to describe B, K, E for each population.

Results SSI were conducted with 14 patients (5 asthma–9 PAH) (mean duration 37 ± 10 min) from December 2013 to April 2014. Medicines were perceived as a “necessity” (6 PAH–3 asthma), a “constraint” (3 PAH) or “poisons” (2 asthma). Three asthma patients didn’t perceive the necessity of corticosteroids but all judged salbutamol and terbutaline as vital. Four PAH patients noticed few people and healthcare professionals who knew PAH and its management. Pharmacists could sometimes be perceived only as “retailers” (2 PAH–3 asthma), “advisors” (3 PAH) or associated with “medicines” (2 PAH–2 asthma). Tasks of pharmacists weren’t well known and defined (5 PAH–4 asthma).

Conclusion Medicines and pharmacists were perceived differently depending on asthma or PAH patients. The ignorance about “what exactly pharmacists do” makes their role ambiguous for the patients leading to difficulties in describing their expectations of pharmaceutical care. More interviews are warranted to improve the B, K, E description of our populations.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DI-069 \ REVIEW OF OFF-LABEL APPLICATIONS IN ORDER TO IMPROVE THE USE

Background Nowadays in hospitals drugs are more frequently used for purposes other than the ones indicated in the summary of product characteristics.

Purpose To analyse the applications for off-label use of drugs in a third level hospital with the aim of reviewing their approval procedures and setting measures to improve their use.

Material and methods An observational and retrospective study was carried out for the applications for off-label use of drugs received January 2010 to September 2014. A case report form was designed using the following variables: drug, therapeutic use, department, Oxford Centre for Evidence-based Medicine 2011 levels of evidence and type of approval (approval, conditional approval, and non-approval). Drugs requiring a protocol approved by the hospital Pharmacy and Therapeutics Committee were excluded.

Results 128 applications for 59 different therapeutic uses were analysed. A total of 117 (91.4%) were approved, of which 16 were conditionally approved due to the low level of study evidence. Approvals were denied for 11 applications, for 2 of which another treatment was suggested and the physician accepted. Most of the applications were made for rituximab (24 applications,18.7%), for 16 different therapeutic uses, omalizumab (10 applications, 7.8%), bevacizumab and tacrolimus, both of them with 7 application each.

The departments with more applications were Oncology and Haematology (24 applications, 18.7%), Neurology (19 applications, 14.8%), Internal Medicine, Ophthalmology, and the Allergology department, with 10 applications.

For most of the applications, physicians took into account studies with low (case-series studies, follow-up studies and no randomization) levels of evidence 3–4.

Conclusion Due to the high number of applications for different therapeutic uses and the poor level of evidence for them, it is necessary to review the criteria for their approval and to check that these criteria are being observed in order to guarantee the correct and efficient use of the drugs.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DI-070 \ INDIRECT COMPARISON OF CETUXIMAB VS. PANITUMUMAB IN METASTATIC COLORECTAL CANCER

Background In the absence of comparative studies of cetuximab vs. panitumumab in metastatic colorectal cancer (MCCR), we suggested performing an indirect comparison of the two drugs for this indication.

Purpose To perform an adjusted indirect comparison of the two pivotal clinical trials of cetuximab and panitumumab, designed versus the best supportive care as a common comparator in patients with chemotherapy-refractory metastatic colorectal cancer.

Material and methods On 5/04/2014 a literature search was performed in PubMed without finding indirect comparisons.

The adjusted indirect comparison was performed with the results shown in subsequent updates of the pivotal clinical trials, in which subgroups of patients with K-RAS wild-type were analysed. We tested that the homogeneity of the population studied
Drug information and pharmacotherapy

and the results of the treatment groups, were comparable with each other directly. Progression-free survival (PFS) was taken as the most clinically relevant variable available, as it allowed a proper comparison, although it was not the primary endpoint in either study. For our study we used the Bucher’s method, which combines the studies through analysis adjusted for the result of the control group. The Comparison Indirect Treatment (ITC) application, developed by the Canadian Agency for Drugs and Technologies in Health (CADTH) was used. The margin of equivalence (the maximum difference considered clinically irrelevant) was defined.

Results In the adjusted indirect comparison by the Bucher method, using the Wells calculator, an insignificant Hazard Ratio (HR) was obtained for cetuximab vs. panitumumab, relative to PFS. Therefore, we have no objective evidence that one drug is superior to another. The HR: 0.933 is very close to 1, and CI95% 0.624–1.396. The margin of equivalence established (0.67–1.49) is exceeded only at the lower limit, affecting a probability of 94.65% that the result is above 0.67, a result obtained by the Shakespeare calculator.

Conclusion We consider that the two treatments might be considered as equivalent alternatives when referring to PFS in the third line.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DI-071 EVEROLIMUS (AFINITOR): A CASE OF STEATOSIS IN THE TREATMENT OF PANCREATIC NEUROENDOCRINE TUMOURS

1M Scaldaferri*, 2E Castellana, 2P Ceraso, 3E Catel, 4E Grossi, 5E Avola, 5S Stecca. 1Città della Salute e della Scienza, Pharmacy, Turin, Italy; 2Città della Salute e della Scienza di Torino, Pharmacy, Turin, Italy; 3Città della Salute e della Scienza, Oncologic Endocrinology, Turin, Italy; 4Città della Salute e della Scienza, Oncologic Endocrinology, Turin, Italy

Background Everolimus (Afinitor) is an inhibitor of mTOR (mammalian target of rapamycin), which has demonstrated anti-neoplastic activity in breast, renal and neuroendocrine pancreatic cancer. At our centre, an uncommon adverse drug reaction (ADR) was detected in a patient treated with everolimus and lanreotide. The patient started lanreotide treatment on July 2013 and, after chemotherapy for hepatic nodules, everolimus 10 mg/day was added. After 5 months, Nuclear Magnetic Resonance (NMR) showed massive steatosis involving the entire left lobe of the liver and part of the right lobe, with no signs of recurrence of neoplastic disease. Treatment with everolimus was stopped.

Purpose To describe an uncommon adverse drug reaction to everolimus and lanreotide, review the literature and search for cases in National and European ADR databases.

Material and methods Searches of the Italian National Pharmacovigilance Network (I-NPN) and EudraVigilance databases and of PubMed and Embase databases were performed for reports of steatosis related to everolimus and lanreotide treatment. The Naranjo algorithm was applied to our case.

Results Searches of literature databases retrieved a single case report of steatosis related to everolimus treatment. No reports were detected in I-NPN. EudraVigilance Database contains 5 cases of steatosis possibly related to treatment with everolimus. According to the Naranjo algorithm, the causal link for our case appears to be “possible”.

Conclusion Our case has a “possible” causal link according to the Naranjo algorithm and the patient is now on NMR follow up. Treatment for his pancreatic neuroendocrine tumour is now based on lanreotide. The detection and follow up of this uncommon ADR has been possible thanks to the close and constant collaboration between Oncology Endocrinologists and Pharmacists and is an important contribution to defining the safety profile of everolimus in patients with pancreatic neuroendocrine tumours.

REFERENCE

No conflict of interest.

DI-072 MOBILE PHONE TEXT MESSAGING TO IMPROVE ADHERENCE TO ANTIRETROVIRAL TREATMENT IN HIV-INFECTED PATIENTS

1M Manzano, 2R Jimenez, 2A Tristano, 2R Monillo, 2C Haro, 2R Cantudo, 2E Calvo, 2E Alvaro*, 2M Robustillo, 2M Guzman. 1Valme University Hospital, Pharmacy, Sevilla, Spain; 2Costa Del Sol Hospital, Pharmacy, Marbella, Spain

Background Non-adherence to antiretroviral treatment (ART) regimens is closely related to treatment failure and in response, researchers have developed interventions to improve adherence.

Purpose To determine the effect of sending mobile phone text messages to remind patients to get more medicines on the adherence to ART in HIV-infected patients.

Material and methods This was an interventional study carried out in HIV-infected outpatients who got their medicines from a hospital pharmacy service during 2012. The intervention group included patients who received mobile phone text messages to remind them to get more medicines during 2012. The control group only received standard pharmaceutical care. Data were collected retrospectively. Adherence to ART was compared between the two groups. ART adherence was measured through pharmacy dispensing records. Patients were considered adherent if ART adherence according to dispensing records was ≥95%. Data collected included age, gender, treatment-naïve status and type of ART. That was classified as: a) 2 nucleoside reverse transcriptase inhibitors (NRTI) plus 1-non-nucleoside reverse transcriptase inhibitor (NNRTI); b) 2 NRTI plus 1 ritonavir-boosted protease inhibitor (PI/r) and others.

Statistical analysis:
To determine the effect of sending mobile text messages on the adherence to ART, we performed the chi-squared test. We used statistical package SPSS 20.0.

Results 120 patients were included. The median age was 47 years (IQR = 42.0–51.7). 68.3% of patients were men. No patients were new to treatment. The type of ART was similar in the two groups. The most frequent regimen consisted of the combination of NTRI plus NNRTI (47.5%) and 38.6% in the intervention and control group, respectively. The percentage of adherent patients was significantly higher in the intervention group compared with the control group (83.9% vs. 63.8%; p = 0.013).

Conclusion Mobile phone text messaging can be an important tool to improve the adherence to ART in HIV-infected patients.

REFERENCE

1 J Subst Abuse Treat 2014;46(1):66–73
No conflict of interest.
OFF LABEL USE OF PSYCHOTROPIC DRUGS IN ELDERLY PATIENTS WITH DEMENTIA IN A PSYCHOGERIATRIC UNIT

Background The use of antidementia drugs indicated for the treatment of certain cognitive, behavioural and psychological symptoms related to dementia (BPSD) in elderly patients is limited because of their low efficacy. Therefore, other psychotropic drugs are commonly prescribed off-label. Data on off-label prescriptions of psychotropic drugs for BPSD are scarce.

Purpose To assess both the frequency of psychotropic prescriptions for the treatment of BPSD and the conformity of prescriptions to official Swissmedic monographs (OSM) and to Swiss recommendations 2014 (SR).

Material and methods Retrospective and descriptive study of patients discharged between June 1st 2013 and January 31st 2014 from the Organic Psychiatric Disorders Unit of the Geriatric Psychiatry Service of a primary and tertiary care university hospital. The number and the type of drugs prescribed were investigated and the percentage of conformity to references was analysed.

Results 835 different drugs were prescribed to the 94 patients included. The average number of drugs per patient was 9 ± 2, including 4 ± 2 psychotropic drugs. Dementia was diagnosed in 89 of them for whom 409 psychotropic prescriptions were identified.

Of these 409 prescriptions, 395 prescriptions targeted the treatment of BPSD. The conformity with OSM and SR were respectively 59.0% and 68.9% according to indication, 54.2% and 64.6% according to the route of administration, 38.0% and 38.8% according to the initial dose, 43.2% and 30.8% according to the maximum dose, 35.4% and 52.2% according to the duration of treatment.

Conclusion Patients treated in a primary and tertiary hospital due to BPSD are systematically prescribed psychotropic medication, often outside the official recommendations. This may emphasise the substantial and unmet needs of approved drugs to treat BPSD.

REFERENCES
1 Swissmedic. http://www.swissmedicinfo.ch/ (last access July 06, 2014)

No conflict of interest.
**Drug information and pharmacotherapy**

**Purpose** To evaluate the differences in clinical efficacy and financial sustainability of two therapeutic management models for patients with rheumatoid arthritis treated with biological drugs who are in stable clinical remission.

**Material and methods** Over a period of 6 years, 81 patients were considered of average age 55 years and who had already had the disease for 3 ± 2 years. They had been in stable clinical remission for at least 6 months at the time of admission treated with biological drugs. 34 patients continued to have the treatment, gradually deferring (extending the length of time between) administrations. The remaining 47 patients were treated discontinuously, so that at the achievement of remission the biological drug was suspended and it was administered again if the condition flared up.

**Results** The mean follow-up was 38.9 months for the group of patients in the deferral. They maintained remission for an average period of 33.8 months; two of them had a relapse that required a return to the normal pattern of administration.

Discontinued treatment patients were followed for a mean follow-up of 48.4 months and showed a duration of cumulative average remission of 27.6 months.

Flare-ups were significantly more frequent in patients with intermittent treatment compared to those with delayed treatment (42/47 or 89% vs. 2/34 or 6%, p < 0.001). Cost analysis showed that discontinuous treatment is not less expensive than delayed treatment as it is burdened with substantial costs for the management of relapse periods.

**Conclusion** Extending the time between biological treatments results in significantly longer periods of stable clinical remission without fluctuations during the course of the disease and with significantly fewer relapses than stopping and re-starting treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

**DI-076**

**INTERUPTION AND DISCONTINUATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN PSITAR HIV COHORT**

1MDLA Robustillo-Cortés, 1R Jiménez-Guálin, 1E Gómez-Fernández, 1AM Tristando-Pérez, 1M Marzano-García, 1E Calvo-Cidóncha, 1E Álvarez Sanz*, 1E Rios Sanchez, 2B Tortajada Gouta, 2R Morillo-Verdugo. 1Valme University Hospital, Pharmacy, Seville, Spain; 2Cantab公告称 Albacete, Pharmacy, Albacete, Spain

10.1136/ejhpharm-2015-000639.264

**Background** Treatment modifications within the first year are extremely important. The first HAART regimen should remain for years. The first regimen toxicity can have a negative impact on adherence and virological efficacy.

**Purpose** To establish the main reason for discontinuing antiretroviral treatment within the first year in an HIV cohort.

**Material and methods** Prospective multicentre study. Treatment-naive adult HIV patients who started treatment between 2011 and 2013 were selected. Basic demographic characteristics (sex and age) and pharmacotherapeutic variables as initial HAART, discontinuation of HAART within the first year and its reasons based on Swiss HIV Cohort¹ were collected. The main reasons for treatment modification were classified as treatment failure, intolerance and/or toxic effects, the patient's choice, the physician's decision, and other reasons.

**Results** 277 patients started HAART in this period, 82.4% men. The mean age was 40 ± 11. The most frequent HAART was emtricitabine/tenofovir/efavirenz (59.1%) followed by emtricitabine, tenofovir, atazanavir/ritonavir (13.6%), emtricitabine, tenofovir, darunavir/ritonavir (9.1%) and other combinations (18.2%). During the first year of HAART, 68 individuals modified their treatment. The reason for treatment discontinuation was: 64.7% intolerance or toxic effects, 16.2% the physician's decision 10.3% treatment failure, 4.4% the patient's decision and 4.4% other reasons. 44 patients modified their treatment because of drug intolerance and/or drug toxicity. CNS adverse events were the most frequent toxic effect (27.3%), followed by gastrointestinal tract intolerance and renal impairment (18.2%), rash (9.1%), biochemical alterations (6.8%) and others (18.2%).

**Conclusion** The number of patients stopping HAART in the first year is acceptable. It is necessary to properly assess starting HAART to reduce adverse reactions involving switching the treatment.

**REFERENCE**


No conflict of interest.

**DI-077**

**USE OF ROMIPLOSTIM IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA**

¹A Valladolid Walsh*, ²N Jimenez Collados, ²M Clemente Andújar, ²C García Gomez, ²G Romero Candel, ²M Pla Paniagua, ²N Monteguado Martinez. ²Gerencia de Atención Integrada de Albacete, Department of Pharmacy, Albacete, Spain; ²Gerencia de Atención Integrada, Pharmacy Department, Albacete, Spain

10.1136/ejhpharm-2015-000639.265

**Background** Romiplostim was approved in 2009 to treat adult splenectomised patients with chronic Idiopathic Thrombocytopenic Purpura (ITP) when refractory to other treatment. It is also considered second-line treatment in non-splenectomised patients in which surgery is not advised.

**Purpose** To determine the effectiveness and safety of romiplostim in patients with ITP who did not respond to 1st line or later treatments.

**Material and methods** Observational and retrospective study. All patients treated with the drug from January 2009 to February 2014 were included. Data collected included demographic, clinical and analytical information, as well as dates of administration of the drug and dose administered.

**Results** 7 patients diagnosed with ITP and not responding to previous treatment lines were included, three splenectomised and four non-splenectomised. Previous lines of therapy varied among patients and included: nonspecific immunoglobulins, corticosteroids, danazol, rituximab and eltrombopag. Platelet count (PC) at the start of treatment was less than 50 × 10⁹/l in 6 patients and higher in 1 patient. Three patients received fewer than six doses, so it was not possible to assess platelet response. The remaining four patients started treatment at a dose of 1 mcg/kg, maximum doses received ranged from 5 to 10 mcg/kg. In the four patients who received more than six doses of the drug response was variable. The percentage of time with sustained PC in one patient was only 19% of the treatment time (99 weeks follow-up) while in the other three it was 73%, 85% and 97%. One patient had PC of 150 × 10⁹/l for four weeks with no dose reduction.
Conclusion Romiplostim was prescribed according to approved use in all cases except for treatment discontinuation in the case of no response. No serious adverse effects were reported. Effectiveness was very variable. A protocol for use including conditions for discontinuation in case of no response could improve use of the drug in our institution.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

DI-078 PRESCRIPTION BY ACTIVE INGREDIENT VERSUS BRAND NAME


10.1136/ehjpharm-2015-000639.266

Background According to the recommendations of scientific societies and legislation, medicines prescription should be performed by the active ingredient (AI) to avoid drug-related problems. In clinical practice, for various reasons, physicians tend to use brand names (BN).

Purpose To evaluate the quality of prescriptions through the prescription by AI in inpatients compared with the prescription by BN and to compare with a previous study in our department.

Material and methods Observational and retrospective study in a tertiary teaching hospital conducted during October 2013. We included all inpatients admitted to non-critical units. Using the Unit Dose Drugs Dispensing System (UDDDS) pharmacists reviewed all the treatment lines of the medical orders. A database was designed and filled with data collected: number of lines of treatment prescribed as an AI or BN and medical service. Furthermore, we classified medicines by their treatment group according to the WHO classification: Anatomical, Therapeutic, Chemical classification system (ATC). As the last step, the results obtained were compared with those found in a similar study in October 2010.

Results During one month, UDDDS revised 1999 treatment lines in 2013 and 1973 treatment lines in the 2010 study. Physicians prescribed 1166 (58%) versus 1303 (66%) by the BN in 2013 and 2010 respectively. At clinical service distribution, lines of inpatient pharmacotherapy admitted to Pneumology (77%) and Psychiatry (72%) were the most prescribed by BN in the 2013 study; in the 2010 study, these were Psychiatry (86%) too, Gynaecology (83%) and Orthopaedic Surgery (83%). In the other clinical services, it appears that the requirements are approximately 50% AI. The reverse trend was observed in the Short Stay Unit, Paediatrics and Neurosurgery reaching around 60% of treatment lines with the AI in the 2013 study and also reaching 60% in the Haematology department in 2010. Sorted by ATC classification, the most prescriptions in 2013 by BN were in the N group with 31%, followed by A, B and J with 23%, 17% and 17% respectively.

Conclusion Most medical orders continue to be prescribed by the BN despite the prescribing quality recommendations. Maybe when computer-assisted prescription comes to our hospital, this situation will be reversed.

REFERENCES

1 http://ejhp.bmj.com/content/21/Suppl_1/A173.1.abstract?sid=d83081ef-56cd-4710-8d47-6094f6a1c969

No conflict of interest.

DI-079 EFFECTIVENESS OF TREATMENT WITH IMMUNOGLOBULIN IN PATIENTS WITH ITP

1M Marzano-García, 1AM Tristano-Pérez, 1CA Haro Marquez, 1Et Alvare Sanz*, 1MJ Fobelo-Lozano, 1RM Cantudo-Cuenca, 2E Calvo-Cidona, 1M Guzmán-Ramos, 1MBLA Robustillo-Cortes, 1Et Gómez-Fernández. 1Valde University Hospital, Pharmacy, Sevilla, Spain; 2Costa Del Sol Hospital, Pharmacy, Marbella, Spain

10.1136/ehjpharm-2015-000639.267

Background Treatment of immune thrombocytopenic purpura (ITP) is a controversial subject. The management varies widely, ranging from observation only, to aggressive management with corticosteroids, intravenous anti-RhD, intravenous immunoglobulin (IVIG), rituximab, splenectomy, etc.

Purpose To assess the effectiveness of treatment by administration of immunoglobulins (Ig) in patients diagnosed with idiopathic thrombocytopenic purpura (ITP).

Material and methods Retrospective descriptive study of about 5 years (January 2009–March 2014). All administrations of Ig in patients diagnosed with ITP in our study period.

The variables analysed were: sex, age, dose Ig, number of administrations to each patient, pre-treatment with corticosteroids, effectiveness of treatment with Ig (being defined as platelet levels increasing to above 30–10^9/L, as indicated by the clinical guidelines for the use of Ig).

Patients and clinical data were selected from the outpatient and inpatient records (Farmatools) and electronic patient clinical histories.

Results A total of 23 patients were treated with PTT Ig in the study period. 6 patients were excluded because their clinical data had not been collected. 17 patients (two of whom were paediatric patients) of whom 41% were males were included. The mean age was 48 years.

The mean dose administered per patient was 40.44 grams of Ig. Mean Ig administration per patient in the study period was 2 administrations per patient.

Pre-treatment with corticosteroids as first-line treatment was performed in 88.23% of patients.

Of the 34 administrations recorded, 61.76% were found to be effective according to the clinical guidelines for the use of Ig for the treatment of ITP.

Conclusion Ig treatment had a higher than 60% efficacy, so it is justified to use it in symptomatic treatment prior to corticosteroids in patients diagnosed with ITP.

REFERENCE

1 Indian Pediatr 2013;50(6):611

No conflict of interest.

DI-080 ANALYSIS OF TEICOPLANIN PRESCRIPTION PRACTICES AND OF THEIR CONFORMITY WITH THE RECOMMENDATIONS

E Granier*, F Loeuluet, A Leray, P Odou. Chu Lille, Pharmacie, Lille, France

10.1136/ehjpharm-2015-000639.268

Background We analysed teicoplanin prescriptions due to the increase of pharmaceutical interventions.
Purpose To evaluate the real use of teicoplanin in our hospital, check the agreement of prescriptions with the recommendations and standardise prescribing.

Material and methods Over 2 months, we analysed every teicoplanin prescription. We identified:

- Patient information (age, sex, weight and renal clearance)
- Prescription information (indications, dose, antibiogram, teicoplanin serum concentration, dose adjustment).

The correct standard used for patients with normal renal function was the PILLY recommendations. For patients with renal failure, the correct standard used was “Guide de Prescription et Rein” recommendations.

Results 22 patients were included: 12 men and 10 women; 8 had renal failure. 63.6% of the indications were documented (100% of the antibiograms indicated sensitive organisms), 31.8% were probabilistic and 4.6% were prophylactic. 17 patients had teicoplanin serum concentrations tested but only 10 were done on right date (i.e. just before the 5th injection). For patients with normal renal function, the initial dose was correct for 10 prescriptions and didn’t follow the recommendation for 3 prescriptions (the effectiveness threshold wasn’t reached for 1 serum concentration). The dose adjustment was correct for 6 prescriptions, non-compliant for 3 prescriptions and 4 prescriptions were stopped. For patients with renal failure, the initial dose was correct for 4 prescriptions and non-compliant for 4 prescriptions (efficacy threshold wasn’t reached for 2 serum concentrations). The dose adjustment was non-compliant for 7 prescriptions and 1 prescription was stopped.

Conclusion Finally therapeutic drug monitoring was performed but not correctly. The doses were not always adjusted. It appeared necessary to follow patients with renal failure. As a result of this analysis, we set up a typical prescription summing up the main indications, initial dose, therapeutic drug monitoring recommendations, dose adjustment based on the serum concentration and on renal function.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

Background Oral chemotherapy is increasingly used in Oncology. It has important advantages, such as patient comfort, but it also brings new challenges which did not exist with the intravenous treatment. Some of these drugs have interactions with food, leading to changes in their bioavailability. As they are drugs with a narrow therapeutic margin, this can lead to alterations in their efficacy and/or toxicity.

Purpose A. To assess the level of knowledge on the administration of oral cytostatics that present restrictions with meals (drugs that have to be taken with/without food) among the outpatients of a third level hospital. B. To minimise the incorrect administration and the risk of food-drug interactions, providing patients with information as to how and when drugs have to be administered.

Material and methods Once the oral cytostatics with food restrictions were identified, we asked the patients in treatment about the information they had received from the doctor and the way they were taking the medicine. We provided those who were taking the drug incorrectly with the right information. In the following visit, it was confirmed if the patients who had previously been taking the cytostatic incorrectly, were now taking them correctly (intervention accepted/not accepted).

Results 97 patients were interviewed (54% men, 46% women). 40% of them were used to taking the drug incorrectly. Of this percentage, 77% correspond to patients treated with capetica- bine, 8% with lapatinib, another 8% with temozolomide, and finally 3% with abiraterone, erlotinib and pazopanib, respectively. We detected a great diversity depending on the drug dispensed. 93% of the 39 interventions made were accepted.

Conclusion The data obtained suggest the need to reinforce the information that the patient receives. It is important to make sure that the patient understands how and when the oral cytostatic should be administered.

REFERENCE


No conflict of interest.
dressing with amphotericin B-impregnated gauze was introduced. Washing of the pleural cavity with 5% glucose solution. Daily on the second and third day, respectively, and then 50 mg, after 75 ml of 5% glucose solution, was infused directly into the pleural cavity. Pleural biopsy showed septate fungal hyphae and empyema and bronchopleural fistula. The patient underwent thoracostomy. Pleural fluid culture grew Aspergillus fumigatus while serum galactomannan antigen was negative. Systemic antifungal therapy, with oral voriconazole at first and then with posaconazole, was performed. The symptoms and the physical signs improved greatly during hospitalisation and the patient left the hospital 3 days after the end of treatment. Repeat pleural fluid culture was negative 2 weeks after the end of treatment. Conclusion ICAB may improve the efficacy of systemic antifungal therapy and it should be considered as an additional treatment option. Moreover, the use of this method avoids repeated needling of the cavity and may allow extended treatment on a domiciliary basis.

REFERENCES

No conflict of interest.

DI-084 COST-UTILITY OF SOFOSBUVIR-BASED TREATMENT FOR UNTREATED GENOTYPE 1 AND 3 Hepatitis C Patients

A Alcobia*, D Dias, M García, A Soares. Hospital García de Orta, Pharmacy, Almada, Portugal

10.1136/ehjpharm-2015-000639.272

Background Hepatitis C virus infection constitutes a major public health problem worldwide due to its long-term impact, ranging from extensive fibrosis to hepatocellular carcinoma. Since the approval of direct-acting antivirals (DDAs), treatment-naïve and -experienced patients with compensated disease have been able to benefit from a broad choice of drug combinations. Nowadays due to financial constraints the need for a financial evaluation of the innovative treatments is recognised.

Purpose To perform a cost-utility analysis of sofosbuvir-based treatment versus standard care in our Hospital for treatment-naïve genotype 1 and 3 patients (ribavirin/peg-interferon followed by boceprevir/ribavirin/peg-interferon in genotype 1 and ribavirin/peg-interferon in genotype 3).

Material and methods Review of recent literature data to evaluate the efficacy of the therapeutic options being analysed. A decision-analytic Markov model was used to estimate long-term health outcomes.1,2 The cost was calculated based on the direct costs of the drugs (2014).

Results The incremental cost-utility ratio calculated for sofosbuvir-based treatment for untreated genotype 1 patients was €38,455.53. For untreated genotype 3 patients, the ribavirin/peg-interferon option was dominant versus sofosbuvir-based treatment.

Conclusion Sofosbuvir-based treatment can be considered a cost-effective option for genotype 1 patients, depending on willingness-to-pay for a quality-adjusted life year. Equally a cost-utility evaluation should be assessed for more than two dozen possible therapeutic schemes.

REFERENCES
1 European Association for the Study of the Liver (EASL). 2014
2 Leedu H, Blacher M, Rosa I. J Viral Hepat 2014;1–7

No conflict of interest.
**DI-085** EVOLUTION OF ANTIRETROVIRAL PRESCRIPTIONS IN TREATMENT-NAIVE HIV-INFECTED PATIENTS

E Martinez de Iarduya Bolado*, M Gómez Martínez, A Gómez Esteban, M Martín Vega, C Abnaira Meriel, A Colín López de Dicastillo, L Senra Afonso, M Oro Fernández, A Ilaro Uranga, M Valero Domínguez. Hospital Marqués de Valdecilla, Hospital Pharmacy, Santander, Spain

10.1136/ehjpharm-2015-000639.273

**Background** The introduction of newly-approved antiretroviral drugs is leading to changes in first-line antiretroviral prescription.

**Purpose** To analyse the evolution of antiretroviral prescription patterns over a 4-year period in treatment-naive HIV-infected patients and to assess rates and reasons for switching first-line HAART.

**Material and methods** Retrospective study including all antiretroviral-naive patients who started HAART in a Spanish tertiary care hospital between 2010 and 2013. Prescription and pharmacy repeat prescription data were collected from the electronic prescription database and medical records.

**Results** 156 antiretroviral-naive patients were included. Tenofovir/emtricitabine co-formulation was used as first-line nucleoside reverse transcriptase inhibitors combination in all but two patients with decreased renal function, who received abacavir/lamivudine instead. Efavirenz was the most commonly associated third drug: 63.1%, 62.5%, 43.2% and 57.1% each year, respectively. Protease inhibitor (PI)-based HAART increased over the years, with darunavir/ritonavir (DRV/r) and atazanavir/ritonavir (ATV/r) replacing lopinavir/ritonavir (LPV/r) as preferred PI: DRV/r was chosen in 23.3%, 31.2%, 21.6% and 21.4% of prescriptions, respectively; ATV/r, first introduced in 2012, was used in 29.7% of prescriptions that year and in 10.7% in 2013. LPV/r use decreased from 7.0% in 2010 to 4.1% and 2.7% in 2011 and 2012, respectively. There were only three prescriptions for raltegravir due to resistance or interaction issues, and one prescription for tenofovir/emtricitabine/rilpivirine, first introduced in late 2013. Treatment changes were necessary in 47 patients, and the main reasons for switching were: adverse events (53.3%), virological failure (14.8%), simplification (12.7%), interactions (10.6%), immunological failure (4.2%) and resistance mutations (2.1%).

**Conclusion** Antiretroviral prescription patterns in first-line HAART have widened in recent years due to the introduction of new agents, and adverse events remain the major reason for switching first-line treatment. With new drugs approved in 2014, practice protocols should be developed and implemented with pharmacist collaboration, in order to optimise clinical outcomes and financial impact of this changes.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**DI-086** INFLUENCE OF THE RECOMMENDATIONS OF THE EUROPEAN MEDICINES AGENCY REGARDING THE MODIFICATION OF THE PRESCRIPTION PATTERN OF METOCLOPRAMIDE

A Colín*, D Gómez Gómez, A Gómez Esteban, E Martínez de Iarduya Bolado, M Martín Vega, M Gómez Martínez, L Senra Afonso, M Oro Fernández, C Abnaira Meriel, M Valero Domínguez. Hospital Universitario Marqués de Valdecilla, Pharmacy, Santander, Spain

10.1136/ehjpharm-2015-000639.274

**Background** In July 2013, the European Medicines Agency (EMA) recommended changes to the use of metoclopramide, including restricting dose (maximum 30 mg/day) and duration (up to 5 days), to minimise the known risks of potentially serious neurological side-effects.

**Purpose** To evaluate the influence of these recommendations on the prescription pattern of metoclopramide in a tertiary care hospital.

**Material and methods** The Pharmacy Department communicated the EMA’s recommendations to physicians through an internal-messaging system. Pharmacists revised new prescriptions with metoclopramide in the electronic prescription database, making recommendations, if required, according to the EMA’s advice.

Subsequently, an observational retrospective study was conducted of all prescriptions of metoclopramide during the same week before (March 2013) and after (March 2014) the EMA’s press release. From the electronic prescription database, patient data (age, sex and reason for admission) and posology and duration of treatment with metoclopramide, were recorded and compared with the EMA’s recommendations. Emergency Service and Paediatrics were not evaluated.

**Results** 213 (51% men) and 225 patients (44% men) with an average age of 59.6 [17–99] and 60.7 [22–93] years old received metoclopramide in the studied weeks of 2013 and 2014, respectively. Reason for admission in 73% and 74% of patients was surgery. 34% and 24% of patients, in 2013 and 2014 respectively, had a fixed-dosing schedule, so the “as needed” schedule was largely selected. Of the patients with a fixed-dose schedule, 44% vs. 46% met the EMA’s prescription recommendations, with no statistically significant difference (p = 0.782, CI = 95%), in 2013 and 2014 respectively. Of these, 34% vs. 46% of prescriptions did not meet therapeutic indication; 27% vs. 22% had a duration in excess of 5 days and 2 patients in 2013 received doses higher than 30 mg/day.

**Conclusion** In our hospital, the pattern of metoclopramide prescribing has not changed significantly after the EMA’s press release. More needs to be done in order to achieve major compliance.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

EMA recommends changes to the use of metoclopramide.

EMA/443003/2013.

No conflict of interest.

**DI-087** SPONTANEOUS REPORTING OF ADVERSE DRUG REACTIONS IN A SECOND LEVEL HOSPITAL: IS PHARMACOVIGILANCE WELL TARGETED?

1 L Borras Trías*, 2 C Pontes García, 1 M García Angelaguet, 1 M De Castro Juve, 1 L Raich Montu, 1 MQ Gorgas Torner. 1 Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Servei de Farmàcia, Sabadell, Spain; 2Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Unitat Farmacologia Clínic, Sabadell, Spain

10.1136/ehjpharm-2015-000639.275

**Background** It has been repeatedly reported that up to 7% of patients have serious adverse drug reactions (ADR) during hospital admissions. Hospital-based pharmacovigilance aims to detect previously unknown serious ADRs arising during differential diagnosis, with focus on special populations, but relies on spontaneous reporting by physicians. As a part of process auditing, we reviewed
spontaneous ADR reports received by the Hospital Pharmacy since the introduction of an intranet-based form for reporting.

**Purpose** To assess whether the system is targeted to detect previously unknown ADRs and serious ADRs in special populations.

**Material and methods** All reports received between January 2011 and December 2013 were reviewed. The suspected drugs and whether they had a regulatory requirement for additional monitoring (i.e., a black triangle on the label), the seriousness of the reaction and the novelty of the clinical association (i.e., absent from the summary of product characteristics) were described.

**Results** There were 53,332 admissions during the period, thus 3,733 serious ADRs were expected (7%). Only 114 notifications were received, which represents 3% of all potential reports, related to 108 patients (13% paediatric and 24% aged ≥75 years), and involving 143 suspected drugs of which 18% had regulatory requirements for additional monitoring. 72% of reports met the seriousness criteria.

Only 5% of the reports described previously unknown associations of which half were confirmed as at least possible reactions: two cases of hepatitis associated with metformin and ritazipram respectively, and leukocytoclastic vasculitis associated with tocilizumab.

**Conclusion** Our audit pointed out serious under-reporting but highly focused reports: most were serious events, one third involved special populations, and one fifth drugs with a regulatory requirement for additional monitoring. Actions to improve notifications are required, but the fact that 3% of the reports were relevant suggests that the system is already focused.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Multidisciplinary team.

No conflict of interest.

**DI-089** EFFECTIVENESS OF ABIRATERONE IN PROSTATE CANCER IN CLINICAL PRACTICE

**Background** Abiraterone is an expensive drug used in hospitals for metastatic prostate cancer and it is necessary to evaluate health outcomes from its use to establish whether it is cost-effective treatment.

**Purpose** To analyse the effectiveness profile of abiraterone for metastatic prostate cancer in a tertiary hospital.

**Material and methods** Retrospective observational study of three years, since abiraterone was first marketed to the present (November 2011–July 2014). All prostate cancer patients treated with abiraterone were included. Variables recorded: age, performance status (ECOG) and progression-free survival (PFS). Data were collected from patients medical records.

The statistical analysis was ANOVA followed by t test. A confidence limit of p < 0.05 was set for the interpretation of results.

**Results** 33 patients were included in the study. The median age was 72.7 (SD 9.1) years old.

The PFS was 7.0 (5.2–8.8) vs. 2.9 (0.7–5.1) months for patients with ECOG 0–1 and ECOG2 respectively (p = 0.01).

5 patients were treated in first line, 3.8 months of PFS (9.1 months for ECOG0–1 patients and 1.0 months for ECOG2 patients).

28 patients in second line, 4.2 months of PFS (5.0 months for ECOG0–1 patients and 2.6 months for ECOG2 patients).

**Conclusion** Our results indicate that ECOG 2 patients derive little clinical benefit from abiraterone.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

To the oncology service.

No conflict of interest.
A PROSPECTIVE, RANDOMISED, CONTROLLED STUDY TO ASSESS THE EFFECT OF PHARMACEUTICAL INTERVENTION ON COMPLIANCE AND KNOWLEDGE OF IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT RECIPIENTS

1A Bessa*, 2J Medina, 3H Tedesco, 4C Felipe. 1Hospital Do Rim, Sao Paulo, Brazil; 2Hospital Do Rim, Nephrology, Sao Paulo, Brazil

No conflict of interest.

Background Pharmacists have important responsibilities inside a multi-professional renal transplant team.

Purpose This work aimed to evaluate the impact of pharmaceutical intervention in the education process and compliance to immunosuppressive therapy.

Material and methods This project was approved by the local ethics committee and conducted in a large transplant-specialised hospital. Adult kidney transplant recipients were identified and recruited by a trained pharmacist within two days after the transplant surgery and received standard immunosuppression therapy. After signing the informed consent patients were randomised to receive a planned intervention of the transplant pharmacist (group 1) or to follow the regular orientation offered by nurses only (group 2). The pharmaceutical-planned intervention consisted of detailed education about indications, doses, frequencies, and schedules for administration of immunosuppressive drugs and these actions were performed at day 3, 5, 7, 14, 21, 28, 60 and 90 days after transplant. A formal evaluation was applied using a standardised scale and a predefined questionnaire to assess compliance and knowledge at days 10, 28 and 90.

Results So far, 89 patients were randomised, 43 in group 1 and 46 in group 2. Preliminary results showed a mean age of 46, 62% male and 40% Caucasian. Regarding the education level, 52% and 30% of patients had not achieved the ninth grade in group 1 and 2, respectively. At day 28 and 90, 85% and 82% of patients showed compliance to immunosuppression in group 1 vs. 77% and 60% in group 2, respectively. Regarding the patients’ knowledge about the use of immunosuppressive drugs and these actions were performed at day 10, 28 and 90, 85%, 88% and 95% of patients in group 1 showed well understanding about immunosuppressive medications vs. 73% (p = 0.049), while 82% and 80%, in group 2 respectively.

Conclusion These preliminary results showed that the intervention of the pharmacist trends to improve the compliance and knowledge of immunosuppression therapy.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Acknowledgements Hospital do Rim.

No conflict of interest.

ASSESSMENT OF AN EDUCATION PROGRAM FOR PATIENTS TREATED WITH ORAL ANTICOAGULANTS IN A CARDIOLOGY DEPARTMENT: A PILOT STUDY

1N Eycherne, 2E Brito, 3O De Teline, 4E Profilo, 5M Roudot, 8B Hux*, 6C Fernandez, 2Z Ederly, 7A Cohen, 8M Antignac. 1Saint-Antoine Hospital, Pharmacy, Paris, France; 2Saint-Antoine Hospital, Cardiology, Paris, France

10.1136/etapharm-2015-000639.279

Background In January 2013, an education program for patients treated with oral anticoagulants called “ETAP” was implemented in the cardiology department of our hospital. The day after the educational intervention, patient knowledge and coping are assessed but long-term knowledge, coping and medicines adherence have never been investigated up to now.

Purpose To assess long-term knowledge, coping and adherence of patients enrolled in ETAP since January 2013.

Material and methods 1) January 2013–August 2014: During hospitalisation, an initial “knowledge and coping score” (E1 score: 0 to 10 points) was awarded for patients enrolled in the education program with a specific questionnaire designed by the ETAP team.

2) June–September 2014: At least one month after discharge from the hospital, a pharmacy student called every patient at home who had given his verbal consent beforehand. A long-term “knowledge and coping score” (E2 score) was awarded with the same questionnaire. Medicines adherence was calculated with the 8-item Morisky Medication Adherence Scale (MMAS-8).

Results Of the 236 patients contacted, 100 patients completed the study. Mean “knowledge and coping scores” were both above 8 points (E1: 8.61 ± 2.36, E2: 8.23 ± 2.03). No significant difference (p = 0.35) was observed between means of E1 and E2 scores. MMAS-8 showed that most patients (70%) had a high level of adherence. No correlation was observed between E1 or E2 scores and adherence.

Conclusion The results of this pilot study suggest that most patients retain their long-term knowledge and coping skills. These data are in agreement with other studies.1 The medicines adherence to oral anticoagulants estimated by MMAS-8 was higher than in routine practice. Assessment of the ETAP program should be improved by including biological and clinical outcomes such as INR or bleeding events collection.

REFERENCE


No conflict of interest.

POPULATION ATTRIBUTABLE RISK OF HIP FRACTURES IN ANTIDEPRESSANT USERS IN HUNGARY AND ESTIMATION OF THE RELEVANT COST CONSEQUENCES

1G Takacs*, 2L Horváth, 1L Böz. 1Pecs University Medical School, Department of Pharmaceutics and Central Clinical Pharmacy, Pecs, Hungary; 2University of Debrecen – Medical Centre, Central Pharmacy, Debrecen, Hungary

10.1136/etapharm-2015-000639.280

Background Pharmacoepidemiological studies have demonstrated an excess risk of hip fractures attributable to the use of antidepressants. In a recent systematic review the pooled relative risk (RR) of hip fracture was 1.70 for antidepressant users, compared to non-users. The potential impact of the use of antidepressants on the rate of hip fracture in Hungary has not been studied before.

Purpose To quantify the possible relationship between antidepressant consumption and the excess risk of hip fracture in Hungary, based on the results of published studies and national drug use data in 2012. The population-attributable risk (PAR) of hip fracture associated with the use of antidepressants was evaluated. We also estimated the yearly cost of the operations after hip fractures related to antidepressant use.

Material and methods For most countries, the prevalence (Pe) of antidepressant use can only be estimated if Intercontinental Medical Statistics and freely available public databases
(Denmark, the Netherlands, Norway) are used for data extraction. Pe in Hungary can be estimated using the following formula:

\[
\text{Estimated } \text{Pe}_{\text{Hungary}} = \left( \frac{\text{Antidepressants DDDs}/1,000 \text{ persons/day}}{\text{Public databases}} \right) \times \text{Pe}_{\text{Public databases}}.
\]

Pe and the pooled RR from the systematic review of published studies were combined with the following formula to calculate country-specific PAR%:

\[
\text{PAR}\% = \left\{ \left( \frac{\text{Pe} (RR - 1)/1 + \text{Pe} (RR - 1))}{100} \right) \right\}.
\]

The cost of the operations after hip fractures was calculated using national data.

**Results** The Hungarian antidepressant consumption is 26.87 DDDs/1,000 persons/day. The estimated PAR of antidepressants on hip fracture rates in Hungary is 2.12% (95% CI, 1.44–2.95). The estimated PAR for the Hungarian population above 65 years is 3.86% (95% CI, 2.62–5.32).

The estimated yearly cost of the operations after hip fractures related to antidepressant use is 1.5–2.5 million Euros in Hungary.

**Conclusion** Our findings suggest that the potential contribution of antidepressant use to the population rate of hip fractures is 2.12% in Hungary, which may cause a significant social burden.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**DI-093 PREDICTORS OF NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS**

1S Llamas*, 2S El Mahmoud, 3E Gutierrez, 2D Lopez, 2A Castillo, 2J Juan, 2J Ortiz de Urbina, 2L Ortega, 2M Medina, 2R Ruano. 1Complejo Asistencial Universitario de Leon, Medicina Familiar, Leon, Spain; 2Complejo Asistencial Universitario de Leon, Farmacia Hospitalaria, Leon, Spain; 3Complejo Asistencial Universitario de Leon, Neumología, Leon, Spain

**Background** Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality, transforming HIV into a chronic disease. The increase in life expectancy in these patients has led to a higher prevalence of comorbidities and use of concomitant medicines, which may limit adherence and therapeutic success.

**Purpose** To determine the prevalence of other chronic diseases in HIV-infected patients and to identify predictors of non-adherence to HAART.

**Material and methods** Single-centre retrospective study that included HIV-infected patients on HAART who attended pharmaceutical care at a pharmacy service from January to December 2013. The dependent variable was non-adherence to HAART (patients were considered non-adherent to HAART if the percentage of adherence through dispensing records was <90%). The independent variables were: sex, age, number of chronic diseases and concomitant medicines, and the presence of specific diseases (viral liver disease, dyslipidaemia, central nervous system disease, cardiovascular disease or hypertension).

**Statistical analysis:** to identify independent predictors of non-adherence, we performed a multivariable logistic regression analysis.

**Results** A total of 598 patients were analysed. 78.9% were men, mean age was 48 years (IQR: 42–52). The average number of comorbidities per patient was 1.6 ± 1.4. 31.3% of patients had viral liver disease, 17.9% dyslipidaemia, 15.6% central nervous system disease and 14.4% cardiovascular disease or hypertension. The average number of concurrent drugs per patient was 1.9 ± 2.7. 85.3% of patients were adherent to HAART. In the multivariate analysis, presence of viral liver disease was the only variable significantly associated with non-adherence to HAART (OR: 1.81); p = 0.02. The number of chronic diseases and concurrent drugs was not associated with non-adherence.

**Conclusion** The prevalence of other chronic diseases in HIV-infected patients was high. The presence of viral liver disease was identified as a predictor of non-adherence in HIV-patients in this study.

**REFERENCE**


No conflict of interest.

**DI-094 TREATMENT OF PULMONARY EMPHYSEMA ASSOCIATED WITH ALPHA-1-ANTITRYPSIN DEFICIENCY**

1Gómez Fernández, 2Jiménez Galan, 3Borrego Izquierdo, 4Mar Canto Cuenca, 2Orantes Casado de Amezua, 3Calvo Cidoncha, 1Manzano García, 2Haro Márquez, 2Morillo Verdugo. 1Hospital de Valme, Pharmacy Service, Seville, Spain; 2Hospital Virgen de Las Nieves, Pharmacy Service, Granada, Spain

**Background** Alpha-1-antitrypsin deficiency (AATD) is an inherited disorder that predisposes to the development of emphysema. Replacement therapy is an expensive chronic treatment.

**Purpose** To describe the characteristics of patients diagnosed with AATD and emphysema in our hospital. To follow up their progress using spirometric data and the number of hospitalizations before and after one year of treatment.

**Material and methods** A retrospective study of the individual progress of patients with AATD who have been treated with replacement therapy. Review of medical records and pharmacy dispensing data. Variables: sex, age at diagnosis, phenotype, FVC, FEV1, FEV1/FVC and number of exacerbations that required hospitalisation before and after treatment.

**Results** 8 patients received replacement therapy. The average age was 51 ± 10 years. 7 patients had the piZZ deficient phenotype and 1 MM phenotype and null/null genotype. The guideline in all cases was 180 mg/kg every 21 days as an intravenous infusion. AAT values at diagnosis ranged from 9 mg/dL to 82 mg/dL. In 2 patients, the number of hospitalizations was low once the treatment started. In 1 patient the number of hospitalizations increased. The average FEV1 before starting treatment was 1.30 ± 0.19 L and one year after was 1.33 ± 0.48 L, representing an increase of 0.029 L. The average FEV1/FVC prior to treatment was 42.9 ± 8.02 L and 46.15 ± 7.24 L a year after, increasing by 3.26 L after one year of treatment.

**Conclusion** The objective in AAT replacement therapy is to slow down the progression of emphysema and respiratory functional impairment, reducing severe exacerbations. We wish with the results obtained that the treatment is effective because the respiratory parameters in our patients were stable after one year of treatment showing a slight increase, and the number of hospitalisation due to respiratory causes was practically unchanged. However, the limited number of cases and follow-up is insufficient to generalise findings. Larger cohorts are required.
General management

GM-001 THE USE OF PERFORMANCE INDICATORS TO IMPROVE STANDARDS, AND TO IDENTIFY ‘PERFORMANCE CONCERNS’ IN INDIVIDUAL PHARMACISTS

1 S Amamleh*, 2 B Oldughir. 1Pharmaceutical Services Manager, Pharmacy Department, Netania, Israel; 2 Volunteer, Pharmacy, Netania, Israel

10.1136/ejhpharm-2015-000639.283

Background Each pharmacist has an ‘area’ of responsibility governed by specific guidelines. How performance indicators (PIs) can be used to audit work and to show continuous improvement is documented in the literature. However, the ability to identify ‘Performance concerns’ in pharmacists, is not well documented.

Purpose To show measurable improvement in the quality of service provision.

To identify any pharmacist (s) with ‘performance concerns’.

Material and Methods The ‘audits’ were performed by a pharmacist qualified in audit work. Three areas were audited – cytotoxic drugs, galenical preparation and narcotics. 52 PIs were used to score various procedures on a scale of 1–10 (1–2 unacceptable, 3–4 poor, 5–7 fair, 8–9 good, 10 excellent). 6 PIs were specific to prescription inaccuracies.

The April 2014 audit covered the previous 3 months’ work. Audits were repeated in June and August 2014. Performance concerns may be indicated by no improvement in repeated audits and/or persistent low scoring PIs.

Results The April audit showed 73% PIs to be good-excellent, 18% fair in ‘Narcotics’. 71% PIs good-excellent, 21% fair in ‘Galenicals’, 41% good-excellent, 23% fair in ‘Cytotoxics’.

The June audit showed 100% PIs to be good-excellent, 0% fair in ‘Narcotics’. 96% good-excellent, 4% fair in ‘Galenicals’. 71% good-excellent, 23% fair in ‘Cytotoxics’.

The August audit showed 100% PIs to be good-excellent, 0% fair in ‘Narcotics’. 96% good-excellent, 4% fair in ‘Galenicals’. 71% good-excellent, 23% fair in ‘Cytotoxics’.

The percentage of inaccurate prescriptions in all 3 areas during the audit period was 7–12%.

Conclusion
1. Using PIs led to improved standards within an 8 month trial period.
2. The area which improved least was cytotoxics. The reason has not been determined but this may indicate a performance concern, which requires further investigation.
3. The rate of inaccurate prescriptions reflects an educational issue.
4. Incorporating PIs into hospital departments would contribute to improving standards and would bring to light performance concerns in health care professionals.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

GM-002 IMPROVING MEDICINES MANAGEMENT IN THE HOSPITAL DISCHARGE SETTING THROUGH PHARMACIST INTERVENTION IN THE SYNCHRONISATION OF COMPUTER APPLICATIONS

E Villamañán*, C Lara, M Ruano, T Baumann, L Balade, H Varela, A Herrero. La Paz University Hospital, Pharmacy, Madrid, Spain

10.1136/ejhpharm-2015-000639.284

Background Lack of synchronisation between hospital applications involved in the medicines use process (MUP) leads to inefficient use of resources.

Purpose To prove that pharmacist intervention (PI) in the integration of information recorded in computer applications improves medicines management in the discharge setting (DS).

Material and methods Longitudinal, prospective, study (10 days) in a tertiary hospital (1,350 beds). Adult patients being discharged from medical and surgical specialties were evaluated (410 beds). Discharges are recorded in a bed management computer application (BMCA). Every 20 min this information is transferred to CPOE so that electronic prescriptions (EPs) are automatically inactivated. At discharge, because of lack of synchronisation, EPs were incorrectly remaining active. This outdated information was transferred to the automated pharmacy medicines dispensing systems (APMDS) which meant that these medicines were being dispensed to the ward as if the discharged patients were being admitted. Subsequently, they were returned to the pharmacy.

Pharmacists confirmed discharges daily, consulting the BMCA. Once verified, they updated EPs in CPOE, avoiding unnecessary dispensing of medicines. Primary endpoint: number of EPs updated by PI in CPOE. We also analysed the number of medicines whose unnecessary dispensing and subsequent return to pharmacy was avoided by PI and working time saved.

Results We evaluated 361 patients DS. PI updated EPs of 132 (36.6%) outdated because of lack of synchronisation between BMCA and CPOE. The remaining 229 didn’t require PI, as the information recorded in CPOE when it was transferred to APMDS was correct. 1,012 EPs out of 3,327 (30.4%) were updated by PI. Without PI, these prescriptions would have generated unnecessary dispensing of 3,601 medicines. PI led to a total saving of 9.36 h of two pharmacy technicians’ work re-entering medicines unnecessarily dispensed to the ward.

Conclusion PIs reduced dispensing failures arising from lack of real-time transmission between hospital applications. Greater synchronisation between BMCA and CPOE would have avoided most of them. PIs improved MUP in DS, saving time and avoidable pharmacy workload.

REFERENCES

1 Nursing staff

No conflict of interest.

GM-003 EVALUATION OF THE EFFECTIVENESS OF A BASIC TRAINING COURSE: THE PROCESS OF PHARMACEUTICAL LOGISTICS, PROSPECTS AND CHALLENGES FOR THE NATIONAL HEALTH SERVICE

1 S Coppolino*, 2 M Pari, 3 S Adami, 4 S Bartolini, 5 M Tommasi, 5 G Turchetti. 1 SIFO, Area Logistica E Innovazione, Messina, Italy; 2 SIFO, Area Logistica E Innovazione, Pisa, Italy; 3 SIFO, Area Logistica E Innovazione, Venezia, Italy; 4 SIFO, Area Logistica E Innovazione, Termini, Italy; 5 SIFO, Area Logistica E Innovazione, Verona, Italy

10.1136/ejhpharm-2015-000639.285

Background Lack of synchronisation between hospital applications involved in the medicines use process (MUP) leads to inefficient use of resources.

Purpose To prove that pharmacist intervention (PI) in the integration of information recorded in computer applications improves medicines management in the discharge setting (DS).

Material and methods Longitudinal, prospective, study (10 days) in a tertiary hospital (1,350 beds). Adult patients being discharged from medical and surgical specialties were evaluated (410 beds). Discharges are recorded in a bed management computer application (BMCA). Every 20 min this information is transferred to CPOE so that electronic prescriptions (EPs) are automatically inactivated. At discharge, because of lack of synchronisation, EPs were incorrectly remaining active. This outdated information was transferred to the automated pharmacy medicines dispensing systems (APMDS) which meant that these medicines were being dispensed to the ward as if the discharged patients were being admitted. Subsequently, they were returned to the pharmacy.

Pharmacists confirmed discharges daily, consulting the BMCA. Once verified, they updated EPs in CPOE, avoiding unnecessary dispensing of medicines. Primary endpoint: number of EPs updated by PI in CPOE. We also analysed the number of medicines whose unnecessary dispensing and subsequent return to pharmacy was avoided by PI and working time saved.

Results We evaluated 361 patients DS. PI updated EPs of 132 (36.6%) outdated because of lack of synchronisation between BMCA and CPOE. The remaining 229 didn’t require PI, as the information recorded in CPOE when it was transferred to APMDS was correct. 1,012 EPs out of 3,327 (30.4%) were updated by PI. Without PI, these prescriptions would have generated unnecessary dispensing of 3,601 medicines. PI led to a total saving of 9.36 h of two pharmacy technicians’ work re-entering medicines unnecessarily dispensed to the ward.

Conclusion PIs reduced dispensing failures arising from lack of real-time transmission between hospital applications. Greater synchronisation between BMCA and CPOE would have avoided most of them. PIs improved MUP in DS, saving time and avoidable pharmacy workload.

REFERENCES

1 Nursing staff

No conflict of interest.
Background The growth of healthcare spending and the concurrent gradual reduction of resources require interventions oriented to the reorganisation of drugs supply chain and medical devices in the various steps from the manufacturer to the bed of the patient and/or his house. Logistics and innovation of hospitals and territorial structures thus possess a key role in increasing the efficiency and quality of health services.

Purpose The purpose of this study is to evaluate satisfaction and effectiveness of a basic training program about pharmaceutical logistic processes organised and held from the Logistic SIFO Area (LSA).

Material and methods During the period starting from February to April 2014 there were three training sessions (Catania, Torino, Pisa) lasting thirteen hours with a total of 70 participants. By administrating a course satisfaction questionnaire and an evaluation of the belonging structure it was possible to characterise both the course participants and the ability to transfer what they have learnt in their working contexts. The responses, assessed anonymously, were processed statistically.

Results 70 satisfaction and 60 self-assessment questionnaires were analysed. 52% of participants judged as "highly important" all topics treated and 50% rated as "very important" the educational quality of the course. The analysis of the questionnaire for the performance assessment showed that participation in the course increased by 70% in the learners' willingness to improve their organisational system and raised awareness in the need for performance investigation analysis tools, new technologies, constraints given by the Regional Administration and LHA. 60% of participants found organisational barriers in the modification of the current pharmaceutical logistics paths.

Conclusion Obtained data allowed us to verify the effectiveness of the methodology adopted by the LSA dealing with issues relevant to the profession, as well as highlighting both the utility to carry out further editions of the Basic Course and to develop an Advanced Course.

REFERENCES AND/OR ACKNOWLEDGEMENTS

None

No conflict of interest.

GM-004 IMPROVEMENT OF CUSTOMER FOCUS USING A QUALITY REQUIREMENT SELF-ASSESSMENT

C Béchet, L Memindon, P Bonnaby, R Pichon. Pharmacie Des Hôpitaux Du Nord Vaudois Et De La Broye, Pharmacy, Yverdon-Les-Bains, Switzerland; 2University Hospitals of Geneva, Pharmacy, Geneva, Switzerland; 3University of Geneva– University of Lausanne, School of Pharmaceutical Sciences, Geneva, Switzerland

Background Quality standards invite organisations to determine and meet customer requirements in order to continually improve customer satisfaction. However, a certification organisation stressed that customer focus was insufficiently developed in our facility. This deficiency could lead to serious repercussions as this hospital pharmacy is independent from its customers and is currently evolving in a changing environment.

Purpose To develop a self-assessment tool to evaluate the pharmacy’s functioning in relation to customer-focused quality requirements.

Material and methods Requirements of an optimal customer-focused quality management system were obtained from two quality standards (ISO 9001 and a hospital pharmacy quality reference system (RQPH)). A three-person workgroup scored these requirements according to the level of realisation, the extent of measurements performed, the suitability of the implemented answer; and its relevance to the organisation (0 pt = non-existent, 1–2 pts = intermediate, 3 pts = optimal). By adding these four scores, a total score of maturity was obtained for each requirement (≤4 pts = insufficient; 5–8 pts = intermediate; ≥9 pts = satisfactory). The requirements that scored 0 pt for any criterion, 1 pt for their degree of realisation or a total score <5 pts, were selected for improvement.

Results 54 requirements were identified (ISO 9001 = 14; RQPH = 14 general, 26 specific). Most of them scored more points on their level of realisation and measurement than on suitability and relevance, indicating that customer-focused activities had probably been implemented merely to answer quality requirements, without being useful, usable or put into use. A mean score of 7.25/12 pts indicated an intermediate global maturity of the customer-focused quality management system. One-third of requirements were selected for improvement (4/14 ISO 9001, 14/40 RQPH). Various practical suggestions for improving the pharmacy’s functioning were finally made based on these results, and are currently being implemented.

Conclusion A quality requirement self-assessment tool was developed and tested successfully. It could be used by other organisations to assess their response to various quality requirements.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

GM-005 FINANCIAL EVALUATION OF CATARACT SURGERY IN A PUBLIC HEALTH HOSPITAL

W Ennefiah*, M El Wardi, A Cheikh, M El Mouabid, D Lezek, Y Rahali, D Daoudi, Y Besnouda. 1Specialties Hospital of Rabat – Faculty of Medicine and Pharmacy, Pharmacy, Rabat, Morocco; 2Cheikh Zaid International Hospital – Faculty of Medicine and Pharmacy, Pharmacy, Rabat, Morocco; 3Specialties Hospital of Rabat – Faculty of Medicine and Pharmacy, “A” Optalmology, Rabat, Morocco

Background With more than 1,000 cataracts operations performed per year, our hospital is considered one of the national reference centres for this surgery.

In contrast to Extracapsular Cataract Extraction (ECCE), phacoemulsification is the most used technique at our hospital (84% of cataracts operated on) and requires costly consumables contributing to the overall cost of care.

Purpose To compare the proportion of Pharmaceutical Products (PPs) costs in the amounts billed according to cataract surgery types and to patients’ Medical Tariff Categories (MTC).

Material and methods To evaluate the cost of the PPs used in uncomplicated cataract surgery with lens implantation by both standard techniques, and its impact on the amount billed to patients’ MTC, we studied data from 1,073 patients operated on in 2013 (901 by phacoemulsification and 172 by ECCE). Information relating to the cost of PPs and billing packages was collected from our hospital’s financial department.

Results Our study results (table 1) reveal that for phacoemulsification, the cost of PPs consumes 64% of the billing package in insured patients and 93% of the billing package in uninsured patients, in contrast to the ECCE for which the cost of PPs consumes only 20% of the billing packages in both patients’ MTC.
Critical analysis of conventional customer satisfaction indicators in hospitals

**Background**
Customer satisfaction is characterised by its complexity and highly subjectivity in hospitals. Indeed, experience has shown that Conventional Customer Satisfaction Indicators (CCSIs) which have proved their relevance in many areas, may not be suitable in hospitals.

**Purpose**
To determine the limits of CCSIs in hospitals.

**Material and methods**
This is a descriptive study of customers and their needs in hospitals followed by a critical analysis of CCSIs. As the model presented, we studied direct customers of our Hospital Pharmacy (HP).

Data on pharmacy customers, their needs and CCSIs for their satisfaction were extracted from our pharmacy procedures booklet and quality manual, as well as from the complaints register and the satisfaction questionnaires completed by the customers concerned.

**Results**
Direct customers of HP are: Care Units (CUs), administrative department, financial department and suppliers.

The table below illustrates pharmaceutical needs of the first category of customers (CUs), CCSIs used and their possible deficiencies:

**Conclusion**
Critical analysis of CCSIs in hospitals allowed us to identify many deficiencies. These findings will be used to develop new indicators that are more appropriate for the hospital context. For example we can imagine introducing an Index for Request Adequacy (IRA) to adjust the conventional RSR: Adjusted RSR = [(Quantity of dispensed drugs/(Quantity of requested drugs × IRA)]) × 100.

\* 0 < IRA ≤ 1 (The IRA must lie between 0 and 1).

**REFERENCES AND/OR ACKNOWLEDGEMENTS**
No conflict of interest.
The records had 15% of errors in the first audit: 4 patients, 2 belonging to RT and 2 D who were registered in GCN. In the second, there was one error (4%): a patient belonging to D was recorded in GCN.

The health area had a 19% errors in the first audit (5 patients). In the second no errors were detected.

The type of patient was wrongly recorded, in the first audit 4 patients (8%), and 2 (4%) in the second.

Conclusion The IP was successful. The first audit showed worse results than the second. Therefore using the Deming cycle enabled us to improve the quality of medical records.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

GM-008 IMPLEMENTATION OF AN OBJECTIVE STRUCTURED CLINICAL EXAMINATION AND EVALUATION CHECKLISTS AT AN INSTITUTE OF CLINICAL PHARMACY
1B Zeiter, 2M Bayer, 1I Kraemer. 1Universitätsmedizin Mainz, Mainz, Germany; 2Universitätsmedizin Mainz, Hospital Pharmacy, Mainz, Germany
10.1136/ejhpharm-2015-000639.290

Background Objective structured clinical examination (OSCE) has proved to be a reliable and valid tool for assessing the communications skills of medical students. As a consequence of introducing the practice-oriented education of pharmacy students into the clinical pharmacy curriculum, the assessment of training success also has to be re-structured. Up till now, only very few voluntary OSCEs are being performed at the pharmacy faculties in the investigated country.

Purpose To implement a reliable and valid OSCE using self-developed evaluation checklists for pharmacy students at a clinical pharmacy Institute.

Material and methods 38 students in the 6th semester of their pharmacy studies took the OSCE during the summer term of 2014. The students’ success was assessed by experts (pharmacists) using self-developed evaluation checklists. The reliability of the checklists was analysed by inter-rater agreement (kappa). Post-hoc all six experts separately evaluated the performance of six students in each of the six OSCE examination units (insulin administration, inhalation, compliance, interaction, over-the-counter medicines, drug information) which was video recorded during the OSCE.

Results According to the results of the evaluation checklists 36 students (95%) passed the exam. The overall medium inter-rater agreement regarding the six units was moderate (k = 0.49). The highest inter-rater agreement was recorded for insulin administration (k = 0.83) and the lowest inter-rater agreement regarding the interaction check (k = 0.22).

Conclusion The design of the OSCE proved to be satisfactory and the evaluation checklists developed turned out to be a reliable fair tool for assessing communication skills in clinical pharmacy.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

GM-009 MULTICENTER STUDY OF ENVIRONMENTAL 5-FU CONTAMINATION DURING NORMAL MIXING OF ANTINEOPLASTIC DRUGS
1Y Sano*, 1T Morita Ogawa, 2Y Hayashi, 3T Ito, 4N Yokote, 5K Inoh, 6Y Suzuki, 7I Kato, 8S Takagi, 9S Sato. 1National Cancer Center Hospital East, Department of Pharmacy, Kashiwa-Shi, Japan; 2National Cancer Center Hospital, Department of Pharmacy, Chuo-Ku, Japan; 3National Hospital Organization Takasaki General Medical Center, Division of Pharmacy, Takasaki-Shi, Japan; 4National Hospital Organization Nishigunuma National Hospital, Division of Pharmacy, Shibakawa-Shi, Japan; 5National Hospital Organization Mito Medical Center, Division of Pharmacy, Higashibaraki-Gun, Japan; 6National Hospital Organization Tokyo Medical Center, Division of Pharmacy, Meguro-Ku, Japan; 7National Hospital Organization Chiba Medical Center, Division of Pharmacy, Chiba-Shi, Japan; 8National Hospital Organization Saitama National Hospital, Division of Pharmacy, Wako-Shi, Japan
10.1136/ejhpharm-2015-000639.291

Background Antineoplastic drugs have often been shown to be mutagenic, teratogenic and carcinogenic, and these drugs are recommended to be prepared in a biological safety cabinet (BSC). Among them, 5-fluorouracil (5-FU) is a common cytotoxic antineoplastic drug, and can potentially cause harm if not handled properly.

Purpose To investigate the relationship between the level of 5-FU contamination during normal mixing, the time spent in preparation, the operator’s experience in mixing, the number of 5-FU vials prepared during this study, and the number of anticancer agents prepared at each hospital.

Material and methods During preparation, 5-FU contamination was determined on 2 stainless steel plates (10 × 10 cm) in the BSC in 8 national hospitals. These stainless steel plates were collected at the end of the study period. Samples were analysed by a validated liquid chromatography coupled to tandem mass spectrometry method.

Results The subjects were 16 pharmacists from 8 hospitals. The median preparation experience was 18 months (1–168 months), and the median number of 5-FU vials prepared by each pharmacist was 7 vials (2–38 vials). The level of 5-FU contamination was 2,079.5 ng (0–10,148.0 ng)/200 cm². Comparing the level of contamination to the amount of 5-FU prepared, the time spent in preparation, the years of preparation experience, and the number of anticancer agents prepared at each hospital, no correlations were observed ($r^2 = 0.0062, 0.0002, 0.0562, 0.016$).

Conclusion 5 pharmacists achieved 5-FU contamination at levels below the detection limit. Importantly, years of preparation experience varied among these pharmacists. These results suggested that even experienced pharmacists may underestimate the risk of environmental exposure during normal preparation. Routine training in mixing skills is needed to safely handle antineoplastic agents.

REFERENCE

No conflict of interest.
Background Drug incompatibilities, such as precipitates, may contribute to the clinical deterioration of paediatric patients (sepsis), especially when infusing vancomycin and piperacillin (VAN/PIP). Drug concentration and infusion sets affect the overall particulate contamination of paediatric infusion protocols. Using multilumen infusion sets could prevent these incompatibilities.

Purpose To define and assess a new way to infuse VAN/PIP during leukæmia treatment in paediatric patients, without any visible precipitate.

Material and methods Two infusion sets were studied, which differed in design and drug dead-space volume (V): 1) a standard single lumen set with 2 four-port manifolds with extension lines (ref RPB4320, Cair LGL, France; V ~ 12 mL) and 2) a 5-lumen infusion set (ML-5) (Edelvaiss-Multiline, Doran International, France; V ~ 1 mL). Different vancomycin concentrations (VANC) were tested to infuse VAN/PIP simultaneously without any precipitate (optimised multidrug protocol). A dynamic particle count test was performed (N = 5) over 24 h to evaluate the overall particulate contamination of our standard (VANc = 42 mg/mL) and optimised (VANC = 4 mg/mL) protocols, using both standard and ML-5. We performed a t-test.

Results No visible particles were detected on reducing VANC (4 mg/mL) instead of the standard dose (42 mg/mL). For the optimised multidrug protocol, using the ML-5 reduced the overall particulate contamination by 68%, compared to the standard infusion set (716,349 ± 89,322 vs. 251,980 ± 49,429; p = 0.002). The number of large particle sizes was significantly reduced when using the ML-5 (~ 60% (p = 0.027) and 90% (p = 0.009) for particle sizes ≥10 and 25 μm, respectively.

Conclusion This study demonstrated the large number of particles administered during parenteral multidrug infusion. This can be minimised through the choice of the drug concentration and/or the type of infusion set. Although this kind of contamination is invisible, further studies are required to evaluate its adverse clinical impact.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
Production and preparation

PP-001 VALIDATION OF CLEANING IN A MULTIPURPOSE FACILITY FOR NON-STERILE PRODUCTS

1. Andersen*, 2. Rasmussen, 3. Thorsen. 1Region Hovedstaden’s Apotek, Production, Herlev, Denmark; 2Region Hovedstaden’s Apotek, Non-Sterile Production, Herlev, Denmark

Background Preparation in Hospital Pharmacies aims at meeting special patient needs. In general facilities and equipment are intended for preparation of a variety of products containing a diversity of Active Pharmaceutical Ingredients (API). Cleaning validation has to be performed according to EU GMP, which requires limits for Maximum Acceptable Carryover (MAC) to be established based on toxicological evaluations. Furthermore, effectiveness of the cleaning has to be documented using validated methods of analysis.

Purpose To develop models for establishing limits for MAC in general, and for validating the cleaning of equipment used for the preparation of suppositories in particular.

Material and methods A model for establishing limits for MAC was developed in close cooperation with acknowledged toxicologists with experience from food science. The MAC was calculated based on toxicological evaluations and calculations of the total surface area of equipment.

Riboflavin was found to be a suitable marker for API and a method was developed in order to detect any residues with a UV lamp. The method was tested for specificity, stability, reproducibility and accuracy. Limit of detection (LOD) was documented by testing a range of different concentrations of riboflavin for UV activity. For hot spots in the equipment it was furthermore documented, that any residues will be detected during the visual control with the UV lamp.

Cleaning validation included preparation of a test batch with riboflavin replacing the worst case API. After production the equipment was cleaned using standard procedures. Subsequently visual control was performed and rinse samples from the equipment were analysed for UV activity.

Results The analytical method was validated and LOD was documented to be 0.05 μg/ml – significantly lower than MAC. Cleaning of equipment used for production of suppositories was successfully validated using the riboflavin UV analytical method.

Conclusion Experience from food science can be used to establish limits for MAC. The riboflavin/UV analytical method is highly suitable for validating the cleaning of equipment used for suppositories.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PP-002 COMPATIBILITY AND STABILITY OF HYOSCINE N-BUTYL BROMIDE AND FUREOSEMIDE ADMIXTURES FOR USE IN PALLIATIVE CARE

1. C Bosch-Ojeda*, 2. M Espinosa-Bosch, 3. Sánchez-Rojas. 1Universidad de Málaga, Facultad de Ciencias, Química Analítica, Málaga, Spain; 2Hospital Regional Universitario de Málaga, UGC de Farmacia, Málaga, Spain; 3Facultad de Ciencias, Universidad de Málaga, Química Analítica, Málaga, Spain

Background In order to avoid separate injections, admixtures of drugs are frequently used in palliative care settings. There is a lack of evidence about the stability and compatibility of the combination of hyoscine N-buty bromide and furosemide.

Purpose To evaluate the compatibility and stability of three admixtures of hyoscine N-buty bromide and furosemide at different concentrations and at two temperatures (25°C and 37°C) in NaCl 0.9% stored in elastomeric infusors protected from light.

Material and methods The samples were prepared and diluted in NaCl 0.9% in elastomeric infusors in triplicate to obtain six different conditions of concentration and/or temperature of storage (concentration: 2.0 mg/ml–2.0 mg/ml, 1.0 mg/ml–0.6 mg/ml and 0.6 mg/ml–0.6 mg/ml of hyoscine N-buty bromide and furosemide respectively; temperature 25°C and 37°C).

The concentration of each constituent drug was periodically determined using a HPLC-UV method. The drugs were chromatographed on a C18 reverse phase column and determined at 220 nm by interpolation from the calibration curves prepared at (0, 1, 2, 3, 7, 11, 15, 20) days from the standards; the mobile phase was acetonitrile-water 80:20 (v/v); flow rate 1.5 ml/min.

Results The stability of the admixtures diluted in NaCl 0.9% were as follows: hyoscine N-buty bromide-furosemide (2.0 mg/ml–2.0 mg/ml) was stable (retained >95% of their initial concentrations) two days at 25°C and 37°C; (1.0 mg/ml–0.6 mg/ml) was stable eight days at 25°C and two days at 37°C; (0.6 mg/ml–0.6 mg/ml) was stable twelve days at 25°C and three days at 37°C.

Conclusion The admixture of hyoscine N-buty bromide and furosemide in NaCl 0.9% in elastomeric infusor can be safely used in palliative care for at least two days. Lower concentrations of the admixture can be prepared in advance and stored at room temperature, but the infusion cannot take longer than three days.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
Production and preparation

PP-003 PRODUCTION AND STABILITY OF A READY-TO-USE HYDROXOCOBALAMIN SOLUTION FOR PAEDIATRIC PARENTERAL USE

R Moudry*, S Homstein, M Fehr-Bigger, S Gayer. Kantonsospital Graubünden, Institute for Hospital Pharmacy, Chur, Switzerland

10.1136/ehjpharm-2015-000639.297

Background A paediatric patient in our hospital suffers from a rare, hereditary transcobalamin II deficiency resulting in an intracellular vitamin B12 deficiency. Treatment consists of massive parental intake of vitamin B12. Parenteral vitamin B12 solution, suitable for children under 3 years of age, is not commercially available in our country.

Purpose The aim was to produce a preservative-free, sterile hydroxocobalamin (vitamin B12) solution at a concentration of 10 mg/2ml for intramuscular use and to develop an analytical method of indicating the stability in order to determine the shelf life of the solution.

Material and methods The entire manufacturing process took place under aseptic conditions. Hydroxocobalamin hydrochloride was dissolved in NaCl 0.9% to give a concentration of 10 mg/2ml. The pH value was adjusted to 4.3–4.5 using hydrochloric acid. The solution was 0.2 μm filtered and finally, 2.4 ml of solution was aseptically added into sterilised brown glass vials. The filter integrity was tested using the bubble point method. The vials were kept in a refrigerator. Alternatively, the solution was autoclaved at 121°C for 15 min and assessed by high performance liquid chromatography (HPLC) for degradation products.

Results The autoclaved solution contained degradation products and the hydroxocobalamin content had decreased by 20%. In contrast, the sterile filtered solution showed no degradation products and no loss in the hydroxocobalamin content was observed after storage for 24 months at 2–8°C. The solution was stable when stored for one month at room temperature and even exposure to 56°C for 2 days did not cause the product to degrade.

Conclusion We produced a hydroxocobalamin solution for intramuscular use with a shelf life of at least 24 months if refrigerated. The treatment of our patient with this solution, administered as an intramuscular injection once a week, has been extremely successful for more than 3 years.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PP-005 COMPLETE FORMULAE FOR PARENTERAL NUTRITION IN NEONATAL INTENSIVE CARE: A STABILITY TRIAL

C Crespini*, G Bersani, E Menegatti. 1ULSS 18 Rovigo, Dipartimento Tecnostruttura Sanitaria – SOC Farmacia Ospedaliera, Rovigo, Italy; 2PoliClinico S. Orsola – Malpighi, Farmacia Clinica, Bologna, Italy; 3Università Degli Studi Di Ferrara, Dipartimento Di Scienze Della Vita E Biotecnologie, Ferrara, Italy

10.1136/ehjpharm-2015-000639.299

Background Parenteral Nutrition (PN) is a technique of Artificial Nutrition used to feed patients who cannot or should not get their nutrition through eating. Preparation is complicated because it involves mixing, with aseptic technique, nutritional substrates with different chemical-physical features (water, glucose, amino acids, electrolytes, trace elements and vitamins) to obtain a sterile nutritional emulsion that must be stable during preparation, storage and administration.

Purpose To check the stability of nutritional formulae for parenteral nutrition.

Material and methods Six nutritional formulae were prepared, three variations for each, using three kinds of lipid emulsion. Also added: long chain triglycerides (LCT) emulsion from soybean oil and medium chain triglycerides (MCT) emulsion from coconut oil; enriched lipid emulsion (LCT + MCT) from soybean, olive, coconut and fish oils; omega-3 emulsion from refined fish oil. Each formula was prepared with different calcium concentrations, which, together with viscosity, is the critical parameter that affects Zeta potential and consequently stability. Analysis was performed using a helium-neon laser granulometer on diluted samples at time 0 and after 24, 48, 72 and 96 h in order to reproduce normal storage conditions and clinical use.

PP-004 QUALITY CONTROL ASSESSMENT OF CYTOTOXIC BAGS BY UV-RAMAN SPECTROMETRY

G Kreutter*, C Boulanger, M Harsdörfer, S Zitouni, A Gairard-Dory, C Boulanger, M Herrada, S Zitouni, A Gairard-Dory, L Perello, B Gourieux, G Ubeaud-Sequier, 1ULSS 18 Rovigo, Dipartimento Tecnostruttura Sanitaria – SOC Farmacia Ospedaliera, Rovigo, Italy; 2PoliClinico S. Orsola – Malpighi, Farmacia Clinica, Bologna, Italy; 3Università Degli Studi Di Ferrara, Dipartimento Di Scienze Della Vita E Biotecnologie, Ferrara, Italy

10.1136/ehjpharm-2015-000639.298

Background About 6,000 cytotoxic bags per year are produced in the compounding unit of a University Hospital Pharmacy. Each bag is checked by UV-Raman spectrometry. This analytical technique presents many advantages for better efficiency: identification and quantification of results, short time of analyses (2 min) and a minimal volume sample (1 mL).

Purpose To evaluate the quality of cytotoxic bags prepared and analysed over 11 months by this spectrometry tool.

Material and methods All the drugs and solvents were identified and a calibration curve was constructed. Each drug is subject to quality control every week. For eleven months, cytotoxic bags were routinely produced and then checked by UV-Raman spectrometry. Criteria for acceptance was ±10% error. Tolerance occurred when error was between 10% and 15%. If ±15% error was found status was rejected.

Results 4838 cytotoxic bags were produced and checked in 11 months. 14 cytotoxic drugs were analysed by UV-Raman: carboplatin, cisplatin, cyclophosphamide, dacarbazine, doxetaxel, doxorubicin, etoposide, ganciclovir, gemcitabine, ifosfamide, oxaliplatin, paclitaxel, pemetrexed, vinorelbine. 92.1% of cytotoxic bags were in the concentration range of ±10%; 3.2% in the range ±15% and 2.0% with a difference of more ±15%. The preparations presenting most non-compliance were doxorubicin (18.8%), cyclophosphamide (14.3%) and ifosfamide (11.1%). 0.6% of analyses were a misidentification of the molecule.

Conclusion This study makes an assessment of the quality of production of our cytotoxic bags and shows that UV-Raman is a suitable technique for the analysis of drugs. These results highlight defects of preparation of some cytotoxic bags. Awareness-raising activities were undertaken in order that the team be more watchful during the preparation and some protocols have been improved. This approach is subject to a process of continuous improvement of the quality of drug preparations, in our laboratory which was recently ISO900 certified.

No conflict of interest.
Results The results of the analyses of lipid particles established different stabilities, depending on the different kind of lipids and concentration of calcium: nutritional formulae prepared with LCT + MCT have proved 96 h stability, independently of calcium concentration; nutritional formulae with enriched lipids and/or LCT/MCT and lipids from refined fish oil have been proved stable only if the calcium concentration is less than 9 mEq/litre.

Conclusion The results suggest a 96 h shelf life from preparation for nutritional formulae prepared with LCT + MCT. Stability is maintained only if the calcium concentration is less than 9 mEq/litre in nutritional formulae prepared with enriched lipids or with the addition of LCT + MCT and fish oil.

REFERENCE
1. SNPE Guidelines for Hospital Artificial Nutrition 2002; RINPE Year 20, 55: Update October 2003

No conflict of interest.


1JD Hecq*, 2SHuvelle, 3MG odet, 3JJ amart, 2LG alanti. 1CHU Dinant Godinne – UCL Namur, Pharmacy, Yvoir, Belgium; 2CHU Dinant Godinne – UCL Namur, Medical Laboratory, Yvoir, Belgium; 3CHU Dinant Godinne – UCL Namur, Scientific Support Unit, Yvoir, Belgium

Background Microwave freeze-thaw treatment (MFTT) of injectable drugs can support the development of centralised intravenous admixtures services (CIVAS).

Purpose The aim of the review is to collect information and results about this method.

Material and methods A systematic review of the scientific literature about drug stability studies was made. The data are presented in a table and describe name of the drug, producer, final concentration, temperature and time of freezing storage, type of microwave oven, thawing power, method of dosage and results after treatment or final long-term storage at 2°C.

Results After treatment and/or LCT/MCT and lipids from refined fish oil have been proved stable only if the calcium concentration is less than 9 mEq/litre.

PP-007 STABILITY OF DILUTED AND RECONSTITUTED ANTINEOPLASTIC DRUGS: UPDATED 2014


Background The lack of published studies on stability of antineoplastic drugs and the contradictory character of the information available increased the need to carry out an internal review in our hospital.

Purpose To investigate the physical-chemical stability of vials of antineoplastic drugs included in the hospital’s Therapeutic Prescription Guide after opening and/or reconstitution.

Material and methods We reviewed all information available in the Spanish Medicines Agency Technical Data Sheets, Micromedex, Stabilis, papers on PubMed and updated guides published by other hospitals in order to establish the physical-chemical stability of these types of drugs.

Results The following storage conditions and maximum storage times were found for 35 cytostatic drugs in use in the hospital: 24 months refrigerated (α 2-B interferon), 90 days at room temperature (RT) (cetuximab), 90 days refrigerated and protected from light (PL) (bevacizumab), 31 days refrigerated PL (pemetrexed), 30 days refrigerated and PL (methotrexate, rituximab, vinorelbine), 28 days at RT (eribulin, etoposide, paclitaxel), 28 days at RT and PL (cisplatin, docetaxel, fluorouracil), 28 days refrigerated (vinblastine), 28 days refrigerated and PL (doxorubicin, pegylated liposomal doxorubicin), 26 days at RT and PL (fludarabine), 22 days refrigerated (mitoxantrone), 21 days refrigerated and PL (carboplatin, ifosfamide), 14 days refrigerated and PL (cyclophosphamide, epirubicin, oxaliplatin, topotecan, mitomycin, vincristine), 8 days frozen with WFI (water for injection) (azacitidine), 7 days at RT (carmustine, irinotecan), 7 days refrigerated and PL (cytarabine), 7 days refrigerated and PL (dactinomycin, daunorubicin, gencitabine, non-pegylated liposomal doxorubicin and idarubicin).

Conclusion The storage protocol was modified for cytostatic vials that had been opened/reconstituted under aseptic conditions using a vertical laminar flow cabinet depending on their maximum stabilities. The resulting document was thereafter incorporated into regular working practice. The updated protocol resulted in the medicines being used safely and significant savings on these costly drugs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Oncology Department
No conflict of interest.

PP-008 PROMETHAZINE HYDROCHLORIDE INJECTION, FORMULATION AND PHARMACODYNAMIC EFFICACY

1E Najdovska*, 2I Bajgar. 1Clinical Hospital – Bitola, Manufacturing of the Steril Products, Bitola, FYROM; *Institute of Nephrology, Hospital Pharmacy, Struga, FYROM

Background Promethazine hydrochloride is phenothiazine derivative which possesses antihistaminic, sedative, anti-motion sickness, antiemetic, and anticholinergic effects. Promethazine is a competitive H1 receptor antagonist, but does not block the release of histamine. Structural differences from the neuroleptic
phenothiazines result in its relative lack of dopamine antagonist properties. Clinical effects are apparent within 5 min of an intravenous injection and within 20 min of an intramuscular injection. Duration of action is four to six hours, effects may persist up to 12 h. Promethazine hydrochloride is metabolised in the liver.

We cannot obtain commercially prepared promethazine injection in our country.

Purpose To formulate promethazine hydrochloride injection and to evaluate its quality and stability.

Material and methods Parenteral promethazine hydrochloride 5% injection (50 mg/ml) was prepared in the Department for Compounding Sterile Products in our hospital, following established procedures for parenteral preparations. The content of promethazine hydrochloride was examined according the requirements of the Ph. Eur. The preparation was stored protected from light.

Results According to the Standard Operating Procedure, parenteral promethazine hydrochloride 5% injection was prepared aseptically in the laminar flow cabinet and sterilised by autoclaving. The final solution was then submitted to quality control, where a set of selected assays have been defined that ensure both raw material and final product are of assured quality.

Conclusion Promethazine hydrochloride 5% injection is a sterile solution of promethazine hydrochloride in water for injection. It contains 99–101% of 3-(10H-phenothiazin-10-yl)-N-dimethylpropan-1-amine hydrochloride calculated with reference to the dried substance. Packaging and storage are in well-closed, light-resistant containers as a single dose or multiple dose, preferably of Type I glass. It is determined with potentiometric titration using 0.1 M sodium hydroxide. The formulation manifested good quality in respect to physical properties, physico-chemical parameters and microbiological quality according to Ph. Eur. The dosage form was stable for a year in the conditions characteristic of the second (II) climate zone.

REFERENCE AND/OR ACKNOWLEDGEMENTS
1 Ph. Eur. monograph 1365
No conflict of interest.

PP-009 THE IPILIMUMAB DRUG DAY: AN INSTRUMENT TO CONTAIN COSTS

F Fiori*, C Laudisio, C Castellani, D Pacetti, A Tarantino, S Giorgi, M Rossetti. Azienda Ospedaliera Universitaria Senese, U. O. Farmacia, Siena, Italy

10.1136/ejhpharm-2015-000639.303

Background The great innovation of ipilimumab (available in our country since 2013) has been accompanied by a high cost that is a heavy burden for our NHS.

Purpose In order to contain the cost of ipilimumab, our hospital has established the Drug Day, with the objective of concentrating in a single day all patients who receive the same drug.

Material and methods With the collaboration of the Oncological-Immunotherapy department, we arrange two consecutive Drug Days (Thursday, Friday). The 21-day cycle of Ipilimumab administration helps us schedule these every 3 weeks, to avoid wasting the drug.

Results Advantages: The first day we prepared ipilimumab (3 May 2013), three patients were scheduled. The total dose was 693 mg, so we used 2 vials of 50 mg and 3 vials of 200 mg. If we had had patients on different days, we would have used 6 vials (750 mg) instead of the 700 mg that we actually used: we saved 1 vial of 50 mg which costs €2,953.

Remaining problems: The short stability of ipilimumab (24 h after reconstitution) restricts the potential of ipilimumab Drug Day. An example: on 5–6 December 2013 we had two patients per day who received the same dose (453 mg). If we could have used what was left over from the previous day we would have saved at least 1 vial of ipilimumab 50 mg in two days.

Conclusion From the introduction of ipilimumab in our hospital, to the end of 2013, we treated 27 patients, with 90 administrations, concentrated in 40 Drug Days. This saved €70,884. The system could be further improved if patients in the area of our hospital could have their blood tests on Thursday, then receive the drug (preparation at around 9:00 am) on Friday; this would allow us to move within 24 h stability, thus permitting the reuse of vials used on Thursday (prepared at around 12:00 pm).

REFERENCE AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PP-010 OPTIMISATION IN THE USE OF DRUGS FOR AGE-RELATED MACULAR DEGENERATION

J González Chávez*, R Madera Pajín, C Gallego Fernández, L Yunquera Romero, I Muñoz Castillo. Hospital Regional Universitario de Málaga, Pharmacy, Málaga, Spain

10.1136/ejhpharm-2015-000639.304

Background Antiangiogenic drugs are the treatment of choice for age-related macular degeneration (AMD). They are expensive due to the high cost of vials and absence of commercial syringes with the necessary dose.

Purpose To compare the efficiency of alternative treatments available for AMD, ranibizumab and aflibercept, when optimising vials to prepare syringes with exact doses in the pharmacotechnical unit of the Pharmacy Service.

Material and methods Retrospective study, from May 2013 to May 2014, of patients with AMD. The therapeutic option was ranibizumab, aflibercept was not yet allowed in the hospital.

Data were obtained from medical prescriptions and computer records of the pharmacotechnical unit. To compare what treatment would have been more cost effective we considered the same patients and the same number of syringes of aflibercept as of ranibizumab in that period. We obtained three syringes of ranibizumab from each vial, and we would have obtained four syringes from each vial of aflibercept, when preparing the necessary dose. Variables studied: number of patients, number of syringes, cost of vials and cost of syringes.

Results During the study period, 1,179 syringes of ranibizumab were prepared, for 151 patients, corresponding to 7.8 syringes per patient. These syringes were obtained from 393 vials of ranibizumab. If we had used the corresponding number of vials, the cost would have been €815,219.55. However, the development cost of these syringes was €271,739.85. The costs with aflibercept would have been, using 1,179 vials, €759,912.66, and syringes, from 295 vials, €759,912.66. The difference between treatments was €55,306.89.

Conclusion The optimisation of the ranibizumab and aflibercept vials saves money for the health system, as well as providing greater accuracy and safety when preparing these sterile syringes in the Pharmacy Service. Assuming equivalence in effectiveness, we propose aflibercept as the more cost-effective treatment.
ACCUACY IN THE PREPARATION OF ANTIBLASTIC TREATMENT

S Corridoni*, E Ciocco, E Liberatore, S Massaccesi. Hospital San Salvatore, Hospital Pharmacy, L’Aquila, Italy

Background Quality oncology preparation requires at least three important conditions: safety, quality and cost effectiveness.

Purpose To compare the quality of the oncology preparations made by two different methods: traditional manual preparation in a vertical laminar flow hood (Hv) and robotic compounding with APOTECAchemo (Ac).

Material and methods 21 different drugs were monitored from January 2013 to June 2014 in terms of dose accuracy (E%), for both procedures.

The dosage accuracy with Ac was extrapolated automatically from the system database.

Concerning the manual compounding, drugs vials were weighed before and after the liquid was withdrawn, by means of an analytical scale. Afterwards, E% was calculated using the density (d) of the solution.

Several technicians were involved in the manual compounding.

Results All the preparations showed dose errors within European Pharmacopoeia standard. E%, Big differences in accuracy among drugs were recorded in both procedures.

These values are related to the specific formulations of some drugs, such as: paclitaxel olate solution (Ac%-0.28 vs Hv%-1.10), nomtinastuzumab (Ac%-1.15 vs Hv%-2.50), eribulin with small withdrawn volumes (Ac%-2.33 vs Hv%-3.80), doxetaxel for the combination with all the above-mentioned factors (Ac%-3.30 vs Hv%-5.50). In the case of lyophilised drugs the error can also occur during reconstitution: cyclophosphamide (Ac%-3.30 vs Hv%-5.50). In the case of lyophilised drugs the error can also occur during reconstitution: cyclophosphamide (Ac%-3.30 vs Hv%-5.50). In the case of lyophilised drugs the error can also occur during reconstitution: cyclophosphamide (Ac%-3.30 vs Hv%-5.50).

In addition, high variability was observed in Hv among different technicians and within the same technician.

Conclusion Both procedures result in oncology preparations among drugs were recorded in both procedures.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

DESENSITISATION PROTOCOL FOR PEMETREXED HYSENSITIVITY: A CASE REPORT

M García Verde*, L Fuster Sanjuán, I Rodríguez Legazpi, I Rodríguez Penin, AM González Rodríguez. Ferrol Health Care Area, Hospital Pharmacy, Ferrol, Spain

Background Desensitisation has been used for some decades now so that patients can be treated with the drug causing the hypersensitivity reaction when an alternative drug with similar efficacy/safety is not available.

Purpose To describe the pemetrexed desensitisation protocol and our experience in one patient with a previous anaphylactic reaction to pemetrexed.

Material and methods A 43-year-old man with stage IV lung adenocarcinoma was treated with cisplatin-pemetrexed, followed by pemetrexed monotherapy 880 mg. During the nineteenth cycle he developed face and hand erythema with urticaria and general discomfort, resolved with dexchlorpheniramine and hydrocortisone.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
Production and preparation

The patient underwent skin testing with pemetrexed 25 mg/ml and intradermal testing with different drug dilutions 1/10,000 to 1/10, obtaining a positive result.

A published standardised 12-step desensitisation protocol developed by Castells MC et al.3 was adapted to pemetrexed desensitisation.

**Results**
The drug was administered in the Medical Intensive Care Unit. Before admission the patient was premedicated with cetirizine 10 mg, ranitidine 150 mg, montelukast 10 mg and acetylsalicylic acid 300 mg (11–12 h before pemetrexed) and dexamethasone 20 mg (8 and 16 h before pemetrexed).

On admission he was premedicated with intravenous ranitidine 50 mg, dexchlorpheniramine 5 mg and dexamethasone 8 mg 1 h before 3 sequential pemetrexed solutions (rate of infusion): a) 1/100 dilution: 0.0352 mg/ml (2, 5, 10 and 20 ml/h each for 15 min), b) 1/10 dilution: 0.352 mg/ml (5, 10, 20 and 40 ml/h each for 15 min) and c) dilution 1/1: 3.520 mg/ml (10, 20, 40 ml/h each for 15 min and 75 ml/h until reaching the total amount of 880 mg).

The patient was monitored continuously during desensitisation; no reactions occurred. The patient did not receive any more pemetrexed.

**Conclusion**
The protocol was safe and well tolerated by our patient.

Desensitisation protocols stand out as an alternative to the standard continuous treatment in patients who are allergic to their chemotherapy agents.

**REFERENCE**

No conflict of interest.

**PP-014 PHYSICAL AND CHEMICAL STABILITY OF SEVOFLURANE IN POLYPROPYLENE SYRINGES**

1D Fernández Gínes, 5S García Muñoz, 7B Rodríguez Cuadros, 4JA Morales Molina, 4M Cortías Saez, 4F Verdejo Reche, 5F Sierra García. 1Hospital Torrecárdenas, Pharmacy, Almería, Spain; 2Hospital Torrecárdenas, Clinical Laboratory, Almería, Spain; 3Hospital Torrecárdenas, Family and Community Medicine, Almería, Spain; 4Hospital de Poniente, Pharmacy, Almería, Spain; 5Hospital Torrecárdenas, Anesthesia, Almería, Spain; 6Hospital Torrecárdenas, Pharmacy, Almería, Spain

10.1136/ejipharm-2015-000639.308

**Background**
The use of an alternative liquid anaesthetic sevoflurane has recently been reported in the literature on vascular ulcers. Topical application for management of analgesia appears to be successful.

**Purpose**
To evaluate the stability of sevoflurane in pure polypropylene amber syringes.

**Material and methods**
Commercial solutions of sevoflurane (Sevorane) were packed in polypropylene syringes. The syringes were stored at 23°C for 14 days in a digitally temperature-controlled chamber. The physical parameters monitored were clarity and color. Chemical stability was determined by means of 19F-Fluorine Nuclear Magnetic Resonance (19F-NMR) and gas chromatography coupled with a Flame Ionisation Detector (GC-FID).

**Results**
Over the 14 days, the clarity and lack of colour of the solutions were maintained. 19F-NMR signals identical to those of the original product were observed in all samples, corresponding to the chemical structure of unchanged sevoflurane.

Meanwhile, in the GC-FID analysis, no additional peaks occurred at the storage temperature. No degradation products were observed by either analytical technique.

**Conclusion**
Pure sevoflurane preserved in amber polypropylene syringes was stable for 14 days at room temperature. This enables it to be stored in a more convenient way, and provides greater comfort in drug instillation onto the ulcer bed from the syringe.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**
University of Almería.
No conflict of interest.

**PP-015 USING A CLOSED-SYSTEM TRANSFER DEVICE LEADS TO BETTER CONTROL OF OCCUPATIONAL EXPOSURE IN ROUTINE PRACTICE**

1N. Simon*, 1M. Vasella, 1M. Pintaud, 3M. Solchot, 3C. Rickev, 3L. Humbert, 3P. Bonnabry, 3D. Allorge, 3B. Décaudin, 3P. Odos, 1CHRU de Lille, Institut de Pharmacie, Lille, France; 2Université Lille 2, Laboratoire de Biopharmacie, Pharmacie Galénique Et Hospitalière, Lille, France; 3AMPH – Hôpital Lariboisière, Laboratoire de Toxicologie Biologique, Paris, France; 4CHRU de Lille, Laboratoire de Toxicologie, Lille, France; 5Hôpitaux Universitaires, Pharmacie, Genève, Switzerland

10.1136/ejipharm-2015-000639.309

**Background**
Closed-system transfer devices (CSTD) are promoted in all recommendations to reduce the occupational exposure to antineoplastic drugs during the compounding process. Numerous in vitro studies have shown that using the PhaSeal system may limit chemical contamination.

**Purpose**
To compare the chemical contamination inside isolators between a standard (S) and a PhaSeal (P) compounding process in routine practice.

**Material and methods**
A 6-month prospective study started at the opening of a new compounding unit (checked as not contaminated). Two isolators with 2 workstations were used, one to compound with standard devices (needles and spikes) and the other one using the PhaSeal devices. Drugs were alternatively compounded in each isolator (90 preparations/day). Sampling was performed by wiping three surfaces (gloves, window (inner surface), worktop), before and after a cleaning process. Exposure to ten antineoplastic drugs (cyclophosphamide, ifosfamide, dacarbazine, 5-FU, methotrexate, gemcitabine, cytarabine, irinotecan, doxorubicin and ganciclovir) was evaluated on wipes by LCMSMS analysis.

Contamination rates (% of samples revealing contamination) were compared using a Chi² test and the drug amounts by a Mann-Whitney test. Significance was defined as p < 0.05.

**Results**
655 samples were analysed (P: n = 327, S: n = 328).

The amounts of drugs compounded in each isolator were not significantly different, excepted for methotrexate. The overall contamination rate before cleaning was significantly lower in the PhaSeal isolator (P: 12.6% vs. S: 25.4%; <0.0001). Both isolators were mainly contaminated before cleaning by gemcitabine (P: 295.9 vs. S: 224.7 ng; p < 0.67) and cyclophosphamide (P: 12.6% vs. S: 25.4%; <0.0001). Both isolators were mainly contaminated before cleaning by gemcitabine (P: 295.9 vs. S: 224.7 ng; p < 0.67) and cyclophosphamide (P: 12.6% vs. S: 25.4%; <0.0001). Only traces of methotrexate were retrieved one time in each isolator.

**Conclusion**
This study demonstrates that using a CSTD significantly reduces the overall contamination without cancellation. This intermediate analysis will be implemented by an analysis of the drug amounts handled and the occurrence of incidents.
REFERENCE

1 Sessiak PK, Tjioe I, Coyne IW. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. Hosp Pharm 2013;48(3):204–12

Conflict of interest

PP-016 VALIDATION OF A NEW METHOD OF STERILITY TESTING FOR THE VITAMIN AND LIPID MIXTURES DESTINED FOR THE NEONATAL DEPARTMENT

1 Thévenet*, 1 M Mourad, 1 E Bermudez, 1 C Chanat, 1 L Malin, 1 I Alasouch, 1 A Casetta, 1 H Poupet, 1 M Brunet, 2 F Chast. 1 Hôpital Cochin AP-HP, Pharmacy, Paris, France; 2 Hôpital Cochin AP-HP, Hygiène, Paris, France; 3 Hôpital Cochin AP-HP, Bacteriology, Paris, France

10.1136/ejhpharm-2015-000639.311

Background Three vitamin and lipid mixtures are produced by the parenteral nutrition unit. Besides the checks performed on these preparations, a membrane filtration sterility test (STERITEST) is carried out as required by the European Pharmacopoeia (EP). Due to constraints associated with these tests (duration, visual interpretation) alternative methods are available such as those for septicemia diagnosis: Bact/ALERT 3D. It consists of directly inoculating a culture medium followed by automated microbial detection. This method doesn't meet all the criteria required by the EP; but seems acceptable if validated.

Purpose To compare the two methods and to assess their respective efficiency.

Material and methods Growth promotion tests of aerobic, anaerobic micro-organisms (MO) and fungi were performed with 5 colony-forming units (CFUs) of S. aureus, B. subtilis, C. sporogenes, A. brasiliensis, C. albicans, and P. aeruginosa seeded in two different media. Afterwards the three kinds of mixture were produced in a microbiological safety cabinet. Both methods were tested at the same time on three samples of each MO and mixture (54 pairs of samples). Daily readings and identifications of MO were then performed in collaboration with the bacteriology department. The averages of the growth period of each method were compared using a t-test.

Results 100% of MO seeded on the 54 pairs of Bact/ALERT were detected versus 91% on STERITEST. The t-test showed a significant difference between the two methods: the average growth period with STERITEST (5.8 days) was longer than that with Bact/ALERT (2.5 days) (p = 1.27 E-18).

Conclusion Bact/ALERT is more efficient than STERITEST for the detection of MO: increased sensitivity and reproducibility, faster detection and identification of MO, less bias of reading. All these reasons drove us to choose the new Bact/ALERT sterility test instead of STERITEST.

REFERENCE

1 European Pharmacopoeia 7.7, sterility 2.6.1

No conflict of interest.

PP-018 PREPARATION OF EYE DROPS FOR VERNAL KERATOCONJUNCTIVITIS: THE PHARMACIST ADDED TO A TEAM ACTS AS A FULCRUM BETWEEN DOCTOR AND PATIENT

1 V Borsito*, 2 C Sgroo, 3 L Scala, 4 S Scialino, 5 A Calvani, 1 L Di Simone, 6 G La Marca, 1 R Caccanetti, 7 N Pucci, 3 C De Liberio, 8 University of Florence, Specialisation School in Hospital Pharmacy, Florence, Italy; 2 A. Meyer University Hospital, Department of Pharmacy, Florence, Italy; 3 A. Meyer University Children’s Hospital, Department of Paediatric Neurosciences, Florence, Italy; 4 A. Meyer University Children’s Hospital, Department of Paediatric Hematology and Oncology, Florence, Italy; 5”A. Meyer” University Children’s Hospital, Department of Paediatric Allergology, Florence, Italy; 6 “A. Meyer” University Children’s Hospital, Department of Clinical Ophthalmology, Florence, Italy

10.1136/ejhpharm-2015-000639.312

Background Vernal Keratoconjunctivitis (VKC) is an allergic conjunctivitis, often not easily diagnosed and properly treated. The disease is very debilitating for patients, may be complicated by corneal lesions and can evolve to keratoconus.

Purpose The exponential increase in VKC patients led us to start a close collaboration between pharmacists and allergists, ophthalmologists, and chemists. The goal was to address and solve problems caused by the lack of adequate knowledge of VKC, in order to find a diagnostic-therapeutic course, improve patient
Production and preparation

Irinotecan release was different in rate and quantity relying on the type and volume of contrast medium admixed. Mixing of irinotecan-loaded beads with non-ionic contrast media decreased the irinotecan loading efficiency by 2.5–18% over a maximum period of 24 h. Because of the initial rapid release (1–9%) it is not recommendable to prepare admixtures of IEBs with contrast medium in advance in centralised cytotoxic preparation units.

Conclusion IEBs are not compatible with typically used non-ionic contrast media. Admixtures should be performed by the interventional radiologists immediately prior to the delivery procedure.

REFERENCE

No conflict of interest.

PP-020 IMPROVING EFFICIENCY BY EXTENDING THE STABILITY OF BORTEZOMIB

R Gavira Moreno*, R Gámez Perez, J Siera Sanchez, L Jimenez Pichardo, F Gomez De Rueda. Hospital Sas Jerez de La Frontera, Pharmacy, Jerez de La Frontera, Spain
10.1136/ejhpharm-2015-000639.314

Background Bortezomib is an expensive drug with a very short stability. For subcutaneous administration each vial should be reconstituted with 1.4 mL of NaCl 0.9% (2.5 mg/mL). According to the manufacturer, reconstituted it is stable at 25°C for only 8 h. Considering the recommended dose of 1.3 mg/m² and the amount of drug per vial (3.5 mg/1.4 mL), the loss of product during preparation may be significant. However, a study published by Walker et co-authors has shown that bortezomib is stable for up to 21 days, permitting an optimisation of costs.

Purpose To evaluate the impact of the extended stability limits of bortezomib on handling practices and the optimisation of costs.

Material and methods Two periods were evaluated: before (January–September 2013) and after (January–September 2014) modification of the stability limits. From the individual preparation files, different parameters were recorded: number of patients and prescription lines, mean dose, theoretical residues, % of residues re-used, value of the residues re-used.

Results Seventy patients were included, 34 in the first period and 36 in the second one. The number of prescription lines was 584 and 452 in the first and second period, respectively. The mean dose in both periods was 2.10 mg. In the first period the theoretical residues were 311.59 mL, the % of residue re-used 56.00 mL (17.9%) and the value of the re-used residues €24,137.57. For the second period, the theoretical residues were 248.39 mL, the % of residue re-used 232.4 mL (93.7%) and the value of the re-used residues €100,170.90. The cost per dose was €983 and €677 in the first and second period, respectively.

Conclusion An extended stability limit for bortezomib as compared to that recommended by the manufacturer should lead to an improvement of manufacturing processes and significant cost savings. The re-use of residues is a real strategy to contain costs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
Background Ready-to-use drug-solutions for syringe pumps produced by industry or hospital pharmacies have advantages over solutions prepared manually on the ward in terms of accuracy of drug concentration and microbiological aspects. A key prerequisite for large-scale productions is to standardise concentrations, as treatment varies at the local level.

Purpose To assess the different concentrations that are being used in intensive care units nationally and the variety of ready-to-use solutions that are being manufactured by hospital pharmacists.

Material and methods Two surveys were conducted among the hospital pharmacies and intensive care units (ICU) in the national university hospitals. The answers were evaluated descriptively.

Results Overall 100 different drugs were used in 262 different locally-standardised concentrations in the responding 17 hospitals. Of those, only 21 drugs were mentioned by at least two thirds of the ICUs: e.g. catecholamines, hypnotics, insulin, heparin, hydrocortisone and amiodarone.

Among the 24 different drugs prepared by the responding 19 hospital pharmacies, the main ones reported were expensive drugs and/or preparations that are extremely prone to error (argatroban, caspofungin). There was only a little overlap (n = 6) between the standardised drugs used in the ICU and the hospital pharmacy-based manufacturing of ready-to-use preparations. Out of these only potassium chloride and heparin were being manufactured by at least five pharmacies.

Conclusion The observed gap might be due to limited manufacturing capacities of the pharmacies and/or limited stability data of the ready-to-use preparations (concentration, diluent and primary container). Standardising the drug concentrations on a national, or even European level might enable hospital pharmacies to cooperate in overcoming the lack of stability data. The capacity deficit at the hospital pharmacies could be lessened by shifting high-turnover-drugs towards pharmaceutical companies. For nationwide recommendations of standardised concentrations of drugs used in intensive care an extensive survey among ICUs is being planned.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PP-022 EVALUATION OF LONG-TERM BIOLOGICAL ACTIVITY OF CETUXIMAB 5.0 mg/ml (ERBITUX) BY AN AD HOC ELISA METHOD

1S. Suárez González*, 1JN. Navas Iglesias, 1A. Salmerón García, 1J. Cabezón Barrera, 1L. Capitán Valero, 1University of Granada-Faculty of Science, Analytical Chemistry, Granada, Spain; 2Department of Analytical Chemistry, Science Faculty, Biomedical Research Institute Ibs. Granada, University of Granada, Campus Fuentenueva s/n; 3UGC Intercentro Intervenéis Farmacia Granada, "San Cecilio Hospital", Biomedical Research Institute Ibs. Granada, Hospitales Universitarios de Granada, E-18012 Granada, Spain

10.1136/ehjpharm-2015-000639.316
Production and preparation

Results The filling was true for all studied volumes (97–103%). The minimum volumes allowing accurate preparation were 100, 3 and 1 mL in the limits of 3%, 5% and 10%, respectively. The repeatability was not influenced by the filling position (Student’s t-test, $p = 0.36$, $n = 180$) or the working day (Student’s t-test, $p = 0.14$ day 1/2, $p = 0.46$ day 1/3, $p = 0.09$ day 2/3, $n = 540$). Accuracy was the same for the 2 manufacturing methods (Student’s t-test, $p = 0.12$, $n = 360$ (individualised doses), $n = 180$ (dose-banding)) and the 2 sizes of syringes (Student’s t-test, $p = 0.46$, $n = 270$). The production time depended on the injected volume and the size of the syringe. The production of 10 bags took $45 \pm 112$ min on average, 30% for the manual steps (pre-processing: 24%, post-processing: 6%) and 70% for the automated step.

Conclusion The automated system produced IV bags from liquid active components. The filling was accurate from a volume of 3 mL for $\leq5\%$ and 1 mL for $\leq10\%$ limits. Results confirmed the potential of such automated systems to increase productivity and to guarantee the safety of patients and operators.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PP-024

NON-STEROILE DRUG COMPOUNDING: PROFESSIONAL PRACTICE EVALUATION

MD Guillerm*, E Jean-Bart, C Le Connauiser, E Renebon, N Herment, IL Bonnefous. Centre Hospitalier de Bourg en Bresse, Pharmacie, Bourg en Bresse, France

10.1136/ehjpharm-2015-000639.318

Background An average of four drugs are compounded per week in our pharmacy, mostly paediatric dose capsules and children’s suppositories. The pharmacy technicians’ team is composed of 16 individuals, who are multi-skilled, serving in different positions of the hospital pharmacy.

Purpose To develop an evaluation of pharmacy technicians’ professional competencies for non-sterile compounding.

Material and methods An assessment grid and a procedure for the evaluator were created for the different stages of production: prescription validation, work surface preparation, hygiene, drug compounding preparation and verification, labelling. Two evaluators observed the preparation and each stage was graded: Mastered (M) Acquired (A), Being Acquired (BA) or Not Acquired (NA). In March 2014, pharmacy technicians were evaluated.

Results A total of 13 pharmacy technicians were evaluated, on 7 pentobarbital suppositories preparations and 6 paediatric dose capsules preparations. Each stage, on average, was rated (A) or (M). For hygiene, 70% of the pharmacy technicians disinfected the work surface before and after preparing, but by using alcohol. Ninety two percent of the pharmacy technicians checked the calibration of the weighing scale but only one (17%) checked the level of the scale, 77% used paper sheets instead of a watch glass. Also, calculation of the confidence interval for the capsules was rarely mastered (16.7%).

The overall results were satisfactory. Some issues were identified: weight was not influenced by the filling position. Student’s t-test, $p = 0.36$, $n = 180$) or the working day (Student’s t-test, $p = 0.14$ day 1/2, $p = 0.46$ day 1/3, $p = 0.09$ day 2/3, $n = 540$). Accuracy was the same for the 2 manufacturing methods (Student’s t-test, $p = 0.12$, $n = 360$ (individualised doses), $n = 180$ (dose-banding)) and the 2 sizes of syringes (Student’s t-test, $p = 0.46$, $n = 270$). The production time depended on the injected volume and the size of the syringe. The production of 10 bags took $45 \pm 112$ min on average, 30% for the manual steps (pre-processing: 24%, post-processing: 6%) and 70% for the automated step.

Conclusion The automated system produced IV bags from liquid active components. The filling was accurate from a volume of 3 mL for $\leq5\%$ and 1 mL for $\leq10\%$ limits. Results confirmed the potential of such automated systems to increase productivity and to guarantee the safety of patients and operators.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PP-025

STABILITY OF INTRAVITREAL BEVACIZUMAB SOLUTION IN POLYPROPYLENE SYRINGES IN NEOVASCULAR MACULAR DEGENERATION

1 F. Gutiérrez Nicolas*, 2 E. Sanchez Negrín, 3 A. Santonella Estévez, 3 J. Nazco Casarejo, 3 V. Virgo Aller, 4 F. Arista Espinosa. 1 Hospital Universitario de Canarias, Hospitalary Pharmacy, Santa Cruz de Tenerife, Spain; 2 Universidad de La Laguna, Tecnologia Farmaceutica, La Laguna, Spain; 3 Hospital Universitario de Canarias, Farmacia Hospitalaria, La Laguna, Spain

10.1136/ehjpharm-2015-000639.319

Background Bevacizumab is used by intravitreal administration as an off-label drug to treat age-related macular degeneration and other ophthalmologic diseases.

Purpose To analyse the physicochemical stability of bevacizumab repackaged in 1-mL polypropylene syringes for intravitreal injection.

Material and methods Bevacizumab syringes were repackaged under laminar flow. Each syringe contained 200 or 900 μL (25 mg/mL). For the stability assessment at 4°C, three storage groups of 2 repacked syringes and 2 original vials were constituted for each analysis time (0, 3, 7, 14 days). For bevacizumab characterisation a HPLC consisting of a Waters pump (600 E), an autosampler (717 plus), a dual UV detector (2487) to 214 nm, as stationary phase ShodexKW804 (8.0 mm × 300 mm) column and a mobile phase (25 mM NaH₂PO₄·2 H₂O and 300 mM NaCl pH 7) at a flow of 1 mL/min. The size distribution of particles in the samples incubated in syringes was determined by a Zetasizer system.

Results The proposed HPLC method allowed us to separate two peaks for the bevacizumab control sample, corresponding to bevacizumab monomer (mean peak) and its oligomer, with retention times of 9.8 and 8.6 min respectively. We used the evolution of the monomer peak area value to indicate the stability. For the original vials the area values remained at 100% of their initial value for 7 days storage. For repackaged bevacizumab this value was maintained for 3 days. The Zetasizer analysis detected submicron particles whose origin could be the repackaging, for the vials mean particle size (17.8 ± 4.7) nm remained constant for 15 days. For repackaged syringes this value remained constant for 3 days, at day 7 we found a small% of particles with size next to 5 μm indicating probable particle contamination of unknown origin.

Conclusion Our results support the physicochemical stability for 3 days at 4°C of repackaged bevacizumab for intravitreal administration.

REFERENCES
1 National Investigation Project of the Ministerio de Ciencia e Innovación in Spain (SAF2010–17083)

No conflict of interest.
PP-026 EVALUATION OF LONG-TERM BIOLOGICAL ACTIVITY OF TRASTUZUMAB 15.0 mg/ml (Herceptin) BY AN AD HOC ELISA METHOD

1I Suárez González*, 2N Navas Iglesias, 3A Martínez Ortega, 1Cabeza Barrera, 1Capitán Valiño, 1University of Granada-Faculty of Science, Analytical Chemistry, Granada, Spain; 2Department of Analytical Chemistry, Science Faculty, Biomedical Research Institute Ibs. Granada, University of Granada, Campus Fuentenueva s/n; 3UGC Intercentro Intermèves Farmacia Granada, "San Cecilio Hospital", Biomedical Research Institute Ibs. Granada, Hospitales Universitarios de Granada, E-18012 Granada, Spain

10.1136/ehjpharm-2015-000639.321

Background Trastuzumab (TRZ) (Herceptin) is a humanised monoclonal antibody IgG1 that acts against human epidermal growth factor receptor 2 (HER2). It is indicated in the treatment of early and metastatic breast cancer and metastatic gastric cancer.

Purpose To evaluate the biological activity (BA) that remains in Herceptin after single-use vials have been opened in a long-term study. We also evaluated the remaining activity when TRZ was exposed to different stress conditions.

Material and methods An indirect non-competitive ELISA was developed for this purpose and validated to test the stability of BA of TRZ. ELISA plates were sensitised with recombinant developed for this purpose and validated to test the stability of BA of TRZ. ELISA plates were sensitised with recombinant

TRZ and exposed to different stress conditions.

Results The BA of Herceptin decreased by 25%, 30% and 47% the initial activity 24 h after opening when vials were stored at 4°C, −20°C and −80°C respectively. The decrease was 50–60% after 2 days for the three storage conditions and it was maintained along the study (up to 15 days). Residual BA remained in all samples submitted to the stress except in samples heated at 70°C. There was no cross reaction with similar IgG1.

Conclusion Herceptin lost a significant percentage of the BA when tested by ELISA after 24 h of storage both refrigerated (4°C) and frozen (−20°C and −80°C). Nevertheless, these results will be further investigated by flow cytometry.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Financial support: PI10/00201 (MICINN, Government of Spain).

No conflict of interest.

PP-027 LONG-TERM STABILITY OF SOLUTIONS OF THE MONOCLONAL ANTIBODY CETUXIMAB

1I Suárez González*, 2N Navas Iglesias, 3A Martínez Ortega, 1Cabeza Barrera, 1Salmerón García, 1Cabeza Barrera, 1University of Granada-Faculty of Science, Analytical Chemistry, Granada, Spain; 2Department of Analytical Chemistry, Science Faculty, Biomedical Research Institute Ibs. Granada, University of Granada, Campus Fuentenueva s/n; 3UGC Intercentro Intermèves Farmacia Granada, "San Cecilio Hospital", Biomedical Research Institute Ibs. Granada, Hospitales Universitarios de Granada, E-18012 Granada, Spain

10.1136/ehjpharm-2015-000639.321

Background Cetuximab (CTX) (Erbitux) is a chimeric mouse-human monoclonal antibody IgG1 targeting epidermal growth factor receptor (EGFR). It is approved for use as treatment for metastatic colorectal cancer and squamous cell carcinoma of the head and neck.

Purpose To access the stability of CTX during storage (in dark glass bottles at 4°C refrigerated and at −2°C (frozen) once the single-dose vial (5 mg/mL) had been opened and when diluted (2 mg/mL in saline solution) in the centralised preparation unit.

Material and methods Methods were developed for this purpose and ICH validated (to indicate stability: in addition to calibration, precision, accuracy, etc., stress studies were also conducted) for assessing the physicochemical and the biological stability: ELISA (to test biological activity), (RP)HPLC-DAD (to quantify), (C)HPLC-DAD (to obtain isoforms profile), (SEC)HPLC-DAD (to see aggregates) and ESI-qTOF-MS (to carry changes in the molecular weight).

Results The decrease of biological activity was only 5% 24 h after the vial had been opened (5 mg/mL), rising to 14% at day 3, 20% after a week, with a final decrease of 85% for the last day we checked (30 days). The overall quantity of CTX was unchanged for the month assessed. No formation of aggregates was detected in the two weeks tested. Changes in the chromatographic isoforms profile (2 mg/mL) were detected after a week, with significant variations in the isoforms from week 2 up to the end of the study (two months). Molecular weight indicated no major changes in the CTX structure (one month).

Conclusion Both the physicochemical and the biological properties assessed indicated good stability of CTX within 24 h after the vial had been opened. There was not even an important decrease in the biological activity a week after the opening of the medicine (20% decrease) with unchanged physicochemical properties for six days.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Financial support: PI10/00201 (MICINN, Government of Spain).

No conflict of interest.

PP-028 LONG-TERM STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY INFliximAB

1I Suárez González*, 2N Navas Iglesias, 3A Martínez Ortega, 1Cabeza Barrera, 1Salmerón García, 1Cabeza Barrera, 1University of Granada-Faculty of Science, Analytical Chemistry, Granada, Spain; 2Department of Analytical Chemistry, Science Faculty, Biomedical Research Institute Ibs. Granada, University of Granada; 3UGC Intercentro Intermèves Farmacia Granada, "San Cecilio Hospital", Biomedical Research Institute Ibs. Granada, Hospitales Universitarios de Granada, E-18012 Granada

10.1136/ehjpharm-2015-000639.322

Background The use of an alternative liquid anaesthetic sevoflurane has recently been reported in the literature on vascular ulcers. Topical application for management of analgesia appears successful. Topical application for management of analgesia appears to be successful.

Purpose To evaluate the stability of sevoflurane in pure polypropylene amber syringes.

Material and methods Commercial solutions of sevoflurane (Sevorane) were packed in polypropylene syringes. The syringes were stored at 23°C for 14 days in a digitally temperature-controlled chamber. The physical parameters monitored were clarity and colour. Chemical stability was determined by means of 19-Fluorine Nuclear Magnetic Resonance (19F-NMR) and gas
chromatography coupled with a Flame Ionisation Detector (GC-FID).

Results Over the 14 days, the clarity and lack of colour of the solutions were maintained. \(^{19}\)F-NMR signals identical to those of the original product were observed in all samples, corresponding to the chemical structure of unchanged sevoflurane. Meanwhile, in the GC-FID analysis, no additional peaks occurred at the storage temperature. No degradation products were observed by either analytical technique.

Conclusion Pure sevoflurane preserved in amber polypropylene syringes was stable for 14 days at room temperature. This enables it to be stored in a more convenient way, and provides greater comfort in drug instillation onto the ulcer bed from the syringe.

REFERENCES AND/OR ACKNOWLEDGEMENTS
University of Almería.
No conflict of interest.

PP-029 NON-COMEDOGENIC FORMULATION OF TOPICAL SIROLIMUS FOR TUBEROUS SCLEROSIS PATIENTS WITH FACIAL ANGIOFIBROMAS DEVELOPING ACNE COSMETICA
G Ros Bernado*, A De Basagotí Gorordo, A Belaustegui Foronda, I Bilbao Meseguer, M Castaño Lopez, U López Giménez, B San José Ruiz, A Bustíroz Tixtutu, Z Baquiran - Kaltzukorta, B Sordo Aisa. Hospital Universitario Cruces, Pharmacy Department, Barakaldo, Spain
10.1136/ehjpharm-2015-000639.323

Background Patients with tuberous sclerosis often develop facial angiofibromas that can be successfully treated with topical 1% sirolimus ointments. Nevertheless, this ointment’s greasy nature can produce acne, causing patients to refuse the treatment.

Purpose To devise a non-oily formula for topical sirolimus for patients with tuberous sclerosis and facial angiofibromas who develop acne due this ointment.

Material and methods We reviewed the literature searching for standard procedures for making alternative topical formulations of sirolimus. In addition, the physicochemical properties of sirolimus were considered in order to find the most suitable formulation for this particular case.

Results No standard ways were found of producing oil-free formulations of sirolimus. We decided to compound a 0.2% sirolimus gel with the following procedure. First, prepare a 2% carmellose gel. For this, heat aqua conservans (Nipagin 0.25 g + Nipasol 0.11 g + distilled water 500 mL) to 50°C. In a mortar, mix 2 g of sodium carboxymethylcellulose and 10 g of glycerol. Then, add the content of the mortar to 88 g of heated aqua conservans and stir the mixture until room temperature is reached. Once the carmellose gel has been prepared, weigh 0.2 g of sirolimus and add a few drops of glycerol to it. Slowly, pour the carmellose gel onto the sirolimus, mixing them by stirring, until 100 g has been added. Let it stand for 12 h until the gel is homogeneous. We give it an expiry date of 2 months, stored in an opaque container and at room temperature (below 25°C). Mask and gloves must be used throughout the procedure.

Conclusion We found a way to formulate sirolimus in non-oily excipients in order to diminish the development of acne with its use. Further studies will be needed to determine the efficacy of this formula in the treatment of facial angiofibromas of patients with tuberous sclerosis and the improvement of the acne presented by these patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PP-030 100,000 TREATMENTS PREPARED BY ROBOT: WHAT HAVE WE LEARNED?
C Bufarini*, A Marinozzi, S Guglielmi, S Leoni, L Losavio, D Paolucci. AO Ospedali Riuniti, Pharmacy, Ancona, Italy
10.1136/ehjpharm-2015-000639.324

Background In 2007, the University Hospital of Ancona started the journey in automating IV compounding. At the end of 2009, the clinical validation process and workflow reorganisation ended, the second robot was introduced to set up a fully automated IV oncology pharmacy. The laboratory is composed of two APOTECChem systems and a laminar airflow cabinet which work from 8 am to 4 pm. There are 3 technicians from 8 am to 2 pm and 1 technician from 10 am to 4 pm. We work in a just-in-time production (80% for outpatients and 20% inpatients) and the rush hours go from 9 am to 1 pm. Two systems are used until 2 pm and one system works for the entire day.

Purpose To take stock of 7 years of experience in automated IV compounding.

Material and methods The production data were analysed in terms of doses and type of preparations delivered, by means of the statistical tools of APOTECChem.

Results Before 2010 10,400 treatments were produced automatically in a year and in 2010 this increased to 16,300 (80% of our annual production). In the following years, production increased with 19,300, 19,600 and 20,300 treatments in 2011, 2012 and 2013 respectively. In August 2014, we passed the threshold of 100,000 treatments compounded with APOTECChem, representing 95% of the treatments compounded. The annual production consists of 85% in bags, 10% in syringes and 5% in elastomeric pumps. 36 different active ingredients are used.

Conclusion
1. Automation ensures the highest quality standards because every step of the compounding process is controlled and traced.
2. Automation can cover more than 90% of daily preparations even in a just-in-time system.
3. Automation allows a more intelligent and efficient management of human resources: for every 10,000 treatments automated, one FTE technician can be elevated to higher value-added tasks.
4. To take advantage of automation, the workflow should be redesigned (i.e. introduce multi-dose vials and drug days).

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PP-031 THE USE OF GUIDELINES IN THE CYTOTOXIC DRUGS PREPARATION UNIT: WHAT IS THE REAL WORKLOAD FOR PHARMACY TECHNICIANS?
B Kadi*, P Cony, R Linossier, N Sangare, JL Pons, JM Descoutures. Centre Hospitalier Victor Dupouy Argenteuil, Pharmacy, Argenteuil Cedex, France
10.1136/ehjpharm-2015-000639.325
CLOTTING CONTROL IN A HAEMODIALYSED PATIENT

Background In order to plan the management of a cytotoxic drugs preparation unit (CPDU), pharmacists used a scientific reference source. It recommended five pharmacy technicians for 26,000 preparations per year. 50% of technician effective working time should be spent to preparation and 50% on associated activities (AA).

Purpose What about in practice? The aim of this study was to assess the technicians’ workload in real life.

Material and methods Five technicians were hired in a CPDU in which 60% of the production was for use outside the hospital. Over one week, the times spent on the preparation and on 15 AAs was measured. The staff had to fill in a form giving the exact start and end times of the tasks. The different data collected were analysed and expressed in percentages.

Results 57% of technician effective working time was allocated to preparation. 9 AAs (36%) were fully done by technicians, the main ones being: preparation of sterilisation trays (17.4%), dressings, hygiene protocols (6%), managing orders (3.4%), schedule organisation (2%). The other AAs such as taking bacterial samples, inventory management, required the help of two additional logistics staff (47% of their working time). Without the help of logistics staff, all the AAs would need 58% of effective working time.

Conclusion Compared with our data, the reference source underestimates the time required for preparation and AAs, by 7.4% and 8% respectively. The additional time needed for preparation is explained by the fact that reference data are not accurate for specific preparations. Furthermore, AAs need more time because of the large amount of work outsourced to our department, which isn’t mentioned in the reference source. This study showed that 6 technicians are necessary, instead of the 5 recommended by the guidelines. Moreover, with the new national law concerning hospital organisation, the CPDUs are going to change and the outsourced work they perform will increase; the guidelines need to be reviewed.

REFERENCE
1 Société Française de Pharmacie Oncologique
No conflict of interest.

CLOTHING CONTROL IN A HAEMODIALYSED PATIENT WITH ALLERGIC TO LOW MOLECULAR WEIGHT HEPARIN (LMWH)

Ll. Poyatos Ruiz, V. Santana-Pareja, C. Villanueva Bueno, E. Montecatine Alonso, MD Santos Rubio*, MJ Sierra Torres, A. Rodríguez Pérez, E. Chamorro De Vega, J. Martinez Turion. Virgen Del Rocio University Hospital, Hospital Pharmacy, Seville, Spain

Background A female with renal failure (renal clearance <20 ml/min), uncontrolled blood clotting, allergic to LMWH, suffered bruising, epistaxis and gastrointestinal bleeding with haemodynamic compromise, requiring repeated transfusions, when she was treated with acenocoumarol.

Purpose To design a therapeutic strategy to control the clotting in this patient.

To describe the most efficient method of preparing argatroban vials.

Material and methods Other alternatives were evaluated (lepirudin, fondaparinux and new oral anticoagulants, NOACs).

A literature review was made to determine drug stability in syringes and polypropylene bags, at different concentrations and storage conditions, to develop a solution with the optimal concentration that allowed us the most efficient use of the vial.

Results NOACs and fondaparinux are contraindicated in renal failure, and lepirudin has not been marketed since 2012. The possible alternatives were danaparoid and argatroban, the latter being the more cost-effective.

Argatroban solutions are stable for 14 days under natural light and temperatures between 2°C and 8°C, in 0.9% NaCl or glucose solution, at 1 mg/ml, when packed in polypropylene syringes and bags. Moreover, they are stable under natural light and 25°C, in 0.9% NaCl at 0.2 mg/ml in the same type of packaging for 180 days. Doses of the initial bolus (13 mg) and the doses administered as a continuous infusion during dialysis (18 mg administered at 6 mg/hour), were in accordance with the Product Information.

Considering the stability conditions and the doses required by the patient, half the vial (1.25 ml) was prepared in a bag with a total volume of 125 ml, at a concentration of 1 mg/ml, from which was obtained the initial bolus and the continuous infusion for 4 dialysis sessions (taking place over 14 days).

Conclusion We succeeded in controlling clotting in this patient. The method of preparation allowed us to make the most efficient use of the argatroban vial.

REFERENCE
1 Coventry DA, Webster NR: Heparin-induced thrombocytopenia and the health economic analysis of argatroban. BJH 2014;112:964–7
No conflict of interest.

NYSTATIN-LIDOCAINE LOZENGES: INNOVATION IN THE TREATMENT OF ORAL MUCOSITIS

PP-033

L. Poyatos-Ruiz, V. Santana-Pareja, C. Villanueva Bueno, E. Montecatine Alonso, MD Santos Rubio*, MJ Sierra Torres, A. Rodríguez Pérez, E. Chamorro-De Vega, J. Martinez-Turion. Virgen Del Rocio University Hospital, Hospital Pharmacy, Seville, Spain

Background Oral mucositis is often challenging to manage as the lesions can be very painful. It can compromise nutrition, oral hygiene and increase the risk of infection.

It is important to develop oral formulations that enhance treatment compliance, improve the administration and ensure the effectiveness of the drug.

Lozenges are described as an effective alternative to mouthwash, especially for their versatility, ease of administration and extended time in the oral cavity.

Purpose To describe the developmental process and stability studies performed of an innovative formulation of nystatin and lidocaine lozenges for the treatment of oral mucositis.

Material and methods An optimised lozenge formulation was developed. Different excipients such as gelatine, polyethylene glycol, sucrose, glycerine and gum arabic were tested. The aim was to obtain chemical and physical properties suitable for administration, storage and therapeutic compliance.

Full pharmaceutical quality testing was carried out, specifically for this dosage form including disintegration and dissolution testing performed with artificial saliva. Appropriate stability-indicating analytical methodology (HPLC) was developed to quantify nystatin and lidocaine. The microbiological and stability tests are still ongoing.
Results A stable formulation of soft lozenges was obtained, presenting suitable palatability for oral administration. It can easily be compounded with standard hospital pharmacy equipment. The compounded product has suitable pharmaceutical characteristics, such as mass and content uniformity, disintegration time (15 min), dissolution rate and a pH value suitable for oral administration.

Conclusion Nystatin-lidocaine lozenges can be an effective alternative to mouthwashes for the treatment of oral mucositis due to their versatility, excellent palatability and easier administration. This formula’s major advantage is the fact that patients can control for how long the drugs are retained in the oral cavity and consequently manage their pain treatment.

The process of clinical application will validate efficacy and optimum dosing frequency.

REFERENCES
1 Marto J, Salgado A, Almeida AJ. Rev-Port-Farmacoterapia 2011;3(3):154–64

No conflict of interest.

ENVIRONMENTAL CONTAMINATION WITH CYTOTOXIC DRUGS IN A RECONSTITUTION UNIT

L Sussamiele*, C Van Cappel de Premont, J Pruneta, V Orabona, J Grassi. CHD de Castelluccio, Ajaccio, France

Background In spite of protective measures and equipment (spike, closed system, vertical laminar airflow safety hood, isolator) the handling of cytotoxic drugs is referred to as an occupational health hazard because it can lead to the contamination of the environment. Absorption through the skin is the main route by which cytotoxics pass into the body. It is necessary to assess and quantify the contamination to protect operators, the environment, patients and their families.

Purpose To evaluate surface contamination with a cytotoxic drug 5 fluorouracil (5FU) in a unit that reconstitutes cytotoxic drugs.

Material and methods A total of 15 wipe samples were taken of surfaces (14 in a unit for reconstituting cytotoxic drugs and 1 in a container for transport of prepared cytotoxic drugs) and analysed for the presence of 5-FU.

The Limit of Quantitation (LoQ) was 0.02 μg. Contamination is considered important if levels are above 5–10 times the LOQ.

Results Only three samples were above the LoQ: kitchen staff (3 × LoQ), container for transport of prepared cytotoxic drugs (5 × LoQ) and the dispensing area (705 × LoQ).

Contamination was considered major only for the dispensing area; it can be explained by the unprotected return of damaged preparations (septum leakage). All other points of the UPA were below the limit of quantification reflecting appropriate methods of preparation, a good attitude of the operators and effective biocleaning.

Conclusion Of the 15 sampling points only 3 were positive, one of which was significant. This result demonstrates that working procedures and cleaning for some areas are appropriate and performed correctly; for further efforts must be made to control contamination (for example, a new procedure for the return of damaged preparations). New samples will be collected after implementation of the new procedures. The lack of a standard for surface contamination by cytotoxic drugs invites us to strengthen and continuously improve our working procedures and cleaning for the lowest possible contamination.

REFERENCE
1 Sessik Arch Environ Health 1994
No conflict of interest.

ALBUMIN DESENSITISATION

C Villanueva Bueno, LL Poyatos Ruiz, V Santana Pareja, E Montecatine Alonso, MI Sierra Torres, MD Santos Rubio*. Hospital Virgen Del Rocio, Pharmacy, Sevilla, Spain

10.1136/ehjipharm-2015-000639.329

Background Report of a case of a patient allergic to albumin. In the absence of therapeutic alternatives we proposed an albumin desensitisation protocol.

Purpose To describe how the samples were prepared and the technique administered. To evaluate the effectiveness and safety of the desensitisation protocol for albumin in a patient who developed a hypersensitivity reaction to it.

Material and methods Review of the clinical history of a 72 year-old female diagnosed with liver cirrhosis HCV that had developed over 8 years, portal hypertension, ascites, oesophageal varices and splenomegaly. She was thought to have suffered an allergic reaction to intravenous albumin, based on symptoms after administration including neck rash, facial flushing and chest tightness, after we had eliminated allergy to any of the product excipients.

Alternatives such as administering albumin with premedication (corticosteroids and antihistamines), diuretics and plasma expanders were evaluated without getting the desired result.

After an unsuccessful literature review in which we could not find an albumin desensitisation protocol or a similar case, a protocol was suggested that involved the administration of increasing doses of albumin until a total cumulative dose achieved therapeutic levels.

Results Three albumin preparations were devised: 0.6 grams of albumin diluted in 250 ml of physiological saline to give a concentration of 0.0024 g/ml, a second one with 6 grams in 250 ml for a concentration of 0.024 g/ml and a third preparation with 60 grams of undiluted albumin, which were administered at infusion rates of 5, 10, 20 and 40 ml/h every 15 min.

After four sessions of paracentesis, with subsequent return of 60 grams of albumin infusion as per the desensitisation protocol, the patient did not have a further anaphylactic reaction. The regimen was well tolerated, achieving a final infusion rate of 50 ml/h.

Conclusion The protocol and formulation have proved to be effective and safe for desensitisation to albumin in the clinical case described.

Multidisciplinary collaboration of the professionals involved has enabled treatment with post-paracentesis albumin to be considered a valid therapeutic strategy for patients in the same clinical situation.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
Pharmacokinetics and pharmacodynamics

PP-036 PREPARATION OF AN EXPERIMENTAL CORD BLOOD SERUM EYE DROPS FOR TOPICAL USE IN SEVERE CORNEAL EPITHELIOPATHY

1A Stancari, 1AM Guaragnini, 1S Maselli, 2G Bersani, 1C Puggioli. 1S. Orsola-Malpighi University Hospital, Clinical Pharmacy, Bologna, Italy; 2Consulting Pharmacist, Bologna, Italy

10.1136/ejhpharm-2015-000639.330

Background The use of cord blood (CB) serum as a tear substitute has been recently proposed to heal severe corneal epithelial damage due to its high concentration of epithelial growth factors. No branded CB serum-based eye drops are available on the market.

Purpose To optimise the preparation of experimental galenical CB serum-based eye drops by ensuring product safety.

Material and methods In S. Orsola-Malpighi Hospital of Bologna, Italy, the drops were made under a vertical laminar flow hood. In the Transfusion Centre serum was collected from CB units, centrifuged for 10 min at 3,500 rpm, aliquoted into 15 ml sterile tubes and frozen at -80°C for six months as a quarantine period. Serological and molecular tests were performed on each serum sample, according to the Italian regulations. Thawed CB serum was sent to the pharmacy laboratory where it was diluted 1:5 with refrigerated sterile physiological saline, filtered (Millex HV 0.45 μm) and aliquoted into 1 ml single-dose PET vials. Filled vials were thermo-welded and packed in sealed labelled envelopes. Finally, they were stored at −20°C for 30 days before delivery to patients. Certification of molecular and serological tests was retained in the pharmacy. CB serum levels of epithelial growth factors were tested at different steps: freshly collected, thawed after quarantine, after filtration, after dilution and after one or two months storage at −20°C, respectively. Sterility was validated by a BacT/Alert test on each batch of eye drops.

Results Sterility tests confirmed that all batches of eye drops remained sterile after handling and storage. Immunological tests showed that CB serum levels were maintained throughout the whole process. Patients must keep the eye drops refrigerated and use them within 12 days.

Conclusion The collaboration among interdisciplinary professionals figures overcame critical preparation problems, providing patients with a safe and effective product.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PP-037 ABSTRACT WITHDRAWN

Pharmacokinetics and pharmacodynamics

PKP-001 CURRENT VANCOMYCIN DOSING RECOMMENDATIONS FOR PAEDIATRIC PATIENTS: A PHARMACOKINETIC EVALUATION

N Rasouli, H Collier*, P Cortos. University Hospital Brussels, Pharmacy Department, Brussels; Belgium

10.1136/ejhpharm-2015-000639.331

Background Current paediatric vancomycin (VANC) dose regimens recommend 40–60 mg/kg bodyweight/day in 3–4 doses, adjusted according trough values (optimum range 10–20 mg/L). Often, multiple dose escalations over several days after the start of treatment are needed to obtain appropriate levels.

Purpose To evaluate the current dosing scheme (4 × 15 mg/kg) against the optimal pharmacokinetic/pharmacodynamic parameters for VANC (AUC/MIC ≥ 400) and trough levels.

Material and methods Setting: a paediatric ward in a tertiary care university hospital. Patients >1 year and <18 years receiving intermittent VANC infusions between 2011 and 2013 were included. All necessary data were obtained from the electronic patient files. VANC clearance and Area Under the Curve (AUC) were obtained using JPKD software (Kaoshing Medical University–Taiwan) using a 1-compartment, first-order kinetic Bayesian analysis. The Minimum Inhibitory Concentration (MIC) was set to 1 mg/L according EUCAST recommendations. For analysis, patients were stratified according age: <6; 6–12; and >12 years. Statistical analysis was done using SPSS 22.0.

Results Twenty-four patients (21 haematological; median age 6.3 years) were included with 183 available trough levels. VANC clearance was correlated with total administered fluid (ρ = 0.410, p < 0.0001) and excreted fluid (ρ = 0.368, p < 0.0001); and inversely correlated with age (ρ = -0.624; p < 0.0001); and weight (ρ = -0.616, p < 0.0001). Agreement between suitable trough levels and AUC/MIC was 86.0%. To obtain AUC/MIC ≥400, the required median dose was 29.36 mg/kg 4× daily for children <6 year; 21.52 mg/kg for 6–12 years; and 13.95 mg/kg >12 years (p < 0.0001). Similar median dosing values (24.89 mg/kg, 20.83 mg/kg and 13.95 mg/kg respectively) were needed when considering suitable trough values.

Conclusion Current paediatric vancomycin dose recommendations are insufficient and should take the patient’s age more into account. In order to quickly obtain appropriate levels, we propose the following daily dosing scheme: <6 years: 4 × 25–30 mg/kg; 6–12 years: 4 × 20 mg/kg; >12 years: 4 × 15 mg/kg/ day. A larger prospective study will be needed to confirm the recommended paediatric vancomycin dose regimen.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PKP-002 DECREASED LINEZOLID SERUM LEVELS IN CRITICALLY ILL PATIENTS: CLINICAL CASE STUDIES OF A DRUG-DRUG-INTERACTION BETWEEN LINEZOLID AND RIFAMPICIN

1U Blassmann*, 2OR Frey, 3AC Rühr, 1C Vetter-Kerkhoff. 1Hospital of the University of Munich, Department of Pharmacy, Munich, Germany; 2Heidenheim Hospital, Department of Pharmacy, Heidenheim, Germany

10.1136/ejhpharm-2015-000639.332

Background Infections caused by multiresistant Gram-positive pathogens present a special challenge, resulting in increased clinical complications. Linezolid is used as reserve antibiotic in case of resistance or contraindication to vancomycin. Lack of effective linezolid levels due to co-administration of rifampicin has been described in healthy subjects. However, the clinical significance of this drug-drug-interaction (DDI) for critically ill patients is still unclear.

Purpose To report a DDI between linezolid and rifampicin resulting in linezolid levels below the minimal inhibitory concentration (MIC) in three patients.
Material and methods  Three patients with linezolid and rifampicin were identified through routine therapeutic drug monitoring. Linezolid serum level was measured by a validated high performance liquid chromatography assay.

Results  The therapeutic range of linezolid serum levels is expected to lie between 4 mg/l (2 × 600 mg IV) and 6 mg/l (2 × 600 mg p.o.). The MIC values of pathogens require trough levels between 2(4)–10 mg/l. However, the majority of observed linezolid levels in three patients were below 2 mg/l, even if rifampicin had already been stopped (Patient 1).

Conclusion  We observed accelerated linezolid clearance in critically ill patients as previously described in healthy subjects. Monitoring of linezolid levels and corresponding dose adjustments could ensure safe and effective antibiotic treatment in patients with rifampicin co-administration as well as with previous rifampicin treatment. Further investigation is necessary to assess the clinical value of combination treatment.

REFERENCE


No conflict of interest.
medicine absorbed, only 18 hinted at CYP450 isoenzyme-associated interactions, but generally limited their comments to grapefruit juice or St. John’s Wort.

Conclusion Food-drug interactions have consequences which go beyond absorption from the GI tract. Although many food ingredients such as caffeine, flavonoids, liquorice, spices, and vitamins are known to be inducers or inhibitors of some of the 57 known human CYP450 isoenzymes [cf. Flockhart Interaction Table, Drugbank, SuperCYP], they are not taken into account in the medicines’ information made available by manufacturers. Thus, risks arising from isoenzyme-associated food-drug interactions are a neglected aspect of drug information.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PKP-005 PROGNOSTIC IMPACT OF NOVEL GENE
POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE
MYELOID LEUKAEMIA ADULTS UNDERGOING
INDUCTION CHEMOTHERAPY

Background Single nucleotide polymorphisms (SNPs) could lead to inter-individual differences in treatment outcomes.

Purpose A recent study reported several novel SNPs involved in cytarabine cytotoxicity using a whole-genome approach, which were associated with clinical outcomes in a paediatric AML population. However their association with effectiveness and toxicity remain undetermined in adults.

Material and methods The six SNPs with clinical significance in the Gamazon study (Table 1) were evaluated in 109 adult patients at initial diagnosis with AML using a mass spectrometry–based multiplex genotyping assay (Sequenom). All patients were treated with idarubicin plus cytarabine.

Genotypes were grouped as dichotomous variables (dominant/recessive model). Efficacy was evaluated comparing complete remission (CR) vs. partial remission or resistance. Toxicities were grouped as binary variables (grade: 0–1 vs. grade: 2–4, Who scale). Haematological toxicity was measured with the time to neutropenia/thrombocytopoenia recovery since first day of chemotherapy. Variables were assessed using \( \chi^2 \) and Mann–Whitney U tests.

Results The median age of patients was 53 years (17–78 years). Among the baseline characteristics analysed (age, gender, haemoglobin, leucocyte, platelet and peripheral or BM blasts count) there was significant difference in genotype distributions regarding age (wild allele carriers of rs9883101 were older, \( p = 0.02 \)) and gender (men had a higher proportion of variant alleles for rs6350826 and rs7729269, \( p = 0.003 \) and 0.006; and wild allele for rs2897047, \( p = 0.005 \)). Toxicities were more frequent with variant alleles of several SNPs (table), but they were not associated with the CR rates.

Conclusion We obtained new associations of these novel polymorphisms with toxicity, not previously studied in adult AML patients, but not in effectiveness. These SNPs could be useful biomarkers in clinical practice.

Abstract PKP-005 Table 1

<table>
<thead>
<tr>
<th>SNP</th>
<th>Cardiac Hepatic Skin</th>
<th>G3–4</th>
<th>Thrombocytopoenia Neutropenia recovery (days)</th>
<th>Neutropenia recovery (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n1203833</td>
<td>GG/GA:32.7-</td>
<td></td>
<td>GG/GA:34.0-</td>
<td>AA/57.5 (0.004)</td>
</tr>
<tr>
<td></td>
<td>AA/57.5 (0.044)</td>
<td></td>
<td>GG/GA:34.0-</td>
<td>AA/68.0 (0.029)</td>
</tr>
<tr>
<td>n1075871</td>
<td>AA/28.4-</td>
<td></td>
<td>CC/38.6 (0.036)</td>
<td>AA/68.0 (0.029)</td>
</tr>
<tr>
<td>n8883101</td>
<td>AA/28.4-</td>
<td></td>
<td>CC/38.6 (0.036)</td>
<td>AA/68.0 (0.029)</td>
</tr>
<tr>
<td>n6550826</td>
<td>CC/28.2-</td>
<td></td>
<td>GG/38.9 (0.027)</td>
<td>AA/68.0 (0.029)</td>
</tr>
<tr>
<td>n2897047</td>
<td>CT/52.0-</td>
<td></td>
<td>CC/32.9-</td>
<td>CC/CT:32.9-</td>
</tr>
<tr>
<td></td>
<td>TT/88.9% (0.044)</td>
<td></td>
<td>TT/51.1</td>
<td>(0.015)</td>
</tr>
<tr>
<td></td>
<td>(0.04)</td>
<td></td>
<td>TT/51.1</td>
<td>(0.015)</td>
</tr>
<tr>
<td></td>
<td>MII:</td>
<td></td>
<td>CC/39.6%</td>
<td>CC/39.6%</td>
</tr>
<tr>
<td></td>
<td>TT/35.9</td>
<td></td>
<td>CC/16.3</td>
<td>(0.031)</td>
</tr>
<tr>
<td></td>
<td>(0.031)</td>
<td></td>
<td>CC/16.3</td>
<td>(0.029)</td>
</tr>
</tbody>
</table>

REFERENCE

No conflict of interest.

PKP-006 COMPARISON BETWEEN THE USE OF TOTAL/IDEAL/ ADJUSTED BODY WEIGHT FOR EMPIRICAL VANCOMYCIN DOSING IN OBESE PATIENTS

Background Pharmacokinetic studies have suggested that total body weight (TBW) could be the optimal approach to calculate the dose of intravenous vancomycin (15–20 mg/kg TBW every 8–12 h) for target achievement (\( \text{Css} > 15 \text{ mg/L} \)). However, recent data concluded that the use of adjusted body weight (ABW) might be a better approach in obese patients.

Purpose To determine which is the preferred method (TBW, ideal body weight (IBW) or ABW) to optimise vancomycin treatment in obese patients.

Material and methods Retrospective, non-interventional, observational study. Inclusion criteria: >18 years-old, body-mass-index (BMI) \( \geq 30 \text{ kg/m}^2 \), creatinine clearance \( \geq 60 \text{ mL/min} \), and vancomycin TDM at steady-state. Non-obese patients were...
Pharmacokinetics and pharmacodynamics

included as a control group. Patients were identified by reviewing TDM reports.

Vancomycin theoretical total daily doses (15–20 mg/kg) were calculated using TBW, IBW and ABW for each patient. They were compared with the dose used in our patients after TDM (Bayesian forecasting; PKSAbbot Software; target: Css > 15 mg/L (TDM dose)).

Dose differences greater than 10–12.5% of the TDM dose were considered unsuitable, since they could be related to clinical failure. Wilcoxon’s test analysis was performed using SPSS; (p < 0.05).

Results Forty obese patients: 35% men; 60.4 ± 12.6 years-old; BMI: 33.3 ± 2.7 kg/m².

Compared to the TDM dose and considering 15–20 mg/kg:
(i) Overdosage was observed in 72.5 (95%), 25 (47.5%) and 32.5 (72.5%) patients for TBW, IBW and ABW, respectively. Statistically significant differences were seen, with mean dose differences higher than 500 mg in the 20 mg/kg group.
(ii) Underdosage was seen in: 22.5 (5.0%), 75 (45%) and 67.5 (27.5%) respectively.

Statistically significant differences were seen with mean dose differences lower than 400 mg in the 15 mg/kg group.

No relevant differences were observed in the control group.

Conclusion Compared to the TDM dose, a high incidence of overdosage would be observed by using TBW. In our obese patient cohort, ABW might be the best approach to set the dose of intravenous vancomycin (15–20 mg/kg), as already seen in previous literature.²

REFERENCES

No conflict of interest.

PKP-007 APPROPRIATENESS OF SAMPLING TIMES FOR DRUG MONITORING IN THE EMERGENCY DEPARTMENT

S Buendía-Bravo*, A De Lorenzo-Pinto, R García-Sánchez, C Maranzano-Secades. Hospital General Universitario Gregorio Marañón, Pharmacy, Madrid, Spain
10.1136/ehjpharm-2015-000639.337

Background Pharmacokinetic monitoring optimises drug treatment. However, blood samples should be carefully collected at the right time after drug administration. Otherwise, drug levels could be interpreted in the wrong way and the physician could make an incorrect clinical decision.

Purpose To evaluate the percentage of blood samples collected at the wrong times in the Emergency Department (ED) with respect to time after drug administration.

Material and methods A prospective observational study was conducted in the ED. All patients who took medicines that should be monitored were included. The study period was 20 days (June 2014). The following variables were recorded: demographics (age and gender) and pharmacokinetics (drug name, time of drug administration, time of sample collection and number of drug levels requested per patient). The collection times recommended in our institution are: a) digoxin: at least 8 h after oral administration and 3 h after intravenous administration; b) paracetamol poisoning: at least 4 h after the last administration; c) valproate, phenobarbital, carbamazepine and lithium: prior to next dose (trough level).

Results A total of 40 patients fulfilled the inclusion criteria. 17 patients had plasma drug concentration measurements (65% were female and the median age was 65). The total number of drug measurements was 40 (1–5 measurements per patient).

Regarding wrong sampling times, 20% blood samples (8/40) were collected at the wrong times: a) digoxin: 5/17 measurements (29%); b) paracetamol: 2/11 (18%), c) valproate: 1/6 (17%), d) phenobarbital: 0/3 (0%); e) carbamazepine: 0/1 (0%); f) lithium: 0/2 (0%).

Conclusion A high percentage of drug levels were collected at the wrong times in the ED. This fact could lead to unnecessary sampling and data misinterpretation. For this reason, pharmacokinetics training provided by clinical pharmacists prior to blood sampling should be mandatory.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PKP-008 IMPROVING THE QUALITY OF CLINICAL DECISION MAKING BASED ON TOTAL PHENYTOIN SERUM LEVELS

R Juwary, M Collins*, M Datis, L Santurio, E Leiva, S Cobo, D Dot, R Jódar.
1Hospital Universitari de Bellvitge, Pharmacy Department, Hospital de Llobregat, Spain; 2Hospital Universitari de Bellvitge, Clinical Laboratory, Hospital de Llobregat, Spain
10.1136/ehjpharm-2015-000639.338

Background Therapeutic drug monitoring of phenytoin is commonly done by measuring the total phenytoin level (TPHEL) in serum or plasma. This result can be misleading in patients with serum albumin <44 g/L needing correction before use in clinical decision-making. However, serum albumin isn’t always requested with phenytoin measurement.

Purpose To design and implement an algorithm, in agreement with the Clinical Laboratory, that includes the albumin serum measurement whenever TPHEL is requested in routine testing in hospitalised patients, in order to facilitate the correct interpretation of TPHEL.

Material and methods Retrospective observational study of hospitalised patients whose TPHEL was determined between January 2013 and August 2014. The algorithm triggers serum albumin analysis in routine testing if it isn’t requested on the same day as phenytoin measurement. Variables collected were age, sex, TPHEL, albumin, creatinine and urea. Albumin-adjusted total phenytoin level (AATPHEL) by the Shiner-Tozer equation and GFR by CKD-EPI were calculated. Phenytoin therapeutic interval considered was 10–20 mg/L. TPHEL and AATPHEL results was classified into infra, supra or therapeutic group and discrepancies among groups were analysed.

Results 561 TPHEL results were studied (206 patients; average age: 60.5 years; 119 female). 74 (13%) TPHEL did not have albumin results because were stat requests. 98.8% of TPHEL (481 out of 487) had serum albumin <44 g/L and required correction and 93% of them (449 out of 481) had GFR >25 mL/min/1.73 m². Based on the TPHEL alone, 44% required an increased dose while only 27% required it when using AATPHEL. In contrast, 16% of TPHEL results taken alone required dose reduction, which jumped to 38% when the AATPHEL was used.

Conclusion The majority of hospitalised patients had albumin inferior to 44 g/L, requiring the calculation of AATPHEL to
Pharmacokinetics and pharmacodynamics

**PKP-010** HIGHER THAN RECOMMENDED DOSES OF COLISTIMETHATE SODIUM IN PATIENTS WITH MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS: A BENEFIT OR AN INCREASED RISK OF TOXICITY?

1 Luque, 2 Sori, 1 Horcajada, 3 N Campillo, 4 Alvarez-Lema, 5 Segura, 4 H Knobel, 2 M Montero, 2 F García, 1 S Grau, 1 Parc de Salut Mar, Pharmacy Department, Barcelona, Spain; 2 Parc de Salut Mar, Infectious Diseases, Barcelona, Spain; 3 Parc de Salut Mar, Intensive Care Department, Barcelona, Spain; 4 Laboratoris de Referencia de Catalunya, Microbiology Department, Barcelona, Spain

**Background** Recent pharmacokinetic studies suggest the administration of higher colistimethate sodium (CMS) doses for treating multidrug resistant Gram-negative (MDR-GNB) infections.

**Purpose** The aim was to compare the efficacy, pharmacokinetics and toxicity of the manufacturer’s recommended CMS doses (RD) versus higher doses (HD).

**Material and methods** Pharmacokinetic study performed at a university hospital in patients with MDR-GNB infections treated with CMS. Data: demographics, severity (APACHE-II), CMS dose, type of infection, colistin plasma concentration (Cminss before next CMS dose and at steady state), nephrotoxicity at day 7 (RIFLE criteria), clinical cure and crude mortality. CMS doses were selected by the clinicians’ criteria. All patients treated with higher doses than those recommended by the national manufacturer were considered HD group. Cminss was measured by HPLC.

**Results** 102 patients included. Clinical and pharmacokinetic characteristics.

<table>
<thead>
<tr>
<th></th>
<th>RD patients (n = 70)</th>
<th>HD patients (n = 32)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)*</td>
<td>64.8 (16.4)</td>
<td>64.6 (15.1)</td>
<td>0.940</td>
</tr>
<tr>
<td>Male</td>
<td>55 (78.6)</td>
<td>24 (75.0)</td>
<td>0.436</td>
</tr>
<tr>
<td>APACHE*</td>
<td>12.3 (5.9)</td>
<td>12.6 (5.3)</td>
<td>0.707</td>
</tr>
<tr>
<td>Severe sepsis</td>
<td>34 (48.6)</td>
<td>14 (43.8)</td>
<td>0.153</td>
</tr>
<tr>
<td>MDR-GNB infection:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchial</td>
<td>16 (22.9)</td>
<td>7 (21.9)</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>12 (17.1)</td>
<td>8 (25.0)</td>
<td></td>
</tr>
<tr>
<td>Urinary tract</td>
<td>11 (15.7)</td>
<td>3 (9.4)</td>
<td></td>
</tr>
<tr>
<td>Bacteremia</td>
<td>7 (10.0)</td>
<td>5 (15.7)</td>
<td></td>
</tr>
<tr>
<td>Bone/Skin and soft tissue</td>
<td>13 (18.6)</td>
<td>4 (12.5)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>11 (15.7)</td>
<td>6 (18.8)</td>
<td>0.838</td>
</tr>
<tr>
<td>Baseline GFR (mL/min/1.73 m²)*</td>
<td>164.3 (117.9)</td>
<td>147.8 (100.3)</td>
<td>0.569</td>
</tr>
<tr>
<td>CMS dose (mg/kg/day)*</td>
<td>5.1 (2.0)</td>
<td>8.5 (3.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cminss (mg/L)*</td>
<td>1.3 (1.1)</td>
<td>2.1 (1.8)</td>
<td>0.024</td>
</tr>
<tr>
<td>Nephrotoxicity</td>
<td>11 (15.7)</td>
<td>15 (46.9)</td>
<td>0.001</td>
</tr>
<tr>
<td>Clinical cure</td>
<td>57 (81.4)</td>
<td>22 (68.8)</td>
<td>0.181</td>
</tr>
<tr>
<td>Mortality</td>
<td>20 (28.6)</td>
<td>13 (40.6)</td>
<td>0.227</td>
</tr>
</tbody>
</table>

*Mean ± SD.

**Conclusion** More than 30% of patients received a higher than recommended CMS dose but they didn’t achieve better clinical outcomes in terms of clinical cure and mortality and they developed nephrotoxicity more frequently, a fact probably related to the higher colistin plasma levels.

*These findings suggest the need to select which patient’s profile can benefit from higher CMS doses.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

None.

No conflict of interest.

**REFERENCE**


No conflict of interest.
Pharmacokinetics and pharmacodynamics

PKP-011 PHARMACOTHERAPEUTICS MONITORING ANALYSIS OF VANCOMYCIN IN THE PHARMACEUTICAL SERVICE
10.1136/ejipharm-2015-000639.341

Background Vancomycin is a widely used antibiotic in nosocomial infections due to methicillin-resistant staphylococcal aureus, a major cause of death, justifying the strict controls on its use as well as serum drug level monitoring (SDLM).

Purpose To evaluate pharmaceutical interventions regarding their impact on the initial regimen and adjustment of serum vancomycin levels.

Material and methods A retrospective observational study of patients for whom pharmacokinetic monitoring of vancomycin was requested in the year 2013. The parameters evaluated were obtained from the computer applications Kinetidex, Clinidata Net and the pharmacotherapeutic profile: creatinine, dose, first dosed serum drug level and suggested dose.

Results 433 serum drug levels of vancomycin were determined. Of the total 159 patients, 63.5% were subjected to pharmacokinetic monitoring, averaging 4.29 serum drug levels per patient.

61.4% patients received vancomycin, in an intermittent regimen (IR), 38.6% received it by continuous infusion (CI), of these only 46.2% had a loading dose.

The average trough serum drug level was 14.07 μg/ml and the intermediate serum drug level in the CI regimen was 23.14 μg/ml.

It was found that 40% of the trough serum drug levels in the IR were within the reference values? (RV) (10–15 μg/ml), 30% of serum drug levels were above and 30% were below.

In CI, 13.9% of intermediate serum drug levels were within the RV (20–25 μg/ml), 33.3% were above and 52.7% were below.

Most pharmaceutical interventions were aimed at maintaining the dosing interval, reflecting the interventions in increasing doses (31.68%) or decreasing doses (20.79%).

Conclusion It was concluded that many patients required an adjustment to the initial treatment regimen, maintaining the dosing interval, but with dose modifications.

A serum drug level lower than the RV is not effective in controlling the infection with the potential emergence of resistant strains. High serum drug levels above the RV may cause toxic effects.

This differentiated pharmaceutical intervention contributed to improved health outcomes and strengthened the regulatory framework in multidisciplinary health teams.

REFERENCE
No conflict of interest.

PKP-012 MONITORING OF VANCOMYCIN IN 62 PATIENTS WITH CENTRAL NERVOUS SYSTEM INFECTIONS
F Franco*, V Vazquez-Guerra, MD Aumente. Hospital Universitario Reina Sofia de Córdoba, Servicio de Farmacia, Córdoba, Spain
10.1136/ejipharm-2015-000639.342

Background Since the release of linezolid vancomycin has been downgraded as an alternative in the treatment of central nervous system (CNS) infections caused by Gram-positive bacteria on account of its bad penetration and high incidence of nephrotoxicity. There are no studies with enough patients to support this trend.

Purpose To evaluate the efficacy and safety of vancomycin in CNS infections, and the impact of monitoring its pharmacokinetics.

Material and methods Descriptive retrospective study which included all patients with CNS infections treated with vancomycin and monitored. Patients aged under 18 and those who received less than 5 days’ treatment with vancomycin were excluded.

Results A total of 62 patients were included, 39 with previous surgical intervention (SI) in the CNS.

The most common diagnoses in the group with prior SI were bacterial meningitis (51%), fistula of cerebrospinal fluid (CSF) (21%) and shunt infection (21%). All had baseline neurological disease – neoplasms (46.2%) and subarachnoid haemorrhage (25.6%).

Most patients without prior SI (n = 23) were diagnosed with bacterial meningitis (n = 21) and just 2 with a brain abscess. The infective pathogen was isolated in 39 samples of CSF. All isolated microorganisms were sensitive to vancomycin. 63.7% of the isolated microorganisms were coagulase-negative Staphylococcus, with a MIC = 2 in 23.7%.

The initial and adjusted mean doses of vancomycin were 35.6 ± 9.3 mg/kg/day and 39.9 ± 15.2 mg/kg/day respectively. The median initial and adjusted Cmin were 10.04 (6.16) mcg/ml and 14.67 (3.66) mcg/ml respectively.

Laboratory-confirmed CSF clearance was obtained in 26 of the 39 isolates, 73.1% during the first 10 days of treatment.

The overall mortality was 3.8%, but only one death was related to the CNS infection.

Although Cmin above 20 mcg/ml was recorded in 15 patients, none developed nephrotoxicity.

Conclusion Vancomycin is still an agent of choice for CNS infections. Vancomycin trough concentrations of 15–20 mcg/ml are recommended to achieve clinical effectiveness for CNS infections without causing nephrotoxicity.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PKP-013 MANAGEMENT OF INCREASED SERUM CREATININE LEVELS IN TELAPREVIR TREATMENT IN COADMINISTRATION WITH AMLODIPINE: A CASE REPORT
1E Marletta*, 1D Spadaro, 1S Guzzardi, 1N Avola, 1D Sgarlata, 2M Distefano, 1G Cacciaguerra. 1ASP Di Siracusa, U. O. C. Farmacia, P. O. Umberto I, Siracusa, Italy; 1ASP Di Siracusa, U. O. C. Malattie Infettive, P. O. Umberto I, Siracusa, Italy
10.1136/ejipharm-2015-000639.343

Background Telaprevir is a protease inhibitor used for the treatment of chronic hepatitis C genotype 1. Amodipine is a drug commonly used by hepatitis C patients and is a substrate of CYP3A. Many studies show that telaprevir is a strong inhibitor of CYP3A and that co-administration with CYP3A substrates should be clinically monitored.

Purpose To describe the management of increased serum creatinine levels in a patient who received telaprevir in co-administration with amloidipine.
Material and methods A 65-year-old man, treated with amioda-pine 10 mg/day, was admitted with chronic hepatitis C genotype 1. His body weight was 64 kg (BMI 24.9) and laboratory evaluation showed the following values: haemoglobin 12.6 g/dl, serum creatinine 0.8 mg/dl, viral load (HCV RNA level) 1,518,241 U/ml. The patient's medical history was reviewed and risk factors were carefully evaluated. A literature search was conducted in PubMed.

Results In May 2014 the patient began triple therapy with telaprevir, peginterferon a-2a (180 mcg/week) and ribavirin (800 mg/ day). Two weeks later, the viral load became undetectable. After four weeks of antiviral treatment, the patient was hospitalised because of high serum creatinine levels (1.7 mg/dl). A drug-drug interaction was suspected and it was decided to suspend amioda-pine and reduce ribavirin to 200 mg/day. The patient was rehy-drated and continued triple therapy, 24 h later, the serum creatinine levels started to decline and returned to the normal range (1.2 mg/dl) within four days.

Conclusion The co-administration of telaprevir with amiodapine may result in significant ADRs. Clinical monitoring and modification of the treatment allowed the continuation of triple ther-apy for a patient with a high probability of success.

REFERENCE

No conflict of interest.

PKP-015 PHARMACOGENETIC STUDY OF THE EFFECT OF POLYMORPHISMS IN THE TRAILR1/TRAIL SYSTEM ON THE RESPONSE TO TREATMENT WITH RITUXIMAB IN FOLLICULAR LYMPHOMA PATIENTS
1MR Gutiérrez Ciccio, ªEspañol Morales, 9 Conesa Zamora, 1G Gutiérrez-Meca Maestre, 1MH García Lagunar, 1Muñoz García, 9Guerrero Baustista, 1Ferti Villanueva, 1A García Márquez, 1L Martínez Penella. 1Hospital General Universitario Santa Lucia, Pharmacy, Cartagena, Spain; 9Hospital General Universitario Santa Lucia, Hematology, Cartagena, Spain; 1Hospital General Universitario Santa Lucia, Molecular Pathology and Pharmacogenetics, Cartagena, Spain
10.1136/ejhpharm-2015-000639.345

Background The interindividual variability in drug response and toxicity is well known and may be related to genetic factors. TRAIL and TRAILR1 are proteins involved in the induction of apoptosis by the extrinsic pathway and may be implicated in the mechanism of action of the anti-CD20 agent, rituximab.

Purpose To assess the influence of the functional gene polymor-phisms rs20576 TRAILR1 and rs12488654 TRAIL on follicular lymphoma (FL) patients.

Material and methods FL patients treated with rituximab in combination with first line chemotherapy in a level 3 Hospital. The clinical response was assessed after the fourth cycle and treatment completed, response criteria used were proposed by the International Working Group [Complete Response (CR), Partial Response (PR), Stable Disease (SD), Relapsed Disease (RD), considered SD and RD for non-responders (NR)]. Genes polymorphisms were determined by allelic discrimination using fluorescence probes and a 7500F real time termocycler. Statistical analysis of the data was performed using the program Epidat 3.1 (p < 0.05 as statistically significant).

Results 40 patients were included (60% men). Average age: 58 ± 16 years. Pharmacogenetic study was performed to 31 patients at the fourth cycle and to 39 at the end of the treat-ment. Distribution for response genotypes:

- After fourth cycle: NR [AA = 1(100%)], PR [AA = 8(50%), CA = 8(50%)], CR [AA = 10(71.4%), CA = 4(28.6%)] (poly-morphism rs20576); NR [GA = 1(100%)], PR [AA = 1(6.3%), GA = 5(31.3%), GG = 10(62.5%)], CR [AA = 1(7.1%), GA = 2(14.3%), GG = 11(78.6%)] (polymorphism rs12488654).
- Treatment completed: NR [AA = 1(100%)], PR [AA = 4(57.1%), CA = 3(42.9%)], CR [AA = 17(54.8%), CA = 13(41.9%), CC = 1(3.2%)] (polymorphism rs20576); NR [GA = 1(100%)], PR [GA = 2(28.6%), GG = 5(71.4%)], CR [AA = 2(6.7%), GA = 7(23.3%), GG = 21(70%)] (polymorphism rs12488654).

There were no statistically significant differences between geno-types of polymorphisms (rs20576; rs12488654) and clinical
response to rituximab after fourth cycle (p = 0.3503; p = 0.3930) and treatment completed (p = 0.9053; p = 0.4908).

Conclusion According to the results of our study, genes polymorphisms rs20576 TRAILR1 and rs12488654 TRAIL do not appear to influence the response to treatment with rituximab in FL.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Haematology Department.
No conflict of interest.

PKP-016 A COMPARISON OF INDIKO AND DIMENSION ENZYMATIC ETHANOL ANALYZERS
M Candela*, C Pastor, M Boquera, G Fernandez-Peinado, R Nalda, G Riera, J Selva, P Más. Hospital General Universitario de Alicante, Pharmacy Department, Alicante, Spain
10.1136/ejhpharm-2015-000639.346

Background In certain clinical settings such as the emergency room, it is necessary to analyse the urinary concentration of ethanol to determine the degree of intoxication. However, in the Addictive Behaviours Unit it is important to detect if the patient is remaining abstinent. In this case, the selection of the analytical technique will be dictated by the sensitivity limit.

Purpose To compare the results of ethanol determinations on the Thermo Scientific Indiko (Indiko) and Siemens Dimension Xpand (Dimension) analysers considering the sensitivity limit of the analytical technique.

Material and methods Urine samples were collected from patients of an Addictive Behaviours Unit and were refrigerated to be determined later. Urine samples were analysed by the Indiko and Dimension using a method based on enzymatic reaction. The sensitivity limit of the ethanol test was 13 mg/dl and 10 mg/dl for the Dimension and Indiko, respectively. An ethanol concentration above the sensitivity limit were considered as positive. Accuracy was calculated for concentrations of 15 mg/dl and 20 mg/dl, near the sensitivity limit. Statistical analysis was performed with SPSS v.17.

Results A total of 60 urine samples were analysed. 58 samples were deemed negative and 2 samples positive by both analysers. Mean concentration for the 15 and 20 mg/dl checks were 12.49 ± 0.46 mg/dl (CV: 3.65%) and 14.34 ± 1.18 mg/dl (CV: 8.22%), and 18.38 ± 0.55 mg/dl (CV: 3.01%) and 18.08 ± 0.37 mg/dl (CV: 2.05%) for the Indiko and Dimension, respectively.

Conclusion In our study with urine samples of patients from an Addictive Behaviours Unit, there were no discrepancies between the ethanol concentration results for the two techniques.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Pharmacy department.
No conflict of interest.

Patient safety and risk management

PS-001 AUDIT ON THE USE OF DIGOXIN IN AN ACUTE GERIATRIC UNIT: REPORT OF A RETROSPECTIVE STUDY
1A Zulfiqar*, 1J Novella, 1M Drame, 1M Millard, 2O Djedda. CHU de Reims, Department of Internal Medicine and Geriatrics, Reims Cedex, France; 2CHU Reims, Pole Research and Innovations, Reims, France; 4CHU Reims, Department of Toxicology-Pharmacology, Reims, France
10.1136/ejhpharm-2015-000639.347

Background Digoxin is the only product in its class of drugs and the only positive inotropic agent available, used to slow the heart rate in atrial fibrillation.

Purpose To perform an audit on the use of digoxin in the elderly, with the aim of being able to optimise the use of digoxin in geriatric units.

Material and methods Retrospective study in an acute geriatric unit, from January to June 2014, including patients over 65 years, who received digoxin 0.25 mg/0.125 mg. The normal digoxin range is between 0.5 and 1.2 mmol/L; the patient doses were individualised taking account of comorbidities, biological parameters (renal/liver function, calcemia/kalemia, serum albumin, presence of an inflammatory syndrome) and drug interactions.

Results 20 patients were enrolled, including 11 women (55%). The median age was 88 years (78–94). 12 (60%) patients had renal failure, seven (35%) had disturbed liver function tests, 11 (55%) had an inflammatory syndrome, 9 (45%) had malnutrition, no patients had hypercalcemia, and only one had hypokalaemia. 7 (35%) patients had high digoxin levels, including 3 with electrical signs related to overdose. Of these 7 patients, 5 had renal failure, 4 were malnourished, and one patient had an inflammatory syndrome. Only 2 patients had liver abnormalities. Considering possible drug interactions, all 3 patients who had electrical signs associated with overdose were taking a cardioselective beta blocker. 5 out of the 7 patients had a proton pump inhibitor; only 2 patients were taking amiodarone (but had no electrical signs). Because of the small patient cohort (20), comparing the qualitative and quantitative variables such as digoxin could not achieve significance in our study.

Conclusion Digoxin should be prescribed cautiously in the elderly if they have kidney failure, inflammatory syndrome or are taking beta blockers.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-002 IMPORTANCE OF PHARMACOVIGILANCE FOR MAINTAINING HOSPITAL PROTOCOLS INCLUDING HIGHLY COMPLEX DRUGS: OUR OWN EGFR-TKI AFFAIR
1D Marquez-Medina, 2M Gilaber-Sotoca*, 2N Pons-Llibet, 1M Marquez-Bafaluy, 3M Martinez Soquet, 3J Schoenenbreger-Amàiz. Hospital Arnau de Vilanova, Medical Oncology, Lleida, Spain; 2Hospital Arnau de Vilanova, Pharmacy, Lleida, Spain
10.1136/ejhpharm-2015-000639.348

Background Two reversible tyrosine-kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) (A and B) were approved for the treatment of EGFR-mutant advanced non-small cell lung cancer (aNSCLC), with similar activity and results. Pharmacovigilance detected efficacy differences between A and B in our centre.

Purpose To define and possibly correct the cause of this finding.

Material and methods Drug A was considered our standard treatment for EGFR-mutant aNSCLC from April 2011 to March 2013, and was replaced with B from April 2013 to the present. EGFR-mutant patients were sequentially diagnosed in two different external platforms (PA and PB) during the same periods of time. We retrospectively reviewed the medical charts of TKI-treated EGFR-mutant aNSCLC patients from April 2011 to March 2014. Progression free survival (PFS) was analysed in any, first, and second line of treatment by Kaplan-Meier curves
and Cox regression. The finding of significant differences in PFS between A and B led to the retrospective review of all EGFR-analysed aNSCLC patients.

Results Fifteen EGFR-mutant aNSCLC patients were treated with A (7 s line), and 16 with B (10 s line). Mean age of the series was 65 years (44–82), and 74.2% were women. PFS benefited A in any (11.43 vs. 4.96 months; p = 0.000), first (13.3 vs. 3.98 months; p = 0.014), and second line of treatment (9.5 vs. 5.53 months; p = 0.023). PA analysed 108 aNSCLC, patients detecting 12.1% EGFR-mutant and 15% non-analysable tissue samples. PB analysed 85 aNSCLC, patients finding 20% EGFR-mutant and 3.5% non-analysable tissue samples.

Conclusion The lower PFS of B-treated aNSCLC patients was attributed to an excessive sensitivity of PB in detecting EGFR-mutation. Re-calibration of the technique modified the current percentage of EGFR-mutant and non-analysable samples to 15.3% and 10% of 129, respectively. Periodic monitoring of selected drugs helps to correct protocol defects, to improve quality of treatments, and to reduce costs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Conflict of interest

PS-003 PHARMACEUTICAL INTERVENTIONS IN THE FIELD OF ONCOHAEMATOLOGY
A Manzaneque*, A Olivé, M Mensa, F Do Pazo-Dublía, N Creus, C Codina. Hospital Clinic i Provincial de Barcelona, Pharmacy, Barcelona, Spain
10.1136/ehjpharm-2015-000639.349

Background Pharmaceutical validation is considered an essential process in detecting medicines errors in chemotherapy.

Purpose To describe and analyse pharmaceutical interventions (PIs) carried out in oncology patients during 2012–13.

Material and methods Retrospective observational study. Data were collected from the PI reporting platform, which comprised both hospitalised and outpatients. Information collected included: demographic data, inpatient or outpatient setting, drug, dosage, reason for PI, type of PI and acceptance. PIs were categorised in 12 groups (dosage adjustment; dosing schedule; drug; administration route; dosage form; frequency; dispensed; initiation and duration of treatment; treatment monitoring; suspension and others) and were associated with 52 different reasons for the intervention.

Drugs involved were classified into chemotherapy (chemo), related or unrelated.

PIs were analysed using Excel. Acceptance data was categorised as accepted or no information available.

Results 3,294 PIs (1,109 patients) were recorded (4.5 PI/day). In-patients accounted for nearly all PIs (95%) and 88% of drugs involved were unrelated to chemo.

The main type of PI reported was others (38.5%). The most common reasons were: incorrect use of electronic prescribing program (21.2%), adapting dosage forms (17.9%), pharmaceutical care/patient information (14%).

Change of dose (24.4%) and schedule adjustment (22.2%) were the most frequent types of PI within chemo-related drugs. Drugs related to higher notification rates were: trastuzumab (4.2%), gemcitabine/carboplatin (2.9%) and paclitaxel/erlotinib (2.0%) among chemo drugs, and antiemetic treatment (38.3%), calcium folinate (6.0%), filgrastim (6.0%) and zoledronic acid (4.9%) within the chemo-related drugs.

PI global acceptance was 51%, but increased to 93% considering only chemo drugs.

Conclusion PIs were mainly recorded in the in-patient setting and focused on non-chemo drugs.

The different acceptance rate between chemo and non-chemo drugs, explained by the lack of recorded acceptances, highlights the need for an improvement in the reporting tool.

The results suggest the need for standardisation of the PI reporting and evaluation process.

REFERENCE
No conflict of interest.

PS-004 EXTRAVASATION OF TAXANES: DEVELOPMENT OF AN ACTION ALGORITHM FOR QUICK AND EFFECTIVE TREATMENT
M Morgado*, I Freire, I Eusébio, J Ribeiro, M Guardado, R Oliveira, R Duarte, S Morgado, O Fonseca. Hospital Centre of Covilha Da Beira, Pharmaceutical Services, Covilha, Portugal
10.1136/ehjpharm-2015-000639.350

Introduction A potential complication of chemotherapy is vesicant cytotoxic extravasation; for example taxanes may harm patients. Therefore, fast acting and active treatment are essential.

Purpose To develop an algorithm for the management of taxane extravasation. It should include management measures, antidote and treatment.

Methods A literature review was performed of guidelines and articles obtained from PubMed from January/2000 to December/2013, intersecting the terms “cytotoxic extravasation”, “chemotherapy extravasation” and “extravasation treatment”. The summary of product characteristics of all of intravenous taxanes available in Portugal was also reviewed.

Results The first course of action is to stop the infusion immediately, not remove the cannula, disconnect the infusion, and with a new syringe aspirate as much of the infusate as possible. The medical staff on service is then notified, the extravasation kit is collected and the extravasated drug is identified. Thereafter, the extravasation area is marked and photographed and the cannula is removed. Warm compresses should be applied to the affected area for 20 min, 4 times/daily for 1–3 days, with minimal pressure, and the antidote hyaluronidase 150 IU/mL must be administrated (several subcutaneous injections of 1–6 mL of hyaluronidase into the extravasation area in a clockwise manner). Analgesia should be provided if required. Each incident of extravasation must be thoroughly documented and the follow-up and long term management is central. An algorithm was developed for the management of taxane extravasation that promotes quick and effective treatment.

Conclusions The algorithm developed is a valuable tool for all hospital services that prepare and administer taxanes, contributing to a quick and effective response to episodes of extravasation.

REFERENCES AND/OR ACKNOWLEDGEMENTS
We thank all Portuguese hospital pharmacists who have contributed to this project with valuable opinions and suggestions.

No conflict of interest.
**PS-005** IMPROVING MEDICINES SAFETY – IMPLEMENTING A BARCODE SCANNING DISPENSING CHECK IN A LARGE TEACHING HOSPITAL

K Berry*. John Hunter Hospital, Pharmacy Department, New Lambton Heights, Australia

10.1136/ehjpharm-2015-000639.351

**Introduction** From a literature search, it was found that there was very little data on how scanning the barcode on a medicine affects medicines safety and error rates in a hospital pharmacy setting.

**Purpose** To reduce medicines dispensing errors by 50% in a large teaching Hospital Pharmacy Department by December 2013 by implementing a final barcode scan step into the dispensing process.

**Methods** Data was collected from 2009 to 2013 by analysing medicines errors occurring in a hospital setting. It was found that since 2009, 37% of errors had been caused by picking the wrong strength of the correct product and 27% of errors were due to picking the wrong drug from the shelf. The primary solution implemented was the addition of a barcode to the pharmacy dispensing label. The implementation strategy included data collection, implementation and then an evaluation phase to ensure the change was successful through series of “Plan Do Study Act” cycles. A new dispensing process was implemented with existing software which included a new reporting system.

**Results** After implementing the modified dispensing practice of using the barcode scanner as a tool for final checks, the technicians were able to detect 100% of their own errors. With ongoing monitoring, it was found that 80% of medicines errors in the pharmacy department were detected through the use of barcode scanning as a checking tool. The remaining 20% of errors were due to typing errors on the labels or misreading the directions on the prescription.

**Conclusions** With ongoing monitoring, we are able to look at which errors are not improving with barcode scanning, which will help identify further projects to ensure patient medicines safety. Future areas being considered are to attach barcodes to medicines manufactured in-house and to use barcode scanning as a tool to reduce picking errors for routine ward stock.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**PS-006** PURE RED CELL APLASIA ASSOCIATED WITH ADALIMUMAB THERAPY

M Quesada Sanz*, E Marquez Fernández, D Guerra Estévez, B Marmesat Rodas, J Gantes Trelles. Hospital Punta de Europa, Pharmacy, Algeciras, Spain

10.1136/ehjpharm-2015-000639.352

**Background** Pure red cell aplasia is a severe, non-regenerative form of anaemia, with selective erythroid aplasia of the bone marrow. Although there are congenital forms, most cases are acquired by toxic, radiation or drugs and 30% are idiopathic.

**Purpose** Our objective is to describe the probable relationship between the occurrence of pure red cell aplasia and the treatment with adalimumab in a patient diagnosed with Crohn’s disease.

**Material and methods** 22 years old woman who was admitted to hospital because of probably central origin anaemia secondary to adalimumab administration, over base severe iron deficiency.

The variables analysed were: haemoglobin (g/dl), hematocrit (%), erythrocytes (x10^7/l), leukocytes (x10^7/l), platelets (x10^7/l), serum iron (µg/dl), transferrin (mg/dl) and transferrin saturation index (%).

**Results** The patient started treatment with adalimumab in November 2013 with an induction dose of 160 mg at week 0 and 80 mg at week 2, followed by 40 mg every other week. Baseline haemoglobin, erythrocytes and hematocrit were 11, 1 (norm. 12–15), 4, 18 (4–5) and 33, 8 (37–47), respectively. Concerning to iron study, baseline values of serum iron, transferrin and transferring saturation index were 22,4 (50–70), 217 (200–360) and 8, 13 (16–50), respectively. Platelets and leukocytes were in the normal range. After 5 months of treatment with adalimumab, the patient was admitted to hospital because of severe anaemia (haemoglobin = 4, 1, hematocrit = 14, 1 and erythocytes = 2, 33), requiring stopping treatment and the administration of intravenous iron, 3 packed red blood cells and subcutaneous erythropoietin 40,000 once a week. After 5 weeks, the patient had haemoglobin values of 10.2 g/dl, showing a partial marrow recovery.

**Conclusion** There have been rare cases of aplastic anaemia associated with the use of tumour necrosis factor antagonists, so that, although their relationship is unclear, patients with confirmed significant hematologic abnormalities should be considered to discontinue the treatment.

**REFERENCE**


No conflict of interest.

**PS-007** SURVEY ON THE USE OF VIALS AND PENS AS INSULIN DELIVERY DEVICES IN HOSPITALISATION UNITS

C Lara, M Ruano, E Villamafañ*, E Pérez, L Balade, A Herrero. La Paz University Hospital, Pharmacy, Madrid, Spain

10.1136/ehjpharm-2015-000639.353

**Background** Insulin is a high-risk drug not always used properly in hospitals according to the current recommendations.

**Purpose** To find out what is the usual practice in use and storage of different types of insulin delivery devices (vials-pens) in hospital.

**Material and methods** Pharmacists surveyed nurses in non-critical wards concerning safety, handling and storage conditions of insulin in a general hospital (420 adult beds).

**Results** A total of 77 questionnaires were returned. Concerning safety, vials were used for several patients (100%). Pens were generally used in the right way, however some nurses (32.5%) admitted using them occasionally for different patients, taking out doses with a syringe. Dispensing sealed pens from the pharmacy was considered an effective safety measure (92%).

In terms of handling the vials, 83% of nurses used them with safety insulin syringes. Pens were used with conventional, non-safety needles (100%), without purging in 52% of cases and 80% removed the needle from the pen after administration. About how the needle was removed: 39% unscrewed it directly to discard it, 35% covered it first with the outside protector and 14% with the inside one. At discharge 50% delivered an opened pen to the patient; otherwise, the pens were left in the unit’s medicines storage area or discarded.

Opened pens and vials were stored in the unit’s medicines storage area, mostly in the refrigerator (67%) and 57%,
Background Anti-TNF drugs (ADs) have been a major advance in the control of chronic rheumatic diseases, however they sometime have important adverse drug effects (ADEs).

Purpose To assess the frequency of AD and disease-modifying antirheumatic drug (DMARD) combinations leading to withdrawal of biological treatment (BT) due to ADEs.

Material and Methods Observational study in a tertiary hospital (1,350 beds). Outpatients on BT followed in a rheumatic disease unit were included. We evaluated patients who had been prescribed infliximab, etanercept or adalimumab concomitantly with DMARDs (between November 1999 and March 2013). The primary end point was BT withdrawal due to ADEs.

Results 444 patients out of 531 took DMARDs at the same time as ADs. 52 (11.7%) discontinued treatment due to ADEs as did 10 patients receiving anti-TNF monotherapy (11.5%) (OR = 0.567; CI95%: 0.319 – 1.010; p > 0.05). There was an increase in ADEs when other DMARDs were used concomitantly with BT. We found less probability of withdrawal for patients taking methotrexate with BT were less likely to develop ADEs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Rheumatology Department
No conflict of interest.
Patient safety and risk management

Background The Institute of Oncology in Ljubljana is the leading institution for cancer care in the country and has a busy pharmacy department. The prescription and preparation of cytostatic drugs must be closely monitored, since they are highly toxic and pose a serious health hazard if errors occur in prescriptions for medicines. Pharmacists with knowledge of chemotherapy protocols are thus a key factor in improving the standard of patient care, as they can spot specific errors on chemotherapy prescriptions.

Purpose To analyse the number of pharmacists’ interventions over a one year period and evaluate their impact on safety and effectiveness of patient care.

Material and methods A review of all pharmacists’ interventions from August 2013 to July 2014 has been carried out. All errors detected were then evaluated by the team of pharmacists and sorted according to their potential to cause harm. Measures to eliminate such mistakes in the future have also been proposed. The interventions were communicated by phone to ensure that the right treatment had been selected and the correct medicines validated in the computer program Cypro.

Results The total number of prescriptions was 22,120 and the pharmacy dispensed 48,442 cytostatic preparations. The errors causing most concern were: wrong treatment protocol selected, different patient selected (two patients with the same or similar name), omitted validation for 1 or more drugs from the treatment protocol and erroneous dose orders due to a variety of input mistakes (wrong weight or height, body surface area and random bias).

Conclusion Medicines errors should not occur when using approved protocols from the computer program (Cypro). Nevertheless, pharmacist supervision is still needed, since medicines prescription errors happen despite the existence of input schemes, as was shown in our study. Only experienced pharmacists with expertise in chemotherapy drugs and pharmacology of cytostatic drugs can identify errors, communicate with physicians and validate the correct treatment orders.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PS-011 IMPROVING THE SYSTEM FOR MONITORING ADVERSE DRUG REACTIONS

M Kim*, M Ahn, S Song, Y Jung, H Jeong. Veterans Health Service Medical Center, Department of Pharmacy, Seoul, Korea-South

10.1136/ejhpharm-2015-000639.357

Background This study examined adverse drug reaction (ADR) reports submitted at this hospital for 32 months from December 2011 to July 2014. The proportion of ADR cases reported by doctors and nurses was 8.7%, while that of pharmacists was 91.3%. Nevertheless, the proportions of ADR of injectables and other drugs reported by doctors and nurses were 4.0% and 6.1%, respectively. Thus, their ADR reporting should largely be improved.

Purpose To investigate the perception of ADR reporting by clinical staff, to examine what is done in response, and to seek to improve the monitoring system and invigorate ADR reporting.

Material and methods A survey was distributed to each department and ward. The completed questionnaires were collected from these participants three days later.

Results Of the participants, 36.5% knew about the ADR reporting procedure in the electronic medical record system. However, only 5.3% had actually reported ADRs. Of participating doctors, 66.7% did not report an adverse reaction since they felt it was too complex and were busy. Of participating nurses, 50.0% did not report ADRs since they were not sure of the cause-effect relationship. However, 28.6% of nurses did not report adverse reactions since they were too minor. To prevent ADR recurrence, 75.4% of clinical staff inputted ADR data into the medical record, while only 12.1% of them inserted such data into the ADR system.

Conclusion For periodic and vigorous promotion of ADR reporting, these authors began an all-out promotion which included distributing an official letter and making an ADR presentation at medical conferences. We are improving the system to simplify the reporting process and to effectively manage the reported cases. Additionally, the ADR feedback system is newly reinforced. We hope that such a feedback system may invigorate quality ADR reporting.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PS-012 MEDICINES RECONCILIATION IN THE INTENSIVE CARE UNIT

1P Nieto Guindo*, 1A Alonso Martin, 1H Mateo Carasco, 1E Molina Cuadrado, 1F Verdejo Reche, 1D Fernández Ginés. 2Torrecardenas, Pharmacy, Almeria, Spain; 1P Nieto Guindo*, 1D Fernández Ginés. 2Torrecardenas, Pharmacy, Almeria, Spain; 3Northampton General Hospital, Pharmacy, Northampton, UK

10.1136/ejhpharm-2015-000639.358

Background Medicines reconciliation is known to minimise medicines errors and reduce morbidity in hospitalised patients. Its role in the Intensive Care Unit (ICU) has not been widely studied.

Purpose To analyse the number, type, and importance of pharmacist contributions in the ICU of a tertiary level hospital.

Material and methods Prospective study conducted in July 2014 to assess the accuracy of in-patient prescription charts. Drug history and medicines reconciliation were undertaken within the first 24 h by a specialist pharmacist. The patient’s own medicines, information from relatives or carers and community pharmacy records, were used as sources of information. Discrepancies between the patient’s regular medicines and prescribed medicines were conveyed to the medical team. Discrepancies were considered medicines errors when they required further intervention by the responsible doctor.

Results 48 patients were included, percentage of females 39.6%, mean age 62 ± 14.04. Average number of regular medicines per patient: 5.41 ± 3.5. Discrepancies were found in 62.5% of patients, of which 79.9% required pharmacy intervention (the rest of them were obviated due to the patient’s clinical condition – mostly inability to swallow). These involved 98 out of 260 drugs prescribed. Of them, the contribution was accepted in 51.3% of cases (40 prescriptions), whereas in the remainder 48.7% of cases, the changes were intentional. According to their pharmacological class, the highest number of contributions was found in anti-hypertensives (9 contributions), followed by statins (6) and diuretics (6). In relation with the type of medicine involved, a total of 33 medicines errors were accountable as omissions, whilst wrong directions were found in 4 cases, and wrong dose occurred in 3 cases.
Conclusion Medicines errors in the ICU have a similar incidence to those in other non-acute clinical settings. This study is in line with previous publications, suggesting that the ICU might benefit from the regular input from a pharmacist, which in turn would result in a reduction of medicines errors.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-013 ERRARE HUMANUM EST, NOT ONLY... A REVIEW OF ERRORS DUE TO COMPUTERISED PHYSICIAN ORDER ENTRY (CPOE)
A Dericquebourg*, M Watel, G Strobbe, G Marliot, I Sakji, S Delbey. Oscar Lambret Center, Pharmacy, Lille, France
10.1136/ehjpharm-2015-000639.359

Background Prescription computerization is an undeniable step forward in terms of safety. It can significantly reduce the errors associated with handwritten prescriptions. However these new practices are the source of new risks associated with interactions between humans and computers.

Purpose To identify and quantify these risks in our institution.

Material and methods We analysed the pharmaceutical interventions performed in DxCare software over a period of 15 months with the query tool Business Objects. We then ranked the interventions according to error types.

Results Over the study period, 48,551 prescription lines were analysed. 3,139 pharmaceutical interventions were performed (6.5% of prescription lines). Among these interventions, 971 (31%) were identified as related to computerization. The main errors identified were: prescription unit errors (n = 561), wrong administration procedures (n = 147), duplicate prescriptions (n = 143), wrong drug prescribed (n = 37), incomplete doses (n = 31), inappropriate use of software features (n = 29) and lastly, prescribed dose was inappropriate (n = 23). The root causes of these errors can be related to defects in software design, a lack of user training or a reluctance to use computers.

Conclusion Our analysis has highlighted that computer-related errors cannot and should not be overlooked. Optimising software and layout could reduce some of these errors. Other methods would require more in-depth training and a better understanding from the users. Finally, as patient safety is paramount, it is vital to see computerization as a tool for improvement and not as a quick fix.

REFERENCE
No conflict of interest.

PS-014 DRUG-DRUG INTERACTION PATTERNS IN A PORTUGUESE HOSPITAL MEDICINES SERVICE
1M Morgado*, 2C Terra, 3S Morgado. 1Centro Hospitalar Cova Da Beira, Pharmaceutical Services, Covilhã, Portugal; 2University of Beira Interior, Health Sciences Faculty, Covilhã, Portugal
10.1136/ehjpharm-2015-000639.360

Background Concomitant administration of several therapeutic agents has the potential to cause drug-drug interactions. The ability of health professionals to detect drug-drug interactions is still limited; they often go unnoticed by the physician when prescribing and by the pharmacist when validating.

Purpose To retrospectively evaluate potential drug–drug interactions that occurred between January 1st and June 30th of 2013 in a hospital medicines service.

Material and methods In the initial phase, the history of each patient’s drug treatment was obtained, using the computer system of Cova da Beira Hospital Centre. All medicines administered were then analysed and potential drug-drug interactions were identified using the Micromedex Drug Information 2.0.

Results This study showed that of 300 patient pharmacotherapeutic profiles analysed, 207 (69.0%) were identified as having at least one potential drug-drug interaction in the prescribed treatment. In total, 784 interactions were identified, of which 8 (1.0%) were classified as contraindicated interactions, 350 (44.6%) as major interactions and 426 (54.3%) as moderate interactions. The 10 most common drug-drug interactions identified by Micromedex represented 30.9% (242/784) of interactions. Enoxaparin was the drug most frequently involved in clinically significant interactions (72 cases), followed by amiodarone (55 cases) and warfarin (49 cases).

Conclusion The occurrence of drug interactions was relatively high and clinically significant interactions occurred in a considerable proportion of hospitalised patients. This study may contribute to the rapid and efficient detection of clinically significant interactions through the implementation of computerised alerts targeting the interactions identified in the present study and visible during the medical prescription and pharmacist validation.

REFERENCES AND/OR ACKNOWLEDGEMENTS
We thank to all the hospital pharmacists who contributed to this project with valuable opinions and suggestions.
No conflict of interest.

PS-015 PHARMACEUTICAL INTERVENTIONS (PIs) IN ELECTRONIC PRESCRIPTIONS
MM Romero Alonso, J Estaire Gutierrez, MA Bolivar Raya*, C Plata Casas. Hospital Infantil Elena, Pharmacy, Huelva, Spain
10.1136/ehjpharm-2015-000639.361

Background PIs add quality and safety to the drug treatment process, through records and their subsequent assessment.

Purpose To analyse the PIs made during the process of validating e-prescriptions at a regional hospital.

Material and methods A prospective, observational study of PIs made between August 2011 and August 2014 during the process of validating e-prescriptions by a software application (Silicon), in line with the adaption to Spain of the medication errors classification system of the National Coordinating Council for Medication Error Reporting and Prevention. The sections analysed were: wrong medicine, dose omission, incorrect dose, length of treatment, inadequate monitoring and other errors that included therapeutic duplication and exchange, the frequency, speed, route and technique of administration, preparation/handling and/or conditioning, and pharmaceutical method.
Patient safety and risk management

Results 413 PIs were recorded: 16.5% medicines errors (22% inappropriate/wrong drug for treatment intended), 8.8% dose omission (80% without a prescription stating the medicine required), 26.3% incorrect dose (59.6% dose higher than stipulated), 3.9% length of treatment (69% longer than necessary), 21% inadequate monitoring (94.1% no clinical review) and 24% other errors (30% frequency of administrative error). 52.8% of the PIs were for women. Average age: 65.8. Service areas: 38% internal medicine, 14.5% orthopaedic, 12% general surgery, 10.7% infectious diseases, 7.4% respiratory, 5.5% digestion, other areas with fewer occurrences. Medicines: n = 107 home treatment, n = 19 acenocoumarol, n = 11 serum therapy, n = 13 omeprazole, n = 8 amoxicillin/clavulanic and digoxin, n = 7 furosemide, n = 6 amloidine and n = 5 metamizole and amphotericin B liposomal.

Conclusion The results show that home treatment accounted for most PIs, which has led to the development of a medicines reconciliation project. Acenocoumarol (high risk drug according to the Institute for Safe Medication Practices) was the drug that generated most PIs, and incorrect dose was the most frequent error. The PI analysis quantified and provided information on the medicines that required intervention, in order to minimise drug-related administration errors.

REFERENCE
1 http://www.nccmerp.org/medErrorTaxonomy.html

No conflict of interest.

DEVELOPING TOOLS FOR ELECTRONIC PRESCRIBING PROGRAM IMPROVEMENT


10.1136/etjpharm-2015-000639.362

Background Medication systems related to clinical decision support, when implemented in an electronic prescribing program, have the potential to reduce adverse drug reactions.

Purpose To increase safety in the prescription and administration of drugs through the introduction of new warning systems, such as of interactions, maximum doses and a guide to the parental administration of drugs, in an electronic prescribing programme (SILICON).

Material and methods 1. The most relevant interactions between the active pharmaceutical ingredients included in the pharmacotherapy guidelines (TFG) were chosen. 2. A search for the maximum dose of the active ingredients present in the parental administration TFG was performed. 3. The necessary information was collected in order to create a link between the proper administration and maintenance of the active pharmaceutical ingredients administered parenterally.

Results A total of 70 interaction pairs, corresponding to 16 different active pharmaceutical ingredients, were selected and introduced in SILICON. 100% of the selected interactions were accompanied by a pharmacotherapeutic recommendation.

From a total of 295 active ingredients, 140 maximum doses were considered useful for prescription and validation, and were included in SILICON. In order not to create confusion when prescribing, 28 (9%) files of active ingredients were duplicated in the program to differentiate oral and parenteral maximum doses.

Finally, for the parenteral administration guide, 224 (76%) of active ingredients were selected. Moreover a direct link from the prescription screen to the administration guide was created. All active substances excluded from the guide, have an administration protocol to follow.

All information entered in the prescription program was included on the pharmacy service website.

Conclusion The insertion of maximum dose alerts and interactions, and a link to the updated parenteral drugs administration guide, into an electronic administration program, provides a safety tool. In this way, we contribute towards reducing medication errors.

REFERENCE
1 Raskin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care 2011;26:104.e1–6

No conflict of interest.

USING TREATMENT PROTOCOLS IN THE VERIFICATION OF ORAL ANTICANCER DRUG PRESCRIPTIONS

1,2FO O’Saughnessy*, 1L Hammond, 1AM De Frein, 1O’Shea, 1C Keane. 1St. Vincent’s University Hospital, Pharmacy, Dublin, Republic of Ireland; 2Trinity College Dublin, School of Pharmacy and Pharmaceutical Sciences, Dublin, Republic of Ireland

10.1136/etjpharm-2015-000639.363

Background A lack of information at the time of dispensing has been identified as a barrier to the safe provision of Oral Anti-cancer Medicines (OAMs) by pharmacists. Access to cancer treatment protocols at the time of pharmacist dispensing is advocated by numerous professional bodies to ensure the safe supply of OAMs.1,2

Purpose To compare the number of OAM prescriptions that could be verified and safely dispensed with and without access to the treatment protocol, and to assess the use of these protocols by pharmacists.

Material and methods One hundred OAM prescriptions were retrospectively reviewed to assess OAM verification with and without the treatment protocol. An electronic questionnaire was also distributed to 493 pharmacists. This questionnaire asked respondents to verify an OAM prescription with and without access to the treatment protocol and to comment on their experience and opinions.

Results When using standard reference sources, the pharmacists had sufficient information to verify 7% (n = 7) of OAM prescriptions reviewed. Having access to the treatment protocol increased the number of prescriptions that could be verified to 16% (n = 16) (p = <0.01). Lack of access to body surface area and failure to communicate deliberate deviations from standard doses prevented the verification of most OAM prescriptions (n = 84). The response rate to the questionnaire was 6.4% (n = 32). Pharmacists reported that the protocols were a valuable source of information and reported they would like access to them in the future.

Conclusion Facilitating access to the treatment protocol at the time of dispensing of OAM increases the number of prescriptions that can be verified and safely dispensed. However, implementing this measure alone is insufficient to address the safety concerns associated with the dispensing of OAM prescriptions by non-specialist pharmacists.
Background The solution for infusion bags prepared by the pharmacy contains an unknown and variable volume of solution in order to keep a minimum volume.

Purpose To determine the potential under-dosing of oncology patients related to the loss of cytostatic drugs in the remaining volume of the solution for infusion bags.

Material and methods Prospective observational study. We randomly assessed 50 cytostatics mixtures prepared by the Pharmacy Service.

Studied variables: total dose of cytostatic drug prescribed, total volume of the mixture and the volume remaining after the intravenous administration. The remaining volume was indicated by the infusion pump. The total volume was obtained from the cytostatics compounding program (Farmatools).

As we found from the literature, it is acceptable that up to 5% of the total dose prescribed by the oncologist may be lost in the process of IV administration.

Results Overfilling was detected in all 50 solutions (100%). In 10 cases (20%), the volume of the solution remaining after administration contained a cytostatic dose less than 5% of the total dose. In 40 cases (80%) the remaining dose was higher than 5%. In 16 of these 40 cases (40%), the non-infused dose was higher than 10% of the total dose (32% of the total of mixtures) and in 6 cases (15% of these 40 cases) was higher than 20% of the dose prescribed (10% of all the preparations).

Conclusion The solutions for infusion bags contain more fluid that specified on the commercial label. If this is not corrected for, the total volume of the mixture will be greater than that shown on the label issued by the Pharmacy Service. The measure adopted is to program an additional volume in the infusion pump, while maintaining the speed shown on the label issued by the Pharmacy Service.

REFERENCES AND/OR ACKNOWLEDGEMENTS

L. Santos
No conflict of interest.
frequency of DPYD*2A or 2846A >T genetic variants and the proportion of patients with these variants developing adverse reactions grade 3–4.

Results The frequency of DPYD*2A in Caucasians was 0.9%, while DPYD 2846A >T occurs in 1.5%. A literature review showed that 68.2% of DPYD*2A and 74.3% of DPYD 2846A >T carriers would develop an adverse event grade ≥ 3 during treatment with fluoropyrimidines (approximately 17 out of 1,000 patients). The average cost of genotyping 1,000 patients for these two polymorphisms in our centre would be €10,000 and the cost of treating an episode of severe fluoropyrimidine-induced neutropenia in 17 patients was €32,300. As a result, €22,300 would be saved for 1,000 patients treated.

Conclusion Avoiding the costs of treating severe adverse reactions due to fluoropyrimidines may justify the costs of DPYD testing. Treatment with fluoropyrimidines guided by DPYD genetic testing could offer a more efficient health outcome versus empirical treatment. Further studies should be carried out to verify our findings.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-021 POTENTIALLY INAPPROPRIATE MEDICINES FOR THE ELDERLY IN THIRD LEVEL HOSPITAL DISCHARGES
JM Sotoca*, M Lopez, M Tuset, C Codina. Hospital Clinic, Pharmacy Service, Barcelona, Spain
10.1136/ejhpharm-2015-000639.367

Background Medicines for which the risk of adverse drug events (ADE) exceeds their expected clinical benefit when they are given to elderly persons, and which can be replaced by better-tolerated alternatives, are called potentially inappropriate medicines (PIMs).

The prevalence of PIMs might be considered as a quality indicator of prescribing practice in the elderly.

Purpose To study the prevalence of three PIMs for elderly patients in third level hospital discharges.

Material and methods Data were obtained from the pharmacy claims database between 1st January 2013 and 31st December 2013.

Patients over 64 years old who had had at least one of the following PIMs dispensed in the community pharmacy during 2013 were included:

- **Fluoxetine (selective serotonin reuptake inhibitor (SSRI))** because of the risk of hyponatremia and central nervous side effects (nausea, insomnia, dizziness, confusion),
- **Glibenclamide (sulfonylurea)** because of its high risk of hypoglycaemia,
- **Metoclopramide (prokinetic)** because of its extrapyramidal side effects.

The proportion of users of these PIMs was calculated and broken down by gender and age.

Results The percentage of elderly patients who were dispensed one of the selected PIMs for the three drug classes is shown in Table 1.

Conclusion The percentage of PIMs in elderly patients is still considerable at discharge, at least for the three drugs considered. Stronger efforts should be made in medicines reviews at hospital discharge in order to minimise PIMs.

<table>
<thead>
<tr>
<th>Potentially inappropriate drug</th>
<th>Drug Class</th>
<th>Percentage of patients</th>
<th>Gender</th>
<th>Mean age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoxetine</td>
<td>Selective serotonin reuptake inhibitor</td>
<td>74% (263/350)</td>
<td>69.2% female</td>
<td>77.6 years</td>
</tr>
<tr>
<td>Glibenclamide</td>
<td>Sulfonylurea</td>
<td>26.5% (26/98)</td>
<td>46.2% female</td>
<td>78.5 years</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Prokinetic</td>
<td>78.4% (182/232)</td>
<td>59.3% female</td>
<td>77.3 years</td>
</tr>
</tbody>
</table>

REFERENCE

No conflict of interest.

PS-022 POLYPHARMACY AND DRUG-DRUG INTERACTIONS IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION
P Lopez-Sanchez*, JM Martinez-Sesmero, AR Rubio Sakadot, M García Palomo, P Miyagomez. Hospital Virgen de La Salud, Hospital Pharmacy, Toledo, Spain
10.1136/ejhpharm-2015-000639.368

Background Studies demonstrate that human immunodeficiency virus (HIV) patients may be at greater risk of age-related comorbidities, polypharmacy and medicines-related problems, such as drug-drug interactions (DDIs).

Purpose To describe the characteristics of polypharmacy and DDIs in HIV patients.

Material and methods We performed an observational-retrospective study of the pharmacotherapeutic profile (all drugs) and clinical record (demographic and clinical data) of adult HIV virus patients on stable antiretroviral treatment (ART, at least 6 months) in a general teaching hospital. We defined polypharmacy as the use ≥5 drugs. To define the impact of DDIs we used the Lexi-Interact drug-interaction database; interactions categorised as D (consider treatment modification) or X (avoid combination) were analysed and further stratified into one of the following groups: Type 1 = ART + non-ART; Type 2 = two non-ARTs; Type 3 = two ARTs.

Results We evaluated 100 patients (female, 28; median age, 48 years; HCV co-infected, 43; HBV co-infected, 2; HCV&HBV co-infected, 7; adherence <95%, 9). There were 54 patients with polypharmacy (mean 7.5 ± 2.6 drugs/patient). ART profile was based on triple therapy with non-nucleosides (NN) in 65 patients, protease inhibitors (PIs) in 18, integrase inhibitor (II) 8 and other combinations in 9. Non-ART drugs most prescribed were statins (38 patients), benzodiazepines (at least one in 26 patients) and proton pump inhibitors (24 patients). We identified 123 DDIs in 43 patients, 83 (67.5%) classified as Category D or X (59 different drug pairs, Type 1: 2.17 DDIs/patient; Type 2: 0.62 DDIs/patient; Type 3: 0.07 DDIs/patient; p < 0.001). The ART drugs involved in DDIs were mainly PIs (34 pairs 57.6%) and non-ART drugs, mainly statins (9 pairs 15.2%).

Conclusion There is a medium-high level of polypharmacy and DDIs in our patients. Type 1 DDIs are significantly higher than the others, therefore greater attention to non-ART prescriptions is needed to ensure the safest drugs use in HIV patients.
Background As part of the WHO’s High 5s project, the Standard Operating Protocol “Medicines Reconciliation” has been used in our hospital centre since 2010. Medicines reconciliation at the time of admission detects medicines errors (ME), called unintended discrepancies (UDs). These MEs are particularly worthy of attention because they are not detected by the computerised physician order entry system (CPOES).

Purpose To analyse the type and the potential seriousness of MEs, to identify the cause of the loss of information and to determine the ATC groups of the drugs most involved.

Material and methods Prospective observational and interventional study.

From July to September 2014

In patients older than 65 years of age hospitalised in short stay units after admission through the Emergency Department:

• Within 48 h of admission, patients’ regularly used medicines are compared with computerised prescriptions at admission.
• Every UD identified is corrected at reconciliation, and recorded in an Excel file.

Results 191 lines of UD were identified among 532 reconciled patients (30% from eligible patients):

• Type of ME: omission (70%), incorrect dose (20%)
• Potential seriousness: minor (32%), significant (48%), major (+20%)
• Identified cause: inattention (60%), regular prescriptions non-available (24%), resumption of an old prescription (7%)
• Most involved ATC groups: C (35%) particularly subgroups C09 (30%) and C10 (30%).

Conclusion Most MEs are omissions, and information is most frequently lost due to inattention; this is easily corrected by reconciliation. Almost half of MEs might have significant consequences for patients if not rectified. Concerning errors in the C09 subgroup, we must improve the equivalence database of our CPOES.

Working within a multidisciplinary team in hospitalisation units, the pharmacist contributes to increasing patient safety. Medicines reconciliation is a time-consuming activity; to keep it steady in our hospital after the end of the WHO project and to be exhaustive, we have to identify which patients are the most important to reconcile.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

References

Rousseaux*, F. Leouillet-Moreau, A. Cotteau-Leroy, P. Oudou. CHRU de Lille, Pharmacy, Lille Cedex, France

10.1136/ehjhp-2015-000639.369

Background The indicatons for rituximab in haematology are classified into 3 categories: group 1: indications for which the medicine was initially marketed (MA), group 2: additional recommendations for temporary use (RTU), and group 3: indications that are not authorised or are lacking sufficient documentation for authorisation by the French Medicines Agency (ANSM), but for which the medicine can be used based on the literature and recommendations. We have a prescription form in which all of the drug’s indications authorised by the ANSM (group 1 and 2) are already written and classified, to encourage safe use of medicines.

Purpose To check if rituximab prescriptions for these indications reflect the actual use of the drug.

Material and methods For each prescription of rituximab from January to April 2014, we compared the indication on the prescription to the one in the patient’s files (multidisciplinary meetings reports and discharge letters). Every indication was classified by group and we analysed the divergence.

Results In our cohort of 52 patients, 80.8% were in prescription group 1, 3.8% in prescription group 2, and 15.4% in prescription group 3. We calculated a 25% divergence between the prescribed indication and the actual one. 16.66% of prescription group 1 and 100% of prescription group 2 indications were in reality group 3 indications. 52.94% of real group 3 prescriptions were not declared as such.

Conclusion This study might question the safety of prefilled prescriptions because doctors might supply incomplete information and pharmacists might therefore approve dispensing of this medicine for incorrect indications. In order to improve safety, we suggest a new kind of prescription form in which all of the medicine’s indications are written without being classified and with more blank spaces to allow the doctor to give additional information about the chemotherapy, the state of the cancer and the number of relapses.

References

No conflict of interest.

References

O’Hild*, K Johnsen. 1Capital Region Pharmacy, Quality, QA, Herlev, Denmark; 2Capital Region Pharmacy, Quality, Microbiology, Herlev, Denmark

10.1136/ehjhp-2015-000639.371

Background Aseptic production is performed by approximately 100 operators. According to the Quality Management System, sampling is performed daily on all operators, both hands. The acceptance criteria established is, that on the total of two gloves; one viable microorganism is accepted.

Over some years, numerous out of specification results were observed. As the amount of data is very large (two samples from each of approx. 100 operators, every day), and as the data is structured inefficiently, it is very difficult to evaluate whether there are trends in the data and also difficult to keep the individual operator informed about her own results.

Purpose To develop an easily accessible quality indicator that can generate an overview of the hygiene data and help the operator to recognise his/her own performance so as to improve working procedures and thereby reduce the number of out of specification results.

References

No conflict of interest.
Material and methods For three selected departments, the 2014 data were evaluated and suitable quality metrics developed. Applying these quality metrics, data were presented graphically, in order for the individual operator to be informed and aware of the results from her own glove fingerprints. Employees from Quality Assurance and Microbiology inspected the aseptic working routines, made observations and gave feedback. Once a month data are updated and the operators informed of their own results.

Results Before, results could not be measured and individual persons were unaware of their own results. After the quality metric was developed, each employee is currently informed in a manageable form, and the number of out of specifications on bacterial contaminations of gloves fingerprints has reduced.

Conclusion Using a quality metric that allows graphical presentation of data on a personal level, it was possible to make the individual employee aware of personal hygiene data and thereby to reduce the number of out of specifications to the benefit of the aseptic procedure and thereby to the safety of the patient.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-026 PERIPHERAL INFUSIONS IN NEONATAL AND PAEDIATRIC INTENSIVE CARE: EXTRAVASATION RATE AND RISK FACTORS

C Fonzo-Christe*, A Parron, C Combesoure, P Pfister, P Rimembrerger, P Bonnabry. Geneva University Hospitals, Pharmacy, Geneva, Switzerland; Geneva University Hospitals, Pharmacy – School of Pharmaceutical Sciences, Geneva, Switzerland; Geneva University Hospitals, Research Center and Division of Clinical Epidemiology, Geneva, Switzerland; Geneva University Hospitals, Neonatology and Pediatric Intensive Care Unit, Geneva, Switzerland

Background Intravenous infusions of highly concentrated drugs and hyperosmolar parenteral nutrition are frequent in our neonatology (NEONAT) and paediatric intensive care (ICU) units, by central or peripheral venous catheters (PVCs). Extravasation may have severe consequences (necrosis, skin graft).

Purpose To determine the extravasation rate of peripheral infusions in two care units (NEONAT/ICU) and associated risk factors.

Material and methods Retrospective study (Jan–Dec 2013, electronic patient data) of all patients hospitalised in NEONAT or ICU and with at least one PVC.

Global PVC (location, duration in situ (days), patient’s age (days) at PVC removal) and patient analyses (sex, age at admission (year), gestational age (GA, week)). "Extravasation group" if PVC was removed or insertion site documented as 'diffusion' and if the patient had at least one extravasated PVC.

Comparison of 'extravasation' and 'no extravasation' groups (median value [IQR25–75]) and multivariate subgroup (NEONAT/ICU) analysis of associated factors.

Results A total of 1,300 PVCs in 695 patients were analysed. An extravasation rate of 11.7% (152/1,300) of PVCs and 17.6% (222/695) of patients was determined. In NEONAT and ICU, a rate of 28.3% (51/180) PVCs and 30.1% (44/146) patients, and 9.1% (101/1,115) PVCs and 14.3% (78/547) patients respectively was observed. In the extravasation group, the PVC remained in situ for longer (1.8d [1.0; 3.1] vs. 1.5d [0.8; 2.7], p = 0.01) and age at PVC removal (131.8d [1.2; 966.3] vs. 98.4d [154.2; 5,146.0], p < 0.0001), age at admission (0.3y [0.0; 2.5] vs. 1.7y [0.1; 9.2], p < 0.0001) and GA (33.4 w [32.0; 37.0] vs. 36.3 w [33.6; 39.4], p = 0.002) were lower. No differences were observed in terms of sex or location. In subgroup analysis, low GA (NEONAT < 32 week), low age at PVC removal (NEONAT/ICU) and in situ duration >3 days (ICU) were independent risk factors.

Conclusion We observed a global extravasation rate of 11.7% (PVC) and 17.6% (patients). Prematurity (NEONAT), low age and PVC remaining in situ >3 days were associated risk factors.

Implementation of PVC management guidelines and of an assessment scale are planned in the next future.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-027 POTENTIALLY INAPPROPRIATE PRESCRIPTIONS ACCORDING TO BEERS AND STOPP CRITERIA IN THE UNIVERSITY HOSPITAL OF FERRARA

C Palladino*, S Bianchi, P Scanavacca. University Hospital of Ferrara, Department of Pharmacy, Ferrara, Italy

Background Inappropriate drug prescriptions or prescriptions outside the therapeutic indications can frequently be the cause of adverse reactions to drugs, which can potentially be avoided. Despite there being a consensus on the definition of inappropriate medicines prescription, it is often difficult to identify and measure inappropriate prescriptions.

Purpose To evaluate the frequency and occurrence of inappropriate drug prescriptions in elderly patients hospitalised in our healthcare setting by using two criteria: Beers and STOPP.

Material and methods The discharge prescriptions coming from the internal and geriatric medicine wards of the Ferrara hospital. We selected the prescriptions for all patients over the age of 70 from July 1st 2013 to June 30th 2014 considering: age, sex, length of hospitalisation, prescribing ward, prescribed drugs and the patient’s pathologies. The main outcome measures were: prevalence of inappropriate prescriptions following the Beers and STOPP criteria, and the drugs that are frequently inappropriately prescribed.

Results Our study involved 950 patients (average age 75). Following the Beers criteria, 37% (28–42%) of patients had received at least one inappropriate prescription. This percentage rose to 45% (38–49%) by following the STOPP criteria.

According to the Beers criteria our analyses observed that 20% of inappropriately prescribed drugs were beta blockers, 25% were NSAIDs, 18% were benzodiazepines. On the other hand, by following the STOPP criteria we observed that aspirin accounted for 45% of inappropriately prescribed drugs, NSAIDs for 22%. The highest frequency of inappropriate prescriptions was detected from the geriatric ward.

Conclusion From the analyses performed we have observed that in our hospital in the medical wards there is a high frequency of inappropriate prescriptions. It could be possible to reduce inappropriate drugs by about 80% by acting on the four main categories of drugs that are more often inappropriately prescribed.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
SUCCESSFUL PREGNANCY OUTCOME WITH INTERFERON-ALPHA IN HAEMATOLOGICAL PATIENTS

J Sánchez Gundín*, A Flor García, M Llorente Serrano, L Recuero Gálve, G Marcos Pérez, D Barreda Hernández. Virgen de La Luz Hospital, Pharmacy Department, Cuenca, Spain

10.1136/ehjpharm-2015-000639.374

Background Pegylated Interferon-alpha-2b (pegIFNα2b) is an effective agent for the treatment of haematological malignancies. As it does not inhibit DNA synthesis, this agent may be safe for use during pregnancy.

Purpose To describe 2 cases of successful pregnancies in patients with haematological disorders treated with pegIFNα2b.

Material and methods Medical record review and literature search.

Results Patient 1: 30-year-old woman diagnosed with polycythemia vera at age 13, well-controlled with hydroxyurea. Chemotherapy was interrupted due to the patient’s desire for a second pregnancy and treatment with pegIFNα2b. 50mcg/week subcutaneously was initiated. (During the first pregnancy she received non-pegylated-IFNα2b with good progression but low tolerance due to influenza-like symptoms). 5 months later, she became pregnant, but was hospitalised due to headaches which caused a dose reduction to 30 mcg/week of pegIFNα2b. Finally, the patient delivered a healthy male infant. 15 days later, pegIFNα2b treatment was interrupted to recommence the usual treatment with hydroxyurea.

Patient 2: 27-year-old woman with Philadelphia chromosome-positive chronic myeloid leukaemia diagnosed at age 22, well-controlled with imatinib. The patient interrupted antineoplastic treatment due to her desire to conceive a child and subcutaneous treatment with pegIFNα2b, at 50 mcg/week was initiated. She became pregnant after 4 months and pegIFNα2b dose was increased to 80 mcg/week and developed hypothyroidism which was treated with levothyroxine. Finally, the patient delivered a healthy male infant and 1 month later, she discontinued pegIFNα2b and levothyroxine treatment to recommence her usual treatment with imatinib.

Both were normal full-term deliveries. Infant growth and development have been normal to date (follow-up time of 2 and 3 years). Blood tests were normal during pregnancies. Only mild anaemia and slight neutrophilia were detected in the first patient, but did not require treatment interruption.

Conclusion PegIFNα2b was well tolerated, safe and effective, and caused no complications during the pregnancies. Since chemotherapy agents involve teratogenic effects, pegIFNα2b might be a safe treatment option during pregnancy, although further teratogenic studies are necessary.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

IMPACT OF HAEMATOLOGICAL ADVERSE EVENTS OF TRIPLE THERAPY IN PATIENTS WITH HEPATITIS C

L Recuero Gálve*, A Mulet Alberola, J Sánchez Gundín, M Llorente Serrano, M Mejía Recuero, D Barreda Hernández. Hospital Virgen de La Luz, Pharmacy Hospital, Cuenca, Spain

10.1136/ehjpharm-2015-000639.375

Background Protease inhibitor treatment (PIT) represents an important advance for patients with hepatitis C. However, PIT may produce haematological adverse events (HAE).

Purpose To analyse the impact of HAE in hepatitis C patients who have been treated with PIT.

Material and methods Retrospective observational study (December 2012–August 2014) of patients with PIT who suffered HAE requiring supportive treatment in a general hospital.

Data collected:

- Medical record review: weight, treatment (drug, dose, length of treatment) and HAE.
- Outpatients database: cost of real (including supportive treatment) and theoretical (without HAE) treatment per patient.

Results 12 patients (7 with telaprevir, 5 with boceprevir) began PIT. 6 (3 male and 3 female) median age 53.3 ± 3.2 years suffered from HAE, requiring supportive treatment (4 patients with weight ≥75 kg).

Telaprevir patients:

- 2 patients presented neutropenia between 8th and 12th week.
- The pegylated-interferon-72a dose was reduced and they were treated with filgrastim 48 MIU until 36th and 43th week, respectively, when they stopped their treatment due to other adverse events (AE).
- 2 patients (1 co-infected with HIV) suffered anaemia from 6th and 8th week. Their ribavirin dose was reduced. One patient was given epoetin-alfa 40,000 IU until 7th week when he stopped treatment due to other AEs. The HIV-co-infected patient started darbepoeitin-alfa 50–100 mcg (treatment finished after 48 weeks). Both needed blood transfusions (this cost was not evaluated).

Boceprevir patients:

- 1 patient stopped PIT at 7th week for severe neutropenia, having reduced pegylated-interferon-2a dose previously. Afterwards, one dose of filgrastim 30 MIU was necessary.
- 1 patient reduced pegylated-interferon-72a dose for severe thrombocytopenia in the 8th week. Later, he was given eltrombopag 25 mg until the end of PIT (48 weeks).

The real cost was €179,439.9 and theoretical cost €169,674.9.

Conclusion 50% of patients with treatment with IP needed supportive treatment to manage HAE. The real cost was higher than the theoretical cost (6.8%), but they could continue their PIT, although 4 patients had to finish it later because of other side effects.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

RISK OF ANTICHOLINERGIC EFFECTS ESTIMATED IN POLYPATHOLOGICAL PATIENTS. THE IMPACT PROJECT

1AM Villalba-Moreno*, 2ER Alfaro-Lara, 3C Pérez-Guerrero, 4B Santos-Ramos, 5MD Nieto-Martin, 6MD Santos Rubio. 1University Hospital Virgen Del Rocio, Pharmacy, Seville, Spain; 2Regional Ministry of Equality, Health and Social Services, Andalusian Agency for Health Technology Assessment, Seville, Spain; 3Facuaty of Pharmacy, Pharmacology, Seville, Spain; 4University Hospital Virgen de Valme, Pharmacy, Seville, Spain; 5University Hospital Virgen Del Rocio, Internal Medicine, Seville, Spain

Background Drugs with anticholinergic and sedative effects carry significant risks in older people. An increased incidence of falls, impaired physical function and cognitive decline has been attributed to the use of these drugs.

Purpose To estimate the Risk of Anticholinergic Effects (RAE) in patients with several conditions based on their pharmacotherapy.
Patient safety and risk management

Material and methods Cross-sectional study of RAE in a cohort of patients included in the IMPACT project (October 2010–April 2012).

Anticholinergic exposure was calculated using the Anticholinergic Risk Score (ARS) and Anticholinergic Cognitive Burden (ACB). These are reliable lists of drugs with a measure for the anticholinergic load. Higher scores are associated with increased RAE.

The age, sex and pharmacotherapy were collected for each patient. The RAE measured was defined as patients treated with at least one anticholinergic drug according to the ARS and ACB scales.

Results Eighty patients were analysed. The mean age was 78.2 ± 8.2 years, 55.0% were men and the mean number of medicines was 12.9 ± 3.5.

The ACB identified 68 patients (85% of individuals) as exposed to a medicine with anticholinergic potency: 47 patients (58.7%) with ACB level of 1, 13 (16.2%) with level 2 and 8 (10.0%) with level 23.

The ARS identified 15 patients (18.7%): 11/15 patients with ARS level of 1 and 4/15 with level 2.

The most common medicines was furosemide (77.5%) as ACB level of 1, digoxin (6.25%) with ACB level of 1, metoclopramide (5%) with ARS level of 1, risperidone (5%) with a level of 1 on both scales, atenolol (3.75%) with ACB level of 1 and paroxetine (3.75%) with ACB level of 3 ACB and ARS level of 1.

Conclusion A high proportion of polymedicated patients are at risk of anticholinergic adverse events due to treatment. Detection of patients with RAE can be an important strategy for optimising drug treatment in these patients.

REFERENCE

No conflict of interest.

PS-031 EFFECTIVENESS AND SAFETY OF ANTIHYPERTENSIVE DRUGS IN ELDERLY PATIENTS

1 N Marrero-Ramón, 1 I Sánchez-Martínez, 1 M Tobanea-Soto, 1 C Caballero-Requejo, 1 P Seli-Sabater, 1 J C Titos-Arcos, 1 B Ambas-Díaz, 1 M Sánchez-Cataláico, 1 N De Bejar-Riquelme, 1 M Soría-Soto. Hospital General Universitario J Morales Meseguer, Pharmacy, Murcia, Spain; 2 Hospital General Universitario Reina Sofía, Pharmacy, Murcia, Spain

10.1136/ehjpharm-2015-000639.377

Background Older hypertensive patients should attempt lifestyle modification to lower the blood pressure. If the blood pressure goal is not attained with lifestyle modification, antihypertensive treatment should be initiated.

Purpose To evaluate the effectiveness and safety of antihypertensive drugs in institutionalised older hypertensive patients.

Material and methods Retrospective descriptive study including all older patients treated with antihypertensive treatment who lived in a public elderly residence. Follow-up was three months (February–May 2014).

Parameters analysed were: systolic (SBP) and diastolic (DBP) blood pressure, kind of hypertension, cardiovascular risk factors (CVRF), vascular and/or organ injury and safety.

The collected data were obtained from Savac (prescription and validation program) and clinical records.

Results A total of 141 residents included 74 hypertensive patients (52.48%). The mean value of SBP was 122.6 mmHg (160–80) and DBP was 65.37 mmHg (89–49). Most patients had primary hypertension.

32.4% of patients had two CVRF, 44.6% had three, 20.3% had four and 2.7% had five. The most important CVRF (excluding age and inactivity) was dyslipidaemia. Cardiovascular risk was stratified in medium (13.5%), high (14.8%) and very high (71.7%). Clinical lesions were diagnosed in 73% of patients.

44.6% of patients were treated with only one antihypertensive but 21.6% and 6.7% were treated with four and five antihypertensive drugs. According to ESH/ESC Guidelines, the prescriptions were adjusted in left ventricular hypertrophy, renal failure and diabetes mellitus (88.89%, 76.92% and 63.64% respectively). The effectiveness was 84.85% with one antihypertensive, 70% with two, 68.8% with three and 40% with four.

The adverse effects were: 31 orthostatic hypotension, 8 dizziness and 8 hyperkalaemia.

The pharmaceutical interventions were conducted by two pharmacists and all accepted.

Conclusion The antihypertensive treatment in the elderly was effective and clinical trials have consistently demonstrated benefit. However, the orthostatic hypotension was higher than in other studies (41.8% vs. 20%).

REFERENCES
1 ESH/ESC Guidelines 2013

No conflict of interest.
patient in 10.5% of cases. The drugs involved more often were carboplatin (33.3%), aprepitant (20.8%), paclitaxel (16.67%), azacitidine (12.5%), irinotecan, oxaliplatin and vincristine (5.3% each). The main MEs were: omission of medicine needed (26.3%), dose higher than needed (15.8%), omission in transcription (13.2%), dose lower than needed (10.5%), administration error (7.9%) and preparation error (5.3%).

Conclusion The pharmacist’s contribution prevented 89.5% of MEs from reaching the patient. These results reveal the importance of incorporating the pharmacist as an essential part of a multidisciplinary team to contribute to the safety of patients. The pharmacist should have a more active role in the areas of medicines preparation and administration; an appropriate ratio of pharmacists vs. number of validated patients is needed.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

**PS-033 PREVENTING MEDICINES ERRORS BY MEDICINES RECONCILIATION AT ADMISSION AND DISCHARGE**


10.1136/ejhpharm-2015-000639.379

**Background** Institutions related to healthcare quality, such as the Joint Commission, recognise that reconciliation errors (REs) compromise the safe use of medicines.

**Purpose** To prevent medicines errors by reconciling the patient’s current medicines (CM) at admission and discharge, quantify and analyse the discrepancies found between the CM and those prescribed and to identify the possible causes of RE.

**Material and methods** A prospective observational study was conducted from May to July 2014, in which patients over 75 years with 6 or more usual drugs were included. The process of medicines reconciliation was conducted by interviewing the patient, reading the primary care electronic medical record, background checks, last admission and outpatient visits. Updated CM was recorded in the hospital electronic medical record system and was compared with the drugs prescribed on admission and at discharge.

**Results** 295 patients were reconciled: 3,205 medicines (average of 10.8 drugs per patient). 238 patients (80.3%) at admission (28 patients were excluded) where 1,020 discrepancies were detected, of which 353 (34.6%) were REs: 29% drug omission, 3% dosage or regimen error, 1% wrong drug and 1% drug prescribing previously concluded. 51% of patients had at least 1 RE, and 32.9% more than 1 RE. 57 patients (19.7%) were reconciled at discharge, all reconciled at admission. 69 discrepancies were detected of which 9 (13%) were reconciliation errors: 2% drug omission, 4% dosage or regimen error, 1% wrong drug and 6% drug prescribing previously concluded. 8.7% of patients had at least 1 RE and 5.2% more than 1 RE.

**Conclusion** Medicines reconciliation at admission and discharge prevents medicines errors, thus increasing patient safety. Key points to avoiding errors were detected: update the record in the electronic medical record of the patient’s CM at admission, and correctly reconcile CM at admission to prevent errors at discharge.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**PS-034 HYPOPHOSPHATEMIA IN HIV PATIENTS TREATED WITH ANTIRETROVIRAL TREATMENT**

1MA Pedroza Naudiz*, 2E Briones Cuesta, 3CJ Duenas Gutierez, 4M Guemes Garcia, 1MA Machin Moron. 1Hospital Universitario de Burgos, Hospital Pharmacy, Burgos, Spain; 2Hospital Universitario de Burgos, Internal Medicine, Burgos, Spain

10.1136/ejhpharm-2015-000639.380

**Background** The summary of product characteristics of tenofovir-disoproxil fumarate (TDF) recommends monitoring renal function periodically, as it has been related to hypophosphatemia and tubulopathy. Evidence links hypophosphatemia in HIV patients with hypovitaminosis D and other antiretrovirals.

However, hypophosphatemia as early marker of renal failure is questionable since bone phosphate reserves could compensate for renal loss.

**Purpose** To analyse hypophosphatemia as an early marker of renal toxicity in HIV patients treated with antiretroviral therapy (ART) and to study TDF involvement as a cause.

**Material and methods** Retrospective, observational study including HIV patients receiving ART who had their renal function monitored from 1 January 2013 to 15 April 2014.

**Results** Hypophosphatemia occurred in 18 (17%) of 107 HIV patients monitored for renal function; 16 (89%) males and 2 (11%) females. Mean age was 50 ± 8 years. Hypophosphatemia was classified as isolated if it was not accompanied in any case by possible alterations of tubulopathy. Regarding TDF involvement, 13 (72%) of patients were exposed to the drug when hypophosphatemia was detected.

Follow-up was feasible in 14 patients (78%). ART was modified in 7 (50%), all of them TDF-exposed, with resolution or improvement of the hypophosphatemia in 5 (36%), no change in 1 (7%) and assessment pending in 1 (7%). In the other 7 (50%) cases, 4 TDF-exposed and 3 non-exposed, the treatment was not changed: 3 (21%) due to multidrug resistance, 3 (21%) to hypovitaminosis D and 1 (7%) who was awaiting assessment.

**Conclusion** The results suggested that hypophosphatemia in HIV patients taking ART might be multifactorial and its use as an early marker of renal toxicity is inconclusive.

To identify the cause of hypophosphatemia in each patient and establish an individualised therapeutic approach, it would be advisable to make a complete baseline study before starting ART.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**PS-035 ARE WE AWARE OF THE RISK OF EYE IRRITATION CAUSED BY SOME EYE DROPS, PARADOXICALLY, IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS?**

Y Rahali*, Hospital Pharmacy, Specialties Hospital of Rabat, University Mohammed V, Rabat, Morocco

10.1136/ejhpharm-2015-000639.381

**Background** The formulation of eye drops needs to prevent any microbial contamination of the eye. For this purpose, pharmaceutical manufacturer can use: the addition of a preservative, the
Patient safety and risk management

use of a specific packaging including a sterilising filter or a single dose packaging.

**Purpose** The purpose of the study is to check if the contents of eye drops indicated for the treatment of allergic conjunctivitis can be irritating for the eye.

**Material and methods** For this purpose, based on Vidal® 2013, we searched for eye drops used in allergic conjunctivitis and we analysed their excipient formulas searching for those known irritating to the eye.

**Results** The 21 analysed formulas revealed that the benzalkonium chloride is the only preservative used in this context. Although it is classified as an excipient known to be irritating to the eye, it is still used in 11 cases and cited as an excipient with known effect in only 1 case, while for the rest it is cited as an antimicrobial preservative. The single-dose packaging is used in 7 cases while the packaging including a sterilising filter is used in only 3 cases.

**Conclusion** Treating allergic conjunctivitis by a potentially irritating drug can be problematic when induced irritation takes over the symptoms of the allergy. This can lead to extend the treatment beyond the expected duration and also create doubts about the efficiency of the drug. It seems wise to choose a drug that does not contain benzalkonium chloride when it comes to treat an allergic conjunctivitis. However, if this is not possible, the ophthalmologist must be aware of this risk when it comes to the clinical evaluation of the patient.

**REFERENCE**

1 Vidal® expert database 2013

No conflict of interest.

**PS-036**

**THE PLACE OF MATERIOVIGILANCE AS TOOL OF TRACEABILITY IN THE QUALITY MANAGEMENT SYSTEM (QMS) IN HOSPITAL PHARMACY**

1A Cheikh*, 2A El Wartiti, 3W Enneffah, 4N Badsi, 5M Ajaja, 6S Al Baroudi, 7A Bennana, 8Mohammed v University Pharmacy, Military Hospital Pharmacy, Rabat, Morocco; 4Mohammed v University Pharmacy, Pharmacology and Toxicology, Rabat, Morocco; 5Mohammed v University Pharmacy, Military Hospital Pharmacy, Rabat, Morocco; 6Mohammed v University Pharmacy, Military Hospital Pharmacy, Rabab, Morocco; 7Casey Zaid Hospital Pharmacy – Department of Pharmacy, Rabat, Morocco; 8Mohammed v University – Faculty of Medicine and Pharmacy, Mohammed v Military Hospital Pharmacy, Rabat, Morocco; 9Mohammed v University – Faculty of Medicine and Pharmacy, Military Hospital Pharmacy, Rabat, Morocco; 5Mohammed v University – Faculty of Medicine and Pharmacy, Cheikh Zaid Hospital Pharmacy, Rabat, Morocco; 7Mohammed v University – Faculty of Medicine and Pharmacy, Cardiac Surgery – CHS, Rabat, Morocco; 8Mohammed v University – Faculty of Medicine and Pharmacy, Cheikh Zaid Hospital Pharmacy, Rabat, Morocco; 9Mohammed v University – Faculty of Medicine and Pharmacy, Cheikh Zaid Hospital Pharmacy, Rabat, Morocco; 8Mohammed v University – Faculty of Medicine and Pharmacy, Cheikh Zaid Hospital Pharmacy, Rabat, Morocco; 5Mohammed v University – Faculty of Medicine and Pharmacy, Clinical Pharmacy-Therapeutic Chemistry, Rabat, Morocco; 8Mohammed v University – Faculty of Medicine and Pharmacy, Cheikh Zaid Hospital General Direction, Rabat, Morocco; 9Mohammed v University – Faculty of Medicine and Pharmacy, Pharmacology and Toxicology, Rabat, Morocco

**Background** Materiovigilance aims to monitor the risk of incidents resulting from the use of Medical Devices. What is its role in the establishment of a QMS in the hospital pharmacy?

**Purpose** To identify materiovigilance notifications within our hospital, to analyse them, to identify measures taken in each case and to establish a QMS that incides the traceability of medical devices.

**Material and methods** Materiovigilance statements that were collected between June 2012 and May 2014 were analysed. Decisions that had been taken were collected in order to make a synthesis of QMS implemented in our pharmacy. Incidents were classified into three categories according to the severity of the event (3 is the worst) and measures taken were classified into three categories (corrective, preventive and palliative).

**Results** 75 notifications were collected, 27 (36%) first degree, 24 (32%) second degree and 24 (32%) the third degree of dangerousness. 24 notifications were from surgery units (gloves, sutures, infusion tubing), 19 from the haemodialysis service (vials of bicarbonate), 12 from ophthalmology (ocular implants) and 7 from the Intensive Care Unit (catheters, tracheal intubation tube, pressure sensors). Similar results have been found and published in EJHP by other national teams. The measures that have been taken were corrective in 16 (21%) of cases (definitive change of medical device), preventive in 6 (8%) of cases (compliance test before use) and palliative in 53 (71%) of cases (exchange of defective device).

**Conclusion** All notifications were selected and sent to suppliers to request information and to exchange defective devices. Some incidents were very serious (coils and stents breaking). Materiovigilance is necessary for the traceability of adverse events related to the use of medical devices. It is essential for the adoption of the QMS that we introduced in our pharmacy. This is particularly important in the absence of a national medical devices industry and specific regulation for these products.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Acknowledgements for Zakia Cheikh.

No conflict of interest.
109 drugs were evaluated, 32 (29.3%) were IPS. 10 DRP were detected in 7 (26.9%) patients. 6 (60%) of the DRPs detected were due to the IP.

The most frequent DRPs were due to interactions [4 (40%)] and adverse events [4 (40%)]. Others were related to erroneous prescribing and incorrect self-administration. Mean DRPs per patient was 0.38. Prevalence of DRPs in outpatients starting treatment was 26.7%.

We performed 23 pharmaceutical interventions, 18 (78.3%) were on information about treatment.

Regarding the whole sample, the average score on the test of knowledge was 6.5/10, whereas in outpatients starting treatment it was 6.0/10.

Conclusion The high incidence of DRPs detected emphasises the necessity for Pharmaceutical Care programs to adequately inform patients included in clinical trials, and to prevent and detect DRPs, especially when starting new treatments.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

**PS-038** APPROPRIATENESS OF NEW ORAL ANTICOAGULANT PRESCRIPTIONS: ANALYSIS OF PHARMACIST INTERVENTIONS
P Carmona*, I Agine, G Lizaga, A Lizardi, MP Bachiller, K Andueza, E Esmida, MA Aranguren, L Leunda, M Umerez. Donostia’s University Hospital, Hospital Pharmacy, San Sebastian, Spain

Background New oral anticoagulants are an alternative to acenocoumarol in the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

Purpose To assess the suitability of prescriptions for new oral anticoagulants for those diagnoses, in accordance with criteria established by the health organisation and to analyse pharmaceutical interventions.

Material and methods A prospective, observational and cross-sectional study of all patients admitted to our hospital who were prescribed dabigatran, rivaroxaban or apixaban from 01/02/2014 to 31/08/2014. Electronic medical records and electronic medical prescriptions were used as data sources. Demographics (age, gender), reason for admission, indication for anticoagulation, risk factors for complications such as renal and hepatic failure, concomitant drugs that increase the risk of bleeding (NSAIDs, platelet inhibitors, low molecular weight heparins) and adverse events were collected. In addition, adverse drug-related events avoided were also recorded.

Results 64 patients (36 men) with mean age of 76 years (range 35–95) were included. 24 patients were treated with dabigatran, 38 with rivaroxaban and 2 with apixaban. 4 of these treatments were used as off-label treatments.

8 patients had renal failure and 23 had a risk of major bleeding due to concomitant treatments, mainly NSAIDs. Pharmaceutical interventions were performed in the 8 cases of renal failure because the doses needed adjustment. 14 patients with concomitant drugs that could increase the risk of bleeding were also monitored. 100% of recommendations were accepted by physicians.

2 severe adverse events were recorded: 2 bleeding episodes.

Conclusion 94% of new oral anticoagulant prescriptions met the criteria established by the healthcare organisation.

Pharmacists were involved in the optimisation of a third of the treatments, with total acceptance. It would be desirable to extend this activity, individualization of anticoagulant treatment, into primary medical care.

**REFERENCE**
Agencia Española de Medicamentos y Productos Sanitarios. Informe de posicionamiento Terapéutico UT/V4/23122013

No conflict of interest.
Patient safety and risk management

Background Paediatric patients receive drug dosages based on their body weights. Consequently only part of a vial with medicine for intravenous (i.v.) administration is often required for a child, contrary to an adult, for whom one vial normally equals one dosage. This does not present a problem when preparing an i.v. drug dosage from an i.v. concentrate or solution. However the problem arises when the drug is formulated as a powder requiring reconstitution. The displacement values of the drug powders can be of negligible or significant sizes. Neglecting to take into account significant displacement values can result in under-dosing. A literature search revealed guidelines highlighting the importance of accounting for displacement values. No recent studies regarding the size of underdosing resulting from ignored displacement values were found.

Purpose To investigate whether displacement values of powders for reconstitution are taken into account in the preparation and administration guide for i.v. drugs at the paediatric ward. If not, then categorising these drugs and calculating the percentage of the resulting underdosing.

Material and methods The preparation and administration guide for i.v. drugs at the paediatric ward was studied to see whether displacement values were actually stated and to establish how the specified drug concentrations of reconstituted powders had been calculated.

For the drugs where displacement values were not stated a description of the drug type was carried out and the size of the deviation between the estimated concentration (where the displacement value was addressed) and the specified concentration was calculated.

Displacement values were obtained through a literature search and by contacting the marketing authorisation holders.

Results Displacement values were taken into account in only 1 in 7 drug powders in the guide, all of them antibiotics, resulting in potential under-dosing ranging from 4–12%.

Conclusion Ignoring displacement values of i.v. antibiotic drug powders for reconstitution can result in under-dosing of children.

REFERENCES AND/OR ACKNOWLEDGEMENTS

None.

No conflict of interest.

PS-041 POLYPHARMACY AND COMPLIANCE WITH START CRITERIA IN PATIENTS ADMITTED TO A REFERENCE HOSPITAL

C. Gallego Muñoz*, M. Domínguez López, G. Blanco Sánchez, F. García Martín, R. Bulo - Concepción, M. V. Marzano Martín. Hospital Universitario Puerta del Mar, Pharmacy, Cádiz, Spain

Background The START criteria aim to ensure the prescription of drugs that have shown to be beneficial in certain diseases, in people over 65 years of age.

Purpose To analyse if these criteria were met in patients in a reference hospital.

Material and methods A cross-sectional study was carried out that included a sample of 138 patients over 65 years of age who were hospitalised in an Internal Medicine ward at a reference hospital. The variables elicited by the physician in charge of each patient were age, gender, number and type of drugs prescribed (excluding serum therapy and topical treatments), and diagnoses by which to check that the drug was being prescribed in response to the patient’s disease, following the START criteria.

Results The mean age was 76.8 ± 6.3 years, (52.6 were male).

Each patient received 11.7 ± 3.6 drugs. 29.9% of the patients received the drugs indicated according to the START criteria; in 37% of the patients 1 START criterion was unmet; in 25.9%, 2 criteria were unmet; in 7.4%, 3 were unmet and in 3.8% of the patients, 4 or 5 criteria were unmet. The START criteria that were met were: statins in diabetes mellitus associated with one or more vascular risk factors (29.6%), platelet antiaggregants in diabetes associated with one or more vascular risk factors (13.6%), clopidogrel or ASA with a history of arteriosclerotic disease in patients with sinus rhythm (12.3%), metformin in type 2 diabetes mellitus in the absence of kidney failure (11.1%), calcium and vitamin D supplements in patients with known osteoporosis (8.6%).

Conclusion Drugs that were prescribed the least, in spite of their indication, were statins and antiaggregants (primary and secondary prevention), possibly due to the perception of the futility of the said treatments in elderly patients. We highlight the low prescribing of calcium and vitamin D in patients with osteoporosis, probably for the aforementioned reason.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PS-042 PARENTERAL NUTRITION (PN) IN PREMATURE INFANTS: RISK ANALYSIS AFTER REDESIGNING A PRODUCTION PROCESS

C. Salazar*, M. Mensa, M. Miana, R. Juncos, S. Ceamanos, C. Lopez, C. Codina. Hospital Clinic, Pharmacy, Barcelona, Spain

Background Prescribing and preparing paediatric PN is an extremely complex processes because of manipulation of small volumes, stability problems, risk of contamination and patient fragility. Therefore, we need to manage the risk of such a delicate process.

Purpose To quantify the risk reduction derived from redesigning the preparation process for parenteral nutrition (PN) for preterm infants, identifying residual risks in the current process and planning measures to solve them.

Material and methods The major changes carried out were e-prescribing and improvements in quality control, by double checking on gravimetric preparations and biochemical control.

We used FMEA (Failure Mode and Effect Analysis) to analyse the risk of the process, and a group of four pharmacists and two pharmacy technicians was formed to agree and discuss the critical points in the different phases of the process: prescription, validation, processing, quality control and labelling. Then, we qualified these errors in terms of their probability of occurrence (O), severity (S) and detection capacity (D) in the process, assigning values from 1 to 10, and considering that the severity only depends on the critical point.

By multiplying these factors, the criticality index (CI = O × S × D) was obtained. The difference between the previous and current CI processes allowed us to compare the risk management in both processes and prioritise those points which required immediate action.

Results We identified 31 critical points and realised that following the old procedure the CI obtained was 4,964, whereas it was
Background Medication errors in critical care are frequent, serious and predictable. Critically ill patients are prescribed twice as many medications as patients outside the intensive care unit and nearly all will suffer a potential error at some point during their stay.

Purpose To quantify and characterise medication errors in a surgical intensive care unit (SICU).

Material and methods We conducted a one-month prospective observational study to detect, quantify and score medication errors in a SICU.

Results A total of 634 observations made over weekdays and weekends were performed including morning, noon and night shifts. 36.27% observations (230) included some type of error; a total of 245 medication errors were detected. According to the type of error found: 52 were prescription errors (21.22%), 2 omissions (0.82%), 44 related to administration technique (wrong speed) (17.96%), 10 omissions of the administration record (4.08%), 97 erroneous preparations (39.59%), 1 wrongly prescribed dose by default (0.41%) and 3 by excess (1.22%), 5 errors related to erroneous administration route (2.04%), 2 erroneous drug monitoring (0.82%) and 29 transcription errors (11.84%). According to severity within categories established by the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP). 26.12% errors were Category A, 10.20% were Category B, 61.63% were Category C, 1.63% Category D and 0.41% Category F.

Conclusion Determining the incidence of medication errors in our system and adopting measures to prevent them is a priority in order to improve the drug treatment process in critically ill patients. The integration of a pharmacist in the intensive care unit is one of the measures that our institution has adopted to reduce medication-related errors and improve quality of care.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
STUDY OF APPROPRIATENESS OF THE INDICATION FOR EVALUATION OF A SYSTEMATIC TOOL TO REDUCE INAPPROPRIATE PN PRESCRIPTION FOR ADULT HOSPITALISED PATIENTS

C Pellicer Franco*, P de la Cruz Murie, P Mendosa Otero, O García Molina, MM Galindo Rueda, B Garrido Corro, M Bizakoa Aizkara, V Arcos Casaf, A de la Rubia Nieto. Virgen de la Arrixaca Hospital, Hospital Pharmacy, Murcia. Spain

Background Parenteral nutrition (PN) is an essential supportive treatment for patients who are unable to meet their nutrition requirements through oral or enteral nutrition. Many studies have noted that PN is often inappropriate prescribed, thereby increasing the risk of associated complications and costs.

Purpose To determine the quality of prescription of PN in our hospital, based on the ESPEN 2009 guidelines and the pharmacy cost.

Material and Methods A prospective, observational study of PN episodes in adults was over a 3-month period. The use of PN was classified as ‘appropriate’ or ‘inappropriate’. Variables collected included: demographic data, underlying diagnoses, indication for PN, number of days on PN and complications related to PN in inappropriate use such as phlebitis, metabolic complications and bacteraemia associated with central venous catheter (BVC). We calculated the cost of the number of inappropriate PN treatments provided.

Results We reviewed the indications for 90 PN treatments. The patients were 53% male with median age of 63.9 years (range, 27 to 96 years), with a principal diagnosis of digestive tract neoplasia (37.8%). In 37.8% of the cases PN was “inappropriate”; the most common indications were prolonged fasting (22.9%), palliative care (20%) and patient refusal to eat (8%). The median duration of “inappropriate” PN prescription was 4.9 days (range, 1 to 17 days). Six patients (17.6%) had complications; 3 cases of BVC, four metabolic complications, and two cases of phlebitis. The number of inappropriate PN treatments was 163 units which cost the pharmacy €6,130.57 for the PN.

Conclusion PN is associated with complications; because of this the indication for PN should comply with the main clinical practice guidelines and requires monitoring by experienced professionals in multidisciplinary Nutritional Units.

In addition, cost savings could be achieved if PN was provided only to the patients who meet these guidelines.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Thanks to my co-workers.

No conflict of interest.

EVALUATION OF A SYSTEMATIC TOOL TO REDUCE INAPPROPRIATE PRESCRIBING (STRIP) IN ADULTS WITH INTELLUCTUAL DISABILITY: A PILOT STUDY

1P Zaal†, 5S Eibens, 3M Borms, 8B De Koning, 9P Van den Bernt, 10H Evenhuis, 1Erasmus MC, Hospital Pharmacy, Rotterdam, The Netherlands; 2DeZeeuwen, Bronlaak, Oplou, The Netherlands; 3Het Raamwerk, Hafakker and Zeebos, Noordwijkerhout, The Netherlands; 4Puyin, Kemnade and Groesbeekse Tehulzen, Nijmegen, The Netherlands; 5Erasmus MC, Family Medicine, Rotterdam, The Netherlands

Background Polypharmacy, a risk factor for inappropriate prescribing, is common in adults with intellectual disability (ID). For older patients with polypharmacy in the general population a Systematic Tool to Reduce Inappropriate Prescribing (STRIP) has been developed recently. This patient review requires the active involvement of the client, which can be complicated in adults with ID.

Purpose This pilot study was performed to evaluate whether STRIP can be used in adults with ID living in a centralised setting.

Material and Methods This observational pilot study was performed in three care organisations. In each organisation nine clients with polypharmacy, defined as concomitant use of five or more drugs, were selected by their pharmacists and ID resident physician for a review using STRIP. Clients, their legal representatives and mentors were invited to participate. The primary outcome was the proportion of clients, legal representatives and mentors who participated. Secondary outcomes were the number of potentially appropriate indicated drugs (according to the START criteria) and the number of potentially inappropriate or unnecessary drugs identified (according to STOPP criteria).

Results 27 reviews were performed in this pilot study. During these 27 reviews, 24 clients (89%), 14 legal representatives (53%) and all 27 mentors (100%) participated.

Thirty potentially appropriate indicated drugs and 44 potentially inappropriate or unnecessary drugs were identified, resulting in suggestions for changes in pharmacotherapy for 21 (78%) clients. Besides, 9 (33%) reviews revealed in total 21 drugs, mainly as required prescriptions, that were never used by the client.

Conclusion A Systematic Tool to Reduce Inappropriate Prescribing (STRIP) with the active involvement of adults with ID, their legal representatives and mentors can be used to identify drug-related problems in this population. The benefits in terms of reduction of patient harm as well as cost-effectiveness of this method should be assessed in this population in future studies.

REFERENCE

1 The Dutch College of General Practitioners, Multidisciplinary Guideline Polypharmacy in the elderly, 2012

No conflict of interest.

MEDICINES SAFETY: THE INCIDENCE AND SEVERITY OF PRESCRIBING ERRORS IN PARENTERAL NUTRITION IN PAEDIATRIC INPATIENTS

1†Hemannspann*, 2†Olikowsky, 3‡Schobes, 4‡Eisert. 1University Hospital of the RWTH Aachen, Pharmacy, Aachen, Germany; 2University Hospital of the RWTH Aachen, Paediatric Clinic, Aachen, Germany

Background Parenteral nutrition (PN) is important for providing sufficient food for neonates, especially premature infants. Individually prescribed PN addresses specific patient requirements. 1 Due to the diversity and complexity of PN prescribing, medicines errors may occur. 2

Purpose To identify the incidence, type and severity of prescribing errors in PN in a paediatric intensive care unit (PICU). In this context the role of a clinical pharmacist should be checked as a member of an interdisciplinary team.

Material and Methods The occurrence of prescribing errors in PN in a PICU in a university hospital was analysed retrospectively between March 2012 and July 2013. First the errors were categorised in seven pre-defined categories. Afterwards the potential severity of each individual error was assessed independently by three medical experts from three different Level III
neonatal units, not involved in any treatment regimen and blinded for patient outcome, based on the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) Index for Categorising Medicines Errors. 

Results 118 prescribing errors were identified from 2,889 PN orders. Each error had been discussed and eliminated before preparing the PN, so no errors reached the patient. The majority of errors constituted the category ‘concentration range’: 65%. Nearly 11% of the errors occurred in the categories ‘dose’ and ‘indication’. Error rates of 5% and lower were due to ‘choice of drug’, ‘compatibility’, ‘patient data’ and ‘osmolarity’. (By using the NCC MERP Index, the three experts classified the errors into several categories.)

Conclusion These results underline that clinical pharmacists can prevent minor as well as major adverse drug events. Physicians as well as clinical pharmacists have to be aware of these risks and have to implement strategies to enhance medicines safety in PN treatment.

REFERENCE
1,2,3 Literature available from the author
No conflict of interest.

PS-048 USE OF ALTERNATIVE TREATMENT IN OUTPATIENTS

L Menéndez Narango*, M Almanchel Rivadeneyra, I Mateo Carmona, C Ramírez Roig, MJ Sánchez Garre, A. de La Rubia Nieto; Hospital Clínico Universitario Virgen de La Arrixaca, Pharmacy, Murcia, Spain
10.1136/ehjpharm-2015-000639.394

Background Alternative treatments (AT) such as homeopathy (H) and/or medicinal herbs (MH) are used concomitantly with medical treatment by some patients to relieve and/or improve the symptoms of a disease. Pharmaceutical care consultations (PCC) are held in order to respond to pharmacotherapeutic needs in outpatients.

Purpose To analyse the concomitant use of H and MH with medical treatment in outpatients who come to PCCs in the Pharmacy service.

Material and methods Observational study of outpatients who came for the first time to collect medicines from the PCC during the first week of September 2014. The information was obtained during the pharmaceutical interview with the patient, using a survey that included type of AT used and the source that had recommended it.

Results 42 new patients (21 men, 21 women) were attended in the PCC, 11 of whom admitted taking some type of AT (7 were male and 4 females, mean age 43.3 years). According to the medical treatment: we had 2 patients with antiretroviral treatment, 2 with anti-TNF alpha, 2 with oral cytostatics, 1 with somatotropin, 1 with drugs for hepatitis virus C, 1 with coagulation factor, 1 with epoetin beta and 1 with gatifloxacin. About the type of AT used: 8 patients were using homeopathy and 4 medicinal herbs. The recommendation to use any of these was by a family member/friend in 5 patients, 3 patients took AT on their own initiative and in 3 patients a community pharmacist had recommended the AT.

Conclusion A quarter of the patients who come to the PCC, are concomitantly using an AT with the medical treatment and mostly without medical or pharmaceutical recommendation. Therefore the safety and efficacy of medical treatments collected in the consultations should be closely monitored.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-049 ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTIONS WITH IMMUNOSUPPRESSIVE DRUGS IN PATIENTS ON THE WAITING LIST FOR RENAL TRANSPLANTATION

1PR Maran*, 1J Kufeldt, 1M Andraschko, 2A Habicht, 3M Fischereder, 1Vetter-Kerkhoff.
1Hospital of the University of Munich, Department of Pharmacy, Munich, Germany;
2Hospital of the University of Munich, Transplantation Centre, Munich, Germany;
3Hospital of the University of Munich, Department of Nephrology, Munich, Germany
10.1136/ehjpharm-2015-000639.395

Background Prerequisites for successful renal transplantation are stable and effective serum concentrations of immunosuppressive drugs such as ciclosporin, mycophenolate mofetil, tacrolimus (CMT). Drug-Drug-Interactions (DDIs) could change blood levels of CMT, potentially leading to toxicity or ineffective transplant function. Patient-specific information on potential DDIs is not accessible to surgical staff at the time of transplantation, when CMT is routinely started.

Purpose To identify and analyse the potential of DDIs of routine treatment with CMT in patients on the waiting list for renal transplantation through a systematic, standardised DDI check by a pharmacist, to increase patient safety.

Material and methods The current drug treatment of 136 patients was recorded. Potential DDIs of each drug with CMT were analysed using three DDI databases (Lexi-Interact, Drugdex, Stockley’s Drug Interactions) and the German SPC. For drugs not listed in these the Swiss-based MediQ-database was used. DDI severity was recorded according to the Lexi-Interact standard (A, D, X). An individual pharmacist-approved DDI risk profile of current drug treatment with CMT was prepared for each patient and made accessible at all times for the transplanting surgeon by adding it to the transplant record.

Results The patients (n = 136) reviewed (65% male, 35% female) had a mean age of 51 (±13 years), took a total of 225 different drugs. Patients took 2 to 22 different drugs (mean 10 ± 4).

Abstract PS-049 Table 1

<table>
<thead>
<tr>
<th>Number of patients with clinically relevant DDIs (Lexi-Interact score ≥C)</th>
<th>C (monitor treatment)</th>
<th>D (modify regimen)</th>
<th>X (avoid combination)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciclosporin</td>
<td>133</td>
<td>68</td>
<td>37</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>70</td>
<td>60</td>
<td>0</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>87</td>
<td>34</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of drugs with clinically relevant DDIs (Lexi-Interact score ≥C)</th>
<th>C (monitor treatment)</th>
<th>D (modify regimen)</th>
<th>X (avoid combination)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciclosporin</td>
<td>61</td>
<td>23</td>
<td>3</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>17</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>24</td>
<td>10</td>
<td>4</td>
</tr>
</tbody>
</table>

Conclusion Starting CMT puts patients at risk of DDIs with concurrent drug treatments they are having for their comorbidities. Readily-accessible individual DDI risk evaluations prepared by drug information pharmacists may improve patient safety for renal transplant patients who are starting on CMT.

REFERENCE
1 LebKuypers DJ. Immunotherapy in elderly transplant recipients. Drugs Aging 2009;26(9):715–37
No conflict of interest.
SUBVISIBLE PARTICULATE MATTER IN INTRAVENOUS PREPARATIONS - A COMPARISON OF INNOVATOR AND GENERIC DICLOFENAC SODIUM

E Lehner*, D Haider. Sozialmedizinisches Zentrum Sued KFI, Pharmacy Department, Vienna, Austria

Background Hazardous effects are brought about by sub-visible particulate contaminants of intravenous preparations being administered into the bloodstream. Pathological consequences ultimately leading to severe harm may result.

Purpose To compare often-used drugs in their innovator and generic form and to optimise the workflow in busy work environments to improve patient safety.

Mixtures of 0.9% sodium chloride solution and two diclofenac sodium preparations (Voltaren and Diclobene) and the effect of a buffer were investigated regarding their particulate count and size.

Material and methods 250 millilitres (mL) of sodium chloride 0.9% solution was mixed with either Diclobene 75 milligram (mg) or Voltaren 75 mg/3 mL injectable solution and the required buffer containing sodium bicarbonate solution.

The number of particles greater than or equal 10 micrometres (µm) and 25 µm were counted shortly after mixing the components and after 30, 60, 90, 120 and 150 min.

Results The prepared Diclobenesolution had a consistently low particulate count which was way below the threshold value for sub-visible particulate matter contamination regulated by the European Pharmacopoeia whereas Voltaren bicarbonate solutions had a high and fluctuating number of particles exceeding the threshold value.

Surprisingly the mixture of Voltaren without the required buffer had an average particulate count below the compulsory threshold.

Conclusion The measurements conducted resulted in substantial changes of neither particulate count nor size in the Diclobenesolution and the Voltaren preparations.

Mixtures of Diclofen with sodium chloride 0.9% solution resulted in a considerably lower particulate count than the Voltaren mixture.

Taken into account that adding the buffer to the preparation of Voltaren is an additional step, Diclofen might be a better choice in a busy ward environment thus enhancing patient safety.

REFERENCES

No conflict of interest.

EVALUATION OF PHARMACEUTICAL INTERVENTIONS IN INTENSIVE CARE UNIT PRESCRIPTIONS

P Rodríguez Quesada*, L López Esteban, J Sánchez Rubio, T Molina García. Hospital Universitario de Getafe, Pharmacy, Madrid Getafe, Spain

Background The implementation of an Antimicrobial Stewardship Program (ASP) in our hospital has attempted to streamline the use of antibiotics. Within this program, pharmacist interventions have been introduced on the de-escalation of antimicrobial treatment and on the adjustment of duration of treatment.

Purpose To analyse ertapenem prescriptions since establishing pharmacist interventions in a tertiary university hospital.

Material and methods This was a retrospective study where we compared ertapenem prescriptions dispensed between March and May 2012 with the prescriptions dispensed in the same period in 2014. We analysed the following variables: number of prescriptions, request for microbiological cultures, duration of treatment, indication and de-escalation performed. The Oncology-Haematology, Orthopaedics and Trauma, Neurosurgery and Neurology, Paediatrics and Gynaecology departments were excluded. To measure and compare the drug consumption, we used the Daily Defined Doses (DDD) per 100 stays.

Results In 2012, there were 167 prescriptions for ertapenem, while in 2014, this figure was 110. Microbiological cultures were required in 64% of cases in 2012 and in 68% in 2014. The mean duration of treatment was 5 days in 2012 and 4 days in 2014. In 2012, ertapenem treatment was interrupted because of discharge from hospital (39.5%), escalation or replacement with other antibiotic with similar spectrum of coverage 37.1% and de-escalation (18.6%); in 2014, these percentages were 37.5%, 27.9% and 29.1% respectively. In 2012, ertapenem was most commonly prescribed for intra-abdominal infections (45.0%), skin and soft tissues infections (21.6%) and respiratory infections (19.0%); whereas in 2014, it was prescribed for intra-abdominal (46%), urinary (20%) and respiratory infections (18.5%) in 2012 was 2.9 and in 2014 was 1.5

Conclusion Since the launch of ASP, we have observed that the consumption of ertapenem has decreased significantly. The duration of treatment is also shorter thanks to the system for de-escalation. Still, more microbiological tests need to be requested.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
Indication:
DRP1: the patient was not using the medicines that he needed.

DRP2: the patient was using medicines that he did not need.

Effectiveness:
DRP3: the patient was using an erroneous medicine.

DRP4: the patient was using a lower dose and/or a different dose schedule than required and/or did not continue treatment for the full course indicated.

Safety:
DRP5: the patient was using a higher dose or a different dose schedule than required and/or exceeding the full course of treatment indicated.

DRP6: the patient was using a medicine that causes an adverse drug reaction.

Overall percentage of interventions accepted and the percentage of interventions accepted in each subgroup were calculated.

Results During the study, 105 interventions were recorded, of which 62 (59.1%) were accepted.

Types of DRP were: DRP1 8 (7.6%); DRP2 17 (16.2%); DRP3 3 (2.9%); DRP4 19 (18.1%); DRP5 32 (30.5%); DRP6 26 (24.8%).

Acceptance rates in each subgroup were: DRP1 5 (62.5%); DRP2 13 (76.5%); DRP3 1 (33.3%); DRP4 10 (52.6%); DRP5 20 (62.5%); DRP6 13 (50.0%).

Conclusion
1. The most common types of pharmacist interventions over ICU prescriptions were in connexion with DRP5 and DRP6.

2. However, the best rates of acceptance by physicians were achieved by interventions regarding with DRP1, DRP2 and DRP5.

REFERENCE

No conflict of interest.

ANALYSIS OF THE USE OF FIDAXOMICIN IN A TERTIARY UNIVERSITY HOSPITAL

S Sadyrbaeva*, 2P Aznarte Padial, 3C Hidalgo Tenorio, 4P Pasquaú, 5M Salazar Bravo. 1Virgen de Las Nieves University Hospital, Pharmacy, Granada, Spain; 2Virgen de Las Nieves University Hospital, Infectious Disease, Granada, Spain

10.1136/ejhpharm-2015-000639.399

Background Nowadays, Clostridium difficile infection (CDI) is the leading cause of nosocomial diarrhoea in industrialised countries and the incidence is increasing.

Purpose To examine whether fidaxomicin prescribing was following the Pharmacy Committee criteria.

Material and methods This was a retrospective observational study carried out over one year. Fidaxomicin prescribing was considered appropriate in the following cases: when the first recurrence had previously been treated with vancomycin and there was a high risk of recurrence (considered in the presence of at least two of these factors: age >65 years, serious underlying disease, concomitant use of antimicrobials) and if the recurrence was severe (10 or more loose stools or fever >38.5°C or leukocyte count >15,000/mm³ or a rise in serum creatinine >1.5 times above the baseline) and if it had a clinical impact (the persistence of the diarrhoea endangered the health of the patient worsening the underlying disease and/or increasing the length of hospital stay); in second or subsequent recurrences after considering the risk or severity of recurrences and their clinical impact.

Results A total of eight prescriptions were written for six patients. 25% did not comply with the approved criteria. The median age was 53 years (range: 41–83). When prescriptions were appropriate (75%), all cases presented severe underlying disease and a recurrence with clinical impact; 66.7% were prescribed as treatment for first recurrence and 75% of the patients were already receiving antimicrobial treatment.

Regarding the severity of the recurrence, leucocytosis was found in 50% of cases, ten or more loose stools in 25% of cases and a rise of serum creatinine in 25%. 12.5% of patients had recurrences after being treated with fidaxomicin. 87.5% of these prescriptions were supervised by the Infectious Disease Unit (IDU).

Conclusion Since fidaxomicin has been introduced into the hospital, there have been few prescriptions for this drug. Most prescriptions were appropriately and accurately prescribed under IDU supervision.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

STORAGE AND USE OF CONCENTRATED INTRAVENOUS POTASSIUM SOLUTIONS IN A HOSPITAL COMPLEX

E Chamorro de Vega, 1MD Santos Rubio*, 2A Vazquez-Gonzalez, 1González Bueno, 2C Peinado-Barraso, 1MD Tascón Guzmán, 1Virgen Del Rocio University Hospital, Pharmacy Department, Sevilla, Spain; 2Virgen Del Rocio University Hospital, Quality Department, Sevilla, Spain

10.1136/ejhpharm-2015-000639.400

Background Intravenous concentrated potassium solution (ICPS) has been identified as a high-alert drug by organisations in Australia, Canada, United States of America and the United Kingdom. Despite that, there are reports of accidental death from the incorrect administration of ICPS.

Purpose To evaluate the storage and use of ICPS in a hospital complex.

To identify the factors that can influence the use of ICPS versus pre-diluted solutions.

Material and methods Descriptive study. An audit was conducted of all hospital complex medical kits (place in clinical management units (CMUs) where drugs are stored); location and identification of vials, CMU accreditation by Health Quality Andalusian Agency and knowledge of ICPS use by personnel. Also, consumption of intravenous concentrated potassium salts was calculated and was compared with the consumption of pre-diluted solutions by the CMUs.

A medical kit was considered appropriate when ICPS lockers were separated, identified and had a safety alert.

Results 78 kits from 30 CMUs were tested. 64 (82%) kits were in correctly identified ICPS lockers and 39 (51.3%) were in ICPS lockers adequately separated from the rest. 20 (25.6%) kits were labelled with safety alerts warning about the use of ICPS: 11 of them were posters and 9 red boxes. 35 (44.9%) kits belonged to an accredited CMU and 23 (29.5%) had received safety clinical sessions.

Only 12 (15.4%) were appropriate medical kits: 9 (75%) belonged to an accredited CMU.

The total ratio mEq potassium concentrated/potassium pre-diluted was 9.68.
The total ratio mEq potassium concentrated/potassium pre-diluted in a CMU is 9.26. The total ratio mEq potassium concentrated/potassium pre-diluted in a CMU trained in prevention of treatment errors was 6.74.

Conclusion The percentage of suitable kits was very low and consumption of pre-diluted solutions was much lower than ICPS. CMUs with an accredited quality management and/or whose staff had been trained in prevention of treatment errors had better concentrated potassium storage conditions and had a slightly higher use of pre-diluted potassium solutions than non-accredited CMUs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Institute for Safe Medication Practice
No conflict of interest.

M Villa*, L Vivas, I Aguilar, C Toro, A Pérez, M Capel. Hospital Dr. Josep Trueta, Pharmacy, Girona, Spain
10.1136/ejhpharm-2015-000639.401
Background The literature reveals that approximately 20% of healthcare professionals fail to document drug allergies (DA) in the electronic records. Breakdowns in the documentation of allergies can lead to medicines errors (MEs).

Purpose The aims of this study were to examine patient DA profiles documented in the electronic records and to determine MEs associated with DAs.

Material and methods Retrospective observational study including all adult patients admitted to our hospital on February 24, 2014. Discharge prescriptions and patient DA profiles entered into the different (non-integrated) electronic records were reviewed.

Results 258 patients were included in the study. In all patients, a history of an allergic reaction to drugs or not was reported in at least one electronic record: 55% in the patient’s admission precription, 60% in the nursing consumption form and 46.4% in the electronic prescription system. Nevertheless, only in 3% of the cases was it reported in all of the records. In 13.2% of the cases, there were discrepancies between different electronic records. DAs were recorded in 60 patients. The drugs most frequently involved were penicillin (50%) and metamizole (25%). 11 MEs were identified in which a drug was prescribed for a patient with a documented DA. In 6 cases the medicine didn’t reach the patient and was prevented by a pharmacist in four cases. In the other 3, the medicine reached the patients. Fortunately, there was no evidence of any reactions following the administration of the drugs.

Conclusion The existence of different non-integrated electronic records favours inaccurately recorded DAs, discrepancies and MEs related to DA. Pharmacists can play an active role in getting adequate DA recording systems into hospitals and improving inpatient safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS
I thank Dra. Ana Pérez for helpful comments.
No conflict of interest.
Material and methods A retrospective and observational study (April 2001–March 2014) was conducted in a General Hospital (600 beds). All patients who had received at least one dose of cisplatin were included. Start date of cisplatin chemotherapy, gender, age, tumour type and blood magnesium levels were collected for each patient. According to the hospital protocol, patients receive magnesium supplementation before and after cisplatin and aggressive hydration in order to prevent nephrotoxicity.

All patients with hypomagnesaemia were classified according to the CTCAE grade.

Results 528 patients (3,682 cisplatin administrations) were included (79.3% male, mean age = 56.68 ± 12.29 years).

Magnesium level was assessed in 6,021 blood tests and it was below the lower limit in 1,421 of them. Hypomagnesaemia was observed in at least one blood test, in 320 patients (60.6%), during or after treatment.

The incidence of hypomagnesaemia was similar for men and women (60.3% vs. 61.7%).

93.9% of patients with haematological malignancies and 57.2% of patients with solid tumours showed hypomagnesaemia in at least one blood test, (OR: 11.47; IC95%: 3.52–37.40; p < 0.05).

Mean time until onset of hypomagnesaemia was 211 days and in the vast majority of patients (89.4%) this happened within the first year of treatment.

Conclusion

• Hypomagnesaemia is a common and long-term side effect of cisplatin but only in very few cases was it considered to be severe. The incidence of life-threatening hypomagnesaemia is extremely low.

• The prevalence of hypomagnesaemia was much higher in haematological patients than in patients with solid tumours.

REFERENCE


No conflict of interest.

A SYSTEMATIC REVIEW OF TRENDS, RATES AND BURDEN OF HARM ASSOCIATED WITH INTRAVENOUS DRUG PREPARATION ERRORS IN HEALTHCARE SETTINGS

N Hedlund*. Baxter Healthcare Corporation, Deerfield, USA

10.1136/ehjpharm-2015-000639.404

Background Intravenous (IV) admixture preparation errors (IAPEs) are a safety concern but their frequency, risk factors and associated burden of harm are not well understood.

Purpose To systematically review published evidence on the occurrence and associated burden of harm from IAPEs in healthcare settings.

Material and methods Searches were conducted in 4 large electronic databases (January 2005–December 2013). Publications reporting rates of IAPE and error types (wrong drug, wrong dose, wrong concentration, wrong diluent, wrong container, wrong route, contamination, and mislabeling) were reviewed.

Results Of 1,267 studies, 21 met the inclusion criteria, with 8 (38%) of these from Europe. Four studies were in critical care settings; 17 in general wards. Of studies reporting on an IV preparation site, 6 reported use of centralised locations with a biological safety cabinet, 11 reported preparation on the nursing ward, and 1 had an even split between the 2. Error types and reported rates varied substantially, including: wrong diluent used in 0.3% to 49% of doses; wrong dilution volumes used in 1% to 21.3% of doses; labelling errors in 9.3% to 99% of IV preparations; and inappropriate sterile technique in 25% to 100% of observed preparations. Higher IAPE rates were reported for ward-based versus centralised IV preparation. The only reports of zero IAPEs involved either computerised dose calculations or the use of automated equipment. The lack of consistent reporting on the types of error and the scarcity of studies reporting error rates made it difficult to identify trends. Error severity and associated burden of harm were not adequately documented to evaluate the impact on patient care or consequences for healthcare facilities.

Conclusion This systematic review identified few studies reporting data on the frequency or burden of harm of IAPEs. The available evidence reported fewer errors when drugs were prepared in the pharmacy than on nursing wards, and when processes were standardised and automated.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Diane Nitzki George for assistance with data abstraction.
Conflict of interest

REVISION OF BENZODIAZEPINES RECONCILIATION AT ADMISSION AND DISCHARGE

M Vázquez-Real, M Donoso Rengifo, L Jiménez Guerrero*, I Castañeda Macías, E Romero Carreño, S Santana Martínez, MD Alvarado Fernández. Hospital Universitario Virgen Macarena, Pharmacy Department, Seville, Spain

10.1136/ehjpharm-2015-000639.405

Background Benzodiazepines (BZD) have to be reconciled within 24 h of admission to avoid withdrawal symptoms. On the other hand, it’s important to check the discharge report to avoid treatment discrepancies.

Purpose To find out the accuracy of BZD reconciliation at admission and discharge in our hospital.

Material and methods Observational prospective study carried out in a tertiary care hospital over two months. Patients over 65 years and without a relevant psychiatric condition were selected. The BZD prescribed at admission was compared with patient’s home treatment. Clinical data was obtained from the electronic clinical history and electronic prescription. The discharge report was also checked for BZD indications. Reconciliation was classified as “reconciled” (same BZD and same half-life), “partially reconciled” (change to another BZD with different half-life) or “Not reconciled”. At discharge, physicians’ indications were revised.

Results 110 patients were included. The median age was 81 (65–95). They were 71 women (64%) and 39 men (36%). At admission the results were: 1) “Reconciled”: 63 patients (57.3%); 2) “Partially reconciled”: 9 patients (8.2%) and 3) “Not reconciled”: 38 patients (34.5%). At discharge, physicians
Patient safety and risk management

indicated the following: 1) “Same treatment”: 69 patients (62.7%); 2) “No mention of BZD”: 25 patients (22.7%); 3) “BZD combination”: 5 patients (4.5%); 4) “Changed to other BZD”: 5 patients (4.5%) and 5) “Withdrawal”: 2 patients (1.8%). Of 4 patients (3.6%) died during the hospitalisation.

Conclusion Almost a third part of patients don’t have their treatment suitably reconciled. It might occur that treatment was changed because it was not warranted, regardless of reconciliation. At discharge, physicians use phrases like “same treatment” or don’t mention anything about BZD. This can lead to treatment discrepancies with Primary Care.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-060 AGREEMENT BETWEEN POTENTIAL DRUG INTERACTIONS IDENTIFIED BY AN ELECTRONIC TOOL AND CLINICAL JUDGMENT: INTERcheck VERSUS PHYSICIANS

1S Antoniazzi, 1M Chiarelli, 2F Venturini*, 3A Nobili, 3L Pasina, 4C Casiraghi, 5S Damanti, 6G Petti, 7R Rossa, 2P Mannucci. 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliChimico, Direzione Scientifica, Milano, Italy; 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliChimico, UOC Farmacia, Milano, Italy; 3IRCCS – Istituto Di Ricerche Farmacologiche Mario Negri, Neuroscienze, Milano, Italy; 4Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliChimico, UOC Medicina Interna Alta Intensità Di Cura, Milano, Italy; 5Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliChimico, UOC Medicina Interna Alta Intensità Di Cura, Milano, Italy; 6Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliChimico, UOC Geriatria, Milano, Italy; 7Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliChimico, UOC Medicina Interna 1B, Milano, Italy; 3Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliChimico, UOC Medicina Interna 3, Milano, Italy

10.1136/ejpharm-2015-000639.406

Background The software INTERcheck provides physicians with the potential drug-drug interactions (pDDIs) associated with a patient’s treatment, classifying them based on clinical relevance from the literature, as A (minor), B (moderate), C (major), D (contraindicated).

Purpose To assess the concordance between the clinical relevance of pDDIs as classified by INTERcheck and the physician’s personal judgement.

Material and methods This retrospective study, conducted in 4 wards between April–October 2014, identified pDDIs from medical records of elderly inpatients aged ≥65 years, on ≥5 drugs, using INTERcheck. Clinical relevance as classified by INTERcheck was then compared with physician’s judgement through a structured interview consisting of four questions, as follows: is the pDDI known? is it clinically relevant?, if yes, why?, would knowledge of the pDDI at the time of prescription have changed your prescribing approach?

Concordance between INTERcheck and the physician’s judgement was defined as: classification of “clinically relevant = yes” by physician and class C or D by INTERcheck; classification of “clinically relevant = no” by physician and class A and B by INTERcheck.

Results Medical records of 60 inpatients were analysed: 1,658 prescriptions, while 9 suspected adverse drug reactions were not notified. In the recognition stage, the dosage form was omitted in 12%, route of administration in 17% of prescriptions, the dose in 12%, route of administration in 20%, and at discharge, 723 and 645 drugs were prescribed, respectively. At the recognition stage, the dosage form was omitted in 17% of prescriptions, the dose in 12%, route of administration in 20%, frequency in 26%.

At discharge rates of omission decreased to 2% for dosage form, 2% for route of administration, 7% frequency.

Overall, 816 potential drug-drug interactions were identified. In 13 medical records medicines were not prescribed in accordance with the hospital formulary; allergies/intolerances were not taken into account in 2 discharge letters and in 2 inpatient prescriptions, while 9 suspected adverse drug reactions were not notified.

Conclusion The review of the actual process of accuracy of drug recording in the patient’s medical record highlights the need for a more structured procedure. An active role for hospital pharmacists is foreseen, in order to ensure the safe use of medicines.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
A PILOT STUDY ON HOW NURSES MANAGE DRUG SUBSTITUTION DUE TO DRUG CHANGES AND DISCREPANCIES BETWEEN PRESCRIPTIONS AND DRUG AVAILABILITY

M Clemmensen, B Myrup, B Andersen. Amgros IVS, SAFE, Copenhagen, Denmark; Department of Cardiology, Nephrology and Endocrinology, Nordjyllands Hospital, Hørsholm, Denmark; Pediatric Department, Nordjyllands Hospital, Hørsholm, Denmark

Background Drug tenders and shortages result in drug changes and may result in discrepancies between prescriptions and available drugs. A high requirement for drug substitution (generic and therapeutic) may pose a potential patient safety risk. Little is known about how nurses manage such challenges.

Purpose To investigate how drug substitution due to drug changes and discrepancies between prescriptions and available drugs are managed by nurses. A secondary aim was to document strategies to manage drug substitution. In 20 of the cases, a different drug from the one prescribed was dispensed. Other strategies included contact with a colleague, contact with the pharmacy, request for a new prescription and obtaining the drug from another department. On average, the nurses spent 7 min on each response. Two cases concerned non-registered drugs and both nurses reported requiring 35 min to solve the problem.

Conclusion Nurses use a variety of strategies to manage drug substitution. Direct generic or therapeutic substitutions were the most common strategies. In all cases nurses spend extra time managing the substitutions. Improved implementation of drug changes and focus on correct prescribing may indeed improve managing the substitutions. Improved implementation of drug changes and focus on correct prescribing may indeed improve optimising home treatment. The high degree of medical acceptance of pharmaceutical interventions shows its usefulness.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

INTERVENTION OF HOSPITAL PHARMACISTS TO OPTIMISE HOME TREATMENT

C Caballero Requejo*, E Urieta Sanz, C García-Molina Sáez, A Trujillano Ruiz, M - Otxeniente Candela, M Castejón Giralda, L Rentero Redondo, M Antequera Lardón. Hospital General Universitario Reina Sofia, Pharmacy Department, Murcia, Spain

Background Drug-related problems (DRPs) are common among elderly patients using several drugs for the treatment of chronic diseases. The aim of the study was to evaluate the role of the hospital pharmacist in detecting and acting on problems related to home treatment.

Outpatient oncology setting

G Casado, C Rueda*, A Sierra, C Sobrino, H Varela, L Martínez, M Ruiz, M Freire, A Herrero. Hospital Universitario La Paz, Department of Pharmacy, Madrid, Spain

Purpose To describe the process used to reduce safety-related errors by using portable data assistants (PDAs) and barcode scanners that ensure the five rights are completed. In addition, we aimed to know the degree of safety perceived by nurses and patients during administration procedures.

Background Administration of antineoplastic agents is a complex process due to the potential risks for patients. The “five rights” should be accepted as a goal of the medication process: the right patient, the right drug, the right dose, the right route, and the right time.

Patient safety and risk management

Purpose To describe and analyse a program that enables a pharmacist to review home treatment at admission to a Short Stay Unit (SSU).

Material and methods The study was conducted from January 2014 to May 2014 in a general hospital. Polymedicated patients over 65 years old and awaiting SSU admission were included. The pharmacist developed the home medicines list using electronic primary care records, interview with the patient/caregiver and review of the medication bag. When DRPs were identified, they were reported to the physician through a document that contained treatment information and appropriate pharmacotherapy recommendations (PR). The physician had the information before the first prescription. The incidence and types of DRPs and acceptance of the PR conducted was measured.

Results 46 patients were selected, registering 529 chronic medicines in total, with an average of 11.5 ± 4.2 per patient. The mean age was 76 ± 9.6. The most frequent reasons for admission were heart failure (19.6%), acute exacerbation of COPD (15.2%), respiratory infection (10.9%) and acute bronchitis (10.9%). The average stay was 3.5 ± 2.7 days. In total 86 PRs were performed on 71.7% of patients (mean 1.9 ± 1.8). 50% of PRs were accepted. The PR distribution was: dose adjustment or posology 35 (62.9% accepted), drug interaction 24 (45.8% accepted), therapeutic equivalent 16 (37.5% accepted), contraindication or dose adjustment for IRC 7 (100% accepted), 1 duplication (1 accepted), 3 others (1 accepted). Therapeutic groups most frequently involved in the recommendations were antihypertensives 17.4%, inhaled β-agonists 16.3%, oral antidiabetics 9.3% and diuretics 8.1%.

Conclusion The high incidence of DRPs in patients considered at risk in our study highlights the importance of this type of intervention, admission to SSU resulting in an opportunity to optimise home treatment. The high degree of medical acceptance of pharmaceutical interventions shows its usefulness.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

AVAILABILITY

SUBSTITUTION DUE TO DRUG CHANGES AND DISCREPANCIES BETWEEN PRESCRIPTIONS AND DRUG AVAILABILITY

Outpatient oncology setting

PS-062

PS-064

PS-063

PS-065
Patient safety and risk management

Information is displayed helping to prevent errors related with the five rights. Opinion survey questionnaires were handed out to 50 patients and 10 nurses to find out how they feel about drug safety.

Results Since the start of the use of a barcode system in November 2009 to July 2014 a total of 58,948 treatment regimens (91,159 drugs) have been administered to 4,560 patients. Regarding questionnaires, 95% of patients answered they felt totally safe when asked about the use of the barcode system. Among nurses, almost every aspect of the service provided was rated good or very good and 80% considered it a valuable tool to prevent medication errors. The increased perception of safety is considered the major advantage of the system.

Conclusion The development of the bar code system proved to be a valuable tool to improve patients’ and nurses’ perception of drug administration safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS

American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards.

No conflict of interest.

PS-065 ANALYSIS OF MEDICINES ERRORS MADE IN A GENERAL HOSPITAL

E Lallana, M Mañes*, B Rubio, MJ Vázquez, JL García, M Segura. Hospital Universitario de Móstoles, Pharmacy, Madrid, Spain

10.1136/ehjpharm-2015-000639.411

Background Hospital pharmacists must be focused on patient safety. Consequently, it is important to evaluate the impact of the occurrence of medicines errors (MEs).

Purpose To analyse MEs taking place in a General Hospital over a period of 5 years (2009–2013).

Material and methods Descriptive observational study of MEs reported in a General Hospital over a period of 5 years (2009–2013). Variables analysed: place, stage, drug, type, causes, consequences.

Results 422 MEs were notified in 5 years: 47, 51, 75, 111, 138. Annual growth: 8.51%, 47.06%, 48%, 24.32% respectively; overall growth: 193,62%.

• Place of detection: 33.65%, Hospital Pharmacy Service; 27.73%, Hospitalisation Units; 17.30%, Day Case Unit; 17.06%, Outpatient Clinics.

• Stage: prescription (63.74%); transcription (28.44%); dispensing, processing, supply manufacturer, validation, administration or labelling (7.82%).

• Drug (Anatomical Therapeutic Chemical classification): 41%, group L (Antineoplastic and immunomodulating agents); 14.22%, group J (Anti-infectives for systemic use); 11.14%, group N (Nervous system); 8.06%, group B (Blood and blood forming organs); 7.35%, group A (Alimentary tract and metabolism); 7.11%, group C (Cardiovascular system).

• Type: errors in dosage (36.02%), inappropriate medicine (24.64%) or patient (22.27%).

• Causes: lack of staff training (29.86%), lack of compliance of work procedures (27.25%), incorrect patient identified (14.93%), insufficient staff, without experience or under stress conditions (13.51%), problems in interpreting the prescription (11.85%).

• Consequences: the error did not reach the patient (70.14%); the error came to the patient but did not cause any damage (16.35%); circumstances or events which may cause error (10.19%).

Conclusion Reporting of MEs is increasing significantly, although the corresponding data are undervalued. Therefore, it is important to continue working on this aspect. It is crucial to report and analyse in detail the MEs taking place in hospitals. This way, the real conditions in which they occur can be known, and improvement strategies can be adopted to improve the safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PS-066 A HIGH-RISK DRUG: INTRAVENOUS CONCENTRATED POTASSIUM CHLORIDE, HOW TO IMPROVE SAFETY AND QUALITY OF CARE?

1C Declaye*, 1Al Sennesael, 2C Vastrade, 1A Spinewine, 1JD Hecq, 1CHU Dinant Godinne – UCL Namur, Pharmacy, Yvoir, Belgium; 2CHU Dinant Godinne – UCL Namur, Nursing, Yvoir, Belgium

10.1136/ehjpharm-2015-000639.412

Background In the High Risk Medicines (HRM) field, intravenous potassium chloride (IV KCl) has an important role.

Purpose To assess nursing and medical practices in the management of hypokalaemia, to evaluate the accreditation norms of the hospital and define potential actions to make the use of IV KCl safe and standardised.

Material and methods A first audit of IV KCl prescriptions and administration practices was conducted, based on 33 electronic patient records regarding appropriateness of use (kalaemia during hospitalisation, administration rate, etc.). A second audit based on the “Adverse Drug Event Trigger Tool” was conducted to determine the number of iatrogenic hyperkalaemia events per 100 patients who received sodium or calcium polystyrene sulphonate, Kayexalate, during their hospitalisation. Finally, a list of the applicable measures was written with relevant actions depending on different actors.

Results The first audit indicated that 49% of the IV KCl administrations were inappropriate, 19% were appropriate because of patients’ kalaemia and the other 32% also if the patient was unable to tolerate oral route. It is noticed from the second audit that 19% of Kayexalate prescriptions stemmed from iatrogenic hyperkalaemia caused by intravenous or oral KCl. Therefore, we decided to prioritise redaction and publication of internal guidelines about KCl use. Rationalisation of the KCl availability should be the second step to implement.

Conclusion Regarding the results, a key issue relates to the health professionals’ training as well as the standardisation of hospital practices. Hypokalaemia and KCl administration management procedures have been validated by the Pharmaceutical and Therapeutic Committee. The availability of the different types of KCl in the Institution will be reviewed. Several improvements can be made in the near future.

REFERENCES


No conflict of interest.
PERIPHERAL NEUROPATHY INDUCED BY OXALIPLATIN: RISK FACTORS

1F Rusu*, 1F Boume, 5H Renault, 5E Malaurie, 5P Poullain, 1Chi de Creteil, Pharmacy, Creteil, France; 1Chi de Creteil, Oncology, Creteil, France

10.1136/ejhpharm-2015-000639.413

Background Oxaliplatin is widely used in the treatment of solid cancers. The main limit of use is the occurrence of peripheral neuropathy (PN). The principal predisposing risk factors (RF) are: diabetes, chronic alcoholism, cumulative dose, malnutrition, history of gastrointestinal surgery (malabsorption of neuroprotectors such as the vitamin B12), anaemia, kidney failure and concomitant neurotoxic drugs.

Purpose To analyse these RFs and to determine a relationship between the number of RFs and the average cumulative dose (ACD) of oxaliplatin.

Material and methods Retrospective 2-year study (2011–2012), n = 96 patients. The RFs mentioned above were identified from patients’ records. From the chemotherapy software Asclepios we identified the total cumulative dose and the threshold dose for occurrence of PN for each patient. The tests used were the Pearson correlation coefficient and Student t-test.

Results The incidence of PN in our sample was 46%. 3 groups were identified: 0–1 RF (59%), 2 RF (27%), 3 RF or more (11%). The proportion for each RF was: anaemia (48%), malnutrition and antecedents of gastrointestinal surgery (40%), diabetes (16%), administration of neurotoxic drugs before or during chemotherapy (16%) and chronic alcoholism (13%). The ACD at the onset of clinical signs was 331 mg/m². According to the Summary of Product Characteristics the cumulative dose is 850 mg/m². In our sample it was 2.6 times smaller (p < 0.05).

Conclusion It has been shown that the greater the number of RFs, the lower the ACD at which PN occurs. According to the literature these RFs do not contraindicate the use of oxaliplatin and in practice the reducing or stopping of oxaliplatin is dictated by the clinical appearance of NP.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

CONTACT

PS-067

PS-068

UTILITY OF ROOT CAUSE ANALYSIS TO IMPROVE SAFETY IN THE USE OF IODINATED CONTRAST AGENTS

1MT Gómez de Traveciedo*, 1A Almendral, 1R Gavira, 1V Vargas, 1M Reinado, 1S De Tena, 1A Parra, 1M Fernandez, 1F Gómez, 1R Gámez. 1Hospital Del Sas de Jerez, Farmacia, Jerez de La Frontera, Spain; 2Hospital Del Sas de Jerez, Radiodiagnostico, Jerez de La Frontera, Spain; 3Hospital Del Sas de Jerez, Farmacia, Jerez de La Frontera, Spain; 4Hospital Del Sas de Jerez, Radiodiagnostico, Jerez de La Frontera, Spain; 5Hospital Del Sas de Jerez, Farmacia, Jerez de La Frontera, Spain

10.1136/ejhpharm-2015-000639.414

Background Following the introduction of a new iodine-containing contrast medium (IC) (iomeprol) to our hospital for-
Patient safety and risk management

Results Number of patients: 270. Average age: 80 years. Total prescribed medications: 2.758, average 10, 2 per patient. The highest prevalence was related to drugs for the cardiovascular system, inhibitors of proton pump, statins and omeprazole.

There were 49%, 59%, 20% PIMs found using Beers, STOPP and START criteria, respectively. The most common PIMs using Beers and STOPP criteria were short-acting benzodiazepine prescribed to elderly patient with a history of falls (31% vs. 24%). The STOPP criteria were duplicate drugs prescriptions among (24%), higher doses than 150 mg/day of aspirin (7%). Common PPOs identified included antplatelet for diabetes with high cardiovascular risk index (18%), vitamin D and calcium supplements for known osteoporosis patients (17%).

Conclusion STOPP/START criteria showed higher MPIs detection capability than Beers criteria. This study confirms the high prevalence of PIMs among older adults comparing prior studies (16.3–62.5%). This can be explained by the diversity in the severity of disease in the study subjects.

REFERENCE
1 Beers, STOPP/START Criteria

No conflict of interest.

PS-071 SUBMANDIBULAR SIALADENITIS CAUSED BY ONDANSETRON IN A PATIENT WITH RISK FACTORS


10.1136/epharm-2015-000639.417

Background Ondansetron is a powerful and highly selective serotonin receptor antagonist used to prevent nausea and vomiting after surgery or chemotherapy. Sialadenitis consists in the formation of stones along the salivary duct.

Purpose To describe a case of ondansetron-induced sialadenitis and the prevention of its reappearance.

Material and methods Data obtained from the medical records and direct interview with the patient, were: age, sex, pathology, concomitant drugs and resolution. Side effects and interactions of each drug were obtained from the product information and Micromedex.

Results A 28-year-old woman in treatment with temozolomide for a low-grade astrocytoma, sought help in her third cycle of chemotherapy for obstruction of the salivary duct.

The patient was taking escitalopram and levetiracetam. Temozolomide, ondansetron and dexamethasone had been recently introduced, so they were the most likely agents to have caused the event.

In the list of possible adverse effects of every agent, sialadenitis is not referenced but xerostomia is described in the information about ondansetron (5%) and escitalopram (4–9%) and it could have worsened with the vomiting and dehydration.

Studying the interactions between the drugs did not warn us. The mechanism of action of ondansetron over the 5-HT4 receptor can explain it. Some antidepressants block cholinergic receptors contributing to this situation but escitalopram has a very low effect over them, the reaction was unexpected.

The Naranjo algorithm assigned 5 points (likely) to both as the causative agents but there are no previous notifications of this adverse event.

The stone dissolved spontaneously after oral hydration and the salivary duct became milky. The pharmacist instructed the patient in correct oral hydration and the event did not occur again during the next 12 months of treatment.

Conclusion High dose of ondansetron added to escitalopram may cause salivary duct stones in patients with other risk factors such as vomiting and dehydration. The pharmacist can prevent new stones from appearing by teaching patients good oral hydration practices during treatment.

REFERENCE
1 www.amps.gob.es/cima/pdfs/es/ft/59070/FT_59070.pdf

No conflict of interest.

PS-072 INCIDENCE, MANAGEMENT AND COST OF TELAPREIVIR/BOCEPREIVIR-INDUCED THROMBOCYTOPENIA DURING THE FIRST 12 WEEKS OF TREATMENT IN PATIENTS WITH HEPATITIS C


1Pharmacy Service, Hospital Dr. Peset, Pharmacy, Valencia, Spain; 2University Hospital Dr. Peset, Pharmacy, Valencia, Spain; 3Hospital Recoletas, Pharmacy, Cuenca, Spain

10.1136/epharm-2015-000639.418

Background Thrombocytopenia is a frequent adverse effect of telaprevir and boceprevir. This is not referenced but xerostomia is described in the information about each drug.

Purpose To study the incidence, management and the associated costs of thrombocytopenia during the first 12 weeks of treatment in patients with hepatitis C.

Material and methods Data obtained from the medical records of 222 patients treated with telaprevir or boceprevir. The diagnosis of thrombocytopenia was made when the platelet count was below 150,000/µl.

Results 220 patient charts were examined during a 2-month period. Drug interactions associated with hypokalemia were observed in 92 charts. Combinations of methylprednisolone sodium succinate, furosemide and theophylline with salbutamol were those most frequently observed to be of concern. Inclusive of 1 other laboratory tests requested for 12 patients, the number of patients observed with a decreasing level of potassium was 32 in total. Consequent to discussion with physicians, treatment was modified for 8 patients and pharmacists continued to monitor potassium levels for 24 patients.

Conclusion Hospitalised patients are frequently prescribed drug combinations that may result in hypokalemia. Pharmacists’ collaboration with physicians and involvement in the care of these patients can lead to better outcomes.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
**Background** Protease inhibitor-based triple therapy increases the expected incidence and severity of haematological adverse events, with repercussions on the total cost.  

**Purpose** To assess the incidence, management and incremental cost of thrombocytopenia in chronic hepatitis C virus (HCV) patients treated during the first 12 weeks with telaprevir/boceprevir-based triple therapy.  

**Material and methods** Retrospective observational study conducted (June 2012–February 2013) at the outpatients department of a general hospital. HCV genotype-1 patients were included treated with telaprevir (750 mg/8 h) or boceprevir (400 mg/8 h), ribavirin (1,000–1,200 mg/day) and Peg-IFN-α2a (180 μg/week) or Peg-IFN-α2b (1.5 μg/kg/week). Patients were monitored during the first 12 week of treatment. Their medical records were reviewed for platelet count at baseline, week 4 and 12 from the start of triple therapy. Thrombocytopenia was categorised according to degree of toxicity and magnitude of change. Additional procedures due to thrombocytopenia (clinical appointments, laboratory tests, drugs and platelet concentrates) were recorded and costed.  

**Results** 53 patients were included: 32 men, 51 ± 10years-old, 73 ± 7kg. 36 patients were treated with telaprevir and 17 with boceprevir. Platelet counts were 107.7 ± 59.1 × 10^9/L at week 4 and 104.2 ± 64.4 × 10^9/L at week 12. No significant differences were found in the magnitude of change at week 4 (-44 × 10^9/L (95% CI: -99 × 10^9/L to 10 × 10^9/L)) and 12 (-48 × 10^9/L (95% CI: -106 × 10^9/L to 10 × 10^9/L)). Table 1 shows the degree of thrombocytopenia. 42 patients experienced thrombocytopenia. In these, 130 medical visits were involved, 13 emergency room visits, 2 days of hospitalisation, 165 blood tests and 2 treatments with eltrombopag. The incremental cost was 12,709 euros (240 euros/patient). Increased costs of 156 euros/patient were estimated with thrombocytopenia grades I-II and 537 euros/patient with grades III-IV.  

**Conclusion** Patients with telaprevir/boceprevir-based triple therapy experience a high incidence of thrombocytopenia during the first 12 weeks, with significant impacts on overall cost, especially for grades III-IV. The cost of adverse events should be taken into account when considering the financial burden of the disease.  

**REFERENCES AND/OR ACKNOWLEDGEMENTS**  
No conflict of interest.
Patient safety and risk management

Report was written reflecting the real use of medicines in every case. All omitted or overprescribed drugs were recorded for statistical analysis.

Results 23 patients were interviewed, 73.6 ± 11.6 years, with a median of 9 drugs in their home treatment (range 5 to 20), 63.6% women. We found that 25.9% of patients had medicine(s) omitted from their medical admission reports, and 17.8% from their electronic primary care history. A total of 83 drugs were omitted in the physician admission reports. These included some high-risk drugs: 3 patients taking digoxin, 3 antiplatelet drugs and 2 anticoagulants. 36 drugs were omitted in the primary care electronic clinical history, including 2 omissions of anticoagulants and 2 antiplatelet agents. Regarding medicines that the patient did not take but were stated in the information sources: the physician admission report overprescribed 30 drugs, including 1 antiplatelet drug, 1 antipsychotic and 1 antidepressant (high-risk drugs). With respect to the electronic clinical history, 24 drugs were overprescribed, including the high-risk drugs 1 antiplatelet drug, 2 antipsychotics and 2 antidepressants.

Conclusion The quality of the data provided by the information sources is not sufficient, creating a risk of drugs omission or over-prescription. Hospital pharmacists could contribute positively to medicines reconciliation at admission.

REFERENCE

No conflict of interest.

PS-075 EVALUATION OF TOXICITY OF STANDARDISED TRIPLE INTRATHecal CHEMOTHERAPY

R Olmos Jiménez*,1 RM Díaz-Carrasco,2 VC Cabañas-Perianes,1 MF Fernández de Palencia-Espinosa,1 VM Valderrey Pulido,2 VM Muraleda Jiménez.1 University Hospital Arrixaca, Pharmacy, Murcia, Spain; 2University Hospital Arrixaca, Hematology, Murcia, Spain

Purpose To describe the incidence and severity of adverse events associated with triple intrathecal chemotherapy are highly variable in clinical practice. Thus, the standardisation of the preparation of the triple intrathecal chemotherapy (TIT) is recommended.

Material and methods Observational, prospective study was evaluated. Drug-drug interactions that could increase this effect were also evaluated. In all administrations: headache (23.2%), vomiting (17.9%), dizziness (5.4%), back pain (3.6%), paresthesias (1.8%) and orthostatic hypotension (1.8%). All AEs were acute: the median time of onset was 26 [1–72] h and the median duration of event 48 [1–720] h. The severity was: 22.6% grade 1, 74.2% grade 2 and 3.2% grade 3. All toxicities resolved.

Conclusion The incidence of mild and moderate AEs associated with TIT is relatively frequent, headache being the most common AE such as described in the literature. No long-term toxicities were observed. Therefore, the TIT shows an acceptable toxicity profile.

REFERENCE
1 CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf [Internet]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

No conflict of interest.
related increased risk of QTc prolongation (limited by a small sample size). It is unknown how further treatment in the hospital affects these patients’ risk. Therefore, it is recommended to evaluate QTc intervals of cardiology patients upon admission and closely monitor for additional risk factors of QTc prolongation and arrhythmias during hospitalisation.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Nursing staff
No conflict of interest.

PS-077 STUDY OF DRUG INTERACTIONS IN A MEDICINE DEPARTMENT
1A Rodrigues*, 1M Oliveira, 1C Santos. 1Centro Hospitalar de Leiria – E. P. E., Pharmacy Department, Leiria, Portugal; 2Instituto Superior de Ciências Da Saúde Egas Moniz, Pharmacy, Lisbon, Portugal
10.1136/ehjopharm-2015-000639.423

Background The potential drug–drug interactions (PDDI) in a multidrug treatment (MDT) regimen must be taken into account when prescribing, as adverse effects (AEs) may occur that might make it necessary to choose an alternative treatment. MDT regimens are usually being prescribed by different doctors. This practice increases the risk of DDI and it is fundamental to acknowledge them and identify at-risk patients early.

The AEs resulting from DDI can be reduced or avoided with dose adjustments or changes in the regimen, or even stopping some drugs.

DDIs can be classified according to severity as major, moderate and minor. The focus of our study was in the group of potential major drug–drug interactions (PMDDI), which can threaten the patient’s life or result in permanent injury.

Purpose To analyse the PDDI profile of medical prescriptions according to severity and identify the most frequent PMDDI and the drugs involved.

Material and methods Retrospective study of PDDIs (checked on Drug Interactions Checker of drugs.com) on all prescriptions of medical ward patients, who were discharged from February to March 2014, by consulting the patient’s clinical record. Descriptive statistical analysis was performed.

The following data were collected: number of prescriptions/patient analysed, patients’ average age, average number of prescribed drugs/prescription, maximum number of major interactions/prescription, % of prescriptions with interactions detected, % of prescriptions with potential major interactions (MI), main drugs involved (MD) and more frequent interactions (MFI).

Results

Abstract PS-077 Table 1

| Prescriptions/patient analysed | 234 |
| Average age | 75.3 ± 15.8 years (1327, 1027) |
| Prescribed drugs/prescription | 11.5 ± 4.5 |
| Major interactions/prescription | 11 |
| % of prescriptions with interactions detected | 79.75% |
| % of prescriptions with potential major interactions | 71.4% |
| Main drugs involved | Enoxaparin (10.9%)/Potassium Chloride (9%) |
| More frequent interactions | Acetylsalicylic Acid-Enoxaparin (11.1%) |

Conclusion The data analysis revealed a huge number of PDDI. This leads us to the conclusion that the pharmacist intervention in this area will increase safety in medicines administration.

In future the development of an intervention plan regarding the most frequent PMDDIs will improve the health care provision.

It’s our goal to introduce an automatic notification system for the prescriber at the time of prescription in order to manage these interactions.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-078 REVIEW OF CLOSTRIDIUM DIFFICILE ISOLATES IN A GENERAL HOSPITAL
1MC Conde García*, 1P Aranque Arroyo, 3MD Fraga Fuentes, 1JC Valenzuela Gámez, 2R Carranza González, 1T Gómez Lluch, 1S Sánchez Cacanueva, 1HG Mancha Centro, Pharmacy, Alcázar de San Juan, Spain; 2HG Mancha Centro, Microbiology, Alcázar de San Juan, Spain; 3Hospital de Tomelloso, Pharmacy, Tomelloso, Spain
10.1136/ehjopharm-2015-000639.124

Background Several studies indicate that 96% of patients with symptomatic C. difficile infection had received antibiotics within 14 days prior to the onset of diarrhea. Complications include dehydration, electrolyte disturbances, toxic megacolon, hypotension, renal failure, systemic inflammatory response syndrome, sepsis and death.

Purpose To analyse patients admitted to our hospital testing positive for toxins A + B of C. difficile over 4½ years and to determine the associated mortality.

Material and methods Descriptive retrospective study conducted between 1 January 2010 and 30 June 2014 that included all hospitalised patients testing positive for C. difficile toxins A + B. Data recorded were antimicrobial treatments before detection of toxins, condition for which they were prescribed, treatment to eradicate C. difficile and its duration. The percentage of patients who died during that admission or within 10 days of discharge was also determined.

Results Results were positive in 60 samples from 54 patients, 51.7% women and 48.3% men, with a mean age of 76.2 years. The most common pathologies for which antibiotics were prescribed were respiratory infection (36.4%), urinary tract infection (27.3%), intra-abdominal infection (16.4%), unspecified febrile syndrome (7.3%) and others (12.6%). 35 patients (64.8%) received more than one antimicrobial prior to detection of C. difficile, mainly β-lactams (63.0%) and fluoroquinolones (27.8%).

Treatments prescribed for eradication of C. difficile were:
- Metronidazole (63.3%): <7 days in 4 isolates, 7–10 days in 18 of them, >10 days for 15 and five patients died during treatment.
- Oral vancomycin (20%): <7 days in 1 patient, 7–10 days in 3 isolates and >10 days for 8 of them.
- No treatment: 10 patients (16.7%).

Of the patients evaluated, 18 died (32.7%).

Conclusion The number of patients in whom toxins A + B of C. difficile were positively identified was low, probably due to the low degree of clinical suspicion and not too satisfactory sensitivity of the technique. Prescribing for treatments for eradication was not appropriate in 27.8% of patients (10 received no treatment and 5 for insufficient time). The mortality rates found in our study agree with data from the literature (22–40%).
IMPLEMENTATION OF PROACTIVE MEDICINES RECONCILIATION TO REDUCE DRUG ERRORS AT ADMISSION

S Renet*, J Raymond, P Bravo, R Haddad, G Bussonne, Laqueriere, R Fic, A Rieutord, N Curatto, AP-HP – Hôpital Antoine Béclère HUPS, Service Pharmacie, Clamart, France; AP-HP – Hôpital Antoine Béclère HUPS, Service Médecine Interne, Clamart, France

Background Medicines reconciliation (MR) is a critical step for reducing medicines errors (ME) at admission to hospital care. However, because of resource constraints it can be difficult to implement in hospital pharmacists’ everyday practice. The Lean method is used to streamline and optimise processes considering all stakeholders and resources.

Purpose To redesign the medicines management process at admission to reduce MEs.

Material and methods A Lean approach review was conducted of the current medicines management process at admission (retroactive MR process) in order to define the new process (proactive MR), with all the stakeholders (clinicians, nurses, pharmacists, pharmacy technicians, head nurses). 5 activities were performed:

- mapping of the current process (retroactive MR process)
- measure of unintended medicines discrepancies (UMDs) at admission
- analysis of the collected data and root cause implementation
- design of a new improved process (proactive MR)
- implementation and measurement of the new process

Only patients more than 65 years old and/or taking at least 3 medicines before admission were included.

Results 52 patients were initially included (75 years, 7.4 medicines/patient). 46% had at least 1 UMD (0.75 UMDs/patient) and 28.2% of UMDs had the potential to cause moderate to severe discomfort or clinical deterioration. After implementation of the new MR process, 50 patients were included (70 years, 6.9 medicines/patient). The percentage of patients with at least 1 UMD decreased to 12% (p < 0.01) (0.16 UMDs/patient) and 28.6% of UMDs had the potential to cause moderate to severe discomfort or clinical deterioration.

Conclusion Results demonstrate that proactive MR is effective in reducing ME on admissions orders and suggest that Lean is fully adapted to improve the medicines management process. Other studies are warranted to evaluate the impact of Lean on ME reduction.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-080 SAFETY SYSTEM IN THE ADMINISTRATION OF INTRAVENOUS CHEMOTHERAPY
C Martinez-Diaz*, S Fenix-Caballero, J Garcia de Paredes-Esteban, J Bomero-Rubio, C Palomo-Palomo, M Gandara-Ladron de Guavara, E Rios Sanchez, El Alegre Del Rey. H. U. Puerto Real, Pharmacy, Puerto Real, Cádiz, Spain

Background Patient identification bracelets and their verification by infrared scanner help to minimise errors during administration of intravenous anticancer drugs.

Purpose To quantify the number of correct administrations, type of mistakes avoided and the level of implementation of the new safety system for administration of intravenous drugs.

Material and methods A retrospective descriptive study was designed with all patients who received intravenous anticancer drugs in Oncology Day Hospital (June 2014–September 2014). The identification bracelet was printed and put on the patient by the nurse. The scanner read the barcode of each intravenous preparation: chemotherapy and supportive treatment, and the Data matrix code of the bracelet with patient data. The system verified that dosages and the administration steps in the order specified in the chemotherapy management software (Farmis-Oncofarm V.2011.0.4.6) were correct. All the information was recorded in a database through a WiFi system. The end points examined were: number of correct administrations and number and type of mistakes that were avoided. The level of implementation of this system was assessed as the number of drugs preparations identified by infrared scanner compared to the total number of completed administrations.

Results During the study period, 476 patients were included with 13,805 administrations (21% cytostatic drugs and 79% supportive treatments). The level of implementation obtained was 67%.

<table>
<thead>
<tr>
<th>Abstract PS-080 Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correct administrations 8,559 92.32</td>
</tr>
<tr>
<td>Mistakes avoided during medication administration 541 5.84</td>
</tr>
<tr>
<td>Order of drug administration 513 5.53</td>
</tr>
<tr>
<td>Wrong-patient medication error 26 0.29</td>
</tr>
<tr>
<td>Expired drug 1 0.01</td>
</tr>
<tr>
<td>Incorrect date of scheduling 1 0.01</td>
</tr>
<tr>
<td>Drug not found in the database 171 1.84</td>
</tr>
<tr>
<td>Total 9,271 100</td>
</tr>
</tbody>
</table>

Conclusion
1. The safety system was used in more than a half of administered cycles.
2. Errors related to order of administration were the most common identified.
3. The level of implementation of the identification system would require an improvement in order to benefit the maximum number of patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.
laboratories. Several problems of cytotoxic leakage, involving syringes, were reported to the pharmacist. As the safety of healthcare staff and patients was evidently being compromised it was decided to systematically analyse and report every undesirable event.

**Purpose** To evaluate the safety problems related to the administration of cytotoxic syringes and to test a different system in order to replace the current device if needed.

**Material and methods** Over 6 months, we systematically interrogated the nurses who were reporting a problem and the devices involved were inspected. Each incident was reported to the manufacturer and the devices were sent back to them. Nurses also tested a new administration system from BD PhaSeal. A scoring table was used to assess the staff satisfaction on technical and safety criteria.

**Results** The Codan device was involved in seven incidents. Breaks were systematically observed at the junction between the tubing containing the cytotoxic and the non-return valve. The safety of nurses, patients and their relatives was then compromised. However, according to the manufacturer, the device was not faulty and our complaint was not followed up.

Consequently, we decided to test the new device from BD (the PhaSeal system). 18 nurses participated, they assigned a score of 2.5/3 for safety criteria and 2.2/3 for handling criteria. This device seemed to improve the safety of patients and staff regarding cytotoxic exposure and microbiological contamination.

**Conclusion** Risk management is an important concern for pharmacists working in paediatric oncology units. Close collaboration with physicians and nurses allowed us to improve the safety of children and staff.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**PS-082** PHARMACISTS AND HOME ARTIFICIAL NUTRITION: WHAT EMERGED FROM A NATIONAL AND REGIONAL SURVEY

SL Borchetto*, D Zenoni, T Angelini Zucchetti, G Zamarbieri, MT Benzoni Fratelli, A Barcella. Azienda Ospedaliera Bolognini, Farmacia, Seriate BG, Italy

10.1136/ejhpharm-2015-000639.428

**Background** Artificial home nutrition (AHN) is a constantly expanding area. This study focuses on the management of AHN on a national level and on the pharmacist’s role in this field.

**Purpose** To screen the management of Artificial Nutrition at a national level by means of a survey.

**Material and methods** About 150 hospital and regional pharmacists answered a questionnaire of 50 questions, focusing on AHN.

**Results** Only 45% of the hospitals offer AHN services and only 35.5% of pharmacists are involved in it. The data given by “Società Italiana Nutrizione Artificiale e Metabolismo” show 83.9% of Hospitals offer Enteral Nutrition at home and 16.1% Parenteral Nutrition at home. Only 10% of hospitals are governed by a regional law, while 65% obey general regulations and more than 25% lack any legislative instrument that guarantees the immediate start of AHN treatment. The survey looked for the existence of AHN working groups at regional level: 44.7% of the people interviewed replied saying there was a working group, while 31.6% answered there wasn’t. Furthermore, 22.4% of the people interviewed were not aware of the benefits offered by a working group. Another significant result concerned the role in charge of training the patient: in 40.8% of the cases it was the doctor, in 51.3% it was the nurse, while in only 3.9% was it the pharmacist. The result is that, when an AHN unit is set up, it manages all the phases of the treatment and standardises the initial phases of the treatment (in more than 80% of the cases).

**Conclusion** The situation of AHN in Italy appears highly fragmented, with various structural differences in each region and the role of the pharmacist is still limited.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

The authors wish to thank all the pharmacists for their contribution.

No conflict of interest.

---

**PS-083** ANALYSING MEDICATION ERRORS REPORTED: A BASIS FOR CONTINUOUS IMPROVEMENT

1L Gutermann*, 2Y Chenet, 1E Camps, 3B Bonan. 1Hôpital Foch, Pharmacy, Suresnes, France; 2Hôpital Foch, Risk Management, Suresnes, France

10.1136/ejhpharm-2015-000639.429

**Background** In France, the reporting, evaluation and prevention of medication errors (ME) are regulatory requirements for hospitals. This represents a key point in the risk management policy and the improvement of the quality of patient care. In our hospital, MEs are reported using electronic software (BLUEMEDI) to facilitate their declaration.

**Purpose** To analyse medication errors reported in order to identify ways of improvement.

**Material and methods** Quantitative and qualitative retrospective analysis of MEs reported from January 2010 to August 2014. The data were extracted from BLUEMEDI software and classified according to ME characteristics, contributing factors and their belonging to the national list of events that should never happen (“never events”). 1 Multidisciplinary team work (MTW) has identified ways of improving.

**Results** 90 MEs were analysed. Most MEs were administration errors (AEs) (75.6%, n = 68) and only 22 (24.4%) were prescribing errors. Regarding the characteristics of AEs, there were 16 drugs errors, 15 administration technique errors, 10 dose errors, 7 drug omissions, 7 drug storage errors, 6 drug administration traceability errors, 5 patient errors, 2 drug preparation errors. Furthermore, 16 (23.3%) of these AEs were part of “never events”: 6 concerned anticoagulants, 5 insulin, 3 potassium chloride, 1 a paediatric solution. All of these “never events” were preventable and the human factor was involved in 14 (87.5%) of situations. To raise awareness among nursing staff about AEs, the MTW suggested implementing a play-based training scenario, error checking in a standardised patient room. Topics have been chosen from the “never events” that have occurred.

**Conclusion** Learning from our mistakes is one of the first steps towards a safer care system. This retrospective analysis allowed us to develop targeted training. Furthermore, establishing a training program based on error detection will not only raise awareness of administration errors but also improve knowledge of them.

**REFERENCE**


No conflict of interest.
PS-084  NEW ERRORS ASSOCIATED WITH COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEM: INCORRECT MEDICATION SCHEDULE

JA Domínguez Menéndez*, N Pardo Santos, S Vallinas Hidalgo, I Lozaga Díaz, LM Mendarte Barrerechea, MI Ynumbaso Ibarreche. Basurto Hospital, Pharmacy, Bilbao, Spain

10.1136/eurjhp-2015-000639.430

Background The introduction of a computerised physician order entry (CPOE) system in 2010 changed the way of working in our hospital. Previously, the administration of medicines was scheduled by nurses, whereas now it is set in advance by physicians. Medicines administration can be delayed or omitted if nurses are unaware of CPOE timetables fixed in advance.

Purpose To quantify and analyse medication errors associated with incorrectly scheduled prescriptions.

Material and methods Retrospective observational study of a 10-day period. To facilitate the study only one daily medicine regimen was selected (levofloxacin). Started or modified treatments (sequential treatment, treatment or timetable change), and their administration records were reviewed the day after. Omission was considered if the medicine was not administered in a 24 h period, and incorrect prescription if the pre-arranged timetable was 8 h later than that stated in the prescription or if a dose was repeated in the day.

Results 20 levofloxacin start treatments and 48 modifications were collected (47 oral and 21 intravenous). Classified by Service: 18 Respiratory (RES), 16 Internal Medicine (IMD), 16 Emergencies (E), 13 Cardiology (CAR), 5 others. 9 omissions (15%) and 6 duplicated doses (9%) were detected. 5 errors occurred on starting and 10 during sequential treatment. Classified by Service: E, 3 omissions and 2 duplications (31%); IMD, 3 omissions and 2 duplications (31%); CAR, 2 omissions and 1 duplication (23%); Others, 1 omission (20%); RES, 1 duplication (5%). Incorrect prescription (35%) was the cause in all errors that occurred.

Conclusion CPOE systems reduce potential errors associated with medication. However, these systems can be a source of new errors if they are used incorrectly. To prevent these errors a system of continuing CPOE training is necessary for physicians. Due to the results, the Pharmacy Service informed all physicians about correctly scheduling medication, giving examples.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PS-085  IMPACT OF DRUG INCIDENT REPORTING ON THE WORK OF PHARMACEUTICAL SERVICES

1D Palma*, 1C Coutinho, 1C Rocha, 1S Valongo, 1A Simões. 1Hospital Dr. José de Almeida, Pharmacy, Cascais, Portugal; 2Hospital Dr. José de Almeida, Quality Department, Cascais, Portugal

10.1136/eurjhp-2015-000639.431

Background The growing introduction of new therapeutic options has contributed to increased awareness of patient safety in Health Care. Different studies have quantified the medication errors that take place at every step of the medicines use process.

Purpose To evaluate the impact of drug incident reporting on the way the Pharmaceutical Services (PS) work.

Material and methods Retrospective study, 2011–2014, of the drugs-related incident reports recorded on the Incidents Reporting Platform (IRP). All notifications were assessed regarding the stage of the medication process, root-cause analysis and categorising of medicines.

These incidents were assessed in the PS and corrective or preventive actions taken according to ISO 9001:2008 by the Quality Department.

Results 425 incident reports were recorded on the IRP, 45 (10.6%) regarding drugs. Of these, 73.3% were related to the dispensing process, 4.4% to preparation, 17.8% to drug administration and 4.4% to patient identification.

Most incidents are potential errors that are detected early and do not reach the patient, considered near misses (JCI).1 The drugs involved were look-alike sound-alike (LASAs), β-lactams and amiodarone. The most frequent causes related to drug dispensing (73.3%) were omission of a medicine (36.4%) and wrong medicine (21%).

Conclusion Reporting systems (RS) are a key element for building a culture of safety. RS are useful if data is assessed and information is provided back to the health professionals involved. Following the assessment of these reports improvements have been implemented in the drug circuit: change in the location, confirmation before dispensing (random or total), and random weekly audits of medicines repackaged at the Pharmacy warehouse facilities. Study limitations include the absence of reports related to prescriptions, which should be encouraged in order to improve safety.

REFERENCE

1 Joint Commission International Accreditation Standards for Hospitals, 5th ed. JCI, April 2014

No conflict of interest.

PS-086  ERRORS ASSOCIATED WITH A COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEM: INCORRECT NON-DAILY MEDICINES REQUESTS

JA Domínguez Menéndez*, S Vallinas Hidalgo, N Pardo Santos, B Balzola Regout, LM Mendarte Barrerechea, MI Ynumbaso Ibarreche. Basurto Hospital, Pharmacy, Bilbao, Spain

10.1136/eurjhp-2015-000639.432

Background Computerised physician order entry (CPOE) systems prevent medicines being requested without a prescription. However, potential errors still occur due to incorrect treatment requests.

Purpose To quantify and analyse potential medicines errors associated with incorrect nurse requests for medicines scheduled less often than every day.

Material and methods Prospective observational study carried out over three months in units using CPOE and unit-dose medicines dispensing systems. Data about non-daily medicines schedules (every 48 or 72h, weekly,...) requested by nurses were collected.

Results 45 medicines requests were checked during this period. Classified by schedule: 14 weekly, 7 every 48 h, 7 biweekly, 5 single dose, 4 Monday-Wednesday-Friday, 8 others. Classified by medicine: 15 epoetin alfa, 4 weekly alendronate, 4 intramuscular risperidone, 4 intramuscular paliperidone, 18 others. Classified by cause: 27 not dispensed in unit doses due to stability or other special issue, 9 starts of treatment, 6 with errors in the requests, 2 dispensing errors, 1 missed medicine.

A total of 6 incorrect requests were detected (13%): weekly epoetin alfa, weekly alendronate, prednisone every 48 h,
mercaptopurine every 48 h, furosemide every 48 h, buprenorphine every 72 h. Only one of these errors occurred in medicines not dispensed in a unit dose (1 of 27 requests), and the others in unit-dose dispensed medicines (5 of 18 requests).

All the incorrect requests had been prescribed correctly.

**Conclusion** CPOE reduces potential errors associated with medicines, such as requests for medicines that have not been prescribed. However, errors associated with medicines requests are still happening. These incorrect requests occur despite a correct prescription, therefore an exhaustive revision of the system for requesting non-daily medicines is necessary to prevent this source of errors.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**PS-087** MEDICINES RECONCILIATION AT HOSPITAL DISCHARGE

1A Gévy*, 1S Boden, 2V Cheilan, 2J Bargin, 5V Virtu, 1D Boucherle. 1Groupe Hospitalier Mutualiste, Pharmacie, Grenoble, France; 2Groupe Hospitalier Mutualiste, Médecine Interne, Grenoble, France

10.1136/ehjpharm-2015-000639.433

**Background** Discharge from hospital is a high-risk period for medicines errors. Unintentional medicines discrepancies may contribute to drug-related problems at home.

**Purpose** To identify and assess the clinical impact of unintentional medicines discrepancies at hospital discharge in order to reduce them.

**Material and methods** Patients admitted to the internal medicine department in August 2014 were included in this prospective study. Any differences between the patient’s current home medicines (based on pre-admission prescriptions and medical history in the patient’s file) and the discharge prescription were listed. Discrepancies were categorised with physicians as intentional or unintentional.

The clinical impact of unintentional discrepancies was assessed by two physicians and one pharmacist as may having no, minor, significant or major consequences.

**Results** 62 patients were included (52.3% men – average age: 73.1 ± 15.5 years). The average number of medicines per patient was 6.1 ± 3.9.

295 discrepancies were identified at discharge: 80.3% intentional and 19.7% unintentional.

The unintentional discrepancies were classified as 43.1% (25) missing chronic medicine, 8.6% (5) addition of a new drug, 8.6% (5) different dose, 15.5% (9) different frequency, 20.7% (12) change to therapeutic equivalent and 3.5% (2) other.

21.8% (12) of discrepancies may have had significant consequences for the patient, 50.9% (28) minor consequences and 27.2% (15.7) no impact.

Only 42.3% (124) of intentional discrepancies were documented in discharge letters.

**Conclusion** Discharge is a particularly vulnerable transitional interface regarding the number of discrepancies and their potential clinical impact.

Omission of chronic medicines and change to therapeutic equivalents – which may be confusing for elderly patients – were the most common discrepancies.

Intentional discrepancies not communicated to family physician can lead to the patient’s care not being changed.

Obtaining a complete picture of medicines at admission is another difficulty due to multiple prescribers.

This study highlights the need for medicines reconciliation to prevent adverse drug events and to improve continuity of care and patient safety.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**PS-088** ASSESSMENT OF ANTICHOLINERGIC EFFECTS OF DRUGS PRESCRIBED FOR THE ELDERLY

A Escolano Pueyo*, P Casajús, I Navarro, M Castiella, M Comet, O Pascual. Universitary Hospital Miguel Servet, Pharmacy, Zaragoza, Spain

10.1136/ehjpharm-2015-000639.434

**Background** Elderly patients have a higher risk of adverse reactions associated with drugs with anticholinergic properties. Anticholinergic drugs may produce cognitive impairment, delirium and falls and can increase functional dependence.

**Purpose** To determine the extent of anticholinergic exposure in older people at admission to an internal medical ward. To assess the association between this exposure and anticholinergic adverse effects using two different scales.

**Material and methods** Observational and retrospective study of elderly patients (≥75 years old) admitted to an internal medical ward in March and April 2014. Total anticholinergic risk was assessed by the Anticholinergic Risk Scale (ARS) and the Anticholinergic Cognitive Burden Scale (ACB). The two scales consider in a different way the drug-associated risk of developing an anticholinergic symptom. Data were obtained from emergency reports while admitting to the internal medical ward and from the pharmaceutical management program Farmatools.

**Results** 148 patients, 49.3% men. Mean age: 84.8 ± 5.4 (75–97). Mean drugs prescribed at admission: 8.4 ± 3.8 (1–20). 86.5% lived at home and 13.5% in a nursing home. 10.3% died during admission. According to the ARS and ACB scales, 28.4% and 62.2% of patients were taking an anticholinergic drug at admission. 37.2% of patients had an anticholinergic symptom.

Results from the ARS scale showed a statistically significant association between taking an anticholinergic drug and developing an anticholinergic symptom (p = 0.008) OR = 6.76. No association was found with the ACB scale (p = 0.485).

42 patients were taking at least one anticholinergic drug at admission, according to the ARS scale. This predicts a grade 1 risk: levodopa-carbidopa, quetiapine, trazodone 19% each; paroxetine 11.9% and risperidone 9.5%. Grade 2 risk: tolterodine 4.7% and amantadine, olanzapine and baclofen 2.4% each. Grade 3 risk: tizanidine and amitriptyline 4.8% each. Average extent of anticholinergic exposure was 1.5 ± 0.74. At discharge, at least one anticholinergic drug was removed from 14.3% of these patients.

**Conclusion** A high percentage of elderly patients admitted to an internal medical ward were taking an anticholinergic drug. In our study, we found a correlation between anticholinergic exposure as defined by the ARS scale and adverse anticholinergic symptoms.

The ARS scale predicts an association between the taking of an anticholinergic drug and the development of an anticholinergic symptom (6.76 times higher risk).
Patient safety and risk management

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-089 IMPLANTATION OF A SAFETY STRATEGY FOR DRUG STORAGE IN A PHARMACY SERVICE
LL Poyatos Ruiz, MD Santos Rubio*, C Álvarez Del Vayo-Benítez, C Villanueva Bueno, E Montecatine Alonso, T Desongles-Corrales, Mt Sierra Torres, A Rodríguez Pérez, MD Toscano Guzmán, A García-Avello. Virgen Del Rocío University Hospital, Hospital Pharmacy, Seville, Spain
10.1136/ehjpharm-2015-000639.435

Background Patient safety is a key factor in the quality of care and it is the object of public attention.

Improvement strategies have stimulated the development of models that allow a better understanding of the adverse effects related to health care. The most common adverse effects are related to drug use and often are preventable. Therefore, they have to develop strategies to reduce and detect them.

Purpose To describe the development of a strategy designed to improve drug’s storage and dispensing in a pharmacy service to ensure patient safety.

Material and methods Literature review about drugs that are confused: drugs that must be stored and dispensed in specific conditions because of their photosensitivity, drugs whose active generic or trade name are written or pronounced in the same way (look-alike, sound-alike: LASA) or drugs that bear a heightened risk when used in error (high alert medication).

Design A colour labelled to avoid the possible confusions. Photosensitive drugs were labelled with yellow point, “LASA” with green and high alert medication with red point. Then, it has been set some posters with the colour code to teach the pharmacist and technicians. After that, we evaluated the results and checked with a survey among the technicians, that this strategy was useful.

Results Of 2,490 drugs that are stored, 89 (3.57%) were categorised as photosensitve drugs, 6 (0.24%) as “LASA” and 66 (2.65%) as high alert medication.

Four error related with dispensation were registered along three months before intervention, however any error has occurred the quarter after that. In addition, after an audit, all the photosensitivity drug’s are stored in optimal conditions.

From 15 technicians surveyed, 90% say to know the strategy implemented and consider it like useful.

Conclusion This strategy has helped the pharmacy service to improve the storage and dispensing quality, avoiding medication error and providing the drugs in optimal conditions to the patients, increasing their safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-090 RESULTS OF A MEDICINES RECONCILIATION PROGRAM IN COMPLEX CHRONIC PATIENTS AT HOSPITAL DISCHARGE
1M Camps, 1M Marcones, 1V García*, 1IQ Moreno, 1C Campins, 1C Agustí, 1D López, 1A Sánchez, 1X Fabregas, 1A Lavado. 1Hospital Mataró, Pharmacy, Mataró, Spain; 2Hospital Mataró, Data Management Unit, Mataró, Spain
10.1136/ehjpharm-2015-000639.436

Background Risk of medicines discrepancies is high during care transitions where treatment changes are frequent.

According to the Institute for Healthcare Improvement, medicines reconciliation is the formal process of obtaining a complete list of the patient’s prior medicines and comparing it with what has been prescribed on admission, care transitions or hospital discharge. Changes should be documented and communicated properly to the follow-up physician and patient or caregiver.

Purpose To determine the drug discrepancies at hospital discharge of complex chronic patients.

Material and methods Cross-sectional study over 6 weeks in a secondary hospital to investigate the prevalence of reconciliation discrepancies of complex chronic patients. The criteria for consideration as a complex chronic patient included: 2 hospitalizations with minimum 9 days length of stay and a chronic disease. We excluded patients whose destination was a nursing home, healthcare centre or home care plus a support program. A pharmacist reviewed a report of all the complex patients’ chronic medicines at discharge and compared them with treatment prescribed in the electronic prescription and medicines prior to regular admission.

Results We reviewed all complex chronic patients who were discharged from July 15th 2014 to August 31st 2014 (n = 103) and we included 92 patients. Mean age was 78.5 years and 58.3% were men. 63% of patients had a discrepancy between the information in the discharge report and electronic prescriptions given to the patient. Overall we found 1.3 discrepancy rate per patient. The highest percentage of discrepancies occurred by omission (49.2%), followed by incorrect frequency (29%), dosing errors (19%) and others (3%).

Conclusion Unjustified medicines discrepancies between discharge report and electronic prescription are frequent. This can lead to medication errors or doubts about the correct overall treatment. A multidisciplinary team: doctor, pharmacist and nurse could prevent a high percentage of these discrepancies with a final review of the medicines prescribed at discharge. Furthermore, it is important to explain the medication plan to the patient or caregiver.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-091 BENEFITS OF MEDICINES RECONCILIATION IN AN EMERGENCY UNIT
1C Deprés, 1F Roulet-Renoleau*, 1B Politi, 11 Nog, 1D Gueyfard Chenevier. 1Centre Hospitalier Intercommunal Du Pays de Cognac, Pharmacie, Cognac Cedex, France; 2Centre Hospitalier Intercommunal Du Pays de Cognac, Service Des Urgences, Cognac Cedex, France
10.1136/ehjpharm-2015-000639.437

Background To improve drug treatment in an emergency unit, we tested Medicines Reconciliation (MR) based on the WHO High5 Medication Reconciliation program method.

Purpose To assess the contribution of MR and to measure the pharmaceutical time required for this activity.

Material and methods This study lasted from June to October 2014. Patients had to meet the following eligibility criteria: admission to Emergency unit followed by admission to hospital, aged between 65 and 90, poly-medicated, with their medicines presenting a risk. Discussions with the patient (or his family if he could not be questioned), his pharmacist, his GP are all information sources (IS) enabled the pharmacist to write an
Optimised Medicines Appraisal (OMA). The MR compared the OMA to the first hospital prescription. The prescriber categorised differences found as intentional (ID) or non-intentional (NID) differences, which equate to medicines errors (ME). NID were categorised according to potential danger (minor, significant, major, critical) and type (oversight, duplication, dose error, dosage error, computer error). Time spent at each stage was measured in minutes.

**Results**

Amongst eligible patients, 1 to 2 (n = 44; 8.76%) were randomly selected daily. Average population age was 79 years (M/F = 1.38) with 9.6 ± 2.8 (median = 9) medicines prior to admission. At least one difference (ID + NID) was found in all patients (44/44). Amongst them, 29 (66%) presented at least one NID: 19/29 with 1 NID, 8/29 with 2 NID and 2/29 with 3 NID. Total NID detected was 39: major 23/39 (59%), significant 8/29 (20.5%) and minor 8/39 (20%). Moreover, 74.4% (29/39) of errors consisted of a medicines oversight, 20.5% (8/39) dosage errors, 5.1% (2/39) dose errors. MR took 36.6 min ± 12 min (median = 36) per patient. Time necessary to avoid 1 major ME was 65 min.

**Conclusion**

Finding more than half of patients with major NID demonstrated the benefits of MR. We have to find the resources to establish MRs in the Emergency unit.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

Patient safety and risk management

---

**PS-092 EVALUATION OF PATIENT SAFETY CULTURE AMONG HEALTHCARE PROFESSIONALS IN A PHARMACY DEPARTMENT**

C Toro Blanch*, M Vila Currius, L Vilas Sague, A Pérez Plasencia, I Aguilar Barcons, R Sanest Guell. Hospital Universitari Dr. Josep Trueta, Pharmacy Department, Girona, Spain

10.1136/ehjpharm-2015-000639.438

**Background**

Patient safety is an important component of healthcare quality. The Hospital Survey on Patient Safety Culture (HSOPSC) designed by the Agency for Healthcare Research and Quality is a validated tool used to assess the patient safety culture in hospitals. However, few studies have been performed exclusively in Pharmacy Departments.

**Purpose**

The aims of the study were to evaluate the patient safety culture of healthcare professionals in a Pharmacy Department, to analyse the strengths and opportunities for improvement and to compare with a multicentre study (n = 2,503) carried out in national hospitals by the Ministry of Health, Social Services and Equality in 2008.

**Material and methods**

Descriptive and cross-sectional study. The national adaptation HSOPSC was delivered to all staff of the Pharmacy Department. It included 12 dimensions related to patient safety culture, the number of events reported during last year and professional profile of the responders.

**Results**

The response rate was 70.7% (n = 28), half of whom were pharmacists (14/15) and the other 50% included technicians, pharmacy assistants, nurses and administrative staff members (14/26). The global score of patient safety culture in our service was 7.5 (on a 10-point scale) and there were no significant differences among professional profiles. 47.8% of respondents reported >2 events last year and there were significant differences between pharmacists (57.1%) and non-pharmacists (33.3%). The most highly-scoring dimension was ‘Organisational learning and continuous improvement’ (84.2%). The worst qualified was ‘Staffing’ (38.7%). In the comparative study, the global score of patient safety culture was 7 and the highest and the worst dimensions were the same (82% and 27.6%, respectively).

**Conclusion**

Patient safety culture in our department is notable and slightly higher than comparison national hospitals. The HSOPSC allowed us to detect the main strengths and opportunities for improvement in order to design patient safety strategies.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**PS-093 PHARMACEUTICAL INTERVENTION TO PREVENT METFORMIN-ASSOCIATED LACTIC ACIDOSIS IN DIABETICS ADMITTED WITH KIDNEY FAILURE**

1M Alañón Pardo*, 1M Moreno Pedrero, 1E Vila Torres, 1A Martín Sagüero, 1A Fernández Marchante, 1M Franco Seneno, 1I Benet Giménez, 1R Pérez Senario, 2A Alañón Pardo, 2E Conchas Barrios. 1Hospital General Universitario de Ciudad Real, Pharmacy Department, Ciudad Real, Spain; 2Hospital Idcsalud, Pharmacy Department, Ciudad Real, Spain

10.1136/ehjpharm-2015-000639.439

**Background**

Metformin is widely used against diabetes type II mellitus. Its most severe adverse effect is lactic acidosis. Although rare, the risk of its development can be increased by kidney failure (KF).

**Purpose**

To report on pharmaceutical interventions (PIs) for preventing metformin-associated lactic acidosis (MALA) in diabetics admitted to hospital with KF and to evaluate their degree of acceptance.

**Material and methods**

This prospective study (October 2013–March 2014) included all metformin-treated patients admitted. Creatinine clearance (CrCl) was estimated with the Cockcroft-Gault equation. PIs were: PI-1, stop-order for metformin when CrCl < 30 mL/min or CrCl = 30–45 mL/min associated with other MALA risk factors (MALA-RFs); PI-2, 50% reduction in maximum dose (2.550 mg/day) when CrCl = 30–45 mL/min with no other MALA-RF; PI-3, request for new renal function analysis when CrCl is unknown. MALA-RFs considered: kidney, liver, heart and respiratory failure, infection, alcoholism, surgery, iodine contrast. Variables recorded: sex, age, hospital department, daily dose, serum creatinine, CrCl, MALA-RFs, PI performed.

**Results**

During the study period, 234 metformin-treated patients were admitted (61.5% males), most frequently to the Cardiology Department (33.3%); mean (standard deviation) age was 71.3 (12.4) yrs; mean dose was 1,552.8 (560.7) mg/day; CrCl < 30 mL/min was recorded in 5.6% of patients, CrCl > 30–45 mL/min in 14.1%, and CrCl was unknown in 1.7%. PIs were performed in 44 patients (52.3% females, 61.4% ≥80 yrs). MALA-RFs: heart failure (34.1%), infection (34.1%), liver failure (22.7%), respiratory failure (18.2%) and surgery (4.5%). PIs performed: 38 PI-1 (34.2% when CrCl < 30 mL/min), 2 PI-2 and 4 PI-3. Acceptance was 64.8% overall, 66.7% for PI-1 (91.7% when CrCl < 30 mL/min) and 66.7% for PI-3. No PI-2s were accepted.

**Conclusion**

A small proportion of these patients had KF. A large majority of these required PI, most frequently PI-1. The degree of satisfaction was high and was especially elevated for PI-1 when CrCl was <30 mL/min.
Patient safety and risk management

REFERENCES AND/OR ACKNOWLEDGEMENTS

AEMPS

No conflict of interest.

PS-094 BISPHOSPHONATE TREATMENT AND ATYPICAL FRACTURES

E. García-Iracano, A. Martí-Lloca, C. Mateses Chirivella, F. Rodríguez-Luzena, A. Andújar Mateos, A. Martínez-Valero, J. Del Moral Sánchez, A. Navarro Ruiz. Hospital General Universitario de Elche, Pharmacy Department, Elche, Spain

10.1136/ehjpharm-2015-000639.440

Background Bisphosphonates are a safe and effective treatment for osteoporotic disease, due to decreasing bone resorption mediated by osteoclasts. However, if the treatment lasts for 2–4 years, it may increase the formation and propagation of microcracks into the bone. As a result, patients may be susceptible to suffer atypical fractures, mainly in the subtrochanteric region and femoral shaft.

Purpose To analyse and assess the prevalence of atypical femur fractures in surgical patients treated with bisphosphonates.

Material and methods Descriptive observational study in a tertiary teaching hospital with 413 beds. We reviewed every inpatient of orthopaedic surgery from February 2013 until September 2014. Data collected included age, gender, domiciliary pharmacotherapy and medical history of the episode.

Results 585 surgery inpatients were studied, of which 34 (5.8%) had long-term bisphosphonate use for osteoporosis. 27 (79.5%) were female and 7 were male patients. The median age was 77 ± 9.5 years and the median duration of treatment was 17 ± 8.5 months.

Among patients reviewed, different bones were involved: 16 (47%) of them had femur fractures and 18 (53%) had other fractures: there were 11 patients with knee fracture (32.2%), 3 (8.8%) with shoulder fracture, 2 (5.9%) with wrist fracture, and the remaining patients had vertebral fractures. The average duration of treatment in patients with atypical femur fracture was 13 ± 3.2 months.

At the time of hospital discharge, 8 (23.5%) patients who had suffered some kind of fracture continued with bisphosphonate treatment, whereas 26 (76.5%) discontinued treatment at home.

Conclusion In our study, half of the patients who have been treated with long-term bisphosphonates suffered atypical femur fracture. Bisphosphonate treatment should be evaluated periodically by the primary care physician to prevent the occurrence of atypical fractures in patients with more than 12 months’ treatment.

REFERENCE

1. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm229171.htm#.VGnQrQexRwI.email

No conflict of interest.

PS-096 DENOSUMAB-INDUCED HYPOCALCEMIA IN PATIENTS WITH METASTATIC BONE DISEASE

R. Gutiérrez Vozmediano*, A. Martínez Valero, A. Andújar Mateos, J. Jiménez Pulido, A. Murcia López, A. Navarro Ruiz, Hospital General Universitario de Elche, Pharmacy Department, Elche, Spain; 2. Hospital Universitarios de Elche, Pharmacy Department, Elche, Spain

10.1136/ehjpharm-2015-000639.442

Background Denosumab is a human monoclonal antibody used to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumours. Although antiresorptive treatment reduces the risk of SREs, it also reduces the release of calcium (Ca) from bone into the bloodstream. In September 2014, the Spanish Agency for Medicines and Health Products issued an alert for the risk of severe hypocalcaemia in patients receiving denosumab, recommending that Ca levels be monitored and adequate Ca and vitamin D supplementation be given.

Purpose To determine the prevalence of hypocalcaemia induced by denosumab.

Material and methods A retrospective review of patients undergoing treatment with denosumab from April 2013 to October
ADMISSIONS CAUSED BY IATROGENIC DISEASE IN A REFERENCE HOSPITAL

C. Gállego Muñoz*, M. Domínguez Cantero, M. Rodríguez Mateos, M. Manzano Martín. Hospital Universitario Puerta Del Mar, Pharmacy, Cádiz, Spain

10.1136/ejhpharm-2015-000639.443

Background Iatrogenic disease is an important cause of admission to hospitals in the Internal Medicine Unit. It is very important to evaluate the doses of the drugs indicated, renal and hepatic functions and possible interactions in order to avoid it.

Purpose To evaluate the prevalence of admissions for iatrogenic illness in the Internal Medicine Unit and to determine which drugs were most frequently associated with adverse events.

Material and methods Retrospective observational analysis in which we investigated patients diagnosed with iatrogenic conditions admitted to the Department of Internal Medicine during 2013. Data were collected related to the drug responsible for the adverse reaction, the severity and type, and also demographic data such as age and gender.

Results 273 patients were admitted to the Internal Medicine Unit. 29 (10.62%) of these admissions were caused by a drug. The mean age was 80.1 ± 6.3 years (55% were male). Drugs implicated and adverse reactions were: 1. Digitalis drugs (27.6%): bradycardia and heart failure. 2. Oral anticoagulants (24.1%): 4 gastrointestinal bleeds and 3 soft tissue hematomas. 3. Diuretics (13.8%): 3 hyponatremia and 1 renal failure. 4. Corticosteroids (10.3%): severe hyperglycaemia. 5. Neuroleptics (10.3%): 2 confusional syndrome and 1 hepatitis. 6. Nonsteroidal anti-inflammatories in 1 person (3.5%): renal failure. 7. Insulin (3.5%): hypoglycaemia. 8. Angiotensin converting enzyme inhibitors (3.5%): renal failure. 9. Spironolactone in 1 person (3.5%): hyperkalaemia. Two patients died (6.8% of iatrogenic patients) one by digitalis poisoning and another because of gastrointestinal bleeding.

Conclusion Drug-induced illness is an important cause of admission to our hospital. Drugs with a narrow therapeutic index such as oral anticoagulants or digoxin are the main ones responsible.
Patient safety and risk management

**Background** Drug interactions in oncology are of particular importance due to the narrow therapeutic range and inherent toxicity. The incidence of interactions increases when patients are polymedicated, which is very common in cancer patients as they often have other co-morbidities.

**Purpose** To identify potential drug–drug interactions in patients with colorectal cancer treated with fluoropyrimidines-based regimens and concomitant treatment.

**Material and methods** Retrospective study to evaluate drug interactions in patients with colorectal cancer who started chemotherapy between January and March 2014, in a central hospital, and who were also prescribed other drugs. Interactions were screened using the Lexi-Interact database between chemotherapy regimens including FOLFOX4, mFOLFOX6, FOLFIRI, capetabine and fluorouracil continuous infusion, supportive treatment for prevention of emesis (dexamethasone, ondansetron) and other prescribed treatment.

**Results** Of the patients who started fluoropyrimidines-based chemotherapy, 29 were also prescribed other drugs, the majority cardiovascular and Central Nervous System drugs. Of the 108 drugs prescribed, 20 interacted with the chemotherapeutic regimen, and accounted for 34 interactions, with an average of 1.2 interactions per prescription. According to the Lexi-Interact database 10 had risk rating C and required monitoring of side effects; 23 had risk rating D and were recommended for treatment modification or aggressive monitoring; 1 had risk rating X which required avoidance of the combination. The drugs included in the chemotherapy regimens with the highest number of interactions were dexamethasone (n = 20) and fluorouracil (n = 8).

**Conclusion** The screening of drugs for the treatment of co-morbidities was based on electronic medical records hence OTC drugs and dietary supplements were not included in this study. The identification of these drug interactions enables their inclusion in the prescription program, allowing alerts to be issued at the time of prescription.

**REFERENCE**


No conflict of interest.

**PS-101** RISK MANAGEMENT OF HBV REACTIVATION IN HAEMATOLOGICAL PATIENTS TREATED WITH RITUXIMAB

A Tristano, MJ Fabelo, S Antacho, CJ Jimenez, S Alvaro*, IM Marzano, E Gamez, Ml Guzman, C Haro. 1Hospital Universitario de Valme, Pharmacy, Seville, Spain; 2Hospital Costa Del Sol, Pharmacy, Seville, Spain

**Background** Treatment with rituximab may cause reactivation of hepatitis B virus (HBV). The incidence of drug interactions between chemotherapy and community-dispensed drugs is high in these patients. The objective of the study was to identify drug interactions in patients treated with rituximab and to establish a protocol to manage these interactions.

**Purpose** To find out if HBV serology for patients with haematological diseases treated with rituximab is routinely performed in accordance with the HBV reactivation prophylaxis protocol. According to the results, to develop a strategy to ensure compliance with the protocol.

**Material and methods** Observational, retrospective study of haematological patients who started treatment with rituximab between December 2012 and April 2014. The HBV reactivation prophylaxis protocol requires patients to be screened before starting treatment with rituximab and, depending on the serological results, the recommendations of the European Association for Study of the Liver and Asociación Española para Estudio del Hígado are to be followed. The following data were collected: date of initiation of treatment with rituximab, date and results of serology (HBsAg, anti-HBc, viral DNA).

**Results** 96 patients were included. The protocol was not followed in 24 patients (25%). Non-compliance was due to no screening for HBV in 21 patients (22%). The remaining 3 patients (3%) were anti-HBc positive and in one of them the viral load was not determined. Furthermore, none of the 3 received the recommended prophylactic treatment required because they were anti-HBc positive. We therefore propose making the proper HBV screening and monitoring of all patients treated with rituximab an essential requisite prior to the start of treatment.

**REFERENCES**

2. Reis A, Rosca N, et al. Guidelines for the prevention, diagnosis and treatment of venous thromboembolism in the medical patient

No conflict of interest.
pharmaceutical validation. This is to ensure that the serological profile of HBV is available and that preventive actions and treatments have been carried out according to the serology results.

**Conclusion**

The risk of reactivation of HBV is due to: absence of HBV serology and absence of viral DNA levels and/or recommended prophylactic treatment according to the protocol. The proposed strategy to prevent HBV reactivation is to include serological profiling as a requirement for pharmaceutical validation of those patients treated with rituximab.

**REFERENCE**

1 Hoofnagle JH. Reactivation of hepatitis B. *Hepatology* 2009;49:5156–65

No conflict of interest.

---

**PS-102 CAN THE PATIENT BRING MEDICINE TO THE HOSPITAL? – THE USE AND RISK OF BROUGHT IN MEDICINES**

1D Csontos*, 2G Sós, 1Hygésán, 2Bajcsy-Zsilinszky Hospital, Institute Pharmacy, Budapest, Hungary; 2University of Szeged, Department of Clinical Pharmacy, Szeged, Hungary

10.1136/ehjpharm-2015-000639.448

**Background**

Due to the limited selection of drugs (adjusted to the specialties of the hospital in question), hospitals are not always able to satisfy the patients’ demands for medicines, therefore the patients often bring their own medicines to the hospital. This seems to be financially beneficial for hospitals, but it is not entirely lawful and the inaccurate administration of drugs (caused by uncontrolled and sometimes hidden drug taking) leads to medicines errors.

This is a significant problem of daily practice and it is unfortunately present in all hospitals in the country.

**Purpose**

To describe the motivation and the attitudes of the stakeholders (physicians, nurses, pharmacists, patients) and their daily practice.

**Material and methods**

Pharmacists were asked to fill in an anonymous printed survey. The response rate was 93%. The attitudes of the inpatients of two wards was also compared, which differed in the average length of in-patient stay (one short-term and one long-term) by interviewing 74 patients.

**Results**

Controversial legislation leads to uncertainty. All the three surveys showed that there is no standardised practice, it follows that individual solutions are used everywhere. However – in spite of the current laws – it is still important to know about and to document the products that are taken by the treated patients.

**Conclusion**

Under current regulations the complexity of what medicines patients are really taking is not clear during the hospital treatment. The survey revealed that there is a strong need among patients and health care staff for new legislation which would clearly regulate the kinds of drugs that can be brought to the hospital, and the conditions under which they can be used.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**PS-103 PRESCRIPTION OF QUETIAPINE FROM THE PERSPECTIVE OF PATIENT SAFETY**

1MR Cantudo-Cuenca, 1AM Tristán-Ortega, 1MDC Saborido-Cansino, 1A Sánchez-Pedrosa, 1MDC González-Medina*, 2S Santos-Ramos. 1Área de Gestión Sanitaria Sur de Sevilla, UGC Farmacia, Sevilla, Spain; 2Hospital Universitario San Cecilio, UGC Intercentros Intervieles Farmacia Granada, Sevilla, Spain

10.1136/ehjpharm-2015-000639.449

**Background**

Atypical antipsychotics need a prescription check (visa), that is, a prior official authorisation of prescriptions, so as to monitor patient safety.

**Purpose**

To describe the prescription of quetiapine in a health area and compare the indications for prescribing with the indications approved on the visa summaries from the perspective of patient safety.

**Material and methods**

We conducted a descriptive observational study of the prescription of quetiapine between 15th September and 15th October 2014 in a visa unit of a health area, formed by a hospital and a primary care district.

We recorded the following variables: gender, age, medical service, indication and acceptance or rejection. Quetiapine indications allowed by the visa are: (1) schizophrenia, (2) depressive episodes associated with bipolar disorder, (3) moderate to severe manic episodes in bipolar disorder, (4) prevention of recurrence of manic or depressive episodes in patients with bipolar disorder who previously responded to quetiapine treatment, (5) add-on ongoing treatment in patients with major depressive disorder who have had sub-optimal response to treatment with other antidepressants, (6) persistent aggressiveness among elderly people with moderate to severe dementia, who have contra-indication or have not responded to other treatments (benzodiazepines, haloperidol, risperidone).

**Results**

We assessed 31 prescriptions for quetiapine (58.1% male, mean age 65 ± 19.4 years). The medical services were primary care (41.9%), mental health (32.3%) and neurology (6.5%). The main indication for quetiapine was “persistent aggressiveness with moderate to severe dementia” (32.3%), “followed by depressive episodes associated with bipolar disorder” (22.6%), “schizophrenia” (19.4%) and “moderate to severe manic episodes in bipolar disorder” (19.4%). Four prescriptions (12.9%) were not correct according to the visa, so they were rejected.

**Conclusion**

Discrepancies between the drug’s visa recommendations and real use of quetiapine commonly occur, which means added risk for the patients. The visa unit is essential to promote the safer use of atypical antipsychotics.

**REFERENCE**

1 Rev Espanol Econ Salud 2006;5:276–85

No conflict of interest.

---

**PS-104 INITIATIVE FOR IMPROVING MEDICINES SAFETY IN SURGICAL INPATIENTS**

1N Gymesí, 2G Sós*, 1M Matuz, 1B Benko, 2M Szabó, 1A Boz, 1P Doró. 1University of Szeged, Department of Clinical Pharmacy, Szeged, Hungary; 2University of Szeged, Department of Surgery, Szeged, Hungary

10.1136/ehjpharm-2015-000639.450

**Background**

We conducted a descriptive observational study of the prescription of quetiapine in a health area and compare the indications for prescribing with the indications approved on the visa summaries from the perspective of patient safety.

**Material and methods**

We conducted a descriptive observational study of the prescription of quetiapine in a health area and compare the indications for prescribing with the indications approved on the visa summaries from the perspective of patient safety.

**Purpose**

To describe the prescription of quetiapine in a health area and compare the indications for prescribing with the indications approved on the visa summaries from the perspective of patient safety.

**Material and methods**

We conducted a descriptive observational study of the prescription of quetiapine in a health area and compare the indications for prescribing with the indications approved on the visa summaries from the perspective of patient safety.
Patient safety and risk management

Background Audits of the drug prescribing process in hospitals can help to identify problematic fields in relation to drug treatment. This can increase patient safety by preventing potential medicines errors.

Purpose To quantify the frequency of drug-related problems (DRPs) and assess consequent interventions in hospitalised patients.

Material and methods The study took place in the vascular and general surgery ward over a 6-week period in 2014. Medicines recorded on patient charts were reviewed by a pharmacy resident in order to identify DRPs. DRPs of chronic medicines and those newly prescribed during the stay in hospital were assessed. Interventions were also recorded. The number of chronic medicines (i.e. including polypharmacy status: taking 26 medicines) in relation to DRPs were analysed (SPSS, T-test).

Results Medicines of 171 patients (vascular surgery: 105, general surgery: 66) were assessed. Overall 123 DRPs were identified from 89 patients. Majority (68%, 84 cases) of DRPs were related to newly prescribed medicines while the rest (32%, 39 cases) were related to chronic medicines. In case of chronic medicines the most frequent type of error (71%) was inaccuracy of product strength or recording of dosing regimen. In newly prescribed drugs the lack of daily update on patient charts was the most frequent DRP (60%). The most frequent types of intervention were clarification of dosage/dosing regimen (60 cases) and clarification of the necessity for daily dosing (50 cases). Association was found between the number of medicines and DRPs: firstly, patients with polypharmacy had significantly higher chances of DRPs (OR: 2.45, 95% CI: 1.14–5.26; p = 0.020), secondly, in the vascular surgical ward, the average number of chronic medicines per patient was significantly higher when DRPs were found (7.1 ± 4.5 vs. 8.9 ± 3.5, p = 0.03).

Conclusion We identified drug-related problems (DRPs) in every second patient. Pharmacists are able to detect and solve DRPs and prevent potential medicines errors.

REFERENCE
1 PCNE Classification of DRP V 6.2
No conflict of interest.

IMPLEMENTATION OF A UNIQUE AUTOMATION AND MANAGEMENT PLATFORM TO EXTEND PROCESS CONTROL TO ALL MEDICINAL PRODUCTS PREPARED FOR CANCER PATIENTS

Background Many publications have demonstrated that robotic automation represents a unique solution to assure absolute quality and safety of the oncologic treatment admixture process. Nevertheless, there are a small number of preparations (i.e. investigational drugs) that are currently not candidates for robotic preparation. In order to extend the total quality concept to the entire production process, we have designed and implemented an automation platform composed of: (1) a robotic system for automated admixtures (APOTECAschema); (2) a guided preparation system to support manual admixtures (APOTECAs); (3) workflow management software that manages all pharmacy production activities for both systems (APOTECAsmanager).

Purpose Here we focus the attention on APOTECAs to analyse the measurable improvements in production quality it has introduced. It is important to understand the overall impact on a pharmacy activity in relation to both error reduction and workload.

Material and methods A 4-month period of using APOTECAs was monitored in the University Hospital of Ancona (the first hospital with the entire platform). Regarding APOTECAs, the production time and errors intercepted were extrapolated from the system log file that records every single operation. Concerning the manual procedure, a third operator clocked the compounding time.

Results The number of medicines analysed was 192 with 25 active ingredients. 11 mistakes were intercepted (5.7%); 3 were associated with wrong component supplied, 4 with tolerance exceeding 10%, 3 with adjustment of amount of drug or solvent. In terms of preparation time, the mean time was 220 s and 125 s respectively for the guided and the manual preparations. The guided procedure came out 1.8 times slower than the traditional manual procedure.

Conclusion The implementation of a guided preparation system increases medicines quality and patient safety. 11 potential medicines errors were intercepted at an early stage, giving us the chance to rectify them. However, a high level of control comes with an important impact on the working time required to produce the products.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

PS-105

ADMINISTRATION MISTAKES IN CYTOSTATIC UNIT

Background The cytostatic unit is a critical area in a hospital, therefore drug-related mistakes should be analysed in order to increase safety and effectiveness in patients treated with chemotherapy.

Purpose To evaluate drug-related mistakes during transcription, preparation or administration of cytostatics.

Material and methods Prospective study, two months duration, in which every member of staff involved in the validation (pharmacists), preparation for compounding, compounding and administration of cytostatics (nurses) reported any mistake found, including category of mistake, date and who detected it.

Results 73 drug-related mistakes were recorded at the cytostatic unit: prescription mistakes (28.3%), transcription mistakes (39.3%), compounding mistakes (16.6%), pre-compounding mistakes (15.8%). Of them, 60.3% were category A, 25.1% category B, 5.1% category C and 9.5% category D. Category A was defined as circumstances or incidents able to end in a mistake, B, there was a mistake but it did not reach the patient, C, the mistake reached the patient but it did not cause any damage, and D, although it caused no damage, monitoring and/or intervention was needed.

A total of 20.6% mistakes were reported by the pharmacist, 30% by nurses in charge of compounding, 32.1% by nurses in...
charge of preparation, 5.8% by staff nurses, and 11.5% by nurses in charge of administration.

**Conclusion** It is vital to ensure a system of safe validation and be sure to avoid any mistakes that could reach the patient in the case of chemotherapy. Cytostatics have a narrow therapeutic range, so therefore minimal mistakes could end in fatal consequences.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Cytostatic unit of a tertiary hospital.

No conflict of interest.

**PS-107 REVIEW OF ABSENCE OR PRESENCE OF LACTOSE IN ORAL CYSTOSTATIC DRUGS**

MA Arias Moya*, EM Martín Gozalo, P Pelegrin Torres, M Forte Pérez-Minayo, E Castillo Bazán, FJ Bécares Martínez, M Bonilla Porras, M Hernández Segurado. Hospital Universitario Fundación Jiménez Díaz, Pharmacy, Madrid, Spain

10.1136/ejhpharm-2015-000639.453

**Background** In humans, lactase activity continues after weaning and in adulthood in about 30% of the population (lactase persistence), but in the others the lactase enzyme is absent (alactasia) or deficient (hypolactasia). It is important to be aware that lactose is often present in a wide range of medicines in higher amounts than previously suspected. It is well known that most patients with lactose intolerance can ingest up to 10–12 g without experiencing symptoms. Others consider the safety limit to be as low as 5 g. However in clinical practice, it is very common to find individuals who have symptoms of lactose intolerance after consuming only very small quantities of the sugar.

**Purpose** To discover the presence or absence of lactose in the oral cytostatic drugs most commonly used in a third level university hospital.

**Material and methods** A descriptive study. We reviewed the product information of the commonly used cytostatic drugs.

**Results** A total of 94 drugs (31 active ingredients) with different doses and manufacturers was reviewed. 48.6% of the active medicines contained lactose as excipient. The median was 84 mg lactose. The oral cytostatic with most of this excipient was Revlimid 10mg whose lactose content was 294 mg and the least was capecitabine 150 mg Accord EFG with 7 mg of lactose.

**Conclusion** The sensitivity to lactose is variable between individuals so it is important to know the degree of individual lactose intolerance and the absence or presence of it in the medicines and in what quantity.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

none

No conflict of interest.

**PS-108 STUDY OF POTENTIAL DRUG INTERACTIONS WITH ORAL ANTI NEOPLASTIC AGENTS IN AN ONCOLOGY OUTPATIENT CLINIC**

18 Mora Rodríguez, 1M Ruiz de Villegas*, 2R Tamayo Bermejo, 1M Muñoz Castillo. 1Hospital Regional de Málaga, Málaga, Spain; 2Hospital Regional de Málaga, Pharmacy, Málaga, Spain

10.1136/ejhpharm-2015-000639.454

**Background** Cancer patients are usually polymedicated, therefore one of the objectives of pharmaceutical care in cancer patients is to identify drug interactions.

**Purpose** To identify potential drug interactions with oral antineoplastic agents and risk factors in order to design a medicines reconciliation programme in an oncology outpatient clinic.

**Material and methods** The study was undertaken at an oncology outpatient clinic during July 2014 in patients taking oral antineoplastic agents. The information regarding patient demographics and drug treatments was collected retrospectively from Hospital and Outpatients records. Potential drug interactions were identified selecting clinically relevant interactions. Drug interactions were assessed by using Micromedex, the summaries of product characteristics of the oral antineoplastic agents and a published interactions guide.

**Results** 174 patients were included: median 65 years old (range: 27–84), 52% female. 41 patients (23.6%) showed 50 potential drug interactions, averaging 1.2 interactions per patient. Of this group of patients, 22 (53.6%) were male. Their age range was 34–83 years (median 64) and they received 1 to 24 concomitant drugs (median 9).

20 oral antineoplastic agents were identified in the patient records, of which 14 had potential interactions, most commonly seen in erlotinib 14 (28%), dabrafenib 6 (12%) and gefitinib 5 (10%). According to the severity the interactions found were: contra-indicated 1 (2%); severe 29 (58%). Recommendations in the literature were: avoid the drug combination, 3; adjust posology/administration, 25 and monitor, 22.

**Conclusion** A large number of patients treated with oral antineoplastic agents had potential drug interactions, especially with the new drugs. However, many of those interactions are predictable and therefore preventable.

It would be helpful to implement a medicines reconciliation programme in polymedicated oncology outpatients.

**REFERENCE**


No conflict of interest.

**PS-109 BARRIERS AND FACILITATORS TO IMPLEMENTING DRUG CHANGES CAUSED BY DRUG TENDERS AND SHORTAGES**

1R Risheøj, 1L Christrup, 2M Clemmensen*. 1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2Amgros I/S, SAFE, Copenhagen, Denmark

10.1136/ejhpharm-2015-000639.455

**Background** Drug tenders and shortages result in drug changes. International studies found that drug changes can adversely affect patient safety and the working procedures of healthcare professionals.1,2 The challenges of drug changes in Danish public hospitals have not previously been studied.

**Purpose** To identify barriers and facilitators for implementing drug changes due to drug tenders and shortages in Danish public hospitals.

**Material and methods** Six focus group interviews were conducted at three hospitals in different regions of the country. At each hospital two focus group interviews were conducted, one including physicians and nurses and one including pharmacists
and pharmacy technicians, respectively. The focus groups consisted of three to four participants. A semi-structured interview guide was applied and the interviews were audio-recorded, transcribed verbatim and categorised thematically through content analysis.

Results Barriers Identified included: frequent changes of labelling, packaging and drug names. Furthermore, implementing drug changes requires extra resources and finance. Technologies such as computerised physician order entry and barcode scanning systems were perceived as potential facilitators, but also as barriers in cases where the quality and implementation of the systems were not adequate. Facilitators included: hospital pharmacy services and lower drug prices. Furthermore recommendations on generic prescription, optimisation of the tendering process and support for drug identification during drug shortages were proposed.

Conclusion This study identified different barriers and facilitators for implementing drug changes. The barriers and facilitators included specific features related to drugs, health care technology as well as to financial and organisational aspects. Future studies should focus on removal of barriers and development and implementation of appropriate facilitators which may indeed improve patient safety and the working procedures of healthcare professionals during drug changes.

REFERENCES
1 Hakonsen H, et al, Adv Ther 2010;27:118–26
2 Fox EB, Tyler LS. Am J Health Syst Pharm 2003;60:245–53

No conflict of interest.

**Patient safety and risk management**

**PS-110**

**EXTENT AND DIVERSITY OF DAY-TO-DAY CLINICAL PHARMACISTS’ INTERVENTIONS IN HOSPITALS**

C Langebrake*, A Ihe-Heffinger, K Leichenberg, M Kunkel, S Kaden, H Hilguth, H C Hohmann, University Medical Centre Hamburg-Eppendorf, Pharmacy, Hamburg, Germany; University Medical Centre Hamburg-Eppendorf, Department of Stem Cell Transplantation, Hamburg, Germany; Klinikum Rechts Der Technischen Universität München, Department of Gynecology, Munich, Germany; Klinikum Rechts Des Isar Der Technischen Universität München, Department of Gynaecology, Munich, Germany; University Hospital Jan a, Department of Pharmacy, Jena, Germany; University Hospital Dresden, Department of Pharmacy, Dresden, Germany; University Medical Center Johannes Gutenberg-University Mainz, Department of Pharmacy, Mainz, Germany; StKlinik Heilbron Gronl, Pharmacy, Heilbronn, Germany; University Medical Centre Hamburg-Eppendorf, Department of Intensive Care Medicine, Hamburg, Germany; StKlinik Fulda gGmbH, Department of Pharmacy, Fulda, Germany

10.1136/ehjphparm-2015-000639.456

**Background** Clinical pharmacy services (CPS) are known to improve medication safety and patients’ clinical outcome. However, in the majority of the European countries their implementation is low and there are no nationwide reports about the nature of clinical pharmacists’ interventions (CPIs) in European hospitals outside the UK.

**Purpose** To evaluate both the extent and diversity of data about national hospital CPIs nationwide.

**Material and methods** Datasets from ADKA-DokuPIK, an anonymous and voluntary German database for the documentation of hospital CPIs with >500 registered users, which were entered between 01/2009 and 12/2012, were analysed descriptively.

**Results** In total, 27,610 CPIs were recorded, with an upward trend over the years. The vast majority of CPIs were performed by ward-based pharmacists (82.3%), mainly on surgical wards (37.8%), followed by anaesthesiology/ICU/IMC (16.8%) and internal medicine (10.8%). More than half of the patients were >65 years. The main reasons for CPIs were inappropriate use of drugs (including over- and underuse, inappropriate choice of drug and/or formulation, generic or therapeutic substitution) (23.2%) and wrong dose or administration interval (22.2%) resulting in the most frequently taken actions of change of dose, change of drug and drug stopped/paused. The therapeutic subgroup with most interventions was antibacterials for systemic use (13.9%) followed by antithrombotic agents (6.9%), analgesics (6.7%), drugs for acid-related disorders (5.9%) and agents acting on the renin-angiotensin system (5.4%). Altogether, the acceptance rate of the CPIs was 85.5%. Underlying medication errors were predominantly classified as “error, no harm”, while 4.1% were classified as “error, harm or death” according to NCC-MERP.

**Conclusion** For the first time we demonstrated clinical pharmacists’ involvement nationwide in daily clinical practice in a non-UK European country. Although the overall rate of CPIs cannot be calculated due to the anonymous and voluntary data collection, the results might help to further strengthen the demand for CPS in Germany.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Thanks to all ADKA-DokuPIK users.

No conflict of interest.
omission. VTE risk assessments were completed in all patients within 24 h.

**Conclusion** Prescribing pharmacists and pharmacy technicians have a pivotal role in completing medicines reconciliation within 24 h and prescribing regular medicines to ensure patients do not miss doses, reducing the risk of post-surgery complications. Early completion of VTE risk assessments and the prescription of appropriate thromboprophylaxis should also reduce post-op complications.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Cohort of prescribing pharmacists and pharmacy technicians who all cover TAU.

All other healthcare members of TAU.

No conflict of interest.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

**PS-112 PHARMACEUTICAL ANALYSIS OF ASSISTANCE ON RECONCILIATION OF PAEDIATRIC MEDICINES**

1Raich Montu*, 2Rudi Silva, 3M De Castro Julve, 4G Silva Ruidigos, 5MO Gorgas Tomer.

1Corporación Sanitaria Parc Taulí, Pharmacy, Sabadell, Spain; 2Corporación Sanitaria Parc Taulí, Hospital Pharmacist, Sabadell, Spain

10.1136/ehjpharm-2015-000639.458

**Background** Medicines reconciliation is one of the strategies used to minimise drug-related adverse effects.  

**Purpose** To detect and analyse potential medicines errors in a paediatric population at the time of admission.

**Material and methods** From May to July 2013 the daily admissions of paediatric patients were reviewed. Only patients who had already been prescribed medicines were selected. We reviewed patients who had previously received treatment appropriate to their current condition as well as drugs prescribed because of an acute illness. Some prescriptions were verified by clinical interviews. Differences were categorised into no discrepancies or discrepancies and these last into justified or unjustified.

The unjustified were defined as drug omissions or drug interactions detected and were communicated to paediatricians.

Data collection was classified by age, sex, and medicine (dose and route of administration).

The time was noted when discrepancies were detected and the gravity measured in a scale from 1 to 3, representing the impact to the patient.

An exclusion criterion was hospitalisation for less than 24 h.

**Results** 30 patients were analysed, 18 boys and 12 girls, mean age 8.6 years. A total of 47 medical prescriptions were reviewed. Clinical interviews were held with 11 patients. Of 47 prescriptions, 11 (23.4%) were categorised as no discrepancies, 17 (36.1%) as justified discrepancies and 19 (40.4%) as unjustified discrepancies. Of these 19 unjustified discrepancies, 18 resulted from drug omissions and 1 drug interaction was detected. 11 (57%) of unjustified discrepancies were communicated to the paediatricians and a change in the medical prescription was requested.

Antimicrobials and inhaled treatments were the most common drugs omitted. Almost all of them were detected on the first day. The mean gravity was 2.4.

**Conclusion** From a total of 47 medical prescriptions, 11 (23.4%) potential medicines errors were avoided. We believe pharmaceutical care focused on medicines reconciliation is an important tool to optimise paediatric medical prescriptions.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Multidisciplinary team

No conflict of interest.
Patient safety and risk management

Background Cancer patients receiving chemotherapy may be at risk of drug interactions between antineoplastic agents and drugs prescribed in primary care, which can lead to an increase in the number and severity of adverse drug events or a reduction in treatment effectiveness.

Purpose To assess the incidence of potential interactions between chemotherapy drugs prescribed by oncologists in hospital care and any other drugs prescribed by general practitioners in primary care.

Material and methods Retrospective and observational study. Patients diagnosed with any type of cancer between 1st May and 30th September 2014 who received oral and intravenous chemotherapy were included. Data were obtained from two computerised order entry systems: Oncowin (hospital setting) and electronic medical history (Primary Care setting). Potential interactions were checked with Micromedex 2.0: minor (limited clinical effects), moderate (interaction may exacerbate the patient’s condition and/or require an alteration of treatment) and major (can lead to hospitalisation/death).

Results 340 patients. Median age 66 years old (28–89) [51.2% >65 years old, 39.1% 45–65 years old and 9.7% <45 years old]. 54.5% men. 1,634 revised drugs, 4.8 drugs/patient (13.8% of patients did not take medicine at home). Potential interactions detected: 67 in 49 different patients (14.4% of patients studied); 1.5% minor interactions, 22.4% moderate and 76.1% major interactions. Interactions detected were more frequent in metastatic setting (52.2%): 85.7% major and 14.3% moderate, followed by adjuvant treatment (19.4%) and neoadjuvant treatment (10.4%). Interactions were most frequent with erlotinib, plicatixal, pemetrexed, methotrexate, capcitabine and pazopanib as cytostatic drugs and omeprazole, simvastatin, dextetoaprofen and acetylsalicylic acid as usual drugs. Highest frequency of severe interactions was between erlotinib with proton pump inhibitors and NSAIDS (11.8% each).

Conclusion The vast majority of potential drug interactions are major and could be reduced by encouraging communication between the pharmacist, oncologist and primary care doctor.

REFERENCE


No conflict of interest.

PS-115

ADVERSE DRUG EVENTS REQUIRING INTENSIVE CARE UNIT ADMISSIONS: THE ROLE OF NON-COMPLIANCE WITH TAKING PRESCRIBED MEDICINES

Jolivot*, C. Pichereau, B. Guidet, C. Hejblum, C. Fernandez, P. Hindlet. *Saint Antoine Hospital, AP-HP, Pharmacy, Paris, France; ‡Saint Antoine Hospital, AP-HP, Intensive Care Unit, Paris, France; †INSERM, UMR_S 1136 – Institut Pierre Louis d’Épidémiologie Et de Santé Publique, Paris, France

10.1136/ejhpharm-2015-000639.461

Background Adverse drug events (ADEs) are defined as any injury from a medical intervention related to a drug including non-compliance. ADEs can even be responsible for intensive care unit (ICU) admissions.

Purpose To assess the incidence of ADEs leading to ICU admission.

Material and methods This observational study lasted one year in an adult medical ICU of a university hospital. All ICU stays were screened by two independent investigators to determine if an ADE could have been responsible for the ICU admission. The ADE preventability was independently assessed using a Schumock and Thornton scale. A main leading cause was identified for each preventable ADE-related stay.

Results During the study period, 743 ICU stays were included. Of these stays, 173 (23.3%) were related to an ADE. Preventability rate was 59% (102 stays) with an excellent inter-rate reliability (kappa-test = 0.98). The main leading cause of preventable ADEs was not taking a medicine (non-compliance) in 30% of ADE-related admissions and 4% of all admissions (31 stays). Drugs related to non-compliance problems were curative in 81% (25 patients) and prophylactic in 19% (6 patients). They were related to the following diseases: diabetes 32% (10 patients), epilepsy 19% (6 patients), infections 19% (6 patients), chronic heart failure 16% (5 patients) and other diseases 14% (4 patients). Reasons for non-compliance were investigated: misunderstanding 32% (10 patients), uncontrolled psychiatric disorders 32% (10 patients), refusal of treatment 27% (8 patients), cognitive disorders 6% (2 patients) and memory lapse 3% (1 patient).

Conclusion To our knowledge, this is the first study to investigate ADEs as a cause of ICU admission that includes non-compliance problems, which appeared to be the major cause of ADE-related ICU admissions. Non-compliance analysis can be used to plan corrective measures such as patient education and social and psychiatric care.

REFERENCES AND/OR ACKNOWLEDGEMENTS

NA

No conflict of interest.

PS-116

EXPOSURE TO ANTICHOLINERGIC AND SEDATIVE DRUGS: RELATIONSHIP BETWEEN DRUG BURDEN INDEX (DBI), ANTICHOLINERGIC RISK SCALES (ARS) AND FALLS IN ELDERLY HOSPITALISED PATIENTS

Jean-Bart*, C. Tetu, C. Mouchoux. Charpennes Hospital Center Hospices Civils de Lyon, Pharmacy, Villeurbanne, France

10.1136/ejhpharm-2015-000639.462

Background Falls have a major impact on public health for elderly. Some scores and scales assess the risk of falls or iatrogenic risk. Few are specific to assess the impact or relationship between drug exposure and falls in elderly.

Purpose Our objective was to evaluate relationship between iatrogenic scores, DBI, ARS and fall risk.

Material and methods A multicenter retrospective study was performed in 5 geriatric hospitals. For faller and nonfaller hospitalised elderly, characteristics, comorbidities and drugs prescriptions were collected. DBI and ARS scores were calculated. Relationship between scores and falls were assessed. Description of drugs classes involved in scores was performed.

Results A total of 313 patients, with a mean age of 87 years, were included, 117 of them were fallers. History of fall within 12 months (OR = 6.5 [3.9 – 10.1]), orthostatic hypotension (OR = 4.3 [2.3 to 7.9]), blurred vision (OR = 1.8 [1.1–2.8]), Mini Mental State Evaluation <20/30 (OR = 2.1 [1.3 to 3.4]), and antidepressant prescription (OR = 1.7 [1.05 to 2.8]) were significantly associated with a fall risk. Within this population, 61% of patients had DBI > 0 and 21% ARS ≥ 3. The drugs that contributed to DBI were respectively among fallers and non-fallers: benzodiazepines (16.2% [19/117]/20.2% [40/198]) and

PS-117
opioids (6.0% (7/117)/14.1% (28/198)). For ARS, these classes were, benzodiazepines (8.6% (10/117)/6.6% (13/198)) and antidepressants (5.1% (6/117)/7.6% (15/198)). Statistical analysis didn’t show any relationship between DBI > 0 or ARS > 0 and fall risk (p > 0.05).

Conclusion Results showed that because of multifactorial characteristic of fall, predicting its risk should be based on a set of factors, directly related or not with patient, with or without drug prescriptions. A specific iatrogenic score, routinely used to identify prescription and fall risk patients would help clinicians and pharmacists to optimise therapeutic for elderly.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PS-117 DATA QUALITY ANALYSIS OF ADVERSE DRUG EVENTS IN A VOLUNTARY REPORTING SYSTEM

M Aznar Saliente*, L Roca Aznar, P Herrera Robles, M Bonete Sánchez, L Pons Martínez, S Ruiz Darbonnens. Hospital Universitario de Sant Joan, Pharmacy, Alicante, Spain

10.1136/ehjpharm-2015-000639.463

Background In 2009, SINEA, a voluntary reporting system for adverse events (AEs) in healthcare was implemented, designed for direct online reporting. It cannot ensure the consistency of the information, nor the quality of the reports.

Purpose To determine the number and type of errors found in the SINEA database reports of drug adverse events (DAE); to propose improvements to reduce them and to note the differences in the results of the raw and refined databases, in order to skip the refining process if possible.

Material and methods AEs reported between 1 January 2014 and 30 August 2014 were extracted and revised by a pharmacist to refine the database considering the field “describe_what_happened” as the gold standard. Percent of medicines errors (MEs), adverse drug reactions (ADRs), potential (PME) and real (RME) medicines errors, description of the effect on the patient, the impact on assistance and the most frequently reported drugs (MFD) were compared in both raw and refined databases. Cohen’s kappa (k) statistic defining concordance was calculated.

Results 364 AEs were reported, of which 66.7% were classified as MEs, 27.9% as ADRs (2 wrongly classified as both, thus total percent > 100) and 31% as other events. After refining, MEs totalled 69.5%; ADRs, 5.8% and events not related to medicines, 24.7% (k = 0.85 CI95% [0.80–0.90]). Before refining, 73.6% of MEs were considered PME versus 82.3% after refining (k = 0.65 CI95% [0.54–0.76]). With refined data, the MFD was trasftuzumab (20.9%), due to exhaustive notification in oncology (all PMEs). The “active Ingredient” field was empty in 133 reports in the raw database. A mean of 1.8 ± 1.9 errors per report were detected.

Conclusion Although concordance is good, the tough refining process cannot be skipped as it provides quality information so that improvements in pharmacotherapy can be implemented. Data quality could be improved by reducing the number of type-in text fields and using checkboxes or drop-down lists and by increasing the staff’s knowledge of DAEs.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PS-118 COMPARATIVE ANALYSIS OF THE SAFETY IN CLINICAL PRACTICE OF BOCEPREVIR AND TELAPREVIR IN THE TREATMENT OF HEPATITIS C


10.1136/ehjpharm-2015-000639.464

Background Telaprevir and boceprevir have revolutionised the treatment of chronic hepatitis C. We are currently starting to have evidence of effectiveness and safety in clinical practice. Making a direct comparison of safety between the two drugs will allow a better understanding of their toxicity profile.

Purpose To compare the safety of peginterferon, ribavirin and telaprevir against boceprevir combination treatment in clinical practice.

Material and methods Retrospective observational study (01–01–2012 to 01–06–2014) of patients with HCV genotype-1 who had completed the combined treatment with telaprevir or boceprevir. Variables were collected to characterise patients and treatment.

Toxicity was graded according to the Division of AIDS v.1.0 criteria. Grades 1 and 2 were defined as mild-moderate toxicity, and grades 3 and 4 as severe toxicity. A descriptive and comparative statistical analysis was performed using SPSS v.15.0.

Results 164 patients were included: 65.2% treated with telaprevir and 34.8% with boceprevir. Increased neutropenia for boceprevir (77.2% vs. 45.8% p < 0.001) and greater hyperbilirubinemia (35.5% vs. 8.8% p < 0.001) and hyperuricaemia (48.6% vs. 8.8% p < 0.001) for telaprevir. Toxicity grades: G1-G2 greater neutropenia (47.4% vs. 30.8% p = 0.028) for boceprevir. With more hyperuricaemia telaprevir G1-G2 (43.9% vs. 8.8% p < 0.001) and higher hyperbilirubinemia both G1-G2 (22.4% vs. 8.8% p = 0.021) and G3-G4 (13.1% vs. 0%, p = 0.002). Further adjustment of ribavirin dose (73.7% vs. 46.7% p = 0.001), hospital admissions (21.1% vs. 8.4% p = 0.021) and use of colony stimulating factors (8.8% vs. 0.9% p = 0.20) with boceprevir.

No differences in discontinuation of treatment (8.7% boceprevir vs. 7.4% telaprevir p = 0.369), blood transfusions (16.8% telaprevir vs. 15.8% boceprevir p = 0.526) and use of exogenous erythropoietin (42.1% telaprevir vs. 29.9% boceprevir p = 0.082).

Conclusion Different toxicity profiles were observed, highlighting a higher ribavirin dose adjustment and hospital admission with boceprevir treatment. Furthermore, incidence of neutropenia was higher with boceprevir, and hyperbilirubinemia and hyperuricaemia with telaprevir.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PS-119 EFFECT OF ANTICOAGULATION AND ANTIPLATELET THERAPY ON THE INCIDENCE OF INTRACRANIAL BLEEDING AFTER THROMBOLYSIS IN PATIENTS WITH ACUTE ISCHAEMIC STROKE – A PHARMACOEPIDEMILOGICAL APPROACH

1. Horváth*, 2. Fekete, 3. Márton, 4. Fekete. University of Debrecen, Medical Centre, Central Pharmacy, Debrecen, Hungary; 1 University of Debrecen, Medical Centre, Department of Neurology, Debrecen, Hungary; 1 University of Debrecen, Faculty of Art, Institute of Political Science and Sociology, Debrecen, Hungary

10.1136/ehjpharm-2015-000639.465

Background Anticoagulation and antiplatelet therapy are commonly used in patients with acute ischaemic stroke. However, the risk of intracranial bleeding after thrombolysis is not well known.

Purpose To investigate the effect of anticoagulation and antiplatelet therapy on the incidence of intracranial bleeding after thrombolysis in patients with acute ischaemic stroke.

Material and methods A prospective cohort study of patients with acute ischaemic stroke treated with thrombolysis who were on anticoagulation and antiplatelet therapy was conducted.

Results The incidence of intracranial bleeding was significantly higher in patients on anticoagulation and antiplatelet therapy compared to those not on such therapy (p = 0.001).

Conclusion Anticoagulation and antiplatelet therapy increase the risk of intracranial bleeding after thrombolysis in patients with acute ischaemic stroke.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
**Background** The rt-PA is an effective therapy in patients with acute ischaemic stroke. Well known complication of the treatment is intracranial bleeding (haemorrhagic transformation, or parenchymal haemorrhage) which can hinder the improvement and can be lethal.

**Purpose** Identifying the effect of anticoagulants and antiplatelet drugs, taken before the stroke, on the intracranial haemorrhage rate after rt-PA treatment.

**Material and methods** The Debrecen Thrombolysis Database was used. Between the 1st of January 2004 and the 31st of December 2010, 415 patients were treated with rt-PA at the Department of Neurology, University of Debrecen. For the analysis 370 patients’ data was used, who fulfilled the protocol. Odds ratio (OR) and Relative risk (RR) were calculated.

**Results**

Comparing groups A and C: OR<sub>anticoagulants</sub> = 1.48; 95% CI = 0.64–3.43; p = 0.338 and RR<sub>anticoagulants</sub> = 1.386; 95% CI = 0.70–2.73; p = 0.346 are in the group which was pre-treated with anticoagulants. Among antiplatelet drugs users (B versus C) OR<sub>antiplatelet drugs</sub> = 0.61; 95% CI = 0.17–2.1; p = 0.437 and RR<sub>antiplatelet drugs</sub> = 0.649; 95% CI = 0.21–1.97; p = 0.447 were found. If those taking anticoagulants and antiplatelet drugs were compared (A vs. B) OR<sub>anticoagulants/antiplatelet drugs</sub> = 2.41; 95% CI = 0.58–9.98; p = 0.223 and RR<sub>anticoagulants/antiplatelet drugs</sub> = 2.13; 95% CI = 0.61–7.39; p = 0.232.

**Conclusion** There was a non-significant trend that may suggest that antiplatelet therapy before stroke reduces the risk of intracranial bleeding, anticoagulant therapy increases it despite the acceptable INR level. Findings have to be confirmed on larger patient population.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**PS-121**

**MODEL FOR ADVISING ON INTERACTIONS AND ADVERSE REACTIONS OF TYROSINE KINASE INHIBITOR TREATMENT**

1R Gazquez Perez, 2A García Borrella, 2R Gavira Moreno*, 1J Sierra Sanchez, 1V Gonzalez Rosa, 1F Gomez De Rueda, 1L Jimenez Pichardo, 1PGomez Germa, 1MGomez De Travecedo Y Calvo, 1M Almendral Vicente. 2Hospital Sas Jerez de La Frontera, Pharmacy, Jerez de La Frontera, Spain; 3Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain

10.1136/ehjpharma-2015-000639.467

**Background** Tyrosine Kinase Inhibitors (TKIs) are drugs that cause significant adverse reactions and interactions in patients. Prescription and dispensing of TKIs both take place in Hospital Pharmacies. Primary Care physicians (PCPs) do not have very much information about either these drugs or patients on TKI treatment.

**Purpose** To describe a model for giving advice with recommendations about interactions and adverse reactions of TKIs, to provide support and information for PC physicians.

**Material and methods** Patients on TKI treatment were identified by the APD-ATHOS Prisma and Oncofarm software. The databases were searched for adverse reactions and interactions due to TKIs, together with their management. We selected the most common adverse reactions and interactions, including those that treatment to drugs that are listed in the hospital formulary. Only limited data are available regarding the quality of those automatic switches in clinical practice.

**Material and methods** A classification model with 13 categories and a six-item scale was developed to determine the quality of switches from home to hospital medicines. This model was applied to 250 drugs and three different CDSS, implemented in three university hospitals. Electronic switches were compared to manual switches by two experienced clinical pharmacists for each hospital. The functionalities of the systems were assessed by a questionnaire.

**Results** The type of switch differed significantly within the three hospitals: same drug: 27–36%, generic substitution: 48–62%, therapeutic substitution (TS): 4–12%, special order (SO): 3–13%. Although the majority of switches was conducted correctly in our setting, the quality ranking of the switch differed significantly, especially in case of TS and SO, although the numbers of those switches were low. Incorrect and/or incomplete switches were caused either by missing alternatives in the hospital formulary and/or limited functionality of the software in terms of customisation.

In theory, all types of switches were possible with each system; however, the algorithms and the covariates considered with which to suggest an appropriate drug were different. Each system had different functionalities with no system scored highly in all aspects.

**Conclusion** The assessment of switch quality seems to depend on the diversity of the hospital formulary and on the ability to implement hospital-specific policies. In future, if the selection of drugs used to test the feasibility of electronic systems were narrowed to TS switches, potential limitations of such systems could be assessed more thoroughly.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**PS-120**

**CHALLENGES IN EVALUATION OF ELECTRONIC SWITCH MODULES FOR HOME MEDICATION**

1C Langebrake*, 2M Hug, 3K Green, 4M Tanja, 1C Sommer, 4HM Seidling. 1University Medical Centre Hamburg-Eppendorf, Pharmacy, Hamburg, Germany; 2University Medical Centre Freiburg, Pharmacy, Freiburg, Germany; 3University Hospital Heidelberg, Pharmacy, Heidelberg, Germany; 4University Hospital Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany

10.1136/ehjpharma-2015-000639.466

**Background** Most clinical decision support systems (CDSS) offer the opportunity to automatically switch patients’ home drug
could cause the patients to consult their general practitioner. Then, we made a document with all the information and PC pharmacists established a link between this document and the Electronic Clinical History of each patient to enable GPs to identify patients who were on TKI treatment and also recommendations about their management.

Results 44 patients were identified (37 with imatinib, 4 with dasatinib and 3 with nilotinib). 29 adverse reactions were found (9 common to all 3 TKIs, plus 8 with dasatinib, 8 with nilotinib and 4 with imatinib). Interactions were classified into: drugs that increase or reduce the effects of TKIs and drugs whose effects and toxicity are increased or decreased by TKIs. The most significant interactions were: imatinib-sinvastatin, imatinib-aceataminophen, imatinib-ibuprofen; nilotinib/dasatinib-proton pump inhibitors, nilotinib/dasatinib-histamine-2 receptor antagonists, nilotinib/dasatinib-drugs that prolong the QT interval, nilotinib/ dasatinib-oral anticoagulants and dasatinib-food.

Conclusion The way of giving advice should help GPs to identify and manage frequent adverse reactions and interactions of TKIs. This process will be repeated for other oral anti-cancer drugs. Further studies are necessary to confirm the usefulness of this tool.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
Improving the prescription of benzodiazepines in an elderly population

C Campabadell Prats,1 J Serrais Benavente,2 M Balaguer Rovira,1 D Fernandez Martí,1 C Salom Garrigues,1 R Pares Martímon,1 Y Cosio Gil,1 A Perello Junca.1 Hospital Igualada, Pharmacy, Igualada, Spain; 2Fundación Sanitaria Sant Josep, Doctor, Igualada, Spain; 3Hospital Igualada, Epidemiology, Igualada, Spain

Background Benzodiazepines (BZP) in the elderly often have pharmacokinetic changes that could represent a potential risk of adverse effects. It is therefore recommended to avoid them or to reduce their usage time, if possible.

Purpose To evaluate the effect of an intervention on the use of BZP in patients admitted to a nursing home.

Material and methods A team composed of a nurse, a doctor and a pharmacist evaluated the drug treatment of the new admissions to one nursing home, trying to adjust the prescriptions and decrease the risk of adverse effects, according to the patient's condition.

Descriptive comparative study before and after an intervention, in patients admitted to a nursing home over 22 months (2013–2014).

The number of BZP taken by the patients was evaluated at admission (pre-intervention period) and at discharge (post-intervention period). The percentages were compared using the χ² test.

Results Two hundred patients were included.

In the pre-intervention period, 51% were taking BZP (36% were taking one kind of BZP, 5% two, and 1.5% three), 22.5% were long half-life.

At discharge 42% were still taking BZP (40% were taking one kind of BZP, 2% two and no patients were taking three), only 11.9% were long half-life (a reduction of 47% p = 0.008).

Conclusion The intervention of this multidisciplinary group reduced the percentage of patients taking BZP discretely, however an significant reduction in combinations of BZP was achieved and especially in the long half-life benzodiazepines, which are the most risky.

References and/or acknowledgements

Hospital d'Igualada
Fundació sanitaria sant josep

No conflict of interest.

Electronic alert system for primary care doctors from a medicines reconciliation application

E Campos-Davila,1 J Campabadell,1 J Raigozo,2 JU Ramos-Baez,1 D Guerra Estévez,1 E Márquez-Fernández.2 Hospital Sas La Linea, Pharmacy, La Linea de La Concepcion, Spain; 2Campos de Gibraltar HealthCare Area, Pharmacy, Algeciras, Spain

Background Our Healthcare Area is implementing Medicines Reconciliation (MedRec) supported by The European Union Network for Patient Safety and Quality of Care. In a situation of limited human resources, computerised MedRec tools could help introduce medicines reconciliation.

Purpose To describe a MedRec application that generates electronic alerts for general practitioners (GP) when patients are discharged from the Hospital with reconciliation errors (RE), and its impact in Primary Care after 3 months of implementation.

Material and methods We have developed an application that can be integrated into the patient’s electronic medical records. The Application records the discrepancies (intentional/unintentional) of every MedRec Form made at admission or discharge and, at pharmacist demand, generates an electronic alert for the GP when a patient goes home with RE unsolved prior to hospital discharge (discrepancies between prescription at discharge and the active electronic prescriptions which allow regular pharmacy dispensing). In this retrospective observational study we measured REs and their severity at discharge, and the percentage of MedRec responded to by the GP after the alert was sent (considered correct if done before 5 days post-discharge). Data were analysed using SPSS.

Results 46 reconciliation errors were found in a total of 63 patients (0.73 per patient) evaluated. Eight (17.4%) REs were considered highly relevant. All REs were found in 34 patients (54%), the other 29 patients being properly reconciled at discharge. From the 34 alerts generated for the corresponding GP, only 15 (44%) were acted upon and the patient’s medicines reconciled in less than 5 days. Five (62.5%) of the highly relevant REs were amended in less than 5 days post-discharge.

Conclusion Less than a half of the alerts sent by the MedRec application were acted upon in a reasonable time. This means, although it can help in decreasing medicines errors in Primary Care, more time/training is needed for the GPs become more familiar with the tool.

References and/or acknowledgements

No conflict of interest.

The rational use of proton pump inhibitors in a geriatric centre

L Roig-Tutés*,1 I Gómez-Sayago,1 L García López,1 P Hidalgo-Colina,1 M Criado Illana.2 Hospital General de Segovia, Hospital Pharmacy, Segovia, Spain

Background The kind of patients we can find in a geriatric centre have various comorbidities, which implies that they usually have more than one medicine. It is common to have drug interactions.

Purpose To evaluate the rational use of proton pump inhibitors (PPIs) in a geriatric centre with 300 beds attached to a second-level hospital.

Material and methods We performed a cross descriptive study in all patients of a geriatric centre with PPI treatment in July 2014.

Medical histories were reviewed and a database was designed: PPI, drug dose, diagnosis and concomitant NSAID treatment.

PPI criteria for use were based on the current evidence available. Esomeprazole was limited to patients with a nasogastric tube, as it’s the only one that can be administered in this way.

Omeprazole was prescribed in 197 patients: 39% (77/197) had a gastrointestinal diagnosis and 61% (120/197) had no indication recorded, of which 57.5% (69/120) were on chronic NSAID treatment. Drug dosages were: 52.3% (103/197) 20 mg/24 h, 20 mg/12 h in 46.7% (92/197) and 0.5% (1/197) with 20 mg/8 h or 40 mg/8 h.
The 42.5% (51/120) of patients whose treatment indication was unknown were re-evaluated: In 19.6% (10/51) the drug was suspended, in 38.8% (30/51) doses were changed to 20 mg/24 h. The remaining 21.6% (11%) patients were not changed without a clear medical reason.

Esomeprazole was prescribed in 45 patients: 24% (11/45) had digestive diseases and 76% (34/45) had no indication recorded, of whom 61.7% (21/34) were on chronic NSAID treatment. Drug doses were: 66.7% (30/45) 20 mg/24 h and 40 mg/24 h in 33.3% (15/45).

The 38.2% (34/84) patients whose treatment indication was unknown were re-evaluated: in 69.2% (9/13) the drug was suspended, 30.8% (4/13) were switched to omeprazole 20 mg/24 h.

Only 28.9% (15/43) were carriers of a nasogastric tube.

Conclusion Inappropriate use of PPIs was observed in terms of indication and drug dose.

Prophylaxis of gastropathy in patients on NSAIDs was the most common correct indication.

It is important to incorporate clinical pharmacists in geriatric centre teams to ensure and promote the rational use of medicines.

REFERENCE
1 http://dx.doi.org/10.4321/S1130-01082008000200003

No conflict of interest.

Background Tocilizumab has been associated with an increase in transaminase levels which may be related to treatment discontinuation.

Purpose To examine changes of transaminase levels (AST/ALT) in patients with rheumatic diseases treated with tocilizumab, as well as analyse the checking interventions.

Material and methods Retrospective observational study. Patients on treatment with tocilizumab between January 2007 and July 2014 were included. The data collected were: demographic, diagnosis, duration and dosage pattern of treatment, AST/ALT levels and concomitant treatment with methotrexate. The data were collected through outpatient electronic medical records.

Results We included 21 patients (86% male, 45.6 ± 13.8 years). 71% of patients had rheumatoid arthritis. The mean duration was 24.4 ± 15.8 months. After the start of treatment with tocilizumab, 52% patients had values above the upper limit of normality (ULN, ALT > 50 U/L and AST > 40 U/L); 36% of them received methotrexate. In 9 patients (82%) the results reached values 1–3 times >ULN and in 2 patients (18%) values were observed 3–5 times >ULN. In 64% of patients the levels remained >ULN during treatment. Higher ALT/AST levels occurred in two patients who received doses of 8 mg/kg of tocilizumab. One of them was also on methotrexate treatment.

The increase of AST/ALT levels occurred in 73% of patients between the first and third doses of treatment. In 3 patients a pharmacological intervention was made. The interventions were to decrease the tocilizumab dose (2 patients) and to decrease both the dose of tocilizumab and methotrexate. Two of them succeeded in normalising AST/ALT levels.

Conclusion Half of the patients treated with tocilizumab suffer an increase in AST/ALT levels, which in most cases is maintained over time. Concomitant treatment with methotrexate seems to predispose to an earlier increase of transaminase levels.

Tocilizumab risk management should include continuous monitoring of transaminase levels so as to identify patients with a higher risk.

REFERENCES
1 Rheumatology (Oxford) 2012;51(Suppl 5):38–47
2 Reumatol Clin 2014;10(2):94–100
3 Adherencia Paciente Preferio 2013;7:653–66

No conflict of interest.

Background Transplantation-associated thrombotic microangiopathy (TMA) is a feared complication of allogeneic hematopoietic stem cell transplantation (HSCT) owing to its high rate of mortality. The use of calcineurin inhibitors or sirolimus for graft-versus-host disease (GVHD) prophylaxis has been suggested as a potential risk factor.

Purpose To analyse the incidence of TMA in patients undergoing HSCT who received ciclosporin as prophylaxis against GVHD; to investigate the cause of this phenomenon.

Material and methods Retrospective observational study that reviewed the medical records of patients who had suffered from TMA after allogeneic HSCT in the haematology service of a tertiary hospital from 2010 to 2014. To obtain the results, the diagnostic criteria associating TMA with the bone marrow transplant of the International Working Group were measured.

Results Of the 50 patients undergoing allogeneic HSCT, 10 suffered ciclosporin-associated TMA. In 4 TMA emerged with the addition of ciclosporin to sirolimus and in 6 when sirolimus was added to ciclosporin. The reason for the addition of these immunosuppressants was acute GVHD in 3 patients and in 7 due to chronic GVHD. The response to TMA was to suspend ciclosporin and maintain sirolimus and corticosteroids in 4 patients whereas in 6 both ciclosporin and sirolimus were suspended. In 4 patients phenytoin was added, in 2 haemodialysis was performed, in 3 plasmapheresis was done and in 1 rituximab was administered. In all the cases the duration of active levels of basal ciclosporin after it had been suspended was about two or four months.

Conclusion The appearance of TMA in patients undergoing allogeneic HSCT is a concern. All cases present moderate to severe haemolytic anaemia, negative direct Coombs, thrombocytopenia, elevated LDH and creatinine, schistocytes >4% and kidney disorders. The cause of the sustained increase in the time of ciclosporin levels is still unknown, it is thought that an ABCB1 genetic polymorphism can produce this phenomenon.
REFERENCES AND/OR ACKNOWLEDGEMENTS
Pharmacogenetics
No conflict of interest.

PS-129 MERCURY TOXICITY AND TREATMENT WITH DIMAVAL
C Martínez-Mugica Barbosa, A Rodríguez Palomo, FJ Álvarez Manceví, FC Cosío Carbajo, A Llorente Romeo, AMartínez Torron, E Lazaro Lopez. Hospital Universitario Central de Asturias, Pharmacy, Oviedo, Spain
10.1136/ejhpharm-2015-000639.476

Background Mercury is a heavy metal with known toxicity. Its toxic effects have been well investigated, and the treatment consists of removing the patient from the source of exposure, supportive care, and chelation treatment.

Purpose To describe our experience treating mercury toxicity with DMPS (2,3-dimercaptopropane-1-sulfonate) and supportive care in a group of workers exposed occupationally to metallic mercury vapour.

Material and methods Blood chemistry data were collected for each patient, as well as urinary analysis, physical examinations and patients’ complaints. Symptomatic treatments and chelator required were monitored. In order to assess DMPS efficacy, a follow-up of symptoms and blood and urinary mercury levels was performed.

Results A total of 14 workers, all males, aged 28 to 51 years, who had been exposed occupationally to mercury vapour were included. They all received symptomatic treatment and mercury mobilising agents. DMPS treatment was started 4 to 7 months after exposure to the metal and consisted of the p.o. administration of 100 mg per day as three divided doses for 7 days. 6 patients in total required a second cycle of treatment. Symptoms observed were similar in all the patients, and consisted of modest alterations in mood (anxiety, insomnia and occasional headaches) treated with non-steroidal anti-inflammatory drugs, cardiovascu-
lar signs, respiratory symptoms and gastrointestinal alterations such as nausea and diarrhoea treated with proton pump inhibitors and antiemetic drugs. During DMPS treatment, one patient presented a skin rash. The highest mercury blood and urinary level reached were 857 mcg/L and 1,830.47 mcg/L respectively.

No conflict of interest.

OHP-002 HEALTH PROFESSIONAL PARTICIPATION IN MOBILE APPLICATIONS RELATED TO MULTIPLE SCLEROSIS
1C Martínez-Cuenca, 2MC Martínez-Cuenca, 3MDG González-Medina, 4CG Gómez-Peña, 5MG Guzmán-Ramón, 6R Morell Verdu, 7Área de Gestión Sanitaria Sur de Sevilla, UGC Farmacia, Sevilla, Spain; 8Hospital San Juan de Dios, Farmacia, Sevilla, Spain; 9Hospital Universitario San Cecilio, UGC Intercentros Intensivos Farmacia Granada, Granada, Spain
10.1136/ejhpharm-2015-000639.477

Background Smartphone applications have been increased efficiency within health practice. However, recent concerns regarding quality of content and regulation have been raised.

Purpose To describe the characteristics and content of mobile applications related to multiple sclerosis (MS), as well as assess the level of participation of health professionals (HP) in their development.

Material and methods A descriptive observational study was carried out during August 2014. Smartphone applications specifically relating to MS were searched for using a keyword search with the term “MS” in the Apple App Store (iOS) and the Goo-
gle Play Store (Android).
Data recorded for every applications included: name, platform, cost, category, user star rating, number of downloads (available for Android only), updated date and target audience. The applications were analysed and categorised based on the information content into four groups: (1) diagnosis and management, (2) general information, (3) news, (4) tracking. Besides, we specifically examined the authorship in order to assess the prevalence of HP participation in their development.

**Results**

Twenty-one applications were identified for Android, 22 apps for iOS, among which there were 12 duplicates. Most of these applications were free of charge (83.8%) and uploaded under the medical category (51.6%).

A total of 23 had customer satisfaction ratings; nine with <3.9 stars (out of 5). The highest rated application was “Multiple sclerosis @Point of care”. Eleven applications had exceeded 1,000 downloads. The most downloaded application was “MS Diagnosis and Management”. 64.5% had been updated in the last year. A total of 15 applications were aimed at patients, while 11 focused on HP (five for both of them).

Eight applications included information about diagnosis and management; four, general information; ten, news and nine, tracking. The participation of HP in the development of applications was 54.8%.

**Conclusion**

Almost half of the applications do not have the scientific backing of a HP so they should be certificated.

**REFERENCE**

1 Evid Based Med 2013;18(3):90–2

No conflict of interest.
**PATTERNS OF USE OF BIOLOGICAL ANTI-TNF AGENTS AMONG PATIENTS WITH RHEUMATOLOGICAL DISEASES**

J M Martinez-Sesmero*, 1 J Manzano Lista, 1 P López Sánchez, AR Rubio Salvador, 1 M García Palomo, 1 P Moya Gómez. Complejo Hospitalario de Toledo, Pharmacy, Toledo, Spain

10.1136/ejhpharm-2015-000639.480

**Background** The role of biological anti-TNF agents (ATBA) in the treatment of rheumatological diseases (RD) has expanded, but dosing patterns have not been thoroughly explored.

**Purpose** To describe patterns of ATBA use among patients with RD.

**Material and methods** To describe patterns of ATBA use we retrospectively collected dispensing records of etanercept, adalimumab, golimumab and infliximab in first line (FL) or subsequent line (SL) settings, from 2011 to 2013, in a general teaching hospital.

Variables included: average dose according to the standard dosing interval, dose escalation and discontinuation (gap in treatment >60 days or switch). Time to discontinuation was assessed with Kaplan-Meier curves and U Mann-Whitney tests for average comparisons (SPSS 15.0).

**Results** Over 3 years, average doses dispensed were: etanercept (N = 238) 40.2 ± 10.9 mg/week, adalimumab (N = 344) 44.9 ± 8.6 mg/2 weeks, golimumab (N = 38) 52.2 ± 1.6 mg/month, and infliximab (N = 139) 489.1 ± 188.6 mg/8 weeks. The overall percentages with dose escalation or discontinuation were greater in the SL for all ATBAs (42.2% SL vs. 28.6% FL, p = 0.039). The proportion with dose escalation was greater for infliximab patients (71.3% SL vs. 52.2% FL, p = 0.012), as well as for discontinuations (15.2% SL vs. 8.6%, p = 0.029). Time to discontinuation was significantly shorter for SL than FL for all ATBAs (median 10.6 vs. 14.9 months; p = 0.018). The hazard ratio for discontinuing SL vs. FL was 1.321 (p = 0.020).

**Conclusion** In RD ATBAs have higher rates of discontinuation, dose escalation, and shorter time to discontinuation in SL than in FL, therefore the correct selection of FL is a key question in this setting.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**PARENTERAL NUTRITION IN HOSPITALISED PATIENTS. A QUALITY CONTROL STUDY**

LM Bravo García-Cuevas*, 1 J Fruns Jimenez, 2 S Martin Clavo, 3 C Bonilla Galán, 4 D Briegas Moreno, 5 C Meneses Marga, 6 Rangel Mayoral. Hospital Infantia Cristina, Farmacy, Badajoz, Spain

10.1136/ejhpharm-2015-000639.482

**Background** Adequate coverage of the nutritional needs during hospitalisation is of the utmost importance for patients’ recovery.

**Purpose** To evaluate the quality of parenteral nutritional support in our hospital to find points for improvement.

**Material and methods** Prospective observational study of all patients with parenteral nutrition (PN) over a period of two months. PN prescription was considered justified, if was in agreement with the ESPEN 2009 criteria. PN length was appropriate if it was for less than 7 days for peripheral PN (PPN) or for more than 7 days for central PN (CPN).

Protein and energy needs were calculated by weight and adjusting for metabolic stress factor (Low, Moderate and High: 1, 1.2 and 1.4 g protein/kg/day respectively for proteins and 150, 130 and 110 nonprotein Kcal/gN respectively for energy).

Nutritional needs were calculated only in patients with CPN and recorded weight. PN was considered adequate if it covered 85–115% of the calculated needs.

Spss 20.0 was used for statistical calculation.

**Results** 49 patients were included. The average age was 65 ± 14 years and average body mass index was 26 ± 5 Kg/m². 40 patients (81.6%) had CPN and 9 (18.4%) PPN. PN prescription was justified in 46 patients (93.6%). PN length was optimal...
in 30 patients (75%) with CPN and 3 (33%) with PPN (p = 0.043).

Nutritional needs were calculated in 37 patients. Caloric and protein intakes were suitable in 22 (59.5%) and 15 (40.5%) patients respectively, 6 patients (16.2%) had caloric overfeeding and 20 (54.1%) had protein overfeeding. 9 patients (24.3%) had insufficient calories and 2 (5.4%) insufficient protein. 10 patients (20.4%) met all objectives and therefore had appropriate PN.

Conclusion PN prescription is generally justified but PPN length is often inappropriate.

In the light of these results, the appropriate coverage of nutritional needs and PPN prescription for seven or fewer days, are the most important points to improve.

REFERENCES AND/OR ACKNOWLEDGEMENTS

To the other professionals from pharmacy department and clinical units, who contributed to conducting this study.

No conflict of interest.

OHP-008 ABILITY OF A SPANISH PHARMACIST REGISTRAR TO CARRY OUT THE INTEGRAL MANAGEMENT OF A PHARMACY DEPARTMENT

1 A Fernández-Ferreiro, 1 P Suárez-Artíme, 2h Mozo-Penalver, 1E Echart-Arieta, 1M González-Barcia, 1Martínez-Bahamonde, 1E Campelo-Sanchez, 1M Lamas Díaz. 1EOXI Santiago de Compostela, Pharmacy, Santiago de Compostela, Spain; 2EOXI Santiago de Compostela, Pharmacy, Santiago de Compostela, Spain; 1EOXI Santiago de Compostela, Pharmacy, Ribeira, Spain

10.1136/ehjpharm-2015-000639.483

Background “Assessment of Registrar Pharmacist Competency in Hospital Pharmacy” was published recently.

Purpose To demonstrate the ability of Spanish pharmacy registrars with the current document “Assessment of Registrar Pharmacist Competency in Hospital Pharmacy (ARCPH)” to carry out the overall management of a Pharmacy Department after completing their training.

Material and methods A Spanish pharmacy registrar (R4) trained according to the Current Teaching Plan (CTP) spends his last training stage in a Pharmacy Service (PS) of a Primary Level Hospital (PLH). He trains in overall management for a month there. R4 pharmacists were offered a questionnaire about the areas of training, similar to those provided in the CT. Once they had finished this rotation, senior pharmacists evaluated every task carried out using a range between 0–3 (minimal rating = 0 points, 3 points maximum rating) according to the ARCPH indications.

Results The R4s were trained in 100% of the areas included in the CTP. In the assessment areas, the following scores were obtained: Evaluation and selection of drugs (2.3), Inventory Management (1.9), masterful formulation (2.8), Validation of the prescribing and dispensing of drugs (2.6), Drug Information and health products (2.4), artificial nutrition (2.1), outpatient pharmaceutical care (2.7), direction and management of PS (1.9). The average overall assessment of the evaluated areas was 2.33, thus reaching a level of training listed as “optimal”.

Conclusion Spanish pharmacist registrars trained according to the CTP are able to train in overall management of the PS in a PLH. This is the first evaluated case based on the recently published document ARCPH.

REFERENCES

1 CTP. http://www.msssi.gob.es/profesionales/formacion/docs/farmaciaHosp.pdf

2 ARCPH. http://www.sefh.es/sefhpdfs/EVALUACION_POR_COMPETENCIAS_VF_2014.PDF

No conflict of interest.

OHP-009 OPTIMISING USE OF RANIBIZUMAB IN THE HOSPITAL PHARMACY: FINANCIAL IMPACT STUDY

E Fernández Alonso*, M Cumbraos Sánchez, MA Alcacer López, MP Pardo Jario, T Salvador Gómez, M Merchante Andreu, E Guart Prades, MA Allende Bandrés. Hospital Clínicas Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain

10.1136/ehjpharm-2015-000639.484

Background In June 2013, it was decided to start a protocol for the use of ranibizumab. Patients were grouped in order to fractionate vials in 0.5 ml syringes as a savings strategy under aseptic conditions. 3 doses of ranibizumab suitable for use are obtained from each vial (0.5 mg/0.05 ml).

Purpose To evaluate and quantify the financial impact of the optimised use of ranibizumab.

Material and methods Data were collected from patients treated with ranibizumab from June 2012 to May 2013, and were compared with patients treated from June 2013 to May 2014, analysing the cost without such optimisation. Total consumption of vials and fractions, the number of patients and the different diagnoses were analysed. Data sources: DOMINION dispensing program.

Results 240 patients were treated from June 2012 to May 2013: 213 (88.75%) with exudative age-related macular degeneration (ARMD) (516 doses), 16 (6.66%) with diabetic macular oedema (24 doses), 10 (4.16%) with neovascularization secondary to pathological myopathy (14 doses) and 1 (0.41%) with macular oedema secondary to retinal vein occlusion (3 doses).

The cost of ranibizumab without fractionation was €430,462. 400 patients were treated from June 2013 to May 2014: 364 (91%) with ARMD (1,140 doses), 29 (7.25%) with diabetic macular oedema (57 doses), 6 (1.5%) with neovascularization secondary to pathological myopathy (13 doses) and 1 (0.25%) with neovascular glaucoma (2 doses). The cost without fractionation would have been €1,029,124. However, due to fractionation it was €440,336 achieving a saving of €588,788 (714 vials) in one year, with an average of €1,471 per patient.

Conclusion The grouping of patients and the fractionation of ranibizumab vials reflects an increase in the burden of care and results in significant savings for the health system. The pathology for which the use of ranibizumab increased was ARMD, around 90%.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

OHP-010 VAC THERAPY TO REDUCE SURGICAL WOUND COMPLICATIONS: THE OPINION OF THE PHARMACIST

M Capozzi*, L Di Maso, M Sarno, P Maiolino. The “G. Pascale” National Cancer Institute, Pharmacy, Naples, Italy

10.1136/ehjpharm-2015-000639.485

Background Vacuum Assisted Closure (VAC) treatment is an innovative system that promotes wound healing by applying negative pressure (vacuum) at the wound site. The use of VAC Therapy removes oedema fluid, increases blood flow and cell proliferation and reduces bacterial colonisation.
Purpose Since oncological surgery is often radical with a long
rehabilitation phase and complications with the surgical wound,
the physicians decided to use VAC Therapy to help two patients
to recover from serious operations. After a careful study of
related literature, pharmacists addressed the supply, ensuring the
prescribed device was safe and clinically appropriate.

Material and methods In this pilot experiment VAC Therapy
was used on two patients:
- D. G. M., female, aged 76, suffering from abdominal wall
sarcoma.
- M. L., male, aged 78, suffering from sacral chordoma.

Pharmacy databases and electronic medical records were also
evaluated.

Results Both patients had undergone complete resection of the
tumour. After surgery VAC Therapy was used.
- Patient D. G. M. was treated for 6 weeks and regained full
functionality in 120 days, for a total cost of €2,219.00.
- Patient M. L. was treated for 2 weeks and regained full func-
tionality in 60 days, for a total cost of €669.90.

No complications were recorded and the treatment was well
tolerated with a therapeutic compliance of 100%.

Conclusion VAC Therapy avoids further extensive reconstructive
operations allowing fast patient recovery.

The device is expensive but it can be a valid option for
patients with high risk of poor healing and reduced compliance.
The cost can be written off by reducing the time of hospitaliza-
tions, and risk of complications and infections.

The pharmacist played a key role in the choice of the most
appropriate treatment for the patient and cost/benefit valuation.

REFERENCE

1 Kaplan M. Negative pressure wound therapy in the management of abdominal

No conflict of interest.

OHP-012 MANAGEMENT OF LEKSELL FRAMES: IMPROVING THE
STERILISATION PROCESS OF A CRITICAL DEVICE
A Bregliano*, C Picard, A Cilia, I Bousnina, B Tehhani. Timone Hospital, Pharmacy
Sterilization, Marseille, France

Background Leksell frames are high precision CE-approved
medical devices used in the stereotactic department, gamma unit
and neurosurgery. They can be considered as “critical” because
of their use and price. The French legislation recommends a
prioncidal detergent to clean sterilisable devices, whereas
the company only recommends enzymatic detergents.

Our position is uncomfortable. We have both to respect the
recommendations provided by the company in order to protect
the device’s surface and the legislation concerning the risk of
prion colonisation, but those 2 elements are contradictory.

Purpose To highlight the impact of the cleaning process on
the frames in order to optimise their management and guarantee
they are used correctly. The cleaning process is selected by and
under the pharmacist’s responsibility.

Material and methods We analysed the treatment of the frames
from their use during surgery to their sterilisation. To build up a
picture library we inspected the frames and their containers.

Results We noted 2 major concerns:
- The plastic containers were damaged, linked to the high rate
  of use of the frames (14 sterilisation cycles/month). The use of
  metal containers would be more suitable.
- 4 out of the 11 frames were showing signs of several anom-
a-1ies concerning the graduations and their visual appearance.

Those anomalies could be linked to the anodized aluminium
surface damaged by the alkaline detergent.

Conclusion The absence of a comprehensive approach of the
data sheet provided by the company (neither including our
detergent on the agreed list, nor prohibiting it) is a true concern,
and involves the company in case of deficiency. After sharing
feedback with other hospitals, it appeared they were being con-
fronted with the same issues. The alkaline detergent seems to
damage the graduations and to accelerate the wear of our
frames. Although we haven’t experienced any aftermath yet, we
must be aware of this concern. The consequences of misuse
could be highly damaging for the patient.

REFERENCE

1 Elekta’s data sheet for use of the Leksell stereotactic system

No conflict of interest.
COST-EFFECTIVENESS STUDY OF CABAZITAXEL IN ACTUAL PRACTICE


10.1136/ejhpharm-2015-000639.488

Background Prostate cancer is the second most frequent malignant tumour among men, with approximately 900,000 new cases per year. However, the financial situation of our public health system and the tight budgets of hospitals demand the best use of healthcare resources. Therefore, physicians should use cost-effective strategies in clinical practice.

Purpose To analyse the incremental cost-effectiveness ratio (ICER) of cabazitaxel as a treatment for metastatic prostate cancer in our hospital, and to compare those results with the available literature.

Material and methods A retrospective observational study was carried out to estimate our population progression-free survival (PFS), measured by the Response Evaluation Criteria in Solid Tumours (RECIST). The study lasted 15 months and included all 0–1 ECOG performance status patients who received cabazitaxel for metastatic prostate cancer in our hospital.

Afterwards, costs were calculated using actual dosages and current prices including industry discounts. Administration or indirect costs were not considered.

The incremental cost-effectiveness ratio (ICER) of cabazitaxel was obtained.

Finally, the literature perspective and our estimation from real practice were compared.

Results Ten patients were treated with cabazitaxel for metastatic prostate cancer during the inclusion period. Median age was 68 years old (range 61–83). The median dose was 20 mg m\(^{-2}\). Four patients required dose reductions (10–15 mg m\(^{-2}\)). The median PFS was 7.0 months.

Pharmacological costs were €15,923.5 per patient treated, and therefore our estimated ICER was €2,274.78/month of PFS.

While published ICERs were estimated at €12,546.32/month of PFS, we obtained a much lower ICER. Hence, a discrepancy of €10,271.54/month of PFS was found.

Conclusion The summary of products characteristics (SPC) recommended dose is higher than actual practice, and consequently costs are overestimated in studies based on SPC data.

On the whole, pharmacoeconomic analyses should be applied in specific settings since general analyses may not be congruous with actual scenarios.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

ELASTOMERIC INFUSION SYSTEMS: SAFE AND EFFICIENT ADMINISTRATION

T Anranz Castella*, J Marquez Pèrèz, J Jiménez Torres, M Gaspar Carneño, R Moreno Díaz, M Queralt Gorgas Torer. Sociedad Española de Farmacia Hospitalaria, Grupo de Productos Sanitarios, Madrid, Spain

10.1136/ejhpharm-2015-000639.489

Background To ensure safe administration of continuous 5-FU infusions to outpatients.

Purpose To make general recommendations for the use of elastomeric infusion devices for cancer patients with continuous 5-FU infusions.

Material and methods Revision of the technical specifications for all the infusion devices available, as well as review of the literature and studies available that show differences in the accuracy of infusion speed. These differences are due to factors in the infusion itself and to factors related to the behaviour and life style of the patient.

The sources of information were:

1. Technical datasheets of the different infusion devices.
2. Information from healthcare Products “Medical devices”: Advice to patients.
3. Literature search in PubMed using the key words “elastomeric infusion devices” and “5-FU infusion” and the resources available through the SEFH Website.

Results Elastomeric infusion devices provide an infusion accuracy of $\pm 15\%$ if the established conditions are followed.

Other variables affecting the accuracy of the infusion are:

1. Temperature. It modifies the viscosity of the mix. It is estimated that a change of one degree in temperature changes the flow speed by $2–3\%$.
2. Viscosity. Viscosity has an inverse effect on flow, and speed decreases when viscosity increases.
3. Concentration. Concentration will have a significant impact on viscosity.
4. Atmospheric pressure. Low pressures (600 mmHg) may reduce the infusion speed significantly.
5. Back pressure. If infusion devices are calibrated in a particular position a change in that position may change the amount infused.
6. Storage. It is important to temper the infusion device before use, to avoid variations in the viscosity of the fluid and in the texture of the elastomer membrane, etc.

Conclusion It is necessary to educate patients and nurses to reduce the incidence of infusion errors.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
study had involved 15 paediatricians, 6 GPs working in outpatient departments.

The average work experience of the respondents was: paediatricians – 28 years, GPs – 42 years.

Research has shown that there are patients for whom commercially available dosages of drugs are not suitable (in paediatric practice – 87% of patients, in GP practice – 17% of patients).

The research has also shown that there are patients for whom commercially available dosages of drugs are not suitable in the standard combination treatment: in paediatric practice – 47% of patients, in GP practice – 67% of patients.

In addition patients were experiencing problems with the use of different dosage forms:

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Paediatricians, %</th>
<th>GPs, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablets</td>
<td>93</td>
<td>50</td>
</tr>
<tr>
<td>Capsules</td>
<td>80</td>
<td>50</td>
</tr>
<tr>
<td>Pills</td>
<td>93</td>
<td>50</td>
</tr>
<tr>
<td>Oral solutions</td>
<td>80</td>
<td>33</td>
</tr>
<tr>
<td>Oral sprays</td>
<td>33</td>
<td>17</td>
</tr>
<tr>
<td>Suppositories</td>
<td>87</td>
<td>33</td>
</tr>
</tbody>
</table>

Most physicians believe that difficulties in using the medicine can cause patients to stop treatment: in paediatric practice – 87%, in GP practice – 33%.

All GPs and 93% of paediatricians agreed that prescribing a large number of drugs simultaneously reduces patient compliance.

Conclusion The midline results identified that there is a number of patients who do not fit industry manufactured medicines in Russia. Such results show that there is a need for individual compounding in pharmacies.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

Material and methods This cross-sectional study included 6 nursing homes.

Results A total of 770 elderly residents living in 6 nursing homes were investigated. Overall, 28% of patients used antipsychotic drugs. Particular antipsychotics such as lithium, amisulpride, aripiprazole, ziprasidone, tiaprilast, risperidone injectable and paliperidone injectable were monitored by psychiatry although in some cases the last mental health reports found were from the last year. 20% of patients were treated with quetiapine; half were followed by psychiatry and the others had dementia. 22% of patients were treated with risperidone, 78% of them had dementia. 12% of patients were treated with haloperidol and 4% with levomepromazine; all of them with dementia.

Conclusion Many patients, 60%, were followed by the psychiatry service but despite recommendations to avoid the use of antipsychotic drugs in patients with dementia, a large proportion of residents continued to receive such agents for this condition. Future work should establish the appropriateness of antipsychotic drugs in patients with dementia.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

OHP-017 ABILITY OF INFUSION DEVICES TO DELIVER THE EXPECTED VOLUME OF ANTI NEOPLASTIC DRUG IN SOLUTION: AN IN VITRO ASSESSMENT

Background For several years, many infusion systems have been marketed for the administration of antineoplastic drugs (AD).

Purpose To compare the ability of these devices to deliver the expected volume of antineoplastic drug in solution.

Material and methods Seven infusion devices were assessed (see table 1) by simulated infusions with a radiotracer (99mTcO4-) as drug substitute. The same activity (370 MBq) was diluted in 250 mL 0.9% NaCl bags. The evolution of the drug concentration at the egress of the infusion system was recorded continuously with a sodium iodine crystal detector. The area-under-curve of drug concentration according to time of both administration (AUCadm) and rinsing (AUCrin) steps were calculated using the linear trapezoidal rule after correcting for radioactivity decay. The rinsing volumes (Vrinh) volumes required to get no more radioactivity, were measured in a graduated test tube. The values were compared using a Kruskall-Wallis test (p < 0.05).

Results Despite the differences in dead-space volume, AUCadm were not significantly different (see table 1). The rinsing volumes were significantly different between the tested devices, ranging between 46.8 ± 5.7 mL and 92.2 ± 8.9 mL.

Conclusion The rinsing conditions required to administer the same dose are really different between devices. The impact of good handling practice of these devices has to be assessed on the pharmacokinetic parameters.
Abstract OHP-017 Table 1

<table>
<thead>
<tr>
<th>Infusion set or device</th>
<th>Supplier</th>
<th>Dead-space volume (mL)</th>
<th>AUC&lt;sub&gt;0-24h&lt;/sub&gt; (cps)</th>
<th>AUC&lt;sub&gt;0-24h&lt;/sub&gt; (cps)</th>
<th>V&lt;sub&gt;100&lt;/sub&gt; (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIS-1</td>
<td>Doran</td>
<td>15.8 ± 0.1</td>
<td>482.5 ± 10.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MFX2307-KS1</td>
<td>Carefusion</td>
<td>18.4 ± 0.2</td>
<td>483.0 ± 36.9</td>
<td>31.0 ± 2.1&lt;sup&gt;1&lt;/sup&gt;</td>
<td>48.3 ± 3.6&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>MFX2306-KS1</td>
<td>Doran</td>
<td>17.8 ± 0.1</td>
<td>499.2 ± 26.9</td>
<td>32.6 ± 1.2&lt;sup&gt;2&lt;/sup&gt;</td>
<td>54.0 ± 4.5&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>PCIMX-KS1</td>
<td>Fresenius</td>
<td>24.7 ± 0.9</td>
<td>506.5 ± 9.7</td>
<td>54.2 ± 1.8</td>
<td>66.8 ± 3.5&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Cyto-Ad set</td>
<td>Codan</td>
<td>33.0 ± 0.4</td>
<td>471.4 ± 32.7</td>
<td>53.8 ± 3.6</td>
<td>92.2 ± 8.9&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>MX2309</td>
<td>Carefusion</td>
<td>18.8 ± 0.2</td>
<td>484.7 ± 24.7</td>
<td>29.4 ± 1.2&lt;sup&gt;2&lt;/sup&gt;</td>
<td>47.0 ± 6.6&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tevatre 2</td>
<td>Teca</td>
<td>17.5 ± 0.2</td>
<td>506.7 ± 8.1</td>
<td>31.4 ± 2.5&lt;sup&gt;1&lt;/sup&gt;</td>
<td>54.7 ± 5.4&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tevatre 4</td>
<td>Teca</td>
<td>17.9 ± 0.2</td>
<td>500.1 ± 21.5</td>
<td>32.4 ± 4.9&lt;sup&gt;1&lt;/sup&gt;</td>
<td>53.5 ± 5.4&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Chemoset</td>
<td>ICU medical</td>
<td>17.7 ± 0.3</td>
<td>502.1 ± 10.9</td>
<td>35.0 ± 1.9&lt;sup&gt;1&lt;/sup&gt;</td>
<td>46.8 ± 5.7&lt;sup&gt;6,9&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>1</sup>p < 0.001  
<sup>2</sup>p < 0.0001

REFERENCE


No conflict of interest.

OHP-018 CHEMICAL DEGRADATION OF METHOXSALEN AFTER ACID AND ALKALINE HYDROLYSIS

Background Photochemotherapy is an effective treatment for psoriasis. The photosensitizer methoxsalen can be applied either orally or topically. When applied topically, the patient is immersed in a bath containing 0.0001% methoxsalen in warm water for 20 min, followed by UVA irradiation (PUVA bath).

Methoxsalen is toxic and has carcinogenic effects when it is swallowed or gets in contact with mucosa. It must be handled with caution.

Purpose To find an effective and simple method for chemical deactivation of methoxsalen, which could be used in the clinical setting after PUVA treatment.

Material and methods Materials: Methoxsalen powder, KOH, Ethanol, NaClO, CHCl₃

Samples: 7 solutions of 200 mg of methoxsalen in 10 ml of ethanol.

Reagents: 3 solutions of KOH (1 M, 0.5 M, 0.2 M), and 3 of NaClO (5%, 0.5%, 0.05% (v/v))

We mixed 10 ml of each reagent with a different methoxsalen sample and stirred. The seventh sample of methoxsalen was used as a blank.

We monitored the chemical reactions with thin layer chromatography at 10 and 30 min. Mobile phase was ethanol 1% in CHCl₃. We used UV light to visualise the chromatogram.

We performed a qualitative analysis of the remaining methoxsalen in each sample, after acid or alkaline hydrolysis.

Results The blank showed that methoxsalen is completely eluted by the mobile phase. In the six samples, we observed that part of the mixture is eluted (methoxsalen), while other compounds are retained in the stationary phase. These may be polar degradation products. The more concentrated the reagents, the smaller the quantity of methoxsalen remaining. The most extensive hydrolysis was seen in the mixture with 1M KOH.

Conclusion Both KOH and HClO hydrolyse methoxsalen. The most efficient reactive was 1M KOH, which hydrolysed almost the whole sample.

These results suggest that KOH 1M may be useful to deactivate methoxsalen after PUVA, although further studies are necessary to characterise degradation products and evaluate their toxicity.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

OHP-019 BUDGET IMPACT OF FINGOLIMOD IN THE TREATMENT OF MULTIPLE SCLEROSIS

Background The high cost of multiple sclerosis (MS) treatment justifies conducting financial analyses to reveal which therapeutic alternatives are more cost effective. From the Clinical Management Unit (CMU) of Pharmacy from Granada (Spain), we looked for various tools to reduce the impact of these drugs on the annual budget without affecting the health of the individual.

Purpose To analyse the cost of treatment with fingolimod in patients attending CMU Pharmacy Granada.

Material and methods Patients receiving drugs for the treatment of MS, dispensed from the CMU Pharmacy Services, were established as the study population. A time horizon of 5 years was chosen (2013–2017) and two scenarios: stage 1, with the standard treatment for MS, and stage 2, with the introduction of fingolimod as second line monotherapy. Only direct healthcare costs: drugs, administration and management of the disease were considered.

Results The average cost of treating patients, considering stage 1, involves an investment of €581,418 annually, with an average cost per patient per year of €12,872. The introduction of fingolimod as the only treatment option for second-line carries an average annual cost of €7,517,054 euros (average cost per patient per year of €12,762). Therefore, the second line treatment of MS based solely on fingolimod means less spending. In the second scenario, there are cost savings: €64,364. What differentiates the two situations are the costs of administration and disease management. On the one hand, the use of fingolimod, being an oral drug, eliminates the day hospital costs. However, it increases spending on disease management: cardiac and ophthalmic monitoring.

Conclusion The introduction of fingolimod does not have a significant budget impact since it involves an expenditure increase of 13% over the next five years. These results are similar to those published in previous relevant studies.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
PROSPECTIVE MONOCENTRIC STUDY: COMPLICATIONS RELATED TO PERIPHERALLY INSERTED CENTRAL CATHETERS (PICC)

Background Peripherally Inserted Central Catheters (PICCs) are long-term intravenous catheters used for drug administration when the duration of parenteral treatment exceeds six days.

Purpose To analyse the incidence and nature of PICC-related complications in routine clinical practice.

Material and methods A monocentric, prospective study. All PICCs implanted between December 1, 2012 and March 6, 2013 were included. Clinical data of inpatients and outpatients were collected until May 1, 2013.

Results Of the 206 PICCs successfully inserted in 184 patients, 204 were analysed. They represented 5,116 catheter-days, of which 1,503 related to outpatients. Antibiotic treatment was the main use (70.5%). At the end of the follow-up, 194 PICCs had been removed with a median duration of 16.0 days (0–97). Complications led to the removal of 58 PICCs: two thromboses, 26 suspected infections, 12 obstructions and 18 accidental removals. The incidence rates were 2.45% or 0.98 per 1,000 catheter-days for catheter-related bloodstream infection with parenteral nutrition as a risk factor (OR = 13.0; CI95: 8.53–20.4, p = 0.01). The pharmacy profession is changing towards patient-centred care. To meet the new challenges but also to improve inpatient care and safety.

Conclusion While the prior pharmacist’s assessments were high, the visibility and its presence resulted in a significant improvement in the perception of the pharmacist figure, both globally and in specific aspects such as patient safety, the importance of treatments’ review and work-time employed perception.

REFERENCES AND/OR ACKNOWLEDGEMENTS

None.

ADVANCES IN PHARMACY EDUCATION: EVALUATION OF A WARD-BASED CLINICAL TEACHING COURSE

Background The pharmacy profession is changing towards patient-centred care. To meet the new challenges but also to drive the profession forward it is necessary to provide students with clinical competencies. Clinical courses with teacher practitioners are part of the pharmacy curriculum in countries like the UK or USA and are increasingly being established within Europe.

Purpose To systematically evaluate the benefits of clinical teaching in our country: a quasi-randomised teaching and learning study.

Material and methods A clinical teaching course on a psychiatric ward was created for small student groups. Learning aims included: communication, drug histories, drug-related problems and counselling. The control group only participated in the theoretical part while the intervention group took part in the complete course. The effects were assessed by an objective structured clinical examination (OSCE) and a student questionnaire.

**REFERENCE TO TABLE 1**

<table>
<thead>
<tr>
<th>Item</th>
<th>PRE</th>
<th>POST</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Asses the role of Hospital Pharmacist reviewing medical prescriptions</td>
<td>3.7</td>
<td>4.6</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>2. Asses how you believe that this revision increases patient’s security</td>
<td>4.4</td>
<td>4.8</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>3. How do you value the time the pharmacist employs reviewing prescriptions?</td>
<td>3.7</td>
<td>4.7</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>4. In Off-Label drugs use. Do you believe pharmacist opinion is important?</td>
<td>4.0</td>
<td>4.6</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>5. Asses the importance of making home treatment reconciliation at income</td>
<td>4.7</td>
<td>4.8</td>
<td>0.37</td>
</tr>
<tr>
<td>6. Asses the importance of pharmacists carrying out reconciliation process</td>
<td>4.3</td>
<td>4.7</td>
<td>0.09</td>
</tr>
<tr>
<td>7. Asses the usefulness of clinical pharmacokinetics</td>
<td>4.6</td>
<td>4.4</td>
<td>0.71</td>
</tr>
<tr>
<td>8. Asses the role of pharmacist prescribing, monitoring and resolving problems related to parenteral nutrition</td>
<td>4.5</td>
<td>4.6</td>
<td>0.86</td>
</tr>
<tr>
<td>9. Asses the impact of pharmacist’s presence in the final quality of treatments</td>
<td>4.1</td>
<td>4.6</td>
<td>0.11</td>
</tr>
<tr>
<td>10. Asses globally pharmacist’s role in your service</td>
<td>4.3</td>
<td>4.8</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>
Results The intervention group achieved a significantly better overall result in the OSCE assessment (46.4 ± 9.3 vs. 28.2 ± 9.0 of 90 points; p < 0.001) with the most positive effect in communication skills (27.4 ± 5.4 vs. 16.3 ± 6.0 of 40 points; p < 0.001). The performance in the theoretical tasks was improved but unsatisfactory in both groups considering the maximum score (12.1 ± 4.1 vs. 8.1 ± 3.2 of 30 points; p < 0.001). 93% of the students rated the course as practice-oriented and 90% felt better prepared for patient contact. Many students suggested an extension of the course in the free text field of the questionnaire.

Conclusion The results suggest significant learning benefits from the ward-based course created. The overall satisfaction was high. Inclusion in the pharmacy curriculum should be considered. Further studies are required to optimise course structure.

REFERENCE

1 Ramos RG. Eur J Hosp Pharm 2014;21:A119

This work was supported by Bayerische Akademie für Klinische Pharmazie/Dr. August und Dr. Anni Lesmiller-Stiftung, Munich, Germany.

The authors are grateful for the expert advice of Dr. Freidank, Fulda Hospital, Germany and PD Dr. Frobenius, MME, Erlangen University Hospital, Germany.

No conflict of interest.

IMPORTANCE OF PREVIOUS MICROBIAL CULTURES IN CARBAPENEMS USE

1M Valdenevo Pulido, 2S Vicente Sánchez, 3R Olmos Jiménez, 4A Pareja Rodriguez De Vera, 5M Fernandez De Palencia Espinosa, 6A de la Rubia Nieto. 1Hospital Clínico Universitario Virgen de la Arrixaca, Hospital Pharmacy, Murcia, Spain; 2Hospital Universitario Virgen de la Arrixaca, Hospital Pharmacy, Murcia, Spain; 3Hospital Universitario Virgen de la Arrixaca, Hospital Pharmacy, Murcia, Spain

No conflict of interest.

Background Carbapenems are widely used as broad-spectrum antibiotics but in several cases microbiological cultures are not taken before carbapenem use, therefore hindering the down-scaling to targetted treatment.

Purpose To evaluate the increasing number of cultures requested before using carbapenems because of a pharmaceutical interventions and the results of the cultures; to describe the sensitivity of microorganisms isolated.

Material and methods Pre-Post and interventional study including adult patients using carbapenems (ertapenem, meropenem, and imipenem-cilastatin).

From June 2014, the department of pharmacy set a recommendation that a sample must be taken from the patient for microbiological culture before carbapenem was used, and the physicians have to check this recommendation to complete the electronic prescription of a carbapenem.

The record of every patient with carbapenem prescription was studied for 3 consecutive months; May, before the intervention was set up; June and July, with the intervention already in progress.

It was defined as a previous culture, 7 days before prescription.

Results Two hundred and sixty one patients (100 in May, 84 in June, 77 in July) were studied; mean age was 60.1 years, 62.1% males.

In May, 75.0% of the carbapenems prescriptions had a culture made before antibiotic use, in June, 82.1% and in July 87.3%.

During the study period, 209 culture requests were done before carbapenem prescription, 48.4% were negatives, 51.6% positives. 89.8% of the microorganisms isolated were sensitive to narrow-spectrum antibiotics, but just 21.6% of prescriptions for them were down-scaled.

Conclusion The outcome shows a clear improvement in the number of cultures requested by physicians; this allows an optimal use of antibiotics, facilitating the down-scaling strategy which avoids the appearance of antibiotic resistance.

Most of the microorganisms isolated were sensitive to antibiotics with a narrower spectrum, which gives more value to the culture at the beginning of the treatment and makes checking the down-scaling of treatment by the department of pharmacy important.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PHARMACIST FOCUS GROUP ABOUT QUALITY OF MEDICINES AND RELATED ISSUES

1A Alghannam*, 2Z Adanpour, 3S Evans, 4F Schifano. 1University of Hertfordshire, Pharmacy, Hatfield, UK

Background The quality of medicines is commonly established through pharmacopoeia testing. Medicines with quality issues can either be substandard or counterfeit according to the World Health Organisation. Limited research has addressed the perceptions of stakeholders about medicine quality and related issues and none were identified within the selected population. Furthermore, few studies report views about generic medicines as being counterfeit or of inferior quality, which could influence the acceptance and use of such medicines.

Purpose To generate a range of views, attitudes and behaviour regarding medicine quality and related issues from the perspective of experienced pharmacists. Additionally, this study will inform the question design for future studies with different stakeholders in the selected population and find translation for technical terms such as counterfeit.

Material and methods A focus group study was video-recorded and conducted in English with five experienced pharmacists following their informed consent. The questions were developed following a literature search and were arranged in a particular order where general questions were asked first and questions regarding counterfeits were asked at the end. Data were analysed thematically using a systematic strategy for focus group analysis.

Results Eight themes emerged including the definition, perception, challenges, knowledge, experience, practices, price and recommendations for medicine quality. A good quality medicine was described in terms of its effect, similar to other studies. Participants believed that the quality of medicines in the selected country was high in contrast to some patients’ views. A single term was used to describe counterfeit medicines in their native language.

Conclusion The result of this study indicates a possible gap between the pharmacists and some patients’ views about the quality of medicines in the selected country. Emerging themes were used to inform the question design in future studies with different stakeholders. The translation of the term counterfeit was achieved.
INVESTIGATIONS FOLLOWING INCREASING COMPLAINTS ABOUT INFUSION SETS FOR SAFE ADMINISTRATION OF CYTOSTATICS


10.1136/ejhpharm-2015-000639.501

Background Systematic use of flushed infusion lines is recommended by the French “Good Compounding Practices” for the administration of chemotherapy drugs. When they are packaged in syringes, the CytoBolus Adapter Set (CODAN) is currently used in a department of paediatric haematology. Since September 2013, 27 adverse events have been reported, including 20 occlusions and 6 leaks of this device. Viscosity has been cited by the manufacturer as a possible causal factor.

Purpose The purpose of this study was to identify risk factors that lead to CytoBolus Adapter Set malfunction, especially viscosity.

Material and methods An Ishikawa diagram was built after meeting with nurses, pharmacists and CODAN representatives. Three connectors were assessed: the CytoBolus Adapter Set, the PhaSeal system and a plain tube (VYGON). In vitro, three solutions with an increasing viscosity were processed by 4 automated Orchestra infusion systems at two extreme flow rates: 1 ml/h for 20 h and 50 ml/h for 1 h. Each combined setting was repeated 3 times.

A two-way ANOVA test was used to compare means of calculated volumes, based on the density of each solution.

Results Cause and effects analysis identified potential causes of the events including cold storage, properties of the solvent, misuse and mishandling, or the lack of resistance of the connector.

No significant differences were observed in the volume delivered by the three medical devices at 50 ml/h whatever the viscosity. Volumes delivered by the PhaSeal system were unexpectedly lower with water for injection than dextrose 5% (p = 0.00405) and dextrose 10% (p = 0.00334) at 1 ml/h but were still acceptable given the 3% precision of the Orchestra (standard NF 590–231). In all the 216 experiments, neither obstruction nor cracking was observed.

Conclusion The viscosity does not appear to be the determining factor that leads to malfunction. Further investigations appear necessary of other causal factors.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Pharmacy Department, Robert Debré Hospital.

No conflict of interest.
role and impact of pharmacists during a workshop. The website Impact-Pharmacie served as support for the presentation. We administered the questionnaire on a voluntary basis; descriptive statistics were performed.

Results Thirty students participated in the survey (57% of participants). Respondents were from 15 different countries: Armenia, Austria, Canada, Egypt, France, Germany, Portugal, Romania, Slovenia, Spain, South Korea, Taiwan, Thailand, Tunisia, United Kingdom. Concerning exposure, 40% (12/30) of students had not read articles describing the role and impact of pharmacists, 43% (13/30) of students had read between 1 and 5 articles. Pharmacy students were in favour of using the best evidence on pharmacy practice models. Respondents considered the website Impact-Pharmacie to be clear (average score of 6.6), relevant (6.8) and applicable (5.9) for use in pharmacy curriculums.

Conclusion Pharmacy students have limited exposure to the literature on the role and impact of the pharmacist. Students found the website Impact-Pharmacie useful as a portal for this literature.

REFERENCE

No conflict of interest.

OHP-028 COST-EFFECTIVENESS OF TRIPLE THERAPY FOR HEPATITIS C COMPARED WITH DUAL THERAPY IN CLINICAL PRACTICE

P Neust*, SM Cano, JA Schonenberger, A Aragonés, M Gilabert, M Martínez, L Mangues. Hospital Universitari Arnau de Vilanova, Pharmacy, Lleida, Spain

10.1136/ehjpharm-2015-000639.503

Background New treatments for Hep C are more effective but also increase the cost of treatment and side effects also increase.

Purpose To compare the cost effectiveness of double therapy with interferon plus ribavirin (group 1) with triple therapy including telaprevir or boceprevir (group 2).

Material and methods Cross sectional and retrospective study that included patients who started treatment for Hep C since 2014, with genotype 1 and >3 months on treatment. Computerised medical records were reviewed and the outcome of treatment defined as sustained viral response (SVR) or failure; the time of treatment in patients who ended treatment (65) was 47 weeks (IQ: 40–47). In 43 patients (66%) a sustained viral response (SVR) was achieved. Group 2 patients responded more than those in group 1: 23/28 (82%) vs. 20/37 (54%) with a relative risk of 1.52 (CI95%: 1.08–2.14). The absolute risk reduction (ARR) of no response was 28% (CI95%: 7–50%) and the number needed to treat (NNT) was 3.56 (CI95%: 2.02–15.01).

Mean global cost for group 1, including hematopoietic stimulating factors, was €16,769 ± 5,063 while for group 2 it was 39,849 ± 9,640. These results yielded an incremental cost-effectiveness ratio (ICER) of 82,164 euros (CI95%: 46,621–34,430), which is very high from the payer’s perspective. Treatment of haematological toxicity added a mean of €2,490 ± 2,494 per course.

Conclusion Treatment with triple therapy is more effective than dual but it’s ICER is very high from the payer’s perspective. Given the large socioeconomic impact of Hep C, an approach based on cost-utility analysis would be preferable from a societal perspective.

REFERENCE

No conflict of interest.

OHP-029 CONTINUOUS IMPROVEMENT PROCESS: INVOLVEMENT OF THE STAFF IN A PHARMACY SERVICE

C Martí Gil*, I Martínez-Valdivieso, G Marcos-Pérez, A Flor García, D Moreno-Rodríguez, D Barredo Hernández. Vígon de La Luz Hospital, Pharmacy Service, Cuenca, Spain

10.1136/ehjpharm-2015-000639.504

Background A Quality Management System (QMS) analyses, controls and monitors the processes in order to identify areas that require improvement.

Purpose To describe the incidents detected by the staff of a Pharmacy Service (PS) during the implementation of a QMS based on the ISO 9001:2008 standard.

Material and methods Descriptive study (December 2013–August 2014). The quality improvement logbook in which the incidents were recorded, was designed by the PS Quality Manager (PSQM), based on the experience of other hospitals and according to a general procedure, authorised by the PS Quality Subcommittee and reflected in the PS Organisation Handbook. The logbook was presented in a PS meeting, where its location and how to fill in [record number, date, process involved, description of the incident, reporting/detecting staff, first actions taken] were explained. Once the incident is booked, it was reviewed by the PSQM and the responsible pharmacist. If needed, due to frequency and/or severity, the PSQM proceeds with the opening of a nonconformity and/or a corrective/preventive action, communicating this to the PS Manager. These are evaluated by the PS Quality Subcommittee.

Results 60 incidents in 4 key processes and 1 support process were recorded. Process distribution: logistics (37), dispensing (11), sterile (6) and non-sterile (5). Prescription, pharmacoeconomics management (1). With respect to the logistics incidents, 18 of them were identified jointly by nursing and administrative assistants and the most common incidents involved the lack of a standard label on the outer package, to indicate that the drug can’t be dispensed outside the hospital (25) and incorrect temperature in fridge (4). In relation to incidents to do with productions, 6 nonconformities were opened (expired drug dispensed, wrong non-sterile preparation dispensed, autologous serum contamination, laminar flow cabinet contamination, mislabelling of a cytostatic and delay in orders for non-sterile materials).

Conclusion It is important to educate health staff in detecting weaknesses or failures in the system in order to perform the “Deming Continuous Improvement Cycle”.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
Background Our institution established in October 2013, in collaboration between the pharmacy unit, haematology laboratory, clinicians and according with recommendations of the GHP, a prefilled prescription form (PPF) for Kanokad® (Prothrombin Complex Concentrate) and Feiba® (activated Prothrombin Complex Concentrate) used in the indication of antagonising DOAs. The PPF has a flow chart and indicates to the prescriber which product and dose to prescribe according to the clinical situation. The PPF was validated by the Hospital Drug Committee.

Purpose The objective of this study is to realise an inventory of good prescribing practices of Kanokad® and Feiba® relative to the established protocol.

Material and methods A retrospective study over 12 months (October 2013–September 2014) was performed with analysis of the prescriptions of Kanokad® and Feiba®. The conformity of the prescriptions was determined based on the choice of the product and the respect of the recommended dosage.

Results 16 patients were treated in the indication of antagonising DOAs. 8 patients received Kanokad®, 7 Feiba® and 1 Feiba® followed by Kanokad®. DOAs concerned was Rivaroxaban (63%) and Dabigatran (31%) (unknown for 1 patient). Indications were: treatment of severe bleeding (76%) and prevention of bleeding during surgery (18%) (unknown for 1 patient). The choice of the medicine and dosage was in consistent with the protocol for 87.5% of patients. For 12.5% of the prescriptions, the prescribed dosages were lower than recommended, and we could not check-up the choice of the product (PPF incomplete). They concerned a unit which has an emergency reserve stock of Kanokad® (pharmaceutical validation performed retrospectively).

Conclusion The PPF is generally well applied. Measures were implemented for the 12.5% non-compliant prescriptions: prescribers were contacted and the PPF was sent them by E-mail. Furthermore, the PPF will now be joined to the Kanokad® bottles at each renewal of the emergency reserve stock.

REFERENCES AND/OR ACKNOWLEDGEMENTS
none

No conflict of interest.
PATIENTS’ HOME TREATMENT UPON HOSPITALISATION
1 M Alonso-Dominguez*, 2 S Fernandez-Calabate, 3 M Ventura-Lopez, 4 De Gorostiza-Frias,
5 Aibas-Oiz, 6 M Sanchez-Muleiro, 7 M Rizo-Cerdà, 8 Selvi-Sabater, 9 Sánchez-Martinez,
11 Mareasa-Ramón, 1 Hospital Morales Meseguer, Murcia, Spain; 2 Hospital Clínico
Universitario de Valladolid, Hospital Pharmacy, Valladolid, Spain; 3 Hospital Morales
Meseguer, Hospital Pharmacy, Murcia, Spain

Background Some patients directly hospitalised via the emergency
department are changed from their current home treatment.
The pharmacy department aims to identify any errors and correct them.

Purpose
- To find out how many home treatment prescriptions could
lead to an error in patients hospitalised by the emergency
medical service.
- To identify any issues and analyse them.

Material and methods Prospective observational study. 366
Patients hospitalised from January 2014 were followed.

The analysis included: medicines prescribed 48 h after admission,
age, gender, team on duty and problems related to the home treatment. We classified the issues found as:
1. Treatment not followed at all
2. Treatment partially followed
3. Patient’s previous medicines not stated
4. Patient’s previous medicines stated incorrectly
5. Illegible writing

Results 76 events were reported, which equated to 92 contamination events. Six types of contamination were identified: environment, staff, patient, errors occurring during radiopharmaceuticals preparation, related to radiopharmaceuticals, medical device dysfunction. Contamination was most frequently classified as affecting the environment (49%) and staff (32%). These results illustrate the problems of preparing and conditioning radiopharmaceuticals. Despite regular briefing on radioprotection measures and practices, it is difficult to completely eradicate any radioactive contamination.

Eleven people had reported events and 16 persons were involved in them. Among the staff, 2 people had reported 75% of events. These results pointed out more awareness of radiation protection issues of these two workers rather than a problem of how they handle radioactive sources. In fact, they were involved in departmental quality processes (risk management, controls, personal protective equipment).

The quiz revealed that all staff knew about the radioprotection events register but only paramedics were using it. Only one worker did not know where it was kept. These results were quite positive, apart from the medical staff.

Conclusion In 2014, these results will be presented during the next triennial radioprotection training sessions. Medical doctors in particular will be encouraged to report incidents. Finally, a new analysis of the register will be made within 3 years before the next regulatory training period in order to check radioprotection practices and reports.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Décision 2008-DC0103 ASN.
No conflict of interest.

OHP-034 TRACEABILITY OF IMPLANTABLE MEDICAL DEVICES (IMDs) IN HOSPITAL: INDUSTRIAL CODIFICATION SYSTEMS STILL INSUFFICIENT

L Durand*, S Drouot, S Frontini, A Tabuet, S Perier Raspaud. CHU de Bicêtre Aphp, Pharmacy, Le Kremlin Bicêtre Cedex, France

Background Tracking implantable medical devices (IMDs) by batch number is mandatory under French law for safety issues in case of adverse events or recalls. The pharmacist is responsible for the database of IMDs and health care providers are in charge of matching a given IMD with patient identity after surgery.

Purpose In order to optimise traceability, this study assessed the use of the industrial barcodes printed on device packaging. We wished to avoid having to re-label with our own barcodes upon delivery of the devices to the pharmacy.

Material and methods We used a healthcare program (PHARMA, Computer Engineering) able to read international standardised barcode systems (HBBC, EAN/GS1, DataMatrix) and print/read its own barcodes containing the required regulatory information (reference, batch number, expiry date). This specific pharmacy barcode is pasted by the pharmacy on each corresponding IMD. During a 2-month assessment, the industrial barcode of devices implanted during radiology interventions was scanned, in order to add the information to the patient records. In case of failure, the pharmacy barcode was used.

Results Eighty-nine IMDs were implanted in 20 patients. Nineteen products from 10 suppliers were tested. Traceability was recorded in all cases: the industrial barcode was read successfully for 32 IMDs (36.0%) whereas the pharmacy label was used in 57 cases (64.0%). The following main difficulties restricted the use of industrial barcodes: (1) related to the industrial barcode

Data source: Savac (prescription and clinical history records), Selene (specialist care medical history records).

Results 366 consultant prescriptions were analysed. 30% of them were for a home treatment.

Patient characteristics: Males: 51%; 85% of the patients were over 60 years; the Internal Medicine ward had the highest number of admissions, 32%; 4.7% of the patients had problems related to home treatment

Based on our classification of the issues found to do with home treatment, the following frequencies were obtained:
- Type 1: 31.5%
- Type 2: 6.25%
- Type 3: 37.5%
- Type 4: 18.75%
- Type 5: 6.25%

Conclusion Issues related to home treatment were identified in 4.7% of the patients.

The most common issue was type 3: Patient’s previous medicines not stated.

The ward with the highest number of issues detected was the orthopaedic surgery department.

REFERENCE

No conflict of interest.
INTERDISCIPLINARY COLLABORATION OVER IMPROVING OUR PHARMACY OUTPATIENT UNIT: ARE WE GOING IN THE RIGHT DIRECTION?

1P Pérez Puente*, 2M Májarres Gordón, 1L Fernández Liáson, 1M Garindo Amégieiras, 1M Martín Cilleró, 1M Gómez Espíñeiro, 1S Rivero Cava, 1L Martín Rizo, 1Hospital San Pedro de Alcántara, Pharmacy, Cáceres, Spain; 2Salamanca University, Pharmacy Faculty, Cáceres, Spain

10.1136/ejhpharm-2015-000639.510

Background Patient satisfaction reflects the quality of service provided by healthcare professionals.

In our Outpatient Unit (OU) important changes have been implemented: change of location, a Programme of Scheduled Appointments (PSA) and opening hours have been extended.

Purpose After the implementation of the changes:

- To assess the degree of outpatient satisfaction
- To collect all comments/suggestions in order to identify areas we could improve further.

Material and methods Non-experimental, cross-sectional study over a period of six months (1 March–1 September) on all patients who attended our OU.

Patients completed two types of questionnaire (all anonymous and voluntary).

All the questions had 5 possible answers, arranged in an ordinal Likert-type scale (1: completely disagree to 5: completely agree) and a section for comments/suggestions.

1. Overall satisfaction was assessed with a previously validated questionnaire, including three sections (patient satisfaction, pharmaceutical care and surroundings).
2. The patient’s opinion about the changes was assessed with a satisfaction survey designed by us that contained three direct questions.

Results A total of 432 patients completed the questionnaires (response rate of 99%). 5% with no education, 43% with basic education, 52% with college education.

<table>
<thead>
<tr>
<th>Satisfaction</th>
<th>Assessment of the nurses</th>
<th>Assessment of the pharmacists</th>
<th>Global satisfaction</th>
<th>Resolution of patient needs</th>
</tr>
</thead>
<tbody>
<tr>
<td>average</td>
<td>4.63 ± 0.56</td>
<td>4.59 ± 0.62</td>
<td>4.56 ± 0.41</td>
<td>4.57 ± 0.55</td>
</tr>
<tr>
<td>scores (1–5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacological care</td>
<td>Availability to answer questions</td>
<td>Treatment information</td>
<td>Consultation privacy</td>
<td>Personal dedication</td>
</tr>
<tr>
<td>average</td>
<td>4.58 ± 0.56</td>
<td>4.35 ± 0.74</td>
<td>4.29 ± 0.53</td>
<td>4.02 ± 0.57</td>
</tr>
<tr>
<td>scores (1–5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surroundings</td>
<td>Schedule</td>
<td>Location</td>
<td>Signage</td>
<td>Waiting time</td>
</tr>
<tr>
<td>average</td>
<td>3.96 ± 0.72</td>
<td>4.06 ± 0.91</td>
<td>2 ± 0.86</td>
<td>3.95 ± 1.04</td>
</tr>
<tr>
<td>scores (1–5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Direct questions about the changes revealed that the worst valued was the new location (3.2 ± 0.55), the best was the extension of opening hours (4.8 ± 0.22).

The most frequent suggestion was to open the OU in the afternoons (22%).

Conclusion Overall, a high degree of satisfaction was observed.

We identified significant opportunities for improvement, some of which could be implemented in the short term, such as the signalling of the consultation. Others will be dealt with in the long term, such as the demand for continued care in the afternoon.
Background In 2009, our general hospital purchased software (Genois) for tracking implantable medical devices (IMDs). Tracking IMDs after implantation not only involves nurses but also pharmacy assistants when problems occur.

Purpose To identify and analyse traceability errors and provide the appropriate solutions and improvements.

Material and methods Each year, an audit is performed to compare the actual stock of IMDs to our computerised database. A first rate is calculated after the inventory phase and a second one results from the pharmacist and nurse reassessment, which consists of comparing different sources of available information from the Genois and Bilocqual systems and from operating room logbooks. Audit results were analysed retrospectively and errors were pointed out.

Results Between 2010 and 2013, the number of IMDs tracked increased from 1,089 to 4,346 implants. This rise reflects progressive computerization of traceability and the increased workload of operating rooms. The intermediate rate of untraced IMDs remains stable (about 2%) over the period while the final rate shows a significant decrease from 1.1% (2010) to 0.2% (2013). This difference is owed to improvements in input errors (34 in 2013) and computer traceability oversights (52 in 2013).

A new version of the software compatible with current interfaces will include a barcode scanner, to decrease the number of input errors. IMDs traceability structure will be reviewed: the 3 different recording medias actually in use will be reduced to one, through the Genois software.

Errors on untraced and lost IMDs are mainly due to packaging issues (batches containing 2 or more IMDs) or related to implanted life-long IMDs (implanted subcutaneous ports): a method of traceability to the single unit has been set up.

Conclusion Traceability of IMDs has been improved thanks to the close collaboration between the pharmacy and the nurses. The next step in management of IMDs is the computerised input of IMDs indications.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Art L.5212–3 CSP.
No conflict of interest.
Material and methods We conducted a prospective study including patients admitted to a 450-bed teaching hospital from April to June 2013 and taking rivaroxaban or dabigatran in prevention of stroke or systemic embolism in non-valvular atrial fibrillation. A clinical pharmacist collected clinical and pharmaceutical data from the electronic medical record and patient interview. Appropriateness of prescribing was evaluated using 9 criteria of the Medication Appropriateness Index.2,3 Explicit instructions specific to the appropriate use of DOACs were added based on EU summary of the product characteristics and (inter)national guidelines. The primary outcome measure was the prevalence of patients with ≥1 inappropriate criterion.

Results Fifty-two patients were evaluated (median age 74 years; 29 and 23 taking Xarelto® and Pradaxa®, respectively). Twenty-eight (53.8%) patients had at least one inappropriate rating: 1 inappropriate criterion in 26.9% and >1 in 26.9% of patients. The most frequent inappropriate criteria were: wrong dosage (32.7%, e.g. dose not adapted to renal function); inappropriate choice and modalities of administration (28.8%, e.g. prescription of a DOAC in a VKA-naïve patient with extreme body weight, once daily administration of Pradaxa®); and impractical modalities of administration (25.0%, e.g. Pradaxa® in non-adherent patients). Twenty-four patients (47.0%) had experienced one adverse event. The clinical pharmacist made 29 interventions during the study period; e.g. 11 request for specific coagulation assay, 8 switches to another oral anticoagulant.

Conclusion The quality of prescribing DOACs was suboptimal. Off-label use was frequent and suggests that reinforcing education of patient and health care professionals is needed.

REFERENCES

No conflict of interest.

INT-003 STABILITY OF VITAMIN C IN DIFFERENT SOLUTIONS FOR PARENTERAL USE IN ONCOLOGY

Background Vitamin C is perceived by the public as a “miracle-pill” capable to heal various illnesses, even cancer. Several in vitro and in vivo studies suggest that ascorbic acid in

1. A health care professional (physician or nurse) is concerned about the patient’s medication or suspects a medication-related problem
2. The patient has particular treatment-induced adverse drug reactions, such as constipation, dry mouth, urinary retention, dizziness, falls, confusion, sweating, restlessness or daytime sleepiness
3. The patient’s GFR is less than 60 ml/min/1.73 m²
4. The patient has orthostatic hypotension

The medication review will use the nurse-conducted medication risk assessment, patient’s medication list, laboratory test results, and it includes review of the following aspects:

1. medication dosing, timely administration, duplication of medication
2. drug–drug interactions
3. anticholinergic medication, serotonergic, orthostatic and sedative burden
4. potentially inappropriate medicines in the elderly (elderly medication database by Finnish Medicines Agency)
5. medication-related laboratory tests
6. renal function and its effect on the medication
7. possible connexion of patient’s symptoms to medication
8. problems in administering the medication and potential alternative formulations
9. medication without indication
10. diagnosis without necessary medication

Results Medication changes were made to 90% of the reviewed patients (n = 31). The emphasis was on interactions and renal function, thus the amount of medicines and/or their doses were reduced.

Conclusion Physicians have received well the new collaborative medication review service. Home care nurses will also learn to identify medication-related problems and use medication review tools. Patients, however, are often attached to their medicines and making changes can be challenging. The need for this kind of collaborative medication review service is obvious and it will be further developed to meet the local needs.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

INT-002 COLLABORATIVE MEDICATION REVIEWS OF HOME-DWELLING PATIENTS IN A HEALTH CENTRE


10.1136/ehjpharm-2015-000639.515

Background Home-dwelling patients have many kinds of symptoms that may be related to their medications and poor coordination of their drug therapy management. In Kirkkonummi municipality, about 84% of home-dwelling patients use multiple medicines (>6 medicines) which pose a risk for inappropriate medication, medication-related problems and additional costs.

Purpose Our objective was to identify those home-dwelling medicines (>6 medicines) which pose a risk for inappropriate medication review service. Home care nurses will also learn to identify medication-related problems and use medication review tools. Patients, however, are often attached to their medicines and making changes can be challenging. The need for this kind of collaborative medication review service is obvious and it will be further developed to meet the local needs.

No conflict of interest.
Pharmacologic concentration exerts anticancer effect, however current clinical evidence (mainly based on case studies) about the therapeutic effect of high-dose intravenous (iv) vitamin C is ambiguous.

Purpose One of our oncology patients who refused further chemotherapy required and was given vitamin C intravenous treatment. The aim of this study was to investigate the role of the clinical pharmacist in the prevention of the high dose vitamin C infusion.

There are two methods to prepare the infusion: diluting from a registered iv. product or preparing parenteral medication from the active ingredient. Although we used the first method (registered product), we decided to investigate the second method as an alternative for future patients. We collected data about the stability of ascorbic acid in different solutions, the technology of the preparation, the quality control and the storage of the infusion.

Material and methods Two different methods of preparation of concentrates for infusion were examined and compared. Both solutions were diluted aseptically to the concentration of 3 mg/V% which was the highest concentration that can be administered to the patient.

After diluting with different vehicles at different pH, the concentration of the active ingredient in the solutions was measured after the preparation and after storing at different temperatures.

Results Concentrates must be filtered instead of sterilisation. The stability of ascorbic acid was mainly affected only by two conditions (pH, temperature). Ascorbic acid was more stable in the pH range of 4.0–5.0°C and in frozen condition.

Conclusion Results from my study can help in establishing a fundamental role in adherence to treatment among rheumatic patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

INT-004 PATIENT ADHERENCE TO TNFα INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS

T Oskarsdottir*, AI Gunnarsdottir, PS Gunnarsson, Love, Gudbjornsson on behalf of ICEBIO. The University Hospital of Iceland; Faculty of Pharmacology; Faculty of Medicine, The University of Iceland, Reykjavik, Iceland

By a retrospective descriptive study of patients treated with colistin from June to September 2014, we analysed number of patients, dosage, type of bacteria and the number of used ampoules per patients. Use of colistin was monitored in patients in intensive care units and departments of internal medicine and surgery at Emergency Centre.

Results In this period, 36 patients were treated, and it was spent 1,631 ampoules. In 18 cases (50%) the posology was 1 MIU/8 h, in 16 cases (44.4%) the posology was 2 MIU/8 h and in 2 cases (5.6%) the posology was 2 MIU/8 h i.v and 1 MIU/8 h by inhalation. Colistin was used in the following units: intensive care units (89%), surgery (6%) and internal departments (5%). At 95% of patients, the drug was introduced in the therapy based on microbiological confirmation of infection with Pseudomonas aeruginosa (resistant to previous therapy with aminoglycosides and carbapenems) and multi-drug resistant strains of Acinetobacter spp. Empirically treatment was started in 5% of patients.

Conclusion The increased number of patients with severe intrahospital infections, it is necessary to establish strict control in the use of colistin (based on antibigrams hemoculture or cerebrospinal fluid).
Background Since January 2013 clinical pharmacists have conducted medication history and review (pharmacist notes) in the Emergency Department (ED) at Bispebjerg Hospital, Copenhagen. Inclusion criteria are patients over 50 years using ≥5 drugs. The aim of the service is to identify drug-related problems, increase patient safety and contribute to a safer medication process.

The pharmaceutical service has been adopted from another hospital. In order to ensure optimal use of the service, it is continuously being evaluated and adapted.

Purpose The purpose is to optimise the pharmaceutical service through continuous evaluation and adaption.

Material and methods The data consists of pharmacist notes compiled in 2014, lists of patients admitted to the ED, a daily logbook and physician’s medical records.

- Monthly analysis of approximately 15% of the produced pharmacist notes. The notes are compared with the physician’s prescriptions to establish the application rate.
- The efficiency is calculated from the number of compiled pharmacist notes in relation to the number of patients over 50 years admitted to the ED.

Adaption:

- Assessment of the changes in the process: The Model for Improvement is applied. Dates of any changes relevant for the pharmaceutical service (i.e. changes in structure of pharmacist notes, organisational changes in the department) is correlated to the application rate and number of compiled pharmacist notes, to assess the influence of the amendments to the pharmaceutical services.

Results The application rate increased from 70% to 79% from January to July 2014.

The efficiency increased from 46% in week 1 to 75% in week 31 in 2014.

Conclusion By continuous evaluation and adaption, the pharmacist increased the application rate and the efficiency; thereby ensure continuous improvement of patient safety in the ED.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.
The EAHP invites you to the 2015 Synergy Satellite event:

"Barcoding the single dose of drugs to improve patient safety"

THURSDAY, 26 March 2015
07:30 - 09:00, CCH Hall 4
Hamburg, Germany

Facilitator
Prof. Dr. Pascal Bonnabry

Presenters
Dr. Thomas de Rijdt
Ulrike Kreysa
Chris Diericks

Find us on: facebook.com/eahp.eu - @EAHPtweet - tini.cc/eahplinkedin
The European Journal of Hospital Pharmacy (EJHP) continues to evolve, offering quality content to help your daily practice, improve your general and specific knowledge of evidence-based practice, and give you some tools to support your activities.

By concentrating on evidence-based content, EJHP now carries crucial research on what hospital pharmacists discover in the daily care of patients, highlighting how to translate the evidence to individual patients and therefore be of great use to the hospital pharmacist.

Read EJHP for thought-provoking editorials, catch up on new research, understand the evidence, and to find out how it can improve your clinical practice.

WHAT’S NEW IN EJHP?
We have added a whole host of features to the journal in line with the continuing development of this essential resource:
• New medicines information section
• Each issue contains a special report on evidence based pharmacy
• Themed issues focus on topics that are important to the hospital pharmacist
• Key research addressing the needs of clinical pharmacists

HELPING HOSPITAL PHARMACISTS PROVIDE BETTER PATIENT CARE

ejhp.bmj.com
Author index

The number next to the author indicates the page number, not the abstract number.

Alamo González O, A97
Álvarez Álvarez, A13
Álvarez Del Vayo-Benito C, A178
Álvaro Alonso EA, A48
Álvaro Sarz E, A107, A108, A109, A171, A193, A202
Ávila R, A210
Abad M, A23, A65
Abdelhadi Álvarez H, A54, A57
Abou Chahta W, A120
Abrasra Merel C, A34, A112
Acosta-García H, A206
Acosta-Robles P, A102, A195
Adán A, A83
Adami S, A116, A164, A171
Alfonso R, A48
Agire I, A157
Aguas M, A104
Aguilar Barcons I, A179
Aguilar E, A27
Aguilar I, A164
Aguilera Villacarpen MJ, A99
Aguinaga Zaldivar I, A69
Agustín MJ, A187
Ahn M, A146
Aicua J, A40
Aisarlarregortia A, A98
Ajaja M, A156
Al Baroudi S, A156
Al Busaidi B, A90
Al Omar S, A81
Alarón Pardo A, A179
Alarón Pardo M, A179
Alaouaich I, A127
Alamo O, A73
Alarcón-Payer C, A18, A193
Alberna C, A51
Alberto A, A51
Alberto M, A103
Alicante Lozana MA, A62, A77, A197
Alicoba A, A111
Alegre Del Rey El, A55, A61, A174, A105
Alfaro-Lara ER, A153
Alfrez García I, A95
Alfonso E, A101
Alghanim A, A203
Alkofo S, A137
Alotto D, A94, A111
Aljumah K, A6, A7
Allende Bandrés MA, A62, A197
Allent C, A39, A76
Allorge D, A126
Almarchel Rivadeneyra M, A101, A161
Almeda A, A133
Almendral A, A74, A169, A187
Almendral Vicente M, A190
Alonso Castro V, A154
Alonso Martín A, A146, A154
Alonso Pérez L, A24
Alonso Ramos H, A10
Alonso V, A56
Alonso-Castro V, A19
Alonso-Dominguez M, A170, A207
Alonso-Dominguez T, A11, A15
Alvarado Fernández MD, A110, A165, A184
Álvarez Marcherillo FJ, A66, A194
Álvarez-Lema F, A139
Álvaro E, A106, A180
Álvaro S, A182
Amar D, A22
Amarante Fente C, A42, A201
Amanah S, A116
Amat López M, A66
Ambros Checa A, A57
Ambrosini Spinella F, A76
Amelia S, A42
Amelung S, A5
Amiri A, A81
Ana V, A78
Andújar A, A109
Andújar Mateos A, A180
Andersen B, A167
Andersen L, A22, A121
Andersen M, A17, A52, A75
Andrés Rosado A, A64, A65, A67
Andrade R, A67
Andreschko M, A89, A161
Andres M, A31
Andresciani E, A28
Andueza K, A157
Andújar I, A27
Angelini Zucchetti T, A175
Anota A, A4
Arón Jiménez L, A43
Antón Torres R, A71
Antequera Lardón MT, A8, A20, A85, A167
Antognac M, A114
Antolovic-Amidzic A, A22
Antoniazzi S, A166
Antoniou S, A33
Aozua A, A57
Aragones A, A205
Araguren MA, A59, A157
Araguren Redondo M, A69
Araujo Arroyo P, A173
Arauso-Rodríguez F, A86, A192
Arcenillas Quevedo P, A54
Arcoari V, A91
Arenas J, A27
Arenas Villafraanca JJ, A51, A171, A202
Arias Moya MA, A11, A88, A155, A185, A198
Armand H, A82
Armarito-Hita J, A58
Arcos Casals V, A20, A64, A103, A160
Arabal Durán P, A98
Arranz Castells T, A199
Arribas-Díaz B, A11, A15, A154, A170, A207
Artao S, A180, A182
Artière F, A16
Arte-time-Rodriguez-Hermida F, A30, A36
Artisneret C, A56
Avat E, A106
Aslanpour Z, A203
Audibert G, A16
Aumente MD, A44, A140, A141
Aumaner C, A202
Aviles Ingles M, A85
Avola N, A48, A90, A101, A140
Aznar Saliente M, A189
Aznarte Padial P, A162, A163
Bécares Martínez FJ, A88, A155, A185, A198
Béchet C, A117
Böhlandt A, A125
Bülow C, A122
Baños Cuello C, A11
Badhellier Cacho M, A69
Badhillier MP, A26, A34, A95, A157
Badracim N, A48
Badsir N, A156
Baehr M, A129
Bagel S, A120, A206
Bajacar J, A123
Balade L, A2, A116, A144
Balague Rostra M, A192
Balza A, A145
Balzola Regout B, A176
Bancourt T, A88
Bandelli G, A51
Bagir W, A3
Barbadillo S, A40
Barbadillo Villanueva S, A41, A97
Barbault-Foucher S, A57
Barcella A, A175
Barjani J, A177
Barradas V, A140
Barragán Pérez L, A68
Barral J, A26, A59
Barral M, A120
Barrera Hernández D, A73, A85, A99, A153, A205
Barrett S, A3
Bartelhélmy C, A120, A200
Bartolini F, A116
Baty M, A74
Basaquoii B, A103
Baxoulegue M, A79
Baxkaraan Kaltzakonta A, A132
Baud G, A49
Bauler S, A93
Baumann T, A116, A145, A172
Bautista-Paloma FJ, A39, A87
Bayer M, A119
Becker A, A89
Begutia T, A51
Belastegui Foronda A, A132
Bellavia G, A60
Belmekki M, A156
Beltramini S, A107
Benet Giménez I, A179
Benito Ibáñez V, A41, A97
Benito V, A40, A73
Benek R, A183
 Bennana A, A118, A156
Benoit G, A174
Bensouda Y, A117
Benziorni Fratelli MT, A175
Bensla S, A92
Bermúdez Vicedo T, A156
Bermúdez E, A127
Bernal Morell E, A99
Bernal-Blanco G, A104
Berry K, A144
Berri S, A122
Beza A, A114
Beuchard I, A81
Bianchi S, A152
Bidon D, A93
Bilbao Meseguer I, A132
Blanque Martinez D, A15, A67
Blanco Dorado S, A42


A213
<table>
<thead>
<tr>
<th>Author index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author Index</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Ching F, A69</td>
</tr>
<tr>
<td>Chini M, A100</td>
</tr>
<tr>
<td>Chouaou N, A25</td>
</tr>
<tr>
<td>Chouquet T, A174</td>
</tr>
<tr>
<td>Chretien M, A4</td>
</tr>
<tr>
<td>Chistrup L, A185</td>
</tr>
<tr>
<td>Ciaccio E, A125</td>
</tr>
<tr>
<td>Ciampalini S, A164</td>
</tr>
<tr>
<td>Cilia A, A198</td>
</tr>
<tr>
<td>Ciuccarelli F, A28</td>
</tr>
<tr>
<td>Clara M, A21</td>
</tr>
<tr>
<td>Clemente Andújar M, A108</td>
</tr>
<tr>
<td>Clemmensen M, A167, A185</td>
</tr>
<tr>
<td>Clintone Martí M, A62, A170</td>
</tr>
<tr>
<td>Clot Silla E, A54</td>
</tr>
<tr>
<td>Cobo S, A138</td>
</tr>
<tr>
<td>Codina C, A69, A82, A83, A137, A143, A150, A158</td>
</tr>
<tr>
<td>Cohen A, A114</td>
</tr>
<tr>
<td>Colin A, A112</td>
</tr>
<tr>
<td>Colín López de Fonsista A, A34, A112</td>
</tr>
<tr>
<td>Collado Borrell R, A48</td>
</tr>
<tr>
<td>Collados Arroyo V, A99</td>
</tr>
<tr>
<td>Collantes-Estevez E, A25</td>
</tr>
<tr>
<td>Collier H, A1, A135</td>
</tr>
<tr>
<td>Collings V, A57</td>
</tr>
<tr>
<td>Cols M, A138</td>
</tr>
<tr>
<td>Cols-González M, A32, A102</td>
</tr>
<tr>
<td>Compegines M, A32</td>
</tr>
<tr>
<td>Combes-Carvalho C, A152</td>
</tr>
<tr>
<td>Combs C, A44</td>
</tr>
<tr>
<td>Comet M, A177</td>
</tr>
<tr>
<td>Compaire Turán V, A62, A64</td>
</tr>
<tr>
<td>Company Altar MJ, A63</td>
</tr>
<tr>
<td>Concepción D, A21</td>
</tr>
<tr>
<td>Concepción M, A103</td>
</tr>
<tr>
<td>Conde Estevez D, A61</td>
</tr>
<tr>
<td>Conde García MC, A105, A173</td>
</tr>
<tr>
<td>Conesa Zamora P, A141</td>
</tr>
<tr>
<td>Conforti A, A171</td>
</tr>
<tr>
<td>Congedo R, A164</td>
</tr>
<tr>
<td>Contet V, A81</td>
</tr>
<tr>
<td>Copeland R, A3</td>
</tr>
<tr>
<td>Coppolino S, A116</td>
</tr>
<tr>
<td>Cores Esperon A, A201</td>
</tr>
<tr>
<td>Coret-Houbart B, A79</td>
</tr>
<tr>
<td>Corridoni S, A125</td>
</tr>
<tr>
<td>Cotés C, A22, A181</td>
</tr>
<tr>
<td>Cotero I, A149</td>
</tr>
<tr>
<td>Cotílitas Saenz M, A126</td>
</tr>
<tr>
<td>Cortoss P, A1, A135</td>
</tr>
<tr>
<td>Cosme Silva F, A133</td>
</tr>
<tr>
<td>Cosserant B, A88</td>
</tr>
<tr>
<td>Cossio Carbajo F, A66, A194</td>
</tr>
<tr>
<td>Cossio Gil Y, A192</td>
</tr>
<tr>
<td>Costa C, A48</td>
</tr>
<tr>
<td>Costes J, A44</td>
</tr>
<tr>
<td>Cotteau-Leroy A, A151</td>
</tr>
<tr>
<td>Coutet J, A100</td>
</tr>
<tr>
<td>Coutinho C, A176</td>
</tr>
<tr>
<td>Crespi C, A13, A122</td>
</tr>
<tr>
<td>Creus N, A149</td>
</tr>
<tr>
<td>Criado Illana M, A192</td>
</tr>
<tr>
<td>Cristina B, A21</td>
</tr>
<tr>
<td>Crossasso P, A106</td>
</tr>
<tr>
<td>Cruz Cruz T, A23</td>
</tr>
<tr>
<td>Cruz T, A204</td>
</tr>
<tr>
<td>Csontos D, A183</td>
</tr>
<tr>
<td>Cuéllar-Monreal M, A1</td>
</tr>
<tr>
<td>Cuervo E, A92</td>
</tr>
<tr>
<td>Cuesta López I, A156</td>
</tr>
<tr>
<td>Cuesta-Montero P, A159</td>
</tr>
<tr>
<td>Cufar A, A21</td>
</tr>
<tr>
<td>Cufarc D, A45</td>
</tr>
<tr>
<td>Cufarc M, A45</td>
</tr>
<tr>
<td>Cumbraos Sánchez M, A62, A64, A77, A197</td>
</tr>
<tr>
<td>Cuny F, A152</td>
</tr>
<tr>
<td>Curatolo N, A174</td>
</tr>
<tr>
<td>Dávila Fajardo CL, A6, A136</td>
</tr>
<tr>
<td>Décaudin B, A70, A120, A126, A200</td>
</tr>
<tr>
<td>Díaz Villamarín X, A6, A136</td>
</tr>
<tr>
<td>Díaz-Carrasco M, A172</td>
</tr>
<tr>
<td>Díaz-Pestana M, A6</td>
</tr>
<tr>
<td>Díaz-Rangel M, A159, A200</td>
</tr>
<tr>
<td>Diez del Pino A, A149</td>
</tr>
<tr>
<td>Dörje F, A202</td>
</tr>
<tr>
<td>Dagrenat I, A151</td>
</tr>
<tr>
<td>Daleur O, A56</td>
</tr>
<tr>
<td>Damant S, A166</td>
</tr>
<tr>
<td>Dámas Fuentes RM, A10, A148</td>
</tr>
<tr>
<td>Dambirne M, A70</td>
</tr>
<tr>
<td>Daniel B, A21</td>
</tr>
<tr>
<td>Daoudi R, A117</td>
</tr>
<tr>
<td>Dastis M, A138</td>
</tr>
<tr>
<td>De Angelis A, A80</td>
</tr>
<tr>
<td>De Antonio Cusco M, A110</td>
</tr>
<tr>
<td>De Basagotti Gonzalo A, A132</td>
</tr>
<tr>
<td>De Bajar Riquelme N, A11, A154, A170</td>
</tr>
<tr>
<td>De Castro Junie M, A112, A113, A187</td>
</tr>
<tr>
<td>De Frein AM, A148</td>
</tr>
<tr>
<td>De Giorgi Salamun I, A107</td>
</tr>
<tr>
<td>De Gorostiza-Frias I, A170, A207</td>
</tr>
<tr>
<td>De Goumoens L, A52</td>
</tr>
<tr>
<td>De Koning B, A160</td>
</tr>
<tr>
<td>De La Fuente-Ruiz S, A25</td>
</tr>
<tr>
<td>De la Llama N, A23</td>
</tr>
<tr>
<td>De la Piedra-Rios E, A53</td>
</tr>
<tr>
<td>De la Rubia Nieto A, A20, A64, A103, A160, A191, A203</td>
</tr>
<tr>
<td>De La Rubia-Nieto MA, A9</td>
</tr>
<tr>
<td>De Libero C, A127</td>
</tr>
<tr>
<td>De Lorenzo-Pinto A, A138</td>
</tr>
<tr>
<td>De Luca S, A164</td>
</tr>
<tr>
<td>De Luca V, A75</td>
</tr>
<tr>
<td>De Marco G, A8</td>
</tr>
<tr>
<td>De Mes M, A28</td>
</tr>
<tr>
<td>De Rivas-Bravo A, A53</td>
</tr>
<tr>
<td>De Sebastián M, A2</td>
</tr>
<tr>
<td>De Tena S, A169</td>
</tr>
<tr>
<td>De Terline D, A114</td>
</tr>
<tr>
<td>De Wredt E, A77</td>
</tr>
<tr>
<td>Declaye C, A74, A168</td>
</tr>
<tr>
<td>Decouceulle C, A88</td>
</tr>
<tr>
<td>Del Barrio Aranda M, A17</td>
</tr>
<tr>
<td>Del Campo Tejedor R, A57</td>
</tr>
<tr>
<td>Del Moral Sánchez J, A109, A180</td>
</tr>
<tr>
<td>de La Cruz Murie P, A160</td>
</tr>
<tr>
<td>Delbay S, A147</td>
</tr>
<tr>
<td>Delgado Cuesta S, A46</td>
</tr>
<tr>
<td>Delgado Sánchez O, A43</td>
</tr>
<tr>
<td>Delpech L, A72</td>
</tr>
<tr>
<td>Delpech A, A120</td>
</tr>
<tr>
<td>Demazy B, A74</td>
</tr>
<tr>
<td>Deprez C, A178</td>
</tr>
<tr>
<td>Derain L, A77</td>
</tr>
<tr>
<td>Delricquebourg A, A147</td>
</tr>
<tr>
<td>Detal N, A3</td>
</tr>
<tr>
<td>Destubouscois A, A151</td>
</tr>
<tr>
<td>Descout J, A57</td>
</tr>
<tr>
<td>Descoutures JM, A73, A132</td>
</tr>
<tr>
<td>Desengles-Carales T, A87, A178</td>
</tr>
<tr>
<td>Desruet M, A39</td>
</tr>
<tr>
<td>Diédara S, A138</td>
</tr>
<tr>
<td>Di Giorgio C, A75</td>
</tr>
<tr>
<td>Di Mazo L, A197</td>
</tr>
<tr>
<td>Di Paolo E, A52</td>
</tr>
<tr>
<td>Di Simone L, A127</td>
</tr>
<tr>
<td>Dias D, A111</td>
</tr>
<tr>
<td>Dias Fanica SM, A182</td>
</tr>
<tr>
<td>Díaz M, A78</td>
</tr>
<tr>
<td>Díaz-Pestano M, A148</td>
</tr>
<tr>
<td>Díaz-Navarro J, A55, A58, A61</td>
</tr>
<tr>
<td>Díez A, A56</td>
</tr>
<tr>
<td>Díez Fernandez R, A7, A37, A164</td>
</tr>
<tr>
<td>Dimas F, A140</td>
</tr>
<tr>
<td>Dimatteo M, A75</td>
</tr>
<tr>
<td>Dinsen-Anderson C, A212</td>
</tr>
<tr>
<td>Dick M, A202</td>
</tr>
<tr>
<td>Distefano M, A140</td>
</tr>
<tr>
<td>Djeroda S, A142</td>
</tr>
<tr>
<td>Do-Paz-Oubri A, F, A143</td>
</tr>
<tr>
<td>Dobravc Verbic M, A17</td>
</tr>
<tr>
<td>Dogné JM, A209</td>
</tr>
<tr>
<td>Dominguez Cantero M, A59, A181</td>
</tr>
<tr>
<td>Dominguez López M, A158</td>
</tr>
<tr>
<td>Domingo-Chiva E, A159, A200</td>
</tr>
<tr>
<td>Dominguez E, A67, A90</td>
</tr>
<tr>
<td>Dominguez Menendez JA, A176</td>
</tr>
<tr>
<td>Donoso Rengifo C, A110</td>
</tr>
<tr>
<td>Donoso Rengifo E, A36</td>
</tr>
<tr>
<td>Donoso Rengifo MC, A184</td>
</tr>
<tr>
<td>Dor P, A183</td>
</tr>
<tr>
<td>Dosda I, A29</td>
</tr>
<tr>
<td>Dot D, A138</td>
</tr>
<tr>
<td>Doukhis J, A209</td>
</tr>
<tr>
<td>Dragovic I, A211</td>
</tr>
<tr>
<td>Drame M, A142</td>
</tr>
<tr>
<td>Drouot S, A207</td>
</tr>
<tr>
<td>Duarte R, A143</td>
</tr>
<tr>
<td>Dueñas Guirreiz CL, A155</td>
</tr>
<tr>
<td>Dumont N, A206, A209</td>
</tr>
<tr>
<td>Durand L, A207</td>
</tr>
<tr>
<td>Durand M, A39</td>
</tr>
<tr>
<td>Ebers S, A160</td>
</tr>
<tr>
<td>Eberl A, A145</td>
</tr>
<tr>
<td>Echamari-Arieta E, A197</td>
</tr>
<tr>
<td>Eche A, A64</td>
</tr>
<tr>
<td>Edery S, A114</td>
</tr>
<tr>
<td>Eisend S, A28</td>
</tr>
<tr>
<td>Eisert A, A129, A160</td>
</tr>
<tr>
<td>Ekoumbe I, A169</td>
</tr>
<tr>
<td>El Hassani A, A156</td>
</tr>
<tr>
<td>El Mahmoud S, A115</td>
</tr>
<tr>
<td>El Mourabit M, A117</td>
</tr>
<tr>
<td>El Wartiti A, A156</td>
</tr>
<tr>
<td>El Wartiti M, A117, A118</td>
</tr>
<tr>
<td>El-Sharkawi R, A96</td>
</tr>
<tr>
<td>Elena A, A51</td>
</tr>
<tr>
<td>Elia C, A48</td>
</tr>
<tr>
<td>Elisa D, A103</td>
</tr>
<tr>
<td>Elsner D, A22</td>
</tr>
<tr>
<td>Elviro Llorens M, A58</td>
</tr>
<tr>
<td>Encinas Barrios C, A57, A179</td>
</tr>
<tr>
<td>Enneffah W, A117, A118, A156</td>
</tr>
<tr>
<td>Ercilla Liceaga M, A69</td>
</tr>
<tr>
<td>Ercilla M, A24, A59</td>
</tr>
<tr>
<td>Escalante Pueyo A, A65, A177, A187</td>
</tr>
</tbody>
</table>
Fernández Ferreiro A, A42, A87, A197
Fernández M, A40, A169
Fernández Martín J, A84
Fernández R, A74
Fernández S, A38
Fernández Vicente M, A41
Fernández-Carlabate S, A207
Fernández-Gabriel E, A194
Fernández-Llimos F, A69
Fernández-Peinado G, A142
Fernandez-Vega A, A92
Ferrandez Martí D, A192
Ferrarese A, A171
Ferrari Piquero JM, A94, A111
Ferreira D, A69
Ferreira M, A133
Ferreira Tátá FI, A182
Ferris Villanueva E, A13, A14, A33, A123, A141
Ferit M, A67, A90
Ferit Martín M, A169
Filieri A, A51
Flórcer R, A174
Fiore F, A124
Fischer E, A125
Fischereider M, A161
Fittler A, A95
Flanzey V, A44
Flór Garcia A, A85, A153, A205
Floret E, A98
Floret M, A26
Fobelo Lozano M, A193
Fobelo MJ, A182
Fobelo-Lozano MJ, A109
Fonseca A, A143
Font P, A25
Font-Noguera A, A1
Fontan J, A25
Fofo Garcia A, A85, A153
Fortuna M, A145
Fraca Fuentes MD, A105, A173
Fraile Clemente C, A35, A41
França L, A69
Franco A, A90
Franco F, A140
Franco Miguel J, A85, A99
Franco Sereno M, A57, A179
Franco-García F, A44, A97, A141
Freire I, A143
Freire M, A2, A167
Fremont D, A204
Frey OR, A135
Friedland K, A202
Fritzsche J, A207
Fruos Jiménez I
Fuster Sanjuñiz L, A92, A125
Gámez R, A74, A169, A187
Gómez de Travevedo MT, A47, A169, A187
Gómez Espírrago M, A208
Gómez Esteban A, A34, A112
Gómez F, A74, A169, A187
Gómez Fernández E, A115, A193
Gómez Gómez D, A34, A112
Gómez Esteban A, A34, A112
Gómez Espárrago M, A208
Gómez de Travevedo MT, A74, A169, A187
González-Martínez E, A68, A108, A109
González-Morelo C, A44, A194
González-Sayago L, A192
González-Vaquero D, A102, A195
Gómez García M, A46, A155
Garcia-Díaz A, A122
Gajardo Álvarez M, A17, A87
Galanti L, A123
Galindo M, A187
Galindo Rueda MM, A20, A160, A191
Gallego Fernández C, A124
Gallego Muñoz C, A34, A59, A158, A181
Gallego V, A24
Gandara-Ladron de Guevara M, A55, A58, A61, A174
Gantes Trelles J, A144
Garaffo E, A91
García Angelgut M, A112
García Coronel M, A99
García Fernández C, A15, A67
García Gomez C, A108
García Iranzo E, A71
García JL, A168
García López L, A12, A13, A30, A96, A98, A192
García Lagarau MH, A13, A14, A33, A123, A141
García Márquez A, A13, A14, A33, A123, A141
García Martín F, A59, A158
García MJ, A149
García Molina O, A64, A103, A160, A191
García Muñoz C, A111
García Muñoz S, A126, A189
García Palomo M, A150, A196
García Panico R, A32, A61, A110
García Piemonte C, A149
García Robles AA, A63
García Simón MS, A13, A14, A33
García V, A178
García X, A149
García-Collado C, A3
García-Gómez P, A1
García-González X, A86, A98, A199
García-Martínez EM, A159
García-Molina Sáez C, A8, A20, A85, A99, A167
García-Sánchez R, A138
García Bonilla A, A187, A190
García C, A22, A24
García de Paredes-Esteban J, A55, A61, A174
García JJ, A31
García L, A38
García Lopez A, A42
García M, A111
García Martínez EM, A159, A200
García Martínez C, A32
García R, A26, A139
García Romero J, A62, A157
García Sabina A, A42
García Verde MJ, A92, A125
García-Avello A, A178
García-Avello Fernández-Cueto A, A62
García-Iturra E, A180
García-Yubero C, A204
Garrido Ameigeiras M, A208
Garrido Coro B, A160
Garrido B, A24
Garrido M, A27
Garriga R, A54
Garzás M, A97
Garzone A, A28
Gaspar A, A140
Author index

A220


Narregard S, A22
Nade Lopez L, A26
Najduska E, A123
Najera-Perez M, A15
Nalda R, A142
Navarro Dávila MA, A35, A41
Navarro Fernando J, A68, A189
Navarro H, A23, A65
Navarro L, A23, A177
Navarro Ruiz A, A71, A109, A180
Navas Iglesias N, A127, A129, A131
Nazco Casariego G, A113
Nazco Casariejo J, A130, A209
Nazer L, A81
Negrovonovic V, A211
Neiken B, A120
Neus P, A205
Ngo T, A178
Nieto Guindo M, A171, A202
Nieto Guindo P, A5, A24, A95, A96, A97, A146
Nieto M, A27
Nieto P, A79
Nieto-Martin MD, A153
Nieto-Sandoval Martin de la Sierra P, A101, A105
Nikou K, A94
Nobili A, A166
Noblot-Rossignol M, A4
Noccioli V, A80
Noewers K, A1
Novella J, A142
Nuorte Gallego B, A149
Nuria M, A78

O’Shaughnessy F, A148
O’Shea J, A148
Oca B, A73
Oca Luis B, A41, A46
Ocaña Gómez MA, A35, A41
Odou P, A70, A109, A120, A126, A151, A200
Olivi A, A143
Olivia Hernandez L, A10
Oliveira M, A48, A173
Oliveira R, A143
Oliver Ferrer E, A113
Olmos Jiménez R, A9, A172, A203
Oldbury B, A116
Ontañón Narase A, A65, A67
Onteniente Candela M, A8, A20, A85, A99, A167
Onteniente-Gonzalez A, A38, A40
Oppomer M, A4
Orabona V, A134
Orantes Casado De Amezua F, A115, A169
Orantes F, A3
Orantes-Casado-de-Amezua F, A139
Orlikovsky T, A160
Oremel M, A80
Oro Fernández M, A34, A112
Ortega L, A115
Ortiz de Urbina J, A115
Ortiz Navarro M, A200
Ortiz Ruiz L, A113
Ortonobes Roig S, A61, A110
Oskandodtter T, A211
Oscario S, A82
Otero-Espinar F, A87
Outeda M, A159
Pérez Á Tristancho, A193
Pérez A, A164
Pérez Calderón R, A19
Pérez Díez C, A23
Pérez E, A144
Pérez Encinas M, A48
Pérez Huertas P, A63
Pérez León M, A6, A10, A66
Pérez Plasencia A, A179
Pérez Puente P, A208
Pérez Serrano R, A54, A57, A179
Pérez-Guerrero C, A153
Pérez-Morales J, A3, A18, A35, A36, A139
Pérez-Navarro M, A181
Pérez-Pérez J, A23
Paasch S, A5
Pablos Bravo S, A94, A111
Padrón García MA, A10, A148
Padulles-Zamora N, A32
Pailhas L, A79
Pajares Alonso M, A79
Palladino C, A152
Palma D, A52, A176
Palomo P, A167
Palomo-Palomo C, A55, A58, A61, A174
Panadero Esteban MI, A88, A155, A198
Pani M, A116
Pannatier A, A52, A107
Padletti D, A124
Paolucci D, A125, A132
Pardo Jorio MP, A197
Pardo Pastor L, A54
Pardo Santos N, A176
Pardo-Ibañez MD, A159
Pardo-Pérez M, A87
Pareja Rodríguez De Vera A, A203
Pares Maniorn R, A192
Parola A, A31
Parra A, A169
Parra Alonso E, A83, A149
Parriñi M, A80
Parron A, A152
Pascal O, A177
Pascal-Atuce B, A181
Pastina L, A166
Pasquau J, A162, A163
Pastor C, A142
Pauwels K, A77
Pedrosa Naudin MA, A155
Peinado R, A172
Pereiro Barraso C, A163
Pelegrín S, A48, A88, A120, A202, A206
Pelegrín Torres P, A155, A185, A198
Pellechía M, A196
Pellejero Hernando E, A58
Pellicer Franco C, A64, A160
Penaud J, A100
Pentespilos I, A100
Perani L, A75
Perdikouri K, A84, A94
Pereló Junca A, A192
Perello L, A122
Perez C, A65
Perez I, A24
Perez M, A120
Perez Marco MT, A44
Perez N, A159
Perez-Blanco JL, A104
Perier Raspaud S, A207
Peristeraki S, A100
Periti G, A166
Pernot C, A4
Perrier J, A16
Perrinet M, A204
Petrongonas M, A72
Petrovic Z, A211
Peyró-García RS, A159
Peyrilles E, A204
Pfluggraf S, A49, A88, A202
Pfluggraf S, A206
Pfister R, A152
Pfimeiro-Ces A, A87
Piñero González M, A6, A148
Picard A, A100
Picard C, A198
Picchereau C, A188
Pichon R, A117
Pickasik G, A208
Pinder N, A5
Pinturaud M, A126, A200
Pires Rebello MA, A182
Piforot C, A168
Pitsounis N, A100
Pia A, A54
Planells-Herrero C, A1
Plasencia García I, A35, A41
Plasas F, A73
Plata Casas C, A147
Plata Paniagua S, A108, A159, A200
Polloni C, A28, A76
Polloni P, A75, A164
Polimeni G, A91
Politis B, A178
Pompe SV, A89
Pomphilo A, A28
Pons JL, A73, A132
Pons Martínez L, A189
Pons-LLibert N, A142
Pontes Garcia C, A112, A113
Porrás Leal M, A54
Porta Oltra B, A62
Portlock J, A72
Pozoio M, A166
Pouliat S, A169
Poseroup H, A127
Poveda J, A137
Poveda-Andrés J, A1
Poyatos Ruiz LL, A62, A133, A134, A178
Pozas del Río MT, A24
Preece D, A77
Price R, A77
Profizi E, A114
Pruetna J, A134
Pucci N, A127
Puchalt-Escribano I, A1
Puerto-Alonso J, A86
Pueto López C, A156
Pugjot G, A135
Puisset F, A44
Queralt Gorgas Torner M, A199
Quezada Sanz M, A144
Quilliet P, A93
Quilllet D, A16
Quirós Lopez R, A171
Quitis E, A84
Röhrl AC, A135
Rabañal-Alvarez M, A194
Raffy F, A16
Rahali F, A117, A155
Raich Monts L, A112, A113, A187
Ramio E, A104
<table>
<thead>
<tr>
<th>Author name</th>
<th>Pages</th>
<th>Author name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vezmar Kovacevic S</td>
<td>A45</td>
<td>Vezmar Kovacevic S</td>
<td>A45</td>
</tr>
<tr>
<td>Viña Romero M</td>
<td>A113</td>
<td>Viña Romero M</td>
<td>A113</td>
</tr>
<tr>
<td>Vilas L, A164</td>
<td></td>
<td>Vilas Sagüé L, A179</td>
<td></td>
</tr>
<tr>
<td>Vicente Sánchez S</td>
<td>A9, A20, A103, A203</td>
<td>Vicente Sánchez S</td>
<td>A9, A20, A103, A203</td>
</tr>
<tr>
<td>Viegas E, A181</td>
<td></td>
<td>Viegas E, A181</td>
<td></td>
</tr>
<tr>
<td>Viguera-Guerra I</td>
<td>A25, A44, A97, A140, A141</td>
<td>Viguera-Guerra I</td>
<td>A25, A44, A97, A140, A141</td>
</tr>
<tr>
<td>Villa Currius M</td>
<td>A179</td>
<td>Villa Currius M</td>
<td>A179</td>
</tr>
<tr>
<td>Villa M, A164</td>
<td></td>
<td>Villa M, A164</td>
<td></td>
</tr>
<tr>
<td>Villa Torres E</td>
<td>A179</td>
<td>Villa Torres E</td>
<td>A179</td>
</tr>
<tr>
<td>Vilanova Molto M</td>
<td>A43</td>
<td>Vilanova Molto M</td>
<td>A43</td>
</tr>
<tr>
<td>Villa A, A105</td>
<td></td>
<td>Villa A, A105</td>
<td></td>
</tr>
<tr>
<td>Villalba-Moreno AM</td>
<td>A153</td>
<td>Villalba-Moreno AM</td>
<td>A153</td>
</tr>
<tr>
<td>Villamarín E, A2, A116, A144, A145, A172</td>
<td>Villamarín E, A2, A116, A144, A145, A172</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Villesen CT, A22</td>
<td></td>
<td>Villesen CT, A22</td>
<td></td>
</tr>
<tr>
<td>Villota E, A92</td>
<td></td>
<td>Villota E, A92</td>
<td></td>
</tr>
<tr>
<td>Vinciguerra V</td>
<td>A78</td>
<td>Vinciguerra V</td>
<td>A78</td>
</tr>
<tr>
<td>Vincio S, A177</td>
<td></td>
<td>Vincio S, A177</td>
<td></td>
</tr>
<tr>
<td>Virant I, A145</td>
<td></td>
<td>Virant I, A145</td>
<td></td>
</tr>
<tr>
<td>Virgos Aller T</td>
<td>A130</td>
<td>Virgos Aller T</td>
<td>A130</td>
</tr>
<tr>
<td>Vitali C, A76</td>
<td></td>
<td>Vitali C, A76</td>
<td></td>
</tr>
<tr>
<td>Viyuela Cal M, A97</td>
<td></td>
<td>Viyuela Cal M, A97</td>
<td></td>
</tr>
<tr>
<td>Viyuela MD, A73</td>
<td></td>
<td>Viyuela MD, A73</td>
<td></td>
</tr>
<tr>
<td>Voirol P, A107</td>
<td></td>
<td>Voirol P, A107</td>
<td></td>
</tr>
<tr>
<td>Volk Markovic P, A21</td>
<td></td>
<td>Volk Markovic P, A21</td>
<td></td>
</tr>
<tr>
<td>Von Gunten A, A107</td>
<td></td>
<td>Von Gunten A, A107</td>
<td></td>
</tr>
<tr>
<td>Von Wichmann M, A34</td>
<td></td>
<td>Von Wichmann M, A34</td>
<td></td>
</tr>
<tr>
<td>Vuelta Arce MF, A37</td>
<td></td>
<td>Vuelta Arce MF, A37</td>
<td></td>
</tr>
<tr>
<td>Vukovic D, A22</td>
<td></td>
<td>Vukovic D, A22</td>
<td></td>
</tr>
<tr>
<td>Watel M, A147</td>
<td></td>
<td>Watel M, A147</td>
<td></td>
</tr>
<tr>
<td>Wilson K, A50</td>
<td></td>
<td>Wilson K, A50</td>
<td></td>
</tr>
<tr>
<td>Winnard NR, A186</td>
<td></td>
<td>Winnard NR, A186</td>
<td></td>
</tr>
<tr>
<td>Wojtek A, A151</td>
<td></td>
<td>Wojtek A, A151</td>
<td></td>
</tr>
<tr>
<td>Wollsten GL, A210</td>
<td></td>
<td>Wollsten GL, A210</td>
<td></td>
</tr>
<tr>
<td>Xiol-Quingles F</td>
<td>A32</td>
<td>Xiol-Quingles F</td>
<td>A32</td>
</tr>
<tr>
<td>Yagudina R, A199</td>
<td></td>
<td>Yagudina R, A199</td>
<td></td>
</tr>
<tr>
<td>Yalcin S, A80</td>
<td></td>
<td>Yalcin S, A80</td>
<td></td>
</tr>
<tr>
<td>Yokote N, A119</td>
<td></td>
<td>Yokote N, A119</td>
<td></td>
</tr>
<tr>
<td>Yoldas F, A80</td>
<td></td>
<td>Yoldas F, A80</td>
<td></td>
</tr>
<tr>
<td>Yunquera Romero L, A87, A124</td>
<td>Yunquera Romero L, A87, A124</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yurrebaso Ibarreche MJ, A176</td>
<td>Yurrebaso Ibarreche MJ, A176</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zeal R, A160</td>
<td></td>
<td>Zeal R, A160</td>
<td></td>
</tr>
<tr>
<td>Zafontes Descallar M, A43</td>
<td>Zafontes Descallar M, A43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zambanier G, A175</td>
<td></td>
<td>Zambanier G, A175</td>
<td></td>
</tr>
<tr>
<td>Zamora Ferrer E, A101, A105</td>
<td>Zamora Ferrer E, A101, A105</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zampogna G, A107</td>
<td></td>
<td>Zampogna G, A107</td>
<td></td>
</tr>
<tr>
<td>Zapico García I, A66</td>
<td></td>
<td>Zapico García I, A66</td>
<td></td>
</tr>
<tr>
<td>Zaragota Rasón M, A79</td>
<td></td>
<td>Zaragota Rasón M, A79</td>
<td></td>
</tr>
<tr>
<td>Zeiter B, A119</td>
<td></td>
<td>Zeiter B, A119</td>
<td></td>
</tr>
<tr>
<td>Zeikos R, A210</td>
<td></td>
<td>Zeikos R, A210</td>
<td></td>
</tr>
<tr>
<td>Zenoni D, A175</td>
<td></td>
<td>Zenoni D, A175</td>
<td></td>
</tr>
<tr>
<td>Zitouni S, A122</td>
<td></td>
<td>Zitouni S, A122</td>
<td></td>
</tr>
<tr>
<td>Zlatian O, A59, A60</td>
<td></td>
<td>Zlatian O, A59, A60</td>
<td></td>
</tr>
<tr>
<td>Zulfikar A, A142</td>
<td></td>
<td>Zulfikar A, A142</td>
<td></td>
</tr>
<tr>
<td>Zuzuanegui Girones M, A169</td>
<td>Zuzuanegui Girones M, A169</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Call for abstracts - 2016 Vienna

21st Congress of the EAHP, 16-18 March 2016, Vienna, Austria
Abstract submission opens 1 August, 2015!

Original contributions from all fields of hospital pharmacy are encouraged and welcomed for poster presentation.

**Deadline for submission: 15 October 2015**

During the review process, the award nominees will be selected and the presenting author of the nominated abstracts will be invited to give an oral presentation after which the final judging will take place.

Please be sure to provide an email address which will not be blocked by spam servers so that EAHP may notify you for modifications and nominations.

(Abstracts may be submitted through the EAHP web site's online submission page.)

**IMPORTANT NOTE:** The online submission form does not recognise some symbols from certain keyboards. Therefore, please proof your abstract after it has been entered into the system and before your final submission.

The format and guidelines for the online abstract submission will be changed. Please visit the EAHP web site at [http://www.eahn.eu/congresses/abstract](http://www.eahn.eu/congresses/abstract) to view the new guidelines and to submit abstracts for the Vienna congress 2016.

Abstracts must be entered into the system by section according to the guidelines.

There will be 5 sections as shown below.

**Background - Purpose - Material and methods - Results - Conclusion**
“Hospital pharmacists taking the lead - partnerships and technologies”

16 -18 March 2016, Vienna, Austria

Registration opens 1st August 2015
Abstract submission deadline: 15th October 2015

The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

EAHP appreciates the continued support of:
Bayer HealthCare and Roche, Platinum Partners - Amgen and Novartis Oncology, Gold Partners - Pfizer and Baxter, Corporate Partners

THE EUROPEAN ASSOCIATION OF HOSPITAL PHARMACISTS REPRESENTS MORE THAN 15,500 HOSPITAL PHARMACISTS IN 34 EUROPEAN COUNTRIES AND IS THE ONLY EUROPEAN ASSOCIATION OF NATIONAL ORGANISATIONS REPRESENTING HOSPITAL PHARMACISTS AT EUROPEAN AND INTERNATIONAL LEVELS.

INFORMATION:
CONGRESS SECRETARIAT
TEL: +32 (0)2/741.68.22
+32 (0)2/741.68.21
FAX: +32 (0)2/734.79.10
EMAIL: CONGRESS@EAHP. EU
WEB: WWW.EAHP.EU

facebook.com/eahp.eu - @EAHPtweet - tini.cc/eahplinkedin